

**American Society of Clinical Oncology
47th Annual Meeting**

Meeting Program

Note: Sessions in which Special Awards are presented
are shaded in gray

Friday, June 3, 2011

**1:00 PM - 2:15 PM
EDUCATION SESSIONS**

Customized Cancer Treatment: A Systems Biology Approach to Drug Selection

Location: E354b

CME credit: 1.25

Track(s): Developmental Therapeutics, Cancer Genetics, Clinical Trials

John Mendelsohn, MD—Chair

University of Texas M. D. Anderson Cancer Center

Customized Cancer Medicine: Are We Ready for What It Will Take?

Jeffrey M. Trent, PhD

TGen

Large-scale, Multidimensional Genomics Data: Making Sense for Patients

Andrea Califano, PhD

Columbia University

Cancer's Complexity: Are We Looking at the Wrong Levels to Develop Effective Interventions?

Endometrial Cancer: Present State and Future Promise

Location: E354a

CME credit: 1.25

Track(s): Gynecologic Cancer

Don S. Dizon, MD—Chair

Warren Alpert Medical School of Brown University

Options in the Treatment of Relapsed Endometrial Cancer: Beyond First-line Therapy

Karen H. Lu, MD

University of Texas M. D. Anderson Cancer Center

Molecular Characterization of Endometrial Cancer: Going beyond Histology

David Scott Miller, MD

University of Texas Southwestern Medical Center

Incorporation of Adjuvant Chemotherapy into Endometrial Cancer Treatment

Neoadjuvant Therapy in Operable Breast Cancer: Who, What, When, Why, and How?

Location: Hall D1

CME credit: 1.25

Track(s): Breast Cancer

Luca Gianni, MD—Chair

Fondazione IRCCS Istituto Nazionale dei Tumori

Neoadjuvant Assumptions and Application to Chemotherapy, Endocrine Therapy, and Biologic Therapy-based Regimens

David W. Ollila, MD

University of North Carolina at Chapel Hill

Surgical Implications of the Neoadjuvant Approach: Facilitating Research Biopsies, Breast Conservation in Previously T3–4 Tumors, and Axillary Staging—Before or After?

Thomas A. Buchholz, MD

University of Texas M. D. Anderson Cancer Center

Radiation in the Setting of Marked Cytoreduction: Do We Radiate a Cleared Nodal Basin or Breast?

Pediatric Bone Sarcomas: Converging Progress on the Biologic and Clinical Fronts?

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology, Sarcoma

Stephen L. Lessnick, MD, PhD—Chair

Huntsman Cancer Institute

*Recent Progress in Understanding the Biology of Bone Tumors***Holcombe E. Grier, MD**

Dana-Farber Cancer Institute

*Advances in the Treatment of Ewing's Sarcoma***Neyssa Marina, MD**

Stanford University School of Medicine

*Update on the Management of Children, Adolescents, and Young Adults with Osteosarcoma***Radiation Therapy Updates for Primary Brain Tumors: Clinical Role for Proton Therapy, Stereotactic Radiosurgery, and Hypofractionated Schedules**

Location: S100bc

CME credit: 1.25

Track(s): Central Nervous System Tumors

John H. Suh, MD—Chair

Cleveland Clinic

*Radiosurgery Applications for Primary Brain Tumors***Eugen Hug, MD**

Paul Scherrer Institut

*Proton Therapy for Primary Brain Tumors: When to Refer***Eric L. Chang, MD**

University of Texas M. D. Anderson Cancer Center

*Abbreviated Course of Radiation Therapy in Older Patients with Glioblastoma***Survivorship Care: Whose Job Is It?**

Location: S406

CME credit: 1.25

Track(s): Patient and Survivor Care, Health Services Research

Julia Howe Rowland, PhD—Chair

National Cancer Institute/National Institutes of Health

*Overview of This Emerging Challenge in Survivors' Care***Paul Han, MD, MA, MPH**

Maine Medical Center Research Institute

*Presentation of Data from the National Cancer Institute— and American Cancer Society—funded Study: Survey of Physician Attitudes Regarding Care of Cancer Survivors***James Ross Waisman, MD**

Breastlink Medical Group Inc.

How to Implement Survivorship Care in Practice

Friday, June 3, 2011

The Identification and Treatment of the “High Risk” Patient with Non-Hodgkin Lymphoma and Myeloma

Location: Arie Crown Theater

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

Francine M. Foss, MD—Chair

Yale Cancer Center

High-risk Peripheral T-cell Lymphoma

Michael Pfreundschuh, MD

Saarland University Hospital

High-risk B-cell Non-Hodgkin Lymphoma

Rafael Fonseca, MD

Mayo Clinic

High-risk Myeloma

1:00 PM - 2:15 PM
MEET THE PROFESSOR SESSION

**Implementing a Quality Research Program in a Community Setting
(M05)—Ticketed Session**

Location: E451a

CME credit: 1.25

Track(s): Clinical Trials, Practice Management and Information Technology, Professional Development

Patrick J. Flynn, MD

Metro Minnesota Community Clinical Oncology Project

Practical Aspects of Clinical Trial Implementation in the Community Setting

Lidia Schapira, MD

Massachusetts General Hospital

Talking to Patients about Clinical Trials

Friday, June 3, 2011

**1:00 PM - 3:15 PM
EXTENDED EDUCATION SESSIONS**

How to Participate in Clinical Research across Borders

Location: S100a

CME credit: 2.25

Track(s): Clinical Trials, International

Eduardo L. Cazap, MD—Chair

Latin American-Caribbean Society of Medical Oncology

Martine J. Piccart-Gebhart, MD, PhD

Jules Bordet Institute

The BIG Experience: Challenges and Opportunities

Edward Lloyd Trimble, MD

National Cancer Institute

Promoting Independent Research at the U.S. National Cancer Institute

Jean-Yves Blay, MD, PhD

Centre Léon Bérard

How to Participate in European Organisation for Research and Treatment of Cancer Trials

Henry Leonidas Gomez, MD

Instituto Nacional de Enfermedades Neoplásicas

Leading Clinical Research in Low-resource Scenarios

Role of Nutrition, Supplements, and Integrative Medicine in Cancer Prevention, Treatment, and Survivorship

Location: E353

CME credit: 2.25

Track(s): Cancer Prevention/Epidemiology, General Oncology, Patient and Survivor Care

Charles L. Loprinzi, MD—Chair

Mayo Clinic

Nutrition Recommendations for Patients with Far-advanced Disease

Heather Greenlee, ND, PhD

Columbia University

Lifestyle Modification and Dietary Supplements in Cancer Prevention: What Is the Role?

Kimberly Robien, PhD, RD

University of Minnesota

Approaches to Nutrition Interventions during Cancer Treatment

Wendy Demark-Wahnefried, PhD, RD

University of Alabama at Birmingham

Nutrition and Physical Activity Recommendations for Cancer Survivorship: What Do We Tell Our Patients and Their Families after Treatment?

Lorenzo Cohen, PhD

University of Texas M. D. Anderson Cancer Center

Improving Patient Outcomes: The Role of Integrative Medicine in Cancer Care

1:00 PM - 3:30 PM
EXTENDED EDUCATION SESSIONS

Grant Writing Workshop I: Basic Grant Writing

Location: S106

CME credit: 2.5

Track(s): Professional Development, Clinical Trials

Charles M. Rudin, MD, PhD—Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Developing Hypothesis and Stating Aims

Lei Ming, PhD

National Cancer Institute

National Cancer Institute Training and Career Development Grants

Kathleen A. Cooney, MD

University of Michigan Medical School, University of Michigan Comprehensive Cancer Center
Conquer Cancer Foundation of ASCO (formerly The ASCO Cancer Foundation) Grants Program

Susan Blaney, MD

Texas Children's Cancer Center

Choosing a Mentor and Obtaining Letters of Support

Heidi Nelson, MD

Mayo Clinic

Tips for Grant Writing in the New National Institutes of Health Format

Donna S. Neuberg, ScD

Dana-Farber Cancer Institute

Statistical Considerations

Mary L. Disis, MD

University of Washington

Grant Writing Pearls

On the Shoulders of Giants: Historical Perspectives on Biomarkers and Colorectal Carcinoma

Location: E350

CME credit: 2.5

Track(s): Professional Development, Gastrointestinal (Colorectal) Cancer

Jill Gilbert, MD—Chair

Vanderbilt University

Robert J. Mayer, MD

Dana-Farber Cancer Institute

History of Systemic Treatment for Colorectal Cancer

S. Gail Eckhardt, MD

University of Colorado School of Medicine, Anschutz Medical Campus

History of the Development of Novel Agents and Integration of Biomarkers in Colorectal Cancer

Katherine Elizabeth Reeder-Hayes, MD

University of North Carolina Hospital

Case Study: Colorectal Carcinoma

Jae Hong Park, MD

Memorial Sloan-Kettering Cancer Center

Case Study: Colorectal Carcinoma

Friday, June 3, 2011

**1:00 PM - 4:00 PM
EXTENDED EDUCATION SESSION**

**Maintenance of Certification and Lifelong Learning Workshop
(MOC)—Ticketed Session**

Location: E451b

Track(s): Professional Development

Alexandria T. Phan, MD—Chair

University of Texas M. D. Anderson Cancer Center

ABIM 2010 Update in Medical Oncology

Gregory A. Masters, MD

Thomas Jefferson University Medical School and Medical Oncology Hematology Consultants

ABIM 2010 Update in Medical Oncology

Anne Moore, MD

Weill Cornell Medical College

ABIM 2010 Update in Medical Oncology

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Central Nervous System Tumors

Display Time: 2:00 PM - 6:00 PM

Display Location: S102

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: S100a

CME credit: 1

Track(s): Central Nervous System Tumors

Mark R. Gilbert, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

John L. Villano, MD—Co-Chair

University of Illinois

Discussion

5:00 PM Martin Kelly Nicholas, MD, PhD (Abstracts #2012–2017)
The University of Chicago

Discussion

5:30 PM Jeffrey J. Raizer, MD (Abstracts #2025–2030)
Northwestern University Feinberg School of Medicine

Discussion

5:45 PM David M. Peereboom, MD (Abstracts #2031–2036)
Cleveland Clinic

- Brd. 1** **A population-based study of glioblastoma multiforme (GBM) in the new Stupp paradigm: Have we improved outcome? (Abstract #2012)**
Z. Lwin, D. MacFadden, A. AL-Zahrani, E. Atenafu, B. Miller, C. Menard, N. Laperriere, W. P. Mason
- Brd. 2** **Improved survival time trends for glioblastoma using the SEER 17 population-based registries. (Abstract #2013)**
M. Koshy, J. L. Villano, T. A. Dolecek, A. Howard, S. Chmura, R. R. Weichselbaum, B. J. McCarthy
- Brd. 3** **Real-life survival in unselected adult glioblastoma patients: A population-based study. (Abstract #2014)**
M. Preusser, A. Woehrer, N. Zielonke, H. Heinzl, C. Auer, T. Waldhoer, K. Roessler, C. Marosi, J. A. Hainfellner
- Brd. 4** **Effects of surgery with BCNU wafer placement on neurocognitive function in patients with one to three brain metastases. (Abstract #2015)**
M. G. Ewend, C. A. Meyers, E. Silva, M. Booth-Jones, S. Jain, S. Brem
- Brd. 5** **Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. (Abstract #2016)**
T. S. Armstrong, J. S. Wefel, M. Wang, M. Won, A. Bottomley, T. R. Mendoza, C. Coens, M. Werner-Wasik, D. Brachman, A. K. Choucair, M. R. Gilbert
- Brd. 6** **Variation over time and interdependence between disease progression and death among patients with glioblastoma (GBM) on RTOG 0525. (Abstract #2017)**
M. Wang, J. Dignam, M. Won, W. J. Curran Jr., M. P. Mehta, M. R. Gilbert
- Brd. 7** **Outcome of grade 3 and 4 cytopenia in newly diagnosed glioblastoma multiforme (GBM) patients treated with temozolomide (TMZ). (Abstract #2018)**
B. E. Sanchez, J. Munoz, H. Y. Ali, J. M. Anderson, P. Kuriakose

- Brd. 8** **Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in patients (pts) with recurrent glioblastoma (rGBM) treated with bevacizumab (BEV) and sorafenib (SOR). (Abstract #2019)**
 S. Anderson, J. M. Lafky, X. W. Carrero, T. K. Kimlinger, T. M. Halling, S. Kumar, P. J. Flynn, H. M. Gross, K. A. Jaeckle, J. C. Buckner, E. Galanis
- Brd. 9** **Detection of IDH1 mutations in a series of 91 oligodendrogliomas: Comparison of immunohistochemistry, DNA sequencing, and allele-specific PCR. (Abstract #2020)**
 D. Loussoarn, A. Le Loupp, J. Frenel, F. Leclair, A. Von Deimling, M. Aumont, S. Martin, M. Campone, M. G. Denis
- Brd. 10** **The role of the development of hypertension or proteinuria in predicting outcome with the use of bevacizumab for patients with glioblastoma multiforme (GBM). (Abstract #2021)**
 C. S. Nangia, D. Wang, L. Scarpace, L. Schultz, A. Khanshour, T. Mikkelsen
- Brd. 11** **Clinical use of personalized molecular biomarkers in patients with glioblastoma. (Abstract #2022)**
 M. Holdhoff, J. O. Blakeley, C. Carson, C. H. Ferrigno, L. Blair, A. S. Balmanoukian, P. Burger, S. A. Grossman, L. A. Diaz Jr.
- Brd. 12** **Triple-negative, low-grade gliomas: A highly aggressive tumor with dismal prognosis. (Abstract #2023)**
 P. Metellus, B. Coulibaly, C. Colin, A. Maués de Paula, A. Barlier, A. Loundou, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-Branger
- Brd. 13** **The role of amide proton transfer imaging in detecting active malignant glioma. (Abstract #2024)**
 J. O. Blakeley, X. Ye, M. Lim, H. Zhu, L. Blair, A. Quinones-Hinojosa, C. Eberhart, P. Barker, J. Laterra, P. C. van Zijl, J. Zhou
- Brd. 14** **Methotrexate (MTX) rechallenge for recurrent primary CNS lymphoma (PCNSL). (Abstract #2025)**
 E. Pentsova, L. M. DeAngelis, A. M. Omuro
- Brd. 15** **Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial. (Abstract #2026)**
 A. Korfel, L. Fischer, P. Martus, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, H. Mergenthaler, T. Hundsberger, M. Leithäuser, T. Birnbaum, A. Florschütz, K. Jahnke, U. Herrlinger, M. Weller, E. Thiel
- Brd. 16** **Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). (Abstract #2027)**
 R. Soffietti, E. Trevisan, R. Ruda, L. Bertero, C. Bosa, M. Fabrin, I. Lolli
- Brd. 17** **Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM). (Abstract #2028)**
 A. M. Omuro, K. Beal, S. Karimi, D. Correa, T. A. Chan, L. M. DeAngelis, I. T. Gavrilovic, C. Nolan, A. Hormigo, A. B. Lassman, T. J. Kaley, I. K. Mellinghoff, C. Grommes, K. Panageas, A. S. Reiner, R. Barradas, L. E. Abrey, P. H. Gutin
- Brd. 18** **Randomized multicenter phase II trial of irinotecan and bevacizumab as neoadjuvant and adjuvant to temozolomide-based chemoradiation versus chemoradiation for unresectable glioblastoma: Interim results of the TEMAVIR study from the ANOCEF group. (Abstract #2029^)**
 B. Chauffert, L. Feuvret, F. Bonnetain, L. Taillandier, H. Taillia, D. Frappaz, R. Schott, J. Honnorat, M. Fabbro, I. Tennevet, F. Ghiringhelli, J. S. Guillamo, X. Durando, D. Castera, M. Frenay, C. Campello, R. Guillevin, J. Skrzypski, T. S. Dabakuyo, O. L. Chinot, Association des Neuro-Oncologues d'Expression Francaise

- Brd. 19** **Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. (Abstract #2030)**
 D. A. Reardon, J. J. Vredenburgh, A. Desjardins, K. Peters, A. D. Coan, J. E. Herndon, H. S. Friedman
- Brd. 20** **Phase II study of erlotinib with concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. (Abstract #2031)**
 J. Welsh, A. Amini, E. S. Kim, P. Allen, J. Y. Chang, L. L. Garland, J. Holt, D. Erdman, R. Komaki, B. Stea
- Brd. 21** **Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas. (Abstract #2032)**
 P. Y. Wen, V. K. Puduvalli, J. G. Kuhn, J. M. Reid, K. Lamborn, T. F. Cloughesy, S. M. Chang, J. Drappatz, W. A. Yung, M. R. Gilbert, H. Robins, F. S. Lieberman, A. B. Lassman, R. M. McGovern, S. Desideri, X. Ye, M. M. Ames, I. J. Espinoza-Delgado, S. A. Grossman, M. Prados
- Brd. 22** **NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study. (Abstract #2033)**
 K. A. Jaeckle, D. Schiff, S. K. Anderson, E. Galanis, P. J. Stella, P. J. Flynn, J. N. Sarkaria, B. W. Scheithauer, B. J. Erickson, J. C. Buckner, NCCTG
- Brd. 23** **TEMOBIC: An ANOCEF phase II study of BCNU and temozolomide (TMZ) combination prior to radiotherapy (RT) in anaplastic oligodendroglial gliomas (AOG). (Abstract #2034)**
 O. L. Chinot, K. Hoang-Xuan, M. Fabbro, L. Taillandier, J. Honnorat, M. Barrie, M. Sanson, C. Kerr, P. Beauchesne, S. Cartalat-Carel, D. Autran, A. Loundou, R. Guillevin, K. Mokhtari, D. Figarella-Branger, J. Delattre, Association des Neuro-Oncologues d'Expression Francaise
- Brd. 24** **Open-label, dose-confirmation study of interstitial ¹³¹I-chTNT-1/b mab for the treatment of glioblastoma multiforme (GBM) at first relapse: Interim results. (Abstract #2035)**
 W. R. Shapiro, D. Gupta, A. K. Mahapatra, S. Gopal, K. Judy, S. J. Patel, J. Shan
- Brd. 25** **A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas. (Abstract #2036)**
 S. A. Jeyapalan, M. Goldmann, J. Donahue, H. Elinzano, D. L. Evans, B. M. O'Connor, M. A. Puthawala, A. Oyelese, D. Cielo, M. Blitstein, M. Dargush, A. Santaniello, M. Constantinou, T. Dipetrillo, H. Safran, Brown University Oncology Group

Friday, June 3, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Gynecologic Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: E354b

CME credit: 1

Track(s): Gynecologic Cancer

Daniela Matei, MD—Co-Chair

Indiana University Simon Cancer Center

Seiko Diane Yamada, MD—Co-Chair

The University of Chicago

Discussion

5:00 PM Paul J. Goodfellow, PhD (Abstracts #5012–5016)
Washington University School of Medicine

Discussion

5:15 PM David R. Spriggs, MD (Abstracts #5017–5024)
Memorial Sloan-Kettering Cancer Center

Discussion

5:30 PM Beth Karlan, MD (Abstracts #5025–5031)
Cedars-Sinai Medical Center

Discussion

5:45 PM Patricia J. Eifel, MD (Abstracts #5032–5036)
University of Texas M. D. Anderson Cancer Center

Brd. 1 A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. (Abstract #5012)

B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman

Brd. 2 Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. (Abstract #5013)

H. Mackay, S. Welch, M. S. Tsao, J. J. Biagi, L. Elit, P. Ghatage, L. Martin, K. S. Tonkin, S. Ellard, S. K. Lau, L. McIntosh, E. A. Eisenhauer, A. M. Oza

Brd. 3 Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. (Abstract #5014)

G. F. Fleming, V. L. Filiaci, P. Hanjani, J. J. Burke II, S. A. Davidson, K. K. Leslie, R. J. Zaino, Gynecologic Oncology Group

Brd. 4 A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II and California Cancer (CCCP) N01 Consortia NCI#8233. (Abstract #5015)

R. Morgan, A. M. Oza, R. Qin, K. M. Laumann, H. Mackay, E. L. Strelvel, S. Welch, D. Sullivan, R. M. Wenham, H. X. Chen, L. A. Doyle, D. R. Gandara, C. Erlichman

Brd. 5 The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer. (Abstract #5016)

L. A. Meyer, B. M. Slomovitz, B. Djordjevic, J. M. Galincea, T. A. Johnston, M. Munsell, J. K. Burzawa, M. Huang, R. Broaddus, D. A. Iglesias, R. L. Coleman, D. M. Gershenson, T. W. Burke, J. Wolf, K. H. Lu

Brd. 6 Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. (Abstract #5017)

R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood

- Brd. 7** **The role of bevacizumab in combination with pegylated liposomal doxorubicin in patients with platinum-resistant recurrent or refractory ovarian cancers. (Abstract #5018)**
H. Kouta, K. Kudoh, M. Takano, R. Kikuchi, T. Kita, T. Goto, K. Furuya, Y. Kikuchi
- Brd. 8** **A phase II study of intermittent sorafenib with bevacizumab in patients with bevacizumab-naïve epithelial ovarian cancer (EOC). (Abstract #5019)**
E. C. Kohn, J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, J. Squires, N. D. Houston, H. X. Chen, J. J. Wright
- Brd. 9** **A phase II trial of weekly nab-paclitaxel with GM-CSF as chemimmunotherapy for platinum-resistant epithelial ovarian cancer. (Abstract #5020)**
R. E. Swensen, J. Childs, D. Higgins, T. Gooley, B. A. Goff, P. A. Fintak, B. Buening, M. L. Disis
- Brd. 10** **A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. (Abstract #5021)**
U. Matulonis, W. P. Tew, D. Matei, K. Behbakht, G. F. Fleming, A. M. Oza
- Brd. 11** **Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC). (Abstract #5022)**
G. Scambia, D. Lorusso, G. Amadio, N. Trivellizzi, A. Pietragalla, R. De Vincenzo, V. Salutari, M. Di Stefano, G. Mangili, S. Montoli, G. Citterio, A. Lambiase, C. Bordignon
- Brd. 12** **Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (Abstract #5023)**
R. A. Burger, M. F. Brady, J. Rhee, M. A. Sovak, H. Nguyen, M. A. Bookman
- Brd. 13** **A single-center experience of EMA/CO chemotherapy for high-risk gestational trophoblastic neoplasia: Induction low-dose cisplatin and etoposide chemotherapy. (Abstract #5024)**
C. Alifrangis, R. Agarwal, D. Short, P. Savage, M. Seckl
- Brd. 14** **Sequence-specific effects on DNA and cell damage with the PARP inhibitor olaparib (AZD2281) and carboplatin. (Abstract #5025)**
J. L. Hays, G. Kim, J. Mariani, R. F. Murphy, M. Angelos, A. McCollum, J. Lu, B. C. Widemann, J. Lee, E. C. Kohn
- Brd. 15** **Germ-line BRCA mutations in high-grade ovarian cancer: A case for routine BRCA mutation screening after a diagnosis of invasive ovarian cancer. (Abstract #5026)**
K. Alsop, S. Fereday, C. Meldrum, A. deFazio, P. Webb, M. J. Birrer, M. Friedlander, S. B. Fox, D. Bowtell, G. Mitchell, The Australian Ovarian Cancer Study (AOCS) Group
- Brd. 16** **Loss of heterozygosity (LOH) as a measure of whole-genome instability in ovarian cancer correlates with clinical outcomes. (Abstract #5027)**
G. Korpany, K. Timms, V. Abkevich, M. Carey, A. Gutin, Y. Li, J. Li, M. Markman, R. Broadus, J. S. Lanchbury, K. H. Lu, G. B. Mills, B. Hennessy
- Brd. 17** **A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD1775) in recurrent ovarian or triple-negative breast cancer. (Abstract #5028)**
J. Liu, G. F. Fleming, S. M. Tolaney, M. J. Birrer, R. T. Penson, S. T. Berlin, C. Whalen, K. Tyburski, K. Matijevich, E. Kasparian, M. Roche, H. Lee, E. P. Winer, S. P. Ivy, U. Matulonis
- Brd. 18** **Effect of WBC BRCA1 promoter methylation on ovarian cancer risk. (Abstract #5029)**
P. Lonning, M. Bjørnslett, S. Knappskog, L. Vatten, P. Romundstad, U. Axcrone, D. G. Evans, A. Howell, A. Dørum, R. Chrisanthar
- Brd. 19** **Associations between MDM2 SNP309 and SNP285C haplotypes and ovarian cancer risk in BRCA1 mutation carriers. (Abstract #5030)**
M. Bjørnslett, S. Knappskog, P. Lonning, A. Dørum

Friday, June 3, 2011

- Brd. 20** **A multivariate longitudinal algorithm for early detection of ovarian cancer using multiple biomarkers. (Abstract #5031)**
Z. Zhang, S. J. Skates, L. J. Sokoll, Z. Lu, C. H. Clarke, M. A. Hernandez, K. H. Lu, R. C. Bast
- Brd. 21** **A phase I trial of concurrent cetuximab (CET), cisplatin (CDDP), and radiation therapy (RT) for women with locally advanced cervical cancer (CXCA): A GOG study. (Abstract #5032)**
K. N. Moore, M. Sill, D. S. Miller, P. Disilvestro, K. De Geest, P. G. Rose, H. R. Cardenas, R. S. Mannel, J. H. Farley, R. J. Schilder, P. M. Fracasso
- Brd. 22** **INCA-GYN001: Erlotinib added to cisplatin and definitive radiotherapy in untreated patients with locally advanced squamous cell cervical carcinoma—Final report of a phase II trial. (Abstract #5033)**
A. N. Rodrigues, I. A. Small, C. C. Carmo, G. M. Moralez, F. Erlich, R. Grazziotin, M. H. Lewer, C. C. Camisao, F. V. Alves, C. G. Ferreira
- Brd. 23** **Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer. (Abstract #5034)**
C. Kunos, S. E. Waggoner, K. M. Zanotti, R. DeBernardo, N. Fusco, A. Heugel, J. Knazek, R. Adams, T. Radivoyevitch, A. Dowlati
- Brd. 24** **Utility of preoperative ferumoxtran-10 enhanced MRI to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN 6671/GOG 0233. (Abstract #5035)**
M. Atri, Z. Zhang, H. Marques, J. Gorelick, M. Harisinghani, A. Sohaib, D. Koh, S. Raman, M. S. Gee, H. Choi, L. M. Landrum, R. S. Mannel, L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Gold, ACRIN/GOG
- Brd. 25** **Estimation of expectedness: How reliable are the predictions for the outcome of standard therapy in randomized phase III studies (RP3) in epithelial ovarian cancer (EOC)? (Abstract #5036)**
V. Castonguay, I. Diaz-Padilla, L. Wang, A. M. Oza

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Head and Neck Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: S403

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: S406

CME credit: 1

Track(s): Head and Neck Cancer

Quynh-Thu Le, MD—Co-Chair

Stanford University Medical Center

Barbara A. Murphy, MD—Co-Chair

Vanderbilt Medical Center

Discussion

5:00 PM Quynh-Thu Le, MD (Abstracts #5507–5515^)
Stanford University Medical Center

Discussion

5:15 PM Bonnie S. Glisson, MD (Abstracts #5516–5520)
University of Texas M. D. Anderson Cancer Center

Discussion

5:30 PM Barbara A. Murphy, MD (Abstracts #5521–5526)
Vanderbilt Medical Center

Discussion

5:45 PM Lisa F. Licitra, MD (Abstracts #5527–5529)
Fondazione IRCCS Istituto Nazionale dei Tumori

- Brd. 1** **Genetic sequence variants (GSV) in relation to acute and late toxicities in head and neck cancer (HNC) patients treated with radiation therapy (RT). (Abstract #5507)**
F. Meyer, I. Bairati, W. Xu, A. Azad, G. Liu
- Brd. 2** **Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment. (Abstract #5508)**
I. Tinhofer, K. F. Klinghammer, W. Weichert, M. Knoedler, A. Stenzinger, T. C. Gauler, V. Budach, U. Keilholz
- Brd. 3** **MDM2 309 single nucleotide polymorphisms (SNP) and clinical outcome in patients with advanced squamous cell carcinoma of head and neck (SCCHN). (Abstract #5509)**
M. Gasco, D. Vivenza, M. Monteverde, L. Lattanzio, I. Colantonio, G. Natoli, E. Miraglio, A. Comino, N. Syed, T. Crook, M. C. Merlano, C. Lo Nigro
- Brd. 4** **Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC). (Abstract #5510)**
V. Papadimitrakopoulou, J. Heymach, S. J. Frank, J. Myers, H. Lin, H. T. Tran, C. Chen, F. R. Hirsch, P. B. Langmuir, J. R. Vasselli, S. M. Lippman, D. Raben
- Brd. 5** **Correlation of circulating tumor cells in SCCNH patients to cancer reoccurrence using a negative enrichment technology. (Abstract #5511)**
K. Jatana, P. Balasubramanian, J. C. Lang, T. N. Teknos, D. E. Schuller, J. J. Chalmers
- Brd. 6** **Predictive value of human papillomavirus (HPV) 16 in situ hybridization (ISH) and p16 immunohistochemistry (IHC) for HPV oncogene expression in paraffin-embedded oropharynx squamous cell carcinoma (OPSCC). (Abstract #5512)**
M. L. Gillison, R. Jordan, M. Lingen, B. Perez-Ordóñez, X. He, R. Pickard, A. Inman, M. Koluder, B. Jiang, P. Wakely, W. Xiao

- Brd. 7** *H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC). (Abstract #5513)*
 T. Rampias, A. Giagini, K. Florou, P. Gouveris, E. Vaja, N. Haralambakis, P. Katsaounis, D. G. Pectasides, T. Economopoulos, A. Psyrri
- Brd. 8** *Molecular prognostic prediction by support vector machine integrated approach for local advanced nasopharyngeal carcinoma. (Abstract #5514)*
 X. Wan, X. Wu, X. Fan, H. Cai, M. Chen, J. Xu, M. Hong, Q. Liu
- Brd. 9** *Exosomal-miRNA profiles as diagnostic and prognostic biomarkers in head and neck squamous cell carcinoma (HNSCC). (Abstract #5515^)*
 G. Rabinowits, C. G. Taylor, G. H. Kloecker, A. Patel, M. B. Hall, D. D. Taylor
- Brd. 10** *Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. (Abstract #5516)*
 N. Y. Lee, Q. Zhang, A. S. Garden, J. J. Kim, D. G. Pfister, J. Mechalakos, K. Hu, Q. Le, B. S. Glisson, A. T. Chan, K. Ang
- Brd. 11** *Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck. (Abstract #5517)*
 C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, A. Dekker, K. Stenson, E. A. Blair, O. I. Olopade, T. Y. Seiwert, E. E. Vokes, E. E. Cohen
- Brd. 12** *Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: Preliminary outcome results. (Abstract #5518)*
 P. M. Harari, D. Khuntia, A. M. Traynor, T. Hoang, D. T. Yang, G. K. Hartig, T. M. McCulloch, R. Jeraj, M. J. Nyflot, P. A. Wiederholt, L. R. Gentry
- Brd. 13** *A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHx), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). (Abstract #5519)*
 T. Y. Seiwert, D. J. Haraf, E. E. Cohen, E. A. Blair, K. Stenson, J. K. Salama, M. Kocherginsky, V. M. Villafior, M. Witt, R. Williams, A. Dekker, E. E. Vokes
- Brd. 14** *Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. (Abstract #5520)*
 W. N. William Jr., R. S. Weber, J. Lee, J. Myers, L. E. Ginsberg, A. K. El-Naggar, E. M. Sturgis, A. L. Sabichi, M. S. Kies, E. Y. Hanna, A. C. Hessel, C. Lu, S. Y. Lai, R. Ayuste, S. M. Lippman, E. S. Kim
- Brd. 15** *A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer. (Abstract #5521)*
 J. S. Kuk, S. Parpia, S. M. Sagar, T. Tsakiridis, D. Kim, D. I. Hodson, C. Zywine, J. R. Wright
- Brd. 16** *Neurocognitive function (NCF) in patients (pts) treated with chemo/bioradiotherapy (C/B-RT) for head and neck cancers (HNC). (Abstract #5522)*
 A. R. Abdul Razak, L. L. Siu, A. Chan, G. R. Pond, K. M. Tirona, E. X. Chen, A. J. Hope, J. Ringash, B. O'Sullivan, J. N. Waldron, K. Chan, H. K. Gan, L. J. Bernstein
- Brd. 17** *Patient-reported fatigue in head and neck cancer survivors. (Abstract #5523)*
 G. B. Gunn, T. R. Mendoza, A. S. Garden, X. S. Wang, W. H. Morrison, S. J. Frank, E. Y. Hanna, C. Lu, B. M. Beadle, K. Ang, C. S. Cleeland, D. I. Rosenthal

- Brd. 18** **Phase III trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation. (Abstract #LBA5524)**
H. S. Antunes, D. Herchenhorn, C. M. Araujo, E. Cabral, E. M. D. S. Ferreira, I. A. Small, M. P. Rampini, N. Teich, P. C. Rodrigues, T. G. P. D. Silva, L. F. Dias, C. G. M. Ferreira
- Brd. 19** **The utility of using area under the curve to analyze symptom burden during radiation/chemoradiation for head and neck cancer. (Abstract #5525)**
T. R. Mendoza, G. B. Gunn, C. D. Fuller, X. S. Wang, D. I. Rosenthal, C. S. Cleeland
- Brd. 20** **Toxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximab. (Abstract #5526)**
A. Chew, J. Hay, J. J. Laskin, J. Wu, C. Ho
- Brd. 21** **Correlation of HPV status and hypoxic imaging using [18F]-misonidazole (FMISO) PET in head and neck squamous cell carcinoma (HNSCC). (Abstract #5527)**
M. E. Trinkaus, R. J. Hicks, R. J. Young, L. J. Peters, B. J. Solomon, M. Bressel, J. Corry, R. Fisher, D. Binns, G. A. McArthur, D. Rischin
- Brd. 22** **Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT. (Abstract #5528)**
B. Pajares, J. Trigo Perez, M. D. Toledo, M. Alvarez, L. Perez-Villa, C. Gonzalez-Hermoso, A. Rueda, J. A. Medina, B. Jimenez, J. Jerez, L. Perez, E. Alba
- Brd. 23** **Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States. (Abstract #5529)**
A. Chaturvedi, E. Engels, R. Pfeiffer, B. Y. Hernandez, W. Xiao, E. Kim, B. Jiang, M. Goodman, M. Sibug-Saber, W. Cozen, L. Liu, C. Lynch, N. Wentzensen, R. Jordan, S. Altekruse, W. F. Anderson, P. Rosenberg, M. L. Gillison

Friday, June 3, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Leukemia, Myelodysplasia, and Transplantation

Display Time: 2:00 PM - 6:00 PM

Display Location: E450b

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: Arie Crown Theater

CME credit: 1

Track(s): Leukemia, Myelodysplasia, and Transplantation

Jane Liesveld, MD—Co-Chair

University of Rochester Medical Center

Harry Paul Erba, MD, PhD—Co-Chair

University of Michigan Medical Center

Discussion

5:00 PM Olatoyosi Odenike, MD (Abstracts #6509–6515)
The University of Chicago

Discussion

5:15 PM Farhad Ravandi, MD (Abstracts #6516–6522)
University of Texas M. D. Anderson Cancer Center

Discussion

5:30 PM Joseph P. Uberti, MD (Abstracts #6523–6528)
Karmanos Cancer Institute, Wayne State University

Discussion

5:45 PM Guido Marcucci, MD (Abstracts #6529–6533)
The Ohio State University Comprehensive Cancer Center

Brd. 1 **Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: Eighteen-month follow-up. (Abstract #6509)**

C. Gambacorti-Passerini, J. E. Cortes, D. Kim, H. Kantarjian, N. Khattry, J. H. Lipton, C. Powell, P. Harris, A. M. Countouriotis, T. H. Brummendorf

Brd. 2 **Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION. (Abstract #6510)**

H. Kantarjian, N. P. Shah, J. E. Cortes, M. Baccarani, M. Bradley-Garelik, C. Zhu, A. Hochhaus

Brd. 3 **Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up. (Abstract #6511)**

R. A. Larson, D. Kim, G. Rosti, L. Stenke, R. Pasquini, A. Hoenekopp, R. E. Blakesley, N. J. Gallagher, A. Hochhaus, T. P. Hughes, G. Saglio, H. Kantarjian

Brd. 4 **Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib. (Abstract #6512)**

N. P. Shah, J. E. Cortes, C. A. Schiffer, F. Guilhot, T. H. Brummendorf, A. C. Chen, D. Healey, A. Lambert, G. Saglio

Brd. 5 **A survey of current practices in the management of chronic myeloid leukemia (CML). (Abstract #6513)**

M. J. Mauro, J. E. Cortes, R. A. Larson, P. M. Herout, V. K. Bollu, A. Niyazov, H. Kantarjian

Brd. 6 **Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. (Abstract #6514)**

A. D. Pardanani, D. Caramazza, G. George, T. L. Lasho, W. J. Hogan, M. R. Litzow, K. Begna, C. A. Hanson, R. F. McClure, L. M. Bavisotto, G. Smith, M. Kowalski, S. Sirhan, A. W. Roberts, V. Gupta, J. Gotlib, A. Tefferi

- Brd. 7 Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. (Abstract #6515)**
H. J. Deeg, O. Odenike, B. L. Scott, Z. Estrov, J. E. Cortes, D. A. Thomas, H. J. Zhu, H. Kantarjian, S. Verstovsek
- Brd. 8 Phase I trial of the targeted alpha-particle nano-generator actinium-225 (²²⁵Ac-lintuzumab; anti-CD33; HuM195) in acute myeloid leukemia (AML). (Abstract #6516)**
J. G. Jurcic, T. L. Rosenblat, M. R. McDevitt, N. Pandit-Taskar, J. A. Carrasquillo, S. M. Chanel, C. Ryan, M. G. Frattini, D. Cicic, S. M. Larson, D. A. Scheinberg
- Brd. 9 Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML. (Abstract #6517)**
E. J. Feldman, K. W. Yee, D. Rizzieri, A. S. Advani, A. Charman, A. Richardson, M. J. Toal, J. E. Cortes
- Brd. 10 Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. (Abstract #6518)**
M. Talpaz, N. P. Shah, M. W. Deininger, M. J. Mauro, I. W. Flinn, S. Lustgarten, W. Lindmark, J. M. Gozgit, T. Clackson, C. D. Turner, F. G. Haluska, H. Kantarjian, J. E. Cortes
- Brd. 11 CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60–75: Safety and efficacy in secondary AML (sAML). (Abstract #6519)**
J. E. Lancet, J. E. Cortes, T. Kovacsovics, D. Hogge, J. E. Koltz, M. S. Tallman, M. Chiarella, A. C. Louie, E. J. Feldman
- Brd. 12 A phase III, open-label, randomized comparison of AS1413 (amonafide L-malate) plus cytarabine with daunorubicin plus cytarabine in secondary acute myeloid leukemia (ACCEDE). (Abstract #6520)**
R. M. Stone, S. L. Allen, A. Pigneux, R. K. Stuart, M. Wetzler, D. Rizzieri, H. P. Erba, L. E. Damon, J. Jang, M. S. Tallman, K. Warzocha, T. Masszi, M. A. Sekeres, E. Miklos, H. Horst, D. L. Selleslag, S. R. Solomon, P. Venugopal, A. S. Lundberg, B. L. Powell
- Brd. 13 A phase I and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor belinostat (BEL) plus azacitidine (AZC) in advanced myeloid malignancies. (Abstract #6521)**
O. Odenike, L. A. Godley, J. Madzo, T. Karrison, M. Green, A. S. Artz, R. J. Mattison, K. W. Yee, M. Bennett, N. Fulton, G. Koval, G. Malnassy, R. A. Larson, M. J. Ratain, W. Stock
- Brd. 14 Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. (Abstract #6522)**
A. F. List, A. Giagounidis, J. T. Backstrom, T. Fu, P. Fenaux
- Brd. 15 Relapse incidence and leukemia-free survival (LFS) in patients (pts) older than age 60 with AM undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO). (Abstract #6523)**
D. Niederwieser, G. Maschmeyer, T. Fischer, L. Uharek, R. Kortmann, U. Hegenbart, P. Dreger, M. Herold, H. G. Sayer, H. Wolf, U. Kreibich, D. Hähling, C. Junghans, N. Grobe, R. Krahl, T. Lange, H. Al-Ali, W. Pönisch, C. Nehring, G. Doelken
- Brd. 16 A randomized, phase III trial comparing BuCy and BuFlu as a myeloablative conditioning regimen. (Abstract #6524)**
S. Kim, J. Lee, Y. Joo, H. Kim, H. Ryoo, M. Kim, G. Lee, W. Lee, J. Park, S. Bae, M. Hyun, D. Kim, Y. Min, Cooperative Study Group A for Hematology (COSAH)
- Brd. 17 Reduced intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment and durable remissions. (Abstract #6525)**
K. Van Besien, H. Liu, E. S. Rich, L. A. Godley, O. Odenike, L. Joseph, J. P. Kline, V. H. Nguyen, J. M. Cunningham, R. A. Larson, W. Stock, A. Wickrema, A. S. Artz

- Brd. 18 Mechanism of thymic renewal after infusion of suicide gene-modified donor T cells after hematopoietic stem cell transplantation (HSCT) in adult patients. (Abstract #6526)**
C. Bordignon, L. Vago, G. Oliveira, M. Noviello, C. Soldati, D. Ghio, I. Brigida, A. Aiuti, M. Lupo-Stanghellini, J. Peccatori, A. Lambiase, A. Bondanza, A. Del Maschio, F. Ciceri, C. Bonini
- Brd. 19 Vincristine sulfate liposomes injection (VSLI) “bridging” to potentially curative hematopoietic stem cell transplantation (HSCT) in adults with Philadelphia chromosome–negative (Ph-) acute lymphoblastic leukemia (ALL). (Abstract #6527)**
G. J. Schiller, S. E. Coutre, M. L. Larson, D. Ben Yehuda, P. Venugopal, S. Goldberg, G. L. Messerschmidt, J. Silverman, S. R. Deitcher, H. Kantarjian
- Brd. 20 A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL). (Abstract #6528)**
J. E. Castro, L. S. Schwartzberg, J. Pinilla-Ibarz, T. J. Kipps, M. J. Cantwell
- Brd. 21 High-throughput mutation analysis in acute myeloid leukemia (AML). (Abstract #6529)**
J. Dunlap, C. L. Corless, W. H. Fleming, R. Braziel, N. Leeborg, K. Gatter, M. Loriaux, K. Kelemen, T. Kovacsovics, G. Fan
- Brd. 22 Association of IDH1 mutations in normal karyotype acute myeloid leukemia samples with higher HIF-1 α and VEGF-A expression. (Abstract #6530)**
M. Smonskey, P. Starostik, G. Deeb, K. Demock, R. Vargas, D. Lal, S. N. Sait, M. Wetzler, E. S. Wang
- Brd. 23 PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. (Abstract #6531)**
F. P. Duhoux, G. Ameye, K. Bahloula, M. Mozziconacci, S. Laibe, I. Wlodarska, L. Michaux, P. Talmant, S. Richebourg, E. Lippert, F. Speleman, C. Herens, S. Struski, S. Raynaud, N. Nadal, M. Lafage, N. Auger, J. Libouton, J. Demoulin, H. A. Poirel, Groupe Francophone de Cytogenetique Hematologique (GFCH) and Belgian Cytogenetic Group for Hematology and Oncology (BCG-HO)
- Brd. 24 The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL). (Abstract #6532)**
I. Iacobucci, A. Ferrari, A. Lonetti, C. Papayannidis, F. Paoloni, M. Abbenante, V. Guadagnuolo, E. Ottaviani, F. Cattina, A. Vitale, S. Paolini, S. Soverini, S. Parisi, M. Vignetti, M. Baccarani, G. Martinelli
- Brd. 25 Novel jumping translocations (JT) associated with genetic instability and aggressive disease in chronic lymphocytic leukemia (CLL). (Abstract #6533)**
C. Miller, F. Racke, G. Lozanski, A. McFaddin, J. C. Byrd, N. A. Heerema

2:45 PM - 4:00 PM EDUCATION SESSIONS

Acute Myeloid Leukemia: Update on Therapy and Molecular Basis

Location: Arie Crown Theater

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology

Martin S. Tallman, MD—Chair

Memorial Sloan-Kettering Cancer Center

Therapy of the Elderly Patient with Acute Myeloid Leukemia

Sami N. Malek, MD

University of Michigan Comprehensive Cancer Center

Update on the Molecular Biology of Acute Myeloid Leukemia: Clinical Implications

Alan Burnett, MD

University of Wales College of Medicine

Therapy of Acute Myeloid Leukemia in Patients Younger Than Age 55

Challenges in HER2-positive Breast Cancer

Location: Hall D1

CME credit: 1.25

Track(s): Breast Cancer

Mark D. Pegram, MD—Chair

University of Miami Sylvester Comprehensive Cancer Center

Overview and Discussion of HER2 Biology: De Novo and Acquired Resistance to Targeting

Giuseppe Viale, MD

European Institute of Oncology

Controversies in Testing for HER2

Eric P. Winer, MD

Dana-Farber Cancer Institute

Therapeutic Implications of HER2 Targeting in Very Small Clinical Low-risk Tumors and HER2 Targeting after Progression

Targeting ALK in Pediatric Malignancies

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology, Lymphoma and Plasma Cell Disorders

Stephan Morris, MD—Chair

St. Jude Children's Research Hospital

The Role of ALK Signaling in Anaplastic Large Cell Lymphoma

Yael P. Mosse, MD

The Children's Hospital of Philadelphia

"Driver" ALK Mutations in Neuroblastoma

Pasi A. Janne, MD, PhD

Dana-Farber Cancer Institute

Developing Drugs That Target ALK and Other Genomic Aberrations

Friday, June 3, 2011

When Adults Are Diagnosed with Children's Sarcomas

Location: S406

CME credit: 1.25

Track(s): Sarcoma, Pediatric Oncology

Karen H. Albritton, MD—Chair

Cooks Children's Medical Center

The Unique Issues of the Adolescent and Young Adult (AYA) with Sarcoma

David Parham, MD

University of Oklahoma Health Sciences Center

Pathologic Differences between Adult and Pediatric Sarcomas

Robert G. Maki, MD, PhD

Mount Sinai School of Medicine

The Management of the Adult with Children's Sarcoma

2:45 PM - 4:00 PM
MEET THE PROFESSOR SESSION

Setting Up a Cancer Genetics Program (M02)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Cancer Genetics, Cancer Prevention/Epidemiology

Jeffrey N. Weitzel, MD

City of Hope

The Academic Perspective

Therese M. Mulvey, MD

Southcoast Hospitals Group

Community Practice Perspective

Friday, June 3, 2011

3:00 PM - 4:30 PM
CLINICAL SCIENCE SYMPOSIUM

Personalized Medicine

Location: E354b

CME credit: 1.5

Track(s): Developmental Therapeutics

James L. Gulley, MD, PhD—Chair

National Cancer Institute

3:00 PM Personalized medicine in a phase I clinical trials program: The University of Texas M. D. Anderson Cancer Center Initiative. (Abstract #CRA2500)
A. M. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen, R. Kurzrock

Discussion

3:15 PM Paula M. Fracasso, MD, PhD (Abstract #CRA2500)
University of Virginia

3:30 PM Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). (Abstract #2501)
D. R. Camidge, Y. Bang, E. L. Kwak, A. T. Shaw, A. J. Iafrate, R. G. Maki, B. J. Solomon, S. I. Ou, R. Salgia, K. D. Wilner, D. B. Costa, G. Shapiro, P. LoRusso, P. Stephenson, Y. Tang, K. Ruffner, J. W. Clark

Discussion

3:45 PM Nasser H. Hanna, MD (Abstract #2501)
Indiana University

4:00 PM The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase I study: The START Center experience. (Abstract #2502)
T. Shimizu, A. W. Tolcher, K. P. Papadopoulos, M. Beeram, D. W. Rasco, L. S. Smith, S. Gunn, L. Smetzer, T. A. Mays, B. Kaiser, C. Alvarez, G. L. Mangold, A. Patnaik

Discussion

4:15 PM James L. Gulley, MD, PhD (Abstract #2502)
National Cancer Institute

3:30 PM - 4:45 PM
SPECIAL SESSION

ASCO/Society of Nuclear Medicine (SNM) Joint Session: Molecular Imaging in Cancer Clinical Trials

Location: S100a

CME credit: 1.25

Track(s): Clinical Trials, Special Session

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

Introduction and Overview

David A. Mankoff, MD, PhD—Co-Chair

University of Washington

The Imaging Perspective

Anthony Frank Shields, MD, PhD

Karmanos Cancer Institute/Wayne State University

The Medical Oncology Perspective

Friday, June 3, 2011

**3:30 PM - 6:00 PM
EXTENDED EDUCATION SESSION**

Career Choices: Options in Academia, Private Practice, Industry, and Government

Location: S404

Track(s): Professional Development

John E. Pippen, MD—Chair

Baylor Sammons Cancer Center and Texas Oncology/US Oncology

Hybrid: Academia and Private Practice

Martine J. Piccart-Gebhart, MD, PhD

Jules Bordet Institute

Academia

Johanna C. Bendell, MD

Sarah Cannon Research Institute

Private Practice

Barbara L. McAneny, MD

New Mexico Oncology Hematology Consultants

Hybrid: Public Policy and Private Practice

Sandra J. Horning, MD

Genentech Inc.

Industry

Richard Pazdur, MD

U.S. Food and Drug Administration

Government

3:45 PM - 6:00 PM
EXTENDED EDUCATION SESSIONS

An Update on Biomarkers for the Early Detection of Cancer, Prediction of Prognosis, and as Surrogate Endpoints for Cancer Prevention Trials

Location: E354a

CME credit: 2.25

Track(s): Cancer Prevention/Epidemiology, Cancer Genetics

Dean E. Brenner, MD—Chair

University of Michigan Medical Center

Overview and Fundamental Concepts of Biomarker Development and Validation

Carol J. Fabian, MD

University of Kansas Medical Center

Biomarkers as Surrogate Endpoints for Cancer Prevention Trials: Where Are We?

Sanford D. Markowitz, MD, PhD

Case Western Reserve University

Biomarkers for the Early Detection of Colon Cancer

Harvey I. Pass, MD

New York University School of Medicine

Early Detection and Prognostic Biomarkers for Lung Cancer

Ian Thompson, MD

University of Texas Health Science Center at San Antonio

Prostate Cancer and Prostate-specific antigen: Our “Perfect Biomarker”—Fact or Fantasy?

Robert C. Bast, MD

University of Texas M. D. Anderson Cancer Center

Ovarian Cancer: CA-125 as a Prototype for an Early-diagnosis Biomarker—Do We Have Reasonable Expectations?

Biologic, Clinical, and Psychosocial Correlates at the Interface of Aging and Cancer: Report from the National Institute on Aging (NIA)/National Cancer Institute (NCI) Conference on Geriatric Oncology Research to Improve Clinical Care

Location: S100bc

CME credit: 2.25

Track(s): Geriatric Oncology

William Dale, MD, PhD—Chair

The University of Chicago Medical Center

Psychosocial Factors at the Interface of Cancer and Aging

Arti Hurria, MD

City of Hope

Improving Geriatric Oncology Clinical Care through Research

Harvey Jay Cohen, MD

Duke University Medical Center

Biologic Factors at the Interface of Cancer and Aging

Supriya Gupta Mohile, MD, MS

University of Rochester Medical Center

Clinical Factors at the Interface of Cancer and Aging

FRIDAY

Friday, June 3, 2011

Second Malignant Neoplasms: Epidemiology, Genetics, and Risk Prediction

Location: E353

CME credit: 2.25

Track(s): Cancer Prevention/Epidemiology, Cancer Genetics, Patient and Survivor Care

Lois B. Travis, MD, ScD—Chair

University of Rochester School of Medicine and Dentistry

Epidemiology of Second Malignant Neoplasms: An Overview

Sophie D. Fossa, MD

Oslo University Hospital, The Norwegian Radium Hospital

Second Malignant Neoplasms in Survivors of Testicular Cancer

M. Eileen Dolan, PhD

The University of Chicago

Genomics and Late Effects of Treatment: Cisplatin as a Paradigm

Margaret R. Spitz, MD

University of Texas M. D. Anderson Cancer Center

Risk Prediction Models for Second Cancers: Synopsis of Ongoing Research and Genetic Predictors

Andrea K. Ng, MD, MPH

Brigham and Women's Hospital and Harvard Medical School

Screening for Second Cancers: Evidence-based Recommendations to Date

Scott Michael Lippman, MD

University of Texas M. D. Anderson Cancer Center

Chemoprevention and Interventional Strategies in Second Cancers: A Review of Evidence-based Recommendations

4:00 PM - 6:00 PM
EXTENDED EDUCATION SESSION

Grant Writing Workshop II: Improving Your Grant Writing Skills (Mock Study Section and Small Group Discussions)

Location: S106

CME credit: 2

Track(s): Professional Development, Clinical Trials

Bruce E. Johnson, MD—Chair
Dana-Farber Cancer Institute

Eric Jay Small, MD
University of California, San Francisco
Small Group Roundtable Discussant

Alex A. Adjei, MD, PhD
Roswell Park Cancer Institute
Small Group Roundtable Discussant

Fabrice Andre, MD, PhD
Institut Gustave-Roussy
Small Group Roundtable Discussant

Dawn L. Hershman, MD, MS
Columbia University Medical Center
Small Group Roundtable Discussant

J. Jack Lee, PhD, DDS
University of Texas M. D. Anderson Cancer Center
Small Group Roundtable Discussant

Wells A. Messersmith, MD
University of Colorado Cancer Center
Small Group Roundtable Discussant

Gary K. Schwartz, MD
Memorial Sloan-Kettering Cancer Center
Small Group Roundtable Discussant

Lillian L. Siu, MD
Princess Margaret Hospital
Small Group Roundtable Discussant

Friday, June 3, 2011

**4:30 PM - 5:45 PM
EDUCATION SESSIONS**

Cancer Predisposition in Children, Adolescents, and Young Adults

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology, Cancer Genetics

David Malkin, MD—Chair

The Hospital for Sick Children, University of Toronto

Familial Cancer Syndromes: Moving past p53

Stephen J. Chanock, MD

National Cancer Institute

Cancer Susceptibility: Methods for Identifying the Key Mutations

Kenan Onel, MD, PhD

The University of Chicago Medical Center

Genetic Predisposition to Secondary Cancers in Survivors of Pediatric Cancer

Updates in Triple-negative Breast Cancer

Location: Hall D1

CME credit: 1.25

Track(s): Breast Cancer, General Oncology, Tumor Biology

Lisa A. Carey, MD—Chair

University of North Carolina at Chapel Hill

Clinical and Molecular Biology of Triple-negative Breast Cancer

William Foulkes, PhD

McGill University

Triple-negative Disease: Basal-like and BRCAness Findings and Implications of Epidemiologic Risk Factor Studies

Andrew Nicholas James Tutt, PhD, MBChB

Guy's Hospital Breakthrough Breast Cancer Research Unit, Guy's Hospital

PARP Inhibitors and DNA Damage Repair as a Therapeutic Target

4:30 PM - 5:45 PM
MEET THE PROFESSOR SESSION

**Cancer Epidemiology for the Clinical Oncologist: When Should We Have
Confidence in Studies and What Should We Tell Our Patients and Colleagues?
(M03)—Ticketed Session**

Location: E451a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology

Christine B. Ambrosone, PhD

Roswell Park Cancer Institute

Friday, June 3, 2011

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Liver-directed Therapy in Colorectal Cancer: What Are the Options and When Should They Be Used? (C01)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer

Alan Paul Venook, MD—Chair

University of California, San Francisco

Under- and Overutilization of Liver-focused Treatments: The Medical Oncologist Perspective of When to Use and When Not to Use

Kenneth Tanabe, MD

Massachusetts General Hospital Cancer Center

Which Patients Should Undergo Hepatic Metastasectomy and Which Should Not?

Stephen Barnett Solomon, MD

Memorial Sloan-Kettering Cancer Center

Radiofrequency Ablation, Cryoablation, Stereotactic Radiosurgery, External Beam Radiation: Lots of Choices, but Which to Use?

7:30 AM - 8:15 AM
EDUCATION SESSION

How to Navigate the Annual Meeting (Fellows and Junior Faculty Only)

Location: S501

Track(s): Professional Development

John E. Pippen, MD—Chair

Baylor Sammons Cancer Center and Texas Oncology/US Oncology

Clifford Hudis, MD

Memorial Sloan-Kettering Cancer Center

Saturday, June 4, 2011

8:00 AM - 9:15 AM
EDUCATION SESSIONS

ASCO/Children's Oncology Group (COG) Joint Session: Designing Trials to Test Novel Treatment Strategies for "Go" or "No Go" Decisions

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology, Clinical Trials, Special Session

Mark J. Ratain, MD—Chair

The University of Chicago

Designing Early-phase Studies with "Go" versus "No Go" Rules

Frank M. Balis, MD

The Children's Hospital of Philadelphia

Early-phase Pediatric Studies: Identifying Valid Endpoints

Susan Blaney, MD

Texas Children's Cancer Center

Challenges of Conducting Early-phase Studies in Pediatrics

Biomarkers in Genitourinary Cancers: Relevance to Clinical Practice

Location: Hall D2

CME credit: 1.25

Track(s): Genitourinary Cancer, Clinical Trials, Tumor Biology

Nancy Ann Dawson, MD—Chair

Georgetown University Hospital Lombardi Comprehensive Cancer Center

Circulating Tumor Cells in Prostate Cancer

Mark Garzotto, MD

Portland Veterans Affairs Medical Center

Prostate-specific Antigen Kinetics in Biochemically Recurrent Prostate Cancer (Castration-naive or -resistant): Does It Guide Management?

Kimryn Rathmell, MD, PhD

University of North Carolina at Chapel Hill

Renal Cell Cancer Biomarkers: Relevance to Clinical Practice

Contemporary Topics in Ovarian Cancer Management

Location: E354a

CME credit: 1.25

Track(s): Gynecologic Cancer, Cancer Genetics, General Oncology

Gottfried E. Konecny, MD—Chair

University of California, Los Angeles

Molecular Characterization of Ovarian Cancer: Where Are We Headed?

Deborah Kay Armstrong, MD

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Doctor, I'm Confused: What Is the Best Treatment for My Advanced Ovarian Cancer?

Martin Eric Gore, PhD

Royal Marsden Hospital

Bevacizumab Incorporation into Ovarian Cancer Treatment: Practical Considerations

Etiology and Treatment of HPV-related Oropharyngeal Cancer

Location: E354b

CME credit: 1.25

Track(s): Head and Neck Cancer

Andy Trotti, MD—Chair

H. Lee Moffitt Cancer Center and Research Institute

Current Therapy and Modifications in HPV-related Oropharyngeal Cancer

Sara Pai, MD, PhD

The Johns Hopkins University School of Medicine

Biology and Immune Therapy of HPV-related Oropharyngeal Cancer

Maura L. Gillison, MD, PhD

The Ohio State University

Epidemiology and Etiology of HPV-related Oropharyngeal Cancer

Identification of Molecular Signatures for Classification, Response, Outcomes, and Novel Targets

Location: S406

CME credit: 1.25

Track(s): Sarcoma

Paul S. Meltzer, MD, PhD—Chair

National Cancer Institute

Identification of Novel Targets through Genomics, Proteomics, and Metabolomics

Matt Van De Rijn, MD, PhD

Stanford University

Molecular Signatures for Classification, Response, and Outcomes

George D. Demetri, MD

Dana-Farber Cancer Institute

Molecular Translation: Bench to Bedside in Sarcomas

PARP Inhibitors, DNA Repair, and Beyond: Theory Meets Reality in the Clinic

Location: S100a

CME credit: 1.25

Track(s): Tumor Biology, Developmental Therapeutics

Michael B. Kastan, MD, PhD—Chair

St. Jude Children's Research Hospital

DNA Damage Response: Opportunities for Therapeutic Targeting

Elizabeth R. Plummer, MD, DPhil

Northern Centre for Cancer Care

Development of PARP Inhibitors and Potential Roles in Chemotherapy Potentiation

Judy Ellen Garber, MD, MPH

Dana-Farber Cancer Institute

Clinical Development of PARP Inhibitors: Current Status

Saturday, June 4, 2011

Running an Oncology Practice in 2011: Finance, Resourcing, and Ancillary Opportunities

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology

Dee Anna Smith—Chair

Sarah Cannon Research Institute

How to Understand the Financial Position of Your Practice: Financial Statements 101

Jeffrey Patton, MD

Tennessee Oncology

How Do You Assess and Implement Ancillary Services That Will Enhance Your Practice?

John Emmett Hennessy, CMPE

Kansas City Cancer Center

How Do You Manage the Resources in Your Office and How Does Technology Enable Efficient Formulary Management and Related Reimbursement Issues?

SATURDAY

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Mechanisms of Metastasis (M04)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Breast Cancer

Larry Norton, MD

Memorial Sloan-Kettering Cancer Center

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

How to Manage Challenging Cases of Urothelial Cancer (C02)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Genitourinary Cancer, Geriatric Oncology

Joaquim Bellmunt, MD, PhD—Chair

University Hospital del Mar-IMIM

Treatment Options for a Patient with Locally Advanced but Unresectable Bladder Cancer and for a Patient with Muscle-invasive but with Mixed Histology or Predominantly Nontransitional Cell

Theresa M. Koppie, MD

University of California, Davis

Palliative Surgery in Patients with Advanced Bladder Cancer and Management of Upper Tract Tumors

Daniel Peter Petrylak, MD

Columbia University College of Physicians and Surgeons

Systemic Therapy for Select Patient Subsets: Renal Dysfunction, Impaired Performance Status, Frail Elderly, or Platinum-refractory Disease

Saturday, June 4, 2011

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Emerging Novel Targets for Lung Cancer

Location: Hall D1

CME credit: 1.5

Track(s): Lung Cancer

George R. Simon, MD—Co-Chair

Medical University of South Carolina

Neeta Somaiah, MD—Co-Chair

Fox Chase Cancer Center

8:00 AM **An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7500)**

K. Wong, M. Koczywas, J. W. Goldman, E. H. Paschold, L. Horn, J. M. Lufkin, R. K. Blackman, F. Teofilovici, G. Shapiro, M. A. Socinski

Discussion

8:15 AM Suresh S. Ramalingam, MD (Abstract #7500)

Winship Cancer Institute of Emory University
Heat Shock Protein Inhibitors: Shock and Awe?

8:30 AM **Open-label, randomized multicenter phase II clinical trial of a toll-like receptor-2 (TLR2) agonist mycobacterium w (Cadi-05) in combination with paclitaxel plus cisplatin versus paclitaxel plus cisplatin in advanced non-small cell lung cancer (NSCLC). (Abstract #7501)**

C. P. Belani, D. Desai, B. M. Khamar, for the Cadi-05 Investigators Study Group

Discussion

8:45 AM Raffit Hassan, MD (Abstract #7501)

National Cancer Institute
Chemoimmunotherapy: A Light in the Darkness?

9:00 AM **Randomized phase III placebo-controlled trial of carboplatin/paclitaxel (CP) with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small cell lung cancer (NSCLC). (Abstract #7502)**

P. Lara, J. Douillard, K. Nakagawa, J. Von Pawel, M. J. McKeage, I. Albert, G. Losonczy, M. Reck, D. S. Heo, X. Fan, A. Fandi, G. Scagliotti

Discussion

9:15 AM Jean-Charles Soria, MD, PhD (Abstract #7502)

Institut Gustave-Roussy
Vascular Disrupting Agents: Is There a Future?

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

**Patient and Survivor Care and Health Services Research Session:
Survivorship—Care Plans, Quality of Care, and Barriers to Care**

Location: S100bc

CME credit: 1.5

Track(s): Patient and Survivor Care, Health Services Research

Wendy Demark-Wahnefried, PhD, RD—Co-Chair

University of Alabama at Birmingham

Lynne I. Wagner, PhD—Co-Chair

Northwestern University

8:00 AM Quality of care for comorbid conditions during the transition to survivorship. (Abstract #9004)

C. F. Snyder, K. D. Frick, R. J. Herbert, A. L. Blackford, B. A. Neville, A. C. Wolff, M. A. Carducci, C. Earle

8:15 AM Results of a multicenter randomized trial to evaluate a survivorship care plan for breast cancer survivors. (Abstract #9005)

E. Grunfeld, M. N. Levine, J. A. Julian, G. R. Pond, E. Maunsell, A. Folkes, S. F. Dent, A. Joy, L. F. Paszat, K. I. Pritchard, G. A. Porter, D. Rayson, A. Robidoux, S. Smith, J. Sussman, L. Provencher, J. Wiernikowski, J. J. Sisler, FUII Trial Investigators, Ontario Clinical Oncology Group

Discussion

8:30 AM Lynne I. Wagner, PhD (Abstract #CRA9006)
Northwestern University

8:45 AM Barriers in providing breast and colorectal cancer survivorship care: Perceptions of U.S. primary care physicians (PCPs) and medical oncologists (MOs). (Abstract #CRA9006)

K. S. Virgo, C. C. Lerro, C. N. Klabunde, C. Earle, P. A. Ganz

9:00 AM Long-term consequences of treatment on paid work after diagnosis of breast cancer. (Abstract #9007)

R. Jagsi, S. T. Hawley, P. Abrahamse, J. J. Griggs, A. S. Hamilton, S. J. Katz

Discussion

9:15 AM Wendy Demark-Wahnefried, PhD, RD (Abstract #9007)
University of Texas M. D. Anderson Cancer Center

Saturday, June 4, 2011

**8:00 AM - 11:00 AM
SPECIAL SESSION**

Designing Clinical Trials for Older Patients: Nuts and Bolts

Location: S106

CME credit: 3

Track(s): Geriatric Oncology, Clinical Trials, Professional Development

Harvey Jay Cohen, MD—Co-Chair

Duke University Medical Center

Hyman Bernard Muss, MD—Co-Chair

University of North Carolina Lineberger Comprehensive Cancer Center

Martine Extermann, MD

H. Lee Moffitt Cancer Center & Research Institute

Defining Eligibility Criteria: Healthy, Vulnerable, Frail

Lazzaro Repetto, MD, PhD

Istituto Nazionale Riposo E Cura Per Anziani

Clinical Trial Recruitment

Heidi D. Klepin, MD, MS

Wake Forest University

Acute Myeloid Leukemia: Bringing Theory to Practice

William Thomas Barry, PhD

Duke University Medical Center

Novel Design of Clinical Trials for Vulnerable Patients

SATURDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Central Nervous System Tumors

Location: Hall A

Track(s): Central Nervous System Tumors

- Brd. 1A Objective responses to chemotherapy in recurrent glioma: A prospective analysis from the German Glioma Network. (Abstract #2037)**
O. Baehr, B. Hentschel, E. Hattingen, S. Nussbaum, H. Berger, M. Tatagiba, J. Tonn, O. Schnell, M. Simon, T. Reithmeier, D. Krex, T. Pietsch, G. Reifenberger, O. Heese, M. Weller, J. Steinbach, M. Loeffler, German Glioma Network
- Brd. 1B Phase II study of dose-intense temozolomide in recurrent glioblastoma. (Abstract #2038)**
S. Hammond, A. D. Norden, G. J. Lesser, J. Drappatz, C. E. Fadul, T. Batchelor, E. C. Quant, R. Beroukhim, A. Muzikansky, A. S. Ciampa, L. M. Doherty, D. C. LaFrankie, S. Ruland, C. A. Bochacki, K. Griffin, M. Gerard, C. Sceppea, M. R. Rosenfeld, P. Y. Wen
- Brd. 1C Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. (Abstract #2039)**
L. Nayak, L. E. Abrey, J. Drappatz, M. R. Gilbert, D. A. Reardon, K. Lamborn, P. Y. Wen, M. Prados, L. M. DeAngelis, A. M. Omuro
- Brd. 1D Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. (Abstract #2040)**
A. D. Norden, S. Hammond, J. Drappatz, S. Phuphanich, D. A. Reardon, E. Wong, S. R. Plotkin, G. J. Lesser, J. J. Raizer, T. Batchelor, E. C. Quant, R. Beroukhim, T. J. Kaley, A. Muzikansky, A. S. Ciampa, L. M. Doherty, K. H. Smith, M. Gerard, C. Sceppea, P. Y. Wen
- Brd. 1E AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome. (Abstract #2041)**
B. Adamo, A. M. Deal, C. Livasy, E. Burrows, K. Fritchie, K. L. Blackwell, E. P. Hamilton, J. Geradts, L. Thorne, A. Ugolkov, C. R. Miller, M. G. Ewend, L. A. Carey, C. M. Perou, V. L. Cryns, C. K. Anders
- Brd. 1F Glioma-associated antigens associated with prolonged survival in a phase I study of ICT-107 for patients with newly diagnosed glioblastoma. (Abstract #2042)**
S. Phuphanich, C. J. Wheeler, J. Rudnick, M. Mazer, M. Nuno, X. Fan, J. Bender, E. S. Hawkins, K. L. Black, J. Yu
- Brd. 1G Phase I study of aflibercept (VEGF Trap) and temozolomide in newly diagnosed, high-grade glioma. (Abstract #2043)**
J. F. De Groot, T. Cloughesy, F. S. Lieberman, S. M. Chang, A. M. Omuro, J. Drappatz, T. Batchelor, L. M. DeAngelis, M. R. Gilbert, W. A. Yung, J. D. Fisher, X. Ye, K. Lamborn, A. P. Chen, S. A. Grossman, M. Prados, P. Y. Wen
- Brd. 2A Circulating endothelial cells and progenitors in recurrent high-grade gliomas treated with bevacizumab and irinotecan. (Abstract #2044)**
M. Eoli, A. Calleri, L. Cuppini, E. Anghileri, S. Pellegatta, E. Prodi, M. Bruzzone, F. Bertolini, G. Finocchiaro
- Brd. 2B Effect of standard therapy on lymphocyte subsets and cytokines in newly diagnosed high-grade gliomas (HGG). (Abstract #2045)**
A. S. Balmanoukian, S. A. Grossman, C. Thoburn, F. Kos, M. Holdhoff, A. Hess
- Brd. 2C A phase II trial of PTK787/ZK 222584 (PTK787) in recurrent high-grade meningioma. (Abstract #2046)**
S. A. Grimm, M. C. Chamberlain, J. Chandler, K. Muro, L. Rice, K. McCarthy, A. Rademaker, I. B. Helenowski, S. K. Johnston, M. M. Mrugala, J. J. Raizer

Saturday, June 4, 2011

- Brd. 2D** **Vascular hemodynamic profiles of vestibular schwannomas and glioblastoma using MRI. (Abstract #2047)**
S. R. Plotkin, D. Jennings, K. Mouridsen, K. E. Emblem, A. G. Sorensen
- Brd. 2E** **FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM). (Abstract #2048)**
C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. Omuro
- Brd. 2F** **CD44 as a prognostic and predictive marker for GBM. (Abstract #2049)**
B. D. Vaillant, K. Bhat, E. P. Sulman, V. Balasubramanian, S. Wang, K. D. Aldape, H. Colman
- Brd. 2G** **A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). (Abstract #2050)**
J. Drappatz, J. J. Raizer, D. Schiff, A. S. Chi, T. Batchelor, S. M. Snodgrass, E. C. Quant, A. D. Norden, R. Beroukhim, S. A. Grimm, L. M. Doherty, A. S. Ciampa, D. C. LaFrankie, S. Ruland, M. Gerard, S. Hammond, P. Y. Wen
- Brd. 3A** **Concurrent temozolomide and radiation as the initial treatment for anaplastic glioma. (Abstract #2051)**
C. Tham, S. See, S. Tan, W. Ng, K. H. Lim, J. Thomas, E. Chua
- Brd. 3B** **Randomized phase II study of neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed primary glioblastoma multiforme. (Abstract #2052)**
K. F. Hofland, S. Hansen, M. Sorensen, H. P. Schultz, A. Muhic, S. Engelholm, A. Ask, C. Kristiansen, C. Thomsen, H. Skovgaard Poulsen, U. N. Lassen
- Brd. 3C** **Prognostic factors in patients with WHO grade 3 gliomas: The Cleveland Clinic experience. (Abstract #2053)**
N. Hashemi-Sadraei, H. S. Bawa, A. Satra, G. Rahmathulla, M. Patel, G. Stevens, T. M. Tekautz, L. A. Rybicki, D. M. Peereboom, J. H. Suh, R. Weil, M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia
- Brd. 3D** **Phase I study of sorafenib in combination with radiation therapy and temozolomide for the first-line treatment of patients with high-grade glioma. (Abstract #2054)**
A. F. Hottinger, A. Ben Aissa, A. Bodmer, D. Squiban, N. Dunkel, N. Maradan, M. I. Vargas, D. C. Weber, E. Brendel, P. Dietrich
- Brd. 3E** **Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. (Abstract #2055)**
E. Lou, D. A. Reardon, K. Peters, A. Desjardins, J. E. Herndon, A. D. Coan, S. G. Turner, A. L. Sumrall, L. Bailey, H. S. Friedman, J. J. Vredenburgh
- Brd. 3F** **Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. (Abstract #2056)**
D. A. Bota, Z. Eroglu, D. A. Reardon, B. D. Fu, J. Norfleet, A. Desjardins, M. E. Linskey, K. Peters, H. S. Friedman, J. J. Vredenburgh
- Brd. 3G** **Temozolomide-based chemoradiation in naive pure and mixed anaplastic astrocytoma: Long-term results of a phase II study. (Abstract #2057)**
S. Chiesa, G. Chiloiro, S. Manfrida, A. Mangiola, G. R. D'Agostino, G. Mantini, A. Albanese, P. De Bonis, C. Anile, M. Balducci
- Brd. 3H** **Prognostic factors in newly diagnosed glioblastoma: Have we missed gender? (Abstract #2058)**
E. Franceschi, A. Tosoni, S. Bartolini, L. Scopece, L. Lombardo, R. Poggi, V. Mazzocchi, L. La Torre, M. Ermani, A. A. Brandes
- Brd. 4A** **Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma. (Abstract #2059)**
F. Bach, M. Westphal, OSAG-101 Study Group

- Brd. 4B Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: A pooled analysis. (Abstract #2060)**
A. Paccapelo, I. Lollo, S. Scoccianti, B. Detti, G. Silvano, M. Fabrini, F. Perrone, G. Savio, S. Cascinu
- Brd. 4C Use of exosome analysis to reveal glioma-specific genetic changes in patient serum. (Abstract #2061)**
B. Carter, F. Hochberg, X. Breakefield, L. Balaj, S. Sivaraman, W. Curry, S. N. Kalkanis, L. Loguidice, L. M. Russo, M. Noerhelm, J. Skog
- Brd. 4D Neurotoxicity of intra-CSF liposomal cytarabine in the treatment of leptomeningeal metastases. (Abstract #2062)**
M. C. Chamberlain, S. K. Johnston
- Brd. 4E Glioblastoma in the elderly: Treatment planning, toxicity, and efficacy in an ambulatory practice. (Abstract #2063)**
W. P. Mason, Z. Lwin, D. MacFadden, A. AL-Zahrani, N. Laperriere, C. Menard, B. Millar, A. Sahgal, C. Massey, L. E. Coate
- Brd. 4F A phase I trial of laromustine (VNP40101M) and temozolomide for patients with malignant gliomas in first relapse or progression. (Abstract #2064)**
J. J. Raizer, L. Rice, A. Rademaker, J. Chandler, K. Muro, R. M. Levy, S. A. Grimm
- Brd. 4G A mathematical model of diffuse low-grade gliomas treated with PCV chemotherapy. (Abstract #2065)**
F. Ducray, M. Peyre, D. Ricard, B. Cajavec-Bernard, E. Grenier, M. Tod, V. Calvez, D. Frappaz, M. Sunyach, A. Vasiljevic, J. Pallud, S. Cartalat-Carel, J. Honnorat, B. Ribba
- Brd. 4H Glioblastoma in the elderly: The Cleveland Clinic experience (1992–2010). (Abstract #2066)**
H. S. Bawa, N. Hashemi-Sadraei, J. H. Suh, G. Stevens, G. Rahmathulla, S. T. Chao, T. M. Tekautz, P. Elson, D. M. Peereboom, L. Angelov, R. Weil, M. A. Vogelbaum, G. Barnett, M. S. Ahluwalia
- Brd. 5A The effect of surgery in determining pseudoprogression and predicting outcome in adults with glioblastoma. (Abstract #2067)**
I. Melguizo, K. R. Hess, D. Blas-Boria, J. Bruner, N. Guha-Thakurta, V. K. Puduvalli
- Brd. 5B Survival after recurrence of medulloblastoma in the contemporary era. (Abstract #2068)**
C. Koschmann, K. L. Schmidt, J. R. Geyer, S. Leary
- Brd. 5C Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). (Abstract #2069)**
E. C. Quant, T. Batchelor, A. B. Lassman, D. Schiff, T. J. Kaley, E. Wong, T. Mikkelsen, J. Drappatz, A. D. Norden, R. Beroukhim, S. E. Weiss, B. M. Alexander, C. Sceppa, M. Gerard, S. D. Hallisey, C. A. Bochacki, K. H. Smith, A. Muzikansky, P. Y. Wen
- Brd. 5D A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). (Abstract #2070)**
A. Desjardins, D. A. Reardon, J. J. Vredenburgh, K. Peters, M. Trikha, J. James, M. Gardner, A. Brickhouse, J. E. Herndon, H. S. Friedman
- Brd. 5E Novel use of MR spectroscopy in detecting CSF lactate for diagnosis of neoplastic meningitis. (Abstract #2071)**
C. L. Weston, O. Zalatimo, J. Sheehan, R. Harbaugh, D. A. Bota, A. Shedden, M. J. Glantz
- Brd. 5F Clinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastoma. (Abstract #2072)**
A. S. Chi, E. L. Kwak, J. W. Clark, D. L. Wang, D. N. Louis, A. J. Iafrate, T. Batchelor

Saturday, June 4, 2011

- Brd. 5G** **Concurrent, 3-times daily ultrafractionated radiation therapy and temozolomide for newly inoperable glioblastoma: TEMOFrac—A phase II trial. (Abstract #2073)**
P. D. Beauchesnes, G. Faure, G. Noel, T. Schmitt, L. Martin, L. Taillandier, C. D. Carnin
- Brd. 5H** **Efficacy of radiation therapy on epileptic seizures of grade 2 and 3 gliomas: A retrospective study. (Abstract #2074)**
R. Ruda, E. Trevisan, U. Magliola, C. Mantovani, U. Ricardi, R. Soffietti
- Brd. 6A** **Value of CA 15–3 detection in cerebrospinal fluid (CSF) of breast cancer leptomeningeal metastases. (Abstract #2075)**
S. Salingue, M. Giroi, I. Rodrigues, S. Taillibert, N. Kotecki, F. Zairi, M. Baranzelli, M. Faivre-Pierret, P. Devos, J. Bonnetterre, F. Dubois, E. Le Rhun
- Brd. 6B** **Prognostic relevance of promoter methylation-associated loss of ID4 expression in glioblastoma multiforme. (Abstract #2076)**
M. Martini, T. Cenci, N. Montano, V. Cesarini, R. Pallini, L. Larocca
- Brd. 6C** **Stereotactic volumetric resection, intracavitary carmustine wafers, and radiation therapy for brain metastases: The Moffitt Cancer Center experience. (Abstract #2077)**
S. Brem, R. Sampath, D. Yu, A. Staller, M. Obadia, M. G. Ewend
- Brd. 6D** **IDH mutation status impact on in vivo hypoxia biomarkers expression: New insights from a clinical, nuclear imaging, and immunohistochemical study in 34 patients with glioma. (Abstract #2078)**
P. Metellus, C. Colini, D. Taieb, E. Guedj, I. Nanni-Metellus, B. Coulibaly, C. Colavolpe, S. Fuentes, H. Dufour, M. Barrie, O. L. Chinot, L. Ouafik, D. Figarella-Branger
- Brd. 6E** **Is cerebrospinal fluid cytology a useful test? (Abstract #2079)**
C. M. Zoccoli, O. Zalatimo, M. J. Glantz
- Brd. 6F** **Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A phase II study. (Abstract #2080)**
F. Zustovich, L. Landi, G. Lombardi, L. Galli, C. Porta, D. Amoroso, A. Fontana, M. Andreuccetti, C. Galli, A. Falcone, V. Zagonel
- Brd. 6G** **Feasibility pilot of attenuated maintenance chemotherapy for adolescents and adults with newly diagnosed localized medulloblastoma and other primitive neuroectodermal tumors. (Abstract #2081)**
J. N. Dagrì, A. Evans, J. Torkildson, J. Portnow, L. S. Ashby, B. Zakotnik, R. J. Brown, G. Dhall, J. L. Finlay
- Brd. 6H** **Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. (Abstract #2082)**
K. C. Cuneo, A. R. Cabrera, J. H. Sampson, K. J. Allen, J. J. Vredenburg, K. Peters, Z. Chang, J. E. Herndon, A. Desjardins, D. A. Reardon, J. Kirkpatrick
- Brd. 7A** **Chemotherapy plus concomitant low-dose fractionated radiotherapy as second-line treatment for recurrent or progressive glioblastoma after temozolomide-based chemoradiation: A pilot study. (Abstract #2083)**
G. R. D'Agostino, B. Diletto, S. Manfrida, A. Mangiola, S. Chiesa, L. De Filippo, V. Frascino, F. Miccichè, C. Anile, M. Balducci
- Brd. 7B** **Use of Tegwondo, a near-continuous temozolomide regimen, in high- and low-grade gliomas. (Abstract #2084)**
H. M. Strik, H. C. Bock, C. Marosi
- Brd. 7C** **Baseline and long-term cognition and neuroimaging in patients with primary CNS lymphoma (PCNSL) treated with enhanced chemotherapy (CHT) delivery. (Abstract #2085)**
N. D. Doolittle, M. A. Lubow, D. F. Kraemer, E. Dosa, N. A. Hedrick, R. Tyson, C. Lacy, L. M. Maron, R. W. Butler, E. A. Neuwelt

SATURDAY

- Brd. 7D** **Bevacizumab and irinotecan in patients with recurrent glioblastoma (GBM): Results of a retrospective cohort study of the OMIT Bretagne and Pays de la Loire. (Abstract #2086)**
F. Grude, M. Campone, J. Frenel, P. Soulie, E. Vauleon, Y. Hadjarab, G. Ganem, F. Denis, J. Egretteau, A. Lortholary, M. Porneuf, H. Simon, P. DAM Hieu, V. Klein, B. Dominique, P. Deguiral, H. Desclos, P. Menei, S. Traoré
- Brd. 7E** **Functional and survival effect of bevacizumab and irinotecan administered at recurrence in a cohort of patients with GBM. (Abstract #2087)**
E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, A. Loundou, O. L. Chinot
- Brd. 7F** **Phase II study of verubulin (MPC-6827) for the treatment of subjects with recurrent glioblastoma naive to treatment with bevacizumab. (Abstract #2088)**
L. J. Kim, M. C. Chamberlain, J. Zhu, J. J. Raizer, S. A. Grimm, S. Phuphanich, C. E. Fadul, S. Rosenfeld, A. H. Balch, C. C. Pope, M. Brulotte, A. A. Beelen, L. D. Recht
- Brd. 7G** **Prospective follow-up of 96 patients with breast cancer with leptomeningeal metastasis recruited from 2007 to 2010. (Abstract #2089)**
E. Le Rhun, N. Kotecki, F. Zairi, I. Rodrigues, A. Mailliez, M. Baranzelli, M. Fèvre-Pierret, P. Devos, J. Cazin, J. Bonnetterre, F. Dubois
- Brd. 8A** **Radiographic pattern of progression of recurrent GBM treated with bevacizumab with or without irinotecan. (Abstract #2091)**
P. Dory-Lautrec, E. Tabouret, M. Barrie, C. Boucard, M. Matta, D. Autran, N. Girard, O. L. Chinot
- Brd. 8B** **Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide (TMZ) therapy for high-grade gliomas (HGG) in Colombia (RedLANO registry). (Abstract #2092)**
L. D. Ortiz, A. F. Cardona, C. E. Fadul, A. Londono, H. A. Becerra, E. Jimenez-Hakim, C. J. Yepes, H. Carranza, R. E. Bruges Maya, C. J. Castro, C. A. Vargas
- Brd. 8C** **Prognostic factors in elderly patients with grade 3 gliomas. (Abstract #2093)**
A. Satra, N. Hashemi-Sadraei, H. S. Bawa, D. M. Peereboom, G. Stevens, L. A. Rybicki, J. H. Suh, M. A. Vogelbaum, R. Weil, G. Barnett, M. S. Ahluwalia
- Brd. 8D** **Photodynamic therapy (PDT) in the multidisciplinary treatment of brain tumors: A feasibility study. (Abstract #2094)**
M. S. Gonzalez, V. Vanaclocha, I. Azinovic, J. Rebollo, R. Cañon, E. Calvo, A. Brugarolas
- Brd. 8E** **The role of plasma GFAP as a biomarker for glioblastoma. (Abstract #2095)**
H. Husain, W. Savage, A. Everett, X. Ye, C. Blair, K. E. Romans, C. Bettegowda, P. Burger, S. A. Grossman, M. Holdhoff
- Brd. 8G** **O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma: Analysis on first and following surgeries. (Abstract #2097)**
F. Bertolini, C. Baraldi, E. Zunarelli, A. Valentini, R. Depenni, A. Falasca, F. Bertoni, F. Cavalleri, A. Chiari, A. Fontana, P. F. Conte, G. Pinna, Gruppo Neuro-Oncologico Modena (GNO-MO)
- Brd. 8H** **Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly diagnosed glioblastoma multiforme (GBM). (Abstract #2098)**
J. J. Vredenburgh, A. Desjardins, D. A. Reardon, K. Peters, J. Kirkpatrick, A. D. Coan, L. Bailey, D. Janney, C. Lu, H. S. Friedman
- Brd. 9A** **A review of how antineoplastic treatments impact the sexuality, fertility, and sexual function of adult patients with brain cancer: Implications for real-time treatment planning. (Abstract #2099)**
E. M. Dunbar, S. Savona, N. Ferree, P. A. Pumphrey

Saturday, June 4, 2011

Brd. 9B Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies. (Abstract #2100)
V. Subbiah, J. M. Slopis, D. S. Hong, L. S. Angelo, I. E. McCutcheon, R. Kurzrock

Brd. 9C A comparative study of pediatric CNS tumor activity as assessed by [18F]-FDG PET imaging and proton magnetic resonance spectroscopic imaging. (Abstract #2101)
S. J. Hipp, E. A. Steffen-Smith, P. Herscovitch, N. J. Patronas, J. M. Solomon, R. Bent, S. M. Steinberg, K. E. Warren

SATURDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Colorectal) Cancer

Location: Hall A

Track(s): Gastrointestinal (Colorectal) Cancer

- Brd. 10A** **The biology of early-onset colorectal cancer: An examination of tumor markers, pathology, and survival in a large cohort of patients. (Abstract #3537)**
S. A. Khan, M. Morris, K. Idrees, M. Gimbel, S. Rosenberg, Z. Zeng, J. Shia, M. P. La Quaglia, P. Paty
- Brd. 10B** **Colorectal cancer cases with de novo germ-line mutations in *MLH1*, *MSH2*, and *MSH6* from the Colon Cancer Family Registry. (Abstract #3538)**
A. Win, M. A. Jenkins, D. D. Buchanan, J. P. Young, S. N. Thibodeau, J. L. Hopper, N. M. Lindor
- Brd. 10C** **Incidence and characteristics of BRAF V600E mutation in colorectal cancer (CRC) with mismatch repair (MMR) protein defect due to loss of MLH1: A prospective evaluation of 104 consecutive patients. (Abstract #3539)**
S. A. Mahesh, E. Hanna, M. Khan, P. Ravichandran, F. Slezak
- Brd. 10D** **The effect of screening on stage of disease and tumor characteristics in patients with operable colorectal cancer. (Abstract #3540)**
M. J. Proctor, E. Chughton, C. H. Richards, D. C. Mcmillan, P. G. Horgan
- Brd. 10E** **Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (Abstract #3541)**
M. R. Mahoney, J. A. Sloan, J. M. Hubbard, H. Liu, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. G. Nair, D. J. Sargent, S. R. Alberts
- Brd. 10F** **The final results of the SWOG S9304 phase III intergroup trial's pharmacogenetic analysis: Association of polymorphisms with survival and toxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation (RT). (Abstract #3542)**
P. M. Wilson, P. O. Bohanes, C. J. Rankin, J. K. Benedetti, C. M. Ulrich, S. R. Smalley, K. W. Makar, W. Zhang, T. Winder, Y. Ning, A. Gerger, L. Benhaim, R. El-Khoueiry, M. J. Labonte, C. D. Blanke, H. Lenz
- Brd. 10G** **Accuracy of endorectal ultrasonography in evaluation of response to chemoradiation in locally advanced rectal cancer. (Abstract #3543)**
B. Farnault, L. Moureau-Zabotto, C. de Chaisemartin, M. Giovannini, G. Monges, J. Delpero, P. Viens, M. Resbeut
- Brd. 10H** **Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer. (Abstract #3544)**
M. Cukier, H. Soliman, A. Smith, S. Wong
- Brd. 11A** **Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks. (Abstract #3545)**
G. J. Chang, I. Park, Y. You, C. Hu, S. R. Hamilton, C. Eng, B. W. Feig, P. Das, S. Krishnan, C. H. Crane, S. T. Nguyen, M. A. Rodriguez-Bigas, J. M. Skibber
- Brd. 11B** **Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07). (Abstract #3546)**
D. Helbling, G. Bodoky, O. Gautschi, H. Sun, F. Bosman, B. Gloor, R. Burkhard, R. C. Winterhalder, A. Madlung, D. Rauch, P. Saletti, L. A. Widmer, M. M. Borner, D. Baertschi, P. Yan, D. Koeberle
- Brd. 11C** **Factors influencing histopathology-assessed TME quality after low anterior rectal resection: Results of a prospective multicenter observational trial. (Abstract #3547)**
B. Garlipp, H. Ptok, U. Schmidt, P. Stuebs, F. Meyer, I. Gastinger, H. Lippert

- Brd. 11D** Morbidity and mortality results from a prospective randomized trial comparing mesorectal excision with or without lateral lymph node dissection for clinical stage II and III lower rectal cancer: Japan Clinical Oncology Group study JCOG0212. (Abstract #3548)
S. Fujita, S. Saito, Y. Moriya, J. Mizusawa, K. Nakamura, N. Saito, Y. Kinugasa, Y. Kanemitsu, M. Ohue, S. Fujii, Y. Akazai, M. Shiozawa, T. Yamaguchi, H. Bandou, T. Aoki, K. Murata, K. Shirouzu, N. Takiguchi, Y. Saida, Colorectal Cancer Study Group of Japan Clinical Oncology Group
- Brd. 11E** Prospective analysis of KRAS, BRAF, and PIK3CA mutational status and EGFR copy number in patients (pts) with locally advanced rectal cancer: A translational substudy of a clinical trial (SAKK 41/07) evaluating the effect of neoadjuvant chemoradiation (CRT) with or without panitumumab. (Abstract #3549)
D. Koeberle, S. Bougel, J. Benhattar, F. Bosman, O. Gautschi, H. Sun, G. Bodoky, R. von Moos, D. Helbling, for the Swiss Group for Clinical Cancer Research (SAKK)
- Brd. 11F** Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer. (Abstract #3550)
T. E. Seery, A. Ziogas, B. S. Lin, C. G. Pan, M. J. Stamos, J. A. Zell
- Brd. 11G** Results of a nationwide Japanese study on lateral pelvic lymph node metastasis in low rectal cancer: Is it regional or distant disease? (Abstract #3551)
T. Akiyoshi, T. Watanabe, S. Miyata, K. Kotake, T. Muto, K. Sugihara
- Brd. 11H** Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. (Abstract #3552)
C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, R. Vera, M. P. Escudero, J. Maurel, J. Aparicio
- Brd. 11H** Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. (Abstract #3552)
C. Fernandez-Martos, C. Pericay, A. Salud, B. Massuti, V. Alonso, M. Safont, R. Vera, M. P. Escudero, J. Maurel, J. Aparicio
- Brd. 12A** Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer. (Abstract #3553)
I. Park, C. Hu, M. A. Rodriguez-Bigas, Y. You, J. M. Skibber, C. Eng, R. A. Wolff, P. Das, C. H. Crane, G. J. Chang
- Brd. 12B** Adherence to NCCN treatment guidelines for rectal cancer: Analysis of national practice patterns. (Abstract #3554)
R. Chagpar, J. N. Cormier, B. W. Feig, G. J. Chang, Y. You, Y. Chiang, M. A. Rodriguez-Bigas, J. M. Skibber, Y. Xing
- Brd. 12C** Comparison of outcomes of intensity-modulated radiotherapy and 3-D conformal radiotherapy for anal squamous cell carcinoma using a propensity score analysis. (Abstract #3555)
D. A. Rothenstein, T. Dasgupta, J. F. Chou, Z. Zhang, J. L. Wright, L. K. Temple, L. Saltz, K. A. Goodman
- Brd. 12D** Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. (Abstract #3556)
Q. Shi, J. M. Hubbard, G. A. Yothers, T. Andre, L. Saltz, G. Francini, B. M. Bot, C. Twelves, M. E. Buyse, A. Grothey, D. J. Sargent, for the ACCENT Collaborative Group

- Brd. 12E** **Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls. (Abstract #3557)**
M. Morse, D. Niedzwiecki, J. Marshall, C. R. Garrett, D. Z. Chang, M. Aklilu, T. S. Crocenzi, D. J. Cole, S. Dessureault, A. Hobeika, T. Osada, B. M. Clary, S. D. Hsu, G. Devi, A. Bulusu, R. Annechiarico, V. Chadaram, T. M. Clay, H. K. Lyerly
- Brd. 12F** **Independent validation of a prognostic classifier (Predictor-C) in a set of 292 patients with colorectal cancer of UICC stage II. (Abstract #3558)**
H. Adams, T. Mayr, B. Hinzmann, A. Rosenthal
- Brd. 12G** **External validation of a tumor derived 5-gene prognostic signature (OncoDefender-CRC) for recurrence (R) of stages I/II colorectal cancer (CRC). (Abstract #3559)**
P. F. Lenehan, L. A. Boardman, D. W. Fry, E. R. Heyman, J. Ohrnberger, W. P. Worzel
- Brd. 12H** **Microsatellite instability to predict the efficacy of adjuvant chemotherapy for stage II colon cancer. (Abstract #3560)**
J. Kim, H. Kim, Y. Hong, J. Lee, M. Ryu, H. Chang, S. Jang, M. Kim, C. Yu, T. Kim
- Brd. 13A** **Initial safety report of ACTS-CC trial (TRICC0706): A randomized phase III trial of UFT/LV versus S-1 as adjuvant therapy for stage III colon cancer. (Abstract #3561)**
A. Takagane, H. Takiuchi, K. Ikejiri, I. Mochizuki, H. Mochizuki, K. Kotake, S. Kameoka, K. Takahashi, T. Watanabe, M. Watanabe, N. Boku, N. Tomita, Y. Matsubara, K. Sugihara
- Brd. 13B** **Updated results of the FIRIS study: A phase II/III trial of 5-FU/I-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC). (Abstract #3562)**
H. Baba, K. Muro, H. Yasui, Y. Shimada, A. Tsuji, S. Sameshima, T. Satoh, T. Denda, K. Ina, K. Sugihara
- Brd. 13C** **Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy. (Abstract #3563)**
F. A. Greco, W. J. Lenington, D. R. Spigel, G. R. Varadhachary, J. D. Hainsworth
- Brd. 13D** **Role of surgical resection among chemotherapy-treated patients with colorectal cancer with stage IV disease: A survival analysis. (Abstract #3564)**
B. S. Lin, A. Ziogas, T. E. Seery, M. J. Stamos, J. A. Zell
- Brd. 13E** **A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. (Abstract #3565)**
E. E. Voest, N. Snoeren, S. B. Schouten, A. M. Bergman, E. van Werkhoven, O. J. Loosveld, T. M. van Gulik, J. M. Smit, A. Cats, E. Boven, E. Hesselink, A. Rijken, M. Tol, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. van der Sijp, I. Borel Rinkes, R. van Hillegersberg
- Brd. 13F** **Biomodulation of irinotecan using ciclosporin: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Abstract #3566)**
G. W. Middleton, S. J. Gwyther, S. R. Brown, T. S. Maughan, C. Olivier, S. Richman, N. R. Maisey, M. Hill, S. Gollins, S. Myint, S. Slater, J. Wagstaff, J. A. Bridgewater, R. Glynne-Jones, G. Hemmings, H. Marshall, D. Blake, V. Napp, P. Quirke, M. T. Seymour, UK NCRI Colorectal Clinical Studies Group
- Brd. 13G** **Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared with FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): Results by Eastern Cooperative Oncology Group (ECOG) performance status (PS). (Abstract #3567^)**
S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan, J. Douillard

- Brd. 13H** **FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim report. (Abstract #3568)**
D. Morton, L. Magill, K. Handley, G. Brown, D. R. Ferry, Z. b. Gray, P. Quirke, M. T. Seymour, B. Warren, R. G. Gray, on behalf of the FOxTROT Collaborative Group
- Brd. 14A** **Initial change in tumor size as an imaging surrogate of outcomes in patients with metastatic colorectal cancer (mCRC) treated with first-line irinotecan and 5-FU combination chemotherapy. (Abstract #3569)**
C. Suzuki, L. Blomqvist, A. Sundin, P. Bystrom, A. Berglund, H. Jacobsson, P. Nygren, B. Glimelius
- Brd. 14B** **Can patients be cured after cytoreductive surgery plus intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis? (Abstract #3570)**
D. Goéré, D. Tzanis, V. G. Gava, L. Maggiori Jr., F. Dumont, M. Ducreux, D. Elias
- Brd. 14C** **Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. (Abstract #3571)**
J. Franko, Q. Shi, C. D. Goldman, B. A. Pockaj, G. D. Nelson, R. M. Goldberg, H. C. Pitot, A. Grothey, S. R. Alberts, D. J. Sargent
- Brd. 14D** **Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies. (Abstract #3572)**
H. Piessevaux, E. Van Cutsem, C. Bokemeyer, M. Schlichting, S. Heeger, S. Tejpar
- Brd. 14E** **Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study. (Abstract #3573)**
B. Chibaudel, C. Tournigand, M. Mabro, M. Bennamoun, P. Artru, S. Nguyen, J. Bachet, N. Aissat, H. Blons, P. Laurent-Puig, A. De Gramont, T. Andre, GERCOR
- Brd. 14F** **Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. (Abstract #3574^)**
M. Peeters, T. J. Price, A. H. Strickland, T. E. Ciuleanu, W. Scheithauer, S. O'Reilly, M. M. Keane, D. R. Spigel, Y. Tian, K. Krishnan
- Brd. 14G** **FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab (mCRC): Analysis of patients with KRAS mutated tumors in the randomized German AIO study KRK-0306. (Abstract #3575)**
S. Stintzing, J. Neumann, A. Jung, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jaeger, T. Heintges, C. Stoll, D. P. Modest, T. Kirchner, W. Scheithauer, V. Heinemann
- Brd. 14H** **Efficacy of chemotherapy plus cetuximab according to metastatic site in KRAS wild-type metastatic colorectal cancer (mCRC): Analysis of CRYSTAL and OPUS studies. (Abstract #3576)**
C. Kohne, C. Bokemeyer, S. Heeger, U. Sartorius, P. Rougier, E. Van Cutsem
- Brd. 15A** **A multicenter, multinational retrospective analysis of mitomycin C (MMC) in refractory metastatic colorectal cancer (mCRC). (Abstract #3577)**
R. Ferrarotto, K. K. Machado, M. P. Mak, V. A. Vieira, T. K. Takahashi, D. Saragiotto, S. Kopetz, M. J. Overman, P. Hoff
- Brd. 15B** **Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 (FFCD 0504 trial): Final results. (Abstract #3578)**
E. Mitry, O. Bouche, J. Seitz, P. Etienne, J. Legoux, T. Aparicio, G. Breysacher, C. Lecaille, T. Lecomte, J. Jouve, FFCD

- Brd. 15C** **Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial. (Abstract #3579)**
S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber, C. Camci, O. Sencan, S. Kilickap
- Brd. 15D** **Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). (Abstract #3580)**
T. Ciuleanu, V. Nikolic, E. Shmueli, D. Vrbaneč, S. Plate, Z. M. Krmptić, M. Dank, G. Purkalne, T. Brodowicz, C. Zielinski
- Brd. 15E** **Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). (Abstract #3581)**
A. D. Baron, C. L. O'Bryant, Y. Choi, A. Ashkenazi, S. Royer-Joo, C. C. Portera
- Brd. 15F** **Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy. (Abstract #3582)**
A. Bessudo, J. C. Bendell, N. Gabrail, M. V. Kopp, L. Mueller, L. L. Hart, V. I. Vladimirov, A. U. Pande, I. Gorbachevsky, C. Eng
- Brd. 15G** **Phase I/II trial of capecitabine (Cap) and oxaliplatin (Ox) in combination with bevacizumab (Bev) and imatinib (Ima) in patients with metastatic colorectal cancer (CRC): AIO KRK 0205. (Abstract #3583)**
G. von Wichert, T. Hoehler, C. C. Schimanski, M. H. Moehler, R. Hofheinz, S. Kanzler, A. Hinke, T. Seufferlein, J. Siebler, A. Hochhaus, D. Arnold, M. Hallek, U. T. Hacker, Arbeitsgemeinschaft Internistische Onkologie (AIO)
- Brd. 15H** **A fixed-sequence, open-label study to determine the activity of SCH 717454 (robatumumab) as assessed by positron emission tomography in patients with relapsed or recurrent colorectal cancer. (Abstract #3584)**
E. H. Lin, H. Lenz, M. N. Saleh, S. Badarinath, J. A. Knost, M. J. MacKenzie, B. N. Polite, P. Kavan, E. X. Chen, L. P. Leichman, K. Pathiraja, B. D. Lu
- Brd. 16A** **Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer. (Abstract #3585)**
B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U. T. Hacker, C. Kohne, M. Kornacker, O. Boix, T. Lin, J. Krauss, R. Fischer, S. Hamann, D. Strumberg, K. B. Moss
- Brd. 16B** **Phase I study of dasatinib in combination with capecitabine, oxaliplatin, and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. (Abstract #3586)**
J. H. Strickler, A. L. Cohn, C. Arrowood, S. Haley, M. Morse, H. Uronis, G. C. Blobe, S. D. Hsu, Y. Zafar, H. Hurwitz
- Brd. 16C** **Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05–102—Final report. (Abstract #3587)**
S. Shahda, M. Yu, J. Picas, J. A. Bufill, W. A. Harb, M. Burns, A. J. Spittler, J. Flynn, Y. Zeng, G. H. Vance, J. Wu, C. R. Currie, P. J. Loehrer, E. G. Chiorean
- Brd. 16D** **The relationship between the development of rash and clinical and health-related quality of life outcomes by KRAS mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. (Abstract #3588)**
C. J. O'Callaghan, D. Tu, C. S. Karapetis, H. Au, M. J. Moore, N. C. Tebbutt, M. G. Trudeau, T. J. Price, D. Yip, D. J. Jonker

- Brd. 16E Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. (Abstract #3589)**
V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H. Hass, H. F. Dietzfelbinger, D. V. Oruzio, S. Klein, K. Zellmann, T. Decker, M. Schulze, W. Abenhardt, G. Puchtler, H. W. Kappauf, J. Mittermueller, C. Haberl, C. A. Giessen, N. Moosmann, S. Stintzing
- Brd. 16F Association of baseline CEA, VEGF, and soluble VEGF receptor 2 with treatment outcomes in two randomized phase III trials of cediranib in metastatic colorectal cancer (mCRC). (Abstract #3590^)**
H. Schmoll, P. M. Hoff, J. D. Robertson, L. Pike, S. Morgan, D. Wilson, J. M. Jürgensmeier
- Brd. 16G Axitinib inhibition of [¹⁸F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations. (Abstract #3591)**
C. Hoh, J. R. Infante, H. A. Burris III, J. C. Tarazi, S. Kim, B. Rosbrook, T. R. Reid
- Brd. 16H Angiogenesis gene polymorphisms and clinical outcome of metastatic colorectal cancer treated with first-line bevacizumab and oxaliplatin-based chemotherapy. (Abstract #3592)**
A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte, P. M. Wilson, L. Benhaim, R. El-Khoueiry, G. Absenger, A. B. El-Khoueiry, S. Iqbal, H. Lenz
- Brd. 17A Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. (Abstract #3593)**
A. Hendlisz, V. Golfopoulos, C. Garcia, P. Emonts, A. Covas, L. Ameye, M. Paesmans, A. Deleporte, G. Machiels, E. Toussaint, B. Vanderlinden, A. Awada, M. Piccart, P. Flamen
- Brd. 17B Evaluation of the association between tagging polymorphisms of the MCCC1 locus and overall survival in patients with colorectal cancer. (Abstract #3594)**
A. Lang, S. Geller-Rhomberg, T. Winder, B. L. Hartmann, K. Gasser, B. Kohler, I. Grizelj, N. Stark, P. Tschann, H. Drexel, A. Muendlein
- Brd. 17C CpG island methylator phenotype and KRAS mutation status as prognostic markers in patients with resected colorectal cancer. (Abstract #3595)**
D. H. Koo, Y. Hong, K. Kim, J. Lee, H. Chang, Y. Kang, C. Yu, J. Kim, M. Kim, S. Jang, T. Kim
- Brd. 17D The prognostic influence and interrelationships of CD8⁺ T-cell infiltration in malignant colorectal tumors. (Abstract #3596)**
C. H. Richards, A. Powell, S. Platt, C. S. Roxburgh, D. C. Mcmillan, P. G. Horgan
- Brd. 17E Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (Abstract #3597)**
A. Sartore-Bianchi, S. Fieuws, S. Veronese, M. Moroni, N. Personeni, M. Frattini, V. Torri, F. Cappuzzo, S. Vander Borgh, V. Martin, M. Skokan, A. Santoro, M. Gambacorta, S. Tejpar, M. Varella-Garcia, S. Siena
- Brd. 17F Determination of genomic profile to predict clinical response to FOLFOX plus bevacizumab in metastatic colorectal cancer. (Abstract #3598)**
T. J. George, H. Liu, L. V. Duckworth, J. E. Sullivan, J. Dong, C. Liu, L. H. Dang, K. Slentz-Kesler, C. J. Allegra
- Brd. 17G Cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan. (Abstract #3599)**
N. Pallisgaard, K. G. Spindler, I. S. Vogelius, A. K. Jakobsen

- Brd. 17H** **The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment: Results of the phase III ACT trial NCT00598156 translational study. (Abstract #3600)**
T. Hansen, R. D. Christensen, R. F. Andersen, K. G. Spindler, A. Johnsson, A. K. Jakobsen
- Brd. 18A** **The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. (Abstract #3601)**
M. M. Vickers, C. S. Karapetis, D. Tu, C. J. O'Callaghan, T. J. Price, N. C. Tebbutt, G. Van Hazel, J. D. Shapiro, N. Pavlakis, P. Gibbs, J. Blondal, U. J. Yu Min Lee, J. M. Meharchand, R. L. Burkes, S. H. Rubin, J. Simes, J. R. Zalcberg, M. J. Moore, L. Zhu, D. J. Jonker
- Brd. 18B** **Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. (Abstract #3602)**
G. A. Van Hazel, D. Tu, N. C. Tebbutt, D. J. Jonker, T. J. Price, C. O'Callaghan, J. R. Zalcberg, M. Taylor, A. H. Strickland, A. T. Tomiak, D. Yip, J. Simes, S. K. Yadav, M. Links, M. J. Burnell, M. Jefford, C. S. Karapetis
- Brd. 18C** **The role of KRAS, BRAF, and PI3K mutations as markers of resistance to cetuximab in metastatic colorectal cancer. (Abstract #3603)**
A. Passardi, P. Ulivi, M. Valgiusti, E. Scarpi, R. Moscati, E. Chiadini, P. Rosetti, L. Saragoni, L. Capelli, A. Casadei Gardini, A. Ragazzini, M. Monti, S. Calpona, W. Zoli, C. Milandri, L. Frassinetti
- Brd. 18D** **Prediction of tumor recurrence in stage II colon cancer through genetic variants in formyl peptide receptor 2 (FPR2). (Abstract #3604)**
R. D. Ladner, W. Zhang, M. J. Labonte, D. Yang, Y. Ning, A. Gerger, P. O. Bohanes, T. Winder, A. B. El-Khoueiry, S. Iqbal, N. Petasis, H. Lenz
- Brd. 18E** **Clinicopathological features of patients with colorectal cancer among KRAS wild-type p.G13D and other mutations: Results from a multicenter, cross-sectional study by the Japan Study Group of KRAS Mutation in Colorectal Cancer. (Abstract #3605)**
H. Uetake, T. Watanabe, T. Yoshino, K. Yamazaki, M. Ishiguro, K. Sugihara, Y. Ohashi
- Brd. 18F** **Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. (Abstract #3606)**
M. J. Deenen, A. Cats, M. K. Sechterberger, J. L. Severens, P. H. Smits, R. Bakker, C. M. Mandigers, M. Soesan, J. H. Beijnen, J. H. Schellens
- Brd. 18G** **Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. (Abstract #3607)**
S. R. Alberts, S. N. Thibodeau, D. J. Sargent, M. R. Mahoney, F. Sinicrope, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, S. G. Nair
- Brd. 18H** **CpG island methylation in PTEN, MGMT, and E/H cadherin promoters, mutations of K-ras and B-raf may indicate how progression in the colorectal adenocarcinoma sequence occurs. (Abstract #3608)**
B. Metzger, M. Dicato, G. Mahon
- Brd. 19A** **Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG). (Abstract #3609)**
H. Guchelaar, J. Pander, S. Bohringer, T. van der Straaten, Y. Ariyurek, J. Houwing-Duistermaat, H. Gelderblom, C. J. Punt

- Brd. 19B** **A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. (Abstract #3610)**
G. Della Vittoria Scarpati, C. Carlomagno, S. Marchini, P. Ubezio, F. Falcetta, M. D'Incalci, S. De Placido, F. Sabbatino, C. Fuscicello, S. Pepe
- Brd. 19C** **Clinical and prognostic relevance of methylation of circulating HLTF and HPP1 tumor DNA and CEA in serum of patients with colorectal carcinoma (CRC). (Abstract #3611)**
F. T. Kolligs, A. B. Philipp, D. Nagel, F. Spelsberg, A. Herbst, P. Stieber
- Brd. 19D** **Cancer stem cell gene variants associated with colon cancer recurrence. (Abstract #3612)**
L. Benhaim, A. Gerger, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, T. Winder, M. J. Labonte, P. M. Wilson, R. El-Khoueiry, A. B. El-Khoueiry, S. Iqbal, H. Lenz
- Brd. 19E** **Use of KRAS mutation status to predict clinical outcomes in patients with metastatic colorectal cancer (mCRC) treated with the VEGF signaling inhibitor cediranib. (Abstract #3613^)**
J. M. Jürgensmeier, P. M. Hoff, L. Pike, J. D. Robertson, S. Morgan, G. McWalter, D. Wilson, J. Smith
- Brd. 19F** **Effects of a neurokinin-1 receptor (NK-1R) antagonist on colon cancer through suppression of colon tumor-initiating cells. (Abstract #3614)**
C. Polytarchou, J. M. Bugni, S. Dry, C. Pothoulakis, D. Iliopoulos
- Brd. 19G** **Effect of body mass index (BMI) and body surface area (BSA) on outcomes in early-stage colon cancer (CC). (Abstract #3615)**
S. Alipour, R. Woods, H. J. Lim, S. Gill, H. F. Kennecke, C. Speers, C. J. Brown, W. Y. Cheung
- Brd. 19H** **Comparison of innovative estimation of efficacy to standard using the ACCENT database. (Abstract #3616)**
J. W. Chapman, C. O'Callaghan, N. Hu, K. Ding, G. A. Yothers, P. J. Catalano, Q. Shi, R. G. Gray, M. J. O'Connell, D. J. Sargent, for the ACCENT collaborative group
- Brd. 20A** **Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC). (Abstract #3617)**
R. Sidhu, A. Rong, S. Dahlberg
- Brd. 20B** **Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). (Abstract #3618)**
H. M. Hassabo, M. Hassan, B. George, S. Wen, V. Baladandayuthapani, S. Kopetz, D. R. Fogelman, B. K. Kee, C. Eng, C. R. Garrett
- Brd. 20C** **Predictive and prognostic value of gender in early-stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database. (Abstract #3619)**
W. Y. Cheung, Q. Shi, M. O'Connell, J. Cassidy, C. D. Blanke, D. J. Kerr, E. Van Cutsem, S. R. Alberts, G. A. Yothers, D. J. Sargent, for the ACCENT Collaborative Group
- Brd. 20D** **Effect of VTE on mortality in patients with stage III colon cancer. (Abstract #3620)**
C. D. Mullins, K. A. Bikov, D. L. McNally, N. C. Onwudiwe, M. R. Dalal, N. Hanna
- Brd. 20E** **Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). (Abstract #3621)**
T. J. Price, D. Zannino, K. Wilson, J. Simes, G. A. Van Hazel, B. A. Robinson, A. Broad, V. Ganju, S. P. Ackland, N. C. Tebbutt
- Brd. 20F** **Short-term outcomes after colorectal cancer among the oldest old patients: A cross-national comparative study. (Abstract #3622)**
A. Syse, J. P. Bynum, H. G. Welch, S. Tretli, S. S. Soneji

SATURDAY

- Brd. 20G Allergic reactions (ARs) induced by FOLFOX4 treatment in colorectal cancer: A comparative analysis between Asian and Western patients (pts). (Abstract #3623)**
K. Sugihara, A. Ohtsu, Y. Shimada, N. Mizunuma, P. Lee, A. De Gramont, R. M. Goldberg, M. L. Rothenberg, T. Andre, S. Brienza
- Brd. 20H Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. (Abstract #3624)**
E. Elimova, C. J. O'Callaghan, D. Tu, C. S. Karapetis, T. J. Price, L. Zhu, J. R. Zalcborg, J. Simes, D. J. Jonker
- Brd. 21A Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). (Abstract #3625)**
M. Kozloff, T. S. Bekaii-Saab, J. C. Bendell, A. L. Cohn, H. Hurwitz, N. Roach, H. Tezcan, S. Fish, E. D. Flick, Y. Mun, D. Dalal, A. Grothey
- Brd. 21B The effect of tumor response on quality of life (QoL) in patients with KRAS wild-type metastatic colorectal cancer (mCRC): Analysis from the CRYSTAL study. (Abstract #3626)**
I. Griebisch, I. Lang, U. Sartorius, E. Van Cutsem
- Brd. 21C Effect of dose modification on the efficacy of capecitabine: Data from six randomized, phase III trials in patients with colorectal or breast cancer. (Abstract #3627)**
J. Cassidy, J. O'Shaughnessy, H. Schmoll, C. Twelves, T. H. Cartwright, A. Buzdar, E. McKenna, F. Gilberg, N. Scotto, D. G. Haller
- Brd. 21D An analysis of the effect of stage at diagnosis of bowel cancer on survival: Findings from the South Australian Clinical Registry (SACR) for metastatic colorectal cancer (mCRC). (Abstract #3628)**
K. Jain, T. J. Price, C. Beeke, R. Padbury, G. P. Young, D. Roder, A. R. Townsend, S. Bishnoi, C. S. Karapetis
- Brd. 21E Surgical treatment of colorectal cancer in the advanced elderly: Does outcome justify treatment? (Abstract #3629)**
J. D. Cull, S. Kukreja, T. J. Hieken
- Brd. 21F Preoperative chemoradiation (CRT) with concurrent capecitabine (Cap), oxaliplatin (Ox), and bevacizumab (Bev) in patients with locally advanced rectal cancer (RC): Effects on pathological complete response (pCR) and surgical complications. (Abstract #3630)**
T. Hoehler, K. Dellas, D. Riesenbeck, T. Reese, F. Wuerschmidt, C. Roedel, W. Wagner, H. Zuehlke, M. Richter, J. Dunst
- Brd. 21G Colorectal cancer in African American and Caucasian patients: A comparison of an urban, university hospital with the National Cancer Institute SEER database. (Abstract #3631)**
E. P. Mitchell, A. Topham, R. Singla, S. Maron, J. Schoenfeld, F. Guiles, S. Goldstein, P. R. Anne, G. Isenberg, P. J. Maxwell IV, J. Palazzo
- Brd. 21H Could baseline health-related quality of life (QoL) improve prognostication of overall survival in metastatic colorectal cancer? Results from GERCOR OPTIMOX 1 study. (Abstract #3632)**
M. Diouf, F. Bonnetain, B. Chibaudel, C. Tournigand, L. Teixeira, H. Marijon, N. Perez-Staub, A. De Gramont
- Brd. 22A Application of adaptive study designs: Phase II and III results from the cediranib (CED) HORIZON (HZ) II and III studies. (Abstract #3633^)**
D. Wilson, P. M. Hoff, H. Schmoll, J. D. Robertson, A. Stone
- Brd. 22B The relationship between quality of life (QoL) and tumor response in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab (pmab) plus FOLFIRI as first-line therapy: An analysis of study 314. (Abstract #3634)**
M. Karthaus, J. Thaler, R. Hofheinz, L. Mineur, H. Letocha, R. Greil, E. Fernebro, E. Gamelin, A. Baños, C. Kohne

Saturday, June 4, 2011

- Brd. 22C** *Let-7a* microRNA levels in *KRAS*-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR. (Abstract #3635)
E. Canestrari, A. Ruzzo, B. Vincenzi, N. Galluccio, G. Perrone, F. Andreoni, P. Lorenzini, E. Rulli, S. d'Emidio, V. Catalano, F. Loupakis, R. Bissonni, I. Floriani, M. De Nictolis, D. Santini, L. Salvatore, G. Tonini, A. Falcone, M. Magnani, F. Graziano
- Brd. 22D** miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy. (Abstract #3636)
L. Landi, F. Biagioni, V. Ludovini, A. Sacconi, A. Destro, G. Blandino, M. Roncalli, L. Crinò, F. Cappuzzo

SATURDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Gastrointestinal (Noncolorectal) Cancer

Location: Hall A

Track(s): Gastrointestinal (Noncolorectal) Cancer

- Brd. 23A Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma (HCC): A multicenter study of over 200 patients. (Abstract #4033)**
 N. Williet, A. Zaanan, M. Hebbar, V. Boige, L. Fartoux, T. Mansourbakht, O. Dubreuil, O. Rosmorduc, F. Bonnetain, J. Taïeb
- Brd. 23B Phase II trial of concurrent chemoradiotherapy consisting of two courses with S-1 and cisplatin for locally advanced esophageal cancer. (Abstract #4034)**
 H. Iwase, M. Shimada, T. Tsuzuki, N. Ryuge, H. Goto
- Brd. 23C Clinical significance of tumor markers as prognostic factors in patients with metastatic gastric cancer receiving first-line chemotherapy. (Abstract #4035)**
 J. Jo, M. Ryu, D. Koo, B. Ryoo, H. Kim, J. Lee, H. Chang, T. Kim, K. Choi, G. Lee, H. Jung, K. Kim, J. Yook, S. Oh, B. Kim, J. Kim, Y. Kang
- Brd. 23D Effect of neoadjuvant chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicentric comparative study. (Abstract #4036)**
 C. Mariette, M. Messenger, J. H. Lefevre, V. Pichot, A. Souadka, T. Thibot, D. Brachet, N. Carrere, M. Fernandez, J. Guiramand, B. Tsilividis, R. Flamein, K. Kraft, J. Balon, F. Borie, A. Glaise, X. d'Journo, F. Peschaud, F. Vandois, G. Piessen, FRENCH
- Brd. 23E Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. (Abstract #4037)**
 S. Lorenzen, S. Blank, K. Becker, R. Langer, F. Lordick, D. Jaeger, J. R. Siewert, K. Ott
- Brd. 23F C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). (Abstract #4038)**
 N. Galluccio, A. Ruzzo, E. Canestrari, P. Lorenzini, S. d'Emidio, V. Sisti, V. Catalano, F. Andreoni, C. Zingaretti, M. De Nictolis, C. Ligorio, F. Cappuzzo, M. Magnani, F. Graziano
- Brd. 23G Multicenter phase II trial to investigate safety and efficacy of an adjuvant therapy with gemcitabine and cetuximab in patients with R0 or R1 resected pancreatic cancer. (Abstract #4039)**
 H. Fensterer, C. Schade-Brittinger, H. Mueller, B. Schupfner, J. Fass, U. Lindig, U. Settmacher, M. P. Ebert, M. Kornmann, R. Hofheinz, E. Endlicher, C. Brendel, P. J. Barth, D. K. Bartsch, T. M. Gress, Arbeitsgemeinschaft Internistische Onkologie (AIO)
- Brd. 23H The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. (Abstract #4040)**
 H. Isayama, Y. Nakai, T. Sasaki, N. Sasahira, K. Hirano, T. Tsujino, M. Tada, M. Omata, K. Koike, GEMSAP study group
- Brd. 24A Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). (Abstract #4041)**
 I. McCaffery, Y. Tudor, H. Deng, R. Tang, S. Badola, H. L. Kindler, C. S. Fuchs, E. Loh, S. D. Patterson, L. Chen, J. L. Gansert

- Brd. 24B Adjuvant treatments in pancreatic cancer: Preliminary data of a pooled analysis. (Abstract #4042)**
F. Drudi, D. Tassinari, C. Castellani, F. Carloni, C. Santelmo, E. Tamburini, M. Fantini, M. Papi, L. Gianni, A. Ravaoli
- Brd. 24C Phase II study of cixutumumab (IMC-A12, NSC742460; C) in hepatocellular carcinoma (HCC). (Abstract #4043)**
G. K. Abou-Alfa, B. Gansukh, J. F. Chou, J. Shia, M. Capanu, M. Kalin, H. X. Chen, N. J. Zojwalla, S. Katz, D. L. Reidy, D. P. Kelsen, L. Saltz
- Brd. 24E Screening for pancreatic cancer in a high-risk cohort: A 7-year experience. (Abstract #4045)**
W. Al-Sukhni, A. Borgida, H. Rothenmund, S. Holter, S. Wilson, M. J. Moore, S. Narod, K. Jhaveri, M. A. Haider, S. Gallinger
- Brd. 24F Clinicopathologic features and treatment outcomes of patients (pts) with HER2-positive (pos) adenocarcinomas (ACA) of the esophagus (E) and gastroesophageal junction (GEJ). (Abstract #4046)**
B. E. Phillips, R. R. Tubbs, T. W. Rice, L. A. Rybicki, T. Plesec, C. P. Rodriguez, G. M. Videtic, J. P. Saxton, D. I. Ives, D. J. Adelstein
- Brd. 24G Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial. (Abstract #4047)**
S. H. Boeck, A. Jung, R. P. Laubender, J. Neumann, R. Egg, C. Goritschan, U. Vehling-Kaiser, C. Winkelmann, L. Fischer von Weikersthal, M. R. Clemens, T. C. Gauler, A. Marten, S. Klein, G. Kojouharoff, M. Barner, M. Geissler, T. F. Greten, U. Mansmann, T. Kirchner, V. Heinemann
- Brd. 24H Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib. (Abstract #4048)**
H. Safran, K. Charpentier, A. Kaubisch, G. Dubel, G. Soares, K. E. Faricy-Anderson, T. J. Miner, Y. Eng, I. Ribizzi-Akhtar, A. M. Plette, N. J. Espat, D. Berz, A. Schumacher, D. Luppe, P. Bakalarski, P. Wingate, J. Victor, K. Rosati, D. Isdale
- Brd. 25A Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). (Abstract #4049)**
J. Lu, H. Deng, R. Tang, C. Hsu, H. L. Kindler, C. S. Fuchs, J. L. Gansert, S. Bray, S. S. Suzuki, E. Loh, M. Zhu
- Brd. 25B Adjuvant therapy in the treatment of biliary tract cancer (BTC): A systematic review and meta-analysis. (Abstract #4050)**
A. M. Horgan, E. Amir, T. Walter, J. J. Knox
- Brd. 25C An evaluation of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy on patients with peritoneal carcinomatosis: Final results of a phase II prospective and randomized clinical trial. (Abstract #4051)**
Y. Li, X. Yang, G. Yang, Y. Zhou, Y. Yonmura
- Brd. 26A Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type 1 receptor (IGF-1R) targeted therapy in pancreatic cancer. (Abstract #4052)**
R. T. Shroff, M. M. Javle, D. Li, R. A. Wolff, D. J. Mauro, G. Naumov, M. Nebozhyn, T. Zhang, Y. Li, S. Sathyanarayanan
- Brd. 26B Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4053)**
P. C. Thuss-Patience, R. Hofheinz, D. Arnold, A. Florschütz, S. Daum, A. Kretzschmar, L. Mantovani-Löffler, D. Bichev, B. Gahn, G. Schumacher, M. Kneba

- Brd. 26C Improved survival in patients with hepatocellular carcinoma over 30 years in Japan: Analysis of nationwide prospective registry of 148,161 patients. (Abstract #4054)**
M. Kudo, N. Izumi, N. Kokudo, M. Sakamoto, Y. Matsuyama, T. Ichida, O. Nakashima, O. Matsui, Y. Ku, M. Makuuchi, for the Liver Cancer Study Group of Japan
- Brd. 27A Prognostic significance of post-treatment standardized uptake value (pSUV) of positron emission tomography (PET) to predict overall survival (OS) and relapse-free survival (RFS) in patients with esophageal or gastroesophageal cancer treated with definitive chemoradiotherapy. (Abstract #4055)**
A. Suzuki, L. Xiao, Y. Hayashi, J. Welsh, S. H. Lin, D. Maru, W. L. Hofstetter, R. J. Mehran, J. H. Lee, M. S. Bhutani, H. A. Macapinlac, Z. X. Liao, J. A. Ajani
- Brd. 27B Bevacizumab (Bev) plus chemotherapy for advanced gastroesophageal adenocarcinoma (GC): Combined U.S. experience. (Abstract #4056)**
E. C. Smyth, P. C. Enzinger, J. Li, M. Vincitore, J. Lacy, B. F. El-Rayes, P. L. Kunz, J. M. Ford, E. Robinson, D. P. Kelsen, M. A. Shah
- Brd. 27C A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced gastric cancer. (Abstract #4057)**
H. Ohnuma, Y. Sato, T. Takayama, T. Sagawa, M. Hirakawa, K. Harada, T. Nobuoka, K. Hirata, Y. Takahashi, S. Katsuki, S. Takahashi, M. Hirayama, M. Takahashi, M. Maeda, T. Sato, K. Miyanishi, M. Kobune, R. Takimoto, J. Kato
- Brd. 28A Quantitation of circulating methylated *RASSF1A* in prognostication and monitoring of treatment response in unresectable hepatocellular carcinoma (HCC). (Abstract #4058)**
S. L. Chan, A. K. Chan, E. P. Hui, S. Yu, L. Leung, H. H. Loong, B. Ma, T. Mok, A. T. Chan, W. Yeo
- Brd. 28B Prognostic factors in Japanese patients with advanced gastric cancer using the data from JCOG9912 study. (Abstract #4059)**
D. Takahari, A. Takashima, J. Mizusawa, Y. Yamada, T. Yoshino, K. Yamazaki, W. Koizumi, Y. Suzuki, N. Boku, A. Ohtsu
- Brd. 28C Final results of feasibility study of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) for clinical stage II/III esophageal squamous cell carcinoma. (Abstract #4060)**
H. Hara, H. Daiko, K. Kato, H. Igaki, S. Kadowaki, Y. Tanaka, Y. Hamamoto, H. Matsushita, M. Nagase, Y. Hosoya, M. Tahara
- Brd. 29A Prognostic microRNAs in patients operated for pancreatic cancer. (Abstract #4061)**
N. A. Schultz, K. K. Andersen, A. Roslind, H. Willenbrock, M. Wøjdemann, J. S. Johansen
- Brd. 29B An evaluation of microRNA signature and response of patients with gastric cancer to cisplatin and fluorouracil. (Abstract #4062)**
H. K. Kim, C. H. Kim, J. Kim, I. J. Choi, D. J. Munroe, J. E. Green
- Brd. 29C Effect of metformin on survival of diabetic patients with pancreatic adenocarcinoma. (Abstract #4063)**
N. Sadeghi, J. L. Abbruzzese, S. J. Yeung, M. Hassan, D. Li
- Brd. 30A Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. (Abstract #4064)**
F. Bi, Q. Li, C. Zhou, J. Yu, X. Cai, M. Qiu, J. Liu, C. Yi, D. Luo, F. Xu, The Western Cooperative Gastrointestinal Oncology Group of China
- Brd. 30B Phase II single-arm, single institution trial of neoadjuvant gemcitabine and oxaliplatin treatment (NT) in patients (pts) with resectable pancreas adenocarcinoma (PC). (Abstract #4065)**
E. M. O'Reilly, W. R. Jarnagin, M. F. Brennan, C. Winston, L. H. Tang, M. Capanu, M. Schattner, L. Y. Chen, R. P. DeMatteo, C. J. DiMaio, M. I. D'Angelica, R. C. Kurtz, D. S. Klimstra, M. A. Lowery, D. G. Coit, D. L. Reidy, P. J. Allen

- Brd. 30C Correlation of HER2 and PTEN status with clinical outcome in esophageal (E), gastric (G), and gastroesophageal junction (GEJ) adenocarcinomas (ACs). (Abstract #4066)**
K. Linos, C. E. Sheehan, J. S. Ross
- Brd. 31A A new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): The Hong Kong Combined Liver Cancer (HKCLC) classification. (Abstract #4067)**
Y. Tang, T. Yao, C. C. Yau, S. Fan, R. Poon
- Brd. 31B Quality of lymphadenectomy for esophageal cancer in the United States: An analysis of the SEER database. (Abstract #4068)**
B. M. Stiles, A. Nasar, F. Mirza, J. L. Port, P. C. Lee, S. Paul, N. K. Altorki
- Brd. 31C A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer. (Abstract #4069)**
A. H. Ko, M. A. Tempero, Y. Shan, W. Su, Y. Lin, E. Dito, A. Ong, Y. Wang, G. Yeh, L. Chen
- Brd. 31D Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Abstract #4070)**
S. Al-Batran, R. Hofheinz, N. Homann, G. Illerhaus, U. M. Martens, J. Stoehlmacher-Williams, H. Schmalenberg, K. B. Luley, N. Prasnikaer, M. Egger, S. Probst, J. T. Hartmann, M. H. Moehler, D. Arnold, W. Fischbach, C. Pauligk, S. P. Moenig, P. Piso, E. Jaeger
- Brd. 31E CA19-9 for the prediction of efficacy of chemotherapy in patients with advanced pancreas cancer: A pooled analysis of six prospective trials. (Abstract #4071)**
T. M. Bauer, T. S. Bekaii-Saab, X. Li, M. A. Villalona-Calero, P. A. Philip, A. F. Shields, M. M. Zalupski, N. Hammad, B. F. El-Rayes
- Brd. 31F Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). (Abstract #4072)**
L. Dahan, B. Chibaudel, F. Di Fiore, P. Artru, L. Mineur, M. Galais, O. Dupuis, V. Blondin, S. Abdiche, M. Attia, A. De Gramont, G. Lledo, GERCOR
- Brd. 31G Prognostic values of microRNAs in phase III clinical trial gastric cancer patients treated with S-1/oxaliplatin or doxifluridine/oxaliplatin. (Abstract #4073)**
J. Jiang, C. Wu, X. Zheng, Q. Zhou, X. Zhang, X. Xu, B. Lu, J. Ju
- Brd. 31H Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4074)**
R. S. Finn, R. Poon, T. Yau, H. Klumpen, L. Chen, Y. Kang, T. Kim, C. Gomez-Martin, C. Rodriguez-Lope, T. Kunz, T. Paquet, K. Asubonteng, R. E. Winkler, O. Anak, D. B. Sellami, J. Bruix
- Brd. 32A Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors: Analysis by primary tumor site from RADIANT-2. (Abstract #4075)**
E. M. Wolin, N. Fazio, S. Saletan, R. E. Winkler, A. Panneerselvam, L. Kvols
- Brd. 32B Use of MTHFR A1298C polymorphism to predict response in a phase II international clinical trial of patients with advanced gastric (GC) or gastroesophageal junction (GEJ) adenocarcinoma treated with first-line lapatinib plus capecitabine. (Abstract #4076)**
M. J. Labonte, D. Yang, W. Zhang, P. M. Wilson, A. Gerger, P. O. Bohanes, Y. Ning, L. Benhaim, R. El-Khoueiry, Y. M. Nagarwala, A. M. Kemner, M. J. Pishvaian, R. K. Hsieh, O. Gladkov, S. Urba, S. Y. Rha, D. Sakaeva, S. Iqbal, A. B. El-Khoueiry, H. Lenz

- Brd. 32C** **A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naïve advanced or metastatic biliary tract cancer: First safety and efficacy data. (Abstract #4077)**
M. H. Moehler, C. C. Schimanski, S. Kanzler, M. A. Woerns, U. Denzer, F. T. Kolligs, M. P. Ebert, A. Distelrath, M. Geissler, S. Zeuzem, F. Lammert, A. W. Lohse, M. M. Dollinger, U. Lindig, E. M. Duerr, N. Lubomierski, S. Zimmermann, M. Kabisch, S. Schadmann-Fischer, P. R. Galle, German AIO
- Brd. 32D** **Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Effect of prior somatostatin analog therapy on progression-free survival in the RADIANT-2 trial. (Abstract #4078)**
L. B. Anthony, M. Peeters, J. D. Hainsworth, E. Baudin, D. Hoersch, J. Klimovsky, K. Grouss, V. Jehl, M. E. Pavel, J. C. Yao
- Brd. 32E** **Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. (Abstract #4079)**
A. J. Zurita, J. Heymach, M. Khajavi, L. Tye, X. Huang, M. Kulke, H. Lenz, N. J. Meropol, W. Carley, S. E. DePrimo, C. S. Harmon
- Brd. 32F** **The role of cytoreductive surgery in patients with carcinomatosis from high-grade appendix cancer in the era of modern systemic chemotherapy. (Abstract #4080)**
H. M. El Halabi, P. Ledakis, V. Gushchin, J. Francis, N. Athas, R. Macdonald, K. Studeman, A. Sardi
- Brd. 32G** **Final toxicity results of a phase I dose-escalation trial of tremelimumab (CP-675206) in combination with gemcitabine in chemotherapy-naïve patients (pts) with metastatic pancreatic cancer. (Abstract #4081)**
M. Aglietta, C. Barone, M. B. Sawyer, M. J. Moore, W. H. Miller Jr., C. Bagalà, D. A. Ferraro, F. Colombi, C. Cagnazzo, L. Gioeni, K. D. Fly, B. Huang, F. Leone
- Brd. 32H** **Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocellular carcinoma after sorafenib failure: A prospective, open-label, phase II study. (Abstract #4082)**
T. Yau, R. C. Leung, H. Wong, J. Chiu, P. Chan, R. Pang, S. Fan, R. Poon
- Brd. 33A** **The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. (Abstract #4083)**
J. Chiu, Y. Tang, T. Yao, A. Wong, H. Wong, R. C. Leung, P. Chan, T. Cheung, R. Poon, S. Fan, C. C. Yau
- Brd. 33B** **HER2 status as an independent prognostic marker in patients with advanced gastric cancer receiving adjuvant chemotherapy after curative gastrectomy. (Abstract #4084)**
Y. Park, M. Ryu, H. Park, H. Kim, B. Ryoo, J. Yook, B. Kim, S. Jang, Y. Kang
- Brd. 33C** **A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC). (Abstract #4085)**
A. X. Zhu, P. J. Gold, A. B. El-Khoueiry, T. A. Abrams, H. Morikawa, T. Ohtomo, P. A. Philip
- Brd. 33D** **C-reactive protein as a biomarker to predict outcomes after liver transplantation for hepatocellular carcinoma. (Abstract #4086)**
H. An, J. Jang, M. Lee, S. Bae, J. Choi, S. Yoon, Y. You, D. Kim, E. Jeon, K. Park, S. Chun
- Brd. 33E** **Combination of exposure-response and case-control analyses in regulatory decision making. (Abstract #4087)**
J. Yang, Y. Wang, H. Zhao, C. Garnett, J. Gobburu, W. Pierce, G. Schechter, J. Summers, P. Keegan, B. Booth, N. Rahman

- Brd. 33F** **Fluoropyrimidine/platinum-based first-line chemotherapy in metastatic esophageal squamous cell carcinoma: Prognostic factor analysis in 239 patients. (Abstract #4088)**
H. Jung, J. Lee, H. Ahn, S. Park, Y. Park, Y. Im
- Brd. 33G** **Clinical/pathologic features and survival of patients with fibrolamellar-hepatocellular carcinoma (FLL-HCC): Data from the Fibrolamellar-Hepatocellular (FLL-HCC) Consortium. (Abstract #4089)**
C. Ang, A. P. Venook, M. A. Choti, R. P. DeMatteo, R. K. Kelley, D. Cosgrove, J. P. McGuire, M. S. Torbenson, T. M. Pawlik, W. R. Jarnagin, M. I. D'Angelica, Y. Fong, J. F. Chou, E. M. O'Reilly, D. S. Klimstra, A. C. Griffin, G. P. Vallarapu, M. Capanu, D. P. Kelsen, G. K. Abou-Alfa
- Brd. 33H** **The association between body mass index and baseline clinical stage of esophageal carcinoma. (Abstract #4090)**
Y. Hayashi, A. M. Correa, W. L. Hofstetter, A. A. Vaporciyan, D. C. Rice, G. L. Walsh, R. J. Mehran, A. Suzuki, J. H. Lee, M. S. Bhutani, S. H. Lin, J. Welsh, D. Maru, S. Swisher, J. A. Ajani
- Brd. 34A** **Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial. (Abstract #4091)**
J. J. Knox, R. Wong, G. E. Darling, J. Lister, M. Guindi, G. Liu, W. Xu, J. J. Kim, D. J. Jonker, J. Wells, W. Kendal, H. Mackay, A. Visbal, R. E. Dinniwell, A. Pierre, R. Feld, S. Sundaresan, A. Bayley, Y. Shargall, A. M. Horgan
- Brd. 34B** **Safety results from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or type II/III oesophagogastric junction (OGJ) adenocarcinoma. (Abstract #4092)**
A. F. Okines, R. E. Langley, L. C. Thompson, S. P. Stenning, L. Stevenson, S. Falk, M. T. Seymour, F. Y. Coxon, G. W. Middleton, D. Smith, L. Evans, S. Slater, J. S. Waters, D. Ford, M. Hall, T. Iveson, R. D. Petty, C. Plummer, W. Allum, D. Cunningham, The National Cancer Research Institute (NCRI) Upper Gastrointestinal Cancers Clinical Studies Group
- Brd. 34C** **Utility of routine endoscopy in the follow-up of resected gastric carcinoma. (Abstract #4093)**
M. Satolli, W. Evangelista, C. Mecca, R. Napoletano, A. Giacobino, A. Novarino, F. Brusa, J. Fiore, L. Pomba, M. Garino, G. Fronza, L. Ciuffreda
- Brd. 34D** **Phase II trial of postoperative adjuvant gemcitabine and cisplatin chemotherapy followed by chemoradiation with gemcitabine in patients with resected pancreatic cancer. (Abstract #4094)**
J. Kwon, E. Chie, J. Kim, S. Im, D. Oh, Y. Kim, S. Han, K. Lee, J. Jang, T. Kim, H. S. Han, S. Kim, Y. Yoon, Y. Bang, S. Ha
- Brd. 34E** **Progression-free survival as surrogate endpoint of overall survival in patients with advanced/recurrent gastric cancer: Individual patient data analysis on 4,102 patients from 20 randomized trials. (Abstract #4095)**
K. Shitara, T. Burzykowski, on behalf of GASTRIC project
- Brd. 34F** **Mature long-term outcome using a continuous 50-Gy shrinking field chemoradiation schedule for squamous cell carcinoma of the anus. (Abstract #4096)**
R. Cooper, K. Spindler, R. Prestwich, P. Byrnes, D. Sebag-Montefiore
- Brd. 34G** **Array-based comparative genomic hybridization analysis to identify prognostic markers for resected pancreatic cancer. (Abstract #4097)**
J. Lee, I. Petrini, J. Hwang, E. Giovannetti, J. Voortman, Y. Wang, S. M. Steinberg, N. Funel, P. S. Meltzer, G. Giaccone
- Brd. 34H** **Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. (Abstract #4098)**
E. Deutsch, C. Lemanski, E. Paris, A. Delarochefordiere, I. Martel-Lafay, E. Rio, L. Miglianico, Y. Becouarn, J. Pignon, J. Berille, P. Ezra, D. Azria

- Brd. 35A Impact of prior procedures on overall survival following radioembolization in patients with unresectable hepatocellular carcinoma (HCC). (Abstract #4099)**
G. M. Ettore, B. Sangro, R. Cianni, D. Gasparini, R. Golfieri, S. Ezzidin, F. T. Kolligs, F. Izzo, on behalf of European Network for Radioembolization using Y90 microspheres (ENRY)
- Brd. 35B Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma. (Abstract #4100)**
D. Ilson, Y. Y. Janjigian, M. A. Shah, D. P. Kelsen, L. H. Tang, J. Campbell, L. Fuqua, M. Capanu
- Brd. 35C Marker driven systemic treatment of inoperable cholangiocarcinomas: Panitumumab and combination chemotherapy in KRAS wild-type tumors. (Abstract #4101)**
L. H. Jensen, J. Lindebjerg, J. Ploen, T. Hansen, A. K. Jakobsen
- Brd. 35D Pancreatic cancer and diabetes mellitus: A retrospective cohort study. (Abstract #4102)**
A. Yacoub, E. Siegel, I. Makhoul
- Brd. 35E Impact of prior chemotherapy on progression-free survival in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET): Results from the RADIANT-3 trial. (Abstract #4103)**
R. F. Pommier, E. M. Wolin, A. Panneerselvam, S. Saletan, R. E. Winkler, E. Van Cutsem
- Brd. 35F Epidemiology, treatment outcome, and survival of primary gallbladder cancer in the United States: A period prevalence SEER database study 1973–2007. (Abstract #4104)**
A. M. Hossain, R. F. Khozouz, R. N. Rahman
- Brd. 35G Clinical factors and outcomes in HPV-associated anal canal cancer. (Abstract #4105)**
J. Nair, Y. Hu, W. M. Mendenhall, C. Liu, C. G. Morris, R. Zlotecki, J. Kirwan, L. H. Dang, S. Tan, E. Huang, C. J. Allegra, T. J. George
- Brd. 35H Oxaliplatin, 5-FU, and leucovorin (FOLFOX) in advanced biliary tract cancer. (Abstract #4106)**
S. Lee, K. Kim, H. Kim, S. Kim, S. Bae, C. Kim, N. Lee, K. Lee, S. Park, J. Won, J. Moon, D. Hong, H. Park
- Brd. 36A TACE plus sorafenib for the treatment of hepatocellular carcinoma: Final results of the multicenter SOCRATES trial. (Abstract #4107)**
A. Erhardt, F. T. Kolligs, M. M. Dollinger, E. Schott, H. Wege IV, M. Bitzer, C. Gog, J. Raedle, M. Schuchmann, C. Walter, D. Blondin, C. Ohmann, D. Haeussinger
- Brd. 36B FOLFIRI followed by radiochemotherapy and surgery in locally advanced gastric cancer: FFCD 0308 phase II trial. (Abstract #4108)**
P. Michel, G. Breysacher, F. Desseigne, L. Dahan, C. Petorin, D. Moussata, J. Grenier, S. Nguyen, F. Viret, N. Carrere, C. Mariette, C. Garnier Tixidre, K. Bouhier Leporrier, M. Galais, F. Fein, I. Iwanicki-Caron, E. Maillard, B. Dousset, F. Mornex, L. Bedenne
- Brd. 36C Meta-analyses of 22 randomized trials assessing the influence of chemotherapy in advanced/recurrent gastric cancer. (Abstract #4109)**
H. Bleiberg, D. J. Sargent, GASTRIC
- Brd. 36D Dose-ranging study of tesetaxel, a novel oral taxane, administered as second-line therapy at a flat dose to patients with advanced gastric cancer. (Abstract #4110)**
J. S. Baker, A. Qureshi, L. Itri, W. Sun, M. F. Mulcahy, J. A. Ajani
- Brd. 36E Outcomes following sequential trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). (Abstract #4111)**
A. Bujold, C. Massey, J. J. Kim, J. D. Brierley, R. Wong, C. Cho, Z. Kassam, R. E. Dinniwell, J. Ringash, B. Cummings, J. J. Knox, M. Sherman, L. A. Dawson

- Brd. 36F Association of the expression of the glioma-associated oncogene homolog (GLI) 1 with nuclear expression of NF- κ B and unfavorable overall survival of patients with pancreatic cancer. (Abstract #4112)**
S. Yang, S. H. Kuo, C. Hsu, J. Lee, Y. Tien, A. Cheng
- Brd. 36G Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: A phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801). (Abstract #4113)**
D. E. Castellano, J. Capdevila, R. Salazar, J. Sastre, V. Alonso, M. Llanos, R. Garcia-Carbonero, A. Abad, I. Sevilla, I. Duran, Spanish Neuroendocrine Tumor Group (GETNE)
- Brd. 36H The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. (Abstract #4114)**
J. Stephenson, D. A. Richards, B. M. Wolpin, C. R. Becerra, J. T. Hamm, W. A. Messersmith, S. Devens, J. Cushing, J. Goddard, T. Schmalbach, C. S. Fuchs
- Brd. 37A Phase II randomized trial on dose-escalated sorafenib (S) versus best supportive care (BSC) in patients with advanced hepatocellular carcinoma (HCC) with disease progression on prior S treatment. (Abstract #4115)**
T. Pressiani, L. Rimassa, C. Boni, R. Labianca, S. Fagioli, A. Ardizzone, P. Foa, E. Cortesi, C. Porta, F. Artioli, L. Latini, C. Carnaghi, R. Lutman, G. Torzilli, M. Tommasini, R. Ceriani, G. Covini, L. Giordano, N. Locopo, A. Santoro
- Brd. 37B Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745. (Abstract #4116)**
J. M. Hubbard, S. R. Alberts, W. S. Loui, M. R. Mahoney, L. R. Roberts, T. C. Smyrk, Z. Gatalica, S. Kumar, S. R. Dakhil, P. J. Flynn, J. M. Lafky, M. J. Bury, NCCTG
- Brd. 37C Influence of tumor infiltrating Foxp3⁺ regulatory T cells on prognosis in resectable gastric cancer. (Abstract #4117)**
J. Kwon, M. Cho, E. Nam, J. Jo, S. Lee
- Brd. 37D S100A2 as a prognostic marker in patients receiving adjuvant therapy for pancreatic cancer (PC): A secondary analysis of RTOG 9704. (Abstract #4118)**
M. A. Tempero, K. A. Winter, G. E. Kim, S. Kakar, T. S. Hyun, W. Regine, R. B. Mowat, K. Charpentier, W. Small Jr., C. Guha, D. K. Chang, A. V. Biankin, RTOG
- Brd. 37E Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC). (Abstract #4119)**
Y. Kang, A. Ohtsu, E. Van Cutsem, L. Roman, J. Nunes, C. Li, D. Otero, F. Rivera, G. Aprile, P. R. Pimentel Alvarez, M. H. Moehler, J. Wu, B. Langer, M. A. Shah
- Brd. 37F Updated results of a phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients (pts) with advanced neuroendocrine tumors (NET). (Abstract #4120)**
J. A. Chan, D. P. Ryan, C. S. Fuchs, A. X. Zhu, T. A. Abrams, B. M. Wolpin, P. Malinowski, E. Regan, M. Kulke
- Brd. 37G Polymorphisms in EGF a+61G, GSTP1 Ile105Val, and MTHFR A1298C to predict response and survival in a phase II study for patients with metastatic or unresectable gastric (G) or gastroesophageal junction (GEJ) cancer treated with capecitabine, oxaliplatin (XELOX), and cetuximab. (Abstract #4121)**
S. Iqbal, M. J. Labonte, D. Yang, W. Zhang, P. O. Bohanes, Y. Ning, L. Benhaim, R. El-Khoueiry, P. M. Wilson, A. Gerger, A. B. El-Khoueiry, H. Lenz

- Brd. 37H** **Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. (Abstract #4122)**
M. Alsina, A. H. Ko, M. Garcia De Paredes, F. Rivera, L. S. Schwartzberg, A. Fattaey, L. A. Kunkel, J. Tabernero, J. A. Ajani
- Brd. 38A** **Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data. (Abstract #4123)**
H. R. Carlson, S. Karanth, M. A. Zazour, R. Lenzi, M. N. Raber, G. R. Varadhachary
- Brd. 38B** **A phase I study of two different schedules of nab-paclitaxel (nab-P) with ascending doses of vandetanib (V) with expansion in patients (Pts) with pancreatic cancer (PC). (Abstract #4124)**
A. B. El-Khoueiry, S. Iqbal, H. Lenz, B. J. Gitlitz, D. Yang, S. Cole, V. Duddalwar, A. Garcia
- Brd. 38C** **BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. (Abstract #4125)**
J. A. Bridgewater, C. Stubbs, J. N. Primrose, National Cancer Research Institute (UK) Upper Gastrointestinal Studies Group
- Brd. 38E** **A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC). (Abstract #4127)**
Z. Meng, L. Liu, Y. Shen, P. Yang, L. Cohen, Y. Huo, Q. Zhao, C. S. Ng, D. Z. Chang, C. R. Garrett
- Brd. 38F** **Inactivation of *BRCA2* cooperates with *Trp53*^{R172H} to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. (Abstract #4128)**
G. Feldmann, C. Karikari, M. dal Molin, S. Durringer, P. Volkmann, D. K. Bartsch, S. Bisht, J. Koorstra, P. Brossart, A. Maitra, V. Fendrich
- Brd. 38G** **Prevention of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) in the levrat rat model of EAC by treatment with a smoothed (SMO) inhibitor. (Abstract #4129)**
M. K. Gibson, A. H. Zaidi, J. M. Davison, B. Hough, A. F. Sanz, T. Foxwell, T. Hoppo, Y. Komatsu, K. S. Nason, C. Rotoloni, U. Malhotra, A. Atasoy, C. Smith, J. D. Luketich, B. A. Jobe, Pittsburgh Esophageal Neoplasia Group
- Brd. 38H** **Identification of a small and lethal subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib by MET amplification. (Abstract #4130)**
J. K. Lennerz, E. L. Kwak, M. Michael, S. B. Fox, A. Ackerman, K. Bergethon, G. Y. Lauwers, J. G. Christensen, K. D. Wilner, D. A. Haber, R. Salgia, Y. Bang, J. W. Clark, B. J. Solomon, A. J. Iafrate
- Brd. 39A** **REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II. (Abstract #4131)**
I. Chau, A. F. Okines, D. Gonzalez de Castro, C. Saffery, Y. Barbachano, A. Wotherspoon, L. Puckey, S. Hulkki Wilson, F. Y. Coxon, G. W. Middleton, D. R. Ferry, T. D. Crosby, S. Madhusudan, J. Wadsley, J. S. Waters, M. Hall, D. Swinson, A. Robinson, D. Smith, D. Cunningham, UK National Cancer Research Institute Upper Gastrointestinal Cancer Clinical Studies Group
- Brd. 39B** **FOLFIRI regimen as second-/third-line chemotherapy in patients with advanced pancreatic adenocarcinoma refractory to gemcitabine and platinum-salts: A retrospective series of 70 patients. (Abstract #4132)**
C. Neuzillet, O. Hentic, B. Rousseau, V. Rebours, L. Bengrine-Lefèvre, F. Bonnetain, E. Raymond, P. Ruzniewski, C. Louvet, P. Hammel

Saturday, June 4, 2011

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Health Services Research

Location: Hall A

Track(s): Health Services Research

- Brd. 40A** **Comparative analysis of lung cancer in a public hospital versus private hospitals in New York. (Abstract #6037)**
V. Gotlieb, V. Verma, J. Fogel, A. Multz, R. J. Gralla
- Brd. 40B** **The development of a value-based pricing index for new drugs in metastatic colorectal cancer. (Abstract #6038)**
G. Dranitsaris, I. Truter, M. Lubbe
- Brd. 40C** **The influence of self-reported conflicts of interest on the conclusions of editorial authors of phase III cancer trials. (Abstract #6039)**
M. C. Miranda, A. T. Lera, A. Ueda, B. Briones, T. Lerner, A. Del Giglio, R. P. Riechelmann
- Brd. 40D** **Perceptions of caregivers on the participation of cancer patients into clinical trials. (Abstract #6040)**
A. T. Lera, M. C. Miranda, P. Santi, G. Brito, P. Prestes, M. Oliveira, A. Del Giglio, R. P. Riechelmann
- Brd. 40E** **Factors influencing patient preferences for outpatient treatment of febrile neutropenia. (Abstract #6041)**
N. Lathia, P. K. Isogai, C. De Angelis, S. Walker, M. C. Cheung, N. Mittmann
- Brd. 40F** **Analysis of dermatologist density and melanoma mortality. (Abstract #6042)**
S. Aneja, J. S. Bordeaux
- Brd. 40G** **Changes in Medicaid reimbursements for cancer screening: Keeping pace with inflation? (Abstract #6043)**
M. T. Halpern, S. G. Haber, F. K. Tangka, D. H. Howard, L. C. Richardson, S. A. Sabatino, S. Sujha
- Brd. 40H** **Preferences of patients with metastatic breast cancer. (Abstract #6044)**
M. Smith, C. B. White, E. Railey, A. M. Storniolo, G. W. Sledge Jr.
- Brd. 41A** **A predictive model to identify cancer patients at risk for in-hospital mortality based on admission criteria. (Abstract #6045)**
K. Ramchandran, J. Shega, M. Schumacher, A. Rademaker, b. Weitner, E. Szmuiowicz, S. A. Weitzman
- Brd. 41B** **Discordance between conclusions in the abstract and conclusions stated in the body of the article: An analysis of randomized controlled trials (RCTs) of lung cancer. (Abstract #6046)**
A. K. Altwairgi, C. Booth, W. Hopman, T. D. Baetz
- Brd. 41C** **Assessing 2-month clinical prognosis in patients with solid tumors: First results of PRONOPALL study. (Abstract #6047)**
H. P. Bourgeois, S. Traoré, P. Solal-Celigny, O. Dupuis, P. Maillart, O. Capitain, R. Delva, P. Soulie, M. Marcq, E. Boucher, G. Ganem, E. Bourbouloux, J. Baudon, M. Kaassis, M. Zinger, C. Lafond, V. Berger, P. Mussault, P. Ingrand, F. Grude
- Brd. 41D** **Factors associated with histologic versus cytologic diagnosis of lung cancer. (Abstract #6048)**
C. S. Lathan, A. Cronin, J. C. Weeks
- Brd. 41E** **Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints. (Abstract #6049)**
A. Kay, J. Higgins, A. G. Day, R. M. Meyer, C. M. Booth
- Brd. 41F** **Socioeconomic position, stage of lung cancer, and time between referral and diagnosis in Denmark, 2001–2008. (Abstract #6050)**
S. O. Dalton, B. L. Frederiksen, E. Jakobsen, M. Steding-Jessen, K. Oesterlind, J. Schuz, M. Osler, C. Johansen

SATURDAY

- Brd. 41G** **Are breast cancer quality metrics being met? (Abstract #6051)**
A. Murphy, G. Rauscher, D. Dupuy, R. Alvarez, T. Macarol, E. Knightly, D. Ansell, P. Grabler, P. A. Robinson, E. A. Marcus
- Brd. 41H** **Implementation of a prospective screening tool for breast cancer clinical trial eligibility at an NCI-designated cancer center. (Abstract #6052)**
K. H. Lethert, S. K. Cheng, D. J. Nauman, D. M. Dilts, A. Sandler, S. Y. Chui
- Brd. 42A** **Predictive markers of utilization of chemotherapy in patients with advanced colorectal cancer (CRC): A population-based study. (Abstract #6053)**
S. Ahmed, T. Zhu, R. Lee-Ying, C. Ubhi, V. Kundapur, R. Alvi, K. Haider
- Brd. 42B** **Assessing two meta-analysis (MA) methods: Individual patient data-based (IPD) versus literature-based abstracted data (AD) in 10 MA including 37,002 patients (pts)—Are there differences of concern? (Abstract #6054)**
E. Bria, R. J. Gralla, H. Raftopoulos, I. Sperduti, M. Milella, F. Cognetti, D. Giannarelli
- Brd. 42C** **Defining indicators for measuring the quality of systemic cancer therapy using administrative data. (Abstract #6055)**
M. K. Krzyzanowska, C. M. Booth, K. K. Chan, K. Enright, M. E. Trudeau
- Brd. 42D** **Attrition bias: Does the benefit of targeted agents (TA) increase the more we search for a selection biomarker? Meta-regression analysis of randomized clinical trials (RCTs) in advanced non-small cell lung and colorectal cancer (NSCLC/CRC). (Abstract #6056)**
D. Giannarelli, M. Milella, F. Loupakis, F. Cuppone, V. Vaccaro, I. Sperduti, P. Carlini, A. Falcone, F. Cognetti, E. Bria
- Brd. 42E** **SBRT for early NSCLC: Markov model insight for optimal patient selection. (Abstract #6057)**
A. V. Louie, G. Rodrigues, M. Hannouf, D. Palma, G. Zaric, S. Senan
- Brd. 42F** **Pathways of care for adolescents with cancer in France. (Abstract #6058)**
E. Desandes, S. Bonnay, C. Berger, L. Brugieres, F. Isfan, V. Laurence, L. Mignot, D. Olive-Sommelet, I. Tron, J. Clavel, B. Lacour
- Brd. 42G** **Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis. (Abstract #6059)**
U. Zurawska, L. K. Hicks, G. Woo, C. M. Bell, M. Krahn, K. K. Chan, J. J. Feld
- Brd. 42H** **The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer. (Abstract #6060)**
A. J. Montero, S. Gluck, G. D. Lopes Jr.
- Brd. 43A** **Prognostic significance of QOL deterioration during early lung cancer survivorship: Secondary analysis of RTOG 0212 and 0214. (Abstract #6061)**
V. Gondj, R. Paulus, D. Bruner, C. A. Meyers, E. Gore, A. H. Wolfson, M. Werner-Wasik, H. Choy, B. Movsas, Radiation Therapy Oncology Group (RTOG)
- Brd. 43B** **Smaller, faster trials: The right way to assess new targeted agents? A simulation study. (Abstract #6062)**
M. Le Deley, K. V. Ballman, D. J. Sargent
- Brd. 43C** **Utilization and clinical practice impact of an interactive tool for guiding choice of systemic adjuvant treatment (adj TX) for patients with early breast cancer (EBC). (Abstract #6063)**
P. Ravdin, S. Martino, M. D. Pegram, N. J. Robert, S. M. Swain, D. Janssen, A. Bowser, J. A. Mortimer, R. W. Carlson
- Brd. 43D** **Clinical practice guidelines (CPGs) for adjuvant chemotherapy (aCT) in colorectal cancer: A population-based analysis of adherence and non-receipt. (Abstract #6064)**
D. Rayson, R. Urquhart, E. Grunfeld, M. Cox, C. Kendell, M. Jorgensen, B. Colwell, G. A. Porter
- Brd. 43E** **Understanding patients' attitudes toward communication about the cost of cancer care. (Abstract #6065)**
A. J. Bullock, E. W. Hofstatter, M. Yushak, M. K. Buss

Saturday, June 4, 2011

- Brd. 43F** **Are African American men adequately represented in prostate cancer randomized controlled trials? A systematic review. (Abstract #6066)**
S. Galeb, T. Reljic, B. Djulbegovic, C. Gwede, N. B. Kumar, A. Kumar
- Brd. 43G** **Costs and utilization of oncology health care services at the end of life. (Abstract #6067)**
B. Chastek, C. R. Harley, J. D. Kallich, L. N. Newcomer, C. J. Paoli, A. Teitelbaum
- Brd. 43H** **Willingness to pay to prevent chemotherapy-induced nausea and vomiting. (Abstract #6068)**
P. Miller, S. Balu, D. Buchner, M. Walker, E. J. Stepanski, L. S. Schwartzberg
- Brd. 44A** **Meta analysis of behavioral interventions to reduce cancer pain. (Abstract #6069)**
S. S. Gorin, H. Badr, P. B. Jacobsen, E. Janke, H. S. Jim, P. Krebs
- Brd. 44B** **Analysis of minority-based community clinical oncology program (MBCCOP) accrual activity. (Abstract #6070)**
E. H. Williams, W. J. McCaskill-Stevens, T. E. Lad
- Brd. 44C** **Surgical treatment of colon cancer in patients older than age 80. (Abstract #6071)**
H. B. Neuman, E. S. O'Connor, J. Weiss, N. K. LoConte, D. Y. Greenblatt, M. Smith
- Brd. 44D** **Cancer in the adolescent and young adult (AYA) population in the United States: Current statistics and projections. (Abstract #6072)**
R. S. Go, J. D. Gundrum
- Brd. 44E** **A review of medical malpractice claims related to clinical genetic testing. (Abstract #6073)**
R. A. Lindor, G. E. Marchant
- Brd. 44F** **ASCO Quality Oncology Practice Initiative (QOPI) quality measures for smoking cessation and survival in metastatic NSCLC. (Abstract #6074)**
I. T. Lennes, J. S. Temel, J. A. Greer, J. O. Jacobson, E. R. Park, V. A. Jackson, E. R. Gallagher, H. Bemis, W. F. Pirl
- Brd. 44G** **A clinical trial with culturally tailored video to increase participation of African Americans in cancer clinical trials. (Abstract #6075)**
D. R. Banda, M. Mete, R. Kapoor, S. M. Swain
- Brd. 44H** **Quantifying the personal financial impact of a career choice in academic hematology/oncology (AHO). (Abstract #6076)**
M. Palmeri, E. Stansfield, A. Stansfield, A. D. Fuld, J. M. Pipas, B. A. Arrick, E. Wadsworth, T. H. Davis
- Brd. 45A** **Comparison of beliefs of lung cancer providers and minority patients. (Abstract #6077)**
C. B. Smith, N. Bickell, E. Halm, A. R. Berman, C. A. Powell, J. Salazar-Schicchi, J. E. Nelson, J. P. Wisnivesky
- Brd. 45B** **Impact of early prostate cancer diagnosis in the United States. (Abstract #6078)**
Y. Zhang, B. K. Hollenbeck, J. E. Montie, J. T. Wei
- Brd. 45C** **Predictors of successful breast-conserving surgery (BCS) in patients with ductal carcinoma in situ (DCIS). (Abstract #6079)**
J. J. Griggs, M. E. Sorbero, G. M. Ahrendt, L. M. Schifffauer, A. Stark, A. W. Dick
- Brd. 45D** **Accelerated partial-breast irradiation using brachytherapy (APBIB) for breast cancer: Predictors of use and guideline concordance. (Abstract #6080)**
J. A. Hattangadi, N. Taback, B. A. Neville, J. R. Harris, R. S. Punglia
- Brd. 45E** **Cost-effectiveness of intraoperative radiation therapy for breast conservation. (Abstract #6081)**
M. Alvarado, E. Ozanne, A. Mohan, L. Esserman

- Brd. 45F Cost effectiveness of a survivorship care plan for breast cancer survivors. (Abstract #6082)**
D. Coyle, E. Grunfeld, K. Coyle, J. A. Julian, G. R. Pond, A. Folkes, M. N. Levine, FUII Trial Investigators, Ontario Clinical Oncology Group
- Brd. 45G Clinical outcome of advanced colorectal cancer patients pre and post bevacizumab therapy using the SEER database. (Abstract #6083)**
M. Choi, G. Dyson, P. A. Philip, A. F. Shields
- Brd. 45H How often are opioids prescribed for cancer patients reporting pain? Results of a population-based analysis. (Abstract #6084)**
L. C. Barbera, H. Seow, A. Husain, D. Howell, C. Atzema, C. Earle, Y. Liu, J. Sussman, R. Sutradhar, D. J. Dudgeon
- Brd. 46A Validation of a claims-based predicted performance status measure in SEER-Medicare. (Abstract #6085)**
F. Hendrick, I. H. Zuckerman, N. B. Pandya, X. Ke, M. J. Edelman, A. J. Davidoff
- Brd. 46B The cost-effectiveness of primary prophylaxis with granulocyte colony-stimulating factor in docetaxel-containing adjuvant chemotherapy in early breast cancer: The impact of risk of febrile neutropenia and its mortality. (Abstract #6086)**
K. K. Chan, M. E. Trudeau, A. Eisen, J. L. Verreault, C. A. Freedman, S. Dent
- Brd. 46C Correlates of poor surgical margins following initial surgery for ductal carcinoma in situ and receipt of additional surgery. (Abstract #6087)**
M. E. Sorbero, J. J. Griggs, G. M. Ahrendt, L. M. Schifflauer, A. Stark, A. W. Dick
- Brd. 46D A year in the life of oncology health services research. (Abstract #6088)**
M. Brundage, C. F. Snyder, B. H. Bass
- Brd. 46E Changing prognosis of glioblastoma multiforme (GBM) in the 21st century: The influence of age and regional income. (Abstract #6089)**
M. V. Mishra, A. Dicker, M. Werner-Wasik, D. W. Andrews, X. Shen, T. N. Showalter, J. Glass, Z. Symon, Y. R. Lawrence
- Brd. 46F Reporting of cancer clinical trial adverse drug events: A RADAR report. (Abstract #6090)**
S. M. Belknap, C. H. Georgopoulos, S. A. Weitzman, L. Qualkenbush, A. T. Samaras, J. M. McKoy, B. J. Edwards, S. T. Rosen, D. P. West
- Brd. 46G A national evaluation of response and factors affecting response to neoadjuvant therapy in breast and rectal cancer. (Abstract #6091)**
S. B. Edge, D. Gress, D. P. Winchester, A. Stewart
- Brd. 46H Evaluation of cancer trial eligibility criteria (with focus on non-AIDS-defining cancers) for inclusion of persons with HIV infection. (Abstract #6092)**
S. A. Weiss, S. Gajavelli, A. Negassa, J. A. Sparano, M. Haigentz Jr.
- Brd. 47A Predictors of accrual to clinical trials in an integrated health care delivery system. (Abstract #6093)**
C. P. Somkin, L. M. Ackerson, G. Husson, T. Kolevska, D. Goldstein, L. Fehrenbacher
- Brd. 47B Emerging trends in radiation therapy use among women older than age 70 with stage I breast cancer from 2000–2007: A population-based analysis. (Abstract #6094)**
X. Shen, A. P. Wojcieszynski, M. V. Mishra, P. R. Anne, T. N. Showalter
- Brd. 47C Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov. (Abstract #6095)**
B. R. Hirsch, R. M. Califf, A. Tasneem, K. Chiswell, J. Bolte, K. A. Schulman, A. P. Abernethy
- Brd. 47D Therapeutic clinical trial enrolment among young adults diagnosed with cancer. (Abstract #6096)**
P. S. Blanchette, M. Crump, A. A. Gupta

Saturday, June 4, 2011

- Brd. 47E Use of radiation therapy after breast-conserving surgery among Medicaid recipients with early-stage breast cancer. (Abstract #6097)**
S. B. Wheeler, Y. Wu, A. Meyer, W. R. Carpenter, L. C. Richardson, J. L. Smith, M. A. Lewis, B. Weiner
- Brd. 47F Risks and benefits of phase I trials: Twelve-years experience from a single institution. (Abstract #6098)**
U. Swami, M. H. Ghalib, I. Chaudhary, J. Y. Hou, S. Aparo, M. H. Einstein, G. L. Goldberg, T. N. Elrafei, S. Gajavelli, B. Cohen, L. Rajdev, A. Kaubisch, M. Haigentz Jr., S. Mani, S. Goel
- Brd. 47G Framing the benefits of cancer treatment: How survival is described influences preferences for care. (Abstract #6099)**
P. Lin, T. W. Concannon, D. Greenberg, G. P. Rossi, J. Hille, C. Fang, H. R. Auerbach, P. J. Neumann
- Brd. 47H Doctor, what do I have? Limited-English-proficient patients and cancer diagnosis knowledge. (Abstract #6100)**
J. C. Leng, L. Yogendran, D. Massie, J. Ramirez, T. Lee, I. Lobach, F. Gany
- Brd. 48A The ASCO Breast Cancer Registry pilot: Implementation of a multisite community practice registry and treatment plan/summary program. (Abstract #6101)**
A. H. Partridge, V. W. Norris, V. S. Blinder, B. A. Cutter, M. T. Halpern, J. Malin, M. N. Neuss, A. C. Wolff, ASCO Breast Cancer Registry Pilot Steering Group
- Brd. 48B Health-related quality-of-life (HRQoL) reporting by randomized cancer trials (RCT): Pitfalls for interpretation. (Abstract #6102)**
L. Testa, C. C. Barbosa, A. C. Chaves, P. M. Hoff, R. P. Riechelmann
- Brd. 48C Prospective validation of risk prediction models for acute and delayed chemotherapy-induced nausea and vomiting (CINV). (Abstract #6103)**
N. Bouganim, G. Dranitsaris, L. Vandermeer, S. Hopkins, S. Dent, P. Wheatley-Price, S. Verreault, C. Young, M. J. Clemons
- Brd. 48D Pharmaceutical involvement in phase II breast cancer clinical trials. (Abstract #6104)**
A. Schneider, T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, J. M. Peppercorn
- Brd. 48E Shifting patterns in the interpretation of phase III clinical trial outcomes in the treatment of advanced NSCLC. (Abstract #6105)**
A. G. Sacher, N. B. Leighl
- Brd. 48F Relationship between physician characteristics and the use of newer chemotherapy for the treatment of colon cancer. (Abstract #6106)**
D. J. Becker, D. L. Hershman, B. J. Insel, A. I. Neugut
- Brd. 48G Uptake of bevacizumab for the treatment of colon cancer. (Abstract #6107)**
A. I. Neugut, D. J. Becker, B. J. Insel, D. L. Hershman
- Brd. 48H Population-based health care cost estimates related to breast cancer by staging. (Abstract #6108)**
N. Mittmann, P. K. Isogai, R. Saskin, N. Liu, J. Hoch, N. B. Leighl, M. C. Cheung, M. E. Trudeau, W. K. Evans, K. Dainty, C. Earle
- Brd. 49A Oncology appointment compliance in navigated and non-navigated patients receiving radiation therapy in an urban public hospital. (Abstract #6109)**
E. A. Marcus, N. Holloway, C. Galligan, R. Cheng, M. McDunn, P. A. Robinson, K. Devine
- Brd. 49B Early success in narrowing age, gender, and racial disparities in clinical trial accrual: Targeted screening efforts through the National Cancer Institute Community Cancer Centers Program (NCCCP). (Abstract #6110)**
S. S. Grubbs, R. S. Go, M. Z. Berger, M. Gonzalez, M. A. Thompson, R. Enos, D. C. St. Germain, A. Denicoff, C. Servididio, J. D. Bearden, H. Zaren, K. Wilkinson, M. Krasna, W. McCaskill-Stevens, M. Bell, R. K. Freeman, S. Miesfeldt, T. S. Ravikumar, S. G. Nair, A. Bashey

- Brd. 49C** **A cost benefit analysis of the 21-gene breast cancer assay within a Canadian health care system. (Abstract #6111)**
S. Hassan, N. Mittmann
- Brd. 49D** **Use of high-cost imaging in elderly patients with metastatic cancer. (Abstract #6112)**
Y. Hu, A. C. Kwok, W. Jiang, N. Taback, S. R. Lipsitz, G. V. Ting, E. T. Loggers, J. C. Weeks, C. C. Greenberg
- Brd. 49E** **The Cancer Therapy Evaluation Program's (CTEP) implementation of the Operational Efficiency Working Group (OEWG) recommendations. (Abstract #6113)**
K. DiPiazza, E. Souhan, S. Finnigan, A. Denicoff, S. Friedman, M. Montello, M. M. Mooney, P. Schettino, J. A. Zwiebel, J. H. Doroshow, J. S. Abrams
- Brd. 49F** **Cost-effectiveness of systemic therapies for metastatic pancreatic cancer. (Abstract #6114)**
V. C. Tam, Y. Ko, N. Mittmann, K. Kumar, S. Hassan, M. C. Cheung, K. K. Chan
- Brd. 49G** **Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries. (Abstract #6115)**
M. A. Dinan, T. J. Robinson, T. M. Zagar, C. D. Scales Jr., L. H. Curtis, S. D. Reed, K. A. Schulman, W. Lee
- Brd. 49H** **The 2010 National Comprehensive Cancer Network (NCCN) research benchmarking survey (RBS): Clinical trials in the academic cancer center. (Abstract #6116)**
S. L. Sherman, M. B. Waldinger, D. E. Paul
- Brd. 50A** **Survivorship care plan assessment checklist (SCPAC): A tool to evaluate breast cancer survivorship care plans. (Abstract #6117)**
C. T. Stricker, L. A. Jacobs, A. DeMichele, A. Jones, B. C. Risendal, S. C. Palmer
- Brd. 50B** **Survival trends and patterns of chemotherapy use in elderly metastatic colorectal cancer (mCRC) patients. (Abstract #6118)**
V. Shankaran, S. J. Beck, D. K. Blough, L. Koepl, Y. Yim, E. Yu, S. D. Ramsey
- Brd. 50C** **Clinical trial availability compared to incidence rates for adolescent and young adult cancer. (Abstract #6119)**
D. J. Indelicato, A. Bleyer, LIVESTRONG Young Adult Alliance
- Brd. 50D** **Conflict of interest in economic analyses of targeted therapies in oncology. (Abstract #6120)**
A. D. Nearchou, A. Valachis, N. P. Polyzos, D. Mauri, P. A. Lind
- Brd. 50E** **Long-term surveillance and preventive practices among healthy young adult cancer survivors. (Abstract #6121)**
E. M. Del Giudice, L. F. Paszat, L. Rabeneck, R. Sutradhar, D. Urbach, D. Wilton, N. N. Baxter
- Brd. 50F** **Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. (Abstract #6122)**
J. A. Sloan, M. R. Mahoney, D. J. Sargent, J. M. Hubbard, H. Liu, E. M. Basch, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, S. R. Alberts
- Brd. 50G** **Perspectives on electronic health information exchange among people affected by cancer. (Abstract #6123)**
E. B. Beckjord, R. Rechis, L. N. Shulman, B. Hesse
- Brd. 50H** **Does insurance coverage affect pancreatic cancer survival? The Medicare age threshold. (Abstract #6124)**
J. K. Smith, J. Dimick, E. R. Witkowski, E. Ragulin-Coyne, T. P. McDade, S. Ng, Z. Zhou, J. F. Tseng
- Brd. 51A** **The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis. (Abstract #6125)**
M. Raphael, J. J. Biagi, W. J. Mackillop, W. Kong, W. D. King, C. M. Booth

Saturday, June 4, 2011

- Brd. 51B Two decades of oncology randomized controlled trials: Factors associated with CONSORT clinical trial reporting checklist compliance. (Abstract #6126)**
G. Rodrigues, I. Arra, V. Velker, B. Rotenberg, T. Sexton
- Brd. 51C Palliative chemotherapy: Does aggressive care beget aggressive care? (Abstract #6127)**
A. A. Wright, H. G. Prigerson
- Brd. 51D Appointment (appt) access for new cancer patients (pts). (Abstract #6128)**
K. Gogineni, K. Armstrong
- Brd. 51E Impact of travel distance on early diagnosis of prostate cancer (CaP) and receipt of curative treatment. (Abstract #6129)**
J. A. Holmes, W. R. Carpenter, Y. Wu, S. P. Hinton, M. Massing, A. P. Schenck, A. Meyer, S. B. Wheeler, P. A. Godley, R. C. Chen
- Brd. 51F Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. (Abstract #6130)**
A. C. Dueck, D. J. Sargent, P. J. Novotny, P. A. Decker, H. Nelson, R. Qin, J. A. Sloan
- Brd. 51G Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study. (Abstract #6131)**
M. Walker, A. Szeto, Z. Meng, B. E. Chen, R. M. Meyer
- Brd. 51H Managing specialty medication services through a network of specialty pharmacies: A case of oral oncology medications. (Abstract #6132)**
S. Aslam, S. Tschida, L. S. Lal, T. T. Khan, W. H. Shrank, G. R. Bhattarai, J. C. Montague- Clouse, L. N. Newcomer
- Brd. 52A Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status. (Abstract #6133)**
L. P. Garrison, D. Lalla, M. G. Brammer, B. Wang, J. Babigumira, E. A. Perez
- Brd. 52B Rapid improvement in evidence-based, quality care of cancer patients with initiation of ASCO's Quality Oncology Practice Initiative (QOPI). (Abstract #6134)**
M. A. Amin, M. H. Hashmi, S. A. Taylor
- Brd. 52C The effect of process engineering on the performance of a chemotherapy outpatient clinic (CC). (Abstract #6135)**
J. Latreille, C. Mimeault, N. Moreau, S. Parent, J. Savaria, J. Bastien, J. Lafreniere, C. C. Prady, O. Blaizel, G. Pie, M. Gannon
- Brd. 52D Computer-assisted outreach by patient care navigators using laptop wireless communication. (Abstract #6136)**
M. Castaldi, T. N. Elrafei, M. Broderick, H. Delany, Albert Einstein College of Medicine

SATURDAY

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Display Time: 8:00 AM - 12:00 PM

Display Location: S403

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: S406

CME credit: 1

Track(s): Developmental Therapeutics

Jeffrey R. Infante, MD—Chair

The Sarah Cannon Cancer Center

Discussion

12:00 PM Janet Dancey, MD (Abstracts #2515–2523)
 Ontario Institute for Cancer Research

Discussion

12:15 PM S. Percy Ivy, MD (Abstracts #2524–2529)
 National Cancer Institute

Discussion

12:30 PM George Coukos, MD, PhD (Abstracts #2530–2535)
 University of Pennsylvania, Abramson Cancer Center

Discussion

12:45 PM Jeffrey R. Infante, MD (Abstracts #2536–2539)
 The Sarah Cannon Cancer Center

- Brd. 1** **First-in-human trial focusing on the immunologic effects of the survivin-derived multiepitope vaccine EMD640744. (Abstract #2515)**
S. Gross, V. Lennerz, E. Gallerani, C. Sessa, N. Mach, S. Boehm, D. Hess, L. von Boehmer, A. Knuth, A. Ochsenbein, U. Gnad-Vogt, J. Zieschang, U. Forssmann, T. Woelfel, E. Kaempgen
- Brd. 2** **The effect of CYP2C19 polymorphism on the tolerability of ARQ 197: Results from phase I trial in Japanese patients with metastatic solid tumors. (Abstract #2516)**
 T. Nishina, T. Hirashima, K. Sugio, K. Muro, S. Akinaga, H. Maeda, T. Takahashi, T. Naito, H. Murakami, H. Yasui, N. Boku, N. Yamamoto
- Brd. 3** **Phase I dose-finding study of trabectedin (T) in combination with cisplatin (C) in patients (pts) with advanced solid tumors. (Abstract #2517)**
C. Sessa, E. Gallerani, G. Del Conte, A. Christinat, A. Perotti, P. Lardelli, C. M. Kahatt, A. Florez, C. Fernandez, M. Miani, L. Gianni
- Brd. 4** **A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors. (Abstract #2518)**
 M. Puglisi, L. van Doorn, M. Blanco-Codesido, M. J. De Jonge, K. Moran, J. Yang, T. Busman, C. Franklin, M. Mabry, A. Krivoshik, R. Humerickhouse, L. R. Molife, F. Eskens
- Brd. 5** **A phase I clinical trial on the combined intravenous (IV) and intradermal (ID) administration of autologous TriMix-DC cellular therapy in patients with pretreated melanoma (TriMixIDIV). (Abstract #2519)**
B. Neyns, S. Wilgenhof, A. M. Van Nuffel, D. Benteyn, C. Heirman, I. Van Riet, A. Bonehill, J. Corthals, K. Thielemans
- Brd. 6** **Phase I study of the PARP inhibitor olaparib (O) in combination with carboplatin (C) in BRCA1/2 mutation carriers with breast (Br) or ovarian (Ov) cancer (Ca). (Abstract #2520)**
J. Lee, C. M. Annunziata, L. M. Minasian, J. Zujewski, S. A. Prindiville, H. L. Kotz, J. Squires, N. D. Houston, J. J. Ji, M. Yu, J. H. Doroshow, E. C. Kohn

- Brd. 7 Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors. (Abstract #2521)**
M. Simonelli, P. A. Zucali, R. De Sanctis, E. Lorenzi, F. De Vincenzo, L. Rimassa, M. C. Tronconi, N. Personeni, G. Masci, M. Zuradelli, M. Perrino, M. Bertossi, L. Giordano, A. Santoro
- Brd. 8 Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. (Abstract #2522)**
P. A. Zucali, M. Simonelli, F. De Vincenzo, E. Lorenzi, L. Rimassa, L. Balzarini, V. Quagliuolo, A. Lambiase, C. Bordignon, A. Santoro
- Brd. 9 Is there a therapeutic benefit for patients participating in modern phase I trials? (Abstract #2523)**
M. N. Stein, A. R. Tan, J. M. Mehnert, D. Gibbon, R. S. DiPaola, R. A. Moss, E. Poplin, E. H. Rubin, B. Saraiya, M. P. Kane, P. Scott, M. LaRosiliere, H. Camisa, P. Kirin, C. M. Thomas, J. Aisner
- Brd. 10 Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors. (Abstract #2524)**
G. A. Daniels, W. E. Carson III, A. C. Mita, K. L. Kendra, M. H. Rahimy, D. W. Inman, J. R. Appleman, J. L. Freddo, D. G. McNeel
- Brd. 11 Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor– (ER) or androgen receptor (AR)–positive advanced breast carcinoma resistant to standard endocrine therapies. (Abstract #2525)**
B. Basu, J. Ang, D. Crawley, E. Folkler, D. Sarker, M. Blanco-Codesido, K. Moran, S. Wan, N. Dobbs, F. Raynaud, S. R. Johnston, M. Dowsett, A. N. Tutt, J. F. Spicer, C. Swanton, J. S. De Bono
- Brd. 12 High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations. (Abstract #2526)**
I. Jawed, L. Amiri-Kordestani, M. Velarde, K. Adams, S. Balasubramaniam, J. Reynolds, K. Pacak, A. T. Fojo
- Brd. 13 Early assessment of efficacy of ixabepilone (IXA) by analysis of the rate of tumor growth and decay using data from phase II and phase III clinical trials in metastatic breast cancer (MBC) patients (Pts). (Abstract #2527)**
L. Amiri-Kordestani, I. Jawed, J. Wilkerson, W. D. Stein, A. T. Fojo, S. M. Swain, S. E. Bates
- Brd. 14 Survival of 1,181 patients in a phase I clinic: The University of Texas University of Texas M. D. Anderson Cancer Center experience. (Abstract #2528)**
B. Stephen, J. J. Wheeler, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, S. Fu, F. Janku, S. L. Moulder, R. Kurzrock
- Brd. 15 Bevacizumab changes in patients with naive, stage II-III breast cancer assessed by 18F-fluoromisonidazole and 18F-fluorotymidine PET-CT. (Abstract #2529)**
V. Boni, I. Dominguez, M. J. Garcia Velloso, J. Lopez Vega, P. Martinez, A. Plazaola, B. Hernando, A. Lombart Cussac, J. Lao, R. S. Gomez, I. Alvarez, J. J. Illarramendi, E. G. Calvo, S. Morales Murillo, T. Puertolas, L. J. Pina, E. Bernedo, G. Palacios, S. J. Scherer, J. Garcia-Foncillas
- Brd. 16 Intraprostatic PSA-TRICOM vaccine administration in patients with locally recurrent prostate cancer. (Abstract #2530)**
C. R. Heery, P. A. Pinto, J. Schlom, K. Y. Tsang, R. A. Madan, D. Poole, M. Vergati, B. Walter Rodriguez, M. Merino, J. L. Gulley

- Brd. 17** **A dose confirmation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine in patients with metastatic melanoma. (Abstract #2531)**
T. K. Eigentler, B. Weide, G. Spitaleri, F. G. De Braud, A. Romanini, R. Gonzales-Inglesias, A. Tasciotti, L. Giovannoni, K. Schwager, V. Lovato, M. Kaspar, E. Trachsel, D. Neri, H. D. Menssen, C. Garbe
- Brd. 18** **Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell–based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. (Abstract #2532)**
R. A. Figlin, A. Amin, A. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, M. DeBenedette, S. K. Pal, V. Master, I. Y. Tcherepanova, R. Jain, W. L. Williams, T. Monesmith, F. Miesowicz, C. A. Nicolette
- Brd. 19** **A dendritic cell–based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study. (Abstract #2533)**
H. K. Lyerly, A. Hobeika, D. Niedzwiecki, T. Osada, J. Marshall, C. R. Garrett, D. Z. Chang, M. Akilu, T. S. Crocenzi, D. J. Cole, S. Dessureault, S. D. Hsu, A. Bulusu, B. M. Clary, R. Annecharico, G. Devi, V. Chadaram, T. M. Clay, M. Morse
- Brd. 20** **Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. (Abstract #2534)**
R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, M. G. Frattini, M. Sadelain
- Brd. 21** **A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ metastatic breast cancer. (Abstract #2535)**
L. A. Emens, R. Gupta, S. Petrik, M. Laiko, J. M. Leatherman, J. Levi, J. M. Asquith, M. M. Daphtary, E. Garrett-Mayer, B. J. Kobrin, N. E. Davidson, T. Dausies, S. Atay-Rosenthal, X. Ye, A. C. Wolff, V. Stearns, E. M. Jaffee
- Brd. 22** **An umbrella protocol for histology-independent, phase I modular study based on EGFR mutation status: Using erlotinib alone or in combination with cetuximab, bortezomib, or dasatinib to overcome resistance. (Abstract #2536)**
J. Fok, R. Kurzrock, A. M. Tsimberidou, S. Wen, A. Naing, D. S. Hong, F. Janku, G. S. Falchook, S. A. Piha-Paul, R. Katz, S. Fu, S. L. Moulder, J. J. Wheler
- Brd. 23** **Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors. (Abstract #2537)**
P. A. Cohen, D. W. Northfelt, G. J. Weiss, D. D. Von Hoff, K. Manjarrez, G. Dietsch, R. M. Hershberg, R. K. Ramanathan
- Brd. 24** **Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients (pts) with advanced cancer: Updated results and assessment of human CSF distribution. (Abstract #2538)**
E. G. Chiorean, E. A. Sausville, E. I. Heath, A. Weise, J. Gomez-Navarro, K. Venkatakrishnan, S. Sankoh, J. Wu, M. Corvez, P. LoRusso
- Brd. 25** **Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as a pharmacodynamic (PD) biomarker in phase I trials of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A). (Abstract #2539)**
J. Fredrickson, I. Chang, M. Friesenhahn, E. Ashton, P. N. Munster, M. S. Gordon, D. S. Chen, L. Naumovski, A. de Crespigny, L. S. Rosen

Saturday, June 4, 2011

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Lymphoma and Plasma Cell Disorders

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E354a

CME credit: 1

Track(s): Lymphoma and Plasma Cell Disorders

John Leonard, MD—Co-Chair

Weill Cornell Medical College

Sonali M. Smith, MD—Co-Chair

The University of Chicago

Discussion

12:00 PM Ann S. LaCasce, MD (Abstracts #8015–8016, 8023)
Dana-Farber Cancer Institute

Discussion

12:15 PM David G. Maloney, MD, PhD (Abstracts #8017–8019)
Fred Hutchinson Cancer Research Center

Discussion

12:30 PM Suzanne Lentzsch, MD, PhD (Abstracts #8021–8022, 8024)
University of Pittsburgh

Discussion

12:45 PM Jonathan L. Kaufman, MD (Abstracts #8025–8027)
Emory University

Brd. 1 **Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study. (Abstract #8015)**

G. S. Nowakowski, C. B. Reeder, B. LaPlant, T. M. Habermann, C. Rivera,
W. R. Macon, D. J. Inwards, I. N. Micallef, P. B. Johnston,
L. F. Porrata, S. M. Ansell, T. E. Witzig

Brd. 2 **Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. (Abstract #8016)**

J. D. Hainsworth, E. Arrowsmith, M. McCleod, L. Fayad, O. Hamid, L. Davis,
B. K. Lin

Brd. 3 **Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). (Abstract #8017)**

B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy,
C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir

Brd. 4 **Day 15 peripheral blood lymphocyte/monocyte ratio post-autologous peripheral hematopoietic stem cell transplantation and survival in diffuse large B-cell lymphoma. (Abstract #8018)**

L. F. Porrata, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston,
W. J. Hogan, S. Markovic

Brd. 5 **Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results. (Abstract #8019)**

L. Devizzi, A. Guidetti, C. Carlo-Stella, C. Tarella, E. Seregini, M. Magni,
M. A. Di Nicola, E. Schiavello, P. Matteucci, S. Viviani, E. Bombardieri,
A. M. Gianni

SATURDAY

- Brd. 6** **Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. (Abstract #8020)**
 M. Boccadoro, F. Cavallo, A. Nagler, D. Ben Yehuda, P. Omedè, M. Cavalli, A. Levi, C. Crippa, A. Siniscalchi, P. Brasca, A. M. Carella, B. Zanetti, F. Patriarca, S. Pezzati, V. Montefusco, A. Stanevsky, B. Lupo, T. Caravita, F. Di Raimondo, A. P. Palumbo
- Brd. 7** **Survival outcomes in elderly patients with plasma cell myeloma: The three-decade Eastern Cooperative Oncology Group (ECOG) experience. (Abstract #8021)**
 E. L. Campagnaro, S. J. Jacobus, H. Uno, M. M. Oken, R. A. Kyle, S. V. Rajkumar, P. R. Greipp, D. H. Vesole, M. Weiss, R. Fonseca, H. M. Lazarus
- Brd. 8** **Bortezomib plus DA-EPOCH-rituximab followed by bortezomib maintenance versus observation in previously untreated mantle cell lymphoma (MCL). (Abstract #8022)**
 C. Grant, K. Dunleavy, M. Tweito, S. M. Steinberg, S. Pittaluga, E. S. Jaffe, A. Wiestner, W. H. Wilson
- Brd. 9** **Activity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previously untreated mantle cell lymphoma: A phase I/II study. (Abstract #8023)**
 S. E. Spurgeon, A. I. Chen, B. Ratterree, C. Okada, G. Palmbach, K. Diaz, N. Subbiah, C. Capper, E. E. Epner
- Brd. 10** **Generation of an automated tool for querying myeloma transcriptomics for multiple gene expression signatures used in risk stratification. (Abstract #8024)**
 R. Fonseca, E. Braggio, J. J. Keats, G. J. Ahmann, J. Mantei, A. K. Stewart, P. L. Bergsagel
- Brd. 11** **Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM). (Abstract #8025)**
 M. Wang, W. Bensinger, T. Martin, M. Alsina, D. S. Siegel, N. Y. Gabrail, P. Hari, S. Singhal, R. A. Vescio, S. E. Assouline, L. A. Kunkel, M. Vallone, A. Wong, R. Niesvizky
- Brd. 12** **The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study. (Abstract #8026)**
 A. K. Stewart, J. L. Kaufman, A. J. Jakubowiak, S. Jagannath, V. Kukreti, K. T. McDonagh, M. Alsina, N. J. Bahlis, A. Belch, N. Y. Gabrail, F. J. Reu, J. Matous, D. H. Vesole, R. Z. Orlowski, L. A. Kunkel, M. Le, P. Lee, M. Sebag, M. Wang, R. Vij, The Multiple Myeloma Research Consortium (MMRC)
- Brd. 13** **PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis. (Abstract #8027)**
 D. S. Siegel, T. Martin, M. Wang, R. Vij, S. Lonial, V. Kukreti, N. J. Bahlis, M. Alsina, G. Somlo, F. Buadi, F. J. Reu, K. W. Song, L. A. Kunkel, A. Wong, M. Vallone, R. Z. Orlowski, A. K. Stewart, S. Singhal, S. Jagannath, A. J. Jakubowiak, The Multiple Myeloma Research Consortium (MMRC)
- Brd. 14** **Phase II study of carfilzomib (CFZ) in combination with current agents for relapsed and refractory multiple myeloma (RRMM). (Abstract #8028)**
 J. Szymonifka, S. Z. Usmani, R. Sexton, S. Panozzo, B. P. Nair, S. Waheed, Y. Alsayed, J. Crowley, B. Barlogie

Saturday, June 4, 2011

8:00 AM - 1:00 PM
POSTER DISCUSSION SESSION

Sarcoma

Display Time: 8:00 AM - 12:00 PM

Display Location: E450a

Discussion Time: 12:00 PM - 1:00 PM

Discussion Location: E354b

CME credit: 1

Track(s): Sarcoma

Robin L. Jones, MD—Co-Chair

University of Washington

Christian Frederick Meyer, MD, PhD—Co-Chair

The Johns Hopkins University

Discussion

12:00 PM Jayesh Desai, MBBS (Abstracts #10009–10017)
Royal Melbourne Hospital

Discussion

12:15 PM Richard F. Riedel, MD (Abstracts #10019–10023)
Duke University Medical Center

Discussion

12:30 PM Warren Allen Chow, MD (Abstracts #10024–10028)
City of Hope

Discussion

12:45 PM Leo Mascarenhas, MBBS, MD, MS (Abstracts #10029–10033)
Children's Hospital Los Angeles

Brd. 1 **Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial. (Abstract #10009)**

H. L. Kindler, N. P. Campbell, K. Wroblewski, R. G. Maki, D. R. D'Adamo, W. A. Chow, D. R. Gandara, C. Antonescu, W. M. Stadler, E. E. Vokes

Brd. 2 **A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study. (Abstract #10010)**

M. Ryu, S. Park, B. Ryoo, S. Im, H. Kwon, S. Lee, B. Kang, Y. Kang

Brd. 3 **An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. (Abstract #10011)**

G. D. Demetri, M. C. Heinrich, B. Chmielowski, J. A. Morgan, S. George, R. Bradley, R. K. Blackman, F. Teofilovici, J. A. Fletcher, W. D. Tap, M. von Mehren

Brd. 4 **The effect of crenolanib (CP-868596) on phosphorylation of the imatinib-resistant D842V PDGFRA activating mutation associated with advanced gastrointestinal stromal tumors. (Abstract #10012)**

M. C. Heinrich, D. Griffith, A. McKinley, A. Presnell, A. Ramachandran

Brd. 5 **Definition of an imatinib trough concentration threshold in the treatment of advanced gastrointestinal stromal tumors (GIST). (Abstract #10013)**

M. Molimard, S. Bouchet, S. Poulette, E. Chauzit, K. Titier, N. Moore, R. Lassalle, A. Abouelfath, A. Italiano, C. Chevreau, F. Duffaud, M. Rios, D. Cupissol, A. Adenis, I. L. Ray-Coquard, O. Bouche, A. Le Cesne, J. Blay, B. Bui Nguyen

Brd. 6 **Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study. (Abstract #10014)**

K. Eechoute, M. N. Fransson, U. De Giorgi, A. K. Reyners, F. A. de Jong, L. E. Friberg, W. Van Der Graaf, A. Sparreboom, J. Verweij, W. J. Loos, R. Mathijssen

- Brd. 7** **Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival. (Abstract #10015)**
 A. Le Cesne, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, A. Cioffi, S. Chabaud, D. Perol, J. Blay
- Brd. 8** **Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). (Abstract #10016)**
 M. von Mehren, M. C. Heinrich, H. Joensuu, C. D. Blanke, E. Wehrle, G. D. Demetri
- Brd. 9** **An analysis of arterial hypertension and mutational status as predictive factors for results of sunitinib (SU) therapy in gastrointestinal stromal tumors (GIST). (Abstract #10017)**
 P. Rutkowski, E. Bylina, T. Switaj, A. Klimczak, S. Falkowski, J. Kroc, I. A. Lugowska, M. Brzeskwiniewicz, A. Wozniak, J. Siedlecki, J. Limon
- Brd. 11** **Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10019)**
 S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo, J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi, P. G. Casali
- Brd. 12** **Preoperative chemoradiation therapy for localized retroperitoneal soft tissue sarcoma (RSTS): A phase II study from the Italian Sarcoma Group. (Abstract #10020)**
 A. Gronchi, A. De Paoli, C. Dani, F. Merlo, V. Quagliuolo, G. Grignani, G. Bertola, P. Navarra, A. P. Dei Tos, P. G. Casali, Italian Sarcoma Group
- Brd. 13** **Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study. (Abstract #10021)**
 R. D. Issels, R. P. Laubender, L. Lindner, U. Mansmann, E. Kampmann, J. Verweij, P. Reichardt, B. Schem, S. Daugaard, M. Niederhagen, Z. Vujaskovic, R. Wessalowski, C. M. Wendtner, K. Jauch, H. Duerr, R. Windhager, W. Hiddemann, J. Blay, P. Hohenberger
- Brd. 14** **A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: Results from 81 randomized patients. (Abstract #10022)**
 P. Pautier, A. Floquet, L. Gladieff, D. Berton-Rigaud, S. Piperno-Neumann, F. Selle, C. Guillemet, I. Ray-Coquard, B. Weber, P. Duvillard, C. Haie-Meder, A. Rey
- Brd. 15** **Sensitivity of well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) to high-dose ifosfamide: Combined analysis from two European referral institutions. (Abstract #10023)**
 R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali
- Brd. 16** **A phase II dose expansion of TH-302 in combination with doxorubicin in soft tissue sarcoma. (Abstract #10024)**
 L. D. Cranmer, K. N. Ganjoo, D. Adkins, D. R. Reed, S. H. Okuno, J. E. Butrynski, D. A. Rushing, G. A. Lorente, S. Kroll, S. P. Chawla
- Brd. 17** **A phase II trial of sorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST). (Abstract #10025)**
 D. R. D'Adamo, M. Keohan, R. D. Carvajal, M. L. Hensley, C. Hirst, L. Qin, C. Antonescu, R. A. Lefkowitz, G. K. Schwartz, R. G. Maki

- Brd. 18** **A dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcoma. (Abstract #10026)**
D. M. Loebl, K. A. DeLorenzo, A. R. Chen, C. F. Meyer, J. Powell
- Brd. 19** **Phase I study of irinotecan and temsirolimus in patients with refractory sarcomas. (Abstract #10027)**
S. Movva, T. Bocklage, B. Schmit, R. Quinn, B. J. Liem, C. F. Verschraegen
- Brd. 20** **Phase II AIDS Malignancy Consortium trial of imatinib in AIDS-associated Kaposi's sarcoma (KS). (Abstract #10028)**
H. B. Koon, K. Honda, J. Y. Lee, A. Noy, AIDS Malignancy Consortium
- Brd. 21** **Use of cellular context to determine sarcoma phenotype in a new mouse sarcoma model. (Abstract #10029)**
S. Hettmer, J. Liu, C. M. Miller, R. T. Bronson, D. M. Langenau, A. J. Wagers
- Brd. 22** **Phase II pilot study of imatinib mesylate in neurofibromatosis (NF1) patients with plexiform neurofibromas. (Abstract #10030)**
K. A. Robertson, D. C. Bowers, F. Yang, T. Vik, C. Ho, J. Croop, L. E. Walsh, C. Hingtgen, K. R. Pradhan, G. Hutchins, J. W. Fletcher, M. Cohen, M. Edwards-Brown, J. B. Travers, M. Yu, G. Nalepa, S. Denne, D. Ingram, W. Clapp
- Brd. 23** **Cixutumumab combined with temsirolimus in patients with refractory Ewing's sarcoma. (Abstract #10031)**
A. Naing, P. LoRusso, S. Fu, D. S. Hong, P. M. Anderson, R. S. Benjamin, J. A. Ludwig, H. X. Chen, L. A. Doyle, R. Kurzrock
- Brd. 24** **Preliminary safety and outcome report of the metronomic therapy from the Latin American osteosarcoma treatment protocol 2006. (Abstract #10032)**
A. S. Petrilli, C. R. Macedo, S. R. Toledo, P. C. Pavoni-Ferreira, M. Grings, M. Scopinaro, S. Ferman, E. Boldrini, M. A. Almeida, C. T. de Oliveira, G. L. Rey, L. A. Castillo, M. Borsato, J. Barreto, V. L. Morais, A. L. Brunetto, D. Lustosa, Grupo Latino Americano para Tratamiento de Osteosarcoma GLATO/GALOP
- Brd. 25** **Activity of toremifene in sporadic desmoid-type fibromatosis. (Abstract #10033)**
M. Fiore, C. Colombo, S. Radaelli, P. Prestianni, R. Sanfilippo, C. Morosi, F. Perrone, S. Stacchiotti, P. G. Casali, A. Gronchi

SATURDAY

**9:30 AM - 12:00 PM
SPECIAL SESSION**

Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award and Lecture, ASCO Humanitarian Award, and the Conquer Cancer Foundation Donor Recognition Awards

Location: Hall B1

CME credit: 1.5

Track(s): Special Session

Kenneth Carl Anderson, MD—Karnofsky Award Recipient

Dana-Farber Cancer Institute

Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma

Saturday, June 4, 2011

**9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION**

The Role of Prevention Services in U.S. Health Care Reform (M01)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology, Health Services Research

Steven Stranne, MD, JD

Polsinelli Shughart

The Role of Prevention in the New Health Care Reform Bill

SATURDAY

9:45 AM - 11:00 AM

CLINICAL PROBLEMS IN ONCOLOGY SESSION

Practical Approaches to the Patient with Complex Gynecologic Cancer (C03)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Gynecologic Cancer

Nadeem Abu-Rustum, MD—Chair

Memorial Sloan-Kettering Cancer Center

Practical Management of Late-stage Complications of Ovarian Cancer

Krishnansu Sujata Tewari, MD

University of California, Irvine Medical Center

Treatment Challenges in the Management of the Advanced Cervical Cancer Patient

Linda R. Duska, MD

University of Virginia Health System

Conservative Management of a Young Patient with Endometrial Cancer: Fertility-sparing Options

Saturday, June 4, 2011

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Colorectal) Cancer

Location: Hall D1

CME credit: 3

Track(s): Gastrointestinal (Colorectal) Cancer

Michael J. Hall, MD—Co-Chair

Fox Chase Cancer Center

John S. Kauh, MD—Co-Chair

Winship Cancer Institute of Emory University

1:00 PM The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. (Abstract #3503)

M. S. Roh, G. A. Yothers, M. J. O'Connell, R. W. Beart, H. C. Pitot, A. F. Shields, D. S. Parda, S. Sharif, C. J. Allegra, N. J. Petrelli, J. C. Landry, D. P. Ryan, A. Arora, T. L. Evans, G. S. Soori, L. Chu, R. V. Landes, M. Mohiuddin, S. Lopa, N. Wolmark

1:15 PM Capecitabine (Cape) versus 5-fluorouracil (5-FU)—based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial. (Abstract #3504)

R. Hoffeinz, F. K. Wenz, S. Post, A. Matzdorff, S. Laechelt, J. T. Hartmann, L. Müller, H. Link, M. H. Moehler, E. Kettner, E. Fritz, U. Hieber, H. Lindemann, M. Grunewald, S. Kremers, C. Constantin, M. Hipp, D. Gencer, I. Burkholder, A. Hochhaus

1:30 PM Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phase III trial. (Abstract #LBA3505)

C. Roedel, H. Becker, R. Fietkau, U. Graeven, W. Hohenberger, T. Hothorn, M. Lang-Welzenbach, T. Liersch, L. Staib, H. Christiansen, C. Wittekind, R. Sauer

1:45 PM An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3–4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (Abstract #3506)

F. Bonnetain, J. Bosset, J. Gerard, G. Calais, T. Conroy, L. Mineur, O. Bouche, P. Maingon, O. Chapet, L. Radosevic-Jelic, N. Methy, L. Collette

Discussion

2:00 PM Robert Glynne-Jones, MD (Abstracts #3503–3506)
Mount Vernon Centre for Cancer Treatment

2:15 PM The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer. (Abstract #3507)

G. A. Yothers, C. J. Allegra, M. J. O'Connell, T. J. George, S. Sharif, N. J. Petrelli, S. Lopa, N. Wolmark

2:30 PM Overall survival (OS) and updated disease-free survival (DFS) results of the NSABP C-08 trial assessing bevacizumab (B) in stage II and III colon cancer. (Abstract #3508)

C. J. Allegra, G. A. Yothers, M. J. O'Connell, S. Sharif, N. J. Petrelli, L. H. Colangelo, N. Wolmark

2:45 PM A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. (Abstract #3509)

T. Andre, E. Van Cutsem, H. Schmoll, J. Tabernero, S. Clarke, M. J. Moore, D. Cunningham, T. H. Cartwright, J. R. Hecht, F. Rivera, S. Im, G. Bodoky, R. Salazar, F. Maindrault-Goebel, E. Shmueli, E. Bajetta, M. Makrutzki, A. Shang, A. De Gramont, P. M. Hoff

Discussion

3:00 PM Howard S. Hochster, MD (Abstracts #3507–3509)
Yale Cancer Center

3:15 PM **Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). (Abstract #3510^)**

J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. L. Burkes, M. E. Barugel, Y. Humblet, D. Cunningham, F. Xu, K. Krishnan

3:30 PM **Influence of *KRAS* G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab. (Abstract #3511)**

S. Tejpar, C. Bokemeyer, I. Celik, M. Schlichting, U. Sartorius, E. Van Cutsem

Discussion

3:45 PM Tanios S. Bekaii-Saab, MD (Abstracts #3510^–3511)
The Ohio State University Medical Center

Saturday, June 4, 2011

1:15 PM - 2:30 PM
SPECIAL SESSION

Pediatric Oncology Award and Lecture

Location: S504

CME credit: 1.25

Track(s): Special Session, Pediatric Oncology

Lee J. Helman, MD

Center for Cancer Research, National Cancer Institute

Pathways to New Targets for Pediatric Sarcomas

SATURDAY

1:15 PM - 2:30 PM
EDUCATION SESSIONS

Direct-to-Consumer Genetic Testing for Cancer: What Physicians Need to Know

Location: E353

CME credit: 1.25

Track(s): Cancer Genetics, General Oncology

Sancy Ann Leachman, MD—Chair

University of Utah Hospitals and Clinics

Direct-to-Consumer Genetic Testing for Cancer: The Consumer Perspective

Daniel B. Vorhaus, JD

Robinson, Bradshaw, & Hinson, P.A.

A Guide to the (Current) Direct-to-Consumer Genetic Testing Landscape

Stacy W. Gray, MD

Dana-Farber Cancer Institute

Direct-to-Consumer Genetic Testing: What We Know about Consumer Attitudes and Behavior

Angela R. Bradbury, MD

Fox Chase Cancer Center

Direct-to-Consumer Genetic Testing for Cancer: Clinical Implications and Challenges

Management of Prostate Cancer in Older Adults: To Treat or Not to Treat

Location: S100bc

CME credit: 1.25

Track(s): Geriatric Oncology, Genitourinary Cancer

Anthony Victor D'Amico, MD, PhD—Chair

Dana-Farber Cancer Institute/Brigham and Women's Hospital

Localized Disease

William Dale, MD, PhD

The University of Chicago Medical Center

Screening

Shabbir M. H. Alibhai, MD, MSc

University Health Network

Biochemical Recurrence

Newer Techniques and Controversies in Breast and Lung Imaging for Cancer Screening and Prevention

Location: S100a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology, Breast Cancer, Lung Cancer

Denise R. Aberle, MD—Chair

University of California, Los Angeles David Geffen School of Medicine

Lung Cancer Screening and CT Imaging

Constance D. Lehman, MD, PhD

University of Washington

Breast Cancer Screening: Magnetic Resonance Imaging, Ultrasound, Mammography—Where Do We Stand?

Saturday, June 4, 2011

Post–Health Care Reform: Facing the New Reality

Location: E354b

CME credit: 1.25

Track(s): Practice Management and Information Technology, Health Services Research

Tom Main, MBA—Chair

Oliver Wyman

Preparing Your Practice for Post–Health Care Reform: How Do Accountable Care Organizations Work? How Do We Define and Manage Risk?

Lee Nisley Newcomer, MD

United Health Group

Payer Perspectives in Oncology

Cecil Wilson, MD

American Medical Association

Response from the Medical Community

The Therapy of High-risk Patients with Lung Cancer

Location: Hall B1

CME credit: 1.25

Track(s): Lung Cancer, Geriatric Oncology

Jeffrey Bogart, MD—Chair

State University of New York Upstate Medical University

Tailoring Radiotherapy for High-risk/Compromised Patients with Early-stage or Locally Advanced Non-small Cell Lung Cancer

Cesare Gridelli, MD

SG Moscati Hospital

Therapy of Elderly Patients with Advanced Lung Cancer

Rogerio Lilenbaum, MD

Cleveland Clinic Florida

Implications of Comorbidities and Performance Status in Patients with Advanced Lung Cancer

SATURDAY

1:15 PM - 2:30 PM
MEET THE PROFESSOR SESSION

Circulating Tumor Cells: We Have the Technology, But What Do We Do with the Information? (M06)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Developmental Therapeutics, Breast Cancer, Genitourinary Cancer

Daniel F. Hayes, MD

University of Michigan Medical Center

1:15 PM - 2:30 PM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Subsequent Therapy after Treatment of Lung Cancer: Consensus? (C04)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Lung Cancer

Kenneth Rosenzweig, MD—Chair

Mount Sinai Medical Center

The Role of Postoperative Radiation Therapy in the Patient with Resected Lung Cancer: When, Why, and How?

Jessica S. Donington, MD

New York University School of Medicine

Surgical Concerns for Adjuvant Therapy

Joan H. Schiller, MD

University of Texas Southwestern Medical Center

Adjuvant Therapy: Who, What, When, and Why?

Saturday, June 4, 2011

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Ovarian Cancer: Novel Approaches to Improve Treatment Outcomes

Location: E354a

CME credit: 1.5

Track(s): Gynecologic Cancer

Amit M. Oza, MD—Chair

Princess Margaret Hospital

1:15 PM **Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens. (Abstract #5000)**

C. Gourley, C. O. Michie, K. E. Keating, S. Deharo, E. J. O'Brien, A. Winter, F. A. McDyer, J. M. Mulligan, L. A. Hill, T. S. Davison, T. Halsey, L. McCoy, C. Wilson, A. Williams, D. J. Harrison, D. P. Harkin, R. D. Kennedy

Discussion

1:30 PM Patricia Shaw, MD (Abstract #5000)
University Health Network

1:45 PM **Effect of screening on ovarian cancer mortality in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer randomized screening trial. (Abstract #5001)**

S. S. Buys, E. Partridge, A. Black, C. Johnson, L. Lamerato, C. Isaacs, D. Reding, R. Greenlee, B. Kessel, M. Fouad, D. Chia, L. Ragard, J. Rathmell, P. Hartge, P. Pinsky, G. Izmirlian, J. Xu, P. Prorok, C. D. Berg

Discussion

2:00 PM Usha Menon, PhD, RN (Abstract #5001)
UCL Elizabeth Garrett Institute of Women's Health

2:15 PM **Randomized double-blind placebo-controlled international trial of abagovomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abagovomab (MIMOSA) Trial. (Abstract #LBA5002)**

J. Pfisterer, J. S. Berek, A. Casado, K. Cwierzka, T. Pinter, A. Pluzanska, E. Pujade-Lauraine, G. Scambia, J. B. Vermorken, C. Simonelli, M. Bertolotti, A. Capriati, P. Sabbatini, AGO-OVAR, COGI, GEICO, GINECO

Discussion

2:30 PM George Coukos, MD, PhD (Abstract #LBA5002)
University of Pennsylvania, Abramson Cancer Center

SATURDAY

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Translational Science Advancing AR Targeting in Prostate Cancer

Location: Hall D2

CME credit: 1.5

Track(s): Genitourinary Cancer

Mark Garzotto, MD—Co-Chair

Portland Veterans Affairs Medical Center

William Kevin Kelly, DO—Co-Chair

Thomas Jefferson University Hospital

1:15 PM Abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) and prior therapy with ketoconazole: A Prostate Cancer Clinical Trials Consortium study. (Abstract #4500)

C. J. Ryan, A. L. Harzstark, A. M. Lin, L. Fong, K. Grycz, R. Z. Szmulewitz, V. K. Weinberg, A. Molina, E. J. Small

Discussion

1:30 PM Mary-Ellen Taplin, MD (Abstract #4500)
 Dana-Farber Cancer Institute

1:45 PM MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. (Abstract #4501)

E. Efsthathiou, M. A. Titus, D. Tsavachidou, A. Hoang, M. Karlou, S. Wen, P. Troncoso, R. Ashe, C. J. Berman, J. Mohler, C. Logothetis

Discussion

2:00 PM Christopher P. Evans, MD (Abstract #4501)
 University of California, Davis

2:15 PM An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model. (Abstract #4502)

H. Matsumoto, H. Kuruma, A. Zoubeidi, L. Fazli, M. E. Gleave

Discussion

2:30 PM Peter Nelson, MD (Abstract #4502)
 Fred Hutchinson Cancer Research Center

Saturday, June 4, 2011

1:30 PM - 4:00 PM
ORAL ABSTRACT SESSION

Lymphoma

Location: S406

CME credit: 2.5

Track(s): Lymphoma and Plasma Cell Disorders

Myron Stefan Czuczman, MD—Co-Chair

Roswell Park Cancer Institute

Gilles A. Salles, MD, PhD—Co-Chair

Hospices Civils de Lyon and Universite de Lyon

1:30 PM R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. (Abstract #8000)

D. Cunningham, P. Smith, P. Mouncey, W. Qian, A. S. Jack, C. Pocock, K. Ardeshna, J. A. Radford, A. J. Davies, A. McMillan, M. D. Linch

1:45 PM Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP±R for eight cycles to CHOP with or without R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (Abstract #8001)

P. J. Stiff, J. M. Unger, J. Cook, L. S. Constine, S. Couban, T. C. Shea, J. N. Winter, T. P. Miller, R. R. Tubbs, D. C. Marcellus, J. W. Friedberg, K. Barton, G. M. Mills, M. L. LeBlanc, L. Rimsa, S. J. Forman, R. I. Fisher

2:00 PM Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). (Abstract #8002)

N. Schmitz, M. Nickelsen, M. Ziepert, M. Haenel, P. Borchmann, C. Schmidt, A. Viardot, M. Bentz, N. Peter, G. Ehninger, G. Doelken, L. H. Truemper, M. Loeffler, M. Pfreundschuh, B. Glass

2:15 PM First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. (Abstract #8003)

S. Le Gouill, N. Milpied, T. Lamy, V. Delwail, R. Gressin, D. Guyotat, G. Damaj, C. Foussard, G. Cartron, H. Maisonneuve, E. Deconinck, F. Dreyfus, E. Gyan, L. Sutton, N. Morineau, M. Alexis, F. Perry, M. Sauvezie

Discussion

2:30 PM Julie Vose, MD (Abstracts #8000–8003)
University of Nebraska Medical Center

2:45 PM Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. (Abstract #8004)

C. Gisselbrecht, B. Glass, G. Laurent, D. S. Gill, M. D. Linch, M. Trneny, D. Bron, O. Shpilberg, H. Hagberg, M. Bargetzi, D. Ma, J. Briere, C. Moskowitz, N. Schmitz

3:00 PM Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: A potentially curative approach? (Abstract #8005)

L. Fischer, M. Haenel, R. Moehle, R. Schroers, T. Elter, M. Reiser, M. H. Dreyling, G. Illerhaus, J. Eucker, C. W. Scholz, B. Metzner, A. Roeth, J. Birkmann, U. Schlegel, P. Martus, E. Thiel, A. Korfel

Discussion

3:15 PM James L. Rubenstein, MD, PhD (Abstracts #8004–8005)
University of California, San Francisco

SATURDAY

- 3:30 PM Predictors of early response and event-free survival in Hodgkin lymphoma (HL): PET versus CT imaging. (Abstract #8006)**
C. L. Schwartz, D. L. Friedman, K. McCarten, S. L. Wolden, S. Voss,
L. S. Constine, L. Chen, Children's Oncology Group

Discussion

- 3:45 PM** Bruce D. Cheson, MD (Abstract #8006)
Georgetown University Medical Center

Saturday, June 4, 2011

1:30 PM - 4:30 PM
ORAL ABSTRACT SESSION

Melanoma/Skin Cancers

Location: Arie Crown Theater

CME credit: 3

Track(s): Melanoma/Skin Cancers

Paolo Antonio Ascierto, MD—Co-Chair

Istituto Nazionale Tumori

Caroline Robert, MD, PhD—Co-Chair

Institute Gustave-Roussy

- 1:30 PM** **A population-based, case-control study of MC1R variants, ultraviolet light exposure, and melanoma. (Abstract #8504)**
E. Ng, E. Vega-Saenz de Miera, B. Tan, W. Gai, J. D. Goldberg, I. Osman, M. Berwick, D. Lazovich, D. Polsky
- 1:45 PM** **Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697). (Abstract #8505)**
S. S. Agarwala, S. J. Lee, L. E. Flaherty, M. Smylie, R. F. Kefford, W. E. Carson III, G. Cohen, J. M. Kirkwood
- 2:00 PM** **Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial (ISRCTN75125874). (Abstract #8506)**
V. Chiarion-Sileni, M. Guida, A. Romanini, R. Ridolfi, M. Mandala, P. Del Bianco, B. Silvestri, M. Medici, M. Michiara, M. Dalla Palma, O. Puccetti, J. Pigozzo, F. Laveder, G. De Salvo, Italian Melanoma Intergroup
- 2:15 PM** **EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-a2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. (Abstract #8506b)**
A. M. Eggermont, S. Suci, M. Santinami, W. Kruit, A. Testori, J. Marsden, C. J. A. Punt, M. E. Gore, R. MacKie, R. Dummer, D. Schadendorf, P. Patel, A. Spatz, and U. Keilholz

Discussion

- 2:30 PM** Helen Gogas, MD (Abstracts #8504–8506b)
Hellenic Cooperative Oncology Group (HeCOG)
- 2:45 PM** **Adoptive transfer of short-term cultured tumor-infiltrating lymphocytes (young TIL) in metastatic melanoma patients. (Abstract #8510)**
R. Shapira-Frommer, M. Besser, I. Kuchuk, R. Nave, D. Zippel, A. Treves, A. Nagler, S. Apter, A. Shimoni, R. Yerushalmi, E. Ben-Ami, A. Ben-Nun, G. Markel, O. Itzhaki, R. Catane, J. Schachter
- 3:00 PM** **A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. (Abstract #8511)**
F. S. Hodi, P. A. Friedlander, M. B. Atkins, D. F. McDermott, D. P. Lawrence, N. Ibrahim, X. Wu, J. Zhou, A. Giobbie-Hurder, G. Murphy, T. Hollman, E. Velazquez, S. Russell, P. Dipro, J. T. Yap, A. D. Van Den Abbeele

Discussion

- 3:15 PM** Mario Sznol, MD (Abstracts #8510–8511)
Yale Cancer Center
- 3:30 PM** **BRAF mutation by age-decade and body mass index in metastatic melanoma. (Abstract #8507)**
A. M. Menzies, L. Visintin, M. D. Chatfield, M. S. Carlino, J. R. Howle, R. A. Scolyer, J. F. Thompson, R. F. Kefford, G. V. Long

3:45 PM **Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. (Abstract #8508)**
W. H. Sharfman, F. S. Hodi, D. P. Lawrence, K. T. Flaherty, R. K. Amaravadi, K. B. Kim, R. Dummer, S. Gobbi, I. Puzanov, J. A. Sosman, K. Dohoney, L. P. Lam, S. Kakar, Z. Tang, O. Krieter, M. B. Atkins

4:00 PM **BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. (Abstract #8509)**
A. Ribas, K. B. Kim, L. M. Schuchter, R. Gonzalez, A. C. Pavlick, J. S. Weber, G. A. McArthur, T. E. Hutson, K. T. Flaherty, S. J. Moschos, D. P. Lawrence, P. Hersey, R. F. Kefford, B. Chmielowski, I. Puzanov, J. Li, K. B. Nolop, R. J. Lee, A. K. Joe, J. A. Sosman

Discussion

4:15 PM Gary K. Schwartz, MD (Abstracts #8507–8509)
Memorial Sloan-Kettering Cancer Center

Saturday, June 4, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

Display Time: 2:00 PM - 6:00 PM
Display Location: E450b
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: Hall B1
CME credit: 1
Track(s): Breast Cancer

Fatima Cardoso, MD—Co-Chair
Champalimaud Cancer Center
Karen A. Gelmon, MD—Co-Chair
British Columbia Cancer Agency

Discussion

5:00 PM Reshma Jagsi, MD, DPhil (Abstracts #1011–1014)
University of Michigan

Discussion

5:15 PM George Somlo, MD (Abstracts #1015–1021)
City of Hope

Discussion

5:30 PM Stephen K. L. Chia, MD (Abstracts #1022–1027)
British Columbia Cancer Agency

Discussion

5:45 PM Ian E. Krop, MD, PhD (Abstracts #1028–1033)
Dana-Farber Cancer Institute

Brd. 1 **Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. (Abstract #1011)**

T. B. Julian, J. P. Costantino, F. A. Vicini, J. R. White, K. A. Winter, D. W. Arthur, R. R. Kuske, R. Rabinovitch, D. S. Parda, E. P. Mamounas, W. J. Curran Jr., N. Wolmark

Brd. 2 **Observation or standard axillary dissection after sentinel-node biopsy in breast cancer: Final results from the German KISS study. (Abstract #1012)**
C. Schem, W. Jonat, H. Ostertag, on behalf of the German KISS study group

Brd. 3 **Contralateral breast cancer risk in patients with familial breast cancer tested negative for BRCA1 and BRCA2. (Abstract #1013)**

K. Rhiem, C. Engel, M. Graeser, W. Janni, M. Kiechle, N. Ditsch, C. Mundhenke, R. Kreienberg, J. Tio, M. Golatta, A. Honig, D. Gadzicki, D. Speiser, K. Kast, S. Briest, A. Meindl, R. Schmutzler

Brd. 4 **Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study. (Abstract #1014)**

M. J. Junqueira, M. Morrow, A. S. Reiner, K. Malone, C. Lynch, J. L. Bernstein, The WECARE Study Collaborative Group

Brd. 5 **Chemotherapy (CT) with or without carboplatin as neoadjuvant treatment in patients with basal-like breast cancer. GEICAM 2006-03: A multicenter, randomized phase II study. (Abstract #1015)**

E. Alba, J. Chacon, A. Lluch, L. Garcia-Estevez, A. Anton, B. Cirauqui, J. Lopez Garcia-Asenjo, E. M. Carrasco, C. Rodriguez, M. Escudero, A. Sanchez, N. Ribelles, C. Romero, J. Alvarez, J. Albanell, on behalf of Spanish Breast Cancer Research Group (GEICAM)

SATURDAY

- Brd. 6** **Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC). (Abstract #1016)**
 A. M. Gonzalez-Angulo, M. C. Green, J. L. Murray, S. L. Palla, K. H. Koenig, A. M. Brewster, V. Valero, N. K. Ibrahim, S. L. Moulder, J. K. Litton, D. J. Crawford, P. R. Flores, M. J. Dryden, W. F. Symmans, S. H. Giordano, L. Pusztai, A. Buzdar, G. B. Mills, G. N. Hortobagyi, F. Meric-Bernstam
- Brd. 7** **A randomized study of individually tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy (FEC) for early breast cancer. (Abstract #1017)**
 H. Lindman, M. Andersson, P. Edlund, K. D. Bjerre, T. Hatschek, H. T. Mouridsen, H. Anderson, B. Ejlersen, S. Møller, E. Lidbrink, C. Kamby, J. Ahlgren, J. Bergh, C. Blomqvist
- Brd. 8** **Intense dose-dense (idd) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (ETC) compared with conventionally scheduled chemotherapy in high-risk breast cancer patients (> 3+LN): Eight-year follow-up analysis. (Abstract #1018)**
 V. Moebus, C. Thomssen, H. Lueck, W. Kuhn, A. Junker-Stein, C. M. Kurbacher, U. Nitz, R. Kreienberg, M. Untch, C. Jackisch, J. B. Huober, A. Hinke, A. Du Bois, A. Schneeweiss
- Brd. 9** **Anthracycline (A) use among women with breast cancer (BC). (Abstract #1019)**
 S. H. Giordano, Y. Lin, Y. Kuo, G. N. Hortobagyi, J. S. Goodwin
- Brd. 10** **Final multivariate analysis of obesity and survival in patients with nodal-positive primary breast cancer: The ADEBAR trial. (Abstract #1020)**
 J. W. Janni, P. G. Hepp, U. Andergassen, N. Harbeck, B. K. Rack, J. K. Neugebauer, K. Annecke, A. Wischnik, W. Simon, M. Rezai, T. N. Fehm, A. Schneeweiss, P. A. Fasching, B. Gerber, T. Zwingers, H. L. Sommer, K. Friese, M. Kiechle
- Brd. 11** **Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials. (Abstract #1021)**
 O. Gluz, C. Liedtke, R. E. Kates, J. B. Huober, S. Mohrmann, A. Hartmann, C. Thomssen, V. Moebus, U. Nitz, N. Harbeck, West German Study Group
- Brd. 12** **Local versus central laboratory discrepancies in the determination of triple-negative breast cancer (TNBC) status in a large phase III (CIBOMA/2004-01/GEICAM/2003-11) trial assessing adjuvant capecitabine (C) maintenance therapy after standard chemotherapy (CT) in early breast cancer (EBC) patients (pts). (Abstract #1022)**
 M. Ruiz-Borrego, C. H. Barrios, A. Lluch, J. Bines, J. Segalla, A. Ruiz, L. Torrecillas, A. Lombart-Cussac, R. Torres, J. Garcia Saenz, J. Lopez Garcia-Asenjo, H. L. Gomez, J. De la Haba, S. Reyes, E. Martinez, J. Baena, L. Perez-Michell, A. Rodriguez-Lescure, A. Anton, M. Martin, on behalf of CIBOMA/GEICAM
- Brd. 13** **Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. (Abstract #1023)**
 K. P. Raghav, L. F. Hernandez-Aya, X. Lei, M. Chavez-Mac Gregor, F. Meric-Bernstam, T. A. Buchholz, A. A. Sahin, K. Do, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 14** **Bcl2 as a surrogate prognostic and predictive marker in triple-negative breast cancer. (Abstract #1024)**
 T. M. Abdel-Fatah, P. D. Dickinson, P. Moseley, J. S. Reis-Filho, A. R. Green, I. O. Ellis, S. Chan

- Brd. 15** **TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. (Abstract #1025)**
S. J. Isakoff, P. E. Goss, E. L. Mayer, T. A. Traina, L. A. Carey, K. Krag, H. S. Rugo, M. C. Liu, V. Stearns, S. E. Come, D. R. Borger, C. A. Quadriano, D. Finkelstein, J. E. Garber, P. D. Ryan, E. P. Winer, L. W. Ellisen, on behalf of the Translational Breast Cancer Research Consortium
- Brd. 16** **Foxp3 expression in breast cancer cells: A new predictor of response to anthracycline versus docetaxel in primary breast cancer treated with adjuvant chemotherapy in the phase III trial FNCLCC/PACS-01. (Abstract #1026)**
F. Ghiringhelli, P. Fumoleau, L. Arnould, G. Mignot, C. Dalban, F. Bonnetain, H. H. Roche, M. Spielmann, C. Levy, A. Lortholary, F. Eichler, C. Mesleard, S. Ladoire
- Brd. 17** **Use of topoisomerase 2 alpha (TOP2A) protein overexpression to predict response to anthracycline-based chemotherapy. (Abstract #1027)**
S. Chan, J. S. Reis-Filho, P. D. Dickinson, P. Moseley, A. R. Green, I. O. Ellis, T. M. Abdel-Fatah
- Brd. 18** **Correlation of various pathological complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. (Abstract #1028)**
G. Von Minckwitz, M. Kaufmann, S. Kuemmel, P. A. Fasching, W. Eiermann, J. U. Blohmer, S. D. Costa, J. Hilfrich, C. Jackisch, B. Gerber, A. Du Bois, J. B. Huober, C. A. Hanusch, G. E. Konecny, W. Felt, E. Stickeler, N. Harbeck, K. Mehta, S. Loibl, M. Untch, GBG and AGO-B study groups
- Brd. 19** **Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial. (Abstract #1029)**
K. Shen, G. Tang, J. P. Costantino, S. J. Anderson, C. Kim, K. L. Pogue-Geile, N. Song, M. J. Gabrin, C. E. Geyer, N. Wolmark
- Brd. 20** **Blinded validation study of genomic predictions for survival following adjuvant sequential anthracycline-docetaxel chemotherapy +/- endocrine therapy. (Abstract #1030)**
W. F. Symmans, F. Andre, M. C. Liu, J. Delacruz, F. Peintinger, S. Borstnar, H. Wang, P. Regitnig, M. Ota, S. Seevaratnam, S. Delalogue, C. Hatzis
- Brd. 21** **Benefit from CMF with or without anthracyclines in relation to biologic profiles in early breast cancer. (Abstract #1031)**
A. Rocca, A. Paradiso, P. Sismondi, E. Scarpi, A. Mangia, L. Medri, S. Bravaccini, D. Casadei Giunchi, D. Amadori, R. Silvestrini
- Brd. 22** **The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. (Abstract #1032)**
M. Cheang, D. Voduc, D. Tu, S. Jiang, S. Leung, S. K. Chia, L. E. Shepherd, M. N. Levine, K. I. Pritchard, T. Vickery, S. Davies, I. J. Stijleman, C. Davis, J. S. Parker, M. J. Ellis, P. S. Bernard, C. M. Perou, T. O. Nielsen
- Brd. 23** **Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer patients: Results of the German SUCCESS trial. (Abstract #1033)**
J. K. Jueckstock, B. K. Rack, T. Zwingers, P. G. Hepp, A. Schneeweiss, M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Pantel, H. Tesch, H. Forstbauer, R. Lorenz, M. Rezai, J. K. Neugebauer, U. Andergassen, K. Friese, W. Janni, SUCCESS Study Group

SATURDAY

- Brd. 24 Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC). (Abstract #1034)**
A. Awada, S. Chan, G. H. Jerusalem, R. E. Coleman, M. T. Huizing, A. Mehdi, S. M. O'Reilly, J. T. Hamm, P. J. Barrett-Lee, V. Cocquyt, K. Sideras, D. E. Young, M. Brown, C. Zhao, A. L. Hannah, L. K. Masuoka, A. Garcia, E. A. Perez, NKTR-102 Study Group
- Brd. 25 Relationship between OS and PFS in metastatic breast cancer (MBC): Review of FDA submission data. (Abstract #1035)**
P. Cortazar, J. J. Zhang, R. Sridhara, R. L. Justice, R. Pazdur

Saturday, June 4, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Developmental Therapeutics—Experimental Therapeutics

Display Time: 2:00 PM - 6:00 PM

Display Location: S403

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: S406

CME credit: 1

Track(s): Developmental Therapeutics

R. Donald Harvey, PharmD—Co-Chair

Winship Cancer Institute at Emory University

Jan H. M. Schellens, MD, PhD—Co-Chair

Netherlands Cancer Institute

Discussion

5:00 PM Patrick Schoffski, MD, MPH (Abstracts #3011–3016)
University Hospitals Leuven

Discussion

5:15 PM Lillian L. Siu, MD (Abstracts #3017–3024)
Princess Margaret Hospital

Discussion

5:30 PM Carlos L. Arteaga, MD (Abstracts #3025–3029)
Vanderbilt-Ingram Cancer Center

Discussion

5:45 PM Mark J. Ratain, MD (Abstracts #3030–3032)
The University of Chicago

Brd. 1 **First human dose (FHD) study of the oral transforming growth factor-beta receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma. (Abstract #3011)**

J. Rodon Ahnert, J. Baselga, E. Calvo, J. Seoane, I. Brana, E. Sicart, I. Gueorguieva, A. Cleverly, M. M. Lahn, S. Pillay, M. Holdhoff, J. O. Blakeley, M. A. Carducci

Brd. 2 **A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors. (Abstract #3012)**

T. Doi, H. Murakami, K. Wan, M. Miki, H. Kotani, N. Sakamoto, N. Yamamoto, A. Ohtsu

Brd. 3 **MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules. (Abstract #3013)**

J. S. Kauh, G. Shapiro, R. B. Cohen, J. W. Clark, R. Harvey, J. M. Cleary, D. Mahalingam, S. Kuan, A. McDonald, A. Berger, B. Dezube, J. Sarantopoulos

Brd. 4 **A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. (Abstract #3014)**

C. M. Rudin, A. Jimeno, W. H. Miller Jr., B. J. Eigl, S. N. Gettinger, A. L. Chang, K. Faia, J. Sweeney, G. Loewen, R. W. Ross, G. J. Weiss

Brd. 5 **Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. (Abstract #3015)**

D. Mahadevan, E. G. Chiorean, W. Harris, D. D. Von Hoff, A. Younger, D. M. Rensvold, F. Cordova, W. Qi, C. F. Shelton, M. D. Becker, J. R. Garlich, R. K. Ramanathan

Brd. 6 **Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S). (Abstract #3016)**

M. L. Maitland, T. Karrison, G. L. Bakris, K. Fox, L. A. Janisch, S. Karovic, M. R. Levine, L. House, J. J. Wright, E. E. Cohen, G. F. Fleming, T. Y. Seiwert, V. M. Villaflor, W. M. Stadler, M. J. Ratain

- Brd. 7 Phase I (Ph) safety, pharmacodynamic (PD), and pharmacokinetic (PK) trial of a pure MEK inhibitor (i), RO4987655, in patients with advanced/metastatic solid tumor. (Abstract #3017)**
S. Leijen, M. R. Middleton, P. Tresca, F. Kraeber-Bodere, V. Dieras, M. E. Scheulen, J. Tessier, Z. X. Xu, E. Shochat, A. Walz, J. Deutsch, S. Blotner, V. Lopez Valverde, V. M. Naegelen, J. H. Schellens, W. E. Eberhardt
- Brd. 8 Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). (Abstract #3018)**
P. N. Munster, R. van der Noll, E. E. Voest, E. C. Dees, A. R. Tan, J. M. Specht, G. S. Falchook, A. Daud, M. P. Lolkema, J. E. Grilley-Olson, E. Y. Yu, S. Fu, E. K. Bergsland, J. Kleha, S. Peng, D. A. Smith, T. A. Lampkin, J. H. Schellens, S. R. Morris, R. Kurzrock
- Brd. 9 Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies. (Abstract #3019)**
N. Houede, S. J. Faivre, A. Awada, E. Raymond, A. Italiano, T. Besse-Hammer, M. Donica, N. Rejeb, C. Luepfert, S. Ongarello, J. Delord
- Brd. 10 A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. (Abstract #3020)**
A. J. Wagner, J. C. Bendell, S. Dolly, J. A. Morgan, J. A. Ware, J. Fredrickson, K. E. Mazina, J. O. Lauchle, H. A. Burris III, J. S. De Bono
- Brd. 11 A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. (Abstract #3021)**
V. Moreno Garcia, R. D. Baird, K. J. Shah, B. Basu, N. Tunariu, M. Blanco, P. A. Cassier, J. V. Pedersen, M. Puglisi, D. Sarker, D. Papadatos-Pastos, A. G. Omlin, A. Biondo, J. A. Ware, H. Koeppen, G. G. Levy, K. E. Mazina, J. S. De Bono
- Brd. 12 First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068. (Abstract #3022)**
J. Tabernero, C. Saura, D. Roda Perez, R. Dienstmann, S. Rosello, L. Prudkin, J. A. Perez-Fidalgo, B. Graña, C. Jones, L. Musib, Y. Yan, P. H. Patel, J. Baselga, A. Cervantes
- Brd. 13 Final results of a first-in-human phase I trial of PBI-05204, an inhibitor of AKT, FGF-2, NF-Kb, and p70S6K in advanced cancer patients. (Abstract #3023)**
H. A. Henary, R. Kurzrock, G. S. Falchook, A. Naing, S. L. Moulder, J. J. Wheler, A. M. Tsimberidou, J. Durand, P. Yang, M. Johansen, R. Newman, R. Khan, U. Patel, D. S. Hong
- Brd. 14 A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity. (Abstract #3024)**
R. D. Baird, B. Venugopal, R. S. Kristeleit, J. Charlton, M. Blanco-Codesido, E. Saunders, K. J. Shah, D. Crawford, P. Stephens, D. Wilkins, L. Sweeting, A. Forslund, J. W. Smit, P. A. Palmer, N. Fourneau, P. Hellems, J. S. De Bono, R. Plummer, U. Banerji, T. Evans
- Brd. 15 Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. (Abstract #3025)**
A. Cervantes, M. Alsina, J. Tabernero, J. R. Infante, P. LoRusso, G. Shapiro, L. G. Paz-Ares, R. Falzone, J. Hill, J. Cehelsky, A. White, I. Toudjarska, D. Bumcrot, R. Meyers, G. Hinkle, N. Svrzikapa, D. W. Sah, A. Vaishnav, J. Gollob, H. A. Burris III
- Brd. 16 A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. (Abstract #3026)**
J. Berlin, V. L. Keedy, P. A. Janne, L. Yee, N. A. Rizvi, X. Jin, C. Copigneaux, T. Hettmann, D. M. Beaupre, P. LoRusso

- Brd. 17** **Two-dimensional phase I study of neratinib (NER) combined with temsirolimus (TEM) in patients (Pts) with solid tumors. (Abstract #3027)**
L. Gandhi, R. Bahleda, J. M. Cleary, A. Hollebecque, E. L. Kwak, S. Pandya, S. Tolaney, R. Abbas, R. Ananthakrishnan, A. Berkenblit, J. Boni, J. Clancy, K. W. Turnbull, M. VoVan, G. Shapiro, J. Soria
- Brd. 18** **A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors. (Abstract #3028)**
H. S. Han, C. Swanton, Y. Y. Janjigian, S. C. Sutherland, S. Chandralapaty, R. Lehman, N. Hamilton, J. Knowles, R. Lee, L. Yan, D. Sullivan, C. Hudis
- Brd. 19** **A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. (Abstract #3029)**
C. Mamot, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz
- Brd. 20** **A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin. (Abstract #3030)**
L. H. Brail, J. E. Gray, H. Burris, G. R. Simon, J. Cooksey, S. F. Jones, D. Farrington, T. Lam, K. Jackson, K. Chow, J. T. Brandt, J. R. Infante
- Brd. 21** **Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors. (Abstract #3031)**
A. Deleporte, H. Dumez, A. Awada, J. Costermans, M. Meeus, T. Berghmans, M. Ould Kaci, N. Juhel, A. Berge, T. Taube, P. Schöffski
- Brd. 22** **Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel. (Abstract #3032)**
D. W. Rasco, A. Patnaik, R. K. Amaravadi, K. P. Papadopoulos, N. B. Haas, A. W. Tolcher, M. Beeram, K. Harlacker, M. A. Drouin, M. Tawashi, J. Wang, A. Karam, C. R. Maroun, C. Bonfils, M. Mehran, J. M. Besterman, P. J. O'Dwyer

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Genitourinary (Prostate) Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: Hall D2

CME credit: 1

Track(s): Genitourinary Cancer

Leonard Joseph Appleman, MD, PhD—Co-Chair

University of Pittsburgh

Iwona Anna Skoneczna, MD—Co-Chair

Institute of Oncology

Discussion

5:00 PM Daniel W. Lin, MD (Abstracts #4521–4524)
University of Washington

Discussion

5:15 PM William K. Oh, MD (Abstracts #4525[^]–4530)
Mount Sinai Medical Center

Discussion

5:30 PM Charles J. Ryan, MD (Abstracts #4531–4535)
University of California, San Francisco

Discussion

5:45 PM Philip W. Kantoff, MD (Abstracts #4536–4545)
Dana-Farber Cancer Institute

Brd. 1 **Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741). (Abstract #4521)**

B. M. Dubray, V. Beckendorf, S. Guerif, E. Le Prise, A. Reynaud-Bougnoux, J. Hannoun Levi, T. D. Nguyen, C. Hennequin, J. Cretin, M. Fayolle-Campana, J. Lagrange, J. Bachaud, D. Azria, A. Grangirard, P. Pommier, J. Simon, V. Harter, M. Habibian, Groupe d'Etude des Tumeurs Uro-Genitales

Brd. 2 **A phase II study of pomegranate extract for men with rising prostate-specific antigen following primary therapy. (Abstract #4522[^])**

C. J. Paller, X. Ye, P. Wozniak, B. Gillespie, P. Sieber, R. Greengold, B. Stockton, B. Hertzman, M. Efos, R. Roper, H. Liker, M. A. Carducci

Brd. 3 **Phase III study of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone in nonmetastatic high-risk prostate cancer (PC) patients (pts): Final results on PSA progression-free survival (Abstract #4523)**

S. Oudard, I. Latorzeff, P. Beuzebec, E. Banu, A. Caty, E. Sevin, R. Delva, F. Rolland, F. Priou, R. Elaidi, S. Culine

Brd. 4 **PSA response and early PSA progression evaluated in patients randomized in a phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer (GETUG-AFU 15/0403). (Abstract #4524)**

G. Gravis, K. Fizazi, F. Joly, S. Oudard, F. Priou, I. Latorzeff, R. Delva, B. Esterni, M. Habibian, M. Soulie

Brd. 5 **Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. (Abstract #4525[^])**

A. O. Sartor, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, J. S. De Bono, For the TROPIC investigators

- Brd. 6** **A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4526[^])**
J. S. De Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. H. Machiels, L. Shen, A. O. Sartor, for the TROPIC investigators
- Brd. 7** **Phase III, randomized, open-label study of triweekly versus biweekly docetaxel (T) as a treatment for advanced hormone-refractory prostate cancer (HRPC): Final analysis of the Finnish Uro-oncological Group Study 1-2003. (Abstract #4527)**
P. Kellokumpu-Lehtinen, U. Harmenberg, T. K. Joensuu, R. McDermott, P. Hovonen, C. Ginman, M. Luukka, P. Nyandoto, T. Luukkaala, H. Joensuu, Prosty study group
- Brd. 8** **A randomized, double-blind phase II trial of docetaxel plus prednisone (DP) combined with either AT-101 or placebo for the first-line therapy of metastatic castration-resistant prostate cancer (CRPC) (Abstract #4528)**
G. Sonpavde, V. B. Matveev, J. M. Burke, J. R. Caton, M. T. Fleming, P. A. Karlov, J. Holmlund, B. A. Wood, M. Brookes, L. H. Leopold
- Brd. 9** **Final results on phase II study of a weekly schedule of ixabepilone in patients with metastatic castrate-refractory prostate cancer (E3803): A trial of the Eastern Cooperative Oncology Group. (Abstract #4529)**
G. Liu, Y. Chen, R. S. DiPaola, M. A. Carducci, G. Wilding, Eastern Cooperative Oncology Group
- Brd. 10** **Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. (Abstract #4530)**
B. Seruga, A. M. Horgan, G. R. Pond, S. M. Alibhai, E. Amir, R. De Wit, M. A. Eisenberger, I. Tannock
- Brd. 11** **Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. (Abstract #4531)**
D. B. Agus, W. M. Stadler, D. H. Shevrin, L. Hart, G. R. MacVicar, O. Hamid, J. D. Hainsworth, M. E. Gross, J. Wang, L. de Leon, D. MacLean, R. Dreicer
- Brd. 12** **A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial. (Abstract #4532)**
E. S. Antonarakis, E. I. Heath, D. C. Smith, D. E. Rathkopf, A. L. Blackford, D. C. Danila, S. King, A. Frost, M. A. Carducci, Prostate Cancer Clinical Trials Consortium (PCCTC)
- Brd. 13** **Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain. (Abstract #4533)**
N. D. Shore, M. R. Smith, M. Jievaltas, K. Fizazi, R. Damião, J. Chin, K. Miller, J. P. Maroto, Y. Qian, A. Feng, K. Chung, C. D. Goessl
- Brd. 14** **Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. (Abstract #4534)**
L. G. Gomella, C. Nabhan, J. B. Whitmore, M. W. Frohlich, D. J. George
- Brd. 15** **Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. (Abstract #4535)**
H. Kübler, T. Maurer, A. Stenzl, S. Feyerabend, U. Steiner, M. Schostak, W. Schultze-Seemann, F. vom Dorp, L. Pilla, G. Viatali, C. Hampel, S. Wedel, L. Trojan, K. Hiller, M. Sommerauer, D. Jocham, B. Scheel, T. Lander, K. Kallen, K. Miller
- Brd. 16** **Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. (Abstract #4536)**
H. Beltran, D. Rickman, K. Park, A. Sboner, T. Macdonald, S. T. Tagawa, M. B. Gerstein, F. Demichelis, D. M. Nanus, M. A. Rubin

- Brd. 17** **Validation of NF-kappaB p65 as a prostate cancer prognostic marker on a large European cohort. (Abstract #4537)**
P. O. Gannon, L. Lessard, V. Forest, L. R. Begin, T. Schlomm, S. Minner, M. Graefen, A. Mes-Masson, F. Saad
- Brd. 18** **Association of angiotensin II blockers with survival among men with prostate cancer: Results from CaPSURE. (Abstract #4538)**
A. Bardia, J. E. Cowan, P. Carroll, A. V. D'Amico, M. A. Carducci
- Brd. 19** **A six-gene panel that predicts survival in men with castration-resistant prostate cancer. (Abstract #4539)**
S. K. Subudhi, G. Heller, A. Anand, D. C. Danila, M. Fleisher, H. I. Scher
- Brd. 20** **Genomic analysis of circulating tumor cells (CTC) from patients with castration-resistant prostate cancer (CRPC) as predictive biomarkers. (Abstract #4540)**
D. C. Danila, A. Anand, J. Yao, M. Gierszewska, M. Kramer, S. Muller, M. Fleisher, W. R. McCombie, H. I. Scher
- Brd. 21** **Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy. (Abstract #4541)**
S. M. Falzarano, C. Magi-Galluzzi, W. F. Novotny, T. Maddala, D. B. Cherbavaz, C. Millward, E. A. Klein
- Brd. 22** **Prognostic value of a 46-gene cell cycle progression (CCP) RNA signature for prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort. (Abstract #4542)**
J. M. Cuzick, G. Fisher, D. Berney, D. Mesher, H. Møller, J. E. Reid, A. Gutin, J. S. Lanchbury, S. Stone
- Brd. 23** **Risk of second primary malignancy in U.S. men diagnosed with prostate cancer from 1992 to 2007. (Abstract #4543)**
E. Davis, C. A. Salinas, L. A. Okoth, K. A. Cooney
- Brd. 24** **Racial disparities in prostate cancer treatment: The contribution of inappropriate care. (Abstract #4544)**
C. J. Presley, A. C. Raldow, L. D. Cramer, P. R. Soulos, J. B. Long, D. V. Makarov, J. B. Yu, C. P. Gross
- Brd. 25** **PARP inhibition reverses radiation resistance conferred by ETS fusions in prostate cancer. (Abstract #4545)**
F. Y. Feng, S. Han, C. Brenner, A. Sabolch, D. A. Hamstra, T. S. Lawrence, A. Chinnaiyan

Saturday, June 4, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Tumor Biology

Display Time: 2:00 PM - 6:00 PM
Display Location: S103
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S100bc
CME credit: 1
Track(s): Tumor Biology

Charles D. Lopez, MD, PhD—Co-Chair

Oregon Health Science University

Joseph A. Sparano, MD—Co-Chair

Albert Einstein College of Medicine

Discussion

5:00 PM Matthew James Ellis, MB, BChir, PhD (Abstracts #10509–10516)
Washington University Medical Center

Discussion

5:15 PM Robert Arthur Kratzke, MD (Abstracts #10517–10521)
University of Minnesota

Discussion

5:30 PM David B. Solit, MD (Abstracts #10522–10527)
Memorial Sloan-Kettering Cancer Center

Discussion

5:45 PM Ravi Salgia, MD, PhD (Abstracts #10528–10533)
The University of Chicago

Brd. 1 **Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). (Abstract #10509)**

J. M. Balko, R. S. Cook, T. W. Miller, N. E. Bholra, M. Sanders,
N. M. Granja-Ingram, V. Sanchez, I. M. Meszoely, J. Salter, M. Dowsett,
K. Stenke-Hale, A. M. Gonzalez-Angulo, G. B. Mills, C. L. Arteaga

Brd. 2 **Early drop of circulating tumor cells (CTC) and increase of circulating endothelial cells (CEC) during neoadjuvant chemotherapy (CT) combined with bevacizumab in HER2-negative inflammatory breast cancer (IBC) in multicenter phase II trial BEVERLY 1. (Abstract #10510)**

J. Pierga, F. Bidard, F. Andre, T. Petit, F. Dalenc, T. Delozier, G. Romieu,
J. Bonnetterre, J. Ferrero, P. Kerbrat, A. Martin, P. Viens

Brd. 3 **Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response. (Abstract #10511)**

J. M. Mulligan, L. A. Hill, S. Deharo, F. A. McDyer, T. S. Davison, M. Bylesjo,
N. M. Lindor, L. Galligan, T. Delaney, I. A. Halfpenny, V. Farztdinov, N. Goffard,
V. Proutski, K. E. Keating, P. B. Mullan, J. E. Quinn, P. G. Johnston, F. J. Couch,
D. P. Harkin, R. D. Kennedy

Brd. 4 **Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastatic breast cancer (MBC). (Abstract #10512)**

M. J. Higgins, D. Jelovac, E. Barnathan, B. Blair, S. Slater, P. Powers, J. Zorzi,
S. C. Jeter, G. R. Oliver, F. Diehl, P. Angenendt, P. Huang, P. Argani, K. Murphy,
A. C. Wolff, B. H. Park

Brd. 5 **Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness, and as such treatment response. (Abstract #10513)**

E. H. Lips, L. Mulder, S. A. Joesse, S. Savola, M. A. Vollebergh, L. F. Wessels,
J. Wesseling, P. M. Nederlof, S. Rodenhuis

SATURDAY

- Brd. 6 Separation of breast cancer from normal tissues using GC-MS-based metabolite profiling. (Abstract #10514)**
J. Budczies, C. Denkert, B. Mueller, S. F. Brockmoeller, M. Dietel, C. Radke, S. Loibl, G. Von Minckwitz, J. L. Griffin, M. Oresic, G. Wohlgemut, O. Fiehn
- Brd. 7 Global gene expression analysis of heterotypic interaction between cancer cells and osteoblasts in vitro to detect signaling pathways relevant for bone metastasis in breast cancer patients. (Abstract #10515)**
M. Buess, M. Rajski, B. Vogel, C. Rochlitz
- Brd. 8 Targeting β -catenin/CBP interaction in breast cancer. (Abstract #10516)**
A. Ring, O. Evgrafov, J. Knoles, M. Kahn
- Brd. 9 Concomitant EGFR mutation and *EML4-ALK* gene fusion in non-small cell lung cancer. (Abstract #10517)**
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. Wu
- Brd. 10 Changes in molecular profile following platinum chemotherapy in NSCLC. (Abstract #10518)**
W. Huang, M. Skokan, Y. Chang, C. Wu, J. Lee, W. Feser, A. E. Barón, P. A. Bunn, M. Varella-Garcia
- Brd. 11 Insulin-like growth factor receptor-1 (IGF1R) and epidermal growth factor receptor (EGFR) amplification and expression in surgically resected NSCLC. (Abstract #10519)**
V. Ludovini, A. Flacco, F. Bianconi, F. R. Tofanetti, M. Ragusa, J. Vannucci, G. Bellezza, M. G. Mameli, R. Chiari, V. Minotti, L. Pistola, A. Siggillino, E. Baldelli, A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinó
- Brd. 12 Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. (Abstract #10520)**
T. Li, P. C. Mack, S. Desai, K. Kelly, J. Cooc, P. V. Danenberg, K. D. Danenberg, D. R. Gandara
- Brd. 13 Blind prediction of response to erlotinib in early-stage non-small cell lung cancer (NSCLC) in a neoadjuvant setting based on kinase activity profiles. (Abstract #10521)**
R. Hilhorst, E. Schaake, R. van Pel, P. M. Nederlof, L. Houkes, M. Mommersteeg, R. de Wijn, M. van den Heuvel, P. Baas, R. Ruijtenbeek, H. M. Klomp
- Brd. 14 Evaluation of p53 mutation as a predictive biomarker for outcome to chemotherapy in ovarian cancer. (Abstract #10522)**
A. H. Calvert, J. C. Jackson, C. Hutton, A. Swart, W. Qian, C. Kwakye, R. Fossati, A. Lissoni, P. G. Harper, N. Colombo, R. J. Edmondson, J. Lunec
- Brd. 15 Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma. (Abstract #10523)**
K. J. Bloom, S. M. Anderson, R. C. Schilling, J. Lee, H. Halait, S. Cheng, R. A. Langland, H. Lawrence
- Brd. 16 Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (Abstract #10524)**
M. Del Re, F. Loupakis, A. Michelucci, A. Di Paolo, A. Falcone, P. Simi, G. Bocci, M. Cantore, R. Bordonaro, A. Di Leo, C. Barbara, F. Cappuzzo, F. G. De Braud, R. Danesi
- Brd. 17 Circulating protein biomarkers of sunitinib (SU) and interferon- α (IFN- α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #10525)**
C. S. Harmon, R. A. Figlin, T. E. Hutson, M. D. Michaelson, S. Négrier, S. T. Kim, X. Huang, J. A. Williams, R. J. Motzer
- Brd. 18 RNA-based molecular tumor typing and immunological infiltrate as response predictors to neoadjuvant chemotherapy: Prospective validation in the GeparQuinto-PREDICT substudy. (Abstract #10526)**
C. Denkert, R. Kronenwett, S. Loibl, V. Nekljudova, S. Darb-Esfahani, B. Gerber, B. Sinn, C. Petry, I. Bauerfeind, J. Budczies, M. Rezag, M. Dietel, I. Schrader, G. Kunz, G. Von Minckwitz, GBG and AGO-B study groups

- Brd. 19** **Effect of everolimus plus octreotide LAR treatment on chromogranin A and 5-hydroxyindoleacetic acid levels in patients with advanced neuroendocrine tumors: Phase III RADIANT-2 study results. (Abstract #10527)**
E. Baudin, E. M. Wolin, D. E. Castellano, G. Kaltsas, J. Lebrech, Z. Tsuchihashi, J. Klimovsky, S. Saletan, J. C. Yao, D. Gross
- Brd. 20** **A hepatocyte growth factor antagonist engineered by site-directed mutagenesis. (Abstract #10528)**
F. Cecchi, D. Pajalunga, A. Fowler, D. C. Rabe, B. Peruzzi, N. J. MacDonald, D. K. Blackman, S. J. Stahl, A. Byrd, D. P. Bottaro
- Brd. 21** **Activity of the cancer metabolism inhibitor MPC-9528 in xenograft models: Comparison of different dosing schedules. (Abstract #10529)**
V. R. Baichwal, J. A. Willardsen, J. W. Lockman, B. R. Murphy, R. Gordillo, T. C. Fleischer, C. Bradford, D. I. Papac, G. G. Mather, R. O. Carlson
- Brd. 22** **In vivo tumor growth inhibition by novel PKM2 cancer metabolism modulators. (Abstract #10530)**
O. M. Becker, V. Behar, O. Bohana-Kashtan, A. Shitrit, D. Sherman, E. Ben-Zeev, R. Ozeri, N. C. Schutz, A. Yacovan
- Brd. 23** **New microRNA-based diagnostic test for lung cancer classification. (Abstract #10531)**
T. B. Edmonston, H. Gibori, M. Kushnir, G. Lithwick Yanai, H. Benjamin, M. Bibbo, C. Thurm, L. Horowitz, Y. Huang, M. Feinmesser, I. Barshack, S. J. Hou, S. Gilad, S. Benjamin, K. Ashkenazi, M. Ezagouri, Y. Goren, C. Hogan, A. Chajut
- Brd. 24** **The effect of fish oil on chemotherapy activity in mice: Clinical implications. (Abstract #10532)**
L. G. Daenen, J. M. Roodhart, E. C. Stigter, M. G. Gerritsen, R. H. Medema, A. B. Brenkman, E. E. Voest
- Brd. 25** **The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC). (Abstract #10533)**
D. E. Gerber, P. Gupta, M. T. Dellinger, J. Toombs, I. Valencia, M. Peyton, N. Loizos, R. A. Brekken

SATURDAY

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Cancer Prevention/Epidemiology

Location: Hall A

Track(s): Cancer Prevention/Epidemiology

- Brd. 1A** **Gender, age, and ethnic representation in non-small cell lung cancer (NSCLC) U.S. registration trials: FDA review. (Abstract #1530)**
S. M. Malik, A. T. Farrell, Q. Xu, R. Sridhara, R. Pazdur
- Brd. 1B** **Recruitment in the Internet era: An efficient strategy for a study of breast cancer risk. (Abstract #1531)**
L. M. Yackowski, F. R. Schnabel, R. Oratz, D. Roses, R. Wieder, C. Kowalczyk, H. Ostrer
- Brd. 1C** **Clinical characteristics of affected BRCA1 and BRCA2 mutation carriers in an underserved population. (Abstract #1532)**
M. El-Masry, C. Ricker, D. V. Spicer, D. Tripathy
- Brd. 1D** **Prophylactic oophorectomy for patients with breast cancer with BRCA results. (Abstract #1533)**
J. C. Schink, K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen, W. J. Gradishar
- Brd. 1E** **Prevalence of recognized bone metastases in the U.S. adult population. (Abstract #1534)**
S. Li, Y. Peng, E. D. Weinhandl, A. H. Blaes, K. Cetin, V. M. Chia, S. Stryker, J. J. Pinzone, J. F. Acquavella, T. J. Arneson
- Brd. 1F** **Suicide in patients with cancer in California: 2000–2005. (Abstract #1535)**
H. R. Mirshahidi, K. Nasser, P. K. Mills
- Brd. 1G** **Perceptions and practices of dietary cancer prevention: Comparison between physicians and patients. (Abstract #1536)**
V. W. Li, J. Ko, W. W. Li
- Brd. 2A** **Cancer in young adults: Characteristics of a cohort of Brazilian patients. (Abstract #1537)**
C. S. Souza, A. V. Melo Mendes, S. D. Simon
- Brd. 2B** **Gestational diabetes and risk of incident primary cancer: A large population-based cohort study in Israel. (Abstract #1538)**
T. Sella, G. Chodick, M. Barchana, A. D. Heymann, A. Porath, E. Kokia, V. Shalev
- Brd. 2C** **Antioxidant supplement use after diagnosis and breast cancer outcomes. (Abstract #1539)**
H. Greenlee, M. L. Kwan, L. Kushi, J. Song, A. Castillo, E. Weltzien, C. Quesenberry, B. J. Caan
- Brd. 2D** **Outcome of effective intervention to improve screening colonoscopy in a downtown Brooklyn community hospital. (Abstract #1540)**
K. Veerabhadrapa, Z. M. Bo, K. T. Lyar, R. Sultana, G. M. Villani
- Brd. 2E** **Diagnosis of breast cancer metastases with PET/TC in patients with elevation of tumor markers: First data update. (Abstract #1541)**
A. Mafodda, A. Prestifilippo, D. Aricò, A. Vadalà, M. Mare, C. Fornito, D. Giuffrida
- Brd. 2F** **Cancer with diabetes: Prevalence, metabolic control, and survival in a general oncology practice. (Abstract #1542)**
N. J. Karlin, A. C. Dueck, C. Cook
- Brd. 2G** **The prevalence of human papillomavirus types 52 and 58 in uterine cervical lesions from Japanese women. (Abstract #1543)**
K. Takehara, T. Nishimura, J. Sakane, Y. Kawakami, T. Mizunoe, M. Nishiwaki, K. Taniyama
- Brd. 3A** **Gender disparities in colorectal cancer screening. (Abstract #1544)**
S. Yager, W. Y. Cheung

- Brd. 3B Environmental organochlorine pesticide pollutants in patients with benign and malignant breast disease. (Abstract #1545)**
K. S. Sodhi, I. D. Sharma, A. Chaturvedi
- Brd. 3C Early adulthood obesity, cumulative smoking, and esophageal cancer survival. (Abstract #1546)**
L. E. Coate, R. Zhai, W. Xu, Z. Chen, K. Asomaning, M. Kulke, R. S. Heist, D. Christiani, G. Liu
- Brd. 3D Breast cancer survival: The association of age within stage of disease. (Abstract #1547)**
C. Parise, K. Bauer, V. Caggiano
- Brd. 3E Trends in survival by race for stomach cancer patients from the U.S. SEER cancer registry. (Abstract #1548)**
L. Chu, L. Wang, M. Shing, W. Dong
- Brd. 3F Long-term history of fasting blood glucose level and the risk of pancreatic cancer: A nested case-control study. (Abstract #1549)**
K. Stefani, H. Kim, S. Ahn, K. Choi, I. Suh
- Brd. 3G Does breast cancer in Asian geriatric patients have the same biological characteristics as in their Western counterparts? A comparison between Shanghai and Vienna. (Abstract #1550)**
M. M. Tea, L. Tang, G. Di, Z. Shao, C. F. Singer
- Brd. 3H Stroger Hospital of Cook County (CCH) AIDS malignancy project: The CHAMP study—A 13-year, single-institution retrospective study of cancers in patients infected with HIV. (Abstract #1551)**
S. Gupta, H. Poola, K. K. Batra, J. M. Orsi, S. Velinova, S. Jain, S. B. Sreenivasappa, M. C. Telfer, M. R. Mullane, A. L. French, P. G. Rubinstein
- Brd. 4B The influence of sociodemographic factors on breast cancer tumor biology. (Abstract #1553)**
K. A. Dookeran, K. Ferrer, M. Sekosan, N. Holloway, W. J. McCaskill-Stevens, S. J. Gehlert
- Brd. 4C Multicenter, prospective, case-control, observational study on the influence of venous thromboembolism on patient outcome. (Abstract #1554)**
M. Mandala, R. Labianca, G. Agnelli, L. Crino, E. Maiello, A. Santoro, D. Fagnani, for the MASTER ONCOLOGY Investigators
- Brd. 4D Compliance to adjuvant hormone therapy for black and white women with breast cancer. (Abstract #1555)**
S. Bhatta, N. Hou, D. Huo, B. N. Polite, G. F. Fleming, O. I. Olopade, S. Hong
- Brd. 4E The accuracy of tobacco assessment during definitive radiotherapy or chemoradiotherapy in patients with head and neck cancer. (Abstract #1556)**
M. R. Kudrimotij, S. M. Arnold, J. Valentino, T. Gal, A. Hyland, A. Singh, V. Rangnekar, K. M. Cummings, J. R. Marshall, G. W. Warren
- Brd. 4F Prospective structured smoking behavior assessment at diagnosis and long-term cancer survival. (Abstract #1557)**
G. W. Warren, K. Kasza, M. E. Reid, K. M. Cummings, J. R. Marshall
- Brd. 4G Factors associated with on-time regular screening among the Korean population eligible to be screened for gastric cancer: A nationwide retrospective cohort study based on National Cancer Screening Program (NCSP) data. (Abstract #1558)**
M. Hahm, K. Choi, H. Lee, J. Jun, E. Park
- Brd. 4H Gynecological cancer screening in women at high risk of Lynch syndrome. (Abstract #1559)**
C. Guillen-Ponce, C. Martinez-Sevila, R. Perea, M. Arenas, M. Molina-Garrido, M. Goicoechea, D. Salas, A. Carrato, Hereditary Cancer Group of the Comunidad Valenciana (Spain)

- Brd. 5A** **An analysis of colorectal cancer (CRC) following a diagnosis of prostate cancer (CaP): Is it due to earlier diagnosis or increased incidence? (Abstract #1560)**
S. Bae, M. Asadi, J. L. Millar, I. Jones, S. McLaughlin, A. Bui, M. Steele, M. W. Chao, D. English, P. Gibbs
- Brd. 5B** **The role of HPV genotypes and persistence in follow-up of cervical intraepithelial neoplasia after treatment. (Abstract #1561)**
Y. Huang, L. Wu, J. Zuo, N. Li, J. An, J. Hu, M. Huang
- Brd. 5C** **Multidisciplinary high-risk program: A community hospital's experience. (Abstract #1562)**
H. Lowry, N. Dekhne, D. Fend, R. Lerman, N. Gregory, J. Boura
- Brd. 5D** **Results from a longitudinal breast MRI surveillance study: Psychological impact for high-risk women. (Abstract #1563)**
L. J. Patrick-Miller, A. R. Bradbury, R. Pius, K. Wroblewski, M. S. Verp, S. Jackson, C. Gulden, G. Newstead, H. Abe, O. I. Olopade
- Brd. 5E** **Racial differences in early-stage colorectal cancer outcomes and prognostic factors. (Abstract #1564)**
J. D. Acoba, C. D. Chong
- Brd. 5F** **Isolation of equol-producing bacterium to realize chemoprevention of prostate cancer. (Abstract #1565)**
H. Tsuji, K. Moriyama, K. Nomoto, N. Miyanaga, H. Akaza
- Brd. 5G** **Management of breast cancer after childhood cancer and Hodgkin lymphoma. (Abstract #1566)**
M. Terenziani, S. Viviani, M. Massimino, A. Moliterni, M. Gennaro, L. Gandola, L. Boschetti, S. Catania, G. Cefalo, A. Di Russo, G. Goisis, G. Mariani, F. Spreafico, M. Zambetti, P. Valagussa, G. Bonadonna
- Brd. 5H** **Impact of dietary habits on epidermal growth factor receptor (EGFR) mutation status of Japanese patients with lung adenocarcinomas. (Abstract #1567)**
Y. Yamane, M. Iwasaki, A. Kawase, K. Tsuchihara, G. Ishii, H. Ohmatsu, S. Niho, K. Yoh, K. Nagai, Y. Ohe, S. Tsugane, A. Ochiai, H. Esumi, K. Goto
- Brd. 6A** **Metachronous contralateral breast cancer: An analysis of risk factors and prognosis in 42,670 women in Sweden. (Abstract #1568)**
V. Vichapat, H. Garmo, M. Holmqvist, L. Holmberg, G. Liljegren, F. Warnberg, M. Lambe, T. Fornander, J. Adolfsson, M. Lichtenborg
- Brd. 6B** **The burden of cancer in Japan, the United States, France, Germany, Italy, Spain, Sweden, and the United Kingdom. (Abstract #1569)**
N. Koinuma, N. E. Wilking, B. Jonsson, D. Hogberg
- Brd. 6C** **Preventing cancer in the colon: Effect of ginger root extract on markers of inflammation in colon mucosa in people at high risk for colorectal cancer. (Abstract #1570)**
S. M. Zick, D. K. Turgeon, S. Vareed, M. T. Ruffin IV, Z. Djuric, A. J. Litzinger, B. Wright, D. P. Normolle, D. E. Brenner
- Brd. 6D** **The new generation of combined hormone contraceptives and risk of gynecologic cancers. (Abstract #1571)**
R. Haque, G. Inzhakova, J. M. Shi, J. Chung, F. Niu, C. T. Cheetham
- Brd. 6E** **Disparities of incidence and survival in lung cancer: A SEER-based analysis on Asian living in the United States 1973–2007. (Abstract #1572)**
R. N. Rahman, S. Rastogi, A. M. Hossain
- Brd. 6F** **Determining the impact of the U.S. mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital. (Abstract #1573)**
I. Habtes, C. Raskind-Hood, K. Adams, E. R. Becker, C. D'Orsi, G. Birdsong II, K. Gundry, R. O'Regan, S. G. Gabram

Saturday, June 4, 2011

- Brd. 6G Fetal microchimerism in breast and colon cancer. (Abstract #1574)**
M. Kamper-Jørgensen, R. J. Biggar, C. L. Stamper, H. Hjalgrim, A. Tjønneland, A. Olsen, A. N. Andersen, K. Rostgaard, N. Kroman, V. K. Gadi
- Brd. 7A Global cancer mortality: The effect of health care system resources on survival from cancer. (Abstract #1576)**
A. Batouli, P. Jahanshahi, J. B. Yu
- Brd. 7B Observations on cancer of the breast among Arab-American women. (Abstract #1577)**
O. R. Signori, K. A. Schwartz, H. Dakhallah, R. M. Pandit, E. E. Signori
- Brd. 7C Association between contralateral prophylactic mastectomy and breast cancer outcomes. (Abstract #1578)**
A. M. Brewster, P. A. Parker, I. Bedrosian, W. Dong, S. K. Peterson, S. B. Cantor, M. Crosby, Y. Shen
- Brd. 7D Impact on stage distribution of gastric cancer by the National Cancer Screening Program (NCSP) in Korea. (Abstract #1579)**
J. Jun, K. Choi, H. Lee, E. Park
- Brd. 7E A combination of fecal tests for the detection of colon cancer: A new strategy for appropriate prioritization of referrals to colonoscopy—A prospective Italian study. (Abstract #1580)**
A. Ardizzoia, F. Parente, B. Marino, A. Ilardo, F. Perna, I. Saracino, A. Zullo, C. Hassan, P. Fracasso, R. A. Moretti, M. Cremaschini, D. Vaira, G. Ucci
- Brd. 7F Knowledge and perceptions of breast cancer risk in adolescent girls at high risk and population risk for breast cancer. (Abstract #1581)**
A. R. Bradbury, L. J. Patrick-Miller, L. Tuchman, C. Moore, P. Rauch, C. B. Sands, R. Shorter, B. Rowan, S. Malhotra, S. Van Decker, L. Bealin, H. Schmidheiser, M. B. Daly
- Brd. 7G A dose-finding clinical trial of mushroom powder in postmenopausal breast cancer survivors for secondary breast cancer prevention. (Abstract #1582)**
M. R. Palomares, J. Rodriguez, S. Phung, F. Z. Stanczyk, S. F. Lacey, T. W. Synold, S. Denison, P. H. Frankel, S. Chen
- Brd. 7H Peripheral blood eosinophil counts and risk of colorectal cancer mortality in a large general population-based cohort study. (Abstract #1583)**
N. Taghizadeh, J. M. Vonk, H. M. Boezen
- Brd. 8A Meta-analysis of insulin glargine and cancer risk. (Abstract #1584)**
P. Boyle, A. Koechlin, P. Boffetta, M. Boniol, G. Bolli, J. Rosenstock
- Brd. 8B Healthcare service barriers to breast cancer screening among Egyptian females. (Abstract #1585)**
H. M. El-Mansy, H. M. Ismail, I. F. Kharboush, M. M. Tawfik, O. G. El Sharkawy, H. Mamdouh, H. Sallam
- Brd. 8C Prospective analysis of association between use of statins or other lipid lowering agents and melanoma risk in the Women's Health Initiative. (Abstract #1586)**
D. B. Jagtap, C. A. Rosenberg, L. Martin, M. Pettinger, P. Greenland, J. D. Khandekar, R. Levy, D. Lane, M. S. Simon
- Brd. 8D Breast ductal lavage (DL) and P16 immunocytochemistry. (Abstract #1587)**
C. Casadio, S. Di Vincenzo Jr., L. Chiapparini, B. Bonanni, M. Cazzaniga
- Brd. 8E Risk of lymphoma in women with breast implants: Analysis of clinical studies. (Abstract #1588)**
J. A. Largent, M. Oefelein, H. M. Kaplan, T. Okerson, P. Boyle
- Brd. 8F Incidence of Kaposi sarcoma in HIV-infected patients receiving antiretroviral therapy: A prospective multicohort study from southern Africa. (Abstract #1589)**
J. Bohlius, F. Valeri, M. Maskew, H. Prozesky, C. Chimbetete, P. Lumano-Mulenga, T. Gsponer, M. Egger, International epidemiologic Database to Evaluate AIDS (IeDEA)

- Brd. 8G** **Racial variation of leptin levels in women with breast cancer. (Abstract #1590)**
T. P. Avery, K. R. Sexton, A. Brewster, R. El-Zein, M. Bondy
- Brd. 8H** **Time since last pregnancy and breast cancer survival: A systematic review and meta-analysis. (Abstract #1591)**
A. Valachis, A. D. Nearchou, D. Mauri, P. A. Lind, N. P. Polyzos
- Brd. 9A** **Aristolochic acid nephropathy in Taiwan: Harbinger of a global iatrogenic disease. (Abstract #1592)**
A. P. Grollman, C. Chen, M. Moriya, K. Dickman, L. Wu, G. Mihalyne, K. L. Edwards, K. Snappin, Y. Pu
- Brd. 9B** **Classification of the components of the MedDietScore in relation to colorectal cancer prevalence. (Abstract #1593)**
N. Kontou, D. B. Panagiotakos, T. Psaltopoulou, N. Soupos, E. Polychronopoulos, D. Xynopoulos, D. Dimitroulopoulos, A. Linos, E. Paraskevas, M. A. Dimopoulos
- Brd. 9D** **What we know from the semiannually repeated CT screening in a high-risk cohort over 15 years: Update of the Anti-lung Cancer Association Project. (Abstract #1595)**
N. Seki, K. Eguchi, M. Kaneko, H. Ohmatsu, R. Kakinuma, E. Matsui, M. Kusumoto, T. Tsuchida, H. Nishiyama, N. Moriyama
- Brd. 9E** **MRI characteristics of BRCA-associated breast cancers. (Abstract #1596)**
A. K. Kelekar, S. Mukherjee, C. Mitri, F. Khan, W. Ducaine, L. Dohany, D. Zakalik
- Brd. 9F** **Do cancer survivors follow screening guidelines better? (Abstract #1597)**
A. B. Chagpar, T. B. Sanft, C. P. Gross
- Brd. 9G** **The impact of screening mammography in breast cancer patients age 40–49 at an urban city hospital. (Abstract #1598)**
C. Checka, S. Dhage, S. Adams, E. Samii, T. Shah, S. Shaylor, K. P. Joseph
- Brd. 9H** **Body mass index: A potential risk factor for breast cancer in minority patients. (Abstract #1599)**
V. Sharma, D. Patel, A. Abichandani, P. Saraf, A. J. Cohen
- Brd. 10A** **Breast cancer characteristics among Hispanic women from a Southwestern county hospital. (Abstract #1600)**
M. N. Kundranda, S. Amar
- Brd. 10B** **Patterns of treatment in young women with early-stage cervical cancer. (Abstract #1601)**
S. Grover, L. L. Lin, G. Suneja
- Brd. 10C** **A survey of suspected familial breast cancer in Iraqi Kurdish women. (Abstract #1602)**
A. M. Saaed, A. K. Sheikha, S. S. Mohammed, H. A. Ameen, S. Y. Sheet, M. Khasraw
- Brd. 10D** **Clinical and pathological profile of breast cancer in a tertiary cancer center in Saudi Arabia. (Abstract #1603)**
S. AlShehri, O. A. Abulkhair, A. Al Kushi, S. Musaad, A. Al Olayan, A. R. Jazieh
- Brd. 10E** **Pattern of malignant diseases in Lagos, Nigeria. (Abstract #1604)**
O. F. Adetayo

Saturday, June 4, 2011

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Head and Neck Cancer

Location: Hall A

Track(s): Head and Neck Cancer

- Brd. 11A** Long-term results from EORTC24971/TAX323: Comparing TPF to PF in patients with unresectable squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5530)
J. B. Vermorken, E. Remenar, C. Van Herpen, M. Degardin, J. S. Stewart, R. Karra Gurunath, C. Fortpied
- Brd. 11B** Prognostic factors of overall survival in head and neck cancer: Post-hoc exploratory results from the SPINNAKER trial—A phase III randomized clinical trial of pemetrexed plus cisplatin versus cisplatin monotherapy. (Abstract #5531)
S. Urba, J. Gatz, W. Shen, A. Hossain, K. Winfree, A. Koustenis, P. Peterson
- Brd. 11C** The effect of cisplatin dose administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. (Abstract #5532)
H. H. Loong, B. Ma, F. Mo, S. Leung, E. P. Hui, M. K. Kam, S. L. Chan, A. T. Chan
- Brd. 11D** Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Analysis of disparities in care. (Abstract #5533)
B. A. Murphy, A. Y. Chen, W. J. Curran Jr., A. S. Garden, P. M. Harari, S. J. Wong, L. A. Bellm, M. Schwartz, J. Newman, D. Adkins, D. N. Hayes, U. Parvathaneni, D. Brachman, B. Ghabach, C. Schneider, M. Greenberg, A. Abitbol, P. R. Anne, K. Ang
- Brd. 11E** Concomitant chemoradiation in locally advanced head and neck squamous cell carcinoma: A literature-based metanalysis on the platinum concomitant chemotherapy. (Abstract #5534)
M. G. Ghi, A. Paccagnella, I. Floriani, D. Garavaglia
- Brd. 11F** Long-term toxicity: A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oropharyngeal cancer patients. (Abstract #5535)
L. Raimondo, M. Garzaro, G. Riva, G. Pecorari, C. Giordano, M. Airolidi
- Brd. 11G** Neoadjuvant chemotherapy and prognostic subgroups defined by survival benefit in patients with locoregionally advanced nasopharyngeal carcinoma. (Abstract #5536)
X. Ji, Y. Zhong, Y. Zhou, F. Zhou, G. Zhang, G. Chen, D. Deng, H. Liu, J. Zhang, C. Xie
- Brd. 11H** Quality of life, physical, and psychologic functioning in patients affected by end-stage head and neck cancer. (Abstract #5537)
M. Airolidi, M. Garzaro, L. Raimondo, G. Riva, G. Pecorari, C. Giordano
- Brd. 12A** A phase II study of pemetrexed combined with cisplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma. (Abstract #5538)
A. W. Lee, T. Yau, T. C. Shum, W. Ng, L. L. Chan, R. M. Yeung
- Brd. 12B** Long-term symptom burden after radiation treatment for oropharynx cancer: A comparison of 3D and IMRT techniques. (Abstract #5539)
D. I. Rosenthal, G. B. Gunn, T. R. Mendoza, A. S. Garden, B. M. Beadle, W. H. Morrison, X. S. Wang, S. J. Frank, R. S. Weber, K. Ang, C. S. Cleeland
- Brd. 12C** Clinical characteristics of an incident cohort of patients with resected squamous cell carcinoma of the head and neck (SCCHN) in the United Kingdom. (Abstract #5540)
K. Kim, M. Amonkar, D. Högberg, F. Kasteng

SATURDAY

- Brd. 12D Pretreatment PET and posttreatment pathologic nodal status as a predictor for distant metastasis in locally advanced head and neck squamous cell carcinoma treated with definitive concurrent chemoradiotherapy. (Abstract #5541)**
K. Hu, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran, S. P. Schantz, P. Costantino, L. B. Harrison
- Brd. 12E Comparison of two schedules in locally advanced nasopharyngeal carcinoma observed in a nonendemic population. (Abstract #5542)**
M. Garzaro, L. Raimondo, G. Pecorari, F. Pedani, C. Giordano, M. Airoidi
- Brd. 12F A phase II trial of induction chemotherapy with cisplatin, docetaxel, and capecitabine followed by concurrent cisplatin-radiotherapy in advanced nasopharyngeal carcinoma. (Abstract #5543)**
M. Yamouni, Y. Beldjilali, K. Benhadji, H. Khellafi, F. Betkaoui, Y. Kaid, L. Benchlef, F. Z. Daim, S. Toubal, A. Boukerche, A. Abdelaoui, L. Djellali
- Brd. 12G Exploring factors in diagnostic delays of head and neck cancer at a public hospital. (Abstract #5544)**
D. W. Lai, S. A. Buckley, B. L. Schmidt, C. Viet, F. Muggia, I. Belitskaya-Levy, R. F. Cohen, M. D. DeLacure, N. Sanfilippo, D. Myssiorek, D. Hirsch, N. Seetharamu
- Brd. 12H Incidence of esophageal cancers among oral cavity and pharynx cancer patients: A review of the SEER database (1973–2007). (Abstract #5545)**
E. Kim, N. Chandra, J. Kim
- Brd. 13A Chemoselection with induction chemotherapy followed by chemoradiation or surgery versus chemoradiation for patients (pts) with locally advanced squamous cell carcinoma of the oropharynx (LASCCOP). (Abstract #5546)**
I. Y. Dobrosotskaya, E. Light, J. M. Maxwell, S. A. Byrd, M. E. Spector, B. Kumar, F. Y. Feng, A. Eisbruch, G. T. Wolf, M. Prince, J. Moyer, T. N. Teknos, D. B. Chepeha, H. M. Walline, J. B. McHugh, K. G. Cordell, S. Urba, C. R. Bradford, T. Carey, F. P. Worden
- Brd. 13B Measurement of distress in patients with nasopharyngeal carcinoma. (Abstract #5547)**
Y. Jiang, Y. Deng
- Brd. 13C Concomitant chemoradiation using weekly cisplatin for advanced squamous cell carcinoma of head and neck: Experience from a tertiary cancer center in India. (Abstract #5548)**
A. Sharma, B. K. Mohanti, A. Thakar, S. P. Chaudhary, S. Bhasker, S. Bahadur
- Brd. 13D Paclitaxel (TLX) and cetuximab (CTX) combination efficiency after failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). (Abstract #5549)**
P. Ceruse, E. Lavergne, G. Buiet, B. Pham, S. Chabaud, B. Favier, D. Girodet, P. Zrounba, J. Fayette
- Brd. 13E Recurrence of T1N0 oral tongue squamous cell carcinoma in Stockholm, Sweden 2000–2009. (Abstract #5550)**
M. Ryott
- Brd. 13F Comprehensive volume hyperfractionated (HFx) re-irradiation (Re-RT) of recurrent head and neck (H/N) cancer is feasible. (Abstract #5551)**
P. Kumar, U. K. Sinha
- Brd. 13G Survival, tumor control, and toxicity with TPF before accelerated radiotherapy potentiated with cetuximab for stage III-IV unresectable head and neck cancer: A phase II study. (Abstract #5552^)**
C. Mercke, H. Sjödin, H. Haugen, G. Adell, G. Wickart-Johansson, E. M. Munck-Wikland, G. von Döbeln, J. Nyman
- Brd. 13H Concurrent chemoradiotherapy with or without induction chemotherapy for locally advanced head and neck cancer. (Abstract #5553)**
J. J. Caudell, S. Spencer, R. Meredith, L. Nabell, J. A. Bonner

Saturday, June 4, 2011

- Brd. 14A** Kinetic analysis of ¹⁸F-fluoroerythronitroimidazole PET/CT during radiotherapy correlates with outcome in head and neck cancer. (Abstract #5554)
M. Hu, J. Yu, L. Kong, Z. Fu
- Brd. 14B** Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer. (Abstract #5555)
V. Espeli, E. Zucca, M. E. Ghielmini, A. Richetti, O. Giannini, F. Martucci
- Brd. 14C** Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning. (Abstract #5556)
A. D. Colevas, A. Quon, A. McMillan, Q. Le
- Brd. 14D** Multiple cases of squamous cell carcinoma of the tongue and oral cavity in patients treated with long-term pegylated liposomal doxorubicin (PLD) for ovarian cancer. (Abstract #5557)
T. L. Cannon, F. Muggia, D. Hirsch, E. A. Andreopoulou, A. R. Kerr, M. D. DeLacure
- Brd. 14E** Influence of induction chemotherapy on patient's compliance to radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. (Abstract #5558)
B. Atassi, O. Ozgursoy, G. H. Yoo, J. R. Jacobs, N. Bhatti, M. Mal, H. Kim, H. Lin, A. Sukari
- Brd. 14F** Use of buccal fat pad to correct defects in the oral cavity after excision of cheek cancer: A prospective study. (Abstract #5559)
S. K. Agrawala, S. Gosh
- Brd. 14G** Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab)-paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). (Abstract #5560)
D. Adkins, J. Ley, B. Nussenbaum, J. Diaz, R. Paniello, W. L. Thorstad, H. A. Gay, J. Subramanian, T. M. Wildes, J. Mathai, T. Rachocki, D. I. Kuperman
- Brd. 14H** Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5561)
L. L. Siu, S. J. Hotte, S. A. Laurie, S. Singh, E. Winkvist, S. K. Chia, E. X. Chen, K. K. Chan, T. Wang, I. Taylor, A. Ruiz-Garcia, C. Mormont, D. Soulieres
- Brd. 15A** Phase II trial of sorafenib in patients with advanced thyroid cancer. (Abstract #5562)
S. M. Keefe, A. B. Troxel, S. Rhee, K. Puttaswamy, P. J. O'Dwyer, L. A. Loevner, S. J. Mandel, M. S. Brose
- Brd. 15B** A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m² for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). (Abstract #5563)
M. G. Fury, E. J. Sherman, D. M. Lisa, N. Agarwal, K. M. Algazy, B. Brockstein, C. J. Langer, D. Lim, R. Mehra, S. K. Rajan, N. Jafri, S. Korte, B. Lipson, F. Yunus, T. Tanvetyanon, S. Smith-Marrone, K. K. Ng, H. Xiao, S. Haque, D. G. Pfister
- Brd. 15C** Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results. (Abstract #5564)
A. Argiris, A. P. Kotsakis, S. Kim, F. P. Worden, P. Savvides, M. K. Gibson, G. R. Blumenschein Jr., H. X. Chen, J. R. Grandis, M. S. Kies
- Brd. 15D** Phase I/II trial of vandetanib and bortezomib in adults with locally advanced or metastatic medullary thyroid cancer: Phase I results. (Abstract #5565)
A. W. Gramza, S. A. Wells, S. Balasubramaniam, A. T. Fojo

- Brd. 15E** **A phase II study of VEGF trap in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. (Abstract #5566)**
E. J. Sherman, A. L. Ho, S. Haque, R. M. Tuttle, R. A. Ghossein, H. Schöder, M. S. Baum, K. Kelly, A. P. Chen, A. R. Shaha, D. G. Pfister
- Brd. 15F** **Cetuximab, docetaxel, and cisplatin (TPEX) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03. (Abstract #5567)**
J. Guigay, J. Fayette, A. Dillies, C. Sire, J. N. Kerger, I. Tennevet, J. H. Machiels, S. Zanetta, Y. Pointreau, L. Bozec Le Moal, L. Brugel Ribere, S. Henry, S. Temam, GORTEC
- Brd. 15G** **Pilot study to evaluate the effect of erlotinib (E) administered before surgery in operable patients with squamous cell carcinoma of the head and neck (SCCHN). (Abstract #5568)**
M. Porosnicu, J. D. Waltonen, C. Sullivan, L. McWilliams, G. L. Kucera, A. Thomas, R. Plasser, J. D. Browne
- Brd. 15H** **Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). (Abstract #5569)**
J. Ley, B. A. Siegel, F. Dehdashti, J. Subramanian, G. Ansstas, T. Rachocki, J. Mathai, T. M. Wildes, D. I. Kuperman, D. Adkins
- Brd. 16A** **Treatment (T) of T2 N0-1 larynx cancer (LC) with hyperfractionated radiotherapy (HRT) and cetuximab (C): Final report. (Abstract #5570)**
R. E. Giglio, A. Navigante, M. D. Pereira, L. Califano, B. M. Roth, P. Saco, M. A. Castro, P. Menendez, P. Aguerre, R. Adan, C. Brosio, C. Pogany
- Brd. 16B** **Human papillomavirus (HPV)-related, p16 positive head and neck squamous cell carcinomas (HNSCCs) after stem cell transplantation (SCT) and solid organ transplantation (SOT). (Abstract #5571)**
C. P. Rodriguez, D. Chute, R. Seth, B. Burkey, J. Scharpf, A. P. Hoschar, D. I. Ives, D. J. Adelstein
- Brd. 16C** **Different cellular p16 localization may signal different survival outcomes in head and neck cancer. (Abstract #5572)**
D. N. Hayes, N. Zhao, M. Ang, M. Patel, M. D. Wilkerson, X. Yin, M. C. Hayward, W. K. Funkhouser Jr., A. Olshan
- Brd. 16D** **Prognostic role of *PI3KCA* and *TP53* in HPV-negative oropharyngeal cancers (OPCs). (Abstract #5573)**
P. Bossi, F. Perrone, R. Miceli, L. Locati, C. Bergamini, A. Mirabile, R. Granata, C. Resteghini, B. Cortelazzi, M. Orsenigo, C. Fallai, E. Orlandi, S. Pilotti, L. F. Licitra
- Brd. 16E** **HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced squamous cell carcinoma of the head and neck treated with chemoradiation therapy at Centre Hospitalier de l'Université de Montréal: A single-center experience. (Abstract #5574)**
E. Thibaudeau, D. Soulieres, B. Fortin, F. Coutlee, P. Nguyen-Tan, X. Weng, M. Audette, O. Abboud, L. Guertin, A. Christopoulos, J. Tabet
- Brd. 16F** **Factors predicting survival outcomes for patients with HPV-positive base of tongue cancer. (Abstract #5575)**
P. Attner
- Brd. 16G** **Lymph node density and response to induction TPF in patients with HPV-related head and neck cancer. (Abstract #5576)**
H. C. Agbahiwe, S. Marur, A. A. Forastiere, G. Sanguineti
- Brd. 16H** **Effects of human papillomavirus (HPV) and other potential risk factors on survival in patients with oropharyngeal cancer. (Abstract #5577)**
M. Knoedler, A. Zakarneh, U. Zimmermann, K. Woelke, O. Kaschke, U. Keilholz

Saturday, June 4, 2011

- Brd. 17A Association of p16 and pEGFR expression with high-risk HPV in head and neck squamous cell carcinoma. (Abstract #5578)**
R. Altaha
- Brd. 17B Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. (Abstract #5579)**
L. J. Wirth, V. Nardi, D. Juric, A. K. Cosper, K. Bergethon, V. Scialabba, D. R. Borger, A. J. Iafrate, L. W. Ellisen, D. Deschler, D. Zhao, P. M. Sadow, D. Dias-Santagata
- Brd. 17C Adenoid cystic carcinoma of the head and neck (ACCHN) incidence and survival trends. (Abstract #5580)**
C. L. Ellington, S. A. Kono, T. K. Owonikoko, S. S. Ramalingam, F. R. Khuri, D. M. Shin, N. F. Saba
- Brd. 17D High-grade transformation in acinic cell carcinoma of the salivary glands: A rare but important clinical entity. (Abstract #5581)**
K. A. Price, W. Shon, J. A. Davidson, J. E. Lewis, D. L. Price, J. J. Garcia
- Brd. 17E 17-allylaminogeldanamycin in advanced medullary and differentiated thyroid carcinoma. (Abstract #5582)**
J. F. Moley, D. Adkins, K. C. Bible, A. M. Traynor, J. R. Molina, G. Colon-Otero, T. J. Pluard, M. H. Shah, R. Suresh, C. Erlichman, S. P. Ivy, V. Suman, S. M. Geyer, P. M. Fracasso, M. S. Cohen, H. Tang, E. Fialkowski, A. Traugott, R. C. Smallridge, P2C
- Brd. 17F Preoperative recombinant adeno-viral human p53 gene (rAd-p53) therapy in treatment of locally advanced papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC). (Abstract #5583)**
J. Zhu
- Brd. 17G Prognostic factors of adenoid cystic carcinoma of head and neck. (Abstract #5584)**
Y. Choi, S. Kim, S. Nam, S. Choi, J. Roh, J. Lee, S. Lee, K. Cho
- Brd. 17H Comparison of native and adaptive immunity profiles of healthy volunteers and patients with well-differentiated thyroid cancer. (Abstract #5585)**
S. Hossain, C. Bhimani, Z. Chen, S. S. Ramalingam, D. M. Shin, C. Cohen, F. R. Khuri, E. Waller, T. K. Owonikoko
- Brd. 18A Pharmacogenetic variations in ABCG2 are associated with cisplatin toxicity in patients with head and neck squamous cell carcinoma. (Abstract #5586)**
B. Lee, R. Slack, J. J. Hwang, K. Steadman, W. Harter, B. J. Davidson, K. A. Newkirk, P. G. Shields, R. Goldman, J. F. Deeken
- Brd. 18B ERCC1 and XPF protein expression in patients with nasopharyngeal carcinoma (NPC) undergoing curative intent radiation with or without platinum chemotherapy. (Abstract #5587)**
A. Jagdis, T. Phan, A. C. Klimowicz, J. J. Laskin, H. Lau, S. K. Petrillo, J. E. Siever, T. A. Thomson, A. M. Magliocco, D. Hao
- Brd. 18C Association of increased lymphocyte infiltration with outcome in patients with head and neck cancer treated with the IRX-2 regimen. (Abstract #5588)**
P. Naylor
- Brd. 18D Gene expression profiling predicts nonresponders to chemoradiation in HPV16-positive head and neck squamous cell carcinoma. (Abstract #5589)**
B. J. Thibodeau, T. J. Geddes, S. Ahmed, B. L. Pruetz, P. Y. Chen, G. D. Wilson, J. A. Akervall
- Brd. 18E Serum C₁₈-ceramide as a biomarker for response: Phase II trial of gemcitabine plus doxorubicin in patients with HNSCC. (Abstract #5590)**
K. Shirai, S. Saddoughi, P. E. O'Brien, L. Afrin, E. Garrett-Mayer, G. R. Simon, U. B. Chaudhary, B. Ogbretmen

SATURDAY

- Brd. 18F Identification of signaling pathways involved in the mechanism of action of the immunomodulatory peptide gamma-D-glutamyl-L-tryptophan. (Abstract #5591)**
J. Papkoff, H. Lee, G. Singh, S. Singh, S. Chitta, K. Andrew, P. Quintel, J. S. Rosenberg, B. A. Watkins, S. T. Sonis, C. W. Tuthill
- Brd. 18G The effect of the immunomodulatory peptide gamma-D-glutamyl-L-tryptophan in leukemia, lymphoma, and head and neck cancer xenograft models. (Abstract #5592)**
C. W. Tuthill, J. Papkoff, B. A. Watkins, S. T. Sonis
- Brd. 18H High dose rate intraoperative radiation therapy for recurrent head and neck cancer: The importance of in-field control on survival. (Abstract #5593)**
L. B. Harrison, W. F. Mourad, M. Perksy, M. Urken, A. Jacobson, B. Culliney, T. Tran, S. P. Schantz, P. Costantino, K. Hu
- Brd. 19A Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. (Abstract #5594)**
B. Jimenez, J. Trigo Perez, M. Saez Medina, C. Quero Blanco, B. Pajares, A. Rueda, E. Alba

Saturday, June 4, 2011

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell

Location: Hall A

Track(s): Lung Cancer

- Brd. 20A** Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI. (Abstract #7029)
G. R. Oxnard, Y. Y. Janjigian, M. E. Arcila, M. G. Kris, M. Ladanyi, C. G. Azzoli, V. A. Miller
- Brd. 20B** Tumor response and toxicity in neoadjuvant erlotinib in early-stage NSCLC patients. (Abstract #7030)
H. M. Klomp, E. Schaake, NEL Study group
- Brd. 20C** Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer. (Abstract #7031)
J. Wang, K. Chen, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, M. Wu, Q. Guo, X. Liu, S. Wang, Y. Wang
- Brd. 20D** The role of EGFR mutation status in patients with stage III nonsquamous non-small cell lung cancer treated with chemoradiotherapy. (Abstract #7032)
F. Li, G. y. Zhu, X. N. Li, R. Yu, A. Shi, L. Yin
- Brd. 20E** Mutations of EGFR, K-ras, and EML-4ALK genes in resected lung adenocarcinoma and their clinical significance. (Abstract #7033)
T. Ohba, K. Sugio, T. Kometani, M. Yamaguchi, M. Hamatake, K. Nosaki, H. Takeoka, H. Kitajima, F. Hirai, T. Seto, Y. Ichinose
- Brd. 20F** The association of epidermal growth factor receptor (EGFR) mutation and survival in N2(+) non-small cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. (Abstract #7034)
H. Ahn, Y. Choi, J. Sun, Y. Ahn, K. Kim, J. Kim, Y. Shim, J. Ahn, K. Park, M. Ahn
- Brd. 20G** Detection of EGFR mutations with mutation-specific antibodies in primary lesions of non-small cell lung cancer. (Abstract #7035)
X. Zhang, L. Yin, X. Yang, J. Yang, Q. Zhou, J. Xu, Z. Xie, S. An, S. Chen, R. Wang, G. Zhu, Y. Gu, Y. Wu
- Brd. 20H** Impact of EGFR mutation status in patients with completely resected lung adenocarcinoma treated with adjuvant platinum-based chemotherapy. (Abstract #7036)
K. Yoh, K. Goto, S. Niho, H. Ohmatsu, K. Nagai, Y. Ohe
- Brd. 21A** Expression of ErbB2 and ErbB3 in resected non-small cell lung cancer (NSCLC) patients (pts). (Abstract #7037)
E. Felip, M. Salcedo, N. Murtra-Garrell, A. Navarro, C. Teixido, J. Hernandez-Losa, S. Cedres, P. Martinez, E. Lopez, M. Montero, V. Freixinos, G. Argiles, I. Nuñez, V. Peg, E. Pallisa, M. Canela, J. Tabernero, S. Ramon y Cajal, N. Tallada
- Brd. 21B** Initial experience with erlotinib in advanced non-small cell lung cancer in the kingdom of Saudi Arabia. (Abstract #7038)
A. A. Alolayan, S. MUSAAD, H. Bamefleh, M. Nounou, A. R. Jazieh
- Brd. 21C** SOCCAR: Sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC. (Abstract #7039)
J. Maguire, R. McMenemin, N. O'Rourke, C. Peedell, M. Snee, S. McNee, V. Kelly
- Brd. 21D** Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). (Abstract #7040)
Y. Chen, J. Moon, K. J. Pandya, K. Kelly, L. E. Gaspar, D. Lau, F. R. Hirsch, D. R. Gandara

- Brd. 21E Predictive factors for symptomatic radiation pneumonitis in 293 consecutively treated non-small cell lung cancer (NSCLC) patients receiving definitive radiation therapy. (Abstract #7041)**
A. Orisamolú, E. Xanthopoulos, A. Fernandes, J. P. Christodouleas, S. Apisarnthanarax, N. Mitra, F. Wan, C. J. Langer, T. L. Evans, J. Stevenson, D. Serman, A. Vachani, A. R. Haas, R. Rengan
- Brd. 21F Long-term survival (LTS) and competing risks within a prospective multicenter German randomized trial comparing induction chemotherapy (CTx) followed by concurrent (cc) chemoradiation (CTx/RTx) plus surgery (SURG) (= TRIMODALITY) supplemented by PCI versus local treatment (Tx) alone (SURG + RTx) in operable IIIA NSCLC. (Abstract #7042)**
 T. C. Gauler, C. Poettgen, H. Wagner, S. Korfee, R. Hepp, G. Stamatis, J. Von Pawel, B. Passlick, V. Budach, H. Wilke, S. Seeber, M. Stuschke, W. E. Eberhardt
- Brd. 21G Endostar in combination with radiotherapy and paclitaxel/carboplatin in patients with unresectable non-small cell lung cancer of stage III: Preliminary results of a phase II study. (Abstract #7043)**
S. Ma, Y. Xu, X. Sun, Y. Ji, Y. Zheng, S. Wang, J. Chen
- Brd. 21H Phase II study of low-dose paclitaxel with timed thoracic radiotherapy (TTR) followed by gemcitabine and carboplatin consolidation in patients with unresectable stage III non-small cell lung cancer (NSCLC): NCT 00449657. (Abstract #7044)**
J. Zhang, S. M. Russo, H. A. Gay, T. Parent, Z. Nelson, S. Eubanks, P. R. Walker
- Brd. 22A Oral vinorelbine (NVBo) at 3 weekly flat-dose intakes (FDI) as single agent or with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage III NSCLC: Escalation-dose phase I trial results. (Abstract #7045)**
D. M. Kowalski, M. J. Krzakowski, K. Zajda, C. Lucas
- Brd. 22B A phase I study of nab-paclitaxel (nP) with carboplatin (C) and thoracic radiation (TRT) in patients with locally advanced NSCLC. (Abstract #7046)**
V. L. Keedy, B. Lu, L. Horn, Y. Shyr, C. F. Winkler, D. P. Carbone, A. Sandler
- Brd. 22C Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): Phase II results (CISTAXOL). (Abstract #7047)**
 W. E. Eberhardt, T. C. Gauler, C. Le Pechoux, R. Hepp, S. Welter, B. Fischer, S. Bildat, D. Grunenwald, G. Stamatis, M. Stuschke, C. Poettgen
- Brd. 22D Long-term follow-up of phase III trial of docetaxel and cisplatin (DP) versus mitomycin, vindesine, and cisplatin (MVP) with concurrent thoracic radiation therapy (TRT) for locally advanced non-small cell lung cancer (OLCSG 0007). (Abstract #7048)**
K. Kiura, N. Takigawa, K. Matsuo, S. Kuyama, S. Hosokawa, K. Fujiwara, A. Hisamoto, T. Kozuki, H. Ueoka, M. Tanimoto, Okayama Lung Cancer Study Group
- Brd. 22E Stereotactic body radiation therapy versus high-dose conventional radiation therapy in early-stage NSCLC: A retrospective study on local failure and survival rates. (Abstract #7049)**
S. Jeppesen, T. Schytte, H. R. Jensen, C. Brink, O. Hansen
- Brd. 22F Fiducial-less stereotactic radiotherapy for early-stage lung cancer: Efficacy and toxicity evaluation. (Abstract #7050)**
J. Bibault, B. Prevost, E. Dansin, X. Mirabel, T. Lacomberie, F. Dubus, E. Lartigau
- Brd. 22G Outcomes of stereotactic body radiotherapy in patients with clinical stage I non-small cell lung cancer who are fit to undergo surgery. (Abstract #7051)**
S. Senan, N. E. Versteegen, C. J. Haasbeek, B. J. Slotman, F. J. Lagerwaard
- Brd. 22H Clinical outcome of cN0 non-small cell lung cancer patient staged by thin slice CT, FDG-PET, and EBUS-TBNA. (Abstract #7052)**
Y. Sakairi, H. Hoshino, T. Nakajima, T. Fujiwara, F. Ishibashi, H. Tamura, H. Wada, T. Iwata, T. Okamoto, T. Mizobuchi, Y. Moriya, S. Yoshida, K. Yasufuku, I. Yoshino

- Brd. 23A** **Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). (Abstract #7053)**
 K. A. Gold, J. Lee, Y. Ping, C. Behrens, D. Liu, H. Lee, J. S. Koo, R. Lotan, L. Solis, W. Rinsurongkawong, D. J. Stewart, W. L. Hofstetter, S. Swisher, S. M. Lippman, I. I. Wistuba, W. K. Hong, E. S. Kim
- Brd. 23B** **Survival analysis of patients with/without lymph node examination after lung cancer resection. (Abstract #7054)**
 R. U. Osarogiagbon, R. A. Ramirez, C. Wang, L. E. Miller, M. Ul-Haq, A. Farooq, J. W. Allen, D. Spencer, A. Berry, A. B. Weir III, H. Cole, T. O'Brien
- Brd. 23C** **Final results of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomized study by the European Lung Cancer Working Party. (Abstract #7055)**
 T. Berghmans, J. Lafitte, V. Giner, M. Berchier, A. Scherpereel, M. Paesmans, A. Meert, T. Bosschaerts, N. Leclercq, J. P. Sculier
- Brd. 23D** **BRCA1 mRNA expression patterns in a large lung cancer cohort. (Abstract #7056)**
 K. Kelly, P. Mack, X. Huang, P. Lara Jr., P. V. Danenberg, K. D. Danenberg, D. R. Gandara
- Brd. 23E** **PI3K pathway and downstream signaling analysis in malignant pleural mesothelioma (MPM). (Abstract #7057)**
 S. Cedres Perez, M. Montero, D. Torrejon, P. Martinez, V. Freixinos, N. Mulet-Margalef, G. Argiles, I. Nuñez, E. Lopez, L. Prudkin, M. Salcedo, N. Tallada, S. Ramon y Cajal, E. Felip
- Brd. 23F** **Role of solid tumor size compared with whole tumor size to predict pathological malignant grade or prognosis in clinical stage IA lung adenocarcinoma: A multicenter study. (Abstract #7058)**
 Y. Tsutani, Y. Ibuki, T. Ikeda, Y. Miyata, H. Nakayama, M. Okada
- Brd. 23G** **Molecular studies support the association between germline genetic variants in the vascular endothelial growth factor (VEGF) pathway and survival in non-small cell lung cancer (NSCLC) patients. (Abstract #7059)**
 D. M. Glubb, W. Zhang, K. Owzar, C. Jiang, O. Mirza, S. Kashyap, W. Rzyman, J. Jassem, F. R. Hirsch, R. Dziadziuszko, F. Innocenti
- Brd. 23H** **Characteristics of the ground-glass opacity nodules showing growth during follow-up. (Abstract #7060)**
 H. Matsuguma, A. Ui, N. Oohata, R. Nakahara, T. Kasai, Y. Kamiyama, S. Igarashi, K. Mori, T. Kodama, K. Yokoi
- Brd. 24A** **Incomplete intrapulmonary lymph node retrieval with routine pathology evaluation of resected lung cancer. (Abstract #7061)**
 R. A. Ramirez, C. Wang, L. E. Miller, C. A. Adair, T. O'Brien, A. Berry, R. U. Osarogiagbon
- Brd. 24B** **A window-of-opportunity trial of vorinostat (V) in patients with resectable non-small cell lung cancer (NSCLC). (Abstract #7062)**
 K. H. Dragnev, T. Ma, F. Galimberti, C. P. Erkmén, V. Memoli, W. Nugent, J. R. Rigas, D. Johnstone, A. Frandsen, S. Simeone, J. Czum, H. Li, J. DiRenzo, S. Freemantle, E. Dmitrovsky
- Brd. 24C** **Induction chemotherapy with gemcitabine-carboplatin-paclitaxel (GEMCAP) in stage III non-small cell lung cancer (NSCLC). (Abstract #7063)**
 G. L. Banna, H. Lipari, C. Buscarino, A. Seca, A. Basile, M. Ippolito, G. Novello, R. Condorelli, S. Cavallaro, G. Squadrito, M. D'Arrigo, V. Gebbia, A. Terminella, S. Saita
- Brd. 24D** **Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). (Abstract #7064)**
 L. Toschi, P. Colombo, C. Soldani, L. Giordano, G. Finocchiaro, L. Siracusano, L. Gianoncelli, M. Incarbone, A. Destro, M. Alloisio, L. Terracciano, M. Varella-Garcia, F. Cappuzzo, M. Roncalli, A. Viola, A. Santoro

SATURDAY

- Brd. 24E Hedgehog inhibition and radiation therapy in non-small cell lung cancer. (Abstract #7065)**
J. Zeng, K. Aziz, M. Armour, B. Aftab, R. Gajula, S. Chettair, T. Salih, C. M. Rudin, P. T. Tran, R. Hales
- Brd. 24F Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. (Abstract #7066)**
G. C. Connolly, M. R. Dalal, J. Lin, A. A. Khorana
- Brd. 24G Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer (NSCLC). (Abstract #7067)**
R. G. Salloum, T. J. Smith, J. Elston-Lafata, G. Jensen
- Brd. 24H Examination of 12-lipoxygenase (12-LOX) as a therapeutic target in non-small cell lung cancer (NSCLC): Mechanisms controlling survival and induction of apoptosis following selective inhibition. (Abstract #7068)**
M. Cathcart, V. Campbell, K. Gately, E. Kay, G. P. Pidgeon, K. J. O'Byrne
- Brd. 25A Smoking, passive smoking and lung cancer cell types among women in Morocco: Analysis of epidemiological profiling of 101 cases. (Abstract #7069)**
H. Errihani, S. Ouaouch, H. Abahssain, R. Razine, H. Mrabti, R. Abouqal, M. Ichou, N. Benjaafar, F. Zakkouri
- Brd. 25B Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with G12C, G12D, or G12V KRAS mutations. (Abstract #7070)**
S. P. D'Angelo, B. J. Park, L. M. Krug, C. Crevar, C. E. Medina, D. K. Sumner, J. Richman, C. Coeshott, D. Apelian, A. Cohn, M. G. Kris, C. G. Azzoli
- Brd. 25C Prognostic role of integrin β_1 , E-cadherin, and rac1 expression in small cell lung cancer. (Abstract #7071)**
M. Chang, K. Lee, Y. Kim, J. Kang
- Brd. 26A Liposomal cisplatin in cancer patients with renal failure. (Abstract #7072)**
G. Stathopoulos, S. Rigatos, J. Stathopoulos, S. Batzios
- Brd. 26B Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors. (Abstract #7073)**
N. Chen, S. P. Chawla, E. G. Chiorean, W. L. Read, M. Gorbaty, A. C. Mita, L. Yung, R. McNally, M. F. Renschler, S. Sharma
- Brd. 26C Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis. (Abstract #7074)**
S. E. Schild, N. R. Foster, J. P. Meyers, K. R. Olivier, H. J. Ross, J. R. Molina, P. J. Stella, L. R. Past, Y. I. Garces, A. A. Adjei, North Central Cancer Treatment Group
- Brd. 27A Retrospective review of extrapulmonary small cell carcinoma and prognostic factors. (Abstract #7075)**
J. E. Brammer, P. D. Lulla, M. A. Bilen, G. R. Lynch
- Brd. 27B A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). (Abstract #7076)**
H. Kenmotsu, S. Niho, T. Ito, Y. Ishikawa, H. Tada, I. Sekine, S. Watanabe, M. Yoshimura, N. Yamamoto, F. Oshita, K. Kubota, K. Nagai
- Brd. 27C Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (Abstract #7077)**
M. G. Viganò, R. Cavina, S. Novello, F. Grossi, A. Santoro, V. Gregorc, G. Scagliotti, I. M. Garassino, G. Rossoni, M. G. Levra, C. Genova, F. Caligaris-Cappio, A. Lambiase, C. Bordignon

- Brd. 28A Predictors of pulmonary toxicity in limited-stage (LS) small cell lung cancer (SCLC) patients treated with concurrent chemotherapy (CTX) and high-dose (70 Gy) daily radiotherapy (RT): A pooled analysis of three CALGB studies. (Abstract #7078)**
 J. K. Salama, L. Hodgson, H. Pang, M. R. Green, J. J. Urbanic, A. W. Blackstock, J. Crawford, J. Bogart, E. E. Vokes, CALGB
- Brd. 28B Phase II study of NK012 in relapsed small cell lung cancer. (Abstract #7079)**
 E. Raefsky, D. R. Spigel, J. R. Infante, J. C. Bendell, S. F. Jones, A. J. Lipman, D. Trent, S. Kawamura, F. A. Greco, J. D. Hainsworth, H. A. Burris III
- Brd. 28C Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small cell lung cancer (SCLC) cells. (Abstract #7080)**
 Z. Wang
- Brd. 29A A phase I study of weekly oral topotecan in patients (pts) with relapsed small cell lung cancer (SCLC). (Abstract #7081)**
 E. Kontopodis, L. Vamvakas, K. Kalbakis, N. K. Vardakis, G. Sfakiotaki, V. Georgoulas, S. Agelaki
- Brd. 29B A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. (Abstract #7082)**
 S. I. Jalal, J. A. Bufill, G. A. Masters, N. Somaiah, K. Koneru, J. McClean, R. E. Sanborn, J. Wu, Z. Yu, L. H. Einhorn
- Brd. 29C Determinants of chemotherapy administration and effects of chemotherapy on survival in elderly patients with small cell lung cancer (SCLC): A SEER-Medicare analysis. (Abstract #7083)**
 L. C. Caprario, D. M. Kent, T. A. Trikalinos, G. M. Strauss
- Brd. 30A Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC). (Abstract #7084)**
 J. Han, K. Lim, H. Kim, S. Oh, T. Yun, J. Lee
- Brd. 30B Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada. (Abstract #7085)**
 A. Hasani, B. Sun, G. Liu, W. Xu, R. Feld, N. B. Leighl
- Brd. 30C Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in malignant pleural mesothelioma. (Abstract #7086)**
 K. Hollevoet, K. Nackaerts, R. Gosselin, W. De Wever, L. Bosquée, P. De Vuyst, P. R. Germonpre, E. Kellen, C. Legrand, Y. Kishi, J. R. Delanghe, J. P. Van Meerbeeck
- Brd. 31A Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients (Italian SoMe Study). (Abstract #7087)**
 V. Mutri, C. Pinto, S. Giaquinta, P. Di Tullio, V. Torri, B. Melotti, F. Sperandi, F. Di Fabio, F. L. Rojas Llimpe, S. Pini, F. Massari, A. Martoni
- Brd. 31B Repeated ambulatory intrapleural chemotherapy for malignant pleural mesothelioma. (Abstract #7088)**
 J. Javidfar, J. R. Sonett, M. E. Ginsburg, J. Miller, E. Hare, M. Bacchetta, R. Fawwaz, R. N. Taub
- Brd. 31C NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM). (Abstract #7089)**
 F. De Vincenzo, G. Rossoni, A. Santoro, V. Gregorc, P. A. Zucali, G. Citterio, M. Simonelli, G. Petrella, F. Caligaris-Cappio, A. Lambiase, C. Bordignon
- Brd. 31D Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of malignant pleural mesothelioma (MPM). (Abstract #7090)**
 F. Rea, A. G. Favaretto, G. Marulli, L. Spaggiari, T. M. De Pas, A. Ceribelli, A. Paccagnella, G. Crivellari, F. Russo, M. Ceccarelli, F. Facciolo

- Brd. 31E** **Imatinib mesylate in thymic epithelial malignancies. (Abstract #7091)**
C. Buonerba, M. Marino, S. Sioletic, S. Conti, L. Petillo, P. Federico, V. Damiano,
G. Merola, A. Evoli, M. Lalle, A. Ceribelli, M. Milella, G. Palmieri

Saturday, June 4, 2011

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Lung Cancer—Metastatic/Non-small Cell

Location: Hall A

Track(s): Lung Cancer

- Brd. 32A Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis. (Abstract #7537)**
K. E. Bickel, J. C. Niland, R. Mamet, C. C. Zornosa, D. S. Ettinger, K. Pisters, G. A. Otterson, M. Koczywas, M. E. Reid, M. S. Rabin, T. A. D'Amico, C. Earle, T. M. Pini, G. P. Kalemkerian
- Brd. 32B Guideline adherence rates and costs of chemotherapy treatment for NSCLC patients treated in U.S. community oncology practices. (Abstract #7538)**
Z. Wang, I. Aksamit, L. Tuscher, B. S. Tom, C. B. Del Buono, U. Campbell, S. Shields, T. Lam, K. B. Whitlock, M. Mayo, J. Huang, A. M. Christman, K. A. Bergstrom
- Brd. 32C The effect of 3 months of integrative cancer treatment on quality of life for patients with lung cancer. (Abstract #7539)**
E. D. Staren, D. Gupta, J. F. Grutsch, D. P. Braun
- Brd. 32D Influence of crossover therapy on the association between progression-free survival (PFS) and overall survival (OS) in randomized trials of molecular-targeted agents for advanced non-small cell lung cancer (NSCLC). (Abstract #7540)**
K. Hotta, K. Kiura, E. Suzuki, N. Takigawa, Y. Fujiwara, E. Ichihara, M. Tabata, M. Tanimoto
- Brd. 32E Factors influencing a specific histological diagnosis of non-small cell lung cancer. (Abstract #7541)**
J. A. Sulpher, S. P. Owen, H. Hon, K. Tobros, F. A. Shepherd, E. Sabri, G. Liu, C. M. Canil, P. Wheatley-Price
- Brd. 32F Surgical, histopathologic, and patient-related factors associated with isolated brain metastases (IBM) in patients with stages I-IIIa non-small cell carcinoma (NSCLC) undergoing surgical resection in comparison to patients developing other distal metastases (ODM). (Abstract #7542)**
J. M. Varlotto, L. N. Medford-Davis, J. Shelkey, J. C. Flickinger, A. Recht, M. Nikolov, M. Reed, J. Toth, M. M. DeCamp
- Brd. 32G Retrospective review of MRIs in lung cancer patients with brain metastases: An assessment of early response. (Abstract #7543)**
R. Zinner, M. Debnam, G. W. Gladish, B. Konda, J. M. Hanneken, D. J. Stewart, R. F. Munden, L. Chi
- Brd. 32H Clinical outcome of patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. (Abstract #7544)**
S. Umemura, K. Kiura, K. Tsubouchi, N. Takigawa, K. Fujiwara, N. Horita, Y. Segawa, N. Hamada, I. Takata, M. Tanimoto
- Brd. 33A Prospective study on incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer (CSP-HOR13). (Abstract #7545)**
N. Katakami, A. Hata, H. Kunikane, K. Takeda, K. Eguchi, K. Takayama, T. Sawa, H. Saito, M. Harada, S. Yokota, K. Ando, Y. Ohashi
- Brd. 33B Can we really treat patients over 70 years old with a chemotherapy doublet for non-small cell lung cancer (NSCLC)? (Abstract #7546)**
M. G. Zauderer, C. S. Sima, B. Korc-Grodzicki, M. G. Kris, L. M. Krug
- Brd. 33C Meta-analysis of efficacy and safety of single-agent and doublet chemotherapy with or without platinum in advanced non-small cell lung cancer in the elderly. (Abstract #7547)**
G. Des Guetz, B. Uzzan, P. Nicolas, K. Chouahnia, G. Sebbane, J. F. Morere

- Brd. 33D Phase II study of bevacizumab and erlotinib in treatment-naive elderly patients (older than age 65) with advanced non-small cell lung cancer (NSCLC). (Abstract #7548)**
H. Borghaei, R. Mehra, M. M. Millenson, H. Tuttle, K. Ruth, A. J. Magdalinski, D. M. Mintzer, J. Lee, J. Stevenson, C. J. Langer
- Brd. 33E Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients. (Abstract #7549)**
C. Reynolds, A. I. Spira, W. L. Gluck, R. E. Pluenneke, K. A. Boehm, F. Zhan, L. Asmar
- Brd. 33F Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (Abstract #7550)**
A. S. Tsao, S. Liu, J. Lee, C. M. Alden, E. S. Kim, G. R. Blumenschein Jr., R. S. Herbst, S. M. Lippman, I. I. Wistuba, W. K. Hong
- Brd. 33G Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. (Abstract #7551)**
M. A. Socinski, I. N. Bondarenko, N. A. Karaseva, A. Makhson, I. Vynnychenko, I. Okamoto, J. K. Hon, V. Hirsh, P. Bhar, G. I. Berk, J. L. Iglesias
- Brd. 33H Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). (Abstract #7552)**
T. Hirashima, I. Okamoto, H. Yoshioka, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, H. Saka, K. Asami, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, T. Sawa, M. Miyazaki, K. Tamura, T. Kurata, M. Fukuoka, K. Nakagawa, West Japan Oncology Group
- Brd. 34A Single-agent maintenance therapy for advanced-stage non-small cell lung cancer: A meta-analysis. (Abstract #7553)**
M. Behera, T. K. Owonikoko, Z. Chen, S. A. Kono, F. R. Khuri, C. P. Belani, S. S. Ramalingam
- Brd. 34B Results of a randomized phase IIb study estimating overall survival of pralatrexate versus erlotinib in platinum-pretreated NSCLC. (Abstract #7554)**
J. D. Patel, C. G. Azzoli, G. A. Weems, A. Koutsoukos, P. Zatloukal, K. Kelly
- Brd. 34C Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials. (Abstract #7555)**
A. Ardizzoni, L. Boni, M. Tiseo, A. Vincent, R. Passalacqua, A. Camerini, R. Labianca, G. Genestreti, F. Zanelli, L. Ciuffreda, F. Di Costanzo, F. De Marinis, L. Crinò, A. Santo, A. Pazzola, F. Barbieri, N. Zilembo, I. Colantonio, C. Tibaldi, E. F. Smit
- Brd. 34D Prognostic score for second-line chemotherapy of advanced non-small cell lung cancer (NSCLC): External validation in a phase III trial comparing vinflunine with docetaxel. (Abstract #7556)**
M. J. Krzakowski, M. Di Maio, K. Perraud, D. M. Kowalski, C. Gridelli
- Brd. 34E The role of gender in predicting for reduced drug clearance and increased toxicity in non-small cell lung cancer (NSCLC) patients receiving carboplatin and paclitaxel. (Abstract #7557)**
V. H. Phan, C. Tan, J. L. Vardy, A. Rittau, H. Xu, F. Zhang, A. J. McLachlan, P. J. Beale, S. J. Clarke
- Brd. 34F Standard chemotherapy strategy versus changing chemotherapy strategy as to FDG-PET response after first cycle of standard chemotherapy for advanced NSCLC. (Abstract #7558)**
S. Kim, J. Kim, K. Kim, D. Lee, C. Choi, D. Moon, J. Ryu, S. Oh, C. Suh, J. Lee

- Brd. 34G** **A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial. (Abstract #7559)**
E. B. Garon, F. F. Kabbinavar, J. A. Neidhart, J. D. Neidhart, N. Y. Gabrail, M. R. Oliveira, S. Lu, J. Balkissoon
- Brd. 34H** **Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment and progression-free and overall survival (PFS, OS). (Abstract #7560)**
J. Aisner, J. Manola, S. R. Dakhil, P. J. Stella, J. H. Schiller, PrECOG, LLC
- Brd. 35A** **Bevacizumab (B) and erlotinib (E) as first-line therapy in metastatic nonsquamous non-small cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression (PD): A multicenter phase II trial SAKK 19/05. (Abstract #7561)**
F. Zappa, C. Droege, D. C. Betticher, R. von Moos, M. H. Brutsche, F. Baty, L. Bubendorf, A. Ochsenein, E. Oppliger Leibundgut, O. Gautschi, P. Froesch, R. A. Stahel, D. Rauch, P. Schmid, M. Mayer, S. Crowe, P. Brauchli, K. Ribi, M. Pless
- Brd. 35B** **AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data. (Abstract #7562)**
F. Barlesi, A. Scherpereel, R. Gervais, V. A. Gorbunova, A. Vikström, M. J. Ahn, J. H. Kim, A. Chella, J. Aerts, N. Ferrer, J. M. Trigo Perez, B. Lutiger, A. Rittmeyer
- Brd. 35C** **Phase II study of topotecan and bevacizumab in advanced refractory non-small cell lung cancer (NSCLC). (Abstract #7563)**
S. F. Powell, A. Beitinjaneh, R. L. Bliss, R. A. Kratzke, J. W. Leach, A. Dudek
- Brd. 35D** **Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). (Abstract #7564)**
S. M. Gadgeel, J. C. Ruckdeschel, A. J. Wozniak, W. Chen, D. Hackstock, C. Galasso, A. Burger, S. P. Ivy, P. LoRusso, M. J. Edelman
- Brd. 35E** **Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #7565)**
G. R. Blumenschein, J. R. Molina, C. D. Lathia, T. J. Ong, D. Roth, P. Rajagopalan, F. V. Fossella, M. S. Kies, R. S. Marks, A. A. Adjei, P. R. Sundaresan
- Brd. 35F** **ALK rearrangement in a selected population of advanced non-small cell lung cancer patients: FISH and immunohistochemistry diagnostic methods, prevalence and clinical outcomes. (Abstract #7566)**
P. Martinez, J. Hernandez-Losa, J. Castellvi, N. Tallada, S. Cedres, M. Montero, V. Rodriguez-Freixinos, I. Nuñez, G. Argiles, N. Mulet-Margalef, D. Torrejon, S. Ramon y Cajal, E. Felip
- Brd. 35G** **Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study. (Abstract #7567)**
M. W. Jones, C. Zhang, K. R. Oettel, J. H. Blank, E. G. Robinson, H. G. Ahuja, R. J. Kirschling, P. H. Johnson, M. S. Huie, J. Kolesar, M. Wims, H. Hernan, T. C. Campbell, A. M. Traynor, T. Hoang
- Brd. 35H** **Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results. (Abstract #7568)**
V. Gregorc, N. Zilembo, F. Grossi, G. Rossoni, F. Pietrantonio, E. Rijavec, A. Bulotta, M. Vitali, G. Barletta, L. Bergamaschi, M. Platania, F. Caligaris-Cappio, A. Lambiase, C. Bordignon

- Brd. 36A** **The effect of talactoferrin on overall survival in prognostically important NSCLC subsets in a randomized, placebo-controlled phase II trial. (Abstract #7569)**
P. M. Parikh, A. Ranade, A. K. Vaid, S. H. Advani, A. Bapna, J. Zhu, Y. Wang, P. M. Ismail, R. K. Malik
- Brd. 36B** **A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC). (Abstract #7570)**
A. C. Mita, M. M. Mita, C. Rocha, C. R. Bradley, J. Sarantopoulos, P. O'Rourke, S. M. Gadgeel, A. J. Wozniak, E. I. Heath
- Brd. 36C** **Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAB) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #7571)**
E. Tan, K. Park, W. T. Lim, M. Ahn, Q. Ng, J. Ahn, D. S. Tan, J. Sun, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, W. Slichenmyer
- Brd. 36D** **A phase I study of MM-10-001 in advanced non-small cell lung cancer. (Abstract #7572)**
M. C. Cristea, M. Koczywas, K. L. Reckamp, S. F. Lacey, A. Rotter, P. H. Frankel, S. Fouladi Rad, X. Liu, V. Tran, E. Reorizo, M. Kalos
- Brd. 36E** **Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). (Abstract #7573)**
P. C. Mack, N. Farneth, C. Mahaffey, P. Lara Jr., D. R. Gandara
- Brd. 36F** **Targeting I2PP2A by FTY720: A novel, mechanism-based treatment strategy for patients with advanced and previously treated non-small cell lung cancer (NSCLC). (Abstract #7574)**
G. R. Simon, S. Saddoughi, A. Mukhopadhyay, Y. Peterson, C. E. Senkal, J. Oaks, D. Perrotti, Y. Hannun, B. Ogretmen
- Brd. 36G** **DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment—A catalogue of clinically relevant somatic mutations in lung cancer. (Abstract #7575)**
L. Horn, H. Chen, C. M. Lovly, J. Andrews, P. Yeh, M. A. Levy, W. Pao
- Brd. 36H** **My Cancer Genome: Web-based clinical decision support for genome directed lung cancer treatment. (Abstract #7576)**
M. A. Levy, C. M. Lovly, L. Horn, R. Naser, W. Pao
- Brd. 37A** **Screening for mutations in Colombian metastatic non-small cell lung cancer (NSCLC) patients (ONCOLGroup). (Abstract #7577)**
A. F. Cardona, P. L. Ramos, R. Duarte, H. Carranza, C. J. Castro, M. Lema, C. A. Vargas, A. Jimenez, H. A. Becerra, R. Rosell
- Brd. 37B** **Development of prognostic biomarker in pathologic stage I NSCLC patients: Protein expressions involving in DNA damage response. (Abstract #7578)**
J. Ryu, C. Choi, S. Yang, H. Nam, H. Kim, M. H. Lee
- Brd. 37C** **Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. (Abstract #7579)**
J. Sun, J. Ahn, K. Park, J. Han, M. Ahn
- Brd. 37D** **Clinical outcome of KRAS mutated advanced non-small cell lung cancer (NSCLC) patients (pts): A mono-institutional analysis. (Abstract #7580)**
R. Chiari, V. De Angelis, C. Bennati, C. Molica, G. Metro, S. Duranti, F. R. Tofanetti, V. Ludovini, V. Minotti, L. Crino
- Brd. 37F** **Role of basal inflammatory status as a predictor of survival in bevacizumab treated advanced non-small cell lung cancer (NSCLC) patients. (Abstract #7582)**
C. Botta, A. Guglielmo, E. Bestoso, S. Apollinari, A. Licchetta, P. Bardi, P. Tassone, G. Chiriaco, V. Barbieri, G. Mantovani, P. Tagliaferri, P. Correale

- Brd. 37G** **Circulating endothelial cells, endothelial progenitor cells, microparticles, and markers of inflammation and coagulation in advanced non-small cell lung cancer. (Abstract #7583)**
T. Fleitas, G. Reynes, V. Martinez-Sales, V. Vila, E. Reganon, D. Mesado, M. Martin, J. Gómez-Codina, J. Montalar
- Brd. 37H** **Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy. (Abstract #7584)**
K. Habben, P. Delmar, C. M. Brownstein, W. Koehler, K. Kuenkele, O. Spleis, S. S. Ramalingam, J. A. Engelman, D. Chen
- Brd. 38A** **Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC). (Abstract #7585)**
W. M. Brueckl, C. Eschbach, G. H. Wiest, J. H. Ficker, S. Zirlik, R. Hake, S. Eidt, A. Hartmann, R. M. Wirtz
- Brd. 38B** **The nuclear factor kb (NFkB) and Notch signalling pathways and BRCA1 mRNA expression in stage IV non-small cell lung cancer (NSCLC) patients (p). (Abstract #7586)**
M. Santarpiá, M. Sanchez-Ronco, I. Magri, S. Viteri, C. Costa, A. Gasco, M. Gonzalez Cao, N. Mederos, F. Salazar, J. Bertran-Alamillo, A. Gimenez Capitan, G. Altavilla, S. Benloch, Z. Yeste, E. Aldeguer, M. Taron, R. Rosell
- Brd. 38C** **Clinical, pathological, and molecular characteristics of patients with non-small cell lung cancer harboring mutations in PIK3CA. (Abstract #7587)**
M. Pietanza, M. E. Arcila, J. E. Chaff, M. F. Zakowski, M. Ladanyi, G. J. Riely, M. G. Kris
- Brd. 38D** **Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7588)**
E. Carcereny, M. A. Molina, J. Sanchez, J. Bertran-Alamillo, C. Mayo, E. Aldeguer, A. Gimenez Capitan, Z. Yeste, C. Costa, S. Benloch, A. Martinez, C. Buges, J. Bosch, D. Isla, M. Domine, M. Provencio, C. Camps, M. Taron, R. Rosell
- Brd. 38E** **Identification of AEG-1 and BARD1 as predictors of erlotinib outcome in EGFR-mutant non-small cell lung cancer (NSCLC) by NanoString multiple target profiling. (Abstract #7589)**
M. Taron, S. Benloch, R. Rosell, J. Sanchez, C. Costa, A. Gimenez Capitan, C. Mayo, J. Bertran-Alamillo, M. A. Molina, B. Massuti, C. Camps, M. Majem, D. Isla, M. Santarpiá, S. Viteri, A. Gasco, T. Moran, E. Carcereny, C. Queralt, I. de Aguirre
- Brd. 38F** **Initial detection of the double epidermal growth factor receptor (EGFR) mutation (L858R or deletion in exon 19 [del 19] plus T790M) in non-small cell lung cancer (NSCLC) patients (p) with brain metastases (mets) and the influence of first-line chemotherapy on outcome to erlotinib. (Abstract #7590)**
T. Moran, J. Sanchez, M. A. Molina, J. Bertran-Alamillo, A. Gimenez Capitan, S. Benloch, M. Taron, B. Massuti, C. Camps, R. Porta, D. Isla, G. Lopez-Vivanco, I. Bover, M. Garcia-Campelo, C. D. Rolfo, F. Salazar, E. Carcereny, F. Cardenal, I. Magri, R. Rosell
- Brd. 38G** **[¹⁸F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib. (Abstract #7591)**
M. Scheffler, T. Zander Jr., L. Nogova, C. Kobe, D. Kahraman, M. Dietlein, I. Papachristou, S. Querings, E. Stoelben, W. Engel-Riedel, B. Neumaier, J. Wolf
- Brd. 38H** **Association of CA repeat number and R497K with PFS to EGFR TKIs in NSCLC patients having sensitive mutation of EGFR. (Abstract #7592)**
J. Kang, E. Jeon, J. Shin, J. Kim, M. Lee, Y. Kim, K. Lee, Y. Wang, E. Cho

SATURDAY

- Brd. 39A** **DAB2 interactive protein (DAB2IP) methylation in serum DNA of non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #7593)**
J. Wei, J. Ramirez, M. Taron, J. Sanchez, S. Benlloch, R. Rosell, M. Botia, M. Perez-Cano, P. Mendez, M. Tierno, C. Queralt, I. de Aguirre, B. Sanchez, A. Martinez, C. Buges, J. Bosch, B. Massuti, C. Camps, T. Moran
- Brd. 39B** **Quantitative detection of the T790M EGFR mutation in circulating tumor DNA of lung cancer patients subjected to EGFR-TKI treatment. (Abstract #7594)**
J. Uchida, K. Taniguchi, F. Imamura, K. Nishino, T. Kumagai, Y. Akazawa, T. Okuyama, K. Kato
- Brd. 39C** **Circulating tumor cells and detection of EGFR mutation in cell-free tumor DNA in blood plasma in metastatic non-small cell lung cancer with EGFR mutation. (Abstract #7595)**
K. Isobe, Y. Hata, S. Sakaguchi, K. Sato, K. Sugino, G. Sano, S. Sakamoto, Y. Takai, K. Shibuya, K. Takagi, S. Homma
- Brd. 39D** **The surfactant protein B (SFTPB) as a surrogate of circulating tumor cells (CTC) with prognostic value in advanced-stage NSCLC. (Abstract #7596)**
R. Sirera, E. Jantus-Lewintre, A. Timon, M. Usó, A. Berrocal, S. Borrego, G. Marcaida, E. Sanmartin, R. Rosell, C. Camps
- Brd. 39E** **First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicenter academic phase II study in caucasian patients (pts) (NCT00339586)—FIELT study group. (Abstract #7597)**
J. De Greve, J. P. Van Meerbeeck, J. F. Vansteenkiste, E. Teugels, C. Geers, A. Meert, P. Vuylsteke, C. N. Focan, J. Canon, Y. Humblet, G. J. Berchem, B. Colinet, D. Galdermans, L. Bosquée, C. A. Dooms, L. Decoster, J. Vermeij, A. Dewaele, D. C. Schallier
- Brd. 39F** **Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). (Abstract #7598)**
G. Lopes, J. Segel, D. S. Tan, Y. Do, T. Mok, E. Finkelstein
- Brd. 39G** **Targeting therapies influence survival of refractory patients with lung advanced adenocarcinoma: A phase III randomized trial. (Abstract #7599)**
K. Zarogoulidis, E. Boutsikou, T. Kontakiotis, P. Zarogoulidis, E. Eleftheriadou, L. Sacas, G. Galaktidou
- Brd. 39H** **Meta-analysis of the chemotherapy versus EGFR-TKI in different selections of patients. (Abstract #7600)**
C. Xu, Q. Zhou, Y. Wu
- Brd. 40A** **Phase II study of dose-dense chemotherapy followed by dose-intense erlotinib for initial treatment of metastatic NSCLC. (Abstract #7601)**
L. L. Waller, A. A. Miller, N. P. Streer, J. F. Lovato, W. J. Petty
- Brd. 40B** **Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. (Abstract #7602)**
T. K. Owonikoko, M. Behera, H. N. Tran, Z. Chen, R. P. Chowdry, N. F. Saba, S. S. Ramalingam, F. R. Khuri
- Brd. 40C** **Randomized phase III trial of gefitinib or pemetrexed as second-line treatment in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01). (Abstract #7603)**
M. Ahn, J. Sun, J. Ahn, S. Kim, K. Lee, Y. Min, H. Yun, H. Kim, H. Song, Y. H. Kim, B. Kim, I. Hwang, I. S. Woo, H. Ryoo, H. Yi, J. Jang, J. Kwon, K. Park
- Brd. 40D** **Safety data and patterns of progression in met diagnostic subgroups in OAM4558g: A phase II trial evaluating MetMAB in combination with erlotinib in advanced NSCLC. (Abstract #7604)**
A. Vashishtha, P. H. Patel, W. Yu, J. G. Bothos, J. Simpson, T. Maneatis, L. Doessegger, A. C. Peterson, C. Clement-Duchene, G. Robinet, M. Krzakowski, G. R. Blumenschein Jr., J. H. Goldschmidt Jr., D. B. Daniel, D. R. Spigel

- Brd. 40E** A phase II study (CTONG0803) of erlotinib as second-line treatment in advanced non-small cell lung cancer (NSCLC) patients (pts) with asymptomatic brain metastases (BM) after first-line chemotherapy (CT). (Abstract #7605)
Y. Wu, C. Zhou, Y. Cheng, S. Lu, G. Chen, C. Huang, Y. Huang, H. Yan, J. Yang, Chinese Thoracic Oncology Group
- Brd. 40F** Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations. (Abstract #7606)
K. Kim, D. Lee, J. Lee, C. Suh, S. Kim, C. Choi, S. Jang, J. Choi
- Brd. 40G** Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic *EGFR* mutations initially treated with gefitinib or erlotinib versus chemotherapy. (Abstract #7607)
S. Heon, B. Y. Yeap, N. I. Lindeman, M. S. Rabin, D. M. Jackman, B. E. Johnson
- Brd. 40H** Cerebral penetration of gefitinib in patients with lung adenocarcinoma. (Abstract #7608)
M. Wang, Z. Jing, C. Minjiang
- Brd. 41A** How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring epidermal growth factor receptor gene sensitive mutations? (Abstract #7609)
A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, Y. Imai, K. Tomii, M. Iwasaku, A. Nishiyama, T. Ishida
- Brd. 41B** Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the SATURN study. (Abstract #7610)
R. Perez-Soler, F. Cappuzzo, L. Leon, S. Wojtowicz-Praga
- Brd. 41C** Implementation of adherence to erlotinib by a treatment-monitoring program. (Abstract #7611)
V. Gebbia, M. Bellavia, P. Russo, G. L. Banna, F. Ferràu, P. Tralongo, N. Borsellino

2:00 PM - 6:00 PM
GENERAL POSTER SESSION

Patient and Survivor Care

Location: Hall A

Track(s): Patient and Survivor Care

- Brd. 42A** **Incidence and predictors of delayed congestive heart failure (CHF) after hematologic malignancies treated with autologous hematopoietic cell transplantation (aHCT). (Abstract #9042)**
S. Armenian, C. Sun, T. Shannon, M. Shangguan, G. Mills III, L. Francisco, F. L. Wong, S. J. Forman, S. Bhatia
- Brd. 42B** **The risk of subsequent malignancies in cervical cancer survivors as compared with breast and colorectal cancer survivors: United States 1992–2007. (Abstract #9043)**
J. Underwood, S. Rim, E. Tai, T. Fairley
- Brd. 42C** **Prevalence and correlates of suicidal ideation among outpatients at a comprehensive cancer center. (Abstract #9044)**
J. M. Randall, L. Bazhenova, M. White, A. A. Bharne, K. A. Shimabukuro, Y. Matusov, K. Messer, A. Lowery, M. Loscalzo, K. Clark, W. Bardwell
- Brd. 42D** **Long-term effects of the diagnosis and treatment of breast cancer upon young breast cancer survivors. (Abstract #9045)**
P. H. Morrow, A. C. Broxson, M. Munsell, K. Basen-Engquist, C. K. Rosenblum, L. H. Nguyen, L. R. Schover, K. Hahn, J. K. Litton, G. N. Hortobagyi
- Brd. 42E** **An evaluation of serum cytokine levels and fatigue and depression in ECOG E4Z02. (Abstract #9046)**
T. A. Rich, J. Manola, D. Cella, R. A. Cruciani, M. Fisch, Eastern Cooperative Oncology Group
- Brd. 42F** **Paclitaxel-associated acute pain syndrome (P-APS) and its association on the development of peripheral neuropathy: NCCTG trial N08C1. (Abstract #9047)**
B. Reeves, S. R. Dakhil, J. A. Sloan, K. N. Burger, N. A. Le-Lindqwister, G. S. Soori, A. J. Jaslowski, J. Kelaghan, D. H. Lachance, C. L. Loprinzi
- Brd. 42G** **Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. (Abstract #9048)**
R. Delarue, C. Haioun, B. Coiffier, L. Fornecker, M. Fournier, N. Mounier, T. J. Molina, S. Bologna, C. Fruchart, S. Picard, H. Tilly, A. Bosly
- Brd. 42H** **Randomized, multicenter, phase II trial of compound Chinese herbal extract LC09 versus placebo for external treatment of hand-foot syndrome induced by anticancer therapy. (Abstract #9049)**
L. Jia, Y. Lou, A. Tian, S. Zhu, X. Zhang
- Brd. 43A** **Structural and functional MRI of the brain as biomarker for postcancer fatigue. (Abstract #9050)**
H. Prinsen, A. Heerschap, G. Bleijenberg, M. Zwarts, M. van der Graaf, M. Rijpkema, H. Van Laarhoven
- Brd. 43B** **Long-term survival rates of older breast cancer patients: Population-based estimates over three decades. (Abstract #9051)**
B. Kanapuru, A. Jemal, C. S. Hesdorffer, W. B. Ershler, J. W. Yates
- Brd. 43C** **A risk stratification schema for predicting diabetes mellitus in cancer survivors. (Abstract #9052)**
A. Moghaddamjoui, A. Y. Tashakkor, P. Birks, W. Y. Cheung
- Brd. 43D** **Quality-of-life concordance between patients with malignant gliomas and their caregivers: Updated data. (Abstract #9053)**
B. V. Stell, D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz, K. Muro, M. H. Marymont, J. Chandler, I. B. Helenowski, L. I. Wagner, J. J. Raizer, C. L. Bennett

Saturday, June 4, 2011

- Brd. 43E** **Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. (Abstract #9054)**
F. L. Day, J. Karnon, D. Rischin
- Brd. 43F** **A prospective, observational study of medication use among outpatients with common solid tumors. (Abstract #9055)**
M. Weiss, J. Manola, M. A. Thompson, M. L. Thomas, M. Fisch
- Brd. 43G** **Reactivation of hepatitis B infection among patients with cancer. (Abstract #9056)**
J. Hwang, M. Fisch, H. Zhang, M. Kallen, M. Routbort, L. S. Lal, J. Vierling, M. Suarez-Almazor
- Brd. 43H** **Analysis of overall survival and self-reported fatigue in patients with locally advanced esophageal cancer: A Mayo Clinic Esophageal Adenocarcinoma and Barrett's Esophagus Registry Consortium study. (Abstract #9057)**
M. C. Stauder, Y. Romero, B. Kabat, P. J. Atherton, M. B. Fredericksen, C. Deschamps, A. Jatoi, J. A. Sloan, M. Botros, R. C. Miller
- Brd. 44A** **Accrual of underrepresented minority women to breast cancer clinical trials in the Inland Empire, California. (Abstract #9058)**
Y. Yuan, P. Uppala, S. S. Lum, C. Garberoglio, H. R. Mirshahidi, R. Cassady, J. Morgan, C. Chen
- Brd. 44B** **Incidence and risk factors predictive of recurrent venous thromboembolism in patients with cancer at a comprehensive cancer center. (Abstract #9059)**
S. Vadhan-Raj, X. Zhou, R. S. Benjamin, G. W. Gladish
- Brd. 44C** **Achievement of personalized pain goal (PPG) in cancer patients referred to a supportive care clinic. (Abstract #9060)**
S. Dalal, D. Hui, L. M. Nguyen, R. Chacko, E. Bruera
- Brd. 44D** **Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic. (Abstract #9061)**
A. Soni, A. Brufsky, R. C. Jankowitz, P. Rastogi, V. G. Vogel, S. Puhalla
- Brd. 44E** **Parenthood in survivors of Hodgkin lymphoma: An EORTC-GELA general population case-control study. (Abstract #9062)**
M. A. van der Kaaij, N. Heutte, P. Meijnders, J. M. Raemaekers, E. Abeillard-Lemoisson, A. Allgeier, B. Meulemans, A. H. Simons, N. Mounier, M. Henry-Amar, J. C. Kluijn-Nelemans, European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
- Brd. 44F** **Is there an advantage to adding inferior vena cava filter (IVCF) placement to anticoagulation with fondaparinux in patients with cancer and venous thromboemboli (VTE): Results of the Cancer and Thrombosis (CAT) prospective randomized clinical trial (RCT). (Abstract #9063)**
M. F. Barginear, R. J. Gralla, M. Akerman, M. Lesser, T. P. Bradley, I. Shapira, N. J. Nier-Shoulson, C. R. Greben, D. R. Budman
- Brd. 44G** **Symptom burden and change among adolescent/young adult (AYA) patients with breast, lung, colorectal, or prostate cancer. (Abstract #9064)**
V. T. Chang, F. Zhao, L. I. Wagner, S. D. Sanford, J. Salsman, M. Fisch
- Brd. 44H** **Prognostic value of multidimensional geriatric assessment (MGA) on survival of a prospective cohort of 880 elderly cancer patients (ECP). (Abstract #9065)**
U. Basso, C. Falci, A. Brunello, V. Zafferri, P. Fiduccia, G. Sergi, S. Lonardi, E. Lamberti, E. Castegnaro, C. Soldà, F. Cossutta, V. Chiarion-Sileni, S. Monfardini, V. Zagonel
- Brd. 45A** **OVERcome: An intervention study to improve sexual function in women with breast cancer. (Abstract #9066)**
I. Juraskova, S. Jarvis, K. Mok, M. Peate, B. Meiser, S. Mireskandari, M. Friedlander

SATURDAY

- Brd. 45B** **Recalling breast cancer presentation and therapy: Associations between patient inaccuracy and demographic characteristics. (Abstract #9067)**
W. C. Mertens, C. Loke, D. Katz, R. Barham, G. Makari-Judson
- Brd. 45C** **Understanding the psychosocial needs of young adults with cancer: Identifying targets for clinical intervention. (Abstract #9068)**
K. M. Trevino, K. Fasciano, A. H. Partridge, P. Maciejewski, E. Kacel, R. Jimenez, S. Block, H. G. Prigerson
- Brd. 45D** **Sleep disturbance in patients with advanced cancer: Frequency and factors associated with response to specialist-based outpatient supportive care. (Abstract #9069)**
S. Yennurajalingam, G. Chisholm, S. L. Palla, E. Bruera
- Brd. 45E** **Quality-of-life (QOL) evaluation within a randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable, advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (Abstract #9070)**
Y. Ohashi, M. Tanaka, N. Boku, H. Ueno, T. Okusaka
- Brd. 45F** **Predicting the risk of cardiovascular comorbidity in cancer survivors. (Abstract #9071)**
A. Y. Tashakkor, A. Moghaddamjou, W. Y. Cheung
- Brd. 45G** **Cancer-related fatigue and sexual functioning in women with early breast cancer: Is there a link? (Abstract #9072)**
K. Webber, K. Mok, B. K. Bennett, I. Juraskova, D. Goldstein, M. Friedlander, A. R. Lloyd, FOLCAN study group
- Brd. 45H** **Clinical trial participation among patients with advanced cancer: What characteristics most influence enrollment? (Abstract #9073)**
R. Jimenez, B. Zhang, M. E. Nilsson, S. Joffe, C. Lathan, H. G. Prigerson
- Brd. 46A** **Stage I lung cancer survivorship: Incidence of secondary malignancies and need for individualized care plan. (Abstract #9074)**
R. Surapaneni, K. Rajagopalan, A. Hageboutros
- Brd. 46B** **Zoledronic acid inhibits adjuvant letrozole-associated bone loss in postmenopausal Japanese women with early breast cancer. (Abstract #9075)**
S. Takahashi, T. Iwase, N. Kohno, T. Ishikawa, T. Taguchi, M. Takahashi, J. Horiguchi, S. Nakamura, M. Fukunaga, S. Noguchi
- Brd. 46C** **Does time-to-antibiotics predict outcome of febrile neutropenia in pediatric cancer? (Abstract #9076)**
M. B. Fletcher, H. Hodgkiss, R. Browning, T. Hoffman, C. Hadden, N. J. Winick, T. L. McCavit
- Brd. 46D** **Health-related quality of life (HRQOL) of patients 3 years after radiation therapy (RT) for early head and neck cancer (HNC). (Abstract #9077)**
I. Bairati, F. Meyer
- Brd. 46E** **Aprepitant is active in biologic therapies induced severe pruritus: Proof of concept study. (Abstract #9078)**
D. Santini, B. Vincenzi, F. Guida, A. Frezza, O. Venditti, M. Silletta, G. Tonini
- Brd. 46F** **Antiemetic control of palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen containing either irinotecan or oxaliplatin. (Abstract #9079)**
M. A. Blazer, J. Reardon, D. Efries, Y. T. Smith, L. M. Weatherby, K. Juergens, T. Criswell, J. S. Rose, G. S. Phillips, N. Griffith, T. S. Bekaii-Saab
- Brd. 46G** **A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy. (Abstract #9080)**
A. Buchner, P. Bias, M. Kaufmann
- Brd. 46H** **Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients (pts) with advanced cancer. (Abstract #9081)**
L. M. Nguyen, M. De la Cruz, D. Hui, J. L. Palmer, H. A. Parsons, E. Bruera

- Brd. 47A** **A population-based study of metastatic colorectal cancer (mCRC) in people age 80 or older: Findings from the South Australian Clinical Registry (SACR) for mCRC. (Abstract #9082)**
 C. Beeke, K. Jain, T. J. Price, R. Padbury, D. Roder, G. P. Young, M. Ly, M. A. Khattak, A. Richards, A. R. Townsend, C. S. Karapetis
- Brd. 47B** **A randomized, noninferiority study of recombinant human G-CSF/human serum albumin fusion (CG-10639) and pegfilgrastim in patients with breast cancer receiving myelosuppressive therapy. (Abstract #9083)**
 O. Gladkov, V. Moiseyenko, I. N. Bondarenko, J. V. Shparyk, S. Barash, J. M. Herpst
- Brd. 47C** **Cancer-related memory problems, demographic, and socioeconomic backgrounds: A cross-sectional study of the United States population. (Abstract #9084)**
 P. Jean-Pierre, P. Winters, T. Ahles, M. Antoni, D. Armstrong, F. Penedo, S. E. Lipschutz, T. L. Miller, K. Fiscella
- Brd. 47D** **Prospective cohort study of depression during androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. (Abstract #9085)**
 N. Timilshina, H. Breunis, S. M. Alibhai
- Brd. 47E** **Mammography-detected breast cancer over time among patients age 75 and older at a community-based cancer center: 1990–2008. (Abstract #9086)**
 J. A. Malmgren, M. K. Atwood, H. G. Kaplan
- Brd. 47F** **CD4+ T-cell count to predict the response to new H1N1 vaccination in pediatric patients with cancer. (Abstract #9087)**
 A. M. Mavinkurve-Groothuis, M. van der Flier, F. Stelma, C. van Leer-Buter, F. Preijers, P. Hoogerbrugge
- Brd. 47G** **Age-dependent effects of intensive chemotherapy (IC) on quality of life (QOL) and physical function in patients with acute myeloid leukemia (AML). (Abstract #9088)**
 H. Z. Mohamedali, H. Breunis, J. Brandwein, M. Li, N. Timilshina, M. Minden, G. A. Tomlinson, S. M. Alibhai
- Brd. 47H** **Survivors' perspectives on cancer: Results from a LIVESTRONG survey. (Abstract #9089)**
 R. Rechis, E. B. Beckjord, S. Nutt, B. M. Hayes-Lattin
- Brd. 48A** **Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. (Abstract #9090)**
 A. L. Sumrall, D. A. Reardon, A. Desjardins, K. Peters, E. Lou, S. G. Turner, L. Bailey, H. S. Friedman, J. J. Vredenburgh
- Brd. 48B** **Analysis of phase III clinical studies for palonosetron, ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). (Abstract #9091)**
 S. Y. Barbour, G. R. Morrow, R. Ahmed, G. Ballinari, M. D. Thorn, D. Cox, L. S. Schwartzberg
- Brd. 48C** **Developing a community-based screening instrument that measures problem-related distress. (Abstract #9092)**
 M. Golant, J. S. Buzaglo, M. Miller, K. Clark, M. Loscalzo, V. Kennedy, K. R. Dougherty, J. Taylor
- Brd. 48D** **An analysis of the prognostic value of handgrip strength and its incorporation into the comprehensive geriatric assessment (CGA) in elderly Asian patients with cancer. (Abstract #9093)**
 R. Kanesvaran, K. Koo, W. Chen, D. Poon
- Brd. 48E** **Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy in patients with colorectal cancer. (Abstract #9094)**
 X. S. Wang, C. S. Cleeland, V. E. Johnson, J. M. Reuben, D. R. Fogelman, M. Malekifar, K. E. Liao, P. Liu, E. N. Cohen, K. R. Gilmore, C. Eng

SATURDAY

- Brd. 48F Barriers to care faced by newly diagnosed patients with cancer. (Abstract #9095)**
S. K. Hendren, P. C. Raich, P. Winters, W. Thorland, S. Loader, S. Rousseau, P. Valverde, E. Whitley, K. Fiscella
- Brd. 48G Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial. (Abstract #9096)**
A. Pickard, D. Cella, M. S. Duh, A. Guerin, N. Mishagina, L. Antràs, M. Neary, L. McCann, R. Hodge, C. Sternberg
- Brd. 48H Effect of a nurse practitioner (ARNP)-directed intervention on the quality of life of patients with metastatic cancer: Results of a randomized pilot study. (Abstract #9097)**
S. H. Dyar, M. Lesperance, R. P. Shannon, J. A. Sloan, G. Colon-Otero
- Brd. 49A To follow up or not? A new model of supportive care for early breast cancer. (Abstract #9098)**
J. Dent, A. Topping, C. Ferguson, J. Stephenson, M. McCoy, V. Allinson, S. Brayford
- Brd. 49B The influence of age on intensity of care at the end of life among older patients with advanced cancer. (Abstract #9099)**
J. A. Zerillo, A. K. Smith, M. A. Schonberg, E. P. McCarthy
- Brd. 49C Functional impairment (FI) after hematopoietic cell transplantation (HCT) and impact on quality of life (QOL). (Abstract #9100)**
A. Bosworth, F. L. Wong, H. Kim, R. Ferrer Danao, J. Gyorffy, S. Patel, S. J. Forman, S. Bhatia
- Brd. 49D Deep vein thrombosis (DVT) and pulmonary embolism (PE): Awareness and prophylaxis practices reported by patients with cancer. (Abstract #9101)**
F. R. Rickles, E. Varga, A. Brownstein, R. J. Friedman, G. A. Maynard, J. Ansell
- Brd. 49E Bupropion for hot flashes control in breast cancer survivors: A prospective, double-blind, randomized cross-over pilot phase II trial. (Abstract #9102)**
G. R. Nuñez, A. Del Giglio, H. Pinczowski, R. M. Zanellato, L. C. Tateyama, F. Schindler, F. A. Fonseca
- Brd. 49F Preventive skin care among cancer survivors. (Abstract #9103)**
S. C. Lau, W. Y. Cheung
- Brd. 49G Quality of life in patients with dermatologic toxicities: Experience from the SERIES clinic. (Abstract #9104)**
J. Gordon, Y. Balagula, S. W. Dusza, D. Chen, S. Berg, D. P. West, M. E. Lacouture
- Brd. 49H The effect of a 3-day oral aprepitant regimen on the prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin. (Abstract #9105)**
Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. Chang, X. Song, J. Liang, H. Liang, J. Hu, S. Yu, J. Chen, J. Wang, H. Pan, A. Carides, D. Chitkara
- Brd. 50A Agreement between breast cancer survivors and oncologists on treatments received. (Abstract #9106)**
T. B. Sanft, V. Northrup, A. B. Chagpar, M. Irwin
- Brd. 50B What topics do patients and caregivers consider most important for support groups? An evidence-based analysis of 3,728 participants. (Abstract #9107)**
R. J. Gralla, K. D. Morse, C. N. Rittenberg, J. A. Petersen, K. Burg, B. J. Davis, C. Sison, L. M. Rosen, M. Lesser
- Brd. 50C Assessing patients' values when standard-of-care options are exhausted. (Abstract #9108)**
R. D. Pentz, Z. L. Farmer, M. J. Green, C. Daugherty, F. J. Hlubocky, S. K. Peterson, C. C. Sun, C. M. Lewis, T. K. Owonikoko, F. R. Khuri, R. D. Harvey

Saturday, June 4, 2011

- Brd. 50D Fertility preservation treatment options: What do patients actually understand about their choices? (Abstract #9109)**
J. Mersereau, L. Kondapalli, U. Balthazar
- Brd. 50E Predictors of quality of life (QOL) and mental health (MH) in caregivers of patients with advanced cancer. (Abstract #9110)**
D. Wadhwa, D. Burman, N. Swami, C. Zimmermann
- Brd. 50F Geriatric factors to predict toxicity and dose-intensity reduction in FFCD 2001–02 phase III study comparing a first-line chemotherapy of LV5FU2 or FOLFIRI in treatment of metastatic colorectal cancer (mCRC) in elderly patients. (Abstract #9111)**
T. Aparicio, J. Jouve, L. Teillet, D. Gargot, V. Le Brun Ly, J. Cretin, C. Locher, O. Bouche, G. Breysacher, J. Charneau, J. Seitz, M. Gasmi, F. Ricard, F. Subtil, E. Mitry, Federation Francophone de Cancerologie Digestive
- Brd. 50G Association between a validated symptom assessment tool and nurse clinical impression in patients with cancer admitted to a palliative care unit. (Abstract #9112)**
W. Rhondali, D. Hui, S. Kim, K. L. Kilgore, J. Kang, L. M. Nguyen, E. Bruera
- Brd. 50H Quality-of-life assessment in patients with malignant ascites: Results of a multicenter phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. (Abstract #9113)**
A. Gonschior, M. M. Heiss, M. H. Moehler, S. L. Parsons, H. Gilet
- Brd. 51A Prevalence of psychosocial distress in a rural community oncology practice and impact of interventions. (Abstract #9114)**
J. S. Smith, D. L. Limesand, M. A. Alikhan
- Brd. 51B Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis. (Abstract #9115)**
G. E. Richardson, T. E. Ciuleanu, L. Costa, S. J. Gans, J. Garcia Saenz, V. Hirsh, V. Hungria, M. Krzakowski, C. Manegold, H. Nahi, S. Novello, A. L. Petzer, M. E. Rader, P. Solal-Celigny, S. Vadhan-Raj, J. F. Vansteenkiste, P. J. Woll, C. Ke, K. Chung, H. Yeh
- Brd. 51C Results from a randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy (REASON). (Abstract #9116)**
C. Lhomme, D. Berton-Rigaud, F. Joly, J. Baurain, F. Rolland, A. Stenzl, T. Schmelter, M. Campone
- Brd. 51D The impact of less than 8% weight loss on overall survival in subjects with non-small cell lung cancer (NSCLC) treated in a phase IIb trial of GTx-024. (Abstract #9117)**
S. Dodson, A. Dobs, M. L. Hancock, M. A. Johnston, M. S. Steiner
- Brd. 51E A multicenter analysis of the predictors of fertility preservation in women with breast cancer: Role of neoadjuvant chemotherapy. (Abstract #9118)**
J. Kim, K. Oktay, C. Gracia, S. Lee, C. Morse, J. Mersereau
- Brd. 51F Cognitive difficulties among patients with cancer receiving chemotherapy affects quality of life: A University of Rochester Clinical Community Oncology Program study of 439 patients. (Abstract #9119)**
M. C. Janelsins, K. Devine, K. M. Mustian, S. G. Mohile, L. J. Peppone, L. Sprod, M. Weiss, V. Vinciguerra, A. Jacobs, G. R. Morrow
- Brd. 51G Sexual side effects (SSE) reported by adolescent/young adult (AYA) versus older cancer survivors. (Abstract #9120)**
C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, G. A. Di Lullo, J. M. Metz
- Brd. 51H Serum 25-hydroxyvitamin D testing at Memorial Sloan-Kettering Cancer Center. (Abstract #9121)**
K. M. Wesa, K. Yeung, G. Jacobs, M. Coletton, B. R. Cassileth

- Brd. 52A** **Impact of geriatric vulnerability parameters on pegylated liposomal doxorubicin (PLD) tolerance and outcome in elderly patients with metastatic breast cancer: Results of the DOGMES multicenter phase II GINECO trial. (Abstract #9122)**
C. Falandry, E. Brain, M. Bonnefoy, F. Mefti, A. Savoye, O. Rigal, S. Oddou-Lagranière, C. El Kouri, L. Uwer, S. Abadie-Lacourtoisie, J. Cretin, J. Jacquin, G. Freyer
- Brd. 52B** **The status of oncofertility resources at NCI-designated comprehensive cancer centers. (Abstract #9123)**
M. L. Clayman, M. Harper, G. P. Quinn, S. Shah, J. Reinecke
- Brd. 52C** **Safety and efficacy of implanted central venous catheters during adjuvant treatment of breast cancer and in a general oncology population. (Abstract #9124)**
M. Wilson, D. J. Porter, A. Maher
- Brd. 52D** **Quality of life in male patients with hormone-independent cancers: The role of testosterone. (Abstract #9125)**
P. Homel, S. B. Fleishman, M. Suhail, V. Rosenwald
- Brd. 52F** **Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening. (Abstract #9127)**
J. Sussman, H. Seow, D. Bainbridge, G. R. Pond, L. Martelli-Reid
- Brd. 52G** **Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of the American Academy of Family Physicians (AAFP). (Abstract #9128)**
T. O. Henderson, P. C. Nathan, M. Kigin, F. J. Hlubocky, K. Wroblewski, T. V. Stewart, J. M. Galliher, K. C. Oeffinger, C. Daugherty
- Brd. 52H** **The trajectory of physical functioning during breast cancer treatment of older women. (Abstract #9129)**
C. Owusu, M. D. Schluchter, S. M. Koroukian, N. A. Berger
- Brd. 53A** **Documenting the complete resolution rates of venous thromboemboli (VTE) with the factor Xa inhibitor fondaparinux sodium (FS) in patients with cancer. (Abstract #9130)**
D. R. Budman, M. F. Barginear, R. J. Gralla, T. P. Bradley, I. Shapira, N. J. Nier-Shoulson, C. R. Greben, M. Akerman, M. Lesser
- Brd. 53B** **Survivorship care plans for colorectal cancer survivors: What do primary care providers want and need? (Abstract #9131)**
T. Salz, K. C. Oeffinger, P. R. Lewis, R. Rhyne, R. L. Williams, M. W. Yeazel
- Brd. 53C** **Intensity of end-of-life cancer care among seniors: Variations by principal health care provider. (Abstract #9132)**
K. Murray, L. Lucas, S. Miesfeldt
- Brd. 53D** **Comparison of patient-reported symptoms and health behaviors to clinician documentation among patients with breast cancer in follow-up care. (Abstract #9133)**
M. E. Melisko, M. Bock, D. H. Moore, D. Hamolsky, M. Mendelsohn, L. Lawson, H. Orlando, H. S. Rugo, A. J. Chien, J. W. Park, M. M. Moasser, P. N. Munster, A. Goga, L. Esserman
- Brd. 53E** **Geriatric assessment (GA) of older patients with cancer in Australia: A national, multicenter audit. (Abstract #9134)**
S. S. Joshi, C. B. Steer, J. Yoong, R. Lakhanpal, S. Kirsop, T. Dunlop, L. R. Mileskin, D. Yip, G. M. Marx, E. J. Hovey, S. Della-Fiorentina, Clinical Oncology Society of Australia
- Brd. 53F** **Aggressiveness of end-of-life care before and after the utilization of a palliative care service. (Abstract #9135)**
W. Gonsalves, T. Tashi, T. Davies, S. Ortman, R. Thota, J. Krishnamurthy, I. T. Aldoss, M. Kalaiah, A. Ganta, N. Didwaniya, C. Eberle, A. Ganti, S. Subbiah, P. T. Silberstein

Saturday, June 4, 2011

- Brd. 53G Patient experience with survivorship care plans: Findings from an online registry of breast cancer survivors. (Abstract #9136)**
J. S. Buzaglo, K. R. Dougherty, M. Amsellem, M. Golant
- Brd. 53H Prospective assessment of symptom burden among cancer survivors with common solid tumors: Results from ECOG trial E2Z02. (Abstract #9137)**
L. I. Wagner, L. Zickl, M. Smith, D. Cella, C. Coles, L. J. Patrick-Miller, J. Manola, M. Fisch
- Brd. 54A Hodgkin lymphoma of the elderly veterans: Veterans Affairs Cancer Registry analysis. (Abstract #9138)**
J. Krishnamurthy, T. Tashi, W. Gonsalves, R. Thota, P. T. Silberstein, S. Subbiah
- Brd. 54B BRCA mutation carriers: Risk factors for psychosocial and physiologic disruption. (Abstract #9139)**
L. B. Wenzel, K. Osann, J. Gross, R. Kurz, E. L. Nelson, B. Y. Karlan
- Brd. 54C The effectiveness of a structured exercise and education program on clinical and quality-of-life outcomes in patients with cancer who are actively undergoing therapy compared with patients not currently receiving therapy. (Abstract #9140)**
L. M. Leach, A. Kleski, K. Spencer, J. Anthony, M. LaLonde, T. J. Sweeney, T. Caulin-Glaser

SATURDAY

3:00 PM - 4:15 PM
SPECIAL SESSION

ASCO/Radiological Society of North America (RSNA) Joint Session: Cancer Screening—Can We See Clearly Now?

Location: E354b

CME credit: 1.25

Track(s): Practice Management and Information Technology, Cancer Prevention/Epidemiology, Special Session

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

N. Reed Dunnick, MD—Co-Chair

University of Michigan

Denise R. Aberle, MD

University of California, Los Angeles David Geffen School of Medicine

Lung Cancer Screening: Results and Implications of the National Lung Screening Trial (NLST)

Mark Helvie, MD

University of Michigan

Breast Cancer Screening: U.S. Preventive Services Task Force Recommendations—Why the Controversy?

Elizabeth Burnside, MD, MPH

University of Wisconsin

Evaluating Screening Studies: Translating the Science to Practice

Saturday, June 4, 2011

3:00 PM - 4:15 PM
EDUCATION SESSIONS

Immunologics and Biologics for Sarcomas: Is There a Role?

Location: S100a

CME credit: 1.25

Track(s): Sarcoma, Pediatric Oncology

Peter Houghton, PhD—Chair

Nationwide Children's Hospital

Emerging Biologic Strategies for Sarcomas

Paul Robbins, PhD

National Cancer Institute Center for Cancer Research

Adoptive Immunotherapy of Synovial-cell Sarcoma Targeting Cancer/Testis Antigens

Crystal Mackall, MD

National Cancer Institute

The Future of Immunotherapy for Sarcomas

Lung Cancer Whole-genome Sequencing: What a Clinician Should Know

Location: Hall D2

CME credit: 1.25

Track(s): Lung Cancer, Tumor Biology

Ramaswamy Govindan, MD—Chair

Washington University School of Medicine

Whole-genome Sequencing of Lung Cancer: Update and Implications for Clinical Research

Elaine Mardis, PhD

Washington University

Whole-genome Sequencing: A Primer for the Clinicians

Neil Caporaso, MD

National Cancer Institute

Lung Cancer Whole-genome Sequencing: Insights into Lung Cancer Biology

Next-generation Sequencing in Cancer Genetics

Location: E353

CME credit: 1.25

Track(s): Cancer Genetics

Stephen B. Gruber, MD, PhD, MPH—Chair

University of Michigan

Next-generation Sequencing: What Are the Clinical Implications?

Veda N. Giri, MD

Fox Chase Cancer Center

Beyond Genome-wide Association Studies in Cancer Susceptibility

Arul Chinnaiyan, MD, PhD

University of Michigan Medical Center

Next-generation Sequencing and Susceptibility to Prostate Cancer

SATURDAY

Prediction, Prevention, and Treatment of Chemotherapy Toxicity in Older Patients

Location: S100bc

CME credit: 1.25

Track(s): Geriatric Oncology, General Oncology

Supriya Gupta Mohile, MD, MS—Chair

University of Rochester Medical Center

Prevention and Management of Nonhematologic Toxicity in Elderly Patients Receiving Chemotherapy

Arti Hurria, MD

City of Hope

Prediction of Chemotherapy Toxicity in Elderly Patients

Gary H. Lyman, MD, MPH

Duke University

Prevention and Management of Hematologic Toxicity in Elderly Patients Receiving Chemotherapy

Saturday, June 4, 2011

**3:00 PM - 4:15 PM
MEET THE PROFESSOR SESSION**

Issues in Therapy for Rectal Cancer (M07)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer

Blase N. Polite, MD, MPH

The University of Chicago

Which Chemotherapy and When: Understanding the Timing and Type of Chemotherapy in Patients with Rectal Cancer

Claus Roedel, MD

University of Frankfurt

Radiation Therapy for Rectal Cancer: When Can It Be Omitted or Shortened?

SATURDAY

3:00 PM - 4:15 PM

CLINICAL PROBLEMS IN ONCOLOGY SESSION

Integrative Oncology: A Mainstream Look at Approaches for Patients with Advanced Cancer (C06)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Professional Development, Cancer Prevention/Epidemiology, Patient and Survivor Care

Nancy E. Davidson, MD—Chair

University of Pittsburgh Cancer Institute

Clinical Trial Design in Integrative Oncology: Advanced Cancer

Edith P. Mitchell, MD

Kimmel Cancer Center at Thomas Jefferson University

Evidence-based Interventions in Integrative Oncology for Patients with Metastatic Cancer

Brent Bauer, MD

Mayo Clinic

What Alternative Therapies Are Hot for Advanced Cancer Patients?

Saturday, June 4, 2011

3:00 PM - 4:30 PM
CLINICAL SCIENCE SYMPOSIUM

Host Genomics and Treatment Outcomes in Breast Cancer

Location: Hall B1

CME credit: 1.5

Track(s): Breast Cancer

Christos Sotiriou, MD, PhD—Chair

Jules Bordet Institute

Discussion

3:00 PM Mark J. Ratain, MD
The University of Chicago

3:15 PM **Genetic associations with taxane-induced neuropathy by genome-wide association study (GWAS) in E5103. (Abstract #1000)**
B. P. Schneider, L. Li, K. Miller, D. Flockhart, M. Radovich, B. A. Hancock, N. Kassem, T. Foroud, D. L. Koller, S. S. Badve, Z. Li, A. H. Partridge, A. M. O'Neill, J. A. Sparano, C. T. Dang, D. W. Northfelt, M. Smith, E. Railey, G. W. Sledge Jr.

Discussion

3:30 PM Howard L. McLeod, PharmD (Abstract #1000)
University of North Carolina Eshelman School of Pharmacy

3:45 PM **Genes regulating estradiol and estrone-conjugate levels in postmenopausal women with resected early-stage breast cancer detected by a genome-wide association study (GWAS). (Abstract #1001)**
J. N. Ingle, B. L. Fridley, A. Buzdar, M. E. Robson, M. Kubo, M. Liu, I. Ibrahim-Zada, A. Batzler, G. D. Jenkins, M. P. Goetz, D. W. Northfelt, E. A. Perez, C. V. Williard, L. Wang, D. J. Schaid, Y. Nakamura, R. M. Weinshilboum

4:00 PM **ESR1 and ESR2 polymorphisms in BIG 1-98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence for early breast cancer. (Abstract #1002)**
M. Bouzyk, K. P. Gray, M. M. Regan, O. Pagani, W. Tang, R. Kammler, R. Maibach, G. Viale, P. Dell'Orto, B. J. Thurlimann, E. Hitre, M. Lyng, H. J. Ditzel, P. Neven, G. MacGrogan, K. N. Price, R. D. Gelber, A. S. Coates, A. Goldhirsch, B. Leyland-Jones, BIG 1-98 Collaborative and International Breast Cancer Study Groups

Discussion

4:15 PM James M. Rae, MD (Abstracts #1001–1002)
University of Michigan

SATURDAY

3:00 PM - 5:30 PM
ORAL ABSTRACT SESSION

Pediatric Oncology I

Location: S504

CME credit: 2.5

Track(s): Pediatric Oncology

Paul C. Nathan, MD, MSc—Co-Chair

The Hospital for Sick Children

Jennifer Lynn McNeer, MD—Co-Chair

The University of Chicago

3:00 PM Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response. (Abstract #9503)

M. Metzger, H. J. Weinstein, M. M. Hudson, A. Billett, E. C. Larsen, A. M. Friedmann, S. S. Donaldson, M. J. Krasin, L. E. Kun, K. C. Marcus, T. I. Yock, N. Tarbell, C. Billups, J. Wu, M. P. Link

3:15 PM Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (Abstract #9504)

N. J. Winick, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, C. L. Willman, S. Hunger, W. L. Carroll, E. C. Larsen

Discussion

3:30 PM Andrea Biondi, MD (Abstract #9504)
 University of Milano-Bicocca

3:45 PM Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): A report from the Children's Oncology Group. (Abstract #9505)

I. Chen, R. Harvey, C. G. Mullighan, M. L. Loh, M. Devidas, M. J. Borowitz, S. K. Tasian, D. Payne-Turner, W. Wharton, J. Pullen, A. J. Carroll, W. L. Carroll, B. M. Camitta, S. Hunger, N. J. Winick, C. L. Willman

4:00 PM Treatment outcomes in older adolescent and young adult (AYA) patients with newly diagnosed AML. (Abstract #9506)

J. A. Canner, T. A. Alonzo, J. Franklin, D. R. Freyer, A. S. Gamis, R. B. Gerbing, B. Lange, S. Meshinchi, W. G. Woods, J. P. Perentesis, J. Horan

4:15 PM Impact of traditional cardiovascular disease risk factors on long-term cardiovascular outcome in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9507)

G. T. Armstrong, Y. Chen, T. Kawashima, C. A. Sklar, D. A. Mulrooney, E. J. Chow, W. Border, J. Durand, A. Mertens, M. Stovall, W. Leisenring, Y. Yasui, L. L. Robison, K. C. Oeffinger, L. Meacham

4:30 PM Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05–159. (Abstract #9508)

S. E. Lipshultz, S. R. Lipsitz, J. Kutok, T. L. Miller, S. D. Colan, D. S. Neuberg, S. E. Dahlberg, L. B. Silverman, J. M. Henkel, V. I. Franco, S. E. Sallan, Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium

4:45 PM Cardiorespiratory fitness in adult survivors of childhood acute lymphoblastic leukemia (ALL). (Abstract #9509)

K. C. Oeffinger, P. G. Snell, C. S. Moskowitz, J. F. Chou, D. A. Kent, E. S. Tonorezos, A. L. Dunn, S. M. Smith, T. S. Church

Saturday, June 4, 2011

5:00 PM **Melanoma as a subsequent neoplasm in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9510)**
A. S. Pappo, G. T. Armstrong, W. Liu, D. K. Srivastava, W. Leisenring,
S. Hammond, M. Stovall, J. P. Neglia, L. L. Robison

Discussion

5:15 PM Louise C. Strong, MD (Abstract #9510)
University of Texas M. D. Anderson Cancer Center

SATURDAY

3:00 PM - 6:00 PM ORAL ABSTRACT SESSION

Gynecologic Cancer

Location: E354a

CME credit: 3

Track(s): Gynecologic Cancer

Ronald J. Buckanovich, MD—Co-Chair

University of Michigan

Gottfried E. Konecny, MD—Co-Chair

University of California, Los Angeles

- 3:00 PM** **Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). (Abstract #5003)**
J. A. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. B. Vergote, G. J. Rustin, C. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, E. Macpherson, C. Watkins, J. Carmichael, U. Matulonis
- 3:15 PM** **A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. (Abstract #5004)**
R. T. Penson, C. Whalen, B. Lasonde, C. N. Krasner, P. Konstantinopoulos, T. E. Stallings, C. R. Bradley, M. J. Birrer, U. Matulonis
- 3:30 PM** **A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. (Abstract #5005)**
M. J. Birrer, P. Konstantinopoulos, R. T. Penson, M. Roche, A. Ambrosio, T. E. Stallings, U. Matulonis, C. R. Bradley
- Discussion**
- 3:45 PM** Stanley B. Kaye, MD (Abstracts #5003–5005)
 The Royal Marsden Hospital
- 4:00 PM** **Result of interim analysis of overall survival in the GCIG ICON7 phase III randomised trial of bevacizumab in women with newly diagnosed ovarian cancer. (Abstract #LBA5006)**
G. Kristensen, T. Perren, W. Qian, J. Pfisterer, J. A. Ledermann, F. Joly, M. S. Carey, P. J. Beale, A. Cervantes, A. M. Oza
- 4:15 PM** **OCEANS: A randomized, double-blinded, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (Abstract #LBA5007)**
C. Aghajanian, N. J. Finkler, T. Rutherford, D. A. Smith, J. Yi, H. Parmar, L. R. Nycum, M. A. Sovak
- 4:30 PM** **Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). (Abstract #5008)**
R. J. Buckanovich, R. Berger, A. Sella, B. I. Sikic, X. Shen, D. A. Ramies, D. C. Smith, I. B. Vergote
- Discussion**
- 4:45 PM** Anil Sood, MD (Abstracts #LBA5006–5008)
 University of Texas M. D. Anderson Cancer Center
- 5:00 PM** **A randomized phase II (RP2) trial of ridaforolimus (R) compared with progesterin (P) or chemotherapy (C) in female adult patients with advanced endometrial carcinoma. (Abstract #5009)**
A. M. Oza, A. Poveda, A. R. Clamp, S. Pignata, G. Scambia, J. Del Campo, M. McCormack, L. Sevcik, B. M. Schwartz, S. Guan, R. Lee, J. D. Cheng, F. G. Haluska

Saturday, June 4, 2011

5:15 PM **A comparative randomized, placebo-controlled, double-blind phase II study with and without enzastaurin in combination with paclitaxel and carboplatin as first-line treatment for advanced ovarian cancer. (Abstract #5010)**

I. B. Vergote, P. Harter, N. Kovalenko, T. Bauknecht, K. Mansouri, Y. Zhang, J. Sehouli

5:30 PM **A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC). (Abstract #5011)**

D. Matei, C. Shen, F. Fang, J. Schilder, M. Li, A. Arnold, Y. Zeng, J. M. Pilrose, C. Kulesavage, C. Balch, W. Berry, P. Wulfridge, T. H. Huang, K. P. Nephew

Discussion

5:45 PM Helga B. Salvesen, MD, PhD (Abstracts #5009–5011)
Haukeland University Hospital, The University of Bergen

SATURDAY

4:30 PM - 6:00 PM CLINICAL SCIENCE SYMPOSIUM

Finding the Targets, Restoring the Vision

Location: Hall D1

CME credit: 1.5

Track(s): Gastrointestinal (Colorectal) Cancer

Ravi Salgia, MD, PhD—Chair

The University of Chicago

4:30 PM A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) *KRAS* metastatic colorectal cancer (mCRC): Primary and biomarker analyses. (Abstract #3500)

C. Eng, E. Van Cutsem, E. Nowara, A. Swieboda-Sadlej, N. C. Tebbutt, E. P. Mitchell, I. Davidenko, K. Oliner, L. Chen, J. Huang, I. McCaffery, E. Loh, D. Smethurst, J. Tabernero

Discussion

4:45 PM Ravi Salgia, MD, PhD (Abstract #3500)

The University of Chicago

Colorectal Cancer: Exploiting the Targets

5:00 PM A randomized phase II/III study of the anti-IGF-1R antibody MK-0646 (dalotuzumab) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory metastatic colorectal cancer (mCRC) with wild-type (wt) *KRAS* status. (Abstract #3501)

D. J. Watkins, J. Tabernero, H. Schmoll, T. Trarbach, F. J. Ramos, J. Howe, H. M. Brown, J. Clark, K. Hsu, B. D. Lu, D. Cunningham

Discussion

5:15 PM Margaret M. Mooney, MD, MBA (Abstract #3501)

National Cancer Institute

The Importance of Biomarker Codevelopment to Success

5:30 PM A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer. (Abstract #3502)

M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, K. Dorsch-Vogel, D. Kuda, T. McAndrew, L. M. Weiner, J. Marshall, J. R. Brody

Discussion

5:45 PM Andrew Nicholas James Tutt, PhD, MBChB (Abstract #3502)

Breakthrough Breast Cancer Research Unit, Guy's Hospital

Saturday, June 4, 2011

4:45 PM - 6:00 PM
SPECIAL SESSION

ASCO/American Society of Hematology (ASH) Joint Session

Location: Arie Crown Theater

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation, Lymphoma and Plasma Cell Disorders, Special Session

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

Welcome and Introduction

Armand Keating, MD—Co-Chair

Princess Margaret Hospital

Welcome and Introduction

Anna Jankowska, MSc

Cleveland Clinic

Impaired Hydroxylation of 5-Methylcytosine in TET2-mutated Patients with Myeloid Malignancies (ASH #33807)

Menno Volkert Huisman, MD, PhD

Leiden University Medical Center

Outpatient Treatment in Patients with Acute Pulmonary Embolism: The Hestia Study (ASH #34998)

Kaan Boztug, MD

CeMM Research Center for Molecular Medicine

Correction of Wiskott-Aldrich Syndrome by Hematopoietic Stem Cell Gene Therapy (ASH #33064)

Kirit Ardesbna, MD

University College London Hospitals

An Intergroup Randomized Trial of Rituximab versus a Watch-and-Wait Strategy in Patients with Stage II, III, IV, Asymptomatic, Nonbulky Follicular Lymphoma (Grades 1, 2, and 3a). A Preliminary Analysis (ASH #27692)

SATURDAY

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Design and Interpretation of Randomized Controlled Trials in Oncology to Achieve Meaningful Benefits for Patients and Society

Location: S100a

CME credit: 1.25

Track(s): Clinical Trials, Ethics

Ralph M. Meyer, MD—Chair

NCIC Clinical Trials Group, Queen's University

Explanatory versus Pragmatic Randomized Controlled Trials in Oncology: How and Why to Make This Distinction in the Design and Interpretation of Clinical Trials

Antonio Tito Fojo, MD, PhD

National Cancer Institute, National Institutes of Health

How Much Is Life Worth: The Multibillion Dollar Question in Contemporary Oncology

Alberto F. Sobrero, MD

Ospedale San Martino

Raising the Bar for Efficacy in Cancer Therapeutics

New Developments in Lynch Syndrome and DNA Mismatch Repair: Screening, Genetics, Prognosis, and Treatment

Location: E353

CME credit: 1.25

Track(s): Cancer Genetics, Gastrointestinal (Colorectal) Cancer

Michael J. Hall, MD—Chair

Fox Chase Cancer Center

Controversies in Screening for Lynch Syndrome

Noralane M. Lindor, MD

Mayo Clinic

Update on the Genetics of Lynch Syndrome: New Genes, New Mechanisms, New Insights

Zsofia Kinga Stadler, MD

Memorial Sloan-Kettering Cancer Center

The Importance of DNA Mismatch Repair in the Prognosis and Treatment of Colorectal Cancer

Saturday, June 4, 2011

Nonphysician Providers in Oncology: Examining Collaborative Approaches and Next Steps

Location: E354b

CME credit: 1.25

Track(s): Practice Management and Information Technology, Patient and Survivor Care, Professional Development

Dean F. Bajorin, MD—Chair

Memorial Sloan-Kettering Cancer Center

Elaine L. Towle, CMPE

Oncology Metrics

Partnering with Nonphysician Providers in the Community Setting: Results of the Study of Collaborative Practice Arrangements Funded by Susan G. Komen for the Cure®

Shirley Shuster, APRN, BC, OCN

Commonwealth Hematology Oncology

Successful Implementation of the Nonphysician Provider in the Community Setting

Michael Goldstein, MD

Beth Israel Deaconess Medical Center/Harvard Medical School

The Past Will Not Predict the Future of the Oncology Workforce

SATURDAY

4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Initial Management of Hepatocellular Carcinoma (M08)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer

Jeff H. Geschwind, MD

The Johns Hopkins University School of Medicine

Nonsurgical Strategies for Hepatocellular Carcinoma

Timothy M. Pawlik, MD, MPH

The Johns Hopkins University School of Medicine

What Are the Upfront Surgical Options for Hepatocellular Cancer?

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Multimodality Approach to Mucosal Melanoma (C05)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Melanoma/Skin Cancers

Vernon Keith Sondak, MD—Chair

H. Lee Moffitt Cancer Center & Research Institute

Role of Surgery for Subtypes of Mucosal Melanoma

Bryan Burmeister, MBBS

Princess Alexandra Hospital

Radiotherapy for Primary and Advanced Mucosal Melanoma

Leslie Anne Fecher, MD

University of Pennsylvania Abramson Cancer Center

Systemic Therapy for Advanced Mucosal Melanoma

Sunday, June 5, 2011

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY SESSION

Highlights of the Day I Including Clinical Trials Participation Awards

Location: Hall D1

CME credit: 1.5

Track(s): Special Session, General Oncology

Douglas W. Blayney, MD—Co-Chair
Stanford University

Daniel F. Hayes, MD—Co-Chair
University of Michigan Medical Center

7:30 AM
Clinical Trials Participation Awards

7:45 AM
Joel E. Tepper, MD
University of North Carolina at Chapel Hill School of Medicine
Gastrointestinal (Colorectal) Cancer

8:00 AM
Gottfried E. Konecny, MD
University of California, Los Angeles
Gynecologic Cancer

8:15 AM
Bruce D. Cheson, MD
Georgetown University Medical Center
Lymphoma

8:30 AM
Antoni Ribas, MD
Jonsson Comprehensive Cancer Center, University of California, Los Angeles
Melanoma/Skin Cancers

SUNDAY

8:00 AM - 9:15 AM
SPECIAL SESSION

ASCO–American Cancer Society Award and Lecture

Location: S100a

CME credit: 1.25

Track(s): Special Session

Jamie Von Roenn, MD

Northwestern University

Personalized Medicine: A Comprehensive Definition

Sunday, June 5, 2011

**8:00 AM - 9:15 AM
EDUCATION SESSIONS**

Diffuse Large B-cell Lymphoma: Present and Future

Location: E354a

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

Jeremy S. Abramson, MD—Chair

Massachusetts General Hospital

Treatment of Diffuse Large B-cell Lymphoma in 2011

Ari Melnick, MD

Weill Cornell Medical College

Transcript Profiling and Novel Targets in Diffuse Large B-cell Lymphoma

Christian Gisselbrecht, MD

Hopital Saint Louis

Novel Therapies for Diffuse Large B-cell Lymphoma

Improving Drug Safety: From Toxicity Assessment to Post-marketing Surveillance

Location: S504

CME credit: 1.25

Track(s): Health Services Research

David Cella, PhD—Chair

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Using Patient-reported Outcomes to Measure Toxicities in Clinical Trials

Richard Pazdur, MD

U.S. Food and Drug Administration

Improving Drug Safety: The U.S. Food and Drug Administration Past and Future

Julia Bohlius, MD, MScPH

Institute for Social and Preventive Medicine, University of Bern

The Importance of Post-marketing Pharmacovigilance

Molecular and Pathologic Controversies for Potentially Curative Lung Cancers

Location: S406

CME credit: 1.25

Track(s): Lung Cancer

Elisabeth Brambilla, MD—Chair

CHU Grenoble

The Histologic Reclassification of Adenocarcinoma of the Lung: Implications for Diagnosis and Therapy

David Harpole Jr., MD

Duke University Medical Center

Genomic Prognostication in Early-stage Non-small Cell Lung Cancer: Past, Present, and Future

Ethan Dmitrovsky, MD

Dartmouth Medical School

MicroRNA Profiling: Clinical Studies in Lung Cancer

Oncology Practice Models: Strategies to Overcome Competitive Disadvantages

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology, Professional Development

Harvey D. Bichkoff, MPH—Chair

California Cancer Care

Practice Model for Success: Community-based/Single-specialty

Denis Brin Hammond, MD

New Hampshire Oncology-Hematology

Practice Model for Success: Hospital/University-affiliated

R. Steven Paulson, MD

Texas Oncology

Practice Model for Success: Regional/Multispecialty

Standard Management of Stage IV Colorectal Cancer: Start and Stop, Maintenance, Bevacizumab beyond Progression? (eQuestions Session)

Location: Hall D2

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer

Axel Grothey, MD—Chair

Mayo Clinic

Bevacizumab beyond Progression

Jeffrey A. Meyerhardt, MD, MPH

Dana-Farber Cancer Institute

Start and Stop, Maintenance, Chemotherapy Holiday

Wells A. Messersmith, MD

University of Colorado Cancer Center

Toxicity of Chemotherapy

The Molecular Biology, New Targets, and Pathways in Head and Neck Cancer

Location: E354b

CME credit: 1.25

Track(s): Head and Neck Cancer, Developmental Therapeutics, Tumor Biology

David Sidransky, MD—Chair

The Johns Hopkins University

Genetic and Epigenetic Targets, High-throughput Technology

Christine H. Chung, MD

The Johns Hopkins University

Targeted Pathways from Bench to Clinic

Ezra E. W. Cohen, MD

The University of Chicago

Clinical Advances in Targeted Therapies

Sunday, June 5, 2011

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Bone Protection in Prostate Cancer: Benefits and Pitfalls (M09)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Genitourinary Cancer, Geriatric Oncology

Matthew Raymond Smith, MD, PhD

Massachusetts General Hospital Cancer Center

Bisphosphonates, RANK-ligand Inhibitors, and Other “Bone Protecting” Agents: The Standard of Care

Ian Tannock, MD, PhD

Princess Margaret Hospital and University of Toronto

Bone-protective Agents: Do They Have Questionable Efficacy and Unacceptable Cost?

8:00 AM - 9:15 AM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Soft-tissue Sarcomas: A Continuing Clinical Conundrum for the Clinician? (C07)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Sarcoma

Raphael E. Pollock, MD, PhD—Chair

University of Texas M. D. Anderson Cancer Center

Surgery for Soft-tissue Sarcomas

Thomas F. DeLaney, MD

Massachusetts General Hospital

Radiation for Soft-tissue Sarcomas

Rashmi Chugh, MD

University of Michigan

Chemotherapy for Soft-tissue Sarcomas

SUNDAY

**8:00 AM - 10:00 AM
SPECIAL SESSION**

Training Program Directors' Breakfast (Training Program Directors Only)

Location: S404

Track(s): Special Session, Professional Development

Thomas H. Davis, MD—Chair

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center

ACGME Open Discussion; MATCH Update; How Can ASCO Recognize Teachers?

Michael P. Kosty, MD

Scripps Clinic

Informational Items: WAG, Classic References, QOPI for Fellows

Frances A. Collichio, MD

University of North Carolina at Chapel Hill School of Medicine

ASCO MedOnc In-training Exam Statistics

Howard R. Terebelo, DO

Providence Hospital

My Experience with Education Essentials for Oncology Fellows (EEOF)

Sunday, June 5, 2011

8:00 AM - 11:00 AM
ORAL ABSTRACT SESSION

Central Nervous System Tumors

Location: S100bc

CME credit: 3

Track(s): Central Nervous System Tumors

Eric L. Chang, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Martin Nicholas, MD, PhD—Co-Chair

The University of Chicago

8:00 AM Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1). (Abstract #2004)

K. Jahnke, A. Korfel, P. Martus, S. Lokka, R. Moehle, F. Griesinger, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, A. Florschütz, L. Fischer, M. Weller, E. Thiel

8:15 AM Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1). (Abstract #2005)

P. Martus, K. Jahnke, A. Korfel, T. Rose, L. Fischer, R. Moehle, H. A. Klasen, M. Rauch, A. Roeth, B. Hertenstein, T. Fischer, T. Hundsberger, H. Mergenthaler, M. Leithäuser, T. Birnbaum, U. Herrlinger, J. Schubert, J. Birkmann, M. Weller, E. Thiel

Discussion

8:30 AM Lisa Marie DeAngelis, MD (Abstracts #2004–2005)

Memorial Sloan-Kettering Cancer Center

8:45 AM RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). (Abstract #2006)

M. R. Gilbert, M. Wang, K. D. Aldape, R. Stupp, M. Hegi, K. A. Jaeckle, T. S. Armstrong, J. S. Wefel, M. Won, D. T. Blumenthal, A. Mahajan, C. J. Schultz, S. C. Erridge, P. D. Brown, A. Chakravarti, W. J. Curran Jr., M. P. Mehta

9:00 AM Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O⁶-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study. (Abstract #2007)

W. Wick, J. Steinbach, S. E. Combs, M. Platten, C. Hartmann, F. K. Wenz, U. Boecker, C. Stoffregen

Discussion

9:15 AM Jeffrey S. Abrams, MD (Abstracts #2006–2007)

National Cancer Institute

9:30 AM Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM). (Abstract #2008)

X. Ye, S. A. Grossman, S. Desideri, S. Piantadosi, for the ABTC CNS Consortium

Discussion

9:45 AM Martin J. Van Den Bent, MD (Abstract #2008)

Daniel den Hoed Cancer Center

- 10:00 AM** **Magnetic resonance (MR) perfusion imaging to differentiate early progression from pseudoprogression following chemoradiotherapy for glioblastoma (GBM). (Abstract #2009)**
J. J. Graber, R. J. Young, A. Gupta, A. D. Shah, T. A. Chan, Z. Zhang, W. Shi, K. Beal, A. M. Omuro
- 10:15 AM** **A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. (Abstract #2010)**
D. D. Eisenstat, L. B. Nabors, W. P. Mason, J. R. Perry, W. R. Shapiro, P. Kavan, S. Phuphanich, Y. Fu, X. J. Cong, M. Shahidi, D. A. Reardon
- 10:30 AM** **Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol. (Abstract #2011)**
G. Dhall, L. Ji, K. Haley, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen, A. Cornelius, K. R. Pradhan, J. H. Garvin, R. S. Olshefski, J. Hukin, M. Comito, S. Goldman, S. J. Thompson, A. Hirt, M. P. Atlas, A. W. Walter, R. Sposto, J. L. Finlay

Discussion

- 10:45 AM** Marc C. Chamberlain, MD (Abstracts #2009-2011)
University of Washington

Sunday, June 5, 2011

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Genitourinary Cancer

Location: Hall A

Track(s): Genitourinary Cancer

- Brd. 1A Identification of mutations of the SWI/SNF complex gene PBRM1 by exome sequencing in renal carcinoma. (Abstract #4571)**
B. T. Teh, I. Varela, P. Tarpey, K. Raine, D. Huang, C. Ong, K. A. Furge, P. J. Campbell, M. R. Stratton, P. Futreal
- Brd. 1B The association between the number of nodes removed at retroperitoneal lymph node dissection and overall- and cancer-specific survival in patients with nonseminomatous germ cell tumor. (Abstract #4572)**
D. Lewinshtein, A. Schatz, C. R. Porter
- Brd. 1C CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for HSP90 inhibition in prostate cancer. (Abstract #4573)**
F. Lamoureux, M. Yin, A. Zoubeidi, M. E. Gleave
- Brd. 1D Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4574)**
X. Huang, Y. M. Ning, M. Mulquin, R. A. Madan, J. L. Gulley, P. G. Kluetz, D. Adelberg, P. M. Arlen, H. L. Parnes, B. Adesunloye, S. M. Steinberg, J. J. Wright, J. B. Trepel, C. Chen, C. Bassim, A. B. Apolo, W. D. Figg, W. L. Dahut
- Brd. 1E A phase II trial of dasatinib in subjects with hormone-refractory prostate cancer previously treated with chemotherapy. (Abstract #4575)**
P. Twardowski, C. Chen, A. S. Kraft, G. S. Chatta, E. Alexson, M. Mitsuhashi, W. Ye, M. Lilly
- Brd. 1F The association of PTEN loss on outcome in patients with early high-risk prostate cancer (CaP) treated with adjuvant docetaxel following radical prostatectomy (RP). (Abstract #4576)**
D. Keizman, Z. Zhang, V. J. Sinibaldi, A. DeMarzo, B. Gurel, T. Lotan, J. Hicks, E. Rosenbaum, E. S. Antonarakis, J. J. Kim, M. A. Carducci, M. A. Eisenberger
- Brd. 1G An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome. (Abstract #4577)**
D. Olmos, J. Clark, D. Brewer, L. Barwell, G. Attard, A. H. Reid, S. K. Sandhu, A. Zivi, D. Bianchini, N. Babu Oomen, E. Thompson, L. R. Molife, S. B. Kaye, C. Parker, C. Cooper, R. J. Jones, J. S. De Bono
- Brd. 2A The effect of tobacco exposure in renal cell carcinoma (RCC) overall and cancer-specific survival. (Abstract #4578)**
N. Kroeger, T. Klatte, F. D. Birkhaeuser, E. N. Rampersaud, D. B. Seligson, N. Zomorodian, F. F. Kabbavar, A. S. Belldegrun, A. J. Pantuck
- Brd. 2B Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). (Abstract #4579)**
A. Jain, M. J. Brames, D. J. Vaughn, L. H. Einhorn
- Brd. 2C Phase III trial comparing long-term versus short-term androgen deprivation combined with high-dose radiotherapy for localized prostate cancer: GICOR protocol DART01/05. (Abstract #4580)**
A. Zapatero, A. Guerrero, X. Maldonado, A. Alvarez, C. González San Segundo, A. Cabeza, V. Macías, F. Casas, A. Pedro-Olivé, S. Villa, A. Boladeras, M. Vazquez de La Torre, C. Martin de Vidales, F. A. Calvo, GICOR (Grupo Investigacion Clinica Oncologia Radioterapica)
- Brd. 2D Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). (Abstract #4581)**
S. J. Snedecor, J. A. Carter, S. Kaura, M. Botteman

- Brd. 2E** **Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4582)**
G. R. Pond, A. J. Armstrong, B. A. Wood, M. Brookes, L. H. Leopold, W. R. Berry, R. De Wit, M. A. Eisenberger, I. Tannock, G. Sonpavde
- Brd. 2F** **Association of progression-free survival (PFS) at 2 or 3 years with overall survival (OS) at 5 years for locally advanced bladder cancer (BC): Evaluation of individual patient data (IPD) from seven randomized trials comparing local therapy with or without neoadjuvant chemotherapy (NC). (Abstract #4583)**
G. J. Chen, G. Sonpavde, C. L. Vale, D. Fisher, T. Powles, Advanced Bladder Cancer Meta-analysis Collaborators (ABCMAC)
- Brd. 2G** **The prognostic significance of LDH levels in patients with relapsed/refractory seminoma and their predictive value of the new international prognostic score. (Abstract #4584)**
T. Powles, C. Mollevi, A. Kramar, A. Lorch, J. Beyer, for the International Prognostic Factors Study Group (IPFSG)
- Brd. 3A** **The interval to biochemical failure versus biochemical failure as predictors for cause-specific and overall survival following dose-escalated external beam radiation therapy for prostate cancer. (Abstract #4585)**
N. S. Kapadia, F. Y. Feng, K. B. Olson, H. M. Sandler, D. A. Hamstra
- Brd. 3B** **Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel: German Association of Urological Oncology (AUO) trial AB 20/99. (Abstract #4586)**
G. Niegisch, R. Fimmers, R. Siener, S. Park, P. Albers, German Association of Urological Oncology (AUO)
- Brd. 3D** **Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): A multicenter phase II trial (SAKK 08/08). (Abstract #4588)**
A. Templeton, C. Rothermundt, R. Cathomas, D. Baertschi, C. Droege, O. Gautschi, M. M. Borner, E. Fechter, F. Stenner, R. C. Winterhalder, B. Mueller, V. Dutoit, P. Dietrich, R. Schiess, P. Wild, G. N. Thalmann, D. Klingbiel, S. Gillessen
- Brd. 3E** **Increased risk of overall and cardiovascular mortality after radical nephrectomy for renal cell carcinoma less than or equal to 2 cm. (Abstract #4589)**
M. Kates, G. M. Badalato, N. Sadeghi, M. S. Pitman, J. M. McKiernan
- Brd. 3F** **An analysis of STAT3 polymorphism on outcomes of interferon-alpha treatment in patients with metastatic renal cell carcinoma. (Abstract #4590)**
M. Eto, T. Kamba, H. Miyake, M. Fujisawa, K. Yoshida, H. Uemura, T. Tsukamoto, Y. Katsuoka, A. Matsubara, K. Nishimura, T. Nakamura, O. Ogawa, S. Naito
- Brd. 3G** **Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC). (Abstract #4591)**
C. Seidel, M. Fenner, C. W. Reuter, A. Ganser, V. Gruenwald
- Brd. 3H** **Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). (Abstract #4592)**
P. J. Wiechno, P. Chlosta, J. Smok-Kalwat, J. Pikilel, D. H. Henry, D. F. Christianson, B. G. Somer, B. Mellado, I. Duran, D. E. Castellano, S. Callies, V. Andre, K. Hurt, M. M. Lahn, M. Stöckle, C. Reuter, B. Heinrich
- Brd. 4A** **Impact of carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC) on free testosterone levels. (Abstract #4593)**
C. W. Reuter, M. A. Morgan, M. Fenner, P. Ivanyi, V. Gruenwald, A. Ganser

Sunday, June 5, 2011

- Brd. 4B** Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer. (Abstract #4594)
J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney
- Brd. 4C** Risk of high-grade liver toxicity with pazopanib in patients with cancer: A meta-analysis. (Abstract #4595)
S. Kapadia, S. Hapani, S. Wu
- Brd. 4D** Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma. (Abstract #4596)
M. S. Soper, J. R. Hastings, M. Tome, K. Lodin
- Brd. 4E** LH-receptor polymorphisms and response to androgen deprivation therapy in prostate cancer. (Abstract #4597)
S. V. Liu, T. B. Dorff, Q. Wang, S. Xiong, E. Thara, M. Keng, S. A. Ingles, J. K. Pinski
- Brd. 4F** Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC). (Abstract #4598)
K. L. Mahon, M. D. Chatfield, M. Lee-Ng, S. N. Breit, D. A. Brown, M. P. Molloy, G. M. Marx, N. Pavlakis, M. J. Boyer, M. R. Stockler, R. Wykes, S. M. Henshall, R. L. Sutherland, L. Horvath
- Brd. 4G** A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC). (Abstract #4599)
A. Reichle, M. Vogelhuber, S. Feyerabend, T. Suedhoff, M. Schulze, J. Hubner, R. Oberneder, M. Baier, A. Ruebel, K. Birkholz, A. Bakshshandeh-Bath, R. Andreesen
- Brd. 4H** Sorafenib and sunitinib in renal cell cancer: A study based on register data. (Abstract #4600)
A. E. Ambring, U. K. Stierner, A. S. Oden, I. N. Bjorholt
- Brd. 5A** Final results of the international, expanded-access program of everolimus in patients with advanced renal cell carcinoma who progress after prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI) therapy. (Abstract #4601)
V. Grünwald, P. I. Karakiewicz, S. E. Babbek, K. Miller, J. H. Machiels, S. Lee, J. M. Larkin, P. Bono, S. Y. Rha, D. E. Castellano, C. U. Blank, J. J. Knox, R. Hawkins, R. R. Yuan, M. Rosamilia, J. L. Booth, I. Bodrogi, on behalf of the REACT Study Group
- Brd. 5B** Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma (RCC): A dynamic tumor model of the RECORD-1 phase III trial. (Abstract #4602^)
A. M. Stein, A. Carter, N. Hollaender, R. J. Motzer, C. Sarr
- Brd. 5C** A study of methylated glutathione *s-transferase 1* (*mGSTP1*) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC). (Abstract #4603)
L. Horvath, K. L. Mahon, W. Qu, J. Devaney, M. D. Chatfield, C. Paul, R. Wykes, M. J. Boyer, M. R. Stockler, G. M. Marx, R. L. Sutherland, S. J. Clark
- Brd. 5D** A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4604)
T. E. Hutson, R. M. Bukowski, B. I. Rini, M. E. Gore, J. M. Larkin, R. A. Figlin, C. H. Barrios, B. Escudier, X. Lin, K. D. Fly, B. Martell, E. Matczak, R. J. Motzer
- Brd. 5E** Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC). (Abstract #4605)
J. Medioni, J. Ferrero, G. Deplanque, T. Maurina, J. P. Rodier, E. Raymond, J. Allyon, S. Renaux, J. Dufour-Lamartinie, S. Oudard

- Brd. 5F** **Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. (Abstract #4606)**
M. I. Milowsky, A. M. Regazzi, I. R. Garcia-Grossman, A. Trout, A. Flaherty, S. Gerst, H. Al-Ahmadie, I. Ostrovnya, D. F. Bajorin
- Brd. 5G** **Does enrollment setting influence patient attributes and outcomes in RTOG prostate cancer trials? (Abstract #4607)**
W. Lee, J. Dignam, D. Bruner, J. A. Efstathiou, Y. Yan, G. E. Hanks, M. Roach III, M. V. Pilepich, H. M. Sandler
- Brd. 5H** **Late toxicity rates following definitive radiotherapy for prostate cancer: A meta-analysis revealing interactions between dose and technique. (Abstract #4608)**
N. Ohri, W. Shi, A. Dicker, T. N. Showalter
- Brd. 6A** **Efficacy and safety of inpatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC). (Abstract #4609^)**
M. E. Gore, R. J. Jones, A. Ravaud, M. Kuczyk, T. Demkow, A. Bearz, N. Laferriere, U. P. Strauss, C. Porta
- Brd. 6B** **Analysis of the relationship between Karnofsky performance status (KPS) and tumor response in the RECORD-1 phase III trial of everolimus in patients with advanced renal cell carcinoma (RCC). (Abstract #4610)**
C. Porta, B. Escudier, T. E. Hutson, R. A. Figlin, E. Calvo, V. Grünwald, S. Osanto, A. Ravaud, A. Panneerselvam, J. J. Knox, R. J. Motzer
- Brd. 6C** **Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension. (Abstract #4611)**
A. A. van der Veldt, K. Eechoute, S. Oosting, M. H. Kappers, J. B. Haanen, A. K. Reyners, H. Gelderblom, H. Guchelaar, C. Van Herpen, E. Boven, R. Mathijssen
- Brd. 6D** **Tumor marker rise during second course high-dose chemotherapy in recurrent testicular cancer: Outcome analysis. (Abstract #4612)**
M. Pant-Purohit, M. J. Brames, R. Abonour, L. H. Einhorn
- Brd. 6E** **Final results of a risk-adapted policy of adjuvant chemotherapy (ACT) in patients with invasive bladder carcinoma (IBC). (Abstract #4613)**
J. Arranz Arijia, Y. Jerez Gilarranz, A. Soria Lovelle, C. López López, P. Sabin Dominguez, M. Riesco, J. Adeva Alfonso, D. Urosa Velasco, E. López Juárez, R. González Beca, M. Martin
- Brd. 6F** **The ZOTECT study: Effect of intravenous zoledronic acid on bone metabolism in patients with metastatic bone disease in prostate cancer (PC) and breast cancer (BC). (Abstract #4614)**
P. Hadji, M. Ziller, T. Maurer, M. Muth, A. Ruebel, C. May, K. Birkholz, J. E. Gschwend
- Brd. 6G** **Long-term response to sunitinib for metastatic renal cell carcinoma (mRCC) patients treated on clinical trials at Memorial Sloan-Kettering Cancer Center. (Abstract #4615)**
A. M. Molina, X. Jia, M. S. Ginsberg, S. Velasco, D. R. Feldman, S. Patil, R. J. Motzer
- Brd. 6H** **Does absolute neutrophil count predict adverse tumor grade in African American men with prostate cancer? (Abstract #4616)**
N. Sadeghi, G. M. Badalato, G. W. Hruby, V. R. Grann, J. M. McKiernan
- Brd. 7A** **Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer. (Abstract #4617)**
Y. Wong, S. Litwin, D. J. Vaughn, E. R. Plimack, W. Song, J. W. Lee, M. B. Dabrow, M. Brody, H. Tuttle, G. R. Hudes
- Brd. 7B** **Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC). (Abstract #4618)**
A. Necchi, N. Nicolai, C. Ortega, T. Sava, C. Messina, C. Sacco, F. Crippa, C. Morosi, R. Lanocita, M. Colechia, L. Mariani, N. Zaffaroni, R. Salvioni

Sunday, June 5, 2011

- Brd. 7C** **Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). (Abstract #4619)**
L. C. Pagliaro, A. J. Zurita, J. C. Araujo, J. F. Ward, J. W. Davis, C. A. Pettaway, S. Tu, J. Kim, P. Dieringer, C. Logothetis, L. L. Pisters
- Brd. 7D** **Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. (Abstract #4620^)**
S. Nilsson, C. G. O'Bryan-Tear, B. Bolstad, A. Lokna, C. C. Parker
- Brd. 7E** **The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4621)**
P. Huang, M. A. Carducci, M. A. Eisenberger, R. Pili, J. J. Kim, E. S. Antonarakis, H. J. Hammers, D. Keizman
- Brd. 7F** **Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers. (Abstract #4622)**
E. Seront, B. Sautois, S. Rottey, L. A. D'Hondt, J. Canon, J. Vandembulcke, N. Whenham, J. Goeminne, O. Feron, J. H. Machiels
- Brd. 7G** **Thioredoxin reductase RNA levels in expressed prostatic secretions as prognostic indicators of prostate cancer. (Abstract #4623)**
J. A. Linehan, R. Torrey, J. P. Clark, G. Babilonia, D. D. Smith, K. Chan, C. Lau, D. Y. Josephson, M. H. Kawachi, T. G. Wilson, S. S. Smith
- Brd. 7H** **A multicenter, randomized phase II study of the second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial hormonal therapy. (Abstract #4624)**
M. Takahashi, R. Kawabata, A. Kawano, Y. Murakami, Y. Sutou, T. Inai, S. Akazawa, T. Hamao, H. Hayashi, T. Fukawa, M. Takemura, Y. Yamamoto, K. Yamaguchi, H. Nakatsuji, T. Kishimoto, H. Izaki, T. Fukumori, H. Kanayama
- Brd. 8A** **Phase II trial of sunitinib in renal cell cancer with untreated brain metastases. (Abstract #4625)**
C. Chevreau, A. Ravaud, B. Escudier, A. Caty, R. Delva, F. Rolland, S. Oudard, R. Herve, E. Blanc, C. Ferlay, N. Lignon, S. Negrier, French Group on Renal Cancer
- Brd. 8B** **Analysis of blood-derived circulating microvesicles for microRNA biomarkers of metastatic and nonmetastatic prostate cancer. (Abstract #4626)**
F. C. Hamdy, R. J. Bryant, T. L. Pawlowski, G. Marsden, S. Smith, R. Vessella, C. D. Kuslich
- Brd. 8C** **Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). (Abstract #4627)**
G. A. Bjarnason, R. Williams, J. M. Hudson, C. Bailey, C. R. Lee, B. A. Lloyd, S. Kandel, J. M. Ebos, A. Kiss, R. S. Kerbel, L. M. Milot, M. Atri, G. J. Stanisz, P. Burns
- Brd. 8D** **Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). (Abstract #4628)**
J. P. Bleuse, H. J. Meulenbeld, E. M. Vinci, E. Raymond, G. Vitali, A. Santoro, L. Dogliotti, R. Berardi, F. Cappuzzo, S. T. Tagawa, C. N. Sternberg, M. Jannuzzo, M. Mariani, A. Petroccione, R. De Wit
- Brd. 8E** **Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial. (Abstract #4629)**
D. M. Waterhouse, W. C. Penley, C. D. Webb, F. A. Greco, H. A. Burris III, J. D. Hainsworth

- Brd. 8F** **Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era. (Abstract #4630)**
R. A. Fisher, A. Pender, K. Thillai, S. Chowdhury, L. M. Pickering, S. St. Rose, M. E. Gore, J. M. Larkin
- Brd. 8G** **Association of Raynaud's phenomenon after bleomycin etoposide cisplatin (BEP) chemotherapy for testicular cancer (TC) with accelerated atherosclerosis. (Abstract #4631)**
R. Altena, H. Boer, C. Meijer, J. Nuver, A. M. van Roon, N. Zwart, E. De Vries, J. D. Lefrandt, A. J. Smit, J. A. Gietema
- Brd. 8H** **Relationship of T lymphocytes, T regulatory cells, and B lymphocytes to clinical outcome in prostate cancer. (Abstract #4632)**
M. Trepel, A. Flammiger, L. Weisbach, T. Schlomm, H. Huland, S. Minner, P. Tennstaedt, C. Bokemeyer, G. Sauter
- Brd. 9A** **Incidence of thyroid dysfunction in renal cell carcinoma (RCC) patients treated with pazopanib in prospective clinical trials. (Abstract #4633)**
P. Wolter, L. McCann, C. N. Sternberg, T. E. Hutson, F. Mehmud, L. N. Pandite, P. Schoffski
- Brd. 9B** **Effect of sunitinib (SU) administration on post-treatment survival in patients with metastatic renal cell carcinoma (mRCC) treated on the upfront randomized phase III trial of sunitinib or interferon alfa (IFN). (Abstract #4634)**
K. B. Blagoev, J. Wilkerson, W. D. Stein, R. J. Motzer, S. E. Bates, A. T. Fojo
- Brd. 9C** **The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (Abstract #4635)**
E. R. Dennis, J. J. Fox, S. M. Larson, J. S. Farrelly, L. H. Schwartz, H. Schöder, E. C. Haupt, L. S. Borwick, H. I. Scher, M. J. Morris
- Brd. 9D** **Quantifying the tradeoffs of active surveillance for low-risk prostate cancer: A clinical decision analysis. (Abstract #4636)**
D. Liu, H. P. Lehmann, K. D. Frick, B. Carter
- Brd. 9E** **Prevalence of prostate cancer (PC) clinical states (CS) in the United States: Estimates using a dynamic progression model. (Abstract #4637)**
K. Solo, M. Mehra, R. Dhawan, J. Valant, H. I. Scher
- Brd. 9F** **A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). (Abstract #4638)**
D. R. Feldman, L. H. Einhorn, D. I. Quinn, A. Horwich, Y. Lorient, J. K. Joffe, D. J. Vaughn, A. Flechon, J. Hajdenberg, A. U. Pande, K. Liu, I. Gorbachevsky, R. J. Motzer
- Brd. 9G** **Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis. (Abstract #4639)**
R. Salvioni, N. Nicolai, L. Piva, M. Catanzaro, T. Torelli, D. Biasoni, S. Stagni, A. Milani, A. Necchi
- Brd. 9H** **Impact of 24 months of androgen deprivation therapy (ADT) on physical function in men with nonmetastatic prostate cancer. (Abstract #4640)**
S. M. Alibhai, H. Breunis, N. Timilshina, S. Duff Canning, N. Fleshner, M. Krahn, I. Tannock, G. A. Tomlinson, P. R. Warde, G. Naglie
- Brd. 10A** **The prognostic significance of prenephrectomy absolute lymphocyte count in clear cell renal cell carcinoma. (Abstract #4641)**
S. Saroha, R. Uzzo, G. R. Hudes, E. R. Plimack, K. Ruth, T. I. Al-Saleem
- Brd. 10B** **A phase II study of neoadjuvant docetaxel (D) plus bevacizumab (B) in patients (pts) with high-risk localized prostate cancer. (Abstract #4642)**
W. K. Oh, M. D. Galsky, M. Barry, F. Fennessey, J. P. Richie, J. H. Hayes, R. S. Bhatt, M. Taplin, P. G. Febbo, R. W. Ross
- Brd. 10C** **Randomized phase II trial evaluating different schedules of zoledronic acid administration on bone mineral density in patients with stage D prostate cancer beginning androgen deprivation. (Abstract #4643)**
J. M. Lang, J. C. Eickhoff, N. C. Binkley, M. J. Staab, G. Liu, G. Wilding, D. G. McNeel

- Brd. 10D Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. (Abstract #4644)**
C. M. Booth, D. R. Siemens, I. Tannock, Y. Peng, G. Li, W. J. Mackillop
- Brd. 10E A case-control study examining associations of germ-line oxidative DNA repair single-nucleotide polymorphisms (SNPs) with lethal prostate cancer (PCa) risk. (Abstract #4645)**
N. M. Hahn, J. Jung, J. Dantzer, S. Philips, Y. R. Patel, K. A. Carr, Y. Mohammadi, D. Magjuka, C. Camp, M. Bolden, E. F. Dropcho, J. A. Knight II, M. L. Moore, A. D. Reed, M. J. Waddell, J. E. Klaunig, L. Li, C. Sweeney, T. C. Skaar
- Brd. 10F Efficacy and safety of sunitinib in patients with metastatic renal cell carcinoma on hemodialysis. (Abstract #4646)**
J. Casper, D. Goebel, V. Gruenwald, A. Flörcken, D. Mueller, K. Toussaint, B. Metzner
- Brd. 10G Variation in sex steroid methyl transferases associated with androgen deprivation therapy (ADT) efficacy in advanced prostate cancer. (Abstract #4647)**
M. Kohli, D. W. Mahoney, H. S. Chai, D. W. Hillman, D. R. Rider, B. A. Costello, J. R. Cerhan
- Brd. 10H Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. (Abstract #4648)**
T. M. Beer, P. F. Schellhammer, J. M. Corman, L. M. Glode, S. Hall, Y. Xu, M. W. Frohlich, D. F. Penson
- Brd. 11A A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. (Abstract #4649)**
M. A. Bilen, D. Liu, P. Mathew, L. C. Pagliaro, C. Logothetis, J. C. Araujo, A. Aparicio, P. G. Corn, J. Hajdenberg, S. R. Dakhil, S. Tu
- Brd. 11B Prostate-specific membrane antigen antibody–drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer. (Abstract #4650)**
D. P. Petrylak, P. W. Kantoff, R. C. Frank, N. D. Shore, Y. Rotshteyn, R. J. Israel, W. C. Olson, T. Ramakrishna, S. Morris
- Brd. 11C Evaluation of PTEN and TMPRSS2-ERG abnormalities in prostate cancer by FISH and immunohistochemistry to address intra- and intertissue heterogeneity and disease progression. (Abstract #4651)**
A. M. Joshua, A. Evans, J. Squire, M. Yoshimoto, O. Ludkovski, S. Tan, A. Dobi, B. Furusato, G. Petrovics, S. Srivastava, I. Sesterhenn
- Brd. 11D 9q32-q33.1 amplification as a prognostic factor for overall survival in metastatic germ cell tumors. (Abstract #4652)**
J. M. Piulats, A. Vidal, M. Nadal, A. Pisa, J. R. Germa-Lluch, E. Condom, A. Villanueva, X. Garcia del Muro
- Brd. 11E Use of P63 expression to define a lethal subset of muscle-invasive bladder cancers. (Abstract #4653)**
W. Choi, J. B. Shah, M. Tran, R. S. Svatek, L. Marquis, I. C. Lee, D. Yu, L. Adam, J. E. Bondaruk, S. Wen, Y. Shen, C. P. Dinney, B. Czerniak, D. J. McConkey, A. O. Siefker-Radtke
- Brd. 11F Lymphovascular invasion in clinical stage I testicular nonseminoma: Potential marker of more aggressive relapses and implications for active surveillance. (Abstract #4654)**
C. R. Nichols, S. Daneshmand, S. Tyldesley, K. N. Chi, N. Murray, A. I. So, P. C. Black, B. M. Hayes-Lattin, C. K. Kollmannsberger
- Brd. 11G Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC). (Abstract #4655)**
E. Y. Yu, F. E. Nathan, C. S. Higano

SUNDAY

- Brd. 11H Clinical features of germ cell tumors (GCT) in men age 50 or older: Successful outcome and tolerability to chemotherapy for advanced disease. (Abstract #4656)**
M. H. Voss, E. P. Jacobsen, S. Patil, S. Turkula, X. Jia, J. Sheinfeld, D. F. Bajorin, G. J. Bosl, R. J. Motzer, D. R. Feldman
- Brd. 12A Follow-up study of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. (Abstract #4657)**
M. Nakabayashi, W. Xie, G. Buckle, G. Bublely, M. S. Ernstoff, W. V. Walsh, D. Morganstern, P. W. Kantoff, M. M. Regan, M. Taplin
- Brd. 12B Prostate-specific membrane antigen (PSMA)-targeted imaging of metastatic prostate cancer (PCa) via small molecule inhibitors: Comparison to bone scan, CT/MRI, and ¹¹¹In capromab. (Abstract #4658)**
R. Coleman, J. A. Barrett, A. Hussain, K. M. Slawin, T. Armor, N. D. LaFrance, J. W. Babich
- Brd. 12C Pazopanib in patients with metastatic renal cell carcinoma previously treated with sunitinib or bevacizumab: A Sarah Cannon Research Institute phase II trial. (Abstract #4659)**
J. A. Reeves, D. R. Spigel, D. B. Daniel, E. K. Friedman, H. A. Burris III, J. D. Hainsworth
- Brd. 12D Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies. (Abstract #4660)**
M. Crepel, B. J. Escudier, J. H. Machiels, M. D. Staehler, A. Ravaud, G. Gravis, F. Joly, C. Chevreau, L. Zini, H. Lang, L. Salomon, P. Bigot Jr., J. Rigaud, J. Patard Sr.
- Brd. 12E Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. (Abstract #4661)**
E. J. Small, C. S. Higano, P. W. Kantoff, J. B. Whitmore, M. W. Frohlich, D. P. Petrylak
- Brd. 12F Phase I/II study of neoadjuvant docetaxel plus intensity-modulated radiotherapy (IMRT) prior to surgery for high-risk prostate cancer. (Abstract #4662)**
M. Garzotto, A. Hung, T. M. Beer, J. J. Alumkal, J. N. Graff, P. E. Farris, J. F. Flamiatos, S. Mongoue-Tchokote, S. N. Carter
- Brd. 12G Quantitative gene expression in primary and highest Gleason pattern cancer specimens identifies genes associated with clinical recurrence and prostate cancer-specific survival after radical prostatectomy. (Abstract #4663)**
E. A. Klein, S. M. Falzarano, T. Maddala, M. Lee, R. J. Pelham, W. F. Novotny, S. Shak, C. Magi-Galluzzi
- Brd. 12H Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. (Abstract #4664)**
D. J. George, S. Halabi, A. J. Zurita, P. Creel, K. Mundy, J. D. Turnbull, S. E. Yenser Wood, A. J. Armstrong, R. J. Varley, J. Madden, J. W. Moul
- Brd. 13A Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. (Abstract #4665)**
J. A. Talcott, A. L. Zietman, I. D. Kaplan, J. A. Clark, A. V. D'Amico
- Brd. 13B Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). (Abstract #4666)**
A. Aparicio, A. L. Harzstark, E. Lin, P. G. Corn, J. C. Araujo, S. Tu, L. C. Pagliaro, R. E. Millikan, W. Arap, J. Kim, C. J. Ryan, A. J. Zurita, N. M. Tannir, A. M. Lin, E. J. Small, P. Mathew, D. M. Jones, P. Troncso, P. F. Thall, C. Logothetis, Prostate Cancer Clinical Trials Consortium

Sunday, June 5, 2011

- Brd. 13C Agent Orange as a risk factor for high-grade prostate cancer detected on initial prostate biopsy. (Abstract #4667)**
N. J. Ansbaugh, J. Shannon, M. Mori, P. E. Farris, L. Collins, M. Garzotto
- Brd. 13D Preoperative sorafenib (Sor) and cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC). (Abstract #4668)**
A. Finelli, A. M. Horgan, A. Evans, T. Kim, K. Durrant, S. Yap, C. A. Cassol, W. Dubinski, N. Fleshner, M. A. Jewett, A. M. Joshua, S. S. Sridhar, A. Zlotta, J. J. Knox
- Brd. 13E ¹¹C-choline-PET/CT (C-PET) versus transrectal ultrasound-guided prostate biopsies (TRUS-BP) to diagnose locally recurrent prostate cancer (PCA) following radiation therapy (RT). (Abstract #4669)**
A. Heidenreich, B. Brehmer, R. Epplen, D. J. Pfister, EURO Prostate Center Aachen
- Brd. 13F Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4670)**
K. M. Slawin, G. Sonpavde, J. D. McMannis, Y. Bai, M. Seethammagari, J. M. Bull, V. Hawkins, T. Dancsak, N. Lapteva, J. M. Levitt, D. M. Spencer

SUNDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Gynecologic Cancer

Location: Hall A

Track(s): Gynecological Cancer

- Brd. 14A** **A phase I/II study of cisplatin and radiation in combination with sorafenib in cervical cancer: Evaluation of biomarkers. (Abstract #5037)**
C. A. Townsley, M. Milosevic, M. A. Haider, H. Mackay, I. Yeung, S. Kim, W. Levin, L. Manchul, S. Bindra, K. MacAlpine, L. M. Tinker, L. Wang, J. Quintos, A. W. Fyles, A. M. Oza
- Brd. 14B** **Response rate and toxicity of primary concomitant radiochemotherapy in locally advanced cervical cancer: Results of an open prospective, multicenter phase II study of the NOGGO. (Abstract #5038)**
A. Mustea, A. Belau, J. Sehouli, K. Drzewiecki, M. H. Eichbaum, K. Bartz, E. Angelidou, S. Saegner, M. O. Langenbruch, P. Ledwon, M. Zygumnt, G. Koehler, D. Koensgen, North-Eastern Society of Gynaecological Oncology
- Brd. 14C** **Expression of embryonic stem cell factor SOX2 in serous ovarian carcinomas. (Abstract #5039)**
T. N. Fehm, D. Pham, V. Scheible, C. Lengerke, S. Perner, H. Neubauer, A. Staebler
- Brd. 14D** **Akt-mTOR pathway in uterine leiomyosarcoma. (Abstract #5040)**
G. Garg, A. Short, J. Liu, A. R. Munkarah, R. Morris, R. Ali-Fehmi
- Brd. 14E** **Treatment of cervical intraepithelial neoplasia with topical imiquimod. (Abstract #5041)**
S. Polterauer, C. Grimm, C. Natter, J. Rahhal, L. Hefler, A. Reinthaller, P. Speiser
- Brd. 14F** **MRI prior to systematic lymphadenectomy in patients with locally advanced cervical cancer. (Abstract #5042)**
M. Gold, Z. Zhang, H. Marques, J. Gorelick, L. M. Landrum, R. S. Mannel, L. T. Chuang, J. Q. Yu, C. K. McCourt, M. Harisinghani, A. Sohaib, D. Koh, S. Raman, M. S. Gee, H. Choi, M. Atri
- Brd. 14G** **Treatment and outcome of patients with invasive extramammary Paget's disease. (Abstract #5043)**
A. Karam, O. Dorigo
- Brd. 14H** **Confirmatory factor analysis of the sexual adjustment and body image scale in women with a diagnosis of gynecologic cancer. (Abstract #5044)**
S. E. Ferguson, C. Massey, C. Classen, M. Wegener, N. Quartey, M. Pulandiran, D. Wiljer, S. Urowitz
- Brd. 15A** **PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer. (Abstract #5045)**
R. W. Naumann, R. L. Coleman, R. A. Burger, T. J. Herzog, R. Morris, E. A. Sausville, E. Kutarska, S. A. Ghamande, N. Y. Gabrail, S. De Pasquale, E. Nowara, L. Gilbert, J. R. Caton, R. H. Gersh, M. G. Teneriello, W. A. Harb, P. Konstantinopoulos, J. T. Symanowski, C. Lovejoy, R. A. Messmann
- Brd. 15B** **Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer. (Abstract #5046)**
B. J. Monk, T. J. Herzog, S. B. Kaye, C. N. Krasner, J. B. Vermorken, F. Muggia, E. Pujade-Lourraine, P. Zintl, T. V. Parekh, A. Poveda
- Brd. 15C** **The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD). (Abstract #5047)**
A. A. Garcia, I. B. Vergote, J. P. Micha, C. H. Pippitt Jr., G. G. Rao, D. L. Spitz, N. Reed, G. G. Dark, E. N. Ibrahim, V. A. Armenio, L. R. Duska, C. J. Poole, C. Gennigens, L. Y. Dirix, J. West, C. Zhao, A. C. Leung, L. K. Masuoka, G. J. Rustin

- Brd. 15D Catumaxomab treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: A phase II study. (Abstract #5048)**
J. S. Berek, R. P. Edwards, L. Parker, L. R. DeMars, T. J. Herzog, S. S. Lentz, R. Morris, W. L. Akerley, R. W. Holloway, M. Method, S. C. Plaxe, J. L. Walker, T. Schindler, E. Schulze, C. N. Krasner, Cooperative Ovarian Cancer Group (COGI)
- Brd. 15E Fibroblast growth factor receptor 4 (FGFR4) expression as a prognostic indicator in high-grade serous ovarian carcinoma (HGSC): Signaling pathway, mechanism, and implication for therapeutic targeting. (Abstract #5049)**
T. M. Zaid, M. Thompson, K. Wong, T. Yeung, Z. Yeung, D. M. Gershenson, M. J. Birrer, S. C. Mok
- Brd. 15F The relationship of polymorphism Mad1 1673 G>A on outcomes in patients with advanced ovarian cancer treated with carboplatine-paclitaxel. (Abstract #5050)**
M. Santibañez, D. Prada, C. Diaz, C. Castro, F. Morales-Vasquez, D. Gallardo Rincon, L. A. Herrera
- Brd. 15G Analysis of polymorphisms in sodium channel, voltage-gated, type I, alpha subunit (SCN1A) as predictors of clinical outcome and toxicity in advanced ovarian cancer patients enrolled in a phase III trial treated with patupilone. (Abstract #5051)**
Y. Ning, W. Zhang, D. Yang, D. Weber, F. Souami, P. O. Bohanes, A. Gerger, M. J. Labonte, L. Benhaim, H. Lenz
- Brd. 15H Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. (Abstract #5052)**
C. Marth, J. Alexandre, L. C. Hanker, C. Brown, J. Kaern, M. Heywood, A. Bonaventura, I. B. Vergote, S. Pignata, A. Ferrero, V. GebSKI, M. Gropp, T. Skeie-Jensen, C. Giede, P. A. Vasey, C. Schauer, N. Reed, G. Ferrandina, R. Fossati, E. Pujade-Lauraine
- Brd. 16A A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: An evidence-based proposal for patient selection. (Abstract #5053)**
W. Tian, D. Chi, J. Sehouli, C. Trope, R. Jiang, A. Ayhan, G. Cormio, Y. Xing, G. Breitbach, E. I. Braicu, C. A. Rabbitt, H. Oksefjell, C. Fotopoulou, H. Meerpohl, A. Du Bois, J. S. Berek, R. Zang, P. Harter
- Brd. 16B Intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: A feasibility study. (Abstract #5054)**
S. Nagao, T. Nishikawa, A. Kurosaki, R. Ohishi, N. Iwasa, K. Hasegawa, K. Fujiwara
- Brd. 16C Multimodality evaluation of excision repair cross-complementation 1 (ERCC1) expression as a predictive biomarker for platinum resistance in epithelial ovarian cancer (EOC). (Abstract #5055)**
C. O. Michie, L. Song, D. Faratian, J. Orr, T. Rye, J. Clark, J. M. Bartlett, D. J. Harrison, D. Melton, A. Williams, C. Gourley
- Brd. 16D Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC). (Abstract #5056)**
D. Jelovac, D. K. Armstrong, S. Weil, M. Phillips, B. M. Schwartz, J. M. Estes, R. D. Alvarez
- Brd. 16E Age-specific prognostic factors for survival in patients with advanced ovarian cancer (OC) treated with platinum/taxane-based primary chemotherapy: A combined explorative analysis of three prospective phase III trials from the AGO study group. (Abstract #5057)**
F. Hilpert, A. Hempel, J. Hedderich, O. Junge, P. Harter, A. Du Bois, J. Pfisterer, AGO Study Group

- Brd. 16F Expression profiles in matched primary and recurrent serous ovarian carcinomas. (Abstract #5058)**
D. A. Zajchowski, B. Y. Karlan, L. K. Shawver
- Brd. 16G Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. (Abstract #5059)**
S. Mahner, W. Meier, A. Du Bois, C. Brown, D. Lorusso, A. Ferrero, J. Cretin, H. Havsteen, P. Bessette, L. Angleitner-Boubenizek, I. B. Vergote, P. A. Vasey, V. GebSKI, B. Slama, J. Herrstedt, L. Kaizer, A. Georgouloupoulos, N. Reed, U. Wagner
- Brd. 16H Phase II trial of trabectedin (T) in heavily pretreated recurrent ovarian cancer (ROC) patients. (Abstract #5060)**
D. Lorusso, P. Malaguti, V. Masciullo, S. Mainenti, A. di Legge, M. Ludovisi, A. Pesce, F. Mascilini, E. Fusco, G. Scambia
- Brd. 17A Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study. (Abstract #5061)**
M. G. del Carmen, J. P. Micha, L. A. Small, D. G. Street, A. Londhe, T. McGowan
- Brd. 17B A North American population-based outcome for early-stage ovarian clear cell carcinoma (OCCC). (Abstract #5062)**
P. Hoskins, J. S. Albarak, N. Le, A. Tinker, K. Swenerton, J. Santos, C. B. Gilks
- Brd. 17C Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer. (Abstract #5063)**
D. S. Tan, T. A. Yap, M. M. Hutka, P. Roxburgh, E. Grzybowska, C. Gourley, M. E. Gore, S. B. Kaye
- Brd. 17D Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. (Abstract #5064)**
H. Gungor, A. Saleem, R. Agarwal, S. P. Blagden, A. Michael, E. A. Stronach, M. Chen, E. Pickford, N. R. Rama, Y. L. Lewis, S. C. Carme, C. Salinas, D. A. Smith, E. Krachey, A. Santiago-Walker, R. N. Gunn, M. El-Bahrawy, S. A. Babar, S. R. Morris, H. Gabra
- Brd. 17E Mathematical modeling of CA125 kinetics in recurrent ovarian cancer (ROC) patients treated with chemotherapy and predictive value of early modeled kinetic parameters in CALYPSO trial: A GCIG study. (Abstract #5065)**
B. You, O. Colombar, M. Heywood, C. Lee, M. Davy, N. Reed, S. Pignata, R. Fossati, G. Emons, K. L. Rehman, K. D. Steffensen, E. Petru, V. GebSKI, A. Burges, N. Tubiana-Matthieu, M. Hansen, P. A. Vasey, U. Denison, P. De Bruyne, A. M. Oza
- Brd. 17F Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: Gynecologic Oncology Group study 9921. (Abstract #5066)**
D. S. Dizon, M. Sill, N. S. Gould, S. C. Rubin, S. D. Yamada, R. DeBernardo, R. S. Mannel, E. L. Eisenhauer, L. R. Duska, P. M. Fracasso, Gynecologic Oncology Group
- Brd. 17G Prediction of progression-free survival (PFS) adjusted by continuous platinum-free interval (PFI) at fixed timepoints in patients with recurrent ovarian cancer (ROC): Results from OVA-301. (Abstract #5067)**
A. Poveda, B. J. Monk, S. B. Kaye, J. B. Vermorken, I. B. Vergote, I. B. Runnebaum, E. Pujade-Lauraine, T. V. Parekh, A. Nieto, J. Gomez, Y. C. Park, N. Colombo
- Brd. 17H Acquired drug resistance in gynecologic cancer detected by drug response marker testing. (Abstract #5068)**
I. Benjamin, H. J. Dalton, B. J. Monk

- Brd. 18A** **A novel plasma amino acid profile-based biomarker for early detection of ovarian cancer. (Abstract #5069)**
E. Miyagi, R. Numazaki, Y. Ihata, T. Muramatsu, A. Imaizumi, H. Yamamoto, M. Yamakado, N. Okamoto, M. Asai-Sato, F. Hirahara
- Brd. 18B** **Operative morbidity and mortality in octogenarians and nonagenarians with ovarian cancer. (Abstract #5070)**
C. L. Walters, K. E. Schneider, J. M. Whitworth, J. M. Fauci, J. M. Straughn, M. N. Barnes
- Brd. 18C** **First quality-of-life data of a sequential dose-dense regimen in advanced ovarian cancer: A multicenter phase II study of the Northeastern German Society of Gynecological Oncology. (Abstract #5071)**
G. Oskay-Özcelik, R. Richter, K. Pietzner, H. Hindenburg, H. L. Sommer, R. Chekerov, O. Camara, E. Keil, J. Einkenkel, W. Lichtenegger, J. Sehouli
- Brd. 18D** **Patterns of recurrence in advanced epithelial ovarian, fallopian tube, and peritoneal cancers treated with intraperitoneal chemotherapy. (Abstract #5072)**
K. M. Esselen, N. Rodriguez, N. S. Horowitz, S. M. Campos
- Brd. 18E** **Extended duration of response with second-line intraperitoneal platinum-based therapy for epithelial ovarian cancer. (Abstract #5073)**
M. E. Skaznik-Wikiel, J. L. Lesnock, W. C. McBee Jr., S. D. Richard, J. L. Kelley, K. K. Zorn, T. C. Krivak, R. P. Edwards
- Brd. 18F** **Regulation of the tumor suppressor gene PAEP in the transition from serous borderline ovarian tumors to low-grade serous ovarian carcinomas. (Abstract #5074)**
E. R. King, Y. T. Tsang, Z. Zu, D. M. Gershenson, S. C. Mok, K. Wong
- Brd. 18G** **Increased expression of C-terminal binding protein-2 in epithelial ovarian carcinoma modulates DNA repair pathways and decreases tumor response to histone deacetylase inhibitors. (Abstract #5075)**
T. May, L. M. Barroilhet, J. Yang, M. Singh, W. R. Welch, S. P. Sugrue, R. S. Berkowitz, S. Ng
- Brd. 18H** **Use of contrast-enhanced ultrasound imaging with microbubbles targeted to $\alpha\beta3$ integrins to enhance detection of early-stage ovarian tumors. (Abstract #5076)**
A. Barua, A. Yellapa, P. Bitterman, J. M. Bahr, S. Sharma, D. B. Hales, J. L. Luborsky, J. S. Abramowicz
- Brd. 19A** **Surveillance for ovarian carcinoma patients after curative-intent treatment. (Abstract #5077)**
F. E. Johnson, K. S. Virgo, F. Gao, D. G. Mutch
- Brd. 19B** **Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC). (Abstract #5078)**
O. Smaletz, M. Diz, C. C. Carmo, J. Sabbaga, G. F. Cunha, S. J. Azevedo, F. C. Maluf, C. H. Barrios, R. L. Costa, A. G. Fontana, V. A. Alves, A. M. Moro, A. M. Scott, E. W. Hoffman, L. J. Old
- Brd. 19C** **Is there a place for neoadjuvant chemotherapy in the management of advanced malignant germ cell tumors of the ovary? (Abstract #5079)**
L. Kumar, S. Talukdar, R. Hariprasad, A. Gupta, A. Mookerjee, S. Kumar, N. Bhatla, S. Mathur
- Brd. 19D** **FDG-PET/CT imaging in gynecologic cancers: Is there an advance on patient management? (Abstract #5080)**
M. Dalla Palma, M. Gregianin, L. Evangelista, A. Cervino, G. Saladini, L. Borgato, M. O. Nicoletto, V. Zagonel
- Brd. 19E** **Prognostic significance of serum HE4 in epithelial ovarian cancer. (Abstract #5081)**
M. Marinaccio, E. Mele, V. Lorusso, A. Larocca, C. Pellegrino, R. Chiappetta, F. Sozzi

- Brd. 19F Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: Two-year efficacy results from a multicenter, single-arm, phase II study. (Abstract #5082)**
J. Sehouli, A. Reinthaller, C. Marth, D. Reimer, T. Reimer, W. Stummvoll, L. Angleitner-Boubenizek, B. Lehnert, M. Marquardt, M. M. Essing, R. Chekerov
- Brd. 19G Assessing the value of weekly full blood counts (FBC) in patients with advanced serous gynecologic cancers receiving weekly carboplatin/paclitaxel (wCP) chemotherapy. (Abstract #5083)**
D. Ulahannan, G. J. Rustin, M. Hall
- Brd. 19H Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer. (Abstract #5084)**
L. J. Havrilesky, R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord, P. A. Gehrig, M. A. Lopez, A. Shafer, L. Van Le, D. C. Dale, J. Crawford, G. H. Lyman
- Brd. 20A Effects of weekly bevacizumab and paclitaxel/carboplatin with or without sorafenib on heavily pretreated patients with recurrent or persistent cervical cancer. (Abstract #5085)**
Y. Kikuchi, M. Takano, T. Goto, H. Kouta, R. Kikuchi, K. Kudoh, T. Kita, K. Furuya, K. Umayahara, K. Takizawa
- Brd. 20B Cyclin D1 and p57 expression in advanced ovarian epithelial carcinoma: A GOG study. (Abstract #5086)**
E. Hill, W. Brady, M. J. Birrer, K. M. Darcy, W. P. McGuire III, W. J. Hoskins, D. P. Warshal, R. D. Drake, P. Hanjani, J. Hurteau
- Brd. 20C The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC). (Abstract #5087)**
I. Pokataev, G. M. Manikhas, V. Borisov, M. Stenina, A. Tjulandina, S. Tjulandin
- Brd. 20D The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. (Abstract #5088)**
C. Kurzeder, L. Zhao, E. A. Eisenhauer, I. B. Vergote, A. Du Bois, D. Tai, Y. Wang, J. F. Gill, H. W. Hirte, B. Richter, L. C. Hanker, J. Bentley, U. A. Wagner, M. Plante, R. Kimmig, J. Pfisterer
- Brd. 20E Phase II trial of weekly irinotecan and carboplatin for relapsed ovarian cancer: A Kansai Clinical Oncology Group study. (Abstract #5089)**
H. Tsubamoto, K. Inoue, R. Kawaguchi, K. Ito, S. Takeuchi, T. Shiozaki, Y. Itani, A. Arakawa, T. Tabata, S. Toyoda
- Brd. 20F Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431. (Abstract #5090)**
M. L. Hensley, S. J. Kravetz, X. Jia, W. P. Tew, L. Pereira, P. Sabbatini, C. Whalen, C. Aghajanian, C. Zarwan, S. T. Berlin
- Brd. 20G Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. (Abstract #5091)**
A. G. Zeimet, S. Abdel-Azim, D. Reimer, E. Mueller-Holzner, B. Winterhoff, U. Puistola, A. Ben-Arie, L. vanKempen, F. Amant, E. Petru, S. Jahn, S. Polterauer, P. Oppelt, M. Weigert, P. Altevogt, M. Huszar, C. Marth, M. Fogel
- Brd. 20H Impact of the *MDM2* promoter polymorphisms SNP285 and SNP309 on endometrial cancer risk among Caucasians. (Abstract #5092)**
S. Knappskog, J. Trovik, J. Marcickiewicz, S. Tingulstad, A. Staff, K. Hveem, L. Vatten, H. B. Salvesen, P. Lonning
- Brd. 21A Pegylated liposomal doxorubicin and carboplatin in malignant mixed epithelial mesenchymal and mesenchymal gynecologic tumors: A phase II trial of the AGO study group. (Abstract #5093)**
P. Harter, U. Canzler, H. Lueck, A. Reuss, W. Meier, T. N. Fehm, A. Staehle, A. Burges, C. Kurzeder, J. Sehouli, K. H. Baumann, L. C. Hanker, P. Wimberger, W. Schroeder, M. Gropp, S. Mahner, A. Du Bois

Sunday, June 5, 2011

- Brd. 21B** The presence of racial disparities in histopathologic characteristics of uterine cancer in an equal-access environment. (Abstract #5094)
K. E. Oliver, L. Enewold, K. Zhu, T. P. Conrads, G. S. Rose, G. L. Maxwell, J. H. Farley
- Brd. 21C** Molecular analysis of endometrial pathogenesis in Lynch syndrome. (Abstract #5095)
M. Huang, B. Djordjevic, D. Urbauer, S. N. Westin, C. C. Sun, J. K. Burzawa, L. Meyer, D. C. Bodurka, R. Broaddus, K. H. Lu
- Brd. 21D** Recombinant adenovirus-p53 (rAd-p53) in combination with radiotherapy for treating cervical cancer. (Abstract #5096)
S. Zhang
- Brd. 21E** A phase II study of recombinant adeno-viral human p53 gene combined with radiotherapy in treatment of patients with locally advanced cervical carcinoma. (Abstract #5097)
J. Pan
- Brd. 21F** Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience. (Abstract #5098)
R. N. Grisham, C. H. Adaniel, D. M. Hyman, W. Ma, A. Iasonos, C. Aghajanian, J. A. Konner
- Brd. 21G** Validation of the predictive value of modeled hCG decline profiles in low-risk gestational trophoblastic neoplasia (GTN) treated with methotrexate (MTX). (Abstract #5099)
G. Freyer, B. You, R. Harvey, F. Golfier, H. Mitchell, P. Savage, M. Tod, C. Philip, T. Hajri, M. Seckl
- Brd. 21H** Exploration of biomarkers for lymph node metastasis in patients with endometrial cancer using exon-expression microarray. (Abstract #5100)
S. Sudo, Y. Konno, T. Odagiri, T. Kato, M. Hosaka, M. Takeda, H. Watari, M. Kaneuchi, N. Sakuragi
- Brd. 22A** The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. (Abstract #5101)
A. N. Viswanathan, J. Szymonifka, C. Tanaka, S. T. Berlin, S. M. Campos, N. S. Horowitz, J. Lee, C. Whalen, U. Matulonis
- Brd. 22B** Phase II trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: A Kansai Clinical Oncology Group study. (Abstract #5102)
M. Takekuma, Y. Hirashima, K. Ito, H. Tsubamoto, T. Tabata, A. Arakawa, Y. Itani, N. Furukawa, H. Murakoshi, S. Takeuchi
- Brd. 22C** Paradigm shift in the management of high intermediate-risk stage I endometrial cancer. (Abstract #5103)
J. O. Schorge, A. H. Russell, L. A. Garrett, A. Goodman, M. G. del Carmen, W. B. Growdon, D. M. Boruta II
- Brd. 22D** Laparoscopic intraoperative sentinel lymph node detection by technetium-99 hysteroscopically injected in endometrial cancer patients. (Abstract #5104)
G. Favero
- Brd. 22E** Genome-wide single nucleotide polymorphism (SNP) arrays as a novel diagnostic tool in synchronous carcinomas. (Abstract #5105)
Y. Ikeda, K. Oda, S. Nakagawa, S. Murayama-Hosokawa, K. Shoji, S. Yamamoto, S. Ishikawa, Y. Uehara, Y. Miyamoto, M. Tanikawa, T. Kashiya, Y. Takazawa, D. Maeda, O. Hiraike-Wada, K. Miyagawa, F. McCormick, M. Fukayama, H. Aburatani, T. Yano, Y. Taketani
- Brd. 22F** Ovarian preservation in premenopausal patients with early-stage endometrial cancer: A multicenter retrospective matched cohort study. (Abstract #5106)
T. Lee, S. Seong, J. Kim, J. Lee, H. Ryu

- Brd. 22G Factors associated with synchronous ovarian and endometrial cancer: A population-based case control study. (Abstract #5107)**
M. M. AlHilli, S. C. Dowdy, A. Weaver, J. St. Sauver, G. L. Keeney, A. Mariani, K. C. Podratz, J. N. Bakkum-Gamez
- Brd. 22H Endometrial cancer screening in patients with Lynch syndrome. (Abstract #5108)**
A. Bats, M. Le Frere-Belda, U. Metzger, P. Laurent-Puig, F. Lecuru
- Brd. 23A Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO. (Abstract #5109)**
D. Koensgen, A. Belau, J. Sehouli, H. L. Sommer, K. Bartz, S. Markmann, L. Schneidewind, J. P. Scharf, M. Ehmke, D. Stengel, P. Ledwon, H. Guba, M. Zygmunt, G. Koehler, A. Mustea, North-Eastern Society of Gynaecological Oncology
- Brd. 23B Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. (Abstract #5110)**
K. Oda, K. Shoji, S. Nakagawa, T. Kashiyama, Y. Ikeda, Y. Miyamoto, M. Tanikawa, H. Kuramoto, M. Nishida, O. Hiraike-Wada, T. Yano, S. Kozuma, Y. Taketani
- Brd. 23C Obesity, diabetes, and race in Type 1 and Type 2 endometrial cancers. (Abstract #5111)**
E. M. Ko, J. Franasiak, K. Sink, W. R. Brewster, P. A. Gehrig, V. L. Bae-Jump

Sunday, June 5, 2011

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Melanoma/Skin Cancers

Location: Hall A

Track(s): Melanoma/Skin Cancers

- Brd. 24A** **IL-6 as a prognostic biomarker in patients with metastatic melanoma. (Abstract #8538)**
L. Hojberg, L. Bastholt, J. S. Johansen, K. Fode, H. Schmidt
- Brd. 24B** **Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF kinase in BRAF-mutant metastatic melanoma. (Abstract #8539)**
M. S. Carlino, C. A. Saunders, V. GebSKI, A. M. Menzies, B. Ma, P. F. Lebowitz, R. Kefford, G. V. Long
- Brd. 24C** **Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. (Abstract #8540)**
L. Poliseno, A. Haimovic, D. Hanniford, M. F. Segura, P. J. Christos, R. L. Shapiro, A. C. Pavlick, R. S. Berman, E. Hernandez, J. Zavadil, I. Osman
- Brd. 24D** **An analysis of altered melanoma matrix metalloproteinase-23 (MMP-23) expression and response to immune biologic therapy. (Abstract #8541)**
M. Krogsgaard, M. W. Ma, E. B. Friedman, E. Vega-Saenz de Miera, F. Darvishian, A. Perez-Garcia, R. S. Berman, R. L. Shapiro, P. J. Christos, I. Osman, A. C. Pavlick
- Brd. 24E** **Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). (Abstract #8542)**
G. V. Long, J. S. Wilmott, J. R. Howle, M. D. Chatfield, V. Tembe, J. F. Thompson, P. Hersey, G. J. Mann, G. A. McArthur, H. Rizos, R. J. Young, L. L. Scurr, R. N. Sharma, R. F. Kefford, R. A. Scolyer
- Brd. 24F** **Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma. (Abstract #8543)**
P. Boasberg, R. W. Weber, S. Cruickshank, O. Hamid, S. O'Day, L. E. Spitzer
- Brd. 24G** **A randomized phase II trial of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in high-risk acral melanoma patients. (Abstract #8544)**
L. Si, L. L. Mao, Z. H. Chi, C. L. Cui, X. N. Sheng, S. M. Li, B. X. Tang, J. Guo
- Brd. 24H** **Abraxane, temozolomide, and oblimersen (The ATG Trial): A final report of toxicity and clinical efficacy in metastatic melanoma patients with normal lactate dehydrogenase (LDH). (Abstract #8545)**
J. L. Chang, P. A. Ott, C. Sorlie, C. Escano, E. Yepes, S. Mendoza, A. Gandhi, L. Liebes, A. C. Pavlick
- Brd. 25A** **A single-arm phase II trial evaluating docetaxel, vinorelbine, and GM-CSF in stage IV melanoma. (Abstract #8546)**
J. P. Fruehauf, Z. Eroglu, K. M. Kong, J. G. Jakowatz, W. L. Akerley, W. E. Samlowski
- Brd. 25B** **Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma. (Abstract #8547)**
J. Hansson, S. Aamdal, L. Bastholt, M. Hernberg, B. Nilsson, U. K. Stiernér, H. von der Maase, Y. Brandberg, Nordic Melanoma Cooperative Group
- Brd. 25C** **An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. (Abstract #8548)**
R. Dummer, J. Rinderknecht, S. M. Goldinger, I. Wagner, L. Mitchell, M. Veronese, S. Nick, P. Hilfiker, S. Gobbi

- Brd. 26A** **MicroRNA oncogenes and tumor suppressors controlling malignant melanoma cell growth, apoptosis, migration, and invasion. (Abstract #8549)**
R. W. Georgantas, K. Streicher, W. Zhu, R. Carrasco, Z. Xiao, Z. Liu, P. Brohawn, C. Morehouse, D. Tice, B. W. Higgs, L. Richman, P. Kiener, B. Jallal, Y. Yao
- Brd. 26B** **Ultrasound (US)-guided fine-needle aspiration cytology (FNAC) for the prediction of sentinel node (SN) metastases and its effect on the nomogram for melanoma patients. (Abstract #8550)**
C. A. Voit, A. C. Van Akkooi, P. Siegel, W. Sterry, A. Schoengen, G. Schaefer-Hesterberg, A. M. Eggermont
- Brd. 26C** **A gene expression profile associated with clinical outcome in stage III melanoma. (Abstract #8551)**
J. Falkenius, J. Lindberg, H. Johansson, M. Frostvik-Stolt, J. Lundeberg, J. Hansson, S. Egyhazi
- Brd. 27A** **Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. (Abstract #8552)**
M. E. Valsecchi, D. Summers, C. M. Intenzo, S. Kim, M. J. Mastrangelo, T. Sato
- Brd. 27B** **Intratumoral neutrophils, plasmacytoid dendritic cells, and pSTAT3 in AJCC stage I/II melanoma prognosis. (Abstract #8553)**
T. O. Jensen, H. Schmidt, H. J. Moller, F. Donskov, M. Hoyer, P. Sjoegren, I. J. Christensen, T. Steiniche
- Brd. 27C** **Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. (Abstract #8554)**
S. O'Day, J. S. Weber, J. D. Wolchok, J. M. Richards, P. Lorigan, D. F. McDermott, W. J. Urba, V. DePril, K. N. Heller, R. A. Ibrahim, A. Hauschild
- Brd. 28A** **Two phase I studies of PTI-188, a radiolabeled murine antimelanin antibody, in patients with metastatic melanoma (MM). (Abstract #8555)**
M. Lotem, T. Peretz, S. Mizrachi, Y. Liberman, E. Dadachova, A. Casadevall, A. de Kater, N. Friedmann, G. B. Thornton, M. Klein
- Brd. 28B** **Association of CT antigen expression and survival in stage III melanoma. (Abstract #8556)**
N. H. Turner, T. John, S. Deb, A. M. Campbell, A. Azad, P. C. Boutros, Y. Chen, J. S. Cebon
- Brd. 28C** **A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor (GRM1) signaling, in advanced melanoma. (Abstract #8557)**
J. M. Mehnert, Y. Wen, J. H. Lee, L. Dudek, L. Pruski-Clark, W. Shih, S. Chen, J. S. Goydos
- Brd. 29A** **A germ-line polymorphism in the RET proto-oncogene predicts risk and recurrence in desmoplastic melanoma. (Abstract #8558)**
N. Kounalakis, C. M. Amato, J. Barr, W. Robinson
- Brd. 29B** **Exploratory analysis of technical factors that influence sentinel lymph node biopsy (SLNB) performance. (Abstract #8559)**
D. Silbermins, M. E. Valsecchi, N. de Rosa, S. L. Wong, G. H. Lyman
- Brd. 29C** **Primary melanoma features associated with increased risk of brain metastasis. (Abstract #8560)**
M. W. Ma, M. Qian, D. Lackaye, R. S. Berman, R. L. Shapiro, A. C. Pavlick, J. Golfinos, E. Parker, E. Hernando, Y. Shao, I. Osman
- Brd. 30A** **Impact of immune modulation on sentinel lymph node positivity and outcome in melanoma patients. (Abstract #8561)**
R. C. Medicherla, M. W. Ma, M. Qian, E. Vega-Saenz de Miera, R. S. Berman, R. L. Shapiro, A. C. Pavlick, N. Bhardwaj, Y. Shao, I. Osman, F. Darvishian
- Brd. 30B** **The prognostic relevance of altered antiglycan antibody profiles in the sera of primary melanoma patients. (Abstract #8562)**
A. Haimovic, M. W. Ma, M. I. Vuskovic, T. Miller, M. DiBenedetto, J. Grossman, R. L. Shapiro, A. C. Pavlick, R. S. Berman, H. I. Pass, M. Huflejt, I. Osman

- Brd. 30C Melanoma pigmentation affects melanoma-specific survival and provides a potential target for radiopharmaceutical-based imaging and therapy. (Abstract #8563)**
D. Kee, W. Liu, B. A. Devitt, R. Wolfe, R. Ware, R. Salemi, A. Dobrovic, S. Brglevska, J. Kelly, J. Callahan, A. Katsifis, P. Roselt, O. C. Neels, T. Bourdier, R. J. Hicks, G. A. McArthur
- Brd. 31A Clinical outcome of patients with metastatic melanoma undergoing phase I clinical trials. (Abstract #8564)**
M. Blanco-Codesido, A. Brunetto, S. Frentzas, V. Moreno Garcia, D. Papadatos-Pastos, J. V. Pedersen, L. Trani, M. Puglisi, D. Sarker, L. R. Molife, U. Banerji
- Brd. 31B The burden of metastatic melanoma (mM): Treatment patterns, healthcare use, and costs. (Abstract #8565)**
C. Reyes, S. DaCosta Byfield, S. Satram-Hoang, A. H. Teitelbaum
- Brd. 31C The effect of E7080, a VEGFR and FGFR tyrosine kinase inhibitor (TKI), on BRAF wild-type melanoma. (Abstract #8566)**
Y. Funahashi, J. Matsui, Y. Minoshima, A. Yokoi, T. Abe, K. Okamoto, K. Takahashi, T. Kadowaki, G. Kuznetsov, S. Agoulink
- Brd. 31D Mechanism of antitumor activity of E7080, a selective VEGFR and FGFR tyrosine kinase inhibitor (TKI), in combination with selective mutant BRAF inhibition. (Abstract #8567)**
J. Matsui, Y. Narita, T. Semba, Y. Adachi, T. Kadowaki, J. Oestreicher, M. Matijevic, M. Byrne, Y. Funahashi
- Brd. 31E Aberrations of KIT, BRAF, NRAS, and PDGFRA in Chinese melanoma patients and their significance: Large-scale analysis of 644 patients. (Abstract #8568)**
Y. Kong, L. Si, J. Guo, Z. H. Chi, C. L. Cui, X. N. Sheng, B. X. Tang
- Brd. 31G Potency of new duplex drugs linking 3'-C-ethynylcytidine and 5-fluoro-2'-deoxyuridine against human melanoma in vitro and in vivo. (Abstract #8570)**
S. Schott, H. Niessner, T. Sinnberg, S. Venturelli, A. Berger, S. Noor, D. Mailaender-Sanchez, C. Garbe, C. Busch
- Brd. 31H Phase I trial of temozolomide, thalidomide, and lomustine in patients with metastatic melanoma in the brain. (Abstract #8571)**
N. E. Papadopoulos, W. Hwu, S. Cain, L. Posada, K. B. Kim, J. Homsí, A. Y. Bedikian, M. A. Davies, P. Hwu
- Brd. 32A Association of response and survival in Allovectin melanoma trials. (Abstract #8572)**
D. D. Kharkevitch, A. Chu, L. G. Strause, L. R. Muenz, R. T. Kenney, A. Rolland
- Brd. 32B A phase I, open-label, cohort study of two doses of coxsackievirus A21 given intratumorally in stage IV melanoma. (Abstract #8573)**
D. Shafren, B. M. Smithers, M. Formby
- Brd. 32C Mutation frequency in BRAF and NRAS genes among primary tumors and different types of metastasis from melanoma patients. (Abstract #8574)**
M. Colombino, M. Capone, M. Maio, V. De Giorgi, A. Cossu, A. Lissia, C. Rubino, B. Massidda, S. Staibano, O. Nappi, G. Botti, C. Caraco, N. Mozzillo, A. Manca, M. Sini, P. A. Ascierto, G. Palmieri, Italian Melanoma Intergroup (IMI)
- Brd. 32D Feasibility and reliability of the assessment of BRAF and c-KIT mutations in cytologic samples from metastatic melanoma. (Abstract #8575)**
M. D. Lozano, T. Labiano, J. I. Echeveste, M. Montana, N. Gomez, M. F. Sanmamed, A. Gurrpide, M. A. Idoate, S. Martin-Algarra
- Brd. 32E Routine imaging to detect recurrences in high-risk melanoma patients. (Abstract #8576)**
T. S. Park, K. H. Lagisetty, R. M. Sherry, J. C. Yang, M. S. Hughes, K. Morton, D. E. White, Y. Klionsky, S. A. Rosenberg, G. Q. Phan

SUNDAY

- Brd. 32F** The results of a randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in uveal melanoma patients with hepatic metastasis. (Abstract #8577)
[D. J. Eschelman](#), C. F. Gonsalves, M. Terai, M. Laudadio, K. L. Sullivan, M. J. Mastrangelo, T. Sato
- Brd. 32G** Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma. (Abstract #8578)
[A. J. Eustace](#), S. Kennedy, A. Larkin, T. Mahgoub, D. Tryfonopoulos, L. O'Driscoll, M. Clynes, J. Crown, N. O'Donovan
- Brd. 32H** Ipilimumab plus temozolomide in metastatic melanoma. (Abstract #8579)
[S. P. Patel](#), A. Y. Bedikian, N. E. Papadopoulos, W. Hwu, K. B. Kim, J. Homs, M. A. Davies, S. E. Woodman, L. G. Radvanyi, K. Woodard, S. Mahoney, P. Hwu
- Brd. 33A** Overall survival (OS) in the management of pretreated patients with unresectable stage III/IV melanoma: A systematic literature review and meta-analysis. (Abstract #8580)
[S. Kotapati](#), P. Dequen, M. Ouwens, M. van Baardewijk, R. A. Ibrahim, S. Wagner, J. P. Jansen
- Brd. 33B** Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. (Abstract #8581)
[K. N. Heller](#), A. C. Pavlick, F. S. Hodi, J. A. Thompson, K. A. Margolin, D. P. Lawrence, D. F. McDermott, W. E. Samlowski, T. Michener, M. Karasarides
- Brd. 33C** Plasma Tie-2 and its ligand Ang-2 in metastatic malignant melanoma: Relationships to clinicopathological parameters and tumor burden. (Abstract #8582)
[R. Mouawad](#), J. Thery, S. Vignot, R. Conforti, D. Khayat, J. Spano
- Brd. 33D** Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. (Abstract #8583)
[R. A. Ibrahim](#), D. M. Berman, V. DePril, R. W. Humphrey, T. Chen, M. Messina, K. M. Chin, H. Y. Liu, M. Bielefeld, A. Hoos
- Brd. 33E** Multicohort model of prevalence estimation of advanced malignant melanoma in the United States: An increasing public health concern. (Abstract #8584)
[A. Y. Lin](#), P. F. Wang, J. Kolker
- Brd. 33F** Correlation between lymphocyte counts and response to outpatient intravenous interleukin-2 preceded by famotidine in metastatic melanoma. (Abstract #8585)
[W. Quan](#), K. N. Donkor, F. M. Quan
- Brd. 33H** Sentinel lymph node detection using laser-assisted indocyanine green dye lymphangiography in melanoma and breast cancer patients. (Abstract #8587)
[B. Phillips](#), V. Jain, N. Conkling, C. R. Pameijer
- Brd. 34A** Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy. (Abstract #8588)
[P. Queirolo](#), A. Morabito, P. Piccioli, S. Lastraioli, S. Callegari, M. Camoriano, P. A. Ascierto, S. Laurent, B. Dozin, M. Pistillo
- Brd. 34B** *BRAF*, *NRAS*, and *KIT* mutational analysis of spindle cell melanoma. (Abstract #8589)
[S. J. Dorkhom](#), J. Kim, A. J. Lazar, M. A. Davies, J. Homs, N. E. Papadopoulos, W. Hwu, A. Y. Bedikian, S. E. Woodman, S. P. Patel, P. Hwu, K. B. Kim
- Brd. 34C** The prognostic utility of LDH and disease-specific graded prognostic assessment for melanoma brain metastases. (Abstract #8590)
[M. Lowe](#), A. Cavitt, J. Shelton, N. Maynard, I. R. Crocker, G. W. Carlson, K. A. Delman, D. H. Lawson, M. Rizzo

Sunday, June 5, 2011

- Brd. 34D Use of microRNA signature to predict patient sensitivity to dendritic cell vaccination in metastatic melanoma. (Abstract #8591)**
L. Ridolfi, I. Vannini, F. Fanini, L. Fiammenghi, M. Petrini, V. Ancarani, A. Granato, M. Guidoboni, E. Pancisi, A. Riccobon, R. Ridolfi, C. Fernandez-Cymering, S. Volinia, C. Milandri, C. M. Croce, M. Fabbri
- Brd. 34E Acral lentiginous melanoma in Hawaii: Characterization of the mTOR pathway in the non-Caucasian population. (Abstract #8592)**
S. Y. Morita, S. Jim, C. A. Lum, D. E. Hemmings, J. Davis
- Brd. 34F A pilot study of endogenous heat shock protein vaccines for metastatic melanoma. (Abstract #8593)**
J. M. Heun, W. K. Nevala, J. B. Allred, V. Suman, M. R. Callstrom, T. D. Atwell, M. A. Farrell, E. Galanis, L. A. Erickson, W. J. Charboneau, S. Markovic
- Brd. 34G Antitumor activity of MLN4924, an investigational inhibitor of NEDD8-activating enzyme (NAE), in preclinical models of melanoma. (Abstract #8594)**
T. Traore, M. Mihollen, J. Garnsey, A. Berger, M. Manfredi, K. Cosmopolous, J. Donelan, P. G. Smith
- Brd. 34H Molecular profiling of melanoma tumor biopsies to identify a response signature to the multi-RTK inhibitor, E7080. (Abstract #8595)**
J. J. Nemunaitis, D. S. Hong, R. Kurzrock, N. N. Senzer, N. C. Twine, T. Kadowaki, M. Ren, Y. Funahashi, J. P. O'Brien, J. S. Simon, A. Eisen
- Brd. 35A Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A retrospective review of a single-center experience. (Abstract #8596)**
S. Markovic, P. A. Burch, B. LaPlant, J. M. Heun, R. Bradshaw
- Brd. 35B Frequency of mutations associated with targeted therapy in malignant melanoma patients. (Abstract #8597)**
S. Cheng, P. Chu, M. Hinshaw, K. Smith, J. Maize, A. Sferruzza

SUNDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Pediatric Oncology

Location: Hall A

Track(s): Pediatric Oncology

- Brd. 38A** **The impact of surveillance imaging on overall survival in patients with recurrent Wilms tumor: A report from the Children's Oncology Group. (Abstract #9536)**
E. A. Mullen, J. R. Anderson, K. J. Steacy, J. I. Geller, D. M. Green, P. Norkool, C. V. Fernandez, G. Khanna, M. H. Malogolowkin, J. Dome
- Brd. 38B** **Association of *GSTP1* hypermethylation with reduced protein expression and its correlation with clinical stage in neuroblastoma. (Abstract #9537)**
F. Gummy-Pause, B. Pardo, M. Khoshbeen-Boudal, M. Ansari, E. F. Attiyeh, H. Ozsahin
- Brd. 38C** **BMP signaling activity in pediatric germ cell tumors. (Abstract #9538)**
N. J. Fustino, D. Rakheja, J. F. Amatruda
- Brd. 38D** **Ewing sarcoma prognostic score (ESPS) at diagnosis, based on fever and metastatic status. (Abstract #9539)**
N. Gaspar, G. Le Teuff, A. Defachelles, C. Schmitt, D. Levy, M. Castex, O. Lejars, C. Verite, E. Plouvier, L. Claude, O. Oberlin
- Brd. 38E** **The effect of topotecan in advanced intraocular retinoblastoma with manageable toxicity. (Abstract #9540)**
I. A. Qaddoumi, C. Billups, C. F. Stewart, J. Wu, K. Helton, B. McCarville, T. E. Merchant, R. C. Brennan, B. Haik, C. Rodriguez-Galindo, M. W. Wilson
- Brd. 38F** **Pilot immunotherapy trial in high-risk pediatric sarcomas. (Abstract #9541)**
M. O. Amoako, M. S. Merchant, D. B. Bernstein, K. Baird, C. Mackall
- Brd. 38G** **Changes in incidence of infant cancer: Analysis of SEER data 1992–2007. (Abstract #9542)**
G. A. Pereira, K. B. Ribeiro, C. Rodriguez-Galindo, L. G. Spector, A. L. Frazier
- Brd. 38H** **A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. (Abstract #9543)**
K. M. Dorris, T. R. Hummel, A. M. Ingle, M. Kim, J. P. Perentesis, M. Fouladi
- Brd. 39A** **Incidence and outcomes of patients with late recurrence of Wilms tumor (WT): The international experience. (Abstract #9544)**
M. H. Malogolowkin, F. Spreafico, J. Dome, N. Breslow, H. van Tinteren, K. Pritchard-Jones, M. van den Heuvel, C. Bergeron, J. De Kraker, N. Graf, COG Renal Tumors Committee and SIOP Renal Tumors Study Group
- Brd. 39B** **A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. (Abstract #9545)**
L. M. McGregor, S. L. Spunt, D. Ward, J. Wu, C. Billups, S. P. Ivy, V. M. Santana, M. Fouladi, W. L. Furman
- Brd. 39C** **Cell cycle and apoptotic effects of PM00104 in pediatric cell lines and xenografts. (Abstract #9546)**
A. Beaugrand, C. Lanvers-Kaminsky, P. Aviles Marin, C. Cuevas Marchante, P. Opolon, L. Le Dret, A. Verschuur, G. Vassal, B. Georger, ITCC Biology and Preclinical Evaluation Committee
- Brd. 39D** **Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose—A report from the Childhood Cancer Survivor Study. (Abstract #9547)**
D. M. Green, V. G. Nolan, D. K. Srivastava, W. Leisenring, J. P. Neglia, C. A. Sklar, M. M. Hudson, L. Diller, M. Stovall, L. L. Robison
- Brd. 39F** **Toxicity of ¹³¹I-MIBG combined with high-dose chemotherapy in children with refractory neuroblastoma. (Abstract #9549)**
L. Amoroso, G. Villavecchia, M. Cabria, A. Piccardo, M. Conte, M. Nantron, A. Garaventa, B. De Bernardi

- Brd. 39G Exposure-response analysis as evidence for antitumor activity of everolimus in the treatment of patients with subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis (TS). (Abstract #9550)**
N. Mehrotra, E. Pfuma, C. Garnett, Q. Liu, B. Booth, N. Rahman, A. H. Shahlaee, K. Liu
- Brd. 39H Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL. (Abstract #9551)**
T. L. Miller, S. E. Lipshultz, R. E. Scully, D. Sawyer, S. R. Lipsitz, L. B. Silverman, H. Smith, J. M. Henkel, V. I. Franco, L. L. Cushman, S. E. Sallan
- Brd. 40A Allogeneic transplantation for patients with high-risk or refractory neuroblastoma. (Abstract #9552)**
T. A. Driscoll, P. L. Martin, J. Moffet, M. Daniel, K. Page, S. Parikh, V. Prasad, P. Szabolcs, J. Kurtzberg
- Brd. 40B Reversal of glucocorticoid resistance by the g-secretase inhibitor PF-03084014 in T-cell acute lymphoblastic leukemia. (Abstract #9553)**
J. B. Samon, M. Castillo-Martin, J. L. Jakubczak, S. Randolph, C. Cordon-Cardo, A. A. Ferrando
- Brd. 40C Phase I trial of TPI 287 as a single agent and in combination with temozolomide (TMZ) in patients with refractory or recurrent neuroblastoma (NB) or medulloblastoma (MB). (Abstract #9554)**
G. L. Saulnier Sholler, D. Eslin, W. D. Roberts, J. Kaplan, G. Bergendahl, T. Ashikaga, T. Higgins, S. Lenox, S. Silberman, W. Ferguson
- Brd. 40D NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors. (Abstract #9555)**
G. Bergholt, C. Dantas Barbosa, G. Dieffenbach, E. Daudigeos-Dubus, H. Blokus, C. Ferreira, J. Boylan, M. Abely, G. Vassal, J. Grill, B. Georger
- Brd. 40E INI1 and mib-1 expression in childhood chordomas. (Abstract #9556)**
H. Yin, K. M. Dorris, L. M. Wagner, M. H. Collins, A. Towbin, R. Nagarajan
- Brd. 40F Nimotuzumab and vinorelbine concomitantly to radiation and as maintenance for diffuse pontine glioma in childhood: Results from a series of 12 patients. (Abstract #9557)**
M. Massimino, V. Biassoni, L. Gandola, E. Schiavello, E. Pecori, F. Bach
- Brd. 40G Survivin expression in Ewing sarcoma family of tumors. (Abstract #9558)**
P. Hingorani, D. Azorsa, A. White-Collins, P. Dickman, M. Seidel
- Brd. 40H PARP-1 inhibitor MK-4827 in combination with radiation as a treatment strategy for metastatic neuroblastoma. (Abstract #9559)**
S. Bhargava, S. Mueller, L. Wehmeijer, X. Yang, A. Gragg, K. K. Matthey, W. A. Weiss, D. A. Haas-Kogan
- Brd. 41A Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents: Analysis of growth signaling pathways expression and clinical outcome. (Abstract #9560)**
J. Mora, C. de Torres, E. Rodriguez, T. M. Cardesa, E. de Alava, O. Cruz
- Brd. 41B Oncologic outcomes of partial versus radical nephrectomy for unilateral Wilms tumor. (Abstract #9561)**
N. G. Cost, J. D. Lubahn, H. A. Penn, C. F. Granberg, B. J. Schlomer, J. E. Wickiser, D. Rakheja, P. C. Gargollo, D. Leonard, L. A. Baker, G. Raj, V. Margulis
- Brd. 41C Back pain and hip pain among survivors of childhood acute lymphoblastic leukemia. (Abstract #9562)**
D. C. Bowers, T. Griffith, L. Gargan, C. Cochran, B. Kleiber, A. Foxwell, A. Farrow-Gillespie, A. Orlino, J. N. Germann
- Brd. 41D A phase I study of temsirolimus and valproic acid for refractory solid tumors in children. (Abstract #9563)**
D. W. Coulter, S. H. Gold, B. Weston, I. Davis, J. Blatt

- Brd. 41E Feasibility and pharmacokinetic study of potential ABCG2 inhibitor, gefitinib (GB), in combination with irinotecan (IRN) for adolescents and young adults (AYA). (Abstract #9564)**
H. Kawamoto, Y. Tabei, T. Kimura, K. Hishima, A. Makimoto
- Brd. 41F Randomized double-blind controlled trial (RCT) of pegfilgrastim as prophylactic therapy in pediatric patients with solid tumors during myelosuppressive chemotherapy. (Abstract #9565)**
S. Anaya Aguirre, V. Wanzke Del Angel, H. Rivera Marquez, M. Villasis Keever, E. Lopez Aguilar, F. Cerecedo Diaz
- Brd. 41G Characteristics of childhood cancer survivors who attend long-term follow-up (LTFU) clinic. (Abstract #9566)**
K. Devine, J. R. Andolina, N. Murray, G. R. Morrow, O. J. Sahler
- Brd. 41H Central nervous system relapse in pediatric acute lymphoblastic leukemia: Should we be making the diagnosis sooner? (Abstract #9567)**
A. E. Aguilar, A. K. Agrawal, J. H. Feusner
- Brd. 42A A survey of insurance retention in pediatric patients diagnosed with malignancies in a vertically integrated health care system. (Abstract #9568)**
R. M. Cooper, V. Y. Chiu
- Brd. 42B B-cell non-Hodgkin lymphomas in childhood: Twenty years experience in a single institution. (Abstract #9569)**
A. Pourtsidis, M. Servitzoglou, M. Baka, D. Bouhoutsou, M. Varvoutsis, D. Doganis, C. Strantzia-Michail, H. Kosmidis
- Brd. 42C Effect of selenium supplementation on anthracycline-induced cardiac toxicity in children treated for cancer: Correlation with pro-brain natriuretic peptide levels. (Abstract #9570)**
N. Tacyildiz, D. Ozyoruk, G. Ozelci Kavas, H. Dincaslan, G. Yavuz, E. Unal, S. Atalay, A. Ikinciogullari, T. Ucar, B. Doganay, G. Oktay, A. Cavdar, O. Kucuk
- Brd. 42D Surviving childhood cancer: What next? Challenges in developing countries. (Abstract #9571)**
P. Kurkure, V. Dhamankar, S. Goswami, N. Dalvi, E. Rawat-Pawar
- Brd. 42E Influence of prognostic factors in pediatric high-grade osteosarcoma survival. (Abstract #9572)**
A. Castellanos-Toledo, R. Rivera-Luna, R. Cardenas-Cardos, J. Figueroa Carbajal, C. Leal-Cavazos
- Brd. 42F Second malignant tumors in childhood cancer survivors. (Abstract #9573)**
R. Kebudi, I. Ayan, O. Gorgun, F. Y. Agaoglu, G. N. Ozdemir, Y. Dizdar, B. Zulfikar, E. Darendeliler
- Brd. 42H Sorafenib (Soraf) and bevacizumab (Beva) for recurrent metastatic hepatoblastoma (HB). (Abstract #9575)**
A. Marsh, L. Lo, J. H. Feusner
- Brd. 43A Long-term echocardiogram monitoring and cardiac outcomes of childhood cancer survivors with exposure to high doses of anthracyclines. (Abstract #9576)**
R. Nagarajan, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, K. C. Burns
- Brd. 43B Secondary leukemia 15 years or more after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9577)**
K. Nottage, J. Lancot, Z. Li, J. P. Neglia, S. Bhatia, S. Hammond, W. Leisenring, A. T. Meadows, D. K. Srivastava, L. L. Robison, G. T. Armstrong
- Brd. 43C Cardiopulmonary outcomes in pediatric survivors of Hodgkin's lymphoma. (Abstract #9578)**
K. C. Burns, J. Correll, D. A. Kent, N. Bakeer, J. P. Perentesis, R. Nagarajan

Sunday, June 5, 2011

- Brd. 43D A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study. (Abstract #9579)**
T. R. Hummel, L. M. Wagner, C. H. Ahern, R. M. McGovern, M. M. Ames, R. J. Gilbertson, T. M. Horton, A. M. Ingle, B. Weigel, S. Blaney, Children's Oncology Group
- Brd. 43E Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. (Abstract #9580)**
A. C. Dietz, S. Sivanandam, C. Kaufman, A. Kelly, J. P. Neglia, P. R. Gaillard, D. A. Mulrooney
- Brd. 43F School attendance in childhood cancer survivors. (Abstract #9581)**
A. E. French, E. Tsangaris, S. Guger, M. Barrera, R. Brown, S. Urbach, D. Stephens, P. C. Nathan

SUNDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Sarcoma

Location: Hall A

Track(s): Sarcoma

- Brd. 44A Denosumab safety and efficacy in giant cell tumor of bone (GCTB): Interim results from a phase II study. (Abstract #10034)**
J. Blay, S. P. Chawla, J. Martin Broto, E. Choy, M. Dominkus, J. Engellau, R. Grimer, R. M. Henshaw, E. Palmerini, P. Reichardt, P. Rutkowski, K. M. Skubitz, D. M. Thomas, Y. Zhao, Y. Qian, I. A. Jacobs
- Brd. 44B A novel combined radiologic method for evaluation of the response to chemotherapy for primary bone sarcoma. (Abstract #10035)**
S. Miwa, T. Shirai, J. Taki, N. Yamamoto, H. Nishida, K. Hayashi, H. Kimura, A. Takeuchi, K. Igarashi, H. Tsuchiya
- Brd. 44C Primary osteosarcomas of the mandible: Joint study of the Groupe Sarcome Francais (GSF), Rare Cancer Network, and Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). (Abstract #10036)**
J. Thariat, I. Ray-Coquard, A. Thyss, A. Italiano, J. Sarini, R. C. Miller, E. Bompas, A. Brouchet, O. Dassonville, S. Salas, P. Maingon, J. Kurtz, H. Reychler, T. de La Motte Rouge, K. Aldabbagh, J. Usseglio, P. Kerbrat, J. Lotz, L. Chaigneau, M. Julieron, Groupe Sarcome Francais-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO), Rare Cancer Network, Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC)
- Brd. 44D Effects of denosumab on pain reduction in giant cell tumor of bone (GCTB): Interim phase II study results. (Abstract #10037)**
C. S. Cleeland, A. P. Staddon, S. Schuetze, A. Powell, A. Lopez Pousa, A. Cioffi, J. R. Kroep, S. Stacchiotti, K. Chung, C. Atchison, Y. Qian, Y. Zhao, I. A. Jacobs
- Brd. 44E Functional characterization of IGFBP5 in the inhibition of osteosarcoma tumorigenicity. (Abstract #10038)**
G. Luther, E. Wagner, H. Luu, R. Haydon, T. He
- Brd. 44F Osteosarcoma of the pelvis and sacrum: A retrospective analysis of 73 patients. (Abstract #10039)**
E. Palmerini, N. Fabbri, E. L. Staals, E. Marchesi, M. Alberghini, A. Tienghi, F. Fagioli, P. Picci, M. Mercuri, S. Ferrari
- Brd. 44G Phase II study of 153-samarium-EDTMP followed by haematopoietic stem cell for patients with osteosarcoma with bone metastasis. (Abstract #10040)**
B. Massimo, G. Grignani, A. Giostra, M. Pagano, S. Ferrari, B. Elia, F. Carnevale-Scianca, M. Aglietta, R. Pellerito, F. Fagioli
- Brd. 44H Clinical outcomes of adult patients with relapsed Ewing sarcoma: A 30-year single institution experience. (Abstract #10041)**
S. I. Robinson, S. K. Ahmed, N. N. Laack, P. S. Rose, S. H. Okuno
- Brd. 45A High-dose chemotherapy plus autologous stem cell transplantation (HDCT/SCT) in patients with sarcoma: A single institution experience. (Abstract #10042)**
A. Stradella, A. Lopez-Pousa, M. Quintana, P. Murata, M. Ortin, O. Gallego, I. Sullivan, L. Robert, A. Sebio, I. Gracia, J. De Vega, A. Barnadas
- Brd. 45B Prevalence of hereditary GIST susceptibility in adults with GIST. (Abstract #10043)**
I. R. Rainville, E. J. Root, M. Salerno, L. DiGianni, D. A. Nelson, C. L. Corless, M. C. Heinrich, M. E. Robson, J. E. Garber

- Brd. 45C** **Patterns of care, prognosis, and survival of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. (Abstract #10044)**
A. Italiano, A. Cioffi, R. G. Maki, P. Schoffski, P. Rutkowski, A. Le Cesne, F. Duffaud, A. Adenis, N. Isambert, E. Bompas, J. Blay, P. G. Casali, P. Coco, D. R. D'Adamo, M. Keohan, M. Toulmonde, C. Antonescu, M. Debiec-Rychter, J. Coindre, B. Bui Nguyen
- Brd. 45D** **Identification of SDHA (subunit A of the succinate dehydrogenase) mutations in KIT/PDGFR WT gastrointestinal stromal tumors (GISTs). (Abstract #10045)**
M. A. Pantaleo, A. Astolfi, V. Indio, P. Paterini, S. Formica, R. Casadio, P. Martelli, A. Maleddu, M. Nannini, A. P. Dei Tos, M. C. Heinrich, D. Santini, F. Catena, C. Ceccarelli, M. Fiorentino, M. di Battista, R. Moore, N. Thiessen, C. Gnocchi, G. Biasco
- Brd. 45E** **Identification of single nucleotide variants in gastrointestinal stromal tumor KIT/PDGFR wild-type (WT GISTs) by massively parallel sequencing. (Abstract #10046)**
V. Indio, M. A. Pantaleo, A. Astolfi, R. Casadio, P. Paterini, S. Formica, P. Martelli, R. Moore, N. Thiessen, M. di Battista, F. Catena, D. Santini, M. C. Heinrich, C. Gnocchi, A. P. Dei Tos, G. Biasco
- Brd. 45F** ***KIT*, *DOG1*, *PDGFR*, and *IGFR1* gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients. (Abstract #10047)**
J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero, Spanish Group for Sarcoma Research (GEIS)
- Brd. 45G** **Who are the long responders to imatinib (IM) in patients with advanced GIST? Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10048)**
A. Blesius, P. A. Cassier, I. Ray-Coquard, A. Italiano, A. Adenis, M. Rios, F. Bertucci, T. Huynh, D. Cupissol, Y. Berge, E. Bompas, J. Emile, S. Chabaud, D. Perol, A. Le Cesne
- Brd. 45H** **Mechanism of early radiographic response to imatinib in GIST. (Abstract #10049)**
J. Gao, J. C. McAuliffe, A. J. Lazar, W. Wang, H. Choi, K. Hunt, D. M. Araujo, R. E. Pollock, R. S. Benjamin, J. C. Trent
- Brd. 46A** **Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). (Abstract #10050)**
A. D. Van Den Abbeele, Y. Tanaka, T. Locascio, C. Sakellis, M. C. Heinrich, M. von Mehren, E. Choy, W. D. Tap, J. Manola, G. D. Demetri, S. George, J. T. Yap
- Brd. 46B** **FDG-PET as a predictive marker for primary resistance to imatinib (IM) in patients with gastrointestinal stromal tumors (GIST) (Abstract #10051)**
S. Oosting, M. W. Den Hollander, B. Rikhof, D. B. Rouw, J. R. De Jong, P. L. Jager, A. H. Brouwers, W. Van Der Graaf, E. De Vries, J. A. Gietema, A. K. Reyners
- Brd. 46C** **Outcome of adjuvant imatinib in patients with gastrointestinal stromal tumor: Results of a population-based, matched cohort study. (Abstract #10052)**
H. T. Hatoum, J. C. Trent, A. Guo, S. Lin, L. A. Sirulnik, M. Sasane
- Brd. 46D** **Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts). (Abstract #10053)**
F. Duffaud, I. Ray-Coquard, A. Blesius, T. Huynh, E. Boucher, O. Bouche, J. Bay, F. Marchal, J. Spano, F. Bertucci, B. Bui Nguyen, O. Collard, L. Chaigneau, N. Isambert, A. Adenis, J. Mancini, A. Le Cesne, J. Blay, French Sarcoma Group (GSF-GETO)

- Brd. 46E Influence of imatinib interruption and imatinib rechallenge on the residual tumor volume in patients with advanced GIST: Results of the BFR14 prospective French Sarcoma Group randomized phase III trial. (Abstract #10054)**
 J. Domont, J. Blay, I. Ray-Coquard, B. Bui Nguyen, A. Adenis, M. Rios, F. Bertucci, F. Duffaud, D. Cupissol, C. Chevreau, E. Bompas, V. Bourne-Branchu, S. Chabaud, A. Le Cesne
- Brd. 46F Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study. (Abstract #10055)**
 J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, I. Sevilla, R. Andres, J. Cruz, M. Safont, J. Martin Broto, X. Garcia-Albeniz, J. Maurel
- Brd. 46G MicroRNA profile in gastrointestinal stromal tumors (GISTs) and correlation with KIT/PDGFR α kinase genotype. (Abstract #10056)**
 S. Formica, A. Astolfi, M. Nannini, M. A. Pantaleo, M. Ferracin, B. Zagatti, M. Negrini, D. Santini, P. Paterini, M. di Battista, A. Maleddu, M. Saponara, M. Pallotti, A. Mandrioli, C. Lolli, F. Catena, A. P. Dei Tos, G. Biasco
- Brd. 46H Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132. (Abstract #10057)**
 D. Wang, Q. Zhang, C. D. Blanke, G. D. Demetri, M. C. Heinrich, J. C. Watson, J. P. Hoffman, S. H. Okuno, J. M. Kane, M. vonMehren, B. L. Eisenberg
- Brd. 47A Exploring the relation between overall survival (OS) and progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) via meta-analysis. (Abstract #10058)**
 R. L. Keyser, K. E. Tranbarger Freier, D. C. Hoaglin, S. Tziveleakis, D. Muston, I. Ozer-Stillman
- Brd. 47B Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM). (Abstract #10059)**
 G. Schiavon, A. Ruggiero, S. Sleijfer, K. Eechoute, G. P. Krestin, J. Verweij, R. Mathijssen
- Brd. 47C Validating innovation: A population-based study of gastrointestinal stromal tumors (GIST) to estimate the survival benefit of imatinib. (Abstract #10060)**
 D. Goldstein, C. Lee, E. Tracey, C. Cook-Yarborough, S. Lord
- Brd. 47D Hypertension monitoring as a tool to predict congestive heart failure (CHF) during sunitinib (SU) therapy in GIST and renal cell carcinoma (RCC). (Abstract #10061)**
 D. Galizia, C. Ortega, E. Palesandro, V. Prati, S. Gallo, L. D'Ambrosio, A. Bonzano, D. Rota Scalabrini, S. Aliberti, G. Grignani, M. Aglietta
- Brd. 47E Study of dynamic contrast-enhanced ultrasound (DCE-US) for the early evaluation of imatinib. (Abstract #10062)**
 G. Abboud, N. Lassau, S. Koscielny, B. Benatsou, F. Tabarout, L. Chami, E. Girard, S. Bidault, J. Domont, A. Cioffi, S. Bonvalot, A. Le Cesne
- Brd. 47F Imatinib efficacy by tumor genotype in Asian patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs): A retrospective study of Korean GIST Study Group (KGSG). (Abstract #10063)**
 H. Kang, M. Ryu, K. Kim, Y. Park, W. Kim, S. Im, S. Park, K. Lee, H. Song, Y. Kang
- Brd. 47G A phase II study of low-dose protracted irinotecan in patients with advanced sarcomas. (Abstract #10064)**
 S. N. Dumont, J. C. Trent, S. Patel, D. M. Araujo, A. G. Dumont, R. S. Benjamin

- Brd. 47H High rates of histopathologic discordance in sarcoma with implications for clinical care. (Abstract #10065)**
C. P. Raut, S. George, J. L. Hornick, J. E. Butrynski, J. A. Morgan, J. Ready, A. F. Nascimento, C. D. Fletcher, G. D. Demetri, E. H. Baldini
- Brd. 48A Differences between neurofibromatosis-1-associated malignant peripheral nerve sheath tumors (MPNST) and sporadic MPNST: The Mayo Clinic experience. (Abstract #10066)**
K. N. Johnson, C. H. Stucky, B. A. Pockaj, R. J. Gray, P. S. Rose, N. Wasif
- Brd. 48B Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi's sarcoma (C06-46). (Abstract #10067)**
R. Porcher, D. Kerob, N. Dupin, B. Guillot, T. Jouary, A. Mathieu-Boué, K. Slimane, V. Furlan, M. Battistella, F. Agbalika, S. Mourah, C. Lebbé
- Brd. 48C Effect of Notch3 to regulate rhabdomyosarcoma growth in vitro and in vivo. (Abstract #10068)**
R. Rota, L. Raimondi, R. Ciarapica, F. Verginelli, M. Gueguen, R. Boldrini, L. De Sio, A. Inserra, M. Locatelli, T. Dang, L. Miele, S. Stifani, I. Limon, F. Locatelli
- Brd. 48D Quantitative analysis of IGF-1R expression in FFPE human rhabdomyosarcoma tumor tissue by mass spectrometry. (Abstract #10069)**
S. Malempati, T. A. Hembrough, S. Thyparambil, L. Cao, M. Darfler, D. Krizman, D. S. Hawkins, S. Skapek, L. J. Helman, J. Burrows
- Brd. 48E Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO). (Abstract #10070)**
E. Bompas, L. Campion, A. Italiano, A. I. Cesne, M. Giaj Levra, C. Chevreau, S. Piperno-Neumann, N. Isambert, A. Thyss, M. Rios, J. Kurtz, C. Delcambre, J. Bay, F. Duffaud, M. Trassard, P. Soulie, J. Blay
- Brd. 48F Advanced well-differentiated/dedifferentiated liposarcomas: Role of chemotherapy and survival. (Abstract #10071)**
M. Toulmonde, A. Italiano, N. Penel, A. Cioffi, A. Le Cesne, N. Isambert, E. Bompas, F. Duffaud, A. Patrikidou, R. G. Maki, J. Coindre, J. Blay, B. Bui Nguyen
- Brd. 48G A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial. (Abstract #10072)**
A. Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo, J. Blay
- Brd. 48H A phase I dose-escalation study of azacitidine in combination with temozolomide in patients with soft tissue sarcomas. (Abstract #10073)**
I. Matushansky, K. E. Coakley, T. S. Uldrick, R. N. Taub
- Brd. 49A Expression of MGMT and response to treatment with temozolomide in patients with leiomyosarcoma. (Abstract #10074)**
A. Marrari, J. L. Hornick, N. H. Ramaiya, J. Manola, A. J. Wagner
- Brd. 49B A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas. (Abstract #10075)**
S. Attia, M. R. Mahoney, S. H. Okuno, D. Adkins, H. G. Ahuja, T. P. Ducker, W. J. Maples, L. Ochs, N. L. Wentworth-Hartung, C. Erlichman, H. H. Bailey
- Brd. 49C A phase II trial evaluating efficacy of neo-/adjuvant EIA CTX, surgery, and radiation therapy in high-risk soft tissue sarcoma. (Abstract #10076)**
T. Schmitt, B. Kasper, M. Bischof, B. Lehner, S. Dietrich, A. Dimitrakopoulou-Strauss, L. G. Strauss, G. Mechtersheimer, P. Wuchter, A. D. Ho, G. Egerer
- Brd. 49D Growth factor receptors and cell cycle proteins as new molecular prognosis markers in high-grade undifferentiated pleomorphic sarcoma (HGUPS). (Abstract #10077)**
C. Serrano, S. Simonetti, C. M. Valverde, R. Morales, C. Suarez, T. Moline, J. Carles, S. Ramon y Cajal, C. Romagosa

- Brd. 49E Adjuvant and neoadjuvant chemotherapy (NAC) with ifosfamide (IFO) and doxorubicin hydrochloride (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG030404. (Abstract #10078)**
 K. Tanaka, J. Mizusawa, H. Fukuda, N. Araki, H. Chuuman, M. Takahashi, T. Ozaki, T. Hiruma, H. Tsuchiya, H. Morioka, T. Morita, T. Wada, M. Hatori, Y. Yoshida, J. Toguchida, S. Abe, A. Matsumine, R. Yokoyama, Y. Iwamoto
- Brd. 49F Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. (Abstract #10079)**
 A. Cioffi, A. Italiano, N. Penel, Y. Berge, M. Toulmonde, S. Salas, C. Chevreau, A. Le Cesne, F. Duffaud, D. R. D'Adamo, M. Keohan, C. Genebes, C. Antonescu, J. Coindre, B. Bui Nguyen, R. G. Maki
- Brd. 49G Effect of the combination of mTOR inhibitor ridaforolimus and HDAC inhibitor vorinostat on in vitro synergism in synovial sarcoma, osteosarcoma, and a range of other tumor subtypes. (Abstract #10080)**
 S. S. Morgan, L. D. Cranmer
- Brd. 49H Identification of potential molecular candidate lesions by molecular analysis of desmoid tumors with QRT-PCR and high-density SNP arrays. (Abstract #10081)**
 P. Erben, D. Nowak, W. Hofmann, R. Hofheinz, P. Hohenberger, B. Kasper
- Brd. 50A Heterogeneity of metastatic behavior among high-grade pleomorphic soft tissue sarcomas identified by gene expression analysis. (Abstract #10082)**
 K. M. Skubitz, P. Francis, A. Skubitz, X. Luo, M. Nilbert
- Brd. 50B Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI). (Abstract #10083)**
 Y. Kojima, K. Hashimoto, M. Ando, K. Yonemori, H. Yamamoto, M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara
- Brd. 50C Topoisomerase-based chemotherapy in adults with relapsed or refractory pediatric-type sarcoma: A retrospective analysis of the German AIO Sarcoma Group/BMBF SAREZ registry. (Abstract #10084)**
 J. T. Hartmann, I. Sturm, R. D. Issels, S. W. Krause, V. Gruenwald, A. Kunitz, L. Lindner, K. San Nicolò, F. Mayer, B. Hertenstein, L. Mueller, U. Kontry, J. Topaly, R. U. Trappe, W. Grothe
- Brd. 50D Metastatic angiosarcomas (mAS): Identification of treatments that significantly improve the outcome. (Abstract #10085)**
 E. Amela, A. Italiano, I. Ray-Coquard, L. Chaigneau, C. Delcambre, B. Bui Nguyen, F. Bertucci, N. Isambert, D. Cupissol, E. Bompas, J. Bay, F. Duffaud, C. Guillemet, N. Corradini, P. A. Cassier, C. Chevreau, J. Blay, N. Penel, French Sarcoma Group (GSF/GETO)
- Brd. 50E Predictive role of topoisomerase II α , gp170, Bcl-2, tumor burden, and histology in neoadjuvant chemotherapy for soft tissue sarcomas of the extremities. (Abstract #10086)**
 A. Comandone, P. Porrino, E. Berardengo, A. Linari, A. Boglione, C. Oliva, G. Gino, C. Faletti, P. Bergnolo, P. Pochettino, A. Bernardi, E. M. Brach del Prever, R. Piana
- Brd. 50F Creatinine clearance and serum albumin as factors for encephalopathy with ambulatory 14-day infusional ifosfamide for advanced liposarcomas. (Abstract #10087)**
 S. M. Alam, C. Benson, R. L. Jones, E. Thanopoulou, S. Mitchell, O. Al-Muderis, A. Dunlop, C. Probert-Lewis, I. R. Judson, M. R. Scurr
- Brd. 50G Pulmonary metastasectomy in soft tissue sarcomas (STS): A single-institution experience. (Abstract #10088)**
 M. Glogowski, L. Talarek, I. A. Lugowska, S. Falkowski, T. Switaj, M. Zmijewski, R. Wlodarczyk, H. Kosela, M. Turski, M. J. Krzakowski, P. Rutkowski

- Brd. 50H Histology and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). (Abstract #10089)**
P. G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini, A. Lombart-Bosch, C. Morosi, A. Messina, M. Mercuri, A. Gronchi
- Brd. 51A Exploratory analysis of prognostic factors for patients (pts) with advanced soft tissue sarcoma (ASTS) receiving combination chemotherapy: A joined study of the EORTC Soft Tissue and Bone Sarcoma Group and the French Sarcoma Group. (Abstract #10090)**
N. Penel, M. M. Van Glabbeke, B. Bui Nguyen, M. Ouali, S. Mathoulin-Pelissier, S. Marreaud, A. Italiano, V. Brouste, P. C. Hogendoorn, J. Coindre, J. Blay, P. Hohenberger
- Brd. 51B Mucocutaneous angiosarcoma (MC-AS) versus non-MC-AS: Clinicopathologic features and treatment outcomes in 44 patients (pts). (Abstract #10091)**
R. H. Quek, M. R. Harunal Rashid, W. Ong, M. J. Lee, R. Jeevan, Z. Ho, F. Chin, L. Soh, D. Poon, M. Teo
- Brd. 51C Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy. (Abstract #10092)**
K. Harano, Y. Kojima, K. Hashimoto, M. Ando, A. Hirakawa, K. Yonemori, M. Kodaira, M. Yunokawa, C. Shimizu, K. Tamura, N. Katsumata, A. Makimoto, Y. Fujiwara
- Brd. 51D Management and outcomes for primary cardiac sarcomas (PCS): A retrospective study of the French Sarcoma Group (FSG). (Abstract #10093)**
N. Isambert, I. Ray-Coquard, B. Bui Nguyen, M. Rios, P. Kerbrat, A. Blouet, L. Chaigneau, F. Duffaud, S. Piperno-Neumann, J. Kurtz, J. Thariat, N. Girard, O. Collard, E. Bompas, N. Penel, J. Bay, C. Guillemet, F. Collin, J. Blay, A. Le Cesne
- Brd. 51E Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). (Abstract #10094)**
U. Bitz, D. Pink, C. Busemann, P. Reichardt
- Brd. 51F Prognostic factors in leiomyosarcoma (LMS): Does primary site influence outcome? (Abstract #10095)**
M. R. Harunal Rashid, W. Ong, M. Teo, M. Tan, L. Foo, Y. Lim, F. Chin, M. J. Lee, Z. Ho, R. Jeevan, J. W. Chia, L. Soh, D. Poon, R. H. Quek
- Brd. 51G The role of E-cadherin expression in response and outcome in patients with leiomyosarcoma treated with chemotherapy. (Abstract #10096)**
V. Ravi, J. Yang, D. M. Araujo, M. S. Park, R. S. Benjamin, W. Zhang, J. C. Trent, S. Patel
- Brd. 51H The role of chemotherapy in advanced hemangiopericyoma/solitary fibrous tumor. (Abstract #10097)**
M. S. Park, S. Patel, V. Ravi, A. P. Conley, J. C. Trent, A. J. Lazar, D. Lev, X. Wang, R. S. Benjamin, D. M. Araujo
- Brd. 52A Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation of preoperative therapy for extremity soft tissue sarcomas (STS). (Abstract #10098)**
J. M. Meyer, K. S. Perlewitz, S. L. Hemmingson, J. B. Hayden, A. Hung, A. Mansoor, M. L. Holtorf, W. J. Woodward, C. S. Springer, W. Huang, C. W. Ryan

SUNDAY

**8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION**

Patient and Survivor Care

Display Time: 8:00 AM - 12:00 PM
 Display Location: S102
 Discussion Time: 11:30 AM - 12:30 PM
 Discussion Location: S100bc
CME credit: 1
 Track(s): Patient and Survivor Care

Thomas J. Smith, MD—Chair

Massey Cancer Center of Virginia Commonwealth University

Discussion

11:30 AM James Lloyd Wade, MD (Abstracts #9017–9022)
 Cancer Care Specialists of Central Illinois

Discussion

11:45 AM Pamela Jean Goodwin, MD (Abstracts #9023–9029)
 Mount Sinai Hospital

Discussion

12:00 PM Patricia A. Ganz, MD (Abstracts #9030–9035)
 University of California, Los Angeles Schools of Medicine and Public Health

Discussion

12:15 PM Teresa Gilewski, MD (Abstracts #9036–9041)
 Memorial Sloan-Kettering Cancer Center

Brd. 1 Gabapentin for the prevention of chemotherapy-induced nausea and vomiting: A pilot study. (Abstract #9017)

F. M. Cruz, A. Del Giglio, D. d. Cubero, P. Taranto, T. Lerner, A. T. Lera, M. C. Miranda, M. C. Vieira, A. B. Fede, F. Schindler, S. O. Afonseca, H. Pinczowski

Brd. 2 Antiemetic choice based on economic advantage. (Abstract #9018)

E. Z. Touloukian, A. Yakan, R. E. Bloom

Brd. 3 Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting. (Abstract #9019)

P. J. Hesketh, V. Moiseyenko, G. Rosati, A. Makhson, J. Levin, M. W. Russo

Brd. 4 A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. (Abstract #9020)

J. L. Vardy, G. R. Pond, A. Dodd, D. Warr, B. Seruga, M. J. Clemons, L. Bordeleau, I. Tannock

Brd. 5 Testing the cutaneous absorption of lorazepam, diphenhydramine, and haloperidol gel (ABH gel) used for cancer-related nausea. (Abstract #9021)

T. J. Smith, J. K. Ritter, P. J. Coyne, G. L. Parker, P. Dodson, D. S. Fletcher

Brd. 6 Effect of GTx-024, a selective androgen receptor modulator (SARM), on physical function in patients with non-small cell lung cancer (NSCLC) with cancer cachexia. (Abstract #9022)

M. S. Steiner, A. Dobs, M. L. Hancock, M. A. Johnston, G. Barnette, S. Dodson

Brd. 7 Buspirone treatment of dyspnea in outpatients receiving chemotherapy: A University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP) study. (Abstract #9023)

P. W. Bushunow, J. A. Roscoe, D. J. Dudgeon, J. J. Kirshner, C. E. Heckler, G. R. Morrow, S. R. Dakhil, T. S. Collins, D. A. Churchill, University of Rochester Cancer Center Community Clinical Oncology Program (URCC CCOP)

- Brd. 8 Mortality reduction by talactoferrin alfa (TLF) in severe sepsis with different types of infections. (Abstract #9024)**
J. Crawford, K. K. Guntupalli, N. C. Dean, P. E. Morris, R. K. Malik, J. P. Schaumberg
- Brd. 9 Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in metastatic breast cancer (mBC). (Abstract #9025)**
J. A. Carter, S. J. Snedecor, S. Kaura, M. Botteman
- Brd. 10 Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer. (Abstract #9026)**
S. Servitja, D. Prieto-Alhambra, M. Martinez-Garcia, L. Garrigos, M. J. Pena, A. Diez-Perez, J. Albanell, X. Nogues, I. Tusquets
- Brd. 11 Phase III randomized, double-blind, placebo-controlled trial of soy protein and venlafaxine for treatment of hot flashes in men with prostate cancer. (Abstract #9027)**
M. Vitolins, L. Griffin, W. V. Tomlinson, J. Vuky, D. B. Fried, P. T. Adams, D. Moose, B. Frizzell, J. E. Radford, T. Shah, E. G. Shaw
- Brd. 12 Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEURO-PAIN-01). (Abstract #9028)**
M. C. Garassino, A. Bianchi, A. Febbraro, I. Spagnoletti, V. Iorno, A. Bramati, C. Carbone, L. Isa, E. Breda, R. Magarotto, V. Torri, G. Farina
- Brd. 13 Acupuncture for chemotherapy-induced fatigue: A randomized controlled trial. (Abstract #9029)**
G. E. Deng, Y. Chan, K. Yeung, A. J. Vickers, B. R. Cassileth
- Brd. 14 Long-term protective effects of the angiotensin-receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and myocardial dysfunction. (Abstract #9030)**
G. Mantovani, C. Madeddu, M. Dessi, E. Massa, G. Antoni, A. Piras, C. Cadeddu, M. Deidda, G. Mercurio
- Brd. 15 The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. (Abstract #9031)**
D. P. Steensma, B. J. Sasu, J. A. Sloan, D. Tomita, C. L. Loprinzi
- Brd. 16 Role of hypoalbuminemia in the development of venous thromboembolism in cancer chemotherapy patients. (Abstract #9032)**
Z. Li, W. B. Webb III, J. Mao, S. Gautam, S. Singh, G. H. Lyman
- Brd. 17 Molecular diagnosis of bacteremia in patients with neutropenic febrile oncohematologic. (Abstract #9033)**
E. Gimeno, L. Sorli, E. Abella, A. Alvarez-Larran, J. Horcajada, L. Garrigos, A. Taus, A. Salar, B. Sanchez, C. Pedro, C. Besses, M. Salvado
- Brd. 18 Effect of YOCAS yoga on circadian rhythm, anxiety, and mood: A URCC CCOP randomized, controlled clinical trial among 410 cancer survivors. (Abstract #9034)**
K. M. Mustian, L. Sprod, L. J. Peppone, S. G. Mohile, M. C. Janelsins, O. Palesh, K. Devine, P. S. Reddy, M. Melnik, J. K. Giguere, G. R. Morrow
- Brd. 19 Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in patients with cancer: A randomized controlled trial. (Abstract #9035)**
B. Oh, P. Butow, N. Pavlakis, P. J. Beale, S. J. Clarke, D. S. Rosenthal, L. Larkey, J. L. Vardy
- Brd. 20 Exercise and side effects among 417 older patients with cancer during and after cancer treatment: A URCC CCOP study. (Abstract #9036)**
L. Sprod, S. G. Mohile, K. Devine, M. C. Janelsins, L. J. Peppone, G. R. Morrow, R. S. Lord, H. M. Gross, K. M. Mustian

- Brd. 21 Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes. (Abstract #9037)**
A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, H. D. Klepin, C. P. Gross, S. M. Lichtman, R. Ramani, J. Brown, V. Katheria, R. Jayani, K. Hansen, K. Togawa, S. Klapper, A. Hurria, Cancer and Aging Research Group
- Brd. 22 Scarring, disfigurement, and quality of life in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. (Abstract #9038)**
K. E. Kinahan, L. K. Sharp, A. Didwania, K. Seidel, W. Leisenring, M. E. Lacouture, M. Stovall, L. L. Robison, K. R. Krull
- Brd. 23 Disability pension among patients with breast cancer: A Norwegian population-based controlled study. (Abstract #9039)**
B. Hauglann, J. Šaltytė Benth, S. D. Fossa, A. A. Dahl
- Brd. 24 What leads to better quality of life at the end of life? (Abstract #9040)**
M. E. Nilsson, B. Zhang, E. Reitschuler-Cross, A. A. Wright, X. Gao, J. S. Temel, T. A. Balboni, H. G. Prigerson
- Brd. 25 Do the preferences of patients with terminal cancer or their family caregivers and end-of-life care discussions influence utilization of hospice-palliative care? (Abstract #9041)**
A. An, Y. Yun, W. Lee, K. Jung, Y. Do, S. Kim, D. S. Heo, J. Choi, S. Park, H. Jeong, J. Kang, J. Ro

Sunday, June 5, 2011

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION

Pediatric Oncology

Display Time: 8:00 AM - 12:00 PM

Display Location: Hall A

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: S504

CME credit: 1

Track(s): Pediatric Oncology

Birgit Georger, MD, PhD—Chair

Institut Gustave Roussy

Discussion

11:30 AM Julia Lynne Glade Bender, MD (Abstracts #9520–9523)
Columbia University

Discussion

11:45 AM Paul Graham Fisher, MD (Abstract #9524)
Stanford Cancer Center

Discussion

12:00 PM William D. Tap, MD (Abstracts #9526–9531)
University of California, Los Angeles

Discussion

12:15 PM Lillian Sung, MD, PhD (Abstracts #9532–9535)
The Hospital for Sick Children

Brd. 36A **A phase I trial of IMC-A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group Study. (Abstract #9520)**

M. Fouladi, J. P. Perentesis, L. M. Wagner, A. M. Ingle, J. Gammon, G. Thomas, D. A. Krueger, P. Houghton, S. Vinks, B. Weigel, S. Blaney

Brd. 36B **Phase I study of clofarabine and liposomal daunorubicin in childhood acute myeloid leukemia. (Abstract #9521)**

P. Kearns, N. J. Graham, M. Cummins, B. Gibson, J. D. Grainger, R. Keenan, D. Lancaster, G. Shenton, J. Vormoor, D. Webb, I. Hawley, P. J. Johnson

Brd. 36C **A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group study. (Abstract #9522)**

J. A. Muscal, P. A. Thompson, T. M. Horton, A. M. Ingle, C. H. Ahern, R. M. McGovern, J. M. Reid, M. M. Ames, B. Weigel, S. Blaney

Brd. 36D **A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: Early-phase evaluation. (Abstract #9523)**

F. Navid, R. C. Barfield, R. Handgretinger, P. M. Sondel, B. L. Shulkin, R. Kaufman, C. Billups, J. Wu, W. L. Furman, L. M. McGregor, M. Otto, S. Gillies, V. M. Santana

Brd. 36E **Vinorelbine in progressive unresectable low-grade glioma in children. (Abstract #9524)**

A. M. Cappellano, E. Bouffet, F. Silva, P. Paiva, M. d. Alves, S. Cavalheiro, N. S. Silva

Brd. 36G **Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval-compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma family of tumors: A Children's Oncology Group trial. (Abstract #9526)**

L. Mascarenhas, J. L. Felgenhauer, M. C. Bond, J. D. Femino, N. N. Laack, S. Ranganathan, M. D. Krailo, N. Marina, Children's Oncology Group

Brd. 36H **The management of pulmonary nodules at diagnosis in patients with Ewing sarcoma (ES). (Abstract #9527)**

C. Owens, M. Le Deley, J. M. Michon, I. Marzouk, E. Thebault, P. Marec Bérard, O. Oberlin

- Brd. 37A Proposal of a prognostic score system for the Brazilian Osteosarcoma Treatment Group (BOTG) patients. (Abstract #9528)**
M. Cypriano, A. Ferraro, C. M. Costa, V. Odone, D. Lustosa, M. Borsato, A. L. Brunetto, L. Calheiros, J. Barreto, S. Epelman, E. Carvalho, W. V. Pereira, E. M. Pontes, R. J. Garcia Filho, M. d. Alves, C. R. Macedo, O. P. de Camargo, P. Pericles, V. Penna, A. S. Petrilli, Sociedade Brasileira de Oncologia Pediatrica (SOBOPE)
- Brd. 37B Parameningeal rhabdomyosarcoma: Results of a pooled analysis from U.S. and European Cooperative Groups. (Abstract #9529)**
J. H. Merks, G. De Salvo, C. Bergeron, G. Bisogno, A. Rey, O. Oberlin, A. Kelsey, I. Zanetti, J. M. Michalski, D. S. Hawkins, J. R. Anderson
- Brd. 37C Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma. (Abstract #9530)**
J. C. van Gaal, U. E. Flucke, M. H. Roeffen, E. S. de Bont, A. J. Suurmeijer, W. Van Der Graaf, Y. M. Versleijen-Jonkers
- Brd. 37D Can the well-credentialed neuroblastoma tumor antigen GD2 be exploited for T-cell-based immunotherapy of pediatric sarcomas? (Abstract #9531)**
S. Ramakrishna, S. Gottschalk, R. Morgan, G. Dotti, M. K. Brenner, R. Orentas, C. Mackall
- Brd. 37E Performance-based physical function in long-term survivors of Hodgkin lymphoma. (Abstract #9532)**
K. K. Ness, M. Metzger, T. T. Huang, G. T. Armstrong, L. L. Robison, M. M. Hudson
- Brd. 37F Risk factors for *clostridium difficile* infection in children with malignancy. (Abstract #9533)**
P. M. De Blank, T. Zaoutis, B. Fisher, A. B. Troxel, J. Kim, R. Aplenc
- Brd. 37G L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol. (Abstract #9534)**
P. V. Plourde, S. Jeha, L. B. Silverman, J. B. Nachman, S. R. Rheingold, G. V. Dahl, E. A. Raetz, T. Mercedes, T. Corn
- Brd. 37H Palonosetron in the prevention of chemotherapy-induced nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. (Abstract #9535)**
H. Schroeder, S. Nadaraja, S. Rosthoelj, P. S. Wehner, H. Thomassen

Sunday, June 5, 2011

9:00 AM - 12:00 PM
ORAL ABSTRACT SESSION

Breast Cancer—HER2/ER

Location: Hall B1
CME credit: 3
Track(s): Breast Cancer

Harold J. Burstein, MD, PhD—Co-Chair

Dana-Farber Cancer Institute

Rebecca Alexandra Dent, MD—Co-Chair

Sunnybrook Health Sciences Centre

9:00 AM Exemestane for primary prevention of breast cancer in postmenopausal women: NCIC CTG MAP.3—A randomized placebo-controlled clinical trial. (Abstract #LBA504)

P. E. Goss, J. N. Ingle, J. Ales-Martinez, A. Cheung, R. T. Chlebowski, J. Wactawski-Wende, A. McTiernan, J. Robbins, K. Johnson, L. Martin, E. Winquist, G. Sarto, J. E. Garber, C. J. Fabian, P. Pujol, E. Maunsell, P. Farmer, K. A. Gelmon, D. Tu, H. Richardson

Discussion

9:15 AM Andrea Decensi, MD (Abstract #LBA504)
Ente Ospedaliero Ospedali Galliera

9:30 AM TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (Abstract #505)

J. C. Chang, I. A. Mayer, A. Forero-Torres, R. Nanda, M. P. Goetz, A. A. Rodriguez, A. C. Pavlick, T. Wang, S. G. Hilsenbeck, C. Gutierrez, R. Schiff, C. K. Osborne, M. F. Rimawi, on behalf of the Translational Breast Cancer Research Consortium

9:45 AM Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined, prior to neoadjuvant breast cancer chemotherapy. (Abstract #506)

F. A. Holmes, Y. M. Nagarwala, V. A. Espina, L. A. Liotta, M. A. Danso, R. I. Gallagher, K. McIntyre, C. R. Osborne, J. M. Mahoney, A. M. Florance, T. C. Anderson, J. O'Shaughnessy

10:00 AM Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). (Abstract #507)

V. Guarneri, A. Frassoldati, A. Bottini, D. G. Generali, K. Cagossi, F. Artioli, G. Bisagni, C. Boni, A. Ravaoli, D. Amadori, A. Musolino, L. Cavanna, M. Untch, L. Orlando, G. Giardina, F. Piacentini, E. Tagliafico, M. Bagnalasta, R. D'Amico, P. F. Conte

Discussion

10:15 AM Gunter Von Minckwitz, MD, PhD (Abstracts #505–507)
German Breast Group

10:30 AM A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and nonamplified metastatic breast cancer. (Abstract #508)

F. Andre, T. D. Bachelot, M. Campone, F. Dalenc, J. M. Perez-Garcia, S. A. Hurvitz, N. C. Turner, H. S. Rugo, M. M. Shi, Y. Zhang, A. C. Kay, A. J. Yovine, J. Baselga

10:45 AM LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole brain radiotherapy (WBR). (Abstract #509)

T. D. Bachelot, G. Romieu, M. Campone, V. Dieras, C. Cropet, H. H. Roche, M. Jimenez, E. Le Rhun, J. Pierga, A. Gonçalves, M. Leheurteur, J. Domont, M. Gutierrez, H. Cure, J. Ferrero, C. Labbe

Discussion

11:00 AM Nancy U. Lin, MD (Abstract #509)
Dana-Farber Cancer Institute

11:15 AM **Patterns and correlates of adjuvant breast cancer endocrine therapy use. (Abstract #510)**

T. M. Pini, J. J. Griggs, A. S. Hamilton, S. J. Katz

11:30 AM **When to intervene to increase use of adjuvant hormone therapy among women with hormone-sensitive breast cancer. (Abstract #511)**

V. P. Quinn, J. A. Strauss, J. E. Schottinger, C. T. Cheetham, R. Haque

Discussion

11:45 AM Dawn L. Hershman, MD, MS (Abstracts #510–511)
Columbia University Medical Center

Sunday, June 5, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Developmental Therapeutics—Experimental Therapeutics

Location: Arie Crown Theater

CME credit: 3

Track(s): Developmental Therapeutics

Patricia LoRusso, DO—Co-Chair

Karmanos Cancer Institute

E. Gabriela Chiorean, MD—Co-Chair

Indiana University Melvin and Bren Simon Cancer Center

Discussion

- 9:30 AM** Sarat Chandralapaty, MD, PhD
Memorial Sloan-Kettering Cancer Center
- 9:45 AM** **Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study. (Abstract #3003)**
H. A. Burris, L. L. Siu, J. R. Infante, J. J. Wheler, C. Kurkjian, J. Opalinska, D. A. Smith, J. M. Antal, J. L. Gauvin, T. Gonzalez, L. M. Adams, P. Bedard, J. F. Gerecitano, R. Kurzrock, K. N. Moore, S. R. Morris, C. Aghajanian
- 10:00 AM** **A phase I dose escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. (Abstract #3004)**
A. W. Tolcher, R. D. Baird, A. Patnaik, V. Moreno Garcia, K. P. Papadopoulos, C. R. Garrett, D. Olmos, K. A. Shannon, V. Zazulina, E. H. Rubin, I. C. Smith, J. Ryan, P. D. Smith, A. Taylor, M. Learoyd, L. Lupinacci, L. Yan, J. S. De Bono
- 10:15 AM** **Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. (Abstract #3005[^])**
G. Shapiro, P. LoRusso, E. L. Kwak, J. M. Cleary, L. Musib, C. Jones, A. de Crespigny, M. Belvin, M. McKenzie, M. R. Gates, I. T. Chan, J. C. Bendell

Discussion

- 10:30 AM** Pasi A. Janne, MD, PhD (Abstracts #3003–3005[^])
Dana-Farber Cancer Institute
- 10:45 AM** **First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumors. (Abstract #3006[^])**
S. O. Dolly, J. Albanell, F. Kraeber-Bodere, U. Banerji, R. Bahleda, M. Martinez Garcia, Z. X. Xu, E. Guarin, J. Tessier, E. Shochat, J. Deutsch, S. Blotner, V. Meresse, J. Soria
- 11:00 AM** **Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86–9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer. (Abstract #3007)**
L. Gore, K. Lewis, D. D. Von Hoff, G. J. Weiss, R. K. Ramanathan, A. A. Adjei, G. K. Dy, W. Ma, N. J. Clendeninn, D. P. Leffingwell, B. Sheedy, C. Iverson, J. N. Miner, Z. Shen, L. Yeh, R. L. Dubowy, M. Jeffers, P. Rajagopalan, C. D. Weekes
- Discussion**
- 11:15 AM** Patrick G. Johnston, MD, PhD (Abstracts #3006[^]–3007)
Queen's University Belfast
- 11:30 AM** **Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP) inhibitor, in patients (Pts) with advanced solid tumors: Results of a phase I study. (Abstract #3008)**
B. I. Sikic, S. G. Eckhardt, G. Gallant, H. A. Burris III, D. R. Camidge, A. D. Colevas, S. F. Jones, W. A. Messersmith, H. A. Wakelee, H. Li, P. G. Kaminker, S. Morris, J. R. Infante

- 11:45 AM** **Phase I study of PF-03446962, a fully human mAb against ALK 1, a TGF β receptor involved in tumor angiogenesis. (Abstract #3009)**
L. W. Goff, R. B. Cohen, J. Berlin, C. Noberasco, H. Borghaei, C. Gallo-Stampino, E. Wang, D. Hu Lowe, W. J. Levin, F. G. De Braud
- 12:00 PM** **Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. (Abstract #3010)**
M. S. Gordon, N. J. Vogelzang, P. Schoffski, A. Daud, A. I. Spira, B. A. O'Keeffe, T. Rafferty, Y. Lee, R. Berger, G. Shapiro
- Discussion**
- 12:15 PM** Jaap Verweij, MD, PhD (Abstracts #3008–3010)
Erasmus University Medical Center

Sunday, June 5, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Lung Cancer—Metastatic/Non-small Cell

Location: Hall D1

CME credit: 3

Track(s): Lung Cancer

D. Ross Camidge, MD, PhD—Co-Chair

University of Colorado Denver

Scott Arthur Kono, DO—Co-Chair

Winship Cancer Institute at Emory University

9:30 AM Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European erlotinib versus chemotherapy (EURTAC) phase III randomized trial. (Abstract #7503)

R. Rosell, R. Gervais, A. Vergnenegre, B. Massuti, E. Felip, F. Cardenal, R. Garcia Gomez, C. Pallares, J. Sanchez, R. Porta, M. Cobo, M. Di Seri, P. Garrido Lopez, A. Insa, F. De Marinis, R. Corre, M. Carreras, E. Carcereny, M. Taron, L. G. Paz-Ares, Spanish Lung Cancer Group

9:45 AM Innovations: Randomized phase II trial of erlotinib (E)/bevacizumab (B) compared with cisplatin (P)/gemcitabine (G) plus B in first-line treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). (Abstract #7504)

M. Thomas, A. Reuss, J. R. Fischer, S. Andreas, C. Kortsik, C. Grah, M. H. Serke, M. von Eiff, C. Witt, J. Kollmeier, E. Müller, L. Müller, M. Schenk, R. Heine, D. M. Behringer, M. Schroeder, N. Reinmuth, P. Schnabel, T. Acker, M. Wolf

10:00 AM Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. (Abstract #7505)

D. R. Spigel, T. J. Ervin, R. Ramlau, D. B. Daniel, J. H. Goldschmidt Jr., G. R. Blumenschein Jr., M. J. Krzakowski, G. Robinet, C. Clement-Duchene, F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, J. Zha, A. Pandita, W. Yu, R. L. Yauch, P. H. Patel, A. C. Peterson

Discussion

10:15 AM Tony Mok, MD (Abstracts #7503–7505)
Prince of Wales Hospital

10:30 AM Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). (Abstract #CRA7506)

M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn

10:45 AM Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. (Abstract #7507)

A. T. Shaw, B. Y. Yeap, B. J. Solomon, G. J. Riely, A. J. Iafrate, G. Shapiro, D. B. Costa, M. Butaney, S. I. Ou, R. G. Maki, Y. Bang, M. Varella-Garcia, R. Salgia, K. D. Wilner, K. Kulig, P. Selaru, Y. Tang, E. L. Kwak, J. W. Clark, D. R. Camidge

Discussion

11:00 AM Ramaswamy Govindan, MD (Abstracts #CRA7506–7507)
Washington University School of Medicine

- 11:15 AM** **Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): An intergroup trial of JCOG0803/WJOG4307L. (Abstract #7509)**
T. Abe, A. Yokoyama, K. Takeda, Y. Ohe, S. Kudoh, Y. Ichinose, H. Okamoto, N. Yamamoto, H. Yoshioka, K. Minato, T. Sawa, Y. Iwamoto, H. Saka, J. Mizusawa, T. Shibata, S. Nakamura, M. Ando, K. Nakagawa, N. Saijo, T. Tamura
- 11:30 AM** **PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #CRA7510)**
L. G. Paz-Ares, F. De Marinis, M. Dediu, M. Thomas, J. Pujol, P. Bidoli, O. Molinier, T. P. Sahoo, E. Laack, M. Reck, J. Corral, S. A. Melemed, W. J. John, N. Chouaki, A. Zimmerman, C. M. Visseren Grul, C. Gridelli
- 11:45 AM** **Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; INFORM; C-TONG 0804). (Abstract #LBA7511)**
L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, L. Yun-Peng, M. Wang, and X. Zhang

Discussion

- 12:00 PM** Martin J. Edelman, MD (Abstracts #7509–LBA7511)
University of Maryland Greenebaum Cancer Center

Sunday, June 5, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Myeloma

Location: E354a

CME credit: 3

Track(s): Lymphoma and Plasma Cell Disorders

Andrzej J. Jakubowiak, MD, PhD—Co-Chair

University of Michigan

Taimur Sher, MBBS—Co-Chair

Roswell Park Cancer Institute

9:30 AM Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. (Abstract #8007)

A. P. Palumbo, M. Delforge, J. Catalano, R. Hajek, M. Kropff, M. Petrucci, Z. Yu, J. M. Mei, M. A. Dimopoulos

9:45 AM Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). (Abstract #8008)

A. C. Rossi, T. M. Mark, D. Jayabalan, P. J. Christos, F. Zafar, K. Pekle, T. Shore, R. N. Pearse, J. Leonard, S. Chen-Kiang, M. Coleman, R. Niesvizky

10:00 AM Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010. (Abstract #8009)

M. A. Dimopoulos, R. Z. Orlowski, R. Niesvizky, S. Lonial, N. A. Brandenburg, D. M. Weber

Discussion

10:15 AM Ola Landgren, MD, PhD (Abstracts #8007–8009)
National Cancer Institute

10:30 AM Does zoledronic acid (ZOL) reduce skeletal-related events (SREs) and improve progression-free survival (PFS) in patients (Pts) with multiple myeloma (MM) with or without bone disease? MRC myeloma IX study results. (Abstract #8010)

K. Boyd, G. Morgan, F. Davies, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, J. A. Child

10:45 AM Are there temporal benefits to long-term bisphosphonate treatment in multiple myeloma (MM)? Insights from temporal analyses of zoledronic acid (ZOL) versus clodronate (CLO) in the MRC Myeloma IX Trial. (Abstract #8011)

F. Davies, G. Morgan, P. Wu, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child

Discussion

11:00 AM G. David Roodman, MD, PhD (Abstracts #8010–8011)
University of Pittsburgh Medical Center

11:15 AM Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma. (Abstract #8012)

N. S. Raje, R. J. Hohl, E. A. Faber, P. G. Richardson, A. Forero-Torres, G. J. Schiller, A. D. Cohen, S. P. Carpenter, D. Cronier, M. Pashkevich, J. Wooldrige, K. C. Anderson

SUNDAY

- 11:30 AM** **Phase I study of lorvotuzumab mertansine (LM, IMG901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). (Abstract #8013)**
J. G. Berdeja, S. Ailawadhi, S. D. Weitman, S. Zildjian, J. J. O'Leary, J. O'Keeffe, R. Guild, K. Whiteman, A. A. Chanan-Khan
- 11:45 AM** **Elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed multiple myeloma: A randomized phase II study. (Abstract #8014)**
P. G. Richardson, P. Moreau, A. J. Jakubowiak, T. Facon, S. Jagannath, R. Vij, D. E. Reece, D. White, M. Raab, L. Benboubker, J. Rossi, C. Tsao, T. Parli, D. M. Berman, A. K. Singhal, S. Lonial
- Discussion**
- 12:00 PM** Asher Alban Akmal Chanan-Khan, MD (Abstracts #8012–8014)
Roswell Park Cancer Institute

Sunday, June 5, 2011

**9:45 AM - 11:00 AM
SPECIAL SESSION**

Innovation in Delivering Quality Care in Low-resource Scenarios

Location: S504

CME credit: 1.25

Track(s): Health Services Research, International, Special Session

Clement Adebayo Adebamowo, MD, ScD—Chair

Institute of Human Virology, University of Maryland School of Medicine

Challenges for Improving the Quality of Care in Low-resource Scenarios

Benjamin O. Anderson, MD

University of Washington

Lessons from the Breast Health Global Initiative

William Tierney, MD

Indiana University School of Medicine

Solutions for Improving Quality in Low-resource Areas: Lessons Learned from HIV

SUNDAY

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Dutasteride, Fenasteride, Micronutrients, and Vitamins for Prostate Cancer Prevention: How Do We Apply What We Have Learned to the Community?

Location: S100a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology, Genitourinary Cancer

Ian Thompson, MD—Chair

University of Texas Health Science Center at San Antonio

PCPT and SELECT: The Southwest Oncology Group Experience

Gerald L. Andriole, MD

Washington University School of Medicine

Dutasteride and Prostate Cancer Prevention

Otis W. Brawley, MD

American Cancer Society

Translating Prostate Cancer Prevention Research to the Community: Barriers to Uptake

Integration of Molecularly Targeted Therapy and Chemotherapy in the Treatment of Advanced Head and Neck Cancers

Location: E354b

CME credit: 1.25

Track(s): Head and Neck Cancer

David G. Pfister, MD—Chair

Memorial Sloan-Kettering Cancer Center

Updates on Concomitant Chemoradiation

David Raben, MD

University of Colorado Denver

Integration of Targeted Therapy with Radiation

Athanassios Argiris, MD, PhD

University of Pittsburgh

Molecularly Targeted Therapy and Combinations with Chemotherapy for Recurrent/Metastatic Head and Neck Cancer

Moving the Bar in Upper Gastrointestinal Malignancies: A Review of Recent Upper Gastrointestinal Phase III Studies—Clinically Meaningful or Just Statistically Positive? (eQuestions Session)

Location: Hall D2

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer

Eileen Mary O'Reilly, MD—Chair

Memorial Sloan-Kettering Cancer Center

Review of Recent Phase III Studies in Upper Gastrointestinal Malignancies

Neal J. Meropol, MD

Case Western Reserve University

Health Care Economics in Relation to Upper Gastrointestinal Cancers

Donna Niedzwiecki, PhD

Duke University

Statistical Review of the Benefit: Is It Meaningful?

Sunday, June 5, 2011

Weight of Evidence: Associations between Body Weight and Health Outcomes (Including Survival) in Cancer Populations

Location: S406

CME credit: 1.25

Track(s): Patient and Survivor Care, Cancer Prevention/Epidemiology, General Oncology

Jennifer A. Ligibel, MD—Chair

Dana-Farber Cancer Institute

Overview of the Current Evidence Supporting Body Weight Status, Adiposity, and Weight Loss on Cancer Outcomes

Rudolf Kaaks, PhD

German Cancer Research Center DKFZ

Biological Mechanisms whereby Weight Status and Weight Loss Affects Cancer Progression

Cheryl L. Rock, PhD

University of California, San Diego

Presentation of the ENERGY Trial in Terms of Rationale, Design, Methods, and Outcomes

SUNDAY

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION

CA-125 Use in Practice: The Promise and Pitfalls (M10)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Gynecologic Cancer

Robert C. Bast, MD

University of Texas M. D. Anderson Cancer Center

Current State and Future Use of CA-125 in the Management of Ovarian Cancer

M. E. L. Van Der Burg, MD, PhD

Erasmus University Medical Center

Breaking the Addiction to CA-125

9:45 AM - 11:00 AM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Treatment of HIV-related Lymphomas: Integration of New Strategies to Control and Monitor HIV while Treating High-risk Lymphomas (C08)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

Amrita Y. Krishnan, MD—Chair

City of Hope

Stem Cell Transplantation for Treatment of HIV-related Malignancies

Steven G. Deeks, MD

University of California, San Francisco School of Medicine

Therapy of HIV Infection: New Antiretrovirals and Monitoring Strategies

Wyndham Hopkins Wilson, MD, PhD

National Cancer Institute

Overview of HIV-related Lymphoma

Sunday, June 5, 2011

**10:30 AM - 12:30 PM
SPECIAL SESSION**

Training Program Directors Session: Talking Business—The Finances of Your Program and Teaching Interprofessional Communication Skills (Training Program Directors Only)

Location: S404

CME credit: 2

Track(s): Special Session, Professional Development

Thomas H. Davis, MD—Chair

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center

Welcome and Introduction

Walter F. Baile, MD

University of Texas M. D. Anderson Cancer Center

The Principles of Communication Mentoring

Daniel E. Epner, MD

University of Texas M. D. Anderson Cancer Center

Measuring Competency in Communication

Lori K. Mihalich-Levin, JD

Association of American Medical Colleges

Medicare Funding of Graduate Medical Education: Fundamentals and the Future

Robert A. Wolff, MD

University of Texas M. D. Anderson Cancer Center

The Business of Running a Training Program: Microeconomics

SUNDAY

11:30 AM - 12:45 PM
EDUCATION SESSIONS

Advanced Renal Cell Cancer: Which Drug to Use and in What Way?
(eQuestions Session)

Location: Hall D2

CME credit: 1.25

Track(s): Genitourinary Cancer

Sandy Srinivas, MD—Chair

Stanford Medical Center

Today's Renal Cell Cancer Therapeutic Landscape

Thomas E. Hutson, DO, PharmD

Baylor Sammons Cancer Center-Texas Oncology PA

Management of Unique Subsets of Patients with Renal Cell Cancer

Eric Jonasch, MD

University of Texas M. D. Anderson Cancer Center

Sequential versus Combination Therapy: Which One Wins?

Diabetes and Antidiabetic Drugs: Association with Cancer Risk and Potential for Primary and Secondary Prevention

Location: S100a

CME credit: 1.25

Track(s): Cancer Prevention/Epidemiology

Pamela Jean Goodwin, MD—Chair

Mount Sinai Hospital

Metformin and Cancer Prevention

Lorraine Lipscombe, MD

University of Toronto

Association of Diabetes and Cancer: Epidemiology Data

Ann D. Thor, MD

University of Colorado Denver

Metformin: In Vivo and in Vitro Studies

Is Patient and Physician Acceptance of Palliative and End-of-Life Care Socially and Culturally Determined?

Location: E353

CME credit: 1.25

Track(s): Ethics, Patient and Survivor Care, Professional Development

Antonella Surbone, MD, PhD—Chair

New York University

Variables in Patients' and Caregivers' Acceptance of Palliative and End-of-Life Care

Guido Biasco, MD

University of Bologna

Cultural Dynamics in Providing Palliative Care

Marjorie Kagawa-Singer, PhD, MA, MN, RN

University of California, Los Angeles School of Public Health

Overcoming Patients, Caregivers, and Health Professionals Cross-cultural Differences at the End of Life

Sunday, June 5, 2011

Melanoma: Therapeutic Decisions for the Practicing Oncologist in 2011

Location: E354b

CME credit: 1.25

Track(s): Melanoma/Skin Cancers, General Oncology

Antoni Ribas, MD—Chair

Jonsson Comprehensive Cancer Center, University of California, Los Angeles

Immunotherapeutic Options in Advanced Melanoma (IL-2, Ipilimumab, Adoptive Cell Therapy, GM-CSF)

Jeffrey Alan Sosman, MD

Vanderbilt University Medical Center

State of Targeted Therapy and How Testing and Treatment Can Be Incorporated into the Care of Patients with Melanoma in 2011

Christopher D. Lao, MD

University of Michigan

When Is Cytotoxic Therapy or Palliative Therapy Indicated in the Era of Increasing Therapeutic and Clinical Trial Options

SUNDAY

11:30 AM - 12:45 PM
MEET THE PROFESSOR SESSION

Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer (M11)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Head and Neck Cancer

Michael Xing, MD, PhD

The Johns Hopkins University

Prognostic Utility of B-RAF Mutation in the Management of Papillary Thyroid Cancer

11:30 AM - 12:45 PM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Doctor, Is There Any Hope? Communicating Prognosis while Maintaining Hope at the End of Life (C09)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Professional Development, Ethics, Patient and Survivor Care

Ross C. Donehower, MD—Chair

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Developing Effective Communication Strategies to Discuss Poor Prognosis

Philip C. Hoffman, MD

University of Chicago Medical Center

Managing End-of-Life Decisions

1:00 PM - 4:00 PM
PLENARY SESSION

Plenary Session Including Science of Oncology Award and Lecture

Location: Hall B1

CME credit: 3

Track(s): Special Session, General Oncology

Kathy Miller, MD—Co-Chair

Indiana University Simon Cancer Center

George W. Sledge Jr., MD—Co-Chair

Indiana University of Simon Cancer Center

1:00 PM Robert Weinberg, PhD—Science of Oncology Award Recipient
Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology
The EMT and the Pathogenesis of High-grade Carcinomas

1:45 PM Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO). (Abstract #LBA1)
H. Joensuu, M. Eriksson, J. Hatrmann, K. Sundby Hall, J. Schutte, A. Reichardt, M. Schlemmer, E. Wardelmann, G. Ramadori, S. E. Al-Batran, B. E. Nilsson, O. Monge, R. Kallio, M. Sarlomo-Rikala P. Bono, M. Leinonen, P. Hohenberger, T. Alvegard, P. Reichardt

Discussion

2:00 PM Charles D. Blanke, MD (Abstract #LBA1)
University of British Columbia/British Columbia Cancer Agency

2:15 PM Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. (Abstract #2)
R. L. Ladenstein, U. Poetschger, R. Luksch, P. Brock, V. Castel, I. Yaniv, V. Papadakis, G. Laureys, J. Malis, W. Balwierz, E. Ruud, P. Kogner, H. Schroeder, A. Forjaz De Lacerda, M. Beck Popovic, P. Bician, M. Garami, T. Trahair, A. D. Pearson, D. Valteau Couanet

Discussion

2:30 PM Julie R. Park, MD (Abstract #2)
Seattle Children's Hospital

2:45 PM Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (Abstract #3)
E. C. Larsen, W. L. Salzer, M. Devidas, J. B. Nachman, E. A. Raetz, M. L. Loh, N. A. Heerema, A. J. Carroll, J. M. Gastier-Foster, M. J. Borowitz, B. L. Wood, C. L. Willman, N. J. Winick, S. Hunger, W. L. Carroll

Discussion

3:00 PM Martin S. Tallman, MD (Abstract #3)
Memorial Sloan-Kettering Cancer Center

3:15 PM Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with ^{V600E}BRAF-mutated melanoma. (Abstract #LBA4)
P. B. Chapman, A. Hauschild, C. Robert, J. M. G. Larkin, J. B. A. G. Haanen, A. Ribas, D. Hogg, S. O'Day, P. A. Ascierto, A. Testori, P. Lorigan, R. Dummer, J. A. Sosman, C. Garbe, R. J. Lee, K. B. Nolop, B. Nelson, J. Hou, K. T. Flaherty, and G. A. McArthur

3:30 PM Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. (Abstract #LBA5)

J. D. Wolchok, L. Thomas, I. N. Bondarenko, S. O'Day, J. S. Weber, C. Garbe, S. Francis, R. A. Ibrahim, A. Hoos, and C. Robert

Discussion

3:45 PM Kim Allyson Margolin, MD (Abstracts #LBA4–LBA5)
University of Washington

Sunday, June 5, 2011

4:30 PM - 5:30 PM
CLINICAL SCIENCE SYMPOSIUM

Antiangiogenic Therapies and Biomarkers in Pediatric Cancer

Location: S504

CME credit: 1

Track(s): Pediatric Oncology

Steven G. DuBois, MD—Chair

University of California, San Francisco

4:30 PM Phase I study of bevacizumab, sorafenib, and low-dose cyclophosphamide (CYC) in children and young adults with refractory solid tumors. (Abstract #9500)

V. M. Santana, S. D. Baker, B. McCarville, C. F. Stewart, J. Wu, C. Billups, S. L. Spunt, W. L. Furman, L. M. McGregor, S. Hu, J. C. Panetta, W. E. Reddick, A. Davidoff, W. H. Leung, F. Navid

4:45 PM Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium Trial. (Abstract #9501)

J. L. Glade Bender, A. Lee, P. C. Adamson, A. M. Ingle, C. H. Ahern, B. Wu, S. Baruchel, P. J. Harris, M. M. Ames, B. Weigel, S. Blaney, Children's Oncology Group

5:00 PM Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. (Abstract #9502)

S. Baruchel, B. Wu, R. B. Mokhtari, J. L. Glade Bender, S. G. DuBois, B. C. Widemann, J. R. Park, D. Stempak, C. H. Ahern, B. Weigel

Discussion

5:15 PM Michael L. Maitland, MD, PhD (Abstracts #9500–9502)
The University of Chicago

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

Geriatric Biology, Screening Tools, Dose Intensity, and Impact on Survival

Location: S406

CME credit: 1.5

Track(s): Patient and Survivor Care, Geriatric Oncology

Gretchen Genevieve Kimmick, MD, MS—Co-Chair

Duke University Medical Center

Christine Ritchie, MD, MSPH—Co-Chair

University of Alabama at Birmingham

4:30 PM Relationship between components of the comprehensive geriatric assessment (CGA), chemotherapy dose intensity, and overall survival in a colorectal cancer (CRC) cohort age 65 and older. (Abstract #9000)
E. E. Ramsdale, B. N. Polite, K. A. Bylow, H. L. Kindler, W. Dale

4:45 PM Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. (Abstract #9001)
P. Soubeyran, C. Bellera, J. Goyard, D. Heitz, H. Cure, H. Rousselot, G. Albrand, V. Servent, O. Saint Jean, C. Roy, S. Mathoulin-Pelissier, M. Rainfray

Discussion

5:00 PM Gretchen Genevieve Kimmick, MD, MS (Abstract #9001)
Duke University Medical Center

5:15 PM P16^{INK4a} expression after chemotherapy in older women with early-stage breast cancer. (Abstract #9002)
H. B. Muss, J. Krishnamurthy, S. M. Alston, A. C. Lacy, T. A. Jolly, G. Williams, L. A. Carey, E. C. Dees, C. K. Anders, W. J. Irvin Jr., N. E. Sharpless

5:30 PM Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo). (Abstract #9003)
H. D. Klepin, A. Gajra, M. Hardt, W. P. Tew, S. G. Mohile, C. Owusu, C. P. Gross, S. M. Lichtman, R. Ramani, V. Katheria, J. Brown, R. Jayani, K. Hansen, K. Togawa, S. Klapper, F. L. Wong, A. Hurria, on behalf of the Cancer and Aging Research Group

Discussion

5:45 PM Matti S. Aapro, MD (Abstracts #9002–9003)
Clinique De Genolier

Sunday, June 5, 2011

4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM

PK/PD According to Dr. Merrill Egorin: A Tribute to a Great Translational Scientist

Location: Arie Crown Theater

CME credit: 1.5

Track(s): Developmental Therapeutics

Duncan Ian Jodrell, MSc, DM, MRCP—Co-Chair

NIHR Cambridge Biomedical Research Centre

S. Percy Ivy, MD—Co-Chair

National Cancer Institute

4:30 PM Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. (Abstract #3000)

P. LoRusso, J. J. Ji, J. Li, L. K. Heilbrun, G. Shapiro, E. A. Sausville, S. A. Boerner, D. W. Smith, M. Pilat, J. Zhang, A. P. Chen, N. Nechiporchik, R. E. Parchment

Discussion

4:45 PM James H. Doroshow, MD (Abstract #3000)
National Cancer Institute

5:00 PM Final results of a translational phase I study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. (Abstract #3001^)

T. A. Yap, L. Yan, A. Patnaik, D. Olmos, I. Fearen, R. D. Baird, K. P. Papadopoulos, N. Tunariu, A. Biondo, H. Keilhack, L. M. Delgado, A. Taylor, S. C. Blackman, C. L. Carpenter, S. Decordova, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher

Discussion

5:15 PM Jerry M. Collins, PhD (Abstract #3001^)
National Cancer Institute

5:30 PM Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors. (Abstract #3002)

S. F. Jones, G. Shapiro, J. C. Bendell, E. X. Chen, P. Bedard, J. M. Cleary, S. Pandya, K. J. Pierce, B. Houk, N. Hosea, K. S. Zandi, W. G. Roberts, S. M. Shreeve, L. L. Siu

Discussion

5:45 PM Alan Hilary Calvert, MD (Abstract #3002)
University College London

**4:30 PM - 6:00 PM
CLINICAL SCIENCE SYMPOSIUM**

Predictive Markers in Breast Cancer: How Many Tests Do We Need, and What Do They Tell Us?

Location: Hall B1

CME credit: 1.5

Track(s): Breast Cancer

Harold J. Burstein, MD, PhD—Chair

Dana-Farber Cancer Institute

4:30 PM Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X), in high-risk EBC: Exploratory Ki-67 analyses. (Abstract #500)

J. E. Phippen, D. Paul, C. T. Stokoe, J. L. Blum, L. Krekow, F. A. Holmes, D. L. Lindquist, S. M. Sedlacek, R. R. Rivera, R. J. Brooks, S. J. Vukelja, K. McIntyre, C. Lopez-Diaz, J. O'Shaughnessy

4:45 PM Neoadjuvant anastrozole or tamoxifen for premenopausal breast cancer: Ki67 expression data from the STAGE study. (Abstract #501^)

T. Kinoshita, N. Masuda, Y. Sagara, H. Iwata, S. Nakamura, Y. Yanagita, R. Nishimura, H. Iwase, S. Kamigaki, H. Takei, H. Tsuda, S. Noguchi

Discussion

5:00 PM Mitchell Dowsett, PhD (Abstracts #500–501^)
The Royal Marsden Hospital

5:15 PM Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. (Abstract #502)

A. Prat, J. S. Parker, C. Fan, M. Cheang, L. D. Miller, J. Bergh, S. K. Chia, P. S. Bernard, T. O. Nielsen, M. J. Ellis, L. A. Carey, C. M. Perou

5:30 PM Using the PAM50 breast cancer intrinsic classifier to assess risk in ER+ breast cancers: A direct comparison to Oncotype DX. (Abstract #503)

R. R. Bastien, M. T. Ebbert, K. M. Boucher, C. M. Kelly, B. Wang, T. Iwamoto, S. Krishnamurthy, L. Pusztai, P. S. Bernard

Discussion

5:45 PM Daniel F. Hayes, MD (Abstracts #502–503)
University of Michigan Medical Center

Sunday, June 5, 2011

4:45 PM - 6:00 PM
SPECIAL SESSION

B. J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Location: S100bc

CME credit: 1.25

Track(s): Special Session, Geriatric Oncology

John M. Bennett, MD

University of Rochester Medical Center

Enhancing Geriatric Oncology Training to Care for Elders with Malignancies

SUNDAY

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Chronic Lymphocytic Leukemia Therapy: An Update on Frontline and Novel Therapies

Location: E354b

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Susan Mary O'Brien, MD—Chair

University of Texas M. D. Anderson Cancer Center

Novel Therapies in Chronic Lymphocytic Leukemia

Michael J. Hallek, MD

University of Cologne

Update on Frontline Therapy for Chronic Lymphocytic Leukemia: Is Fludarabine, Cyclophosphamide, and Rituximab (FCR Regimen) the Treatment of Choice?

John C. Byrd, MD

The Ohio State University Comprehensive Cancer Center and Arthur G. James Cancer Hospital and Solove Research Institute

Molecular, Biochemical, and Clinical Predictive Factors in Chronic Lymphocytic Leukemia: An Update

Clinical Problems in Management of Multiple Myeloma (eQuestions Session)

Location: Hall D2

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders, General Oncology

Asher Alban Akmal Chanan-Khan, MD—Chair

Roswell Park Cancer Institute

Complications of Antimyeloma Therapies

Ivan Borrello, MD

The Johns Hopkins University School of Medicine

Smoldering and Asymptomatic Myeloma

G. David Roodman, MD, PhD

University of Pittsburgh Medical Center

Bone Disease and Its Management in Multiple Myeloma

Early-phase Cancer Clinical Trials: Are the Goals Therapeutic or Scientific?

Location: E353

CME credit: 1.25

Track(s): Ethics, Clinical Trials, Developmental Therapeutics

Steven Joffe, MD, MPH—Chair

Dana-Farber Cancer Institute

Introduction to the Ethics of Early-phase Clinical Trials

Nancy King, JD

Wake Forest University School of Medicine

The Need to Emphasize the Research Orientation of Early-phase Clinical Trials

Razelle Kurzrock, MD

University of Texas M. D. Anderson Cancer Center

Early-phase Trials as Optimal Therapy in Some Settings

Sunday, June 5, 2011

Genetic Syndromes in Upper Gastrointestinal Cancer for the Clinical Oncologist: Syndromes, Testing, and Screening

Location: Hall D1

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer, Cancer Genetics

Manish A. Shah, MD—Chair

Memorial Sloan-Kettering Cancer Center

Incidence of Hereditary Upper Gastrointestinal Cancers: How Common Are They and What Are the Genetic Considerations?

Zsofia Kinga Stadler, MD

Memorial Sloan-Kettering Cancer Center

Genetic Testing: Indications, Insurance/Legal Ramifications, and What Tests Should Be Done

Marcia Canto, M.D.

The Johns Hopkins University

Indications for Screening: Pancreatic, Esophageal, and Stomach Cancers

Inclusion of Patients with Brain Metastases in Clinical Trials

Location: E354a

CME credit: 1.25

Track(s): Clinical Trials, Central Nervous System Tumors, Developmental Therapeutics

Lauren E. Abrey, MD—Chair

Memorial Sloan-Kettering Cancer Center

Overview of the Treatment of Brain Metastases in Patients with Solid Tumors

Karen Kelly, MD

University of California, Davis Cancer Center

Pharmacokinetic/Pharmacodynamic Issues in the Treatment of Brain Metastases

Minesh P. Mehta, MD

Northwestern University

Radiation Therapy for Brain Metastases: Techniques, Trials, and Outcomes

Next-generation Therapeutic Targets and Drugs

Location: S404

CME credit: 1.25

Track(s): Tumor Biology, Developmental Therapeutics

Kapil N. Bhalla, MD—Chair

University of Kansas Cancer Center

Molecular Chaperones in Tumor Biology and Therapy

Jean-Pierre J. Issa, MD

University of Texas M. D. Anderson Cancer Center

Deregulated Epigenetic Mechanisms: Developing Therapeutic Opportunities

Anil Sood, MD

University of Texas M. D. Anderson Cancer Center

siRNA and miRNA Therapeutics: Rapid Translation from Bench to Bedside

SUNDAY

You Can Write an Outstanding Manuscript

Location: S100a

CME credit: 1.25

Track(s): Professional Development

Daniel G. Haller, MD—Chair

University of Pennsylvania

An Editor's Perspective

Stephen A. Cannistra, MD

Beth Israel Deaconess Medical Center

How to Reach Meaningful Conclusions

Cynthia Dunbar, MD

National Heart, Lung, and Blood Institute

How to Present Data Effectively

Sunday, June 5, 2011

4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION

Therapy of the Elderly Patient with Acute Myeloid Leukemia (M12)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation, Geriatric Oncology

Charles Alan Schiffer, MD

Wayne State University

Therapy of the Elderly Patient with Acute Myeloid Leukemia

Harry Paul Erba, MD, PhD

University of Michigan Medical Center

Controversies in Treating the Elderly Patient with Acute Myeloid Leukemia

4:45 PM - 6:00 PM
CLINICAL PROBLEMS IN ONCOLOGY SESSION

Current State of Neuro-oncology: Successes, Failures, and the Future (C10)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Central Nervous System Tumors

John L. Villano, MD, PhD—Chair

University of Illinois

Henry S. Friedman, MD

Duke University Medical Center

Jan C. Buckner, MD

Mayo Clinic

SUNDAY

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY SESSION

Highlights of the Day II Including Partners in Progress Award

Location: Hall D1

CME credit: 1.5

Track(s): Special Session, General Oncology

Charles D. Blanke, MD—Chair

University of British Columbia/British Columbia Cancer Agency

7:30 AM

Benjamin O. Anderson, MD—Partners in Progress Award Recipient

University of Washington

7:40 AM

Stephen R. D. Johnston, MA, MD, PhD

Royal Marsden Hospital

Breast Cancer—HER2/ER

7:55 AM

Jyoti D. Patel, MD

Northwestern University

Lung Cancer—Metastatic/Non-small Cell

8:10 AM

Ivan Borrello, MD

The Johns Hopkins University School of Medicine

Myeloma

8:25 AM

Gregory T. Armstrong, MD, MSCE

St. Jude Children's Research Hospital

Pediatric Oncology

Monday, June 6, 2011

**8:00 AM - 9:15 AM
SPECIAL SESSION**

ASCO/European Society for Medical Oncology (ESMO) Joint Session: Cancer in Low- and Middle-income Countries

Location: S406

CME credit: 1.25

Track(s): Developmental Therapeutics, Clinical Trials, International, Special Session

David J. Kerr, MD, PhD—Co-Chair

University of Oxford

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

Peter Boyle, PhD

International Prevention Research Institute

Epidemiologic Overview of Cancer in Low- and Middle-income Countries

Jan Agosti, MD

Bill and Melinda Gates Foundation

Cervical Cancer and HPV Vaccines in Low- and Middle-income Countries

Henry L. Y. Chan, MD

Chinese University of Hong Kong

Hepatocellular Carcinoma: Prevention and Control in Low- and Middle-income Countries

MONDAY

8:00 AM - 9:15 AM
EDUCATION SESSIONS

Breast Cancer in Older Women: The Whole Picture

Location: Hall B1

CME credit: 1.25

Track(s): Breast Cancer, Geriatric Oncology, International

Richard C. Zellars, MD—Chair

The Johns Hopkins University School of Medicine

Locoregional Implications for Therapy in Older Women

Arti Hurria, MD

City of Hope

Patterns of Care and Outcomes Disparities in Older Patients inside and outside of the United States

Hyman Bernard Muss, MD

University of North Carolina Lineberger Comprehensive Cancer Center

Overview and Medical Therapeutic Implications of Breast Cancer in Elderly Patients

Communicating Effectively across the Trajectory of Cancer Care and Survivorship (eQuestions Session)

Location: E353

CME credit: 1.25

Track(s): Patient and Survivor Care, Health Services Research

Edward G. Shaw, MD—Chair

Wake Forest University School of Medicine

Communication from the Perspective of the Physician

Neeraj Arora, PhD

National Cancer Institute

Enhancing the “Patient Centeredness” of Communication between the Care Team and Patients and Their Family Members: Understanding Patient Perspectives

Jessie Gruman, PhD

Center for Advancing Health

Communication on Both the Giving and Receiving End: Perspectives from a Physician and a Patient

Intraperitoneal Chemotherapy and Cytoreductive Surgery in Colon Cancer: A Debate

Location: Arie Crown Theater

CME credit: 1.25

Track(s): Gastrointestinal (Colorectal) Cancer

David P. Ryan, MD—Chair

Massachusetts General Hospital and Harvard Medical School

Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: Stop Selecting Patients and Start Proving Efficacy

Paul H. Sugarbaker, MD

Washington Hospital Center

Surgical Debulking and Hyperthermic Chemotherapy for Metastatic Colon Cancer: If You Select the Right Patients, Long-term Survival Can Be Achieved

Monday, June 6, 2011

Optimizing the Use of Alkylators in Neuro-oncology

Location: S100a

CME credit: 1.25

Track(s): Central Nervous System Tumors

James R. Perry, MD—Chair

Sunnybrook Health Sciences Centre

Temozolomide in Upfront Therapy for Low- and High-grade Gliomas

Wolfgang Wick, MD

University Hospital Heidelberg

Temozolomide in Refractory Disease-alternative Schedules

Michael Weller, MD

University Hospital Zurich

What about the Older Generation Alkylators? Revisiting the Role of Nitrosoureas in Neuro-oncology

The Patient Protection and Affordable Care Act of 2010: Reform Initiatives and Their Implications

Location: E354b

CME credit: 1.25

Track(s): Health Services Research, Practice Management and Information Technology

David Christopher Miller, MD, MPH—Chair

University of Michigan

ACOs and Their Implications for Cancer-related Quality and Spending

Lee Nisley Newcomer, MD

United Health Group

Payment Bundling and Its Implications for Improving Cancer-related Quality

Scott Gottlieb, MD

American Enterprise Institute for Public Policy Research

The IPAB and Implications for Cancer-related Medicare Spending

Transition from Therapy Improvement to Potential Cure for Chronic Myelogenous Leukemia: Roadblocks and Opportunities

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Moshe Talpaz, MD—Chair

University of Michigan Comprehensive Cancer Center

The Frontline Therapy of Chronic Myelogenous Leukemia: Nilotinib or Imatinib?

Jorge E. Cortes, MD

University of Texas M. D. Anderson Cancer Center

Resistant Disease: Assessment, Monitoring, and Therapy

Ravi Bhatia, MD

City of Hope

The Chronic Myelogenous Leukemia Stem Cell: The Roadblock to Cure?

MONDAY

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSIONS

Management of Neuroendocrine Tumors of the Lung Exclusive of Small Cell Lung Cancer (M13)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Lung Cancer

William D. Travis, MD

Memorial Sloan-Kettering Cancer Center

Neuroendocrine Tumors of the Lung: Update on Histology

Update in Hereditary Renal Cancer (M20)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Cancer Genetics, Genitourinary Cancer

W. Marston Linehan, MD

National Institutes of Health

Monday, June 6, 2011

8:00 AM - 11:00 AM
ORAL ABSTRACT SESSION

Genitourinary (Nonprostate) Cancer

Location: Hall D2

CME credit: 3

Track(s): Genitourinary Cancer

Evan Y. Yu, MD—Co-Chair

Fred Hutchinson Cancer Research Center

Carsten Bokemeyer, MD—Co-Chair

University Medical Center Hamburg-Eppendorf

- 8:00 AM** **Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. (Abstract #4503)**
B. I. Rini, B. Escudier, P. Tomczak, A. Kaprin, T. E. Hutson, C. Szczylik, J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer
- 8:15 AM** **Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). (Abstract #4504)**
D. Cella, B. Escudier, B. I. Rini, C. Chen, H. Bhattacharyya, J. C. Tarazi, B. Rosbrook, S. Kim, R. J. Motzer
- 8:30 AM** **Final results from an EORTC (GU Group)/NCRI randomized phase III trial of adjuvant interleukin-2, interferon alpha, and 5-fluorouracil in patients with a high risk of relapse after nephrectomy for renal cell carcinoma (RCC). (Abstract #4505)**
M. Aitchison, C. A. Bray, H. Van Poppel, R. Sylvester, J. Graham, C. Innes, L. McMahon, P. A. Vasey
- 8:45 AM** **Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (Abstract #4506)**
F. A. Schutz, K. P. Gray, M. Pomerantz, M. B. Atkins, J. E. Rosenberg, M. S. Hirsch, D. F. McDermott, G. M. Lee, S. Signoretti, P. W. Kantoff, M. L. Freedman, T. K. Choueiri

Discussion

- 9:00 AM** Bruce G. Redman, DO (Abstracts #4503–4506)
University of Michigan
- 9:15 AM** **Superior survival after sequential high-dose chemotherapy (HDCT) as compared to single HDCT in patients with relapsed or refractory germ cell tumors (GCT): Six-year long-term follow-up of a prospective, randomized phase II trial. (Abstract #4507)**
A. Lorch, A. Kleinhans, A. Kramar, J. T. Hartmann, C. Bokemeyer, O. Rick, J. Beyer, for the German Testicular Cancer Study Group
- 9:30 AM** **A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604). (Abstract #4508)**
R. A. Huddart, R. Gabe, F. Cafferty, P. Pollock, J. D. White, J. Shamash, S. P. Stenning, TE23 Trial Management Group and Collaborators, NCRI Testis Cancer Clinical Studies Group
- 9:45 AM** **A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). (Abstract #4509)**
R. De Wit, I. A. Skoneczna, K. Gedske Daugaard, M. de Santis, A. Garin, N. Aass, J. A. Witjes, P. Albers, J. White, J. Germa-Lluch, S. Osanto, S. Marreaud, L. Collette

Discussion

- 10:00 AM** Christopher Sweeney, MBBS (Abstracts #4507–4509)
Dana-Farber Cancer Institute

10:15 AM **Prospective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin [MVAC] versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial cancer. (Abstract #4510)**

A. Bamias, A. Karadimou, S. Lampaki, G. Aravantinos, I. Xanthakis, C. Papandreou, G. Lainakis, F. Zagouri, N. Soupos, E. Kostouros, E. Samantas, C. Hatzimouratidis, C. Konstantinidis, C. Deliveliotis, D. G. Pectasides, G. Fountzilas, M. A. Dimopoulos, Hellenic Cooperative Oncology Group

10:30 AM **Association of germ-line variation with platinum-based chemotherapy response in patients (pts) with urothelial carcinoma (UC). (Abstract #4511)**

D. J. Gallagher, V. Joseph, R. J. Hamilton, I. Ostrovnaya, I. R. Garcia-Grossman, J. C. Riches, A. M. Regazzi, J. A. Przybylo, M. Gaudet, M. I. Milowsky, K. Offit, D. F. Bajorin

Discussion

10:45 AM Maria De Santis, MD (Abstracts #4510–4511)
KFJ Spital Austria

Monday, June 6, 2011

8:00 AM - 11:00 AM
ORAL ABSTRACT SESSION

Pediatric Oncology II

Location: S504

CME credit: 3

Track(s): Pediatric Oncology

Edward F. Attiyeh, MD—Co-Chair

Children's Hospital of Philadelphia

Alejandro Gutierrez, MD—Co-Chair

Dana-Farber Cancer Center

- 8:00 AM** **The prognostic value of semi-quantitative ¹²³I mIBG scintigraphy at diagnosis in high-risk neuroblastoma: Validation of the SIOPEN score method. (Abstract #9511)**
V. Lewington, U. Poetschger, A. Boubaker, Z. Bar-Sever, B. Drake, A. Staudenherz, M. Castellani, B. Lambert, K. Grange, P. Brock, A. Garaventa Sr., I. Yaniv, D. Valteau Couanet, V. Castel, A. Forjaz De Lacerda, J. Malis, H. Schroeder, R. Luksch, K. Beiske, R. L. Ladenstein
- 8:15 AM** **Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. (Abstract #9512)**
K. K. Matthey, B. D. Weiss, J. Villablanca, J. M. Maris, G. A. Yanik, S. G. Groshen, H. Jackson, R. Hawkins, F. Goodarziyan, A. Panigrahy, S. G. DuBois, J. Stubbs, A. Towbin, J. A. Barrett, N. D. LaFrance, J. W. Babich
- 8:30 AM** **Phase I study of vincristine, irinotecan, and ¹³¹I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. (Abstract #9513)**
S. G. DuBois, L. Chesler, S. G. Groshen, R. Hawkins, F. Goodarziyan, G. A. Yanik, C. F. Stewart, Y. P. Mosse, J. M. Maris, J. Villablanca, K. K. Matthey

Discussion

- 8:45 AM** Mark Gaze, MD (Abstracts #9511–9513)
University College London
- 9:00 AM** **Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy. (Abstract #9514)**
D. Weiser, M. Laudenslager, E. Rappaport, E. Carpenter, E. F. Attiyeh, S. Diskin, W. B. London, J. M. Maris, Y. P. Mosse
- 9:15 AM** **Ototoxicity in children with high-risk neuroblastoma: Prevalence, risk factors, and concordance of grading scales—A report from the Children's Oncology Group (COG). (Abstract #9515)**
W. Landier, K. R. Knight, F. L. Wong, J. K. Lee, O. Thomas, H. Kim, S. G. Kreissman, M. L. Schmidt, L. Chen, W. B. London, S. Bhatia, J. G. Gurney, Children's Oncology Group
- 9:30 AM** **Shorter duration therapy that includes vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children's Oncology Group (COG). (Abstract #9516)**
D. Walterhouse, A. S. Pappo, J. L. Meza, J. C. Breneman, A. A. Hayes-Jordan, D. Parham, T. P. Cripe, W. H. Meyer, D. S. Hawkins
- 9:45 AM** **Randomized comparison of VAC versus VAI chemotherapy (CT) as consolidation for standard risk (SR) Ewing sarcoma tumor (ES): Results of the Euro-EWING.99-R1 trial. (Abstract #9517)**
O. Oberlin, M. Le Deley, U. Dirksen, I. J. Lewis, A. Ranft, J. M. Michon, M. Paulussen, J. Whelan, R. L. Ladenstein, B. Brennan, P. Marec Bérard, V. Laurence, H. Van Den Berg, L. Hjorth, C. Douglas, K. Wheatley, M. M. Van Glabbeke, I. R. Judson, A. W. Craft, H. Juergens, European Ewing Tumour Working Initiative of National Groups

10:00 AM Outcome of Head Start III multinational protocol for newly diagnosed central nervous system (CNS) primitive neuroectodermal tumors (pnet) of young children. (Abstract #9519)

T. B. Davidson, L. Ji, K. Haley, G. Dhall, J. P. Grimm, F. H. Gilles, S. L. Gardner, J. C. Allen, A. A. Bedros, M. M. Etzl, R. S. Olshefski, A. Cornelius, J. Torkildson, G. A. Kennedy, J. R. Fangusaro, S. R. Rassekh, M. J. Joyce, S. J. Bertolone, R. Sposto, J. L. Finlay

Discussion

10:15 AM Roger Packer, MD (Abstract #9519)
Children's National Medical Center

10:30 AM Relevance of germ-line genetic variations for treatment response in pediatric osteosarcoma patients. (Abstract #9518)

M. Hagleitner, P. Hoogerbrugge, B. W. Schreuder, U. E. Flucke, M. J. Coenen, D. M. Te Loo

Monday, June 6, 2011

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Location: Hall A

Track(s): Developmental Therapeutics

- Brd. 1A** Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand. (Abstract #2540)
D. J. Schwartzenruber, J. M. Kirkwood, M. J. Guarino, J. M. Richards, O. Hamid, S. O'Day, J. J. Nemunaitis, J. E. Talmadge, S. Chada, K. B. Menander, K. Shafer-Weaver, J. H. Senesac, M. O. Thornton, J. J. Lewis, R. B. Herberman
- Brd. 1B** Effect of a costimulatory endodomain on the performance of T cells expressing CD19-directed chimeric antigen receptors (CARs) in subjects with relapsed/refractory B-cell malignancies (Abstract #2541)
C. A. Ramos, B. Savoldo, E. Liu, C. M. Bollard, M. P. Mims, M. J. Keating, A. P. Gee, Z. Mei, C. M. Rooney, H. E. Heslop, M. K. Brenner, G. Dotti
- Brd. 1C** Identification of pre- and post-treatment markers of efficacy in patients with renal cancer treated with MVA-5T4 in a phase III study. (Abstract #2542)
R. Harrop, W. H. Shingler, M. McDonald, P. Treasure, R. J. Amato, R. E. Hawkins, H. Kaufman, J. de Belin, M. Goonewardena, S. Naylor
- Brd. 1D** Phase II trial of linifanib in patients (pts) with advanced renal cell carcinoma (RCC): Analysis of pts receiving extended therapy. (Abstract #2543)
E. M. Posadas, N. M. Tannir, Y. Wong, M. S. Ernstoff, C. K. Kollmannsberger, J. Qian, P. J. Ansell, E. M. McKeegan, M. D. McKee, J. L. Ricker, D. M. Carlson, D. Michaelson
- Brd. 1E** Eribulin dosing in patients with advanced solid tumors and hepatic impairment. (Abstract #2544)
L. A. Devriese, P. Witteveen, E. E. Voest, E. N. Overkleeft, M. Langenberg, J. H. Beijnen, L. Reyderman, J. Wanders, D. R. Mould, A. Gupta, Z. Hussein, J. H. Schellens
- Brd. 1F** The role of the electrocardiogram (ECG) in phase I drug development in patients with cancer: The University of Texas M. D. Anderson Cancer Center experience with 8,966 ECGs. (Abstract #2545)
H. Veasey Rodrigues, A. Naing, D. S. Hong, G. S. Falchook, S. Fu, J. J. Wheler, A. M. Tsimberidou, S. L. Moulder, F. Janku, S. Wen, S. N. Fessahaye, E. C. Golden, D. I. Westerhold, M. Ewer, R. Kurzrock
- Brd. 1G** A phase I study of once-weekly aminoflavone prodrug (AFP464) in solid tumor patients. (Abstract #2546)
M. P. Goetz, J. M. Reid, Y. Qi, A. Chen, R. M. McGovern, M. J. Kuffel, P. D. Scanlon, C. Erlichman, M. M. Ames
- Brd. 2A** The effect of enoxaparin on inflammatory and thrombotic mediators in cancer patients as studied using protein and biochip array approaches. (Abstract #2547)
D. Hoppensteadt, E. Litinas, H. Khan, J. Cunanan, I. Thethi, J. Fareed
- Brd. 2B** T-cells targeted with anti-CD3 x anti-HER2 bispecific antibody for treatment of women with stage IV breast cancer (phase I): Clinical and immune function results. (Abstract #2548)
L. G. Lum, R. Rathore, Z. Al-Kadhimi, P. Davol, A. Thakur, C. Pray, Q. Liu, E. Tomaszewski, F. Cummings, P. Steele, J. Wedge, N. Kouttab, A. Maizel, W. Colaiace, R. Joyrich, V. Ratanatharathorn, J. P. Uberti
- Brd. 2C** Population pharmacokinetics and pharmacogenomics of erlotinib: Effect of drug exposure on treatment outcomes in Japanese patients with non-small cell lung cancer. (Abstract #2549)
M. Fukudo, Y. Ikemi, Y. Togashi, K. Masago, Y. Kim, T. Mio, M. Mishima, K. Inui, T. Katsura

- Brd. 2D Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer. (Abstract #2550)**
 W. P. Caron, J. C. Lay, A. M. Fong, N. M. La-Beck, S. E. Newman, D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. Zamboni
- Brd. 2E Safety and immunogenicity of heat-treated zoster vaccine (ZV_{HT}) in adults with solid tumor malignancy (STM). (Abstract #2551)**
 K. M. Mullane, M. R. Mullane, B. M. Wong, Y. Zhao, T. Sterling, S. Manoff, P. W. Annunziato
- Brd. 2F Evaluation of response rate and disease control rate as potential predictors of overall survival in anthracycline-pretreated women receiving first-line chemotherapy for metastatic breast cancer (MBC). (Abstract #2552)**
 J. Liu, K. S. Albain, S. Chan, A. D. Seidman, D. Tai, Y. Wang, L. Zhao
- Brd. 2G Procoagulant and inflammatory mediators in small cell lung carcinoma: Potential role in thromboembolic complications. (Abstract #2553)**
 I. Thethi, D. Hoppensteadt, H. Khan, M. Demir, C. Adiguzel, E. Litinas, J. Fareed
- Brd. 3A Phase I study of anti-VEGF monoclonal antibody bevacizumab and HDAC inhibitor valproic acid in patients with advanced cancers. (Abstract #2554)**
 J. J. Wheler, F. Janku, T. Jackson, S. Fu, M. Sun, H. Yang, A. Naing, S. L. Moulder, A. M. Tsimberidou, D. S. Hong, G. S. Falchook, S. A. Piha-Paul, G. Garcia-Manero, R. Kurzrock
- Brd. 3B Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. (Abstract #2555)**
 J. Ang, D. Olmos, V. Moreno Garcia, A. Brunetto, D. Papadatos-Pastos, H. Arkenau, M. Blanco, R. D. Baird, P. A. Cassier, D. S. Tan, R. S. Kristeleit, S. Dolly, K. J. Shah, B. Amin, B. G. Anghan, L. R. Molife, U. Banerji, J. S. De Bono, S. B. Kaye
- Brd. 3C Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. (Abstract #2556)**
 J. P. Connor, R. Stupp, M. C. Cristea, N. Lewis, L. D. Lewis, M. R. Mattiacci, M. Felder, S. Stewart, J. Henslee-Downey, R. Neugebauer, P. B. Komarnitsky
- Brd. 3D Adoptive immunotherapy with autologous CD3/CD28-costimulated T-cells after fludarabine-based chemotherapy in patients with chronic lymphocytic leukemia. (Abstract #2557)**
 S. J. Schuster, C. Hosing, E. J. Shpall, B. Levine, N. Aqui, E. A. Chong, J. Svoboda, A. Gordon, J. D. McMannis, D. Bosque, J. Cotte, A. Brennan, Z. Zheng, L. Leinbach, Y. Xu, E. A. Veloso, W. Decker, C. M. Bollard, M. J. Keating, C. H. June
- Brd. 3E Effect of cellular vaccination of prostate cancer patients on IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens. (Abstract #2558)**
 G. P. Hemstreet, V. M. Pisarev, C. A. Enke, R. J. Hauke, G. R. Rossi, L. Tennant, W. J. Ramsey, N. N. Vahanian, C. J. Link
- Brd. 3F Blinded independent radiologic review (BIRR) versus investigator radiologic evaluation (IRE) for response assessment in metastatic colorectal cancer (mCRC): Systematic review and meta-analysis. (Abstract #2559)**
 J. S. Lima, F. M. Carcano, F. H. Souza, L. V. dos Santos
- Brd. 3G Clinical effects of Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1-expressing solid tumors as compared to patients with AML/MDS. (Abstract #2560)**
 A. Letsch, C. Scheibenbogen, A. Asemissen, K. Zimmermann, S. Bauer, M. Voelker-Call, D. Stather, E. Thiel, U. Keilholz

Monday, June 6, 2011

- Brd. 3H** **Posterior reversible encephalopathy syndrome in patients with cancer. (Abstract #2561)**
A. M. Parker, L. Chi, M. C. Ruiz, M. E. Loghin
- Brd. 4A** **Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs). (Abstract #2562)**
H. K. Gan, B. You, G. R. Pond, E. X. Chen
- Brd. 4B** **RECIST 1.0 versus 1.1: Implications for trial interpretation and design in advanced prostate cancer. (Abstract #2563)**
C. I. Piatek, B. B. Desai, D. Wei-Tsao, R. Tang, F. Acosta, J. K. Pinski, T. B. Dorff, A. Goldkorn, H. Jadvar, D. I. Quinn
- Brd. 4C** **A dose-finding study of a MUC-1 vaccine in conjunction with *poly-IC:LC* (polyinosinic-polycytidylic acid stabilized with polylysine and carboxy methylcellulose) in immunosuppressed (IS) patients (pts) with advanced prostate cancer (PCa) . (Abstract #2564)**
A. K. Patel, L. J. Appleman, W. E. Gooding, D. Friedland, J. McKolanis, A. M. Salazar, O. J. Finn, G. S. Chatta
- Brd. 4D** **Autologous heat shock protein vaccine (HSPPC-96) for patients with recurrent glioblastoma (GBM): Results of a phase II multicenter clinical trial with immunological assessments. (Abstract #2565)**
A. Parsa, C. Crane, S. Han, V. Kivett, A. Fedoroff, N. A. Butowski, S. M. Chang, J. L. Clarke, M. S. Berger, M. McDermott, M. Aghi, C. Yanes, M. Prados, A. E. Sloan, J. N. Bruce
- Brd. 4E** **Incidence of hypersensitivity reactions (HSRs) to albumin-bound paclitaxel (ABI) in patients (pts) with a history of HSR to cremophor-based paclitaxel (P). (Abstract #2566)**
J. P. Timoney, D. McGuffy, D. DeRitis, E. Tyler, J. Sumka, M. Pozotrigio, V. Bhatt, A. Chan, N. T. Sklarin
- Brd. 4F** **Comparison of 12 current staging systems for advanced hepatocellular carcinoma not amendable to locoregional therapy as inclusion criteria for clinical trials. (Abstract #2567)**
X. Li, Q. Lin, M. Dong, X. Wu, L. Wei, J. Wen, X. Ma, Z. Chen
- Brd. 4G** **First-in-human phase I study of the antiangiogenic vaccine (OTS11101) targeting VEGFR-1 in patients with solid tumors. (Abstract #2568)**
H. Hayashi, T. Kurata, Y. Fujisaka, T. Satoh, M. Takeda, M. Miyazaki, T. Okabe, H. Kiyota, K. Tanaka, T. Tsunoda, K. Nakagawa
- Brd. 4H** **Pro- versus antitumor effects of bisphosphonate-activated $\gamma\delta$ T cells in cancer immunotherapy. (Abstract #2569)**
V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-Koehler, M. Goebeler, J. Birkmann, J. Becker, I. Schmidt-Wolf, H. Einsele, M. Wilhelm
- Brd. 5A** **Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer. (Abstract #2570)**
J. Delord, N. Isambert, P. Fumoleau, A. Ravaud, T. Nguyen, P. Ferre, S. Favrel, M. Pinel, J. Tourani
- Brd. 5B** **Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, MetMab, in patients with advanced solid tumors. (Abstract #2571)**
S. Bai, Y. Xin, D. Jin, S. Kaur, I. Nijem, J. G. Bothos, A. C. Peterson, P. H. Patel
- Brd. 5C** **The effect of elotuzumab on natural killer (NK) cell function against multiple myeloma (MM). (Abstract #2572)**
S. M. Collins, C. E. Bakan, Y. Alghothani, H. Kwon, B. Balasa, G. Starling, A. Rice, D. M. Benson Jr.
- Brd. 5D** **Melphalan and whole-blood stem cell reinfusion in castration-resistant prostate cancer (CRPC): A phase I/II study. (Abstract #2573)**
J. Shamash, J. Jacob, T. Powles, S. Agrawal, K. Mutsvangwa, N. Saunders, P. Wilson, J. Stebbing

- Brd. 5E** **Systemic immune responses induced by intratumoral plasmid IL-12 electroporation in patients with melanoma. (Abstract #2574)**
E. Cha, A. Daud, D. G. McNeel, R. Heller, L. Fong
- Brd. 5F** **Humoral tumor-associated immune responses induced by catumaxomab in patients with malignant ascites. (Abstract #2575)**
P. Ruf, M. Jäger, B. Foerster, H. Martinius, D. Seimetz, H. Lindhofer
- Brd. 5G** **Reduction of toxicity by reversing the order of infusion in docetaxel and cyclophosphamide (TC). (Abstract #2576)**
D. Miura, M. Fujii, T. Iwatani, T. Takano, H. Kawabata
- Brd. 5H** **A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging. (Abstract #2577)**
J. V. Pedersen, E. M. Karapanagiotou, A. Biondo, N. Tunariu, M. Puglisi, K. A. Denholm, S. Sassi, D. Mansfield, T. A. Yap, J. S. De Bono, K. J. Harrington
- Brd. 6A** **A phase 0 microdosing trial of an in vivo assay for predicting chemoresistance to platinum. (Abstract #2578^)**
C. Pan, S. Wang, R. deVere White, D. R. Gandara, P. Lara Jr., T. Li, P. Mack, A. Rodriguez-Fahrni, J. S. Lee, M. Malfatti, K. Turteltaub, P. T. Henderson
- Brd. 6B** **New lesions versus growth of existing disease: Does it impact prognosis? (Abstract #2579)**
A. Grothey, J. M. Heun, M. Branda, R. M. Goldberg, D. J. Sargent
- Brd. 6C** **Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial. (Abstract #2580)**
J. T. Lettieri, A. L. Mazzu, L. Huang, C. D. Lathia
- Brd. 6D** **Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult patients with cancer with advanced solid tumors. (Abstract #2581)**
A. Thomas-Schoemann, M. Tod, O. Mir, N. Bancelin, R. Coriat, F. Taieb, P. Boudou-Rouquette, H. Abbas, S. Ropert, J. Durand, A. Dauphin, F. Goldwasser, B. Blanchet
- Brd. 6E** **Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC). (Abstract #2582)**
M. D. Walsh, H. Giovino, A. Sheikh, M. Ivanovic, A. B. Whitlow, S. E. Newman, N. M. La-Beck, R. J. Kowalsky, B. A. Zamboni, D. L. Clarke-Pearson, W. R. Brewster, L. Van Le, V. L. Bae-Jump, P. A. Gehrig, W. Zamboni
- Brd. 6F** **Meta-analysis of the pharmacokinetic variability of liposomal anticancer agents compared with nonliposomal anticancer agents. (Abstract #2583)**
B. Sidone, B. A. Zamboni, W. Zamboni
- Brd. 6G** **Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial. (Abstract #2584)**
M. Sebastian, L. von Boehmer, A. Zippelius, F. Mayer, M. Reck, D. Atanackovic, M. Thomas, F. Schneller, J. Stoehlmacher, E. Goekkurt, H. Bernhard, A. Groeschel, R. Bals, S. Schmidt, B. Scheel, S. D. Koch, T. Lander, K. Kallen, A. Knuth
- Brd. 6H** **Phase I trial assessing safety and pharmacokinetics of afatinib (BIBW 2992) with intravenous weekly vinorelbine in advanced solid tumors. (Abstract #2585)**
R. Bahleda, J. Soria, Y. Berge, C. Massard, S. Wind, M. M. Uttenreuther-Fischer, F. Fleischer, H. De-Montserrat, F. Solca, I. Tschoepe, J. Delord
- Brd. 7A** **Population pharmacokinetic (PK) analysis supports fixed dosing for the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. (Abstract #2586)**
Y. Xin, M. S. Gordon, D. Jin, E. Wakshull, D. S. Chen, L. S. Rosen, P. N. Munster, L. Naumovski, S. Bai

Monday, June 6, 2011

- Brd. 7B Assessment of association between BRAF mutation status in melanoma tumors and response to ipilimumab. (Abstract #2587)**
J. Jackson, G. Whitney, O. Hamid, H. Schmidt, S. D. Chasalow, S. Alaparthi, Y. Bao, V. Shahabi
- Brd. 7C Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC). (Abstract #2588)**
R. F. Gabbitass, N. E. Annels, J. Crawshaw, H. S. Pandha, G. W. Middleton
- Brd. 7D Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Regin-G and Regin-C for chemotherapy-resistant cancers. (Abstract #2589)**
J. G. Ignacio, H. Bruckner, R. E. Manalo, F. S. San Juan, L. Baniqued, A. Madamba, E. M. Gordon, F. L. Hall
- Brd. 7E Outcomes in phase II trials of metastatic breast cancer: Where is the bar? (Abstract #2590)**
A. Kamal, T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, J. M. Peppercorn
- Brd. 7F AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors. (Abstract #2591)**
J. F. Deeken, M. A. Rudek, D. M. Abouafia, R. J. Sullivan, J. F. Gerecitano, M. E. Cianfrocca, D. H. Henry, L. Ratner, B. J. Dezube, K. Mosby, M. Tibbals, R. F. Little, S. P. Ivy, P. C. Moore, R. T. Mitsuyasu
- Brd. 7G A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens. (Abstract #2592)**
E. P. Hui, G. S. Taylor, B. Ma, S. L. Chan, R. Ho, W. Wong, H. Jia, C. Edwards, A. B. Rickinson, A. T. Chan, N. M. Steven
- Brd. 7H Metabolic profiles as predictive biomarkers of erlotinib-induced adverse effects in patients with non-small cell lung cancer. (Abstract #2593)**
A. Hamada, J. Sasaki, S. Saeki, N. Iwamoto, M. Inaba, S. Ushijima, H. Kishi, S. Fujii, H. Semba, K. Kashiwabara, Y. Tsubata, Y. Kai, T. Isobe, H. Kohroggi, H. Saito
- Brd. 8A An evaluation of plasma homocysteine levels and the hematological toxicity of pemetrexed even with folate supplementation. (Abstract #2594)**
A. Horiike, H. Tanaka, T. Sakatani, R. Saito, K. Kaburaki, N. Yanagitani, K. Kudo, F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio
- Brd. 8B Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials. (Abstract #2595)**
F. De Braud, C. Catania, A. Onofri, C. Pierantoni, S. Cascinu, M. Maur, C. Masini, P. F. Conte, L. Giovannoni, A. Tasciotti, V. Lovato, D. Neri, H. D. Menssen
- Brd. 8C NAD(P)H oxidase genetic polymorphisms and anthracyclines-induced cardiac lesions in patients with cancer. (Abstract #2596)**
A. Cascales, F. Pastor, B. Sanchez-Vega, J. Corral, A. Vicente, T. Garcia, V. Vicente, F. Ayala
- Brd. 8D Key drug development features in the design of early-phase oncology trials: An FDA perspective. (Abstract #2597)**
R. Charlab Orbach, G. M. Blumenthal, P. Cortazar, K. K. Filipski, C. Grimstein, L. Zhang, P. Mummaneni, B. Booth, I. Zineh
- Brd. 8E Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors. (Abstract #2598)**
M. A. Eldon, U. Hoch
- Brd. 8F A pilot study of vaccination with sialyl Lewis^a (sLe^a)–keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts). (Abstract #2599)**
A. Diab, G. Ragupathi, W. W. Scholz, K. Panageas, C. Hudis, P. O. Livingston, T. Gilewski

- Brd. 8G** **A phase I dose-escalation study of LY2523355, an Eg5 inhibitor, administered either on days 1, 5, and 9; days 1 and 8; or days 1 and 5 with pegfilgrastim (peg) every 21 days (NCT01214642). (Abstract #2600)**
K. C. Shih, J. R. Infante, K. P. Papadopoulos, J. C. Bendell, A. W. Tolcher, H. A. Burris III, M. Beeram, L. Jackson, R. Arcos, E. H. Westin, D. Farrington, A. McGlothlin, S. Hynes, J. Leohr, J. T. Brandt, A. Nasir, A. Patnaik
- Brd. 8H** **The effect of the trifunctional anti-EpCAM antibody catumaxomab on the development of tumor-specific immune responses in patients with gastric cancer. (Abstract #2601)**
H. Reinhard, S. K. Meyer, K. Bartels, R. Fischer, D. Seimetz, C. Bokemeyer, D. Atanackovic
- Brd. 9A** **Correlation between adverse event reports of hypothyroidism and clinical response in patients treated with vascular endothelial growth factor receptor inhibitors (VEGFR-I). (Abstract #2602)**
G. Speranza, L. Rubinstein, S. P. Ivy, P. J. Harris
- Brd. 9B** **Added value of pre- and on-treatment tumor growth kinetics assessment to RECIST in patients (pts) treated with molecularly targeted agents (MTAs). (Abstract #2603)**
C. Le Tourneau, V. Servois, L. Ollivier, X. Paoletti
- Brd. 9C** **A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. (Abstract #2604)**
R. A. Madan, M. Bilusic, J. W. Hodge, K. Y. Tsang, P. M. Arlen, C. R. Heery, M. Rauckhorst, S. McMahon, C. Intrivici, T. A. Ferrara, A. Cohn, D. Apelian, A. Franzusoff, Z. Guo, J. Schlom, J. L. Gulley
- Brd. 9D** **Development and validation of a prediction tool for hand-foot skin reaction (HFSR) in patients receiving sorafenib. (Abstract #2605)**
J. Yu, G. Dranitsaris, M. D. Vincent, L. Huang, F. Fang, M. E. Lacouture
- Brd. 9E** **Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK). (Abstract #2606)**
G. J. Fetterly, K. E. Thudium, J. Kalabus, M. Murphy, P. D. Zagst, J. Prey, E. Kittleman, A. A. Adjei, T. L. O'Connor, J. G. Blanco
- Brd. 9F** **A phase I dose escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment. (Abstract #2607)**
N. R. Dickson, S. F. Jones, H. A. Burris III, R. K. Ramanathan, G. J. Weiss, J. R. Infante, J. C. Bendell, W. McCulloch, D. D. Von Hoff
- Brd. 9G** **The effect of metformin (M) on overall survival (OS) of patients (Pts) with colorectal cancer (CRC) treated with chemotherapy (CTX). (Abstract #2608)**
M. Bansal, E. Siegel, R. Govindarajan
- Brd. 9H** **Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies. (Abstract #2609)**
S. Vemulapalli, A. C. Mita, N. S. Gallegos, G. Anderson, J. Charles, J. M. Rogers, A. Kousba, K. K. Sankhala, J. J. Nemunaitis
- Brd. 10A** **Enrichment of allogeneic tumor antigen-specific T-cells from bone marrow (BM) of patients treated with high-dose post-transplant cyclophosphamide (Cy): A novel approach to adoptive immunotherapy. (Abstract #2610)**
K. Noonan, L. Luznik, I. Borrello
- Brd. 10B** **Returning research results to clinical trial participants: A survey of patients with cancer. (Abstract #2611)**
K. Elzinga, C. V. Fernandez, D. Y. Heng, P. A. Tang
- Brd. 10C** **Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function. (Abstract #2612)**
D. Mahalingam, J. Sarantopoulos, M. S. Gordon, N. B. Pandya, B. R. Tan, A. C. Mita, C. Zergebel, K. Saito, C. H. Takimoto, M. Saif

Monday, June 6, 2011

- Brd. 10D Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy. (Abstract #2613^A)**
H. Kristeleit, M. Puglisi, G. W. Middleton, D. Propper, M. T. Kelleher, L. Trani, K. A. Denholm, G. Wallenstein, P. Stopfer, S. Buschke, M. M. Uttenreuther-Fischer, E. Bent, D. O'Brien, J. F. Spicer, L. R. Molife
- Brd. 10E A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. (Abstract #2614)**
L. S. Rosen, M. S. Gordon, S. Bai, P. Hegde, J. Fredrickson, D. S. Chen, I. Chang, R. P. Funke, G. S. Chandler, L. Naumovski, P. N. Munster

MONDAY

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Developmental Therapeutics—Experimental Therapeutics

Location: Hall A

Track(s): Developmental Therapeutics

- Brd. 10F Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irinot) in patients (pts) with advanced solid tumors. (Abstract #3033)**
 A. L. Ho, J. C. Bendell, J. M. Cleary, G. K. Schwartz, H. A. Burris III, P. Oakes, F. Agbo, P. N. Barker, A. M. Senderowicz, G. Shapiro
- Brd. 10G Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. (Abstract #3034)**
 A. A. Adjei, J. A. Sosman, R. E. Martell, G. K. Dy, L. W. Goff, W. Ma, L. Horn, G. J. Fetterly, S. A. Michael, J. A. Means, F. Chai, M. Lamar, G. M. Strauss, W. Chiang, J. Jarboe, B. E. Schwartz, I. Puzanov
- Brd. 10H A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase. (Abstract #3035)**
 A. Patnaik, L. J. Appleman, J. M. Mountz, R. K. Ramanathan, M. Beeram, A. W. Tolcher, K. P. Papadopoulos, M. T. Lotze, D. P. Petro, C. Laymon, L. Paige, P. Rajagopalan, M. Jeffers, D. Roth, R. L. Dubowy
- Brd. 11A A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies. (Abstract #3036)**
 A. P. Moore, S. Thomas, C. J. Ryan, T. M. Jahan, S. G. DuBois, J. K. Chan, K. T. Thurn, E. A. Collisson, A. Reinert, A. Daud, P. N. Munster
- Brd. 11B Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. (Abstract #3037^)**
 A. Biondo, T. A. Yap, L. Yan, A. Patnaik, I. Fearen, R. D. Baird, K. P. Papadopoulos, L. M. Delgado, A. Taylor, L. Lupinacci, S. C. Blackman, S. Decordova, M. Tall, S. Heaton, M. D. Garrett, D. Sullivan, J. S. De Bono, A. W. Tolcher
- Brd. 11C A phase I trial of VB-111, a tissue- and condition-specific dual action vascular disruptive and antiangiogenic agent, for treatment of patients with advanced metastatic cancer. (Abstract #3038)**
 A. J. Brenner, Y. Cohen, F. J. Giles, E. C. Borden, E. Breitbart, L. Bangio, N. Sher, P. L. Triozzi
- Brd. 11D Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. (Abstract #3039)**
 A. Beryozkina, G. L. Nichols, M. Reckner, L. T. Vassilev, R. Rueger, L. Jukofsky, S. Middleton, M. Andreeff, S. Padmanabhan, R. Strair, M. L. Delioukina, P. G. Maslak, P. Hillmen, R. Kurzrock, L. Gore, A. Patnaik, R. G. Maki, G. K. Schwartz, A. J. Wagner, J. Zhi
- Brd. 11E A phase I study of R(-)-gossypol (AT-101) in combination with cisplatin (P) and etoposide (E) in patients (pts) with advanced solid tumors and extensive-stage small cell lung cancer (ES-SCLC). (Abstract #3040)**
 A. M. Traynor, J. Kolesar, R. M. Marnocha, J. C. Eikhoff, D. B. Alberti, N. Takebe, G. Wilding, G. Liu, W. R. Schelman
- Brd. 11F Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. (Abstract #3041)**
 A. R. Tan, D. Toppmeyer, M. N. Stein, R. A. Moss, M. Gounder, D. C. Lindquist, J. J. Ji, A. P. Chen, M. J. Egorin, B. Kiesel, J. H. Beumer, R. S. DiPaola

Monday, June 6, 2011

- Brd. 11G Development and validation of biomarker assays to assess pharmacodynamic modulation of MET. (Abstract #3042)**
A. K. Srivastava, M. G. Hollingshead, J. Weiner, S. Khin, S. Borgel, P. Risbood, T. D. Pfister, S. M. Lawrence, R. J. Kinders, D. P. Bottaro, J. E. Tomaszewski, R. E. Parchment, J. H. Doroshov
- Brd. 11H Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy. (Abstract #3043)**
B. Grana, H. A. Burris III, J. Rodon Ahnert, A. R. Abdul Razak, M. J. De Jonge, F. Eskens, L. L. Siu, Q. C. Ru, N. F. Homji, D. Demanse, E. Di Tomaso, J. G. Coesaert, C. Quadt, J. Baselga, J. C. Bendell
- Brd. 12A A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). (Abstract #3044)**
B. Besse, J. Soria, C. Gomez-Roca, J. A. Ware, A. A. Adjei, G. K. Dy, G. Shankar, R. K. Brachmann, H. J. Groen
- Brd. 12B Genetic correlations with chemotherapy-induced hepatic injury. (Abstract #3045)**
C. H. Pilgrim, K. Brettingham-Moore, A. Pham, W. Murray, E. Link, M. Smith, V. Usatoff, P. M. Evans, S. Banting, B. N. Thomson, M. Michael, W. A. Phillips
- Brd. 12C A phase I dose escalation study of the polo-like kinase 1 inhibitor volasertib (BI 6727) with two different dosing schedules in patients with advanced solid malignancies. (Abstract #3046)**
C. Lin, W. Su, C. Yen, A. Cheng, Y. Lu, C. Hsu, D. C. Huang, H. Fritsch, F. Voss, R. Schreck, T. Taube, C. Yang
- Brd. 12D Angiogenic factors and soluble receptors in NCIC CTG BR.24. (Abstract #3047)**
C. L. Addison, K. Ding, H. Zhao, A. Le Maitre, S. A. Laurie, G. D. Goss, F. A. Shepherd, P. A. Bradbury, L. Seymour
- Brd. 12E Imaging with [¹⁸F]-fluorodeoxyglucose positron emission tomography (FDG-PET) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) as markers of drug effect in a phase I dose-escalation study of combined RAD 001 and cetuximab. (Abstract #3048)**
C. A. Martin, R. F. Perini, A. N. Avadhani, M. Redlinger, K. Harlacker, K. T. Flaherty, M. A. Rosen, C. R. Divgi, P. J. O'Dwyer
- Brd. 12F A phase I schedule optimization study of pegylated glutaminase (PEG-PGA) plus 6-diazo-5-oxo-L-norleucine (DON) in patients (pts) with advanced solid tumors. (Abstract #3049)**
C. Unger, C. Mueller, M. P. Bausch, K. Krzemieniecki, S. Ochendusko, B. Wilk, E. Jaeger, S. Al-Batran
- Brd. 12G A phase Ib study for MNRP1685A (anti-NRP1) administered intravenously with bevacizumab with or without paclitaxel to patients with advanced solid tumors. (Abstract #3050^)**
C. D. Weekes, P. LoRusso, V. Ramakrishnan, L. M. Shih, W. C. Darbonne, P. Hegde, Y. Xin, R. Yu, H. Xiang, R. K. Brachmann, A. Patnaik
- Brd. 12H A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report. (Abstract #3051)**
D. C. Cho, E. I. Heath, J. M. Cleary, E. L. Kwak, L. Gandhi, D. P. Lawrence, C. Zack, F. Teofilovici, R. Bradley, M. D. Karol, G. Shapiro, P. LoRusso
- Brd. 13A A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. (Abstract #3052^)**
D. D. Von Hoff, P. LoRusso, G. D. Demetri, G. J. Weiss, G. Shapiro, R. K. Ramanathan, J. A. Ware, R. Raja, J. Jin, G. G. Levy, K. E. Mazina, A. J. Wagner

- Brd. 13B Integrated research platform (iGXT) for enhancing drug development and personalizing cancer therapy: Pilot study results. (Abstract #3053)**
 D. R. Gandara, T. A. Van Dyke, Z. Weaver Ohler, T. Li, P. Lara Jr., P. C. Mack, R. F. Calhoun, R. Gandour-Edwards, K. D. Danenberg, R. de Vere White, N. Goodwin
- Brd. 13C Poly (ADP ribose) polymerase (PARP) inhibition in peripheral blood lymphocytes (PBLs): Does it reflect PARP inhibition in tumor? (Abstract #3054)**
 D. R. Shalinsky, D. D. Wang, K. A. Kern, P. English, N. J. Curtin, R. Plummer
- Brd. 13D First-in-human dose-escalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. (Abstract #3055)**
 D. S. Mendelson, L. S. Rosen, M. S. Gordon, J. W. Goldman, A. J. Olszanski, H. Dai, R. Perea, A. Gollerkeri
- Brd. 13E Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235. (Abstract #3056)**
 D. Bottino, J. Tabernero, H. A. Burris III, C. Britten, L. Chen, J. C. Bendell, O. Chiparus, V. Duval, E. Di Tomaso, C. Sarr, W. Hackl, J. Baselga, J. Rodon Ahnert
- Brd. 13F First-in-human phase I study of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3) in patients with advanced solid tumors. (Abstract #3057)**
 D. Strumberg, B. Schultheis, U. Traugott, C. Vank, A. Santel, O. Keil, K. Giese, J. Kaufmann, J. Drevs
- Brd. 13G Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. (Abstract #3058)**
 E. A. Sausville, P. LoRusso, M. A. Carducci, P. N. Barker, F. Agbo, P. Oakes, A. M. Senderowicz
- Brd. 13H Effects of the antiangiogenic drug bevacizumab on tumor perfusion and drug delivery of ¹¹C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): Implications for scheduling of antiangiogenic agents. (Abstract #3059)**
 E. F. Smit, M. Lubberink, I. Bahce, M. Walraven, M. P. de Boer, H. N. Greuter, N. Hendrikse, J. Eriksson, A. D. Windhorst, P. E. Postmus, H. M. Verheul, E. H. Serne, A. A. Lammertsma, A. A. van der Veldt
- Brd. 14A Early targeted drug development: Pilot FDA review of PI3K inhibitor phase I studies using a knowledge management database. (Abstract #3060)**
 G. M. Blumenthal, R. Charlab Orbach, I. Zineh, P. Cortazar, R. L. Justice, R. Pazdur
- Brd. 14B Investigation of hand-foot syndrome (HFS) observed in pazopanib (P)-treated patients (pts) with renal cell carcinoma (RCC). (Abstract #3061)**
 H. A. Ball, Y. Lin, Z. Xue, B. Suttle, C. Xu, L. Huang, L. McCann, T. E. Hutson, C. N. Sternberg, L. N. Pandite
- Brd. 14C Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. (Abstract #3062)**
 H. A. Tawbi, J. Rodon Ahnert, R. Dummer, A. L. Thomas, C. Granvil, Y. Shou, J. Dey, M. M. Mita, D. D. Amakye, A. C. Mita
- Brd. 14D A first-in-human phase I clinical trial of CXR1002 in patients (pts) with advanced cancer. (Abstract #3063)**
 I. R. MacPherson, D. Bissett, R. D. Petty, B. Tait, L. M. Samuel, J. MacDonald, M. Smith, J. A. Birse-Archbold, A. L. Barnett, C. R. Wolf, C. R. Elcombe, A. Jeynes-Ellis, T. Evans

Monday, June 6, 2011

- Brd. 14E** **A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 δ , in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. (Abstract #3064)**
I. W. Flinn, M. T. Schreeder, S. E. Coutre, J. Leonard, N. D. Wagner-Johnston, S. De Vos, R. V. Boccia, L. Holes, S. Peterman, L. L. Miller, A. S. Yu
- Brd. 14F** **Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors. (Abstract #3065)**
I. Garrido-Laguna, R. Kurzrock, J. J. Wheler, G. S. Falchook, S. A. Piha-Paul, S. Fu, A. Naing, C. Hinojosa, R. Mistry, A. Scamardo, K. S. Culotta, S. Ekmekcioglu, S. Wen, L. H. Camacho, S. P. Ivy, D. S. Hong
- Brd. 14G** **A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors. (Abstract #3066)**
J. D. Peyton, J. Rodon Ahnert, H. Burris, C. Britten, L. Chen, J. Tabernero, V. Duval, N. Rouyrre, A. P. Silva, C. Quadt, J. Baselga
- Brd. 14H** **Combination study of navitoclax with gemcitabine (G) in patients (pts) with solid tumors. (Abstract #3067)**
J. M. Cleary, C. S. Rocha Lima, H. Hurwitz, A. J. Montero, G. Shapiro, C. Franklin, J. Yang, A. M. Graham, T. Busman, M. Mabry, K. D. Holen, A. Krivoshik, R. Humerickhouse, H. Uronis
- Brd. 15A** **Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. (Abstract #3068)**
J. H. Schellens, G. Shapiro, A. C. Pavlick, R. Tibes, S. Leijen, S. M. Tolaney, I. Diaz-Padilla, R. K. Ramanathan, T. Demuth, J. Viscusi, J. D. Cheng, R. Lam, Y. Xu, A. M. Oza
- Brd. 15B** **Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis. (Abstract #3069)**
J. J. Luke, L. A. Callahan, C. H. Darby, E. Moss, J. Winkelman, J. Barth, G. L. Elfring, A. Ogden, G. K. Schwartz, M. M. Gounder
- Brd. 15C** **Phase I study of ACE-041, a novel inhibitor of ALK1-mediated angiogenesis, in patients with advanced solid tumors. (Abstract #3070)**
J. C. Bendell, M. S. Gordon, H. Hurwitz, C. H. Condon, Y. Yang, D. Wilson, K. M. Attie, M. L. Sherman, S. Sharma
- Brd. 15D** **The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study. (Abstract #3071)**
J. A. Thompson, A. Forero-Torres, E. I. Heath, S. M. Ansell, S. K. Pal, J. R. Infante, S. De Vos, P. A. Hamlin, B. Zhao, K. Klussman, N. C. Whiting
- Brd. 15E** **Phase I pharmacokinetic study of temsirolimus (CCI-779) in patients with advanced malignancies and normal and impaired liver function: An NCI Organ Dysfunction Working Group (ODWG) study. (Abstract #3072)**
J. Sarantopoulos, H. Lenz, P. LoRusso, S. Shibata, S. Kummar, D. Mulkerin, R. K. Ramanathan, M. M. Mita, P. O'Rourke, S. C. Remick, S. Goel, M. Gutierrez, S. S. Ramalingam, A. Murgo, A. M. Davies, S. Mani, J. Boni, M. Shapiro, S. P. Ivy, C. H. Takimoto, National Cancer Institute Organ Dysfunction Working Group
- Brd. 15F** **A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors. (Abstract #3073)**
J. W. Goldman, M. S. Gordon, H. Hurwitz, R. Pili, D. S. Mendelson, B. J. Adams, D. Alvarez, B. K. Seon, C. P. Theuer, B. R. Leigh, L. S. Rosen
- Brd. 15G** **Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. (Abstract #3074)**
K. K. Sankhala, A. W. Tolcher, M. M. Mita, M. S. Gordon, L. S. Rosen, K. P. Papadopoulos, A. Patnaik, R. L. Drenkler, A. C. Mita, J. Sarantopoulos, R. G. Bristow, G. Fine, G. S. Choy, M. Azab

- Brd. 15H** **A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. (Abstract #3075)**
K. P. Papadopoulos, D. S. Mendelson, A. W. Tolcher, A. Patnaik, H. A. Burris III, D. W. Rasco, J. C. Bendell, M. S. Gordon, G. Kato, H. Wong, D. Bomba, S. Lee, H. H. Gillenwater, T. Woo, J. R. Infante
- Brd. 16A** **First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort. (Abstract #3076)**
L. Chen, L. S. Rosen, T. Iyengar, J. W. Goldman, R. Savage, J. Kazakin, T. C. Chan, B. E. Schwartz, G. Abbadessa, D. D. Von Hoff
- Brd. 16B** **Phase Ib results of c-MET inhibitor ARQ 197 in combination with gemcitabine in a cohort of patients (pts) with advanced breast, ovarian, and uterine tumors. (Abstract #3077)**
L. H. Camacho, S. Pant, M. N. Saleh, G. Abbadessa, J. Kazakin, B. E. Schwartz, J. C. Bendell
- Brd. 16C** **Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors. (Abstract #3078)**
M. A. Dickson, P. LoRusso, E. A. Sausville, N. Rao, E. Kobayashi, M. R. Kurman, S. Akinaga, G. K. Schwartz
- Brd. 16D** **Brivanib (BMS-582664) in advanced solid tumors (AST): Results of a phase II randomized discontinuation trial (RDT). (Abstract #3079)**
M. J. Ratain, G. K. Schwartz, A. M. Oza, C. M. Rudin, S. B. Kaye, M. J. De Jonge, D. Khayat, A. Awada, M. B. Sawyer, J. C. Obel, J. Medioni, T. Evans, J. De Greve, P. M. Soetekouw, J. Baurain, P. J. O'Dwyer, C. Hartman, V. Poulart, I. B. Walters
- Brd. 16E** **A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. (Abstract #3080)**
M. M. Mita, A. C. Mita, J. Moseley, J. Poon, K. A. Small, Y. Jou, P. Kirschmeier, D. Zhang, P. Statkevich, K. K. Sankhala, J. Sarantopoulos, J. M. Cleary, L. R. Chirieac, S. Rodig, R. Bannerji, G. Shapiro
- Brd. 16F** **Phase I trial of weekly and every 3 weeks ixabepilone (Ix) and sunitinib (S) in advanced solid tumors (STs). (Abstract #3081)**
M. Kittaneh, A. J. Montero, K. Kovacs, V. D. Guardiola Amado, A. M. Flores, A. Ferrell, M. Vulfovich, M. D. Pegram, P. W. Benedetto, C. S. Rocha Lima, J. R. Merchan
- Brd. 16G** **Quality appraisal of clinical validation studies for multigene prediction assays of chemotherapy response in early-stage breast cancer. (Abstract #3082)**
N. M. Kuderer, E. Culakova, M. Huang, M. S. Poniewierski, G. S. Ginsburg, W. T. Barry, P. K. Marcom, N. Ready, A. P. Abernethy, G. H. Lyman
- Brd. 16H** **MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with erlotinib: Phase I clinical experience. (Abstract #3083)**
P. J. O'Dwyer, K. P. Papadopoulos, A. W. Tolcher, U. R. Teitelbaum, K. Harlacker, M. Beeram, D. Sohal, M. Mehran, M. Tawashi, M. A. Drouin, C. R. Maroun, J. Wang, M. Fournel, A. Karam, J. M. Besterman, A. Patnaik
- Brd. 17A** **Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. (Abstract #3084)**
P. A. Cassier, V. Moreno Garcia, C. Gomez-Roca, D. Olmos, R. Morales, G. Del Conte, E. Gallerani, A. Brunetto, P. Schoffski, S. Marsoni, J. H. Schellens, N. Penel, E. E. Voest, T. Evans, R. Plummer, R. H. Wilson, J. Soria, J. Tabernero, J. Verweij, S. B. Kaye, European Drug Development Network

Monday, June 6, 2011

- Brd. 17B Phase I dose escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). (Abstract #3085)**
R. Kurzrock, A. Patnaik, L. Rosenstein, S. Fu, K. P. Papadopoulos, D. A. Smith, G. S. Falchook, G. Chambers, J. L. Gauvin, A. Naing, L. S. Smith, T. Gonzalez, A. M. Tsimberidou, T. A. Mays, D. S. Cox, D. S. Hong, D. J. DeMarini, N. T. Le, S. R. Morris, A. W. Tolcher
- Brd. 17C A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors. (Abstract #3086)**
R. D. Carvajal, M. M. Gounder, C. M. Coughlin, J. Fishel, J. Heyburn, D. O'Shannessy, L. Grasso, C. Schweizer, J. Parno, L. J. Old, N. S. Azad, L. A. Diaz Jr.
- Brd. 17D Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. (Abstract #3087)**
R. F. Marschke, M. J. Borad, R. W. McFarland, R. H. Alvarez, J. K. Lim, C. S. Padgett, D. D. Von Hoff, S. E. O'Brien, D. W. Northfelt
- Brd. 17E Phase II/pharmacodynamic trial of PD0332991 in patients with breast, colon, germ cell, and epithelial tumors containing amplification of CCND1. (Abstract #3088)**
R. F. Perini, A. DeMichele, D. J. Vaughn, M. Gallagher, W. Sun, B. J. Giantonio, U. R. Teitelbaum, S. Randolph, J. G. Christensen, R. D. Courtney, D. A. Pryma, C. R. Divgi, P. J. O'Dwyer
- Brd. 17F Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors. (Abstract #3089)**
R. Dienstmann, A. W. Tolcher, K. P. Papadopoulos, D. W. Rasco, J. Tabernero, I. Brana, A. Piera, N. Skartved, H. Aladdin, J. Petersen, A. Patnaik
- Brd. 17G A phase I study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors. (Abstract #3090)**
R. J. Kelly, A. Rajan, G. Chun, A. Lopez-Chavez, G. Giaccone
- Brd. 17H A phase I dose escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors. (Abstract #3091)**
R. C. Donehower, A. Scardina, M. Hill, J. Bowman, R. C. Newton, X. Liu, P. Scherle, Q. Wang, S. Diamond, J. Boer, F. Lee, T. Gau, H. A. Burris III, J. C. Bendell, S. F. Jones, J. R. Infante
- Brd. 18A Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. (Abstract #3092)**
S. R. Palmer, C. Erlichman, M. Fernandez-Zapico, Y. Qi, L. Almada, A. McCleary-Wheeler, M. J. Borad, J. R. Molina, A. Grothey, H. C. Pitot, A. Jatoi, D. W. Northfelt, R. R. McWilliams, S. H. Okuno, P. Haluska, G. P. Kim, G. Colon-Otero
- Brd. 18B Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. (Abstract #3093)**
S. P. Anthony, I. Puzanov, P. S. Lin, K. B. Nolop, B. West, D. D. Von Hoff
- Brd. 18C Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies. (Abstract #3094)**
S. Sharma, R. Kurzrock, L. Gouw, D. S. Hong, K. Jones, X. Zhou, H. Shi, H. Fingert, G. S. Falchook
- Brd. 18D A phase I/II study of the hypomethylating agent azacitidine with the nanoparticle albumin bound paclitaxel in the treatment of patients with advanced or metastatic solid tumors. (Abstract #3095^)**
T. L. Dumlaio, T. W. Butler, D. L. Dyess, H. T. Khong

- Brd. 18E** **First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor. (Abstract #3096)**
 U. Banerji, C. Aghajanian, E. Raymond, R. Kurzrock, M. Blanco-Codesido, E. Oelmann, L. Grinsted, W. Burke, S. B. Kaye, A. Naing
- Brd. 18F** **Phase I, dose-finding study of monotherapy with AZD8931, an inhibitor of ErbB1, 2, and 3 signaling, in patients (pts) with advanced solid tumors. (Abstract #3097)**
 U. Keilholz, V. Moiseyenko, A. Makhson, V. Semiglazov, M. Learoyd, A. Saunders, M. Stuart, S. Tjulandin
- Brd. 18G** **Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. (Abstract #3098^)**
 V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, C. M. Rudin, A. Manukyants, S. Gogov, S. Poondru, R. Gedrich, S. M. Gadgeel
- Brd. 18H** **A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. (Abstract #3099)**
 W. A. Harb, C. Sessa, H. W. Hirte, S. B. Kaye, R. Simantov, S. N. Banerjee, A. Christinat, D. W. Sternberg, M. Singh, R. Light, S. Poondru
- Brd. 19A** **A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. (Abstract #3100)**
 W. A. Messersmith, P. LoRusso, J. M. Cleary, A. Dasari, X. Zhang, M. N. Shaik, R. D. Courtney, S. Randolph, G. Shapiro
- Brd. 19B** **Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. (Abstract #3101)**
 W. Ma, W. A. Messersmith, G. K. Dy, E. Freas, A. Whitworth, F. Wilhelm, S. G. Eckhardt, A. A. Adjei, A. Jimeno
- Brd. 19C** **First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). (Abstract #3102)**
 W. R. Schelman, S. K. Sandhu, V. Moreno Garcia, G. Wilding, L. Sun, C. Toniatti, M. Stroh, N. Kreischer, C. L. Carpenter, L. R. Molife, S. B. Kaye, J. S. De Bono, R. M. Wenham
- Brd. 19D** **Predictive value of Fc gamma receptor IIIa genotype in response to conatumumab in three phase II studies. (Abstract #3103)**
 Y. Pan, V. Haddad, T. Sabin, N. Baker, Y. Hei, F. Galimi, J. Graves, C. Huang, S. Cottrell
- Brd. 19E** **Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. (Abstract #3104)**
 Y. Drew, J. A. Ledermann, A. Jones, G. Hall, G. C. Jayson, M. Highley, D. Rea, R. M. Glasspool, S. E. Halford, G. Crosswell, S. Colebrook, A. V. Boddy, N. J. Curtin, E. R. Plummer
- Brd. 19F** **Phase I, dose-finding study of AZD8931, an inhibitor of ErbB1, 2, and 3 receptor signaling, in combination with paclitaxel (P). (Abstract #3105)**
 J. A. Lopez-Martin, M. Vidal Losada, J. Cortes, B. Bermejo, A. Lluch Fernandez, M. Learoyd, A. Saunders, M. Stuart, J. Baselga
- Brd. 19G** **FDA evaluation of hepatotoxicity related to tyrosine kinase inhibitors. (Abstract #3106)**
 J. Chang, M. Rand, G. M. Blumenthal, P. Cortazar, C. Kulick, E. Hausman, S. Chang, R. Pratt, B. Habtemariam, Y. Chen, J. Bullock, R. Charlab Orbach, I. Zineh, R. L. Justice, R. Pazdur

Monday, June 6, 2011

8:00 AM - 12:00 PM
GENERAL POSTER SESSION

Tumor Biology

Location: Hall A

Track(s): Tumor Biology

- Brd. 20A** Evaluation of the prognostic significance of human mammaglobin expression in pleural effusion from patients with negative thoracoscopy. (Abstract #10534)
A. Vigani, P. A. Canessa, C. Manta, P. Ferro, M. C. Franceschini, A. Morabito, M. Sivori, V. Fontana, F. Fedeli, M. Pistillo, S. Roncella
- Brd. 20B** Clinical characteristics and outcomes of patients with BRAF-mutant advanced cancer in a phase I clinic: The University of Texas M. D. Anderson Cancer Center experience. (Abstract #10535)
H. E. El-Osta, G. S. Falchook, A. M. Tsimberidou, D. S. Hong, A. Naing, K. B. Kim, S. Wen, F. Janku, R. Kurzrock
- Brd. 20C** The association of long pentraxin 3 on prognosis in pancreatic carcinoma patients on gemcitabine-based chemotherapy. (Abstract #10536)
S. Kondo, H. Ueno, C. Morizane, F. Koizumi, K. Tamura, T. Okusaka
- Brd. 20D** The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. (Abstract #10537)
M. Maitah, S. Ali, P. LoRusso, F. H. Sarkar, S. M. Gadgeel
- Brd. 20E** Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. (Abstract #10538)
B. C. Creelan, G. Bepler, S. Antonia, T. Garrett, H. H. Soliman
- Brd. 20F** The predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Abstract #10539)
S. Keskin, Y. Eralp, E. Akisik, A. Igci, M. Muslumanoglu, S. Yilmaz, M. Tunaci, H. Camlica, S. Tuzlali, P. Saip, N. Dalay, V. Ozmen, E. Topuz
- Brd. 20G** Role of the type III TGF- β receptor in modulating antitumor immunity during breast cancer progression. (Abstract #10540)
B. A. Hanks, O. M. Campbell, J. D. Lee, M. Morse, T. M. Clay, H. K. Lyerly, G. C. Blobe
- Brd. 20H** Astrocyte elevated gene 1 (AEG-1) mRNA expression in non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations. (Abstract #10541)
S. Viteri, R. Rosell, C. Costa, M. Taron, J. Sanchez, S. Benlloch, T. Moran, B. Massuti, C. Camps, M. Majem, E. Carcereny, F. Cardenal, A. Gasco, N. Mederos, I. Magri, C. D. Rolfo, M. Garcia-Campelo, A. Gimenez Capitan, I. de Aguirre, C. Queralt
- Brd. 21A** The relationship between the number of aberrantly methylated regions and the methylation status of p73 and RARB genes and prognosis in patients with breast cancer. (Abstract #10542)
D. M. Marzese, F. Gago, J. I. Orozco, O. M. Tello, L. M. Vargas-Roig, M. Roqué
- Brd. 21B** An evaluation of molecular imaging with ¹¹c-PD153035 PET/CT and its association in predicting outcomes in non-small cell lung cancer treated with EGFR-TKI. (Abstract #10543)
X. Meng, J. Yu, B. W. Loo, L. Ma, X. Sun, J. D. Murphy, S. Q. Zhao, L. Kong, G. R. Yang, W. L. Li, X. G. Zhao

- Brd. 21C** **A metabolic phenotyping approach to understanding relationships between metabolic syndrome and breast tumor responses to chemotherapy. (Abstract #10544)**
J. Stebbing, A. Sharma, B. North, T. J. Athersuch, A. Zebrowski, D. Pchejetski, R. C. Coombes, J. K. Nicholson, H. C. Keun
- Brd. 21D** **The prognostic role of calretinin expression and neutrophil-to-lymphocyte ratio (NLR) in patients with malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP). (Abstract #10545)**
S. C. Kao, S. Klebe, D. Henderson, G. Reid, M. D. Chatfield, N. Armstrong, T. Yan, J. L. Vardy, S. J. Clarke, N. Van Zandwijk, B. McCaughan
- Brd. 21E** **The relationship of HOXB9 expression promoting tumor cell proliferation and angiogenesis to clinical outcomes of patients with breast cancer. (Abstract #10546)**
T. Hayashida, H. Jinno, H. Seki, M. Takahashi, M. Sakata, S. Hirose, M. Mukai, Y. Kitagawa
- Brd. 21F** **Correlation of 18F-FDG uptake and EGFR/KRAS mutations in surgically resected lung cancer. (Abstract #10547)**
K. Takamochi, S. Oh, M. Fukui, K. Suzuki
- Brd. 21G** **The potential of circulating microRNA (miRNA) levels as a biomarker in drug development: An analysis of tumor-serum samples from patients on a phase I trial of saracatinib-paclitaxel (P)-carboplatin (C). (Abstract #10548)**
D. S. Tan, S. Aamdal, G. Freyer, R. J. Jones, S. B. Kaye, E. Pujade-Lauraine, J. Fog, M. Wrang Teilum, C. Glue, A. Baker, U. A. Emeribe, P. Elvin, C. Stephens, M. Stuart, J. Walker, E. Boven
- Brd. 21H** **Molecular characterization of primary breast cancer in older women using partitioned clustering and correlation with long-term clinical outcome. (Abstract #10549)**
B. M. Syed, A. R. Green, D. Soria, E. C. Paish, J. Garibaldi, D. A. Morgan, I. O. Ellis, K. Cheung
- Brd. 22A** **Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue derived from lung cancer patients. (Abstract #10550)**
A. J. Yee, T. Raz, A. Amzallag, D. Lipson, E. Giladi, H. Lopez, D. R. Borger, M. Mino-Kenudson, J. F. Thompson, A. J. Iafrate, P. Milos, D. A. Haber, S. Ramaswamy
- Brd. 22B** **MicroRNA expression patterns in lobular neoplasia. (Abstract #10551)**
L. A. Stead, A. Ramnauth, S. Fineberg, O. Loudig
- Brd. 22C** **Identification of LASEP3 as a new serological and prognostic biomarker for lung cancer. (Abstract #10552)**
A. Takano, Y. Nakamura, Y. Daigo
- Brd. 22D** **Clinical relevance of circulating CK-19mRNA-positive tumor cells at first diagnosis in patients with metastatic breast cancer. (Abstract #10553)**
N. E. Androulakis, M. Perraki, S. Apostolaki, V. Bozionelou, A. G. Pallis, K. Kalbakis, S. Agelaki, A. Xyrafas, D. Mavroudis, V. Georgoulas
- Brd. 22E** **Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumor cells in patients with early breast cancer. (Abstract #10554)**
N. Xenidis, M. Perraki, S. Apostolaki, S. Agelaki, K. Kalbakis, N. K. Vardakis, A. Kalykaki, A. Xyrafas, S. Kakolyris, D. Mavroudis, V. Georgoulas
- Brd. 22F** **Microarray-based gene expression profiles reliably predict ELISA-derived uPA and PAI-1 levels in breast cancer biopsies, a comparison between fresh frozen (FF) and formalin-fixed paraffin-embedded (FFPE) samples. (Abstract #10555)**
C. Matuschek, H. Prisack, E. Boelke, W. Budach, M. Peiper, M. Rezai, W. Janni, H. Bojar

Monday, June 6, 2011

- Brd. 22G The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology. (Abstract #10556)**
Y. Kato, C. Mascoux, M. W. Wynes, B. Reyna Asuncion, C. Tran, K. Yoshida, J. Matsubayashi, E. Nakajima, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, F. R. Hirsch
- Brd. 22H Clinical relevance of mesenchymal stem cell–induced resistance to chemotherapy. (Abstract #10557)**
J. M. Roodhart, L. G. Daenen, E. C. Stigter, R. H. Medema, A. C. Martens, A. B. Brenkman, E. E. Voest
- Brd. 23A A polymorphism in the coding sequence of *WT1* is an independent prognostic marker in 1,101 patients with lobular breast cancer. (Abstract #10558)**
M. Heuser, F. Damm, P. Schuermann, M. Zucknick, M. Shah, P. Harrington, P. Pharoah, M. Schmidt, A. Broeks, R. van Hien, R. A. Tollenaar, H. Nevanlinna, T. Heikkinen, K. Aittomaki, C. Blomqvist, J. Krauter, P. Hillemanns, A. Ganser, T. Park-Simon, T. Dork
- Brd. 23B The prognostic value of the downregulation of leukocyte cell–derived chemotaxin 2 gene of hepatocellular carcinoma. (Abstract #10559)**
C. Yang, M. Ho, C. Chen, H. Hsu, P. Lee, M. Kuo
- Brd. 23C Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis. (Abstract #10560)**
D. S. Thompson, J. D. Hainsworth, C. M. Lane, W. J. Lenington, D. R. Spigel, F. A. Greco
- Brd. 23D Non-small cell lung cancer biomarkers: Discovery using mab proteomics. (Abstract #10561)**
L. Takacs, M. Guergova-Kuras, I. Kurucz, N. Tardieu, J. Kadas, C. Malderez-Bloes, A. Jullien, Y. Kieffer, B. Dezso, B. Karger
- Brd. 23E Performance characteristics and validation of automated tumor-infiltrating lymphocyte counting. (Abstract #10562)**
C. C. Hoyt, I. S. Hagemann, A. R. Hagemann, L. Wang, E. Hung, K. Lane, G. Coukos, M. D. Feldman
- Brd. 23F Thymidylate synthase expression in adenosquamous carcinoma of lung. (Abstract #10563)**
C. Shu, H. Cheng, A. Wang, M. Mansukhani, C. A. Powell, B. Halmos, A. C. Borczuk
- Brd. 23G Comprehensive next-generation sequencing for clinically actionable mutations from formalin-fixed cancer tissues. (Abstract #10564)**
J. S. Ross, D. Lipson, R. Yelensky, M. Jarosz, A. Parker, C. E. Sheehan, F. Juhn, Z. Zwirko, K. Brennan, T. Bloom, S. Downing, J. Curran, M. T. Cronin
- Brd. 23H Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors. (Abstract #10565)**
Y. Liu, M. Starr, H. Pang, J. Marcello, B. R. Leigh, C. P. Theuer, H. Hurwitz, A. B. Nixon
- Brd. 24A Disparities in the prognostic significance of proliferation amongst different molecular subtypes in node-negative breast cancer. (Abstract #10566)**
M. Schmidt, I. Petry, D. Boehm, A. Lebrecht, S. Gebhard, H. Koelbl, M. Gehrmann, J. G. Hengstler
- Brd. 24B SmgGDS splice variants: Potential novel targets for breast cancer therapeutics. (Abstract #10567)**
C. Bergom, A. Hauser, E. L. Lorimer, R. Li, A. C. Mackinnon, C. L. Williams
- Brd. 24C Discovery of oncoproteins as cancer biomarkers and molecular targets for antibody-based immunotherapy. (Abstract #10568)**
Y. Daigo, A. Takano, Y. Nakamura

- Brd. 24E Exonic expression variations of EGFR and KRAS in small bronchoscopic biopsies from patients with advanced non-small cell lung cancer treated by combined bevacizumab/erlotinib therapy followed by platinum-based chemotherapy at disease progression: A multicenter phase II trial SAKK19/05. (Abstract #10570)**
M. H. Brutsche, M. Frueh, S. Crowe, K. Na, C. Droege, D. C. Betticher, R. von Moos, F. Zappa, M. Pless, L. Bubendorf, F. Baty, on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
- Brd. 24F An integrated analysis of three distinct IBC/non-IBC affymetrix gene expression data sets to study the transcriptional heterogeneity both between IBC and non-IBC and within IBC. (Abstract #10571)**
S. J. Van Laere, N. T. Ueno, P. Finetti, P. B. Vermeulen, A. Lucci Jr., D. Birnbaum, F. Robertson, T. Iwamoto, P. A. van Dam, W. A. Woodward, P. Viens, L. Y. Dirix, J. M. Reuben, F. Bertucci
- Brd. 24G Circulating tumor cell (CTC) as a clinical marker in malignant pleural mesothelioma (MPM). (Abstract #10572)**
F. Tanaka, K. Yoneda, N. Kondo, M. Hashimoto, T. Takuwa, S. Matsumoto, S. Hasegawa, Y. Okumura, T. Tsujimura, K. Fukuoka, T. Nakano
- Brd. 24H Pathway analysis of primary human non-small cell lung cancer (NSCLC). (Abstract #10573)**
N. Daraselia, Y. Wang, A. Budoff, A. Lituev, O. Potapova, J. Monforte, V. Ossovskaya
- Brd. 25B A second generation microRNA-based assay for diagnosing tumor tissue origin. (Abstract #10575)**
R. T. Aharonov, S. Rosenwald, T. B. Edmonston, I. Barshack, M. Feinmesser, M. Huszar, W. C. Mueller, F. Fogt, H. Shomin, L. Cohen, I. Burnstein, E. Goren, B. St. Cyr, Y. Spector, N. Dromi, E. Meiri
- Brd. 25C NY-ESO-1 as a predictive marker for neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer (NSCLC). (Abstract #10576)**
T. John, Y. Chen, M. H. Starmans, M. Walkiewicz, P. Russell, A. Azad, S. Deb, N. K. Altorki, P. C. Boutros, P. Mitchell, J. S. Cebon
- Brd. 26A Circulating endothelial cell (CEC), a surrogate of tumor angiogenesis, as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM). (Abstract #10577)**
K. Yoneda, F. Tanaka, N. Kondo, H. Orui, M. Hashimoto, T. Takuwa, S. Matsumoto, Y. Okumura, A. Sato, T. Tsujimura, N. Tsubota, K. Kuribayashi, K. Fukuoka, T. Nakano, S. Hasegawa
- Brd. 26B A microRNA-based diagnostic test for kidney tumor classification. (Abstract #10578)**
A. Chajut, E. Fridman, I. Barshack, Z. A. Dotan, M. Zepeniuk, S. Tabak, D. Lebanony, E. Klinke, S. Rosenwald, O. Zion, A. Faerman, M. Ben-David, A. Bokish, Y. Spector
- Brd. 26C Use of immunohistochemical evaluation of DNA repair proteins to demonstrate cisplatin response prediction in resected NSCLC squamous cell carcinoma. (Abstract #10579)**
W. E. Pierceall, K. M. Sprott, E. Brambilla, R. Pirker, H. H. Popper, X. Wang, Y. Chen, S. Quan, M. Filipits, L. Alparthi, J. Kutok, D. T. Weaver, M. Al-Adhami, F. Andre, T. Le Chevalier, B. E. Ward, J. Soria
- Brd. 27A MYC and human telomerase gene (TERC) gene copy number gain in resected in non-small cell lung cancer (NSCLC). (Abstract #10580)**
A. Flacco, V. Ludovini, F. R. Tofanetti, F. Bianconi, G. Bellezza, M. G. Mameli, G. Metro, C. Bennati, L. Cagini, N. Daddi, L. Pistola, A. Siggillino, E. Baldelli, A. Sidoni, F. Puma, M. Varella-Garcia, L. Crinò
- Brd. 27B A novel inflammatory-based prognostic score in hepatocellular carcinoma. (Abstract #10581)**
D. J. Pinato, H. S. Wasan, L. Maslen, B. North, R. Sharma

Monday, June 6, 2011

- Brd. 27C** **Disseminated tumor cells in the bone marrow of ductal carcinoma in situ patients. (Abstract #10582)**
N. Sanger, K. E. Effenberger, S. Riethdorf, E. Ruckhaberle, L. C. Hanker, I. Wiegatz, K. Strebhardt, K. Pantel, M. Kaufmann
- Brd. 28A** **SOX2-related micrnas, miR-145 and miR-367, as prognostic markers of time to recurrence (TTR) in surgically resected non-small cell lung cancer (NSCLC) patients (p). (Abstract #10583)**
A. Navarro, M. Campayo, N. Vinolas, V. Ciria, T. Diaz, R. M. Marrades, L. Molins, J. Ramirez, M. Monzo
- Brd. 28B** **Evaluation of anti-CTLA4 treatment in a murine model of intestinal polyposis. (Abstract #10584)**
J. D. Phillips, N. R. Blatner, M. F. Mulcahy, P. Beckhove, D. J. Bentrem, K. Khazaie
- Brd. 28C** **ALK chromosomal alterations in neuroendocrine tumors. (Abstract #10585)**
C. Montagut, E. Arriola, A. B. Galvan, F. G. Rojo, M. Salido, M. Gallen, M. Garcia, A. Martinez, F. Pons, S. Servitja, M. Iglesias, S. Menendez, S. Serrano, F. Sole, A. Rovira, J. Albanell, J. Bellmunt
- Brd. 29A** **Correlation of high levels of immature blood vessels in colorectal tumors with longer survival following bevacizumab treatment. (Abstract #10586)**
S. Noonan, P. Martin, M. Biniecka, A. Maguire, M. Tosetto, J. Hyland, K. Sheahan, D. O'Donoghue, H. Mulcahy, D. Fennelly, J. O'Sullivan
- Brd. 29B** **A single nucleotide polymorphism (SNP) in a microRNA (miRNA)-binding site of KRT81 and time to recurrence (TTR) in patients (p) with surgically resected non-small cell lung cancer (NSCLC). (Abstract #10587)**
M. Campayo, A. Navarro, N. Vinolas, R. Tejero, C. Munoz, T. Diaz, R. M. Marrades, M. L. Cabanas, J. M. Gimferrer, J. Ramirez, P. Gascon, M. Monzo
- Brd. 29C** **Gastrin-releasing peptide receptor expression in Brazilian and Japanese patients with lung cancer and normal lung tissue samples from healthy individuals. (Abstract #10588)**
J. Mattel, Y. Kato, M. W. Wynes, C. Cano, R. D. Achcar, B. Reyna Asuncion, B. R. de Macedo, L. Meurer, J. Kulczynski, R. Roesler, K. Yoshida, J. Matsubayashi, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, A. Brunetto, G. Schwartzmann
- Brd. 30A** **Prognostic value of CA27.29 trend during adjuvant chemotherapy and until 2 years thereafter in patients with primary breast cancer. (Abstract #10589)**
B. K. Rack, P. G. Hepp, U. Andergassen, J. K. Neugebauer, J. Salmen, G. Heinrich, J. Schreier, A. Hoenig, D. Finas, T. Zwingers, R. Kreienberg, M. W. Beckmann, W. Lichtenegger, H. L. Sommer, K. Friese, W. Janni, SUCCESS Study Group
- Brd. 30B** **Body mass index (BMI) and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials. (Abstract #10590)**
N. R. Foster, F. Sinicrope, G. A. Yothers, C. J. Allegra, D. J. Sargent
- Brd. 30C** **Reactivation of oncogene-induced senescence in KRAS mutant non-small cell lung cancer by inhibition of TWIST1. (Abstract #10591)**
T. F. Burns, I. Dobromilskaya, S. Murphy, S. Thiyagarajan, S. Das, P. T. Tran, C. M. Rudin
- Brd. 31A** **Clinical validity of circulating tumor cell (CTC) enumeration in 841 subjects with metastatic breast cancer (MBC). (Abstract #10592)**
M. C. Liu, M. Mego, S. Nakamura, F. Nole, J. Pierga, M. Toi, E. Munzone, H. Yagata, M. T. Sandri, F. Bidard, H. Wang, D. F. Hayes, M. Cristofanilli
- Brd. 31B** **Computer-aided volumetry analysis in assessing pulmonary chemotherapy response in advanced NSCLC comparing with RECIST criteria. (Abstract #10593)**
L. Ding, R. L. Bliss, M. Ingebrand, T. Allen, P. Ives, A. Dudek, R. A. Kratzke

- Brd. 31C** **Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial. (Abstract #10594)**
T. Degenhardt, O. Gluz, H. H. Kreipe, R. E. Kates, C. Liedtke, S. Shak, M. R. Clemens, D. Augustin, U. Nitz, N. Harbeck, on behalf of the Plan B investigators
- Brd. 31D** **Association of the MDM2 T309G polymorphism and gastroesophageal reflux disease (GERD) with overall survival (OS) in esophageal adenocarcinoma (EAC). (Abstract #10595)**
D. J. Renouf, B. Sun, R. Zhai, W. Xu, R. S. Heist, M. Kulke, L. Su, D. C. Christiani, G. Liu
- Brd. 31E** **Molecular and clinicopathologic characteristics of HER2-mutant lung adenocarcinoma (ADC). (Abstract #10596)**
M. E. Arcila, J. E. Chaft, K. Nafa, M. G. Kris, M. F. Zakowski, M. Ladanyi
- Brd. 31F** **PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test. (Abstract #10597)**
M. T. Ebbert, R. R. Bastien, L. R. Rowe, P. A. Miller, D. Anderson, K. M. Boucher, L. M. Pappas, C. Fauron, B. W. Lyons, T. Dowell, D. E. Wall, L. Barley, P. S. Bernard
- Brd. 31G** **Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases. (Abstract #10598)**
A. Tamburrino, A. A. Molinolo, P. Salerno, R. Chernock, M. Raffeld, L. Xi, J. S. Gutkind, J. F. Moley, S. A. Wells, M. Santoro
- Brd. 31H** **Molecular predictors of metastases and stage of thymoma. (Abstract #10599)**
S. S. Badve, C. Goswami, Y. Gokmen-Polar, R. P. Nelson Jr., J. Henley, N. Miller, R. K. Jain, R. J. Mehta, N. A. Zaheer, G. W. Sledge Jr., L. Li, K. Kesler, P. J. Loehrer
- Brd. 32A** **Expression of Adam28 as a prognostic biomarker of survival in patients with early-stage non-small cell lung cancer. (Abstract #10600)**
Y. Zhang, X. Zhang, Y. Wu, G. Zhang, H. Cheng, S. Dong
- Brd. 32B** **An analysis of serum heparan sulfate concentration and EGFR tyrosine kinase inhibitor treatment in patients with non-small cell lung adenocarcinoma. (Abstract #10601)**
M. Nishio, T. Yamanaka, K. Matsumoto, H. Kimura, K. Sakai, A. Sakai, T. Sone, A. Horiike, F. Koizumi, K. Kasahara, T. Ohira, N. Ikeda, N. Saijo, T. Arao, K. Nishio
- Brd. 32C** **Signatures of drug sensitivity in non-small cell lung cancer. (Abstract #10602)**
H. Gong, D. G. Beer, S. Singh
- Brd. 32D** **Elucidating the biological basis of prognosis in young women with early breast cancer (BC) using gene expression profiling. (Abstract #10603)**
H. A. Azim, S. Michels, P. Bedard, D. Fumagalli, S. K. Singhal, B. Haibe-Kains, M. Piccart, C. Sotiriou, S. Loi
- Brd. 32E** **A mouse model of rectal cancer that mimics the clinical disease. (Abstract #10604)**
H. Kishimoto, M. Momiyama, R. Aki, H. Kimura, A. Suetsugu, M. Bouvet, T. Fujiwara, R. M. Hoffman
- Brd. 32F** **MicroRNA analysis as a potential diagnostic tool in the cytological diagnosis of non-small cell lung cancer. (Abstract #10605)**
A. Fassina, R. Cappellesso, A. Olivotto, M. Fassan
- Brd. 32G** **TGF β 1 gene polymorphisms with the risk of radiation pneumonitis in non-small cell lung cancer in different ethnic study. (Abstract #10606)**
X. Niu, S. Lu, H. Li, Y. Liu, Z. Chen, D. Zhou, M. Kan, Z. Li, Y. Yu, C. LV
- Brd. 32H** **Functional metabolic tomographic optical breast imaging (TOBI) to monitor response to neoadjuvant therapy in breast cancer. (Abstract #10607)**
S. Carp, C. Wanyo, M. Specht, L. Schapira, B. Moy, D. Finkelstein, D. Boas, S. J. Isakoff

Monday, June 6, 2011

- Brd. 33A Diagnostic and therapeutic significance of the cerebrospinal fluid (CSF) EGFR mutation analysis for the patients with NSCLC suffering meningitis carcinomatosa harboring active EGFR mutation, after gefitinib therapy failure. (Abstract #10608)**
S. Sasaki, Y. Yoshioka, R. Ko, Y. Katsura, Y. Namba, K. Koike, M. Yoshioka, S. Tominaga
- Brd. 33B KRAS and BRAF mutation analysis on paired biopsy and resection specimens of patients with colorectal cancer: Molecular analysis using high-resolution melting, direct sequencing, KRAS ARMS-scorpion PCR and BRAF pyrosequencing. (Abstract #10609)**
L. C. Krol, N. A. Hart, N. Methorst, A. J. Knol, C. Prinsen, J. E. Boers
- Brd. 33C An evaluation of bone marrow stromal-derived growth factor-1 and interleukin-8 levels in stage I-III breast cancer patients with disseminated tumor cells. (Abstract #10610)**
C. Hall, S. Krishnamurthy, A. Lodhi, A. Bhattacharyya, A. Anderson, H. M. Kuerer, I. Bedrosian, A. Lucci Jr.
- Brd. 33D Circulating levels of RANK/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: A prospective study. (Abstract #10611)**
T. Ibrahim, L. Mercatali, E. Sacanna, R. Ricci, E. Scarpi, P. Serra, F. Fabbri, C. Tison, D. Amadori
- Brd. 33E Differential efficacy of pemetrexed in non-squamous NSCLC based on human cytokeratin fragment antigen 21-1 (CYFRA21-1) serum levels. (Abstract #10612)**
K. Kaburaki, A. Horiike, T. Sakatani, R. Saito, H. Tanaka, N. Yanagitani, K. Kudo, F. Ohyanagi, S. Hagiwara, T. Horai, M. Nishio
- Brd. 33F Combined use of MammaPrint and molecular subtyping profile (BluePrint) to identify subgroups with marked differences in response to neoadjuvant treatment. (Abstract #10613)**
F. De Snoo, P. Roepman, O. Krijgsman, R. A. Bender, R. Bernards, A. Glas
- Brd. 33G A miRNA assay for the classification of benign and neoplastic lesions in pancreatic fine needle aspirates. (Abstract #10614)**
A. E. Schwarzbach, A. Adai, M. Lloyd, B. F. Andruss
- Brd. 33H Collecting tissue for research purposes: A survey of 16 institutions in the Translational Breast Cancer Research Consortium (TBCRC). (Abstract #10615)**
E. S. Frank, R. T. Burns, N. E. Carbine, L. Cargen, C. Chauhan, D. K. Cline, R. Kleban, S. A. Mertz, A. H. Meyn, J. Perlmutter, C. A. Rufenbarger, M. Smith, P. A. Spears, L. V. Vincent, A. C. Wolff
- Brd. 34A Use of the DEPArray platform to detect, isolate, and molecularly characterize pure tumor cells from peripheral blood samples enriched using the CellSearch system. (Abstract #10616)**
G. Medoro, S. Gross, N. Manaresi, M. Sergio, F. Fontana, S. Gianni, A. Calanca, E. Peruzzi, M. Banzi, G. Signorini, C. Rao, J. Patel, J. Karkera, G. Giorgini, M. Mata, M. C. Connelly
- Brd. 34B The prognostic impact of circulating tumor cells in patients with small cell lung cancer. (Abstract #10617)**
T. Naito, F. Tanaka, K. Yoneda, T. Takahashi, H. Murakami, Y. Nakamura, A. Tsuya, M. Endo, H. Kenmotsu, K. Kaira, T. Shukuya, A. Ono, H. Akamatsu, S. Miura, M. Kimura, N. Yamamoto
- Brd. 34C Significance of FANCJ expression as a predictive marker of sensitivity to 5-fluorouracil in colorectal cancer. (Abstract #10618)**
R. Nakanishi, H. Kitao, N. Yamashita, N. Kubo, Y. Fujinaka, M. Iimori, E. Oki, M. Morita, Y. Kakeji, Y. Maehara

- Brd. 34D Implications of specific T-cell responses by different novel and known immunogenic tumor-associated antigens (TAA) in patients with metastatic lung cancer. (Abstract #10619)**
A. M. Babiak, M. Steinhauser, S. Hofmann, J. Conzelmann, V. Schneider, M. Goetz, L. Zhang, H. Dohner, J. Greiner
- Brd. 34E Influence of KRAS status of colorectal cancer liver metastases in patients receiving neoadjuvant chemotherapy including bevacizumab prior liver resection. (Abstract #10620)**
S. Stremitzer, J. Maresch, T. Aschacher, B. Wolf, F. Wrba, T. Gruenberger, B. Gruenberger
- Brd. 34F Intravital evaluation of time-course efficacy of anticancer drugs on colorectal liver metastases in the same living mice using two-photon laser scanning microscopy. (Abstract #10621)**
K. Tanaka, Y. Morimoto, Y. Toiyama, S. Saigusa, Y. Okugawa, Y. Inoue, K. Uchida, K. Matsushita, M. Kawamura, A. Mizoguchi, M. Kusunoki
- Brd. 34G Clinical, biological, and pathological features predicting non-sentinel lymph node (NSLN) status in breast cancer (BC). (Abstract #10622)**
J. Furlanetto, E. Fiorio, G. Pollini, Z. Franchini, P. Pietrarota, Q. Piubello, F. Bonetti, R. Micciolo, E. Manfrin, G. L. Cetto, A. Molino
- Brd. 34H Prognostic role of interleukin-1B and interleukin-1-receptor antagonist polymorphisms in localized gastric cancer. (Abstract #10623)**
E. Goekkurt, G. Folprecht, S. Lehmann, L. Obermann, M. Kramer, A. Rentsch, S. Wilop, G. Ehninger, T. H. Brummendorf, J. Stoehlmacher-Williams
- Brd. 35A Effect of everolimus treatment on chromogranin A, neuron-specific enolase, gastrin, and glucagon levels in patients with advanced pancreatic neuroendocrine tumors (pNET): Phase III RADIANT-3 study results. (Abstract #10624)**
E. De Vries, L. B. Anthony, L. Sideris, L. Chen, J. Lebec, Z. Tsuchihashi, R. E. Winkler, J. C. Yao, K. E. Oberg
- Brd. 35B Comparison of predictive and prognostic impact of molecular subtypes and central grade regarding taxane-based therapy in intermediate-risk breast cancer: Results from the EC-Doc trial. (Abstract #10625)**
U. Nitz, O. Gluz, C. Liedtke, J. B. Huober, A. Hartmann, R. E. Kates, H. H. Kreipe, E. Pelz, W. Kuhn, N. Harbeck, on behalf of the EC-Doc investigators (West German Study Group/AGO-B)
- Brd. 35C Correlation of CA 27.29 and circulating tumor cells before, at the end, and 2 years after adjuvant chemotherapy in patients with primary breast cancer: The SUCCESS trial. (Abstract #10626)**
P. G. Hepp, B. K. Rack, H. Tesch, M. Rezai, T. Beck, J. Salmen, U. Andergassen, U. Ortmann, T. Zwingers, M. W. Beckmann, W. Lichtenegger, J. W. Janni, SUCCESS Study Group
- Brd. 35D Determining argininosuccinate synthetase (ASS) expression in melanoma patients treated with arginine depleting therapy. (Abstract #10627)**
V. Dinh, M. You, N. Savaraj, C. Wu, M. T. Kuo, M. Wangpaichitr, L. G. Feun
- Brd. 35E Pathoepidemiological patterns of contralateral breast cancers in Black and White women. (Abstract #10628)**
H. Nsouli-Maktabi, A. M. Schwartz, S. D. Cleary, N. Younes, H. A. Young, D. E. Henson
- Brd. 35F Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (Abstract #10629)**
R. Audet, R. Duchnowska, K. Adamowicz, J. Zok, W. Rogowski, M. M. Litwiniuk, S. Debska, M. Jaworska, M. Foszczynska-Kloda, M. Kulma-Kreft, K. Zabkowska, C. Shen, S. Edgerton, K. V. Nielsen, A. D. Thor, J. C. Chang, K. Miller, J. Jassem, G. W. Sledge Jr., B. Leyland-Jones
- Brd. 35G Biomarkers affecting metastasis and survival in paired tissues of 107 patients with metastatic breast cancer. (Abstract #10630)**
E. Kim, H. Lee, G. Gong, K. Jung, J. Ahn, B. Son, S. Ahn, H. Kim, S. Kim

Monday, June 6, 2011

Brd. 35H Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH. (Abstract #10631)

F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter, J. A. Mayer

Brd. 36A Proof of concept of immuno-PET molecular imaging of met using ⁷⁶Br- and ⁸⁹Zr-labeled MetMab. (Abstract #10632)

M. Merchant, J. Marik, J. Peng, S. P. Williams, A. Ogasawara, J. N. Tinianow, V. Bhadrasetty, L. Lang, S. M. Lee, I. Kim, M. Williams, L. Szajek, K. E. Raffensperger, F. Cecchi, E. Jagoda, P. L. Choyke, C. Paik, D. P. Bottaro

MONDAY

8:00 AM - 12:00 PM
TRIALS IN PROGRESS POSTER SESSION

Trials in Progress Poster Session

Location: Hall A

Track(s): Clinical Trials; Special Session

- Brd. 36B** **A randomized phase II study of PD 0332991, cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole for first-line treatment of patients with postmenopausal, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. (Abstract #TPS100)**
R. S. Finn, K. Boer, I. Lang, R. J. Parikh, R. Patel, M. Schmidt, C. T. Hagenstad, H. J. Lim, T. Pinter, D. Amadori, D. Chan, R. Dichmann, S. T. Kim, S. Randolph, D. J. Slamon, J. P. Crown
- Brd. 36C** **Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. (Abstract #TPS101)**
S. D. Ramsey, W. E. Barlow, C. Moinpour, A. M. Gonzalez-Angulo, G. N. Hortobagyi, D. L. Veenstra, L. P. Garrison, S. R. Tunis, L. H. Baker
- Brd. 36D** **MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). (Abstract #TPS102)**
P. A. Ellis, C. H. Barrios, Y. Im, M. Patre, F. Branle, E. A. Perez
- Brd. 36E** **A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC; NCIC Clinical Trials Group MA.32). (Abstract #TPS103)**
W. Parulekar, B. E. Chen, C. Elliott, L. E. Shepherd, K. A. Gelmon, K. I. Pritchard, T. J. Whelan, J. A. Ligibel, D. L. Hershman, I. A. Mayer, T. J. Hobday, P. Rastogi, J. Lemieux, P. A. Ganz, V. Stambolic, P. J. Goodwin
- Brd. 36F** **SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less. (Abstract #TPS104)**
A. M. Gonzalez-Angulo, W. E. Barlow, J. Gralow, F. Meric-Bernstam, D. F. Hayes, C. Moinpour, S. D. Ramsey, A. F. Schott, D. B. Sparks, K. S. Albain, G. N. Hortobagyi
- Brd. 36G** **Ongoing clinical development of lapatinib in HER2-positive (HER2+) metastatic breast cancer (MBC): An innovative approach to recruit patients in clinical studies. (Abstract #TPS105)**
S. R. Johnston, K. A. Gelmon, X. B. Pivot, W. J. Gradishar, A. Conner, D. Kothari, P. Legenne, M. Leigh, L. O'Rourke, R. Parikh
- Brd. 36H** **A phase I dose-escalation study of ABT-888 (veliparib) in combination with carboplatin in HER2-negative metastatic breast cancer (MBC). (Abstract #TPS106)**
S. Viswanathan, R. Wesolowski, R. M. Layman, G. Alejandra, B. Miller, J. J. Chalmers, S. Bejastani, W. Zhao, G. Pierluigi, J. Cotrill, M. A. Phelps, L. J. Schaaf, S. M. Geyer, N. Hall, M. V. Knopp, C. L. Shapiro, M. A. Villalona-Calero, A. Chen, M. R. Grever, B. Ramaswamy
- Brd. 37A** **An open-label positron emission tomography (PET) study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing (HER2+) advanced or metastatic breast cancer (MBC). (Abstract #TPS107)**
R. C. Coombes, J. A. Reise, M. Lau, S. C. Carme, G. E. Searle, M. Huiban, P. Burgess, K. Koch, A. Das-Gupta, A. Saleem

Monday, June 6, 2011

- Brd. 37B Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG) MA.31/GSK EGF 108919). (Abstract #TPS108)**
W. Parulekar, J. W. Chapman, S. Aparicio, Y. Murray, F. M. Boyle, A. Di Leo, B. Kaufman, C. Levy, A. Manikhas, M. Martin, K. I. Pritchard, L. S. Schwartzberg, M. J. Burnell, S. Dent, S. Ellard, K. S. Tonkin, T. J. Whelan, J. Lemieux, L. Bordeleau, K. A. Gelmon
- Brd. 37C Safety and efficacy of single-agent adjuvant trastuzumab in older women with breast cancer. (Abstract #TPS109)**
C. Owusu, H. D. Klepin, G. G. Kimmick, L. Sutton, A. Brufsky
- Brd. 37D A phase II study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor-positive (ER+) breast cancer. (Abstract #TPS110)**
S. Ebbinghaus, J. L. Blum, J. Cortes, H. S. Rugo, C. Swanton, L. Eaton, Y. Song, T. Zhang, J. Baselga
- Brd. 37E Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer. (Abstract #TPS111)**
P. Haluska, A. Dhar, X. Hou, F. Huang, D. S. Nuyten, J. Park, A. H. Brodie, J. N. Ingle, J. M. Carboni, M. M. Gottardis, A. C. Wolff, F. G. Finckenstein
- Brd. 37F A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer. (Abstract #TPS112)**
V. M. Moyo, M. J. Higgins, R. Aravelo-Araujo, N. Iannotti, V. Charu, N. Dhindsa, P. E. Goss
- Brd. 37G HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515). (Abstract #TPS113)**
N. U. Lin, M. A. Danso, A. K. David, J. J. Muscato, C. E. Ellis, S. Lahiri, T. Sessa, Y. M. Nagarwala, E. Winer
- Brd. 37H Randomized, double-blind, placebo-controlled phase II trial of low-dose metronomic cyclophosphamide alone or in combination with veliparib (ABT-888) in chemotherapy-resistant ER and/or PR-positive, HER2/neu-negative metastatic breast cancer: New York Cancer Consortium trial P8853. (Abstract #TPS114)**
E. Andreopoulou, A. P. Chen, J. Zujewski, M. Kim, D. L. Hershman, K. Kalinsky, T. Cigler, L. T. Vahdat, G. Raptis, B. Ramaswamy, Y. Novik, F. Muggia, J. A. Sparano
- Brd. 38A A phase III, multicenter, double-blind, randomized trial of celecoxib versus placebo in primary breast cancer patients: Randomized European Celecoxib Trial (REACT). (Abstract #TPS115)**
R. C. Coombes, G. Von Minckwitz, J. Hicks, P. Klare, A. A. Evans, M. Schmidt, A. Makris, R. Grieve, S. Loibl, L. Maher, K. Mousa, K. Buchsenschutz, R. A'Hern, J. M. Bliss
- Brd. 38B EMILIA: A phase III, randomized, multicenter study of trastuzumab-DM1 (T-DM1) compared with lapatinib (L) plus capecitabine (X) in patients with HER2-positive locally advanced or metastatic breast cancer (MBC) and previously treated with a trastuzumab-based regimen. (Abstract #TPS116)**
S. Verma, V. Dieras, L. Gianni, D. Miles, M. Welslau, M. D. Pegram, J. Baselga, E. Guardino, L. Fang, C. M. Linehan, K. L. Blackwell
- Brd. 38C Trial of perioperative endocrine therapy: Individualizing care (POETIC). (Abstract #TPS117)**
I. E. Smith, L. Johnson, M. Dowsett, J. F. Robertson, L. E. Robison, J. S. Kokan, A. A. Evans, C. Holcombe, K. Horgan, A. Skene, R. Prasad, M. S. Absar, R. Vidyia, N. J. Bundred, C. Harding-Mackean, D. A. Wheatley, M. W. Kissin, I. F. Pinhel, L. S. Kilburn, J. M. Bliss, on behalf of the POETIC Trialists

- Brd. 38D** **Trastuzumab plus capecitabine with or without pertuzumab in patients with HER2-positive MBC whose disease has progressed during or following trastuzumab-based therapy for first-line metastatic disease: A multicenter, randomized, two-arm, phase II study (PHEREXA). (Abstract #TPS118)**
M. Munoz-Mateu, A. Urruticoechea, R. Separovic, J. Erfán, T. D. Bachelot, J. Canon, N. Kovalenko, E. Staroslawska, B. Pikó, C. Veyret, O. Pribylova, D. L. Ciule, J. Ratnayake, S. Das, K. Mayne, G. Ross
- Brd. 38E** **A phase I/II study of MM-111, a novel bispecific antibody that targets the Erb2/Erb3 heterodimer, in combination with trastuzumab in advanced refractory HER2-positive breast cancer. (Abstract #TPS119)**
M. J. Higgins, N. Y. Gabrail, K. Miller, S. V. Agresta, S. Sharma, C. McDonagh, J. Murray, K. Andreas, S. Frye, V. M. Moyo, C. Niyikiza, P. D. Ryan
- Brd. 38F** **A randomized trial assessing the use of electro-acupuncture for aromatase inhibitor-induced arthralgia. (Abstract #TPS120)**
J. M. Beith, E. Segelov, K. Orme, A. McLean, B. Oh
- Brd. 38G** **Serum NT pro-BNP and individual genetic polymorphisms as predictors of trastuzumab-related cardiotoxicity. (Abstract #TPS121)**
S. Goel, J. Lynch, L. A. Chantrill, J. J. Rutovitz, B. Murray, E. A. Abdi, R. Bell, A. L. Sullivan, A. Goldrick, T. M. Hayes, G. Asghari, N. Wilcken, N. J. McCarthy, J. M. Beith
- Brd. 38H** **TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). (Abstract #TPS122)**
A. Gucalp, S. M. Tolaney, S. J. Isakoff, J. N. Ingle, M. C. Liu, L. A. Carey, K. L. Blackwell, H. S. Rugo, L. Nabell, A. Abbruzzi, J. Gonzalez, D. D. Giri, S. Patil, K. Feigin, G. D'Andrea, M. Theodoulou, P. Drullinsky, N. T. Sklarin, C. Hudis, T. A. Traina, Translational Breast Cancer Research Consortium
- Brd. 39A** **Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer. (Abstract #TPS123)**
L. S. Schwartzberg, M. Beeram, A. Patnaik, A. W. Tolcher, L. Itri, A. L. Olson, A. D. Seidman
- Brd. 39B** **Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). (Abstract #TPS124)**
J. Baselga, L. S. Schwartzberg, O. Petrenciuc, M. Shan, W. J. Gradishar
- Brd. 39C** **ACRIN 6688 phase II study of fluorine-18 3-deoxy-3 fluorothymidine (FLT) in invasive breast cancer. (Abstract #TPS125)**
P. R. Jolles, L. Kostakoglu, H. D. Bear, M. O. Idowu, K. A. Kurdziel, L. Shankar, D. A. Mankoff, F. Duan, D. L'Heureux
- Brd. 39D** **ANZ1001 SORBET: Study of Oestrogen Receptor Beta and Efficacy of Tamoxifen—A single-arm, phase II study of the efficacy of tamoxifen in triple-negative but oestrogen receptor beta-positive metastatic breast cancer. (Abstract #TPS126)**
B. E. Kiely, K. Phillips, P. A. Francis, F. M. Boyle, J. F. Forbes, S. B. Fox, L. Murphy, V. GebSKI, D. F. Lindsay, R. L. Sutherland, H. Badger
- Brd. 39E** **TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). (Abstract #TPS127)**
C. K. Anders, R. Nanda, M. C. Liu, K. L. Blackwell, C. H. Van Poznak, V. G. Abramson, A. M. Storniolo, N. U. Lin, V. Stearns, A. Melhem, S. Puhalla, J. T. Carpenter, M. E. Melisko, A. M. Deal, C. Hudis, E. P. Winer, C. M. Perou, C. R. Bradley, A. C. Wolff, L. A. Carey, Translational Breast Cancer Research Consortium

Monday, June 6, 2011

- Brd. 39F** **TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer. (Abstract #TPS128)**
A. Forero-Torres, N. U. Lin, M. C. Liu, H. S. Rugo, S. Puhalla, R. Nanda, I. A. Mayer, A. M. Storniolo, T. A. Traina, D. F. Hayes, M. F. Rimawi, M. P. Goetz, F. J. Esteva, W. J. Irvin Jr., A. C. Wolff, on behalf of the Translational Breast Cancer Research Consortium
- Brd. 39G** **An observational study using γ -H2AX foci to investigate cardiac doses of radiation following adjuvant radiotherapy for breast cancer: Standard external beam radiotherapy to the breast versus intraoperative radiotherapy. (Abstract #TPS129)**
D. Woolf, R. Bakhshi, S. Fawcitt, M. Worku, D. B. Ghosh, S. Sivabalasingham, N. R. Williams, S. Short, K. Pigott, M. R. Keshtgar
- Brd. 39H** **PARP inhibition after preoperative chemotherapy in patients with triple-negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. (Abstract #TPS130)**
S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge Jr., K. Miller
- Brd. 40A** **Phase III randomized French multicentric study to evaluate the impact of a localized 16-Gy boost after conservative surgery and a 50-Gy whole-breast irradiation in breast ductal carcinoma in situ (the BONBIS trial). (Abstract #TPS131)**
D. Azria, D. Cowen, C. Bourcier, B. de la Lande, S. Gourguou-Bourgade, Z. Douadi Gaci, M. Leblanc-Onfroy, I. Latorzeff, O. Pradier, P. Maingon, I. Lecouillard, P. Bontemps, S. Ellis, C. Levy, A. Benyoucef, S. Racadot, H. Laharie-Mineur, P. Lagarde, C. Marchal, C. Lemanski
- Brd. 40B** **A phase IIa clinical biomarker trial of aspirin and dietary arginine restriction in colorectal cancer patients. (Abstract #TPS132)**
J. A. Zell, C. E. McLaren, C. G. Albers, E. W. Gerner, L. B. Wenzel, F. L. Meyskens
- Brd. 40C** **Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB) and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric). (Abstract #TPS133^A)**
M. Khasraw, S. McCowatt, Z. Kerestes, M. E. Buyse, M. Back, H. Wheeler
- Brd. 40D** **CeCil: A randomized, noncomparative phase II clinical trial of the effect of radiation therapy (RT) plus temozolomide (TMZ) combined with cilengitide or cetuximab on the 1-year overall survival of patients with newly diagnosed MGMT-promoter unmethylated glioblastoma. (Abstract #TPS134)**
V. Verschaeve, L. A. D'Hondt, L. M. Verbeke, F. Van Fraeyenhove, S. Du Four, J. Duerinck, B. Neyns
- Brd. 40E** **A phase II and pharmacodynamic trial of RO4929097 for patients with recurrent/progressive glioblastoma. (Abstract #TPS135)**
D. M. Peereboom, J. N. Rich, J. G. Supko, K. Lamborn, X. Ye, A. E. Sloan, M. Prados, S. A. Grossman, Adult Brain Tumor Consortium (ABTC)
- Brd. 40F** **AVAGlio: A phase III trial of bevacizumab added to standard radiotherapy and temozolomide in patients with newly diagnosed glioblastoma. (Abstract #TPS136)**
O. L. Chinot, W. Wick, F. Saran, W. P. Mason, R. Henriksson, R. Nishikawa, A. H. Zeaiter, N. Moore, A. Das, T. F. Cloughesy
- Brd. 40G** **A phase III trial of adjuvant neratinib (NER) after trastuzumab (TRAS) in women with early-stage HER2+ breast cancer (BC). (Abstract #TPS137)**
P. E. Goss, C. H. Barrios, A. Chan, S. K. Chia, S. Delaloge, B. Ejlertsen, J. N. Ingle, B. Moy, H. Iwata, F. A. Holmes, J. Mansi, G. Von Minckwitz, L. Han, A. Thiele, V. Agrapart, A. Freyman, J. Truscello, A. Berkenblit, D. Finkelstein

- Brd. 40H A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma. (Abstract #TPS138)**
 N. M. Reddy, R. Simmons, M. Caldwell, M. H. Jagasia, D. S. Morgan, S. I. Park, J. P. Greer, K. L. Richards
- Brd. 41A Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM). (Abstract #TPS139)**
 L. M. Krug, A. S. Tsao, S. Kass, V. W. Rusch, W. D. Travis, K. Panageas, P. S. Adusumili, M. G. Kris, P. G. Maslak, D. A. Scheinberg
- Brd. 41B CYTAM-BRUT 2: A prospective multicenter observational study in the neoadjuvant and metastatic setting investigating tamoxifen response between women with a favorable versus unfavorable endoxifen profile. (Abstract #TPS140)**
 A. Dieudonné, H. Wildiers, D. Lambrechts, H. Guchelaar, V. O. Dezentje, M. Joerger, K. Zaman, I. B. Vergote, P. Neven
- Brd. 41C A phase I study of NPC-1C, a novel therapeutic antibody to treat pancreas and colorectal cancers. (Abstract #TPS141)**
 N. S. Azad, L. A. Diaz Jr., C. E. Devoe, D. Laheru, D. T. Le, D. Cosgrove, L. Zheng, A. De Jesus-Acosta, R. C. Donehower, P. M. Arlen, J. A. Bristol
- Brd. 41D A pilot study of the safety, efficacy, and effects on functional imaging of the combination of cG250 and sunitinib in patients (pts) with advanced renal cell carcinoma (RCC). (Abstract #TPS142)**
 M. Ciprotti, I. D. Davis, D. W. Pook, F. T. Lee, T. Cavicchiolo, S. Lee, B. Chappell, G. J. O'Keefe, H. Tochon-Danguy, F. E. Smyth, W. Hopkins, A. M. Scott
- Brd. 41E Validation of the phase 0 concept. (Abstract #TPS143)**
 J. R. Westin, S. Fu, D. S. Hong, T. Helgason, F. Ouyang, L. S. Angelo, K. S. Culotta, S. N. Westin, R. Kurzrock
- Brd. 41F A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. (Abstract #TPS144)**
 T. Ikdahl, I. Davidenko, C. Bassi, E. Tomasetto, L. Smith, S. McLachlan, S. Jones, M. Raponi, J. Isaacson, C. Voong, L. Rolfe, A. R. Allen, E. Poplin
- Brd. 41G First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. (Abstract #TPS145)**
 J. A. Sosman, A. A. Adjei, P. LoRusso, S. A. Michael, G. K. Dy, A. Bowditch, B. Chmielowski, S. Lee, R. M. Walker, S. Faucette, E. S. Izmailova, V. Bozon, A. Ribas
- Brd. 41H A phase I clinical trial of QBI-139, a human ribonuclease variant, in solid tumors. (Abstract #TPS146)**
 L. E. Strong, J. A. Kink, B. Mei, M. N. Shahan, R. T. Raines
- Brd. 42A Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer. (Abstract #TPS147)**
 K. Kalinsky, J. A. Sparano, M. Kim, K. D. Crew, M. A. Maurer, B. Taback, S. M. Feldman, H. Hibshoosh, L. Wiechmann, K. B. Adelson, D. L. Hershman
- Brd. 42B Valproic Acid Signature Trial (VAST): A proof-of-principle study correlating pharmacology, pathology, and advanced imaging with genomic prediction of drug sensitivity in breast cancer. (Abstract #TPS148)**
 A. L. Cohen, M. Schabel, A. Bild, T. L. Werner
- Brd. 42C First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. (Abstract #TPS149)**
 J. Soria, F. G. De Braud, R. Cereda, R. Bahleda, A. Delmonte, E. Angevin, A. Varga, C. Noberasco, E. Dall'O', N. Lassau, C. Dromain, M. Bellomi, F. Farace, F. Bertolini, M. Zucchetti, S. Marsoni, M. G. Camboni

Monday, June 6, 2011

- Brd. 42D** Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available. (Abstract #TPS150)
R. E. Martell, E. G. Chiorean, H. Youssoufian, M. D. Rutstein, B. Pytowski, L. Benjamin, L. Abad, J. Patel, T. Steele, M. Dowd, A. Qin, C. F. Kukul, F. E. Fox, A. Dontabhaktuni, A. Morozov
- Brd. 42E** Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20–0903/NCT01234402). (Abstract #TPS151)
L. T. Vahdat, K. Miller, J. A. Sparano, H. Youssoufian, J. D. Schwartz, S. Nanda, W. Wang, L. Abad, A. Dontabhaktuni, M. D. Rutstein
- Brd. 42F** A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE). (Abstract #TPS152)
P. E. Goss, C. H. Barrios, R. Bell, D. Finkelstein, H. Iwata, M. Martin, A. H. Braun, R. D. Dansey, R. E. Coleman
- Brd. 42G** Integrative and multidisciplinary clinical trial using imaging, molecular, and dynamic biomarkers to predict bevacizumab plus chemotherapy response in breast cancer. (Abstract #TPS153)
J. Lopez Vega, E. G. Calvo, A. Plazaola, B. Hernando, S. Morales Murillo, A. Anton, R. S. Gomez, I. Alvarez, J. J. Illarramendi, A. De Juan, P. Martinez, A. Llombart, S. J. Scherer, L. Sabariz, A. la Huerta, L. J. Pina, I. Dominguez, M. J. Garcia Velloso, V. Boni, J. Garcia-Foncillas
- Brd. 42H** Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib. (Abstract #TPS154)
A. Leary, L. M. Pickering, J. M. Larkin, M. O. Leach, M. E. Gore, A. Sohaib, D. J. Collins, D. Koh
- Brd. 43A** Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma. (Abstract #TPS155)
G. Anandappa, E. Sala, H. K. Cheow, N. J. Bird, A. Shaw, A. N. Priest, A. Gill, T. Fryer, Y. T. Hong, R. Smith, A. Backen, B. Whitcher, A. Jonson, D. Richards, L. Cookson, W. M. Lee, C. Dive, K. M. Fife, D. I. Jodrell, T. Eisen
- Brd. 43B** A phase I, single-institution open label, dose-escalation trial with an expansion cohort evaluating the safety and tolerability of AZD6244 and IMC-A12 in subjects with advanced solid malignancies. (Abstract #TPS156)
S. R. Ahmed, D. Cosgrove, D. Ball, R. C. Donehower, B. Nelkin, E. Petito, M. Downs, H. X. Chen, A. Doyle, A. Scardina, M. A. Carducci, N. S. Azad
- Brd. 43C** Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC). (Abstract #TPS157)
M. R. Khawaja, A. Younger, J. M. Funke, M. J. Waddell, D. R. Jones, K. Pollok, N. K. Prasad, W. Berry, G. Sandusky, E. G. Chiorean
- Brd. 43D** A pharmacokinetics/pharmacodynamics study of sequence specificity of the PARP inhibitor olaparib with carboplatin in refractory/recurrent women's cancers: NCT01237067. (Abstract #TPS158)
J. Lee, J. Squires, J. L. Hays, H. L. Kotz, D. Nielsen, N. D. Houston, E. C. Kohn
- Brd. 43E** A phase I first-in-human study of REGN910, a fully human and selective angiopoietin-2 monoclonal antibody, in patients with advanced solid tumor malignancies. (Abstract #TPS159)
K. P. Papadopoulos, N. G. Chau, A. Patnaik, L. Adriaens, A. S. Lalani, C. Daly, L. L. Siu

- Brd. 43F** **A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment. (Abstract #TPS160)**
L. A. Fecher, Y. McGrath, D. D. Williams, N. J. Hassan, M. Kalos, L. M. Schuchter, R. K. Amaravadi, A. Chew, E. A. Veloso, B. J. Czerniecki, G. Karakousis, G. P. Linette, B. K. Jakobsen, C. H. June
- Brd. 43G** **A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy. (Abstract #TPS161)**
A. L. Thomas, R. H. Wilson, W. P. Steward, R. A. Adams, S. E. Bridges, A. C. Casbard, T. S. Maughan, G. Griffiths, NCRI Colorectal Clinical Studies Group
- Brd. 43H** **A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT). (Abstract #TPS162)**
A. R. Townsend, L. Pirc, J. Hardingham, C. S. Karapetis, N. C. Tebbutt, N. Singhal, T. J. Price
- Brd. 44A** **A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial. (Abstract #TPS163)**
J. D. Shapiro, L. L. Siu, J. R. Zalcborg, M. J. Moore, J. Ringash, N. Mittmann, J. Simes, C. J. O'Callaghan, D. Tu, I. B. Walters, N. Magoski, P. Smith, D. Nomikos, L. Zhu, M. Savoie, S. Virk, F. El-Tahche, R. Gill, T. J. Price, D. J. Jonker
- Brd. 44B** **PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study. (Abstract #TPS164)**
J. Maurel, X. Garcia-Albeniz, C. Méndez Méndez, M. Martin-Richard, C. Pericay, R. Vera, J. Aparicio, M. Rubini, M. Cuatrecasas, on behalf of the GEMCAD Cooperative Group
- Brd. 44C** **Developing a biomarker-stratified trial design in advanced colorectal cancer: The MRC FOCUS 3 feasibility study. (Abstract #TPS165)**
T. S. Maughan, R. H. Wilson, G. T. Williams, M. T. Seymour, S. Richman, P. Quirke, M. Pope, J. Pope, M. Parmar, A. Nelson, A. M. Meade, S. L. Kenny, B. Jasani, E. Hodgkinson, D. Fisher, R. Butler, J. A. Bridgewater, R. A. Adams, R. S. Kaplan
- Brd. 44D** **LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases—A randomized, double-blind, placebo-controlled, multicenter, multinational, phase II trial. (Abstract #TPS166)**
C. C. Schimanski, P. R. Galle, H. Lang, M. Schoen, M. H. Moehler
- Brd. 44E** **The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint. (Abstract #TPS167)**
R. Salazar, R. Rosenberg, M. Lutke Holzik, J. Marshall, J. J. Van Der Hoeven, B. Glimelius, F. Bibeau, L. Stork-Sloots, R. A. Bender, J. Capdevila
- Brd. 44F** **A phase II, multicenter, randomized, double-blind, placebo-controlled, ascending, multidose, U.S. study of oral LX1606 (aka LX1032) in patients with refractory symptomatic carcinoid syndrome. (Abstract #TPS168)**
M. Kulke, T. M. O'Dorisio, A. T. Phan, R. M. Langdon Jr., B. J. Marek, N. Iklaque, E. K. Bergsland, J. Freiman, K. Frazier, J. Jackson, B. Zambrowicz
- Brd. 44G** **IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer. (Abstract #TPS169)**
S. A. Szyldergemajn, A. Gonçalves, J. Metges, K. Gunzer, C. Montagut, R. Salazar, M. Alsina, T. Evans, D. Swinson, R. D. Petty, H. Singer, C. M. Kahatt

Monday, June 6, 2011

- Brd. 44H** **A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer. (Abstract #TPS170)**
M. J. Pishvaian, R. Slack, A. Witkiewicz, A. R. He, J. J. Hwang, A. Hankin, L. Ley, S. K. Apte, S. J. Littman, L. M. Weiner, J. Marshall, J. R. Brody
- Brd. 45A** **PAZONET: A phase II trial of pazopanib in patients with metastatic neuroendocrine tumors (NETs) who may have previously received antiangiogenic or mTOR treatment. (Abstract #TPS171)**
J. Capdevila, A. Teule, D. E. Castellano, J. Sastre, R. Garcia-Carbonero, I. Sevilla, I. Duran, P. Escudero, J. Fuster, E. Grande Pulido
- Brd. 45B** **Phase I trial of sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation (LT). (Abstract #TPS172)**
A. B. Siegel, R. Hidalgo, D. Tsushima, J. Zaretsky, J. Emond, T. Kato, R. S. Brown Jr.
- Brd. 45C** **A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376). (Abstract #TPS173)**
D. J. Cohen, L. Liebes, R. Xu, N. Takebe, J. A. Sparano, New York Cancer Consortium
- Brd. 45D** **A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer. (Abstract #TPS174)**
W. M. D. Tai, W. S. Ooi, J. Y. Ngeow, N. Deng, H. Wang, C. K. Tham, H. Y. Lim, S. P. Choo, P. Tan, H. C. Toh, I. B. Tan
- Brd. 45E** **Evaluation of sorafenib in combination with local microtherapy guided by gadolinium-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma. (Abstract #TPS175)**
J. Ricke, K. Schuette, I. W. Graziadei, A. Jakob, C. Verslype, B. Sangro, J. Walecki, H. Klümpen, B. Peynircioglu, S. Yalcin, C. Bartolozzi, H. Amthauer, P. Malfertheiner
- Brd. 45F** **Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer. (Abstract #TPS176)**
M. J. Borad, D. Sigal, H. Uronis, J. Stephenson Jr., N. Bahary, M. U. Rarick, L. C. DeMarco, T. J. Finnegan, E. G. Chiorean, D. P. Ryan, A. L. Cohn, B. K. Ulrich, V. C. Harish, E. N. Anderes, W. Ma, P. P. Yu, F. Sinicrope, C. Eng, U. K. Sunkara, S. G. Reddy
- Brd. 45G** **ACRIN 6690: Can contemporary imaging reduce false-positive rate in liver transplant (LT) allocation? A multicenter comparison of CT and MRI for diagnosis of hepatocellular carcinoma (HCC). (Abstract #TPS177)**
C. Wald, M. Nalesnik, E. A. Pomfret, M. Russo, M. A. Rosen, D. M. Hartfeil, P. Fox, M. L. Heckel, C. Gatsonis
- Brd. 45H** **Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial. (Abstract #TPS178)**
D. Malka, S. Gourgou-Bourgade, J. Emile, P. Laurent-Puig, J. Taïeb
- Brd. 46A** **The Personalized RNA Interference to Enhance the Delivery of Individualized Cytotoxic and Targeted Therapeutics (PREDICT) approach to biomarker discovery in renal cell carcinoma. (Abstract #TPS179)**
M. Gerlinger, L. Albiges, on behalf of the PREDICT Consortium (www.predictconsortium.eu)
- Brd. 46B** **SYNERGY: A randomized phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC). (Abstract #TPS180)**
K. N. Chi, J. S. De Bono, C. S. Higano

- Brd. 46C** A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (Abstract #TPS181)
C. G. Drake, H. I. Scher, W. R. Gerritsen, R. Ezzeddine, T. F. Fitzmaurice, J. Cuillerot, K. M. Chin, P. Gagnier
- Brd. 46D** Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC). (Abstract #TPS182)
T. M. Beer, C. Logothetis, P. Sharma, W. R. Gerritsen, R. Ezzeddine, J. P. Fairchild, P. Gagnier, K. M. Chin, J. Cuillerot
- Brd. 46E** IMA901 Multi-peptide Vaccine Randomized International Phase III Trial (IMPRINT): A randomized, controlled study investigating IMA901 multi-peptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. (Abstract #TPS183)
B. I. Rini, T. Eisen, A. Stenzl, W. Brugger, T. Weinschenk, A. Mahr, J. Fritsche, N. Hilf, R. Mendrzyk, J. Lindner, A. Schmid, A. Kirner, S. Walter, H. Singh, C. Reinhardt
- Brd. 46F** A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). (Abstract #TPS184)
F. Saad, H. Akaza, M. A. Eisenberger, J. Nelson, H. I. Scher, K. Suzuki, M. Wirth, I. J. Webb, J. Wang, D. MacLean, R. De Wit
- Brd. 46G** Phase I/II trial to establish the safety and preliminary efficacy of the combination of docetaxel, prednisone, and SOM 230 in metastatic castrate-resistant prostate cancer (CRPC). (Abstract #TPS185)
H. M. Vankayala, L. K. Heilbrun, J. A. Fontana, U. N. Vaishampayan
- Brd. 46H** A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. (Abstract #TPS186)
M. I. Milowsky, G. L. Carlson, M. M. Shi, G. Urbanowitz, Y. Zhang, C. N. Sternberg
- Brd. 47A** Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence. (Abstract #TPS187)
D. F. Bajorin, P. Sharma, R. B. Sims, A. Sandler, S. P. Lerner
- Brd. 47B** A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. (Abstract #TPS188)
K. Fizazi, T. Powles, D. J. George, C. H. Poehlein
- Brd. 47C** Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate-specific antigen (PSA) after primary therapy. (Abstract #TPS189)
E. S. Antonarakis, A. S. Kibel, D. W. Lin, R. C. Tyler, M. Tabesh, C. G. Drake
- Brd. 47D** A first-in-human, open-label, phase I/II safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive advanced castration-resistant prostate cancer (CRPC). (Abstract #TPS190)
D. E. Rathkopf, D. C. Danila, S. F. Slovin, M. J. Morris, J. E. Steinbrecher, Y. Chen, M. Fleisher, S. M. Larson, C. L. Sawyers, H. I. Scher
- Brd. 47E** Predicting response to platinum chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) using a genomic signature for "BRCAness": A phase II clinical trial of satraplatin in men with mCRPC who have progressed on docetaxel. (Abstract #TPS191)
S. M. Seng, M. D. Galsky, C. Tsao, J. Li, P. G. Febbo, W. K. Oh

Monday, June 6, 2011

- Brd. 47F** **A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma (NCI 8727). (Abstract #TPS192)**
E. Jonasch, P. Lara Jr., N. M. Tannir
- Brd. 47G** **Radiolabeled antiprostata specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial. (Abstract #TPS193)**
S. T. Tagawa, N. M. Hahn, D. A. Vaena, D. I. Quinn, W. K. Kelly, P. J. Christos, J. Osborne, S. Vallabhajosula, K. Nadeau, G. Mileo, L. Tyrell, A. Saran, C. Ecker, H. Beltran, S. J. Goldsmith, D. M. Nanus
- Brd. 47H** **Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. (Abstract #TPS194)**
T. E. Hutson, J. Sarantopoulos, T. Logan, G. Sonpavde, M. D. Galsky, C. Sweeney, D. C. Bibby, G. Kremmidiotis, E. E. Doolin, N. M. Hahn, Hoosier Oncology Group
- Brd. 48A** **A phase II study to evaluate the efficacy and safety of catumaxomab as consolidation treatment in patients with epithelial ovarian cancer in second or third complete remission. (Abstract #TPS195)**
A. M. Oaknin, L. Chiva, I. Romero, A. Romero, M. M. Essing, A. González-Martín, GEICO
- Brd. 48B** **Concomitant chemoradiation or RT/cetuximab versus induction TPF followed by chemoradiation or RT/cetuximab in locally advanced head and neck squamous cell carcinoma: A randomized phase III factorial study. (Abstract #TPS196)**
A. Paccagnella, M. G. Ghi, I. Floriani, A. Gava, A. Buffoli, on behalf of the GSTTC Italian Collaborative Group
- Brd. 48C** **EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence. (Abstract #TPS197)**
C. Liberatoscioli, J. A. Langendijk, C. Van Herpen, L. Collette, E. M. Ozsahin, R. Karra Gurunath, D. A. Lacombe, A. Gulyban, N. Gosselin, W. Budach
- Brd. 48D** **PAPILLOPHAR: Impact of the human papillomavirus (HPV) status in the prognosis of oropharynx squamous cell carcinoma (OSCC). (Abstract #TPS198)**
J. Lacau Saint Guily, J. Pretet, G. Agius, A. Rousseau, B. Barry, X. Dufour, S. Perie, M. Lefevre, P. Birembaut, C. Mouglin, T. Simon, C. Clavel, PAPILLOPHAR Group
- Brd. 48E** **CALGB 10603 (RATIFY): A randomized phase III study of induction (daunorubicin/cytarabine) and consolidation (high-dose cytarabine) chemotherapy combined with midostaurin or placebo in treatment-naïve patients with FLT3 mutated AML. (Abstract #TPS199)**
R. M. Stone, H. Dohner, G. Ehninger, M. Villeneuve, T. Teasdale, J. D. Virkus, L. R. Bressler, M. M. Seiler, G. Marcucci, R. A. Larson, on behalf of all study investigators
- Brd. 48F** **A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). (Abstract #TPS200)**
J. R. Gotlib, H. Kluijn-Nelemans, M. J. Mauro, O. Hermine, E. O. Hexner, J. H. Lipton, F. T. Awan, Z. G. Nikolova, S. H. Gross, C. Dutreix, B. Dharan, T. George, P. Horny, C. Akin, K. Hartmann, P. Valent, A. Reiter, on behalf of all PKC412 D2201 study investigators

MONDAY

- Brd. 48G Adaptive design of VALOR, a phase III trial of vosaroxin or placebo in combination with cytarabine for patients with first relapsed or refractory acute myeloid leukemia. (Abstract #TPS201)**
C. R. Mehta, G. Michelson, M. Salganik, J. Feaster, R. Allen, A. L. Cahill, J. A. Fox, S. B. Ketchum, F. Ravandi, H. P. Erba, G. J. Schiller, R. K. Stuart, N. Vey, E. J. Feldman
- Brd. 48H Multicenter, single-arm phase II study of nilotinib in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic-phase (CML-CP) patients with low imatinib trough plasma concentrations. (Abstract #TPS202)**
S. Lim, R. C. Holdridge, M. Talpaz, C. N. Abboud, S. Yi, E. Noon, S. Ericson, M. Jones
- Brd. 49A RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU). (Abstract #TPS203)**
S. Verstovsek, J. Kiladjian, R. J. Waltzman, V. Sandor, J. Lukawy, W. M. Garrett, K. Malek, R. M. Huber, A. M. Vannucchi
- Brd. 49B A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib. (Abstract #TPS204)**
I. W. Flinn, S. Goldberg, R. L. Robles, D. Rizzieri, J. P. Radich, M. J. Mauro, S. Ericson, J. E. Cortes
- Brd. 49C Prospective, observational registry of branded imatinib and nilotinib exposure in pregnant women: Voluntary postauthorization safety study. (Abstract #TPS205)**
M. Juma, S. Ericson, D. Eng, A. Adeoye
- Brd. 49D A randomized phase III study of elacytarabine versus limited investigator's choice in patients with refractory acute myeloid leukemia (AML). (Abstract #TPS206)**
D. Rizzieri, N. Vey, M. Gobbi, D. L. Selleslag, M. W. Dennis, K. Kuliczkowski, U. Krug, F. Moscardo, D. Bron, A. D. Moicean, A. Venditti, T. F. Jacobsen, O. Foss, F. J. Giles
- Brd. 49E A phase II study of elacytarabine plus idarubicin as second-course remission-induction therapy in patients with acute myeloid leukemia. (Abstract #TPS207)**
D. Rizzieri, U. Krug, R. F. Schlenk, N. Vey, X. G. Thomas, F. Huguet, M. Johansen, T. F. Jacobsen
- Brd. 49F SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIa non-small cell lung cancer. (Abstract #TPS208)**
B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo, E. Carcereny Costa, R. Arrabal, J. Astudillo, I. Barneto, R. De Las Penas, C. Baamonde, G. Sales, J. Gonzalez-Larriba, G. Lopez-Vivanco, F. Hernando-Trancho, J. Pac, A. LRCal-Cortes, J. Rivas, R. Rosell, J. Sanchez, Spanish Lung Cancer Group / SLCG-GECP
- Brd. 49G The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR). (Abstract #TPS209)**
N. A. Pennell, J. W. Neal, R. Govindan, P. A. Janne, T. L. Evans, D. B. Costa, R. P. Rosovsky, M. Lanuti, C. G. Azzoli, L. V. Sequist

Monday, June 6, 2011

- Brd. 49H** **MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIa NSCLC. (Abstract #TPS210)**
P. Therasse, J. F. Vansteenkiste, M. Zielinski, T. M. De Pas, D. Atanackovic, L. V. Sequist, E. Vallieres, S. Swisher, S. Adams, B. Passlick, W. E. Eberhardt, D. Grunenwald, T. Mok, M. Boyer, A. Katz, J. Douillard, M. Debois, V. G. Brichard, N. K. Altorki
- Brd. 50A** **Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (Abstract #TPS211)**
B. Halmos, P. Fu, N. A. Pennell, G. A. Otterson, T. Mekhail, M. R. Snell, J. P. Kuebler, S. M. Gadgeel, A. Conrad, A. T. Stefanski, A. Dowlati
- Brd. 50B** **A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab. (Abstract #TPS212)**
B. T. McLaughlin, S. Land, A. A. Tarhini, J. Siegfried, A. Argiris
- Brd. 50C** **Randomized phase II study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAB) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. (Abstract #TPS213)**
T. Mok, E. Tan, K. Park, J. Jac, M. Han, F. C. Payumo, M. Credi, K. McKee, M. M. Cotreau, P. Bhargava, W. Slichenmyer
- Brd. 50D** **PROSE: Randomized proteomic stratified phase III study of second-line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC). (Abstract #TPS214)**
C. Sorlini, S. Barni, F. Petrelli, S. Novello, F. De Marinis, T. M. De Pas, F. Grossi, A. Bearz, M. Mencoboni, M. Aieta, A. Caprioli, P. Antonelli, N. Zilembo, A. Bachi, I. Floriani, H. Roder, J. Roder, J. Grigorieva, C. Lazzari, V. Gregorc
- Brd. 50E** **A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #TPS215)**
L. V. Sequist, W. A. Harb, M. Modiano, D. M. Jackman, K. Wong, J. A. Engelman, R. Nering, M. Onsum, V. M. Moyo
- Brd. 50F** **Randomized, multicenter phase II study of erlotinib (E) or E plus fulvestrant (F) in previously treated advanced non-small cell lung cancer (NSCLC). (Abstract #TPS216)**
E. B. Garon, S. M. Dubinett, F. F. Kabbinavar, K. L. Reckamp, D. C. Marquez-Garban, L. Goodglick, S. Sharma, L. P. Stabile, J. Siegfried, R. J. Pietras
- Brd. 50G** **A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) . (Abstract #TPS217)**
A. Sandler, J. H. Schiller, V. Hirsh, L. V. Sequist, J. Soria, J. Von Pawel, Q. Wang, A. U. Pande, B. E. Schwartz, E. G. Garmey, I. Gorbachevsky, G. Scagliotti
- Brd. 50H** **A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BpM) following carboplatin, paclitaxel, and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). (Abstract #TPS218)**
S. E. Dahlberg, S. S. Ramalingam, C. P. Belani, J. H. Schiller

- Brd. 51A** Study ESOGIA-GFPC 08-02: Phase III, randomized, multicenter trial involving subjects over age 70 with stage IV non-small cell lung cancer and comparing a “classical” strategy of treatment allocation (dual-agent therapy based on carboplatin or monotherapy with docetaxel alone), based on performance status and age, with an “optimized” strategy allocating the same treatments according to a simplified geriatric screening scale, plus a more thorough geriatric evaluation if necessary. (Abstract #TPS219)
R. Corre, C. Chouaid, F. Barlesi, H. Le Caer, E. Dansin, A. Vergnenegre, P. Fournel, GFPC
- Brd. 51B** Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). (Abstract #TPS220)
D. R. Spiegel, P. G. Harper, J. D. Hainsworth, F. De Marinis, F. F. Kabbinavar, E. S. Kim, T. J. Lynch, R. Rosell, F. A. Shepherd, M. A. Socinski, A. Vergnenegre
- Brd. 51C** E3508: A phase II randomized trial of carboplatin (C), paclitaxel (P), and bevacizumab (B) with or without IMC-A12 (cixutumumab) in patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). (Abstract #TPS221)
A. Argiris, J. Lee, J. H. Schiller, Eastern Cooperative Oncology Group
- Brd. 51D** Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma. (Abstract #TPS222)
A. Bair, G. Hess, J. Boni, F. Offner
- Brd. 51E** A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501). (Abstract #TPS223)
V. A. Morrison, S. Jung, J. L. Johnson, J. Leonard, B. D. Cheson, Cancer and Leukemia Group B
- Brd. 51F** An open-label phase II study of intravenous bortezomib and oral panobinostat (LBH589) in adult patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) after failure of conventional chemotherapy. (Abstract #TPS224)
D. C. Tan, P. Chan, B. L. Ng, B. K. Yap, Y. H. Chan, L. P. Koh, F. A. Wahid, S. Lim, N. S. Chin, W. Kim, S. Y. Tan, Y. T. Goh
- Brd. 51G** A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). (Abstract #TPS225)
P. Moreau, A. P. Palumbo, A. K. Stewart, V. Rajkumar, A. J. Jakubowski, K. Halka, S. Goranov, H. Bumblea, K. B. Pendergrass, A. Lupu, A. Dimopoulos, A. O. Rocafiguera, J. G. Gandhi, G. Mihaylov, T. Masszi, J. Matous, G. Fonseca, R. Bryce, D. S. Siegel
- Brd. 51H** PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification. (Abstract #TPS226)
J. Leonard, J. Reeves, B. Ferhanoglu, K. T. Doner, H. Eom, I. W. Flinn, J. Raposo, N. M. Chowhan, C. Suh, S. Noga, G. Tumyan, S. Aung, J. Hajdenberg, B. K. Ulrich, K. B. Pendergrass, G. Mulligan, A. Rizo, S. Kussick, F. Offner
- Brd. 52A** PANORAMA1: A randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. (Abstract #TPS227)
J. F. San-Miguel, S. Lonial, V. Hungria, P. Moreau, H. Einsele, J. Lee, S. Yoon, P. Corradini, W. W. Jedrzejczak, D. C. Tan, K. Yong, A. Guenther, M. M. Wroclawska-Swacha, H. J. Weber, P. M. Bourquelot, P. G. Richardson

Monday, June 6, 2011

- Brd. 52C** **A phase II trial of nilotinib in the treatment of patients with *KIT* mutated advanced acral and mucosal melanoma (NICAM). (Abstract #TPS229)**
J. M. Larkin, S. Turajlic, P. D. Nathan, P. Lorigan, G. Stamp, D. Gonzalez de Castro, N. Martin, J. Griffiths, K. Edmonds, S. Sarker, M. G. James, R. A'Hern, G. Coombes, C. Snowdon, J. M. Bliss, M. E. Gore, R. Marais
- Brd. 52D** **A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. (Abstract #TPS230)**
A. Di Giacomo, P. A. Ascierto, E. Fonsatti, E. Pittiglio, P. Queirolo, L. Pilla, R. Ridolfi, M. Santinami, A. Testori, G. Parmiani, M. Maio
- Brd. 52E** **PREDICT phase II: A trial to prospectively validate a gene signature associated with clinical benefit from MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) in patients with unresected metastatic cutaneous melanoma. (Abstract #TPS231)**
P. Saiag, J. S. Weber, B. Dreno, A. Hauschild, C. Jamoul, O. Peeters, P. Therasse
- Brd. 52F** **DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. (Abstract #TPS232)**
J. M. Kirkwood, B. Dreno, A. Hauschild, D. Schadendorf, A. Testori, P. Hersey, C. Jamoul, O. Peeters, P. Therasse
- Brd. 52G** **A randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. (Abstract #TPS233)**
N. Shinohara, N. Nonomura, G. Kimura, M. Eto, H. Minami, N. Yamazaki, S. Naito, Japanese Society of Renal Cancer
- Brd. 52H** **The use of subcutaneous natural ghrelin to treat cachexia (CC) related symptom distress, nutritional intake (NI), and physical functioning: A two-step phase I/II study with an inpatient dose escalation followed by maintenance treatment. (Abstract #TPS234)**
F. Strasser, D. Blum, R. Oberholzer, S. deWolf-Linder, C. Driessen, T. Cerny
- Brd. 53A** **A phase II/III study of sotatercept (ACE-011), an activin antagonist, for chemotherapy-induced anemia in patients with metastatic non-small cell lung cancer treated with first-line platinum-based chemotherapy. (Abstract #TPS235)**
H. Raftopoulos, A. Laadem, M. Puccio, R. D. Knight
- Brd. 53B** **Phase II trial of subcutaneous methylalntrexone in the treatment of severe opioid-induced constipation in cancer patients. (Abstract #TPS236)**
M. Mori, T. Ashikaga, S. M. Grunberg
- Brd. 53C** **Randomized clinical trial to evaluate an e-health intervention for fear of cancer recurrence, anxiety, and depression among cancer survivors. (Abstract #TPS237)**
L. I. Wagner, J. Duffecy, K. A. Lehman, S. D. Sanford, M. Begale, E. Nawacki, D. C. Mohr
- Brd. 53D** **A randomized placebo-controlled trial of testosterone replacement for fatigue in male hypogonadic patients with advanced cancer. (Abstract #TPS238)**
E. Del Fabbro, J. Garcia, R. Dev, J. L. Palmer, C. Klingner-Winton, L. E. Roberts, J. Allo, G. Cardwell, E. Bruera
- Brd. 53E** **Lenalidomide in solid tumor patients with inflammatory cancer cachexia: A multicenter, randomized, double-blind, proof-of-concept study of fixed dose or CRP-response-guided dose or placebo. (Abstract #TPS239)**
F. Strasser, R. Oberholzer, D. Blum, M. Joerger, C. Driessen, S. deWolf-Linder, S. R. Haile, R. von Moos, N. Zerkiebel, A. Jatoi, R. Woelky, K. Fearon, T. Cerny, Swiss Group for Clinical Cancer Research (SAKK 96/10)

- Brd. 53F** **A longitudinal study of alterations in cognitive function and brain metabolites among women receiving chemotherapy for primary breast cancer. (Abstract #TPS240)**
S. Kohli, J. C. Buckner, J. H. Cerhan, K. Kantarci, D. L. Barton, J. A. Sloan, P. J. Novotny
- Brd. 53G** **Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or refractory ovarian cancer: The symptom benefit study (ANZGOG-0701/GCIG/PoCoG). (Abstract #TPS241)**
M. Friedlander, M. R. Stockler, M. King, A. M. Oza, M. Voysey, J. Martyn, K. Gillies, K. M. Sjoquist, P. Butow, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Psycho-Oncology Group (PoCoG), Gynecologic Cancer Intergroup (GCIG)
- Brd. 53H** **A multicenter study assessing 12-weekly intravenous bisphosphonate therapy in women with low-risk bone metastases from breast cancer: The TRIUMPH trial. (Abstract #TPS242)**
N. Bouganim, J. F. Hilton, L. Vandermeer, S. Hopkins, D. Robbins, E. Amir, S. Dent, C. Milano, O. C. Freedman, R. A. Dent, G. Dranitsaris, M. J. Clemons
- Brd. 54A** **Effect of Chinese herbal medicine JDXZO on epidermal growth factor receptor inhibitor (EGFRIs)-related skin toxicity. (Abstract #TPS243)**
H. Lin, J. Li
- Brd. 54B** **Clinical performance, efficacy, and safety of the DigniCap system, a scalp-hypothermia system, in preventing chemotherapy (CTX)-induced alopecia in patients (pts) with early-stage breast cancer (BC). (Abstract #TPS244)**
A. Glencer, M. E. Melisko, L. Esserman, S. A. Melin, H. S. Rugo
- Brd. 54C** **A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. (Abstract #TPS245)**
M. I. Hu, R. Gucaip, K. L. Insogna, I. Glezerman, H. G. Bone, A. Jaccard, W. Misiorowski, B. W. Yu, H. Yeh
- Brd. 54D** **AMC 070: A phase I/II study of lenalidomide in patients with AIDS-associated Kaposi sarcoma (Abstract #TPS246)**
K. A. Shimabukuro, E. G. Reid, AMC 070 Study Team
- Brd. 54E** **Cancer Research UK Stratified Medicine Programme. (Abstract #TPS247)**
J. Peach, A. Tuff, J. Bull, F. Hemsley, L. Jones, M. Jones, C. Westwood, P. W. Johnson
- Brd. 54F** **A pilot study of tumor-derived exosomes as diagnostic and prognostic markers in breast cancer patients receiving neoadjuvant chemotherapy. (Abstract #TPS248)**
R. E. Raab, T. L. Pawlowski, D. Spetzler, M. R. Klass, C. D. Kuslich, L. S. Bellin, J. H. Wong, A. S. Asch
- Brd. 54G** **ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). (Abstract #TPS249)**
B. J. Tromberg, J. A. Butler, D. A. Mankoff, S. J. Isakoff, N. M. Hylton, A. G. Yodh, D. Boas, K. Paulsen, B. W. Pogue, P. A. Kaufman, R. S. Mehta, P. M. Carpenter, A. Cerussi, Z. Zhang, D. M. Hartfeil, D. L'Heureux

Monday, June 6, 2011

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION

Cancer Prevention/Epidemiology

Display Time: 8:00 AM - 12:00 PM

Display Location: S102

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: S100a

CME credit: 1

Track(s): Cancer Prevention/Epidemiology

Gary E. Goodman, MD—Co-Chair

Swedish Cancer Institute

Marie Wood, MD—Co-Chair

University of Vermont

Discussion

11:30 AM Claudine Isaacs, MD (Abstracts #1509–1513)
Lombardi Comprehensive Cancer Center

Discussion

11:45 AM Susan M. Domchek, MD (Abstracts #1514–1518)
Abramson Cancer Center, University of Pennsylvania

Discussion

12:00 PM Stephen B. Gruber, MD, PhD, MPH (Abstracts #1519–1524)
University of Michigan

Discussion

12:15 PM Kala Visvanathan, MD, MHS (Abstracts #1525–1529)
The Johns Hopkins University Bloomberg School of Public Health

Brd. 1 **Feasibility and yield of offering genetic counseling to all patients with newly diagnosed high-grade epithelial ovarian cancer. (Abstract #1509)**
A. G. Arnold, J. Bhatia, M. F. Phillips, G. J. Gardner, K. M. Bell-McGuinn, C. Aghajanian, R. R. Barakat, K. Offit, N. D. Kauff

Brd. 2 **Does maternal or paternal inheritance of BRCA mutation affect the age of cancer diagnosis? (Abstract #1510)**
I. Shapira, R. J. Gralla, M. Akerman, L. R. Weiselberg, V. S. John, H. Raftopoulos, V. Vinciguerra, J. L. Lovecchio, A. Menzin, S. Cohen

Brd. 3 **Effect of rapid genetic testings on the rate of bilateral prophylactic mastectomy in BRCA1/2 mutation carriers. (Abstract #1511)**
L. Cortesi, E. De Matteis, E. Razzaboni, V. Medici, G. Tazzioli, A. Andreotti, M. Federico

Brd. 4 **Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (Abstract #1512)**
N. Elsayegh, S. Bayraktar, A. M. Gutierrez-Barrera, H. Lin, H. M. Kuerer, K. I. Muse, K. Ready, J. K. Litton, F. Meric-Bernstam, G. N. Hortobagyi, B. Arun

Brd. 5 **Identification of BRCA1/BRCA2 carriers by screening in the healthy population and its implications. (Abstract #1513)**
E. Levy-Lahad, E. Gabai-Kapara, B. Kaufman, R. Catane, S. Segev, P. Renbaum, U. Beller, M. King, A. Lahad

Brd. 6 **Prevalence and ancestral origin of hispanic BRCA mutations: Insights for ancestry-informed genetic cancer risk assessment. (Abstract #1514)**
J. N. Weitzel, J. N. DeHart, R. M. Ogaz, A. E. Martir-Negron, J. Herzog, C. Ricker, J. Congleton, C. Cina, P. R. Duncan, G. W. Unzeitig, J. Saldivar, M. Beattie, N. R. Feldman, S. Sand, D. Port, E. M. John, C. Haiman, R. Varma, S. L. Neuhausen, G. P. Larson, Cancer Genetics Community Research Network

Brd. 7 **Analysis of genomic ancestry in a sample of hereditary breast cancer high risk patients from Bahia, Brazil. (Abstract #1515)**
I. O. Nascimento, T. B. Machado, B. Toralles, L. A. Ferreira, M. Romeo, C. A. Sandes, L. Meyer, B. Garicochea, R. Meyer, S. Freire, K. Abe-Sandes

MONDAY

- Brd. 8** **Prospective study of breast cancer risk in mutation-negative women from *BRCA1* or *BRCA2* mutation-positive families in the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab). (Abstract #1516)**
 S. Harvey, R. L. Milne, K. E. Birch, P. Weideman, S. McLachlan, M. Friedlander, D. Goldgar, J. L. Hopper, K. Phillips
- Brd. 9** **Correlation of germ-line *BRCA2* mutations with aggressive prostate cancer and outcome. (Abstract #1517)**
 E. Castro, C. L. Goh, D. Olmos, D. Leongamornlert, E. Saunders, M. Tymrakiewicz, N. Mahmud, T. Dadaev, K. Govindasami, M. Guy, L. O'Brien, E. Sawyer, A. Hall, R. Wilkinson, Z. Kote-Jarai, R. A. Eeles, The UKGPCS collaborators
- Brd. 10** **Risk of breast cancer (BC) after *BRCA*-mutation associated ovarian cancer (*BRCA-OC*): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (Abstract #1518)**
 K. L. Jhaveri, S. Patil, M. Khasraw, J. Bhatia, Z. K. Stadler, N. D. Kauff, C. Hudis, K. Offit, M. E. Robson
- Brd. 11** **Breast cancer phenotype in women with *TP53* germ-line mutations: An LFS consortium effort. (Abstract #1519)**
 S. Masciari, D. Dillon, M. G. Dick, M. E. Robson, J. N. Weitzel, J. M. Ford, J. Balmaña, S. B. Gruber, D. Euhus, J. E. Garber
- Brd. 12** **Li-Fraumeni syndrome: Retesting archival DNA samples identifies previously unrecognized germline *p53* mutations. (Abstract #1520)**
 A. Novokmet, B. Baskin, D. Malkin
- Brd. 13** **Factors associated with type I and type II endometrial cancers in women with a germline mutation in a mismatch repair gene. (Abstract #1521)**
 Y. C. Antill, A. Win, P. Webb, J. L. Hopper, S. Gallinger, N. M. Lindor, P. A. Newcomb, R. W. Haile, J. Church, L. Le Marchand, I. Winship, A. B. Spurdle, M. A. Jenkins, Colon Cancer Family Registry
- Brd. 14** **Incremental impact of breast cancer SNP panel on risk classification and screening. (Abstract #1522)**
 K. Armstrong, E. Conant, J. Chen, E. Handorf, M. Jones, L. Boghossian, S. M. Domchek
- Brd. 15** **Single nucleotide polymorphisms and expression/amplification of *HER2* in patients with breast cancer. (Abstract #1523)**
 A. V. Boddy, N. Cresti, D. Jamieson, M. Pinkilgton, M. W. Verrill
- Brd. 16** **Prognostic value of single nucleotide polymorphisms (SNPs) of candidate genes associated with inflammation in early-stage breast cancer. (Abstract #1524)**
 J. L. Murray, P. Thompson, R. Zhou, S. Y. Yoo, Y. Liu, K. Do, A. A. Sahin, M. Bondy, A. M. Brewster
- Brd. 17** **Performance of the Gail model in individual women with benign breast disease. (Abstract #1525)**
 Y. Tarabishy, L. C. Hartmann, M. H. Frost, S. D. Maloney, R. A. Vierkant, V. S. Pankratz
- Brd. 18** **Presentation of breast cancer (BC) diagnosed at or before age 30: Implications for screening women at hereditary risk. (Abstract #1526)**
 P. de Alcantara Filho, T. A. King, E. A. Morris, C. Hudis, M. E. Robson
- Brd. 19** **Safety and efficacy of HRT and low dose tamoxifen in a phase II trial (HOT): Analysis of mammographic density and endometrial thickness. (Abstract #1527)**
 B. Bonanni, P. Maisonneuve, D. Serrano, C. Varricchio, M. Cazzaniga, M. Lazzeroni, B. Santillo, R. Di Pace, L. Meneghetti, A. Tagliafico, U. Veronesi, A. De Censi

Monday, June 6, 2011

- Brd. 20** **25-hydroxy vitamin D (VitD) and associated variables as predictors of breast cancer (BC) risk and tamoxifen benefit in NSABP-P1. (Abstract #1528)**
E. Amir, R. S. Cecchini, P. A. Ganz, J. P. Costantino, S. Beddows, N. Hood, P. J. Goodwin
- Brd. 21** **Relationship of body mass index to the intrinsic subtypes of breast cancer. (Abstract #1529)**
C. A. Santa-Maria, Y. Zhao, N. Ketring, I. Rodriguez, A. Condren, D. Euhus

MONDAY

8:00 AM - 12:30 PM POSTER DISCUSSION SESSION

Gastrointestinal (Colorectal) Cancer

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: Hall D1

CME credit: 1

Track(s): Gastrointestinal (Colorectal) Cancer

Blase N. Polite, MD, MPH—Co-Chair

The University of Chicago

Sharlene Gill, MD—Co-Chair

British Columbia Cancer Agency

Discussion

11:30 AM John S. Kauh, MD (Abstracts #3512–3517)
Winship Cancer Institute of Emory University

Discussion

11:45 AM Chris R. Garrett, MD (Abstracts #3518–3522)
University of Texas M. D. Anderson Cancer Center

Discussion

12:00 PM Josep Tabernero, MD (Abstracts #3523–3528)
Vall d'Hebron University Hospital

Discussion

12:15 PM Sabine Tejpar, MD, PhD (Abstracts #3529–3536)
University Hospital Gasthuisberg

- Brd. 1** **The dose-effect relationship in preoperative chemoradiation of locally advanced rectal cancer: Preliminary results of a phase III trial. (Abstract #3512)**
A. K. Jakobsen, A. L. Appelt, J. Lindebjerg, J. Ploeen, S. R. Rafaelsen, T. Vuong
- Brd. 2** **EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer. (Abstract #3513)**
A. Dewdney, J. Capdevila, B. Glimelius, A. Cervantes, D. M. Tait, G. Brown, A. Wotherspoon, D. Gonzalez de Castro, Y. Chua, R. Wong, Y. Barbachano, J. R. Oates, I. Chau, D. Cunningham
- Brd. 3** **Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treated with TME. (Abstract #3514)**
J. Garcia-Aguilar, J. Marcet, T. Coutsoftides, P. Cataldo, A. Fichera, L. E. Smith, S. Oommen, S. R. Hunt, D. Herzig, D. Dietz, M. G. Varma, C. A. Ternent, M. J. Stamos, K. Avila, D. D. Smith
- Brd. 4** **Postoperative adjuvant chemotherapy (CTX) use in patients (Pts) with stage II/III rectal treated with neoadjuvant therapy: A National Comprehensive Cancer Network (NCCN) analysis. (Abstract #3515)**
P. Khrizman, J. C. Niland, A. ter Veer, D. Milne, K. Bullard Dunn, W. E. Carson III, P. F. Engstrom, S. Shibata, J. M. Skibber, M. R. Weiser, D. Schrag, A. B. Benson
- Brd. 5** **Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. (Abstract #3516)**
R. Sauer, T. Liersch, S. Merkel, H. Becker, W. Hohenberger, H. Witzigmann, C. F. Hess, R. Fietkau, C. Wittekind, C. Roedel, German Rectal Cancer Study Group

Monday, June 6, 2011

- Brd. 6 Efficacy endpoints of RTOG 0247: A randomized phase II study of neoadjuvant capecitabine (C) and irinotecan (I) or C and oxaliplatin (O) with concurrent radiation therapy (RT) for locally advanced rectal cancer. (Abstract #3517)**
S. J. Wong, J. Moughan, N. J. Meropol, P. R. Anne, L. A. Kachnic, A. Rashid, J. C. Watson, E. P. Mitchell, J. Pollock, M. G. Haddock, B. Erickson, C. G. Willett
- Brd. 7 Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581. (Abstract #3518)**
A. P. Venook, D. Niedzwiecki, M. Lopatin, M. Lee, P. N. Friedman, W. Frankel, K. Clark-Langone, C. Yoshizawa, C. Millward, S. Shak, R. M. Goldberg, N. N. Mahmoud, R. L. Schilsky, M. M. Bertagnolli, Cancer and Leukemia Group B
- Brd. 8 Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. (Abstract #3519)**
R. Adam, E. Barroso, C. Laurent, G. Nuzzo, C. Hubert, G. Menta, J. Ijzermans, L. Capussotti, S. Lopezben, D. Mirza, G. Kaiser, E. Oussoultzoglou, T. Gruenberger, G. J. Poston, O. Skipenko, The LiverMetSurvey Centers
- Brd. 9 An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). (Abstract #3520)**
C. Moulton, M. N. Levine, C. Law, R. Hart, L. Ruo, C. Gu, A. Hendler, K. Y. Gulenchyn, M. A. Haider, M. Marcaccio, V. Tandan, D. Quan, D. Jalink, R. Fairfull Smith, S. Hanna, P. D. Greig, M. Husien, T. Finch, J. A. Julian, S. Gallinger
- Brd. 10 Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial. (Abstract #3521)**
J. N. Primrose, A. Fuller, P. Rose, R. Perera-Salazar, J. Mellor, A. Corkhill, S. George, D. Mant
- Brd. 11 Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. (Abstract #3522)**
J. Huang, D. J. Sargent, M. R. Mahoney, A. F. Shields, E. Chan, R. M. Goldberg, S. Gill, M. S. Kahlenberg, J. T. Quesenberry, T. C. Smyrk, A. Grothey, F. Sinicrope, S. G. Nair, S. R. Alberts
- Brd. 12 Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC). (Abstract #3523)**
M. T. Seymour, S. R. Brown, S. Richman, G. W. Middleton, T. S. Maughan, C. Olivier, S. J. Gwyther, J. Wadsley, I. Chau, T. Hickish, L. K. Dawson, S. Falk, A. O'Callaghan, K. Benstead, N. Wadd, A. Oliver, P. Chambers, H. Marshall, V. Napp, P. Quirke, UK NCRI Colorectal Clinical Studies Group
- Brd. 13 A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. (Abstract #3524)**
Y. Park, H. Lim, J. Lee, T. Kim, Y. Hong, S. Kim, J. Baek, J. Kim, K. Lee, I. Chung, S. Cho, S. J. Shin, H. Kang, D. Shin, S. Jo
- Brd. 14 Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). (Abstract #3525)**
C. Becerra, R. Salazar, R. Garcia-Carbonero, A. L. Thomas, F. Vázquez-Mazón, J. Cassidy, T. Maughan, M. Gallén, T. Iveson, M. Hixon, A. Gualberto, D. Yin, D. Li, E. K. Bergsland
- Brd. 15 A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC). (Abstract #3526)**
A. Johnsson, J. Frodin, A. Berglund, H. Hagman, J. Sundberg, D. Bergstrom, R. D. Christensen, N. Keldsen, K. G. Spindler, A. K. Jakobsen

- Brd. 16** **A double-blind, randomized, placebo-controlled, phase II study of maintenance enzastaurin with 5-FU/leucovorin plus bevacizumab following first-line therapy for metastatic colorectal cancer (mCRC). (Abstract #3527)**
R. A. Wolff, W. Schepp, M. Di Bartolomeo, A. Hossain, C. Stoffregen, S. Nicol, V. Heinemann
- Brd. 17** **An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (Abstract #3528)**
R. Geva, B. V. Jensen, G. Fountzilas, T. Yoshino, D. Paez, C. Montagut, I. Sougklakos, F. Cappuzzo, A. Cervantes-Ruiperez, D. Papamichael, M. Frattini, B. Vincenzi, T. Macarulla, F. Loupakis, K. G. Spindler, C. Qvortrup, F. Ciardiello, S. Tejpar
- Brd. 18** **Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). (Abstract #3529)**
M. Lin, E. Hawk, M. Huang, J. Lin, J. Gu, L. M. Ellis, X. Wu, C. Eng
- Brd. 19** **Evaluation of gene mutations beyond KRAS as predictive biomarkers of response to panitumumab in a randomized, phase III monotherapy study of metastatic colorectal cancer (mCRC). (Abstract #3530)**
K. Oliner, M. Peeters, S. Siena, E. Van Cutsem, J. Huang, Y. Humblet, J. Van Laethem, T. Andre, J. S. Wizezorek, S. D. Patterson
- Brd. 20** **Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. (Abstract #3531)**
A. J. Weickhardt, D. Williams, C. Lee, J. Simes, C. Murone, K. Wilson, M. Cummins, K. Asadi, T. J. Price, J. Mariadason, N. C. Tebbutt, Australasian GI Trials Group
- Brd. 21** **Prediction of survival in patients with metastatic colorectal cancer treated with third-line cetuximab and irinotecan through changes in microRNA expression in whole blood during treatment (Abstract #3532)**
J. V. Schou, K. K. Andersen, B. V. Jensen, D. L. Nielsen, P. Pfeiffer, E. V. Høgdall, M. Yilmaz, M. Kruhoffer, J. S. Johansen
- Brd. 22** **The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. (Abstract #3533)**
C. H. Lieu, H. T. Tran, Z. Jiang, M. Mao, M. J. Overman, C. Eng, J. Morris, L. M. Ellis, J. Heymach, S. Kopetz
- Brd. 23** **The role of activating mutations of KRAS, BRAF, and PIK3CA pathway convergence at the transcriptional level and prediction of treatment response to cetuximab in colorectal cancer. (Abstract #3534)**
I. Simon, S. Tian, V. Moreno, P. Roepman, J. Tabernero, M. Snel, T. Macarulla, L. van't Veer, R. Bernards, G. Capella
- Brd. 24** **Primary colorectal tumors and their metastasis are genetically not the same: Implications for choice of targeted treatment? (Abstract #3535)**
J. S. Vermaat, I. J. Nijman, M. J. Koudijs, W. M. Roessingh, F. L. Gerritse, M. Mokry, R. H. Giles, P. J. van Diest, E. Cuppen, E. E. Voest
- Brd. 25** **Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. (Abstract #3536)**
A. L. Russo, D. R. Borger, D. P. Ryan, K. C. Fan, H. Lopez, V. Scialabba, L. S. Blaszkowsky, E. L. Kwak, J. W. Clark, J. N. Allen, R. C. Wadlow, A. X. Zhu, R. Wang, D. Dias-Santagata, T. S. Hong, A. J. Iafrate

Monday, June 6, 2011

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION

Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell

Display Time: 8:00 AM - 12:00 PM

Display Location: E450a

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: Hall D2

CME credit: 1

Track(s): Lung Cancer

Katherine Pisters, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

William J. Petty, MD—Co-Chair

Wake Forest University

Discussion

11:30 AM Tetsuya Mitsudomi, MD, PhD (Abstracts #7007–7010)
Aichi Cancer Center Hospital

Discussion

11:40 AM Enriqueta Felip, MD (Abstracts #7011–7015)
Vall d'Hebron University Hospital

Discussion

11:55 AM Joseph Kamel Salama, MD (Abstracts #7016–7020)
Duke University Medical Center

Discussion

12:05 PM Kaoru Kubota, MD (Abstracts #7021–7023)
National Cancer Center

Discussion

12:20 PM Nasser H. Hanna, MD (Abstracts #7024–7028)
Indiana University

Brd. 1 **Use of a three-microRNA signature to discriminate prognostic groups in early-stage NSCLC patients in the IFCT-0002 trial. (Abstract #7007)**

C. Mascaux, G. Levallet, E. Bergot, L. Baudrin, M. Antoine, G. Anthoine, V. Westeel, A. Lavole, E. A. Quoix, D. Debieuvre, J. Mazieres, J. Pujol, D. Moro-Sibilot, F. Morin, B. Milleron, G. Zalcman, on behalf of the Intergroupe Francophone de Cancerologie Thoracique (IFCT)

Brd. 2 **Association between DNA-repair gene and glutathione S-transferase gene polymorphisms and clinical outcome in patients (pt) with localized non-small-cell lung cancer (NSCLC) treated with sequential radiochemotherapy. (Abstract #7008)**

J. Stoecklmacher-Williams, B. Krassler, M. Kramer, G. Ehninger, G. Hoeffken, E. Goekkurt

Brd. 3 **Genetic variations in multiple drug action pathways and survival in advanced-stage non-small cell lung cancer treated with chemotherapy. (Abstract #7009)**

P. Yang, Y. Li, Z. Sun, J. M. Cunningham, M. Aubry, J. A. Wampfler, G. Croghan, C. Johnson, D. Wu, J. Aakre, J. R. Molina, L. Wang, V. S. Pankratz

Brd. 4 **Use of a gene expression signature related to epithelial-to-mesenchymal transition (EMT) to predict for overall survival (OS) in cohorts of lung and head and neck cancer (HNSCC) patients. (Abstract #7010)**

J. S. Yordy, L. Shen, L. Diao, J. Wang, K. Coombes, U. Giri, Y. Xie, J. D. Minna, L. Girard, J. Weinstein, J. Heymach, K. Ang, M. D. Story, R. Meyn

Brd. 5 **Oncologists', physicians', and surgeons' opinions on the perceived value and appropriateness of the speciality to inform patients on adjuvant chemotherapy after radical surgery for non-small cell lung cancer. (Abstract #7011)**

K. Khor, D. Tai, S. Popat, M. Beckles, M. Leung, M. Al Sahaf, E. K. Lim

MONDAY

- Brd. 6** **Adoption of adjuvant chemotherapy (ACT) for non-small cell lung cancer (NSCLC) in the elderly: A population-based outcomes study. (Abstract #7012)**
S. Cuffe, C. M. Booth, Y. Peng, G. E. Darling, G. Li, W. Kong, W. J. Mackillop, F. A. Shepherd
- Brd. 7** **Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early stage non-small cell lung cancer (NSCLC). (Abstract #7013)**
H. A. Wakelee, S. E. Dahlberg, S. M. Keller, D. R. Gandara, S. L. Graziano, N. B. Leighl, A. A. Adjei, J. H. Schiller, Eastern Cooperative Oncology Group
- Brd. 8** **Platinum-based adjuvant chemotherapy (ACT) in elderly patients with non-small cell lung cancer (NSCLC) in the SEER-Medicare database: Comparison between carboplatin- and cisplatin-based regimens. (Abstract #7014)**
F. Gu, G. M. Strauss, J. P. Wisnivesky
- Brd. 9** **Adjuvant chemotherapy (AC) in stage IB non-small cell lung cancer (NSCLC): Long-term follow-up of Cancer and Leukemia Group B (CALGB) 9633. (Abstract #7015)**
G. M. Strauss, X. F. Wang, M. Maddaus, D. Johnstone, E. Johnson, D. Harpole, H. H. Gillenwater, L. Gu, D. Sugarbaker, M. R. Green, S. L. Graziano, R. A. Kratzke, R. L. Schilsky, J. Crawford, E. E. Vokes
- Brd. 10** **Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). (Abstract #7016)**
T. Stinchcombe, M. A. Socinski, D. T. Moore, S. N. Gettinger, R. H. Decker, W. J. Petty, A. W. Blackstock, G. Schwartz, S. Lankford, D. E. Morris
- Brd. 11** **Phase II study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III non-small cell lung cancer. (Abstract #7017)**
J. Y. Chang, R. Komaki, C. Lu, H. Y. When, P. Allen, A. S. Tsao, M. Gillin, R. Mohan, J. D. Cox
- Brd. 12** **An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. (Abstract #7018)**
Y. Ung, C. Gu, K. Cline, A. Sun, R. M. MacRae, J. R. Wright, E. Yu, L. Ehrlich, K. Y. Gulenchyn, H. Shulman, I. S. Dayes, S. K. Dhesy-Thind, G. E. Darling, N. B. Leighl, W. K. Evans, J. A. Julian, M. N. Levine
- Brd. 13** **Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). (Abstract #7019)**
A. P. Kotsakis, S. S. Ramalingam, A. A. Tarhini, D. E. Heron, R. Smith, D. Friedland, D. P. Petro, L. E. Raez, J. R. Brahmer, J. S. Greenberger, S. Dacic, P. Hershberger, R. J. Landreneau, C. P. Belani, J. D. Luketich, A. Argiris
- Brd. 14** **Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. (Abstract #7020)**
R. Komaki, G. R. Blumenschein Jr., I. I. Wistuba, J. Lee, P. Allen, X. Wei, J. Welsh, M. O'Reilly, R. S. Herbst, X. Tang, R. Meyn, D. Liu, W. K. Hong
- Brd. 15** **Surgical resection in early limited stage small cell lung cancer: Time to rethink? A retrospective analysis of the VA Central Cancer Registry. (Abstract #7021)**
T. Tashi, I. T. Aldoss, W. Gonsalves, A. Ganti, P. T. Silberstein, P. Townley, S. Subbiah

Monday, June 6, 2011

- Brd. 16** **COCIS individual patient data (IPD) meta-analysis: Carboplatin- or cisplatin-based chemotherapy (CT) as first-line treatment of small cell lung cancer (SCLC). (Abstract #7022)**
A. Rossi, M. Di Maio, P. Chiodini, R. Rudd, H. Okamoto, D. Skarlos, M. Frueh, W. Qian, T. Tamura, E. Samantas, T. Shibata, F. Perrone, C. Gallo, C. Gridelli, O. Martelli, S. M. Lee
- Brd. 17** **Thymoma: A population-based study of the management and outcomes for the province of British Columbia. (Abstract #7023)**
C. J. Mariano, D. Ionescu, W. Y. Cheung, R. Ali, J. J. Laskin, H. Carolan, K. Evans, N. Murray
- Brd. 18** **Predictive value of thymidylate synthase and folylpoly-glutamate synthetase for clinical benefit from pemetrexed in malignant pleural mesothelioma. (Abstract #7024)**
D. C. Christoph, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, J. Wohlschlaeger, D. Theegarten, T. C. Gauler, M. H. Schuler, W. E. Eberhardt, F. R. Hirsch
- Brd. 19** **Does disease control rate (DCR) at 9 and 18 weeks predict overall survival (OS) in patients with malignant pleural mesothelioma (MPM)? An individual patient data combined analysis of 10 European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG) studies. (Abstract #7025)**
L. Greillier, B. Hasan, P. Baas, J. J. Welch, J. P. Van Meerbeeck, R. M. Gaafar, R. Sylvester, D. A. Lacombe, M. O'Brien
- Brd. 20** **Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response. (Abstract #7026)**
R. Hassan, E. Sharon, B. Schuler, Y. Mallory, J. Zhang, A. Ling, I. Pastan
- Brd. 21** **Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago phase II consortium. (Abstract #7027)**
N. P. Campbell, R. Kunnavakkam, N. B. Leighl, M. D. Vincent, D. R. Gandara, M. Koczywas, B. J. Gitlitz, E. S. Agamah, S. P. Thomas, W. M. Stadler, E. E. Vokes, H. L. Kindler
- Brd. 22** **Forced vital capacity (FVC) as a reproducible measure of pulmonary function (PF) in chemotherapy-pretreated patients with malignant pleural mesothelioma (MPM). (Abstract #7028)**
L. M. Krug, J. Arduino, X. Sun, H. L. Kindler, C. Manegold, D. Fennell, G. M. Lubiniecki, P. Baas

8:00 AM - 12:30 PM POSTER DISCUSSION SESSION

Melanoma/Skin Cancers

Display Time: 8:00 AM - 12:00 PM

Display Location: S403

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: S406

CME credit: 1

Track(s): Melanoma/Skin Cancers

Bartosz Chmielowski, MD, PhD—Co-Chair

University of California, Los Angeles

Georgina V. Long, MBBS, PhD—Co-Chair

Royal Prince Alfred Hospital

Discussion

11:30 AM David Fisher, MD, PhD (Abstracts #8513–8520)
Massachusetts General Hospital

Discussion

11:45 AM Michael S. Sabel, MD (Abstracts #8521–LBA8526^)
University of Michigan

Discussion

12:00 PM Christopher D. Lao, MD (Abstracts #8527–8532)
University of Michigan

Discussion

12:15 PM F. Stephen Hodi, MD (Abstracts #8533–8537)
Dana-Farber Cancer Institute

Brd. 1 **An analysis of sera-based microRNAs as biomarkers of recurrence in melanoma. (Abstract #8513)**

E. B. Friedman, S. Shang, E. Vega-Saenz de Miera, M. W. Ma, R. S. Berman, R. L. Shapiro, A. C. Pavlick, E. Hernandez, Y. Shao, I. Osman

Brd. 2 **Functional characterization of an oncogenic role for the miRNA-506–514 cluster in initiating melanocyte transformation and promoting melanoma growth. (Abstract #8514)**

K. Streicher, W. Zhu, K. Lehmann, R. W. Georgantas III, C. Morehouse, P. Brohawn, R. Carrasco, Z. Xiao, D. Tice, B. W. Higgs, L. Richman, B. Jallal, Y. Yao

Brd. 3 **Whole-genome expression profiling of brain metastases from melanoma (BrMM) provides preliminary insights into its biology and mechanisms of development. (Abstract #8515)**

M. T. Krauze, R. H. Hamilton, S. Bortoluzzi, S. C. Buch, M. Romkes, A. H. Mintz, D. Kondziolka, J. M. Kirkwood, S. J. Moschos

Brd. 4 **Targeting histone deacetylase to overcome resistance of B-RAF^{V600E} melanoma cells to apoptosis. (Abstract #8516)**

P. Hersey, Chen Chen Jiang, Fritz Lai, Xu Dong Zhang

Brd. 5 **Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (RG7204, PLX4032). (Abstract #8517)**

F. Su, H. Yang, B. Higgins, K. D. Kolinsky, K. Packman, M. Kim, B. J. Lestini, G. Bollag, D. C. Heimbrosk

Brd. 6 **Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (Abstract #8518)**

F. E. Meier, D. Beck, H. Niessner, K. T. Flaherty, J. Iovanna, D. Kulms, D. Schadendorf, C. Garbe

Monday, June 6, 2011

- Brd. 7** **Pattern and outcome of disease progression in phase I study of vemurafenib (RG7204) in patients with metastatic melanoma (MM). (Abstract #8519)**
K. B. Kim, K. T. Flaherty, P. B. Chapman, J. A. Sosman, A. Ribas, G. A. McArthur, R. K. Amaravadi, R. J. Lee, K. B. Nolop, I. Puzanov
- Brd. 8** **Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (Abstract #8520)**
M. E. Lacouture, P. B. Chapman, A. Ribas, J. A. Sosman, G. A. McArthur, K. T. Flaherty, K. B. Kim, I. Puzanov, K. B. Nolop, A. K. Joe, O. Spleiss, A. Koehler, W. Wu, C. Robert, A. Hauschild, D. Schadendorf, J. L. Troy, M. Duvic, K. Trunzer
- Brd. 9** **Impact of population genetic substructure on association studies and risk assessment for melanoma. (Abstract #8521)**
I. Lobach, I. Belitskaya-Levy, J. D. Goldberg, H. Ostrer, R. S. Berman, A. C. Pavlick, R. L. Shapiro, I. Osman, P. Manga
- Brd. 10** **Disparities in the management of melanoma in elderly patients: An analysis of patients from the National Cancer Database. (Abstract #8522)**
S. Tsaj, S. Soong, C. M. Balch, J. R. Lange
- Brd. 11** **The impact of gender on the outcome of malignant melanoma: Overview of seven EORTC phase III trials. (Abstract #8523)**
A. Joosse, S. Collette, S. Suci, E. de Vries, T. Nijsten, P. Patel, U. R. Kleeberg, U. Keilholz, A. M. Eggermont, J. W. Coebergh, EORTC Melanoma Group
- Brd. 12** **The effect of beta-blocker treatment in patients with cutaneous melanoma. (Abstract #8524)**
V. De Giorgi, M. Grazzini, S. Gandini, S. Benemei, T. Lotti, N. Marchionni, S. Rossari, A. Gori, P. Geppetti
- Brd. 14** **A phase III study of receptor-targeted ^{99m}Tc-tilmanocept versus blue dye in evaluation of SLNs in breast cancer and melanoma. (Abstract #LBA8526^)**
F. O. Cope, V. K. Sondak, A. M. Wallace
- Brd. 15** **Assessment of clinical activity of E7080, a multitargeted kinase inhibitor, in patients with advanced melanoma treated in two phase I trials. (Abstract #8527)**
D. S. Hong, D. S. Boss, H. Glen, J. Mink, M. Ren, C. Andresen, J. P. O'Brien, R. Kurzrock, J. H. Schellens, J. J. Nemunaitis, T. Evans
- Brd. 16** **A phase II clinical/translational trial of sequential axitinib/carboplatin/paclitaxel in melanoma. (Abstract #8528)**
A. P. Algazi, E. Cha, C. Soon, S. Ortiz-Urda, B. Cortez, L. Ziani, F. V. Coakley, A. Daud
- Brd. 17** **MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with metastatic melanoma: Results of a phase I study. (Abstract #8529)**
S. Bhatia, O. Hamid, A. C. Pavlick, G. Mulligan, P. G. Smith, M. D. Pickard, M. Shultz, R. M. Walker, B. Dezube, S. O'Day
- Brd. 18** **Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM). (Abstract #8530)**
J. H. Beumer, H. A. Tawbi, A. A. Tarhini, S. J. Moschos, M. J. Egorin, S. C. Buch, Y. Lin, J. M. Kirkwood
- Brd. 19** **Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). (Abstract #8531)**
A. Y. Bedikian, C. Lebbé, C. Robert, S. S. Agarwala, T. Cousin, J. Wu, C. Garbe, J. J. Grob

MONDAY

- Brd. 20** **A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775). (Abstract #8532)**
L. A. Kottschade, V. Suman, D. G. Perez, R. R. McWilliams, J. S. Kaur, T. Amatruda, F. J. Geoffroy, H. M. Gross, P. A. Cohen, A. J. Jaslowski, M. L. Kosel, S. Markovic
- Brd. 21** **Phase II study of recombinant adeno-viral human p53 (rAd-p53) gene therapy combined with surgery in treatment of melanomas of oral mucosa. (Abstract #8533)**
L. Li
- Brd. 22** **Combination immunotherapy for high-risk and advanced melanoma patients. (Abstract #8534)**
A. I. Riker, N. N. Vahanian, C. J. Link, L. Tennant, W. J. Ramsey, G. R. Rossi, L. C. Alsfeld, E. Davila, M. Harrison
- Brd. 23** **Active immunization toward the MAGE-A3 antigen in patients with metastatic melanoma: Four-year follow-up results from a randomized phase II study (EORTC16032-18031). (Abstract #8535)**
W. Kruit, S. Suci, B. Dreno, V. Chiarion-Sileni, L. Mortier, C. Robert, M. Maio, F. Lehmann, V. G. Brichard, A. Spatz, A. M. Eggermont, U. Keilholz
- Brd. 24** **Neoadjuvant ipilimumab in patients with stage IIIB/C melanoma: Immunogenicity and biomarker analysis. (Abstract #8536)**
A. A. Tarhini, H. Edington, L. H. Butterfield, M. Sinha, S. J. Moschos, H. Tawbi, Y. Shuai, J. Shipe-Spotloe, M. Simonetta, C. Milburn, M. Horak, C. Sander, J. M. Kirkwood
- Brd. 25** **Clinical benefit of ipilimumab in patients with metastatic melanoma who progress on high-dose IL-2. (Abstract #8537)**
R. W. Joseph, P. Hwu, M. A. Davies, M. B. Atkins, R. J. Sullivan

Monday, June 6, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

Location: Hall B1

CME credit: 3

Track(s): Breast Cancer

Lisa Yee, MD—Chair

The Ohio State University

9:30 AM NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer (Abstract #LBA1003)

T. J. Whelan, I. Olivetto, I. Ackerman, J. A. W. Chapman, B. Chua, A. Nabid, K. A. Vallis, J. R. White, P. Rousseau, A. Fortin, L. J. Pierce, L. Manchul, P. Craighead, M. C. Nolan, J. Bowen, D. R. McCready, K. I. Pritchard, M. N. Levine, and W. Parulekar

Discussion

9:45 AM Thomas A. Buchholz, MD (Abstract #LBA1003)

University of Texas M. D. Anderson Cancer Center

10:00 AM First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer. (Abstract #1004)

G. T. Budd, W. E. Barlow, H. C. Moore, T. J. Hobday, J. A. Stewart, C. Isaacs, M. Salim, J. K. Cho, K. Rinn, K. S. Albain, H. K. Chew, G. V. Burton, T. D. Moore, G. Srkalovic, B. A. McGregor, L. E. Flaherty, R. B. Livingston, D. Lew, J. Gralow, G. N. Hortobagyi, SWOG

10:15 AM The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. (Abstract #LBA1005)

H. D. Bear, G. Tang, P. Rastogi, C. E. Geyer, A. Robidoux, J. N. Atkins, L. Baez, A. Brufsky, R. S. Mehta, L. Fehrenbacher, E. R. Pajon, F. M. Senecal, R. Gaur, R. G. Margolese, P. T. Adams, H. M. Gross, S. M. Swain, E. P. Mamounas, J. P. Costantino, N. Wolmark

10:30 AM Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 686 triple-negative primary breast cancers: Second day endpoint analysis of the GEPARQUINTO study (GBG 44). (Abstract #1006)

B. Gerber, H. Eidtmann, M. Rezaei, P. A. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. A. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch, G. Kunz, J. U. Blohmer, J. B. Huober, M. Hauschild, S. Loibl, V. Nekljudova, M. Untch, G. Von Minckwitz, GBG/AGO Study Groups

Discussion

10:45 AM Hope S. Rugo, MD (Abstracts #1004–1006)

University of California, San Francisco

11:00 AM A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). (Abstract #1007)

J. O'Shaughnessy, L. S. Schwartzberg, M. A. Danso, H. S. Rugo, K. Miller, D. A. Yardley, R. W. Carlson, R. S. Finn, E. Charpentier, M. Freese, S. Gupta, A. Blackwood-Chirchir, E. P. Winer

Discussion

11:15 AM Lisa A. Carey, MD (Abstract #1007)

University of North Carolina at Chapel Hill

11:30 AM Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009–05 study. (Abstract #1008)

M. L. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora, M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Garcia Saenz, A. Casado, I. Chacón, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira

- 11:45 AM Sorafenib (SOR) plus chemotherapy (CRx) for patients (pts) with advanced (adv) breast cancer (BC) previously treated with bevacizumab (BEV). (Abstract #1009)**
C. Hudis, K. W. Tauer, R. C. Hermann, G. Makari-Judson, C. Isaacs, J. T. Beck, V. G. Kaklamani, E. J. Stepanski, H. S. Rugo, W. Wang, K. M. Bell-McGuinn, H. Chera, B. Zaugg, S. Ro, S. Li, L. S. Schwartzberg
- 12:00 PM Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2. (Abstract #1010)**
A. Brufsky, V. Valero, B. Tiangco, S. R. Dakhil, A. Brize, N. Bousfoul, H. S. Rugo, D. A. Yardley
- Discussion**
- 12:15 PM** Stephen R. D. Johnston, MA, MD, PhD (Abstracts #1008–1010)
Royal Marsden Hospital

Monday, June 6, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Health Services Research

Location: S404

CME credit: 3

Track(s): Health Services Research

Monika K. Krzyzanowska, MD—Co-Chair

Princess Margaret Hospital

Christopher Ryan Friese, RN, PhD—Co-Chair

University of Michigan

- 9:30 AM Identification of barriers to clinical trials: The impact of education level. (Abstract #CRA6003)**
J. R. Eads, T. L. Albrecht, B. Egleston, J. S. Buzaglo, R. B. Cohen, L. Fleisher, T. Foster, M. Katz, T. Kinzy, S. Manne, D. M. Miller, S. M. Miller, S. Raivitch, N. Roach, A. Silver, N. J. Meropol
- 9:45 AM The impact of socioeconomic status on cancer care and survival. (Abstract #6004)**
S. L. Wong, N. Gu, M. Banerjee, J. D. Birkmeyer, N. J. Birkmeyer
- 10:00 AM The impact of economic recession on the incidence and treatment of cancer. (Abstract #6005)**
K. Y. Ennis, M. Chen, G. C. Smith, A. V. D'Amico, Y. Zhang, L. B. Harrison, R. D. Ennis
- 10:15 AM Impact of out-of-pocket expenses on cancer care. (Abstract #6006)**
Y. Zafar, A. M. Goetzinger, R. Fowler, A. Gblokpor, D. Warhadpande, D. H. Taylor, D. Schrag, J. M. Peppercorn, A. P. Abernethy
- 10:30 AM Cancer diagnosis as a risk factor for personal bankruptcy. (Abstract #6007)**
S. D. Ramsey, C. R. Fedorenko, K. S. Snell, A. C. Kirchhoff, W. Hollingworth, D. K. Blough

Discussion

- 10:45 AM** Neal J. Meropol, MD (Abstracts #CRA6003–6007)
Case Western Reserve University
- 11:00 AM Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. (Abstract #CRA6008)**
M. Fisch, J. Lee, M. Weiss, L. I. Wagner, V. T. Chang, D. Cella, J. Manola, L. M. Minasian, W. J. McCaskill-Stevens, T. R. Mendoza, C. S. Cleeland
- 11:15 AM Effect of early palliative care on chemotherapy utilization and end-of-life care in patients with metastatic non-small cell lung cancer (NSCLC). (Abstract #6009)**
J. A. Greer, W. F. Pirl, V. A. Jackson, I. T. Lennes, R. S. Heist, E. R. Gallagher, J. S. Temel

Discussion

- 11:30 AM** Susan Yount, PhD (Abstracts #CRA6008–6009)
Northwestern University, Feinberg School of Medicine
- 11:45 AM Correlates of contralateral prophylactic mastectomy in a population-based sample. (Abstract #6010)**
S. T. Hawley, R. Jagsi, M. Morrow, S. J. Katz
- 12:00 PM Quality of non-small cell lung cancer (NSCLC) care in the Veterans Health Administration (VHA): Impact of patient preference and clinical judgment. (Abstract #6011)**
J. J. Ryoo, B. Kim, D. L. Ordin, S. M. Oishi, S. M. Asch, A. M. Antonio, R. He, M. K. Gould, J. Malin

MONDAY

Discussion

12:15 PM David J. Bentrem, MD (Abstracts #6010–6011)
Northwestern University, Feinberg School of Medicine

Monday, June 6, 2011

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Leukemia, Myelodysplasia, and Transplantation

Location: Arie Crown Theater

CME credit: 3

Track(s): Leukemia, Myelodysplasia, and Transplantation

Attaya Suvannasankha, MD—Co-Chair

Indiana University

Guido Marcucci, MD—Co-Chair

The Ohio State University Comprehensive Cancer Center

9:30 AM Results of COMFORT- I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). (Abstract #6500)

S. Verstovsek, R. A. Mesa, J. R. Gotlib, R. S. Levy, V. Gupta, J. F. DiPersio, J. Catalano, M. Deininger, C. B. Miller, R. T. Silver, M. Talpaz, E. F. Winton, J. H. Harvey, K. Vaddi, S. K. Erickson-Viitanen, I. Koumenis, W. Sun, V. Sandor, H. Kantarjian, on behalf of all COMFORT-I investigators

9:45 AM Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) (Abstract #LBA6501)

C. N. Harrison, J. J. Kiladjian, H. K. Al-Ali, H. Gisslinger, R. J. Waltzman, V. Stalbovskaya, M. McQuitty, D. S. Hunter, R. S. Levy, F. Cervantes, A. M. Vannucchi, T. Barbui, G. Barosi

10:00 AM The incidence of BCR-ABL mutations in patients (pts) with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) treated with nilotinib or imatinib in ENESTnd: Twenty-four-month follow-up. (Abstract #6502)

G. Saglio, H. Kantarjian, J. Reiffers, S. Jootar, M. E. Kalaycio, H. Shibayama, X. Fan, N. J. Gallagher, Y. Shou, R. A. Larson, T. P. Hughes, A. Hochhaus

Discussion

10:15 AM Ross L. Levine, MD (Abstracts #6500–6502)
Memorial Sloan-Kettering Cancer Center

10:30 AM Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. (Abstract #6503^)

S. Faderl, M. Wetzler, D. Rizzieri, G. J. Schiller, M. H. Jagasia, R. K. Stuart, S. Ganguly, D. Avigan, M. Craig, R. Collins, M. B. Maris, T. Kovacovics, S. Goldberg, K. Seiter, P. Hari, F. Ravandi, E. S. Wang, S. Eckert, D. Huebner, H. Kantarjian

10:45 AM Results from a randomized phase III trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. (Abstract #6504)

X. G. Thomas, A. Dmoszynska, A. Wierzbowska, K. Kuliczowski, J. Mayer, T. Shelekhova, J. Gau, W. Chou, R. Buckstein, J. Cermak, C. Kuo, A. O. Rocafiguera, V. Koza, F. Ravandi, H. Kantarjian

11:00 AM Sequential azacitidine and lenalidomide in elderly acute myeloid leukemia: completed results of the phase I study. (Abstract #6505)

D. A. Pollyea, H. E. Kohrt, L. Gallegos, B. Zhang, M. Figueroa, A. Melnick, C. Berube, S. E. Coutre, J. R. Gotlib, J. L. Zehnder, M. Liedtke, B. S. Mitchell, B. C. Medeiros

MONDAY

- 11:15 AM Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. (Abstract #6506)**
G. Borthakur, L. Popplewell, M. H. Kirschbaum, J. M. Foran, T. M. Kadia, E. Jabbour, M. Boyiadzis, A. Verma, R. B. Walter, P. S. Wissel, L. Xu, J. W. Bauman, J. Z. Zhu, J. Mazumdar, M. Baccus, J. M. Connor, J. E. Cortes, H. Kantarjian

Discussion

- 11:30 AM** Gail J. Roboz, MD (Abstracts #6503^–6506)
Weill Medical College of Cornell University
- 11:45 AM Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). (Abstract #6507)**
E. Jabbour, S. M. O'Brien, D. A. Thomas, F. Ravandi, S. York, M. Kwari, S. Faderl, T. M. Kadia, C. Wilson, R. Tarnai, A. S. Advani, G. Garcia-Manero, J. E. Cortes, H. Kantarjian
- 12:00 PM The Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 is highly active and tolerable in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. (Abstract #6508)**
J. C. Byrd, K. A. Blum, J. A. Burger, S. E. Coutre, J. P. Sharman, R. R. Furman, I. W. Flinn, B. W. Grant, D. A. Richards, W. Zhao, N. A. Heerema, A. J. Johnson, R. Izumi, A. Hamdy, S. M. O'Brien

Discussion

- 12:15 PM** Ross L. Levine, MD (Abstracts #6507–6508)
Memorial Sloan-Kettering Cancer Center

Monday, June 6, 2011

**9:45 AM - 11:00 AM
SPECIAL SESSION**

AIDS-associated Malignancies in Low- and Middle-income Countries

Location: E354b

CME credit: 1.25

Track(s): Special Session, Cancer Prevention/Epidemiology, International

Clement Adebayo Adebamowo, MD, ScD—Chair

Institute of Human Virology, University of Maryland School of Medicine

AIDS-associated Malignancies: An Epidemic Foretold

Ronald T. Mitsuyasu, MD

University of California, Los Angeles Care Center

Conducting Clinical Trials in Resource Low-income Countries: Challenges and Opportunities

William A. Blattner, MD

University of Maryland Baltimore

Patterns and Trends in HIV-associated Malignancy

E. Akin Abayomi, MBBS, MRCP, MPhil

Stellenbosch University

Effect of Antiretroviral Therapy on the Evolving Pattern and Incidence of HIV-related Lymphoma in South Africa

MONDAY

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Assessing Patients' Psychosocial Needs: How to Do This in (Your Busy) Practice

Location: S100a

CME credit: 1.25

Track(s): Patient and Survivor Care, Breast Cancer

Michelle Joy Naughton, PhD—Chair

Wake Forest University School of Medicine

Overview of Psychosocial Problems and Risk Factors among Cancer Survivors

Paul B. Jacobsen, PhD

H. Lee Moffitt Cancer Center & Research Institute

Psychosocial Screening for Patients with Cancer: Opportunities and Challenges

David Goldstein, MD

Prince of Wales Hospital

Translating Research into Everyday Patient Care: Applying the Outcomes of Psychosocial Screening and Intervention Trials into Clinical Practice

Immunotherapy for Advanced and High-risk Melanoma: Lessons Learned and Future Directions

Location: E354a

CME credit: 1.25

Track(s): Melanoma/Skin Cancers

John M. Kirkwood, MD—Chair

University of Pittsburgh Medical Center

Historical Perspective of Immunotherapy for Advanced or Metastatic Melanoma

Thomas Gajewski, MD, PhD

The University of Chicago

Limitations of Immunotherapy, Mechanisms of Resistance, Immune Escape, Effect of Tumor Microenvironment, and Why Immunotherapy Strategies May Have Been Ineffective

Suzanne Louise Topalian, MD

The Johns Hopkins University School of Medicine

Overview of the Future of Immunotherapy Strategies for Advanced Melanoma

New Targeted Therapies in Neuroendocrine Cancers: What Should Be the Sequence of Therapy?

Location: Hall D1

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer, Developmental Therapeutics

Matthew Kulke, MD, MMSc—Chair

Dana-Farber Cancer Institute

What Is the Best Sequence of Therapy for Pancreatic Neuroendocrine Tumors?

Emily K. Bergsland, MD

University of California, San Francisco Cancer Center

What Is the Best Sequence of Treatment for Carcinoid Tumors?

Martyn Caplin, MD

Royal Free Hampstead NHS Trust

The Role of Somatostatin Analogs in the Treatment of Neuroendocrine Tumors: When Should They Be Started and When Do We Add Other Agents?

Monday, June 6, 2011

What Is Going on with Mesothelioma?

Location: S406

CME credit: 1.25

Track(s): Lung Cancer, Sarcoma

Harvey I. Pass, MD—Chair

New York University School of Medicine

Surgery for Pleural Mesothelioma: Are We Closer to Personalized Selection?

Michele Carbone, MD, PhD

University of Hawaii Cancer Center

New Concepts in Mesothelial Carcinogenesis: Fibers, Inflammation, and Hotspots

Anna K. Nowak, MBBS, PhD

Sir Charles Gairdner Hospital

Mesothelioma Chemotherapy, Biologic Therapy, and Immunotherapy: Pathways, Personalized Prediction, and Results to Date

MONDAY

9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSIONS

Follicular Lymphoma Case Studies: Blending the Art and Science of Medicine Together (M14)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders

Myron Stefan Czuczman, MD
Roswell Park Cancer Institute

Preparing for New Cultural Competence Requirements for Oncology Professionals (M21)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Ethics, Patient and Survivor Care, Professional Development

Marjorie Kagawa-Singer, PhD, MA, MN, RN

University of California, Los Angeles School of Public Health

Understanding the Notion of Culture and Its Influence on Health-related Matters and Oncology Practice

Antonella Surbone, MD, PhD

New York University

Meeting Oncologists' Educational Needs in Preparation for the Joint Commission 2012 Standards in Cultural Competence

Monday, June 6, 2011

**9:45 AM - 11:15 AM
SPECIAL SESSION**

**ASCO/American Association for Cancer Research (AACR) Joint Session:
Telomeres and Telomerase in Cancer**

Location: S100bc

CME credit: 1.5

Track(s): Tumor Biology, Special Session

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

Welcome and Introduction

Elizabeth H. Blackburn, PhD—Co-Chair

University of California, San Francisco

Telomeres and Telomerase in Human Cancer and in the Aging Population

Steven Artandi, MD, PhD

Stanford School of Medicine

Functional Involvement of Telomerase in New Cellular Functions

Kathy Miller, MD

Indiana University Simon Cancer Center

The Clinical Perspective: Where We Are Going with Telomeres and Telomerase

MONDAY

11:30 AM - 12:45 PM
EDUCATION SESSIONS

Advances in Risk Stratification, Biology, and Treatment of Neuroblastoma

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology

Susan Lerner Cohn, MD—Chair

University of Chicago Pritzker School of Medicine

Refining Risk Classification for Children with Neuroblastoma

Meredith Irwin, MD

The Hospital for Sick Children

What Role Do “Stem Cells” Play in Neuroblastoma?

Rochelle Bagatell, MD

The Children’s Hospital of Philadelphia

Advances in the Treatment of Patients with High-risk Neuroblastoma

Considerations When Standard of Care Fails (eQuestions Session)

Location: E353

CME credit: 1.25

Track(s): Ethics, Clinical Trials, Practice Management and Information Technology

Jeffrey M. Peppercorn, MD, MPH—Chair

Duke University Medical Center

Options to Consider in Developing an Individualized Approach to Advanced Cancer Care

Robert L. Erwin, MS

Marti Nelson Cancer Foundation

A Patient’s Perspective on Options to Consider When Standard Interventions Are Exhausted

Thomas J. Smith, MD

Massey Cancer Center of Virginia Commonwealth University

How and Why to Discuss Palliative Care with Patients with Advanced Cancer after Standard Care Has Failed

Management of Complications and Palliative Care for Patients with Brain Tumors

Location: E354b

CME credit: 1.25

Track(s): Central Nervous System Tumors, Patient and Survivor Care

Denise Correa, PhD—Chair

Memorial Sloan-Kettering Cancer Center

An Overview of Cognitive Functions in Patients with Brain Tumors

Nigel Key, MD

University of North Carolina at Chapel Hill

Approach to Thromboembolic Disease in Patients with Brain Tumors

Alan D. Valentine, MD

University of Texas M. D. Anderson Cancer Center

Pharmacologic Stimulant Therapies, Such As Methylphenidate and Modafinil

Monday, June 6, 2011

The Art and Business of a Successful Early Clinical Trials Program: Academic, Private, and Industry Perspectives

Location: E354a

CME credit: 1.25

Track(s): Developmental Therapeutics, Clinical Trials

Chris H. M. Takimoto, MD, PhD—Chair

University of Texas Health Science Center at San Antonio

Industry Considerations for Phase I Partnerships

Patricia LoRusso, DO

Karmanos Cancer Institute

Academic Phase I Program: If You Build It, Will They Come?

Lee S. Rosen, MD

Premiere Oncology

A Private Model for a Successful Phase I Clinical Trials Program

MONDAY

11:30 AM - 12:45 PM
MEET THE PROFESSOR SESSIONS

Melanoma FISH 'n' Chips (M15)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Melanoma/Skin Cancers

Hensin Tsao, MD

Massachusetts General Hospital

Multidisciplinary Treatment of Skull Base Tumors (M22)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Head and Neck Cancer

Francis P. Worden, MD

University of Michigan Cancer Center

Chemotherapy for Skull Base Malignancies

Ehab Y. Hanna, MD

University of Texas M. D. Anderson Cancer Center

Surgical Management of Base of Skull Tumors

Monday, June 6, 2011

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Location: Arie Crown Theater

CME credit: 3

Track(s): Developmental Therapeutics

Tyler J. Curiel, MD—Chair

University of Texas Health Science Center at San Antonio

- 1:00 PM Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. (Abstract #2506)**
H. Okada, P. Kalinski, A. H. Mintz, J. A. Engh, L. H. Butterfield, R. H. Hamilton, D. M. Potter, A. M. Salazar, F. S. Lieberman
- 1:15 PM Effect of denileukin diftitox on serum GM-CSF and clinical responses in stage IV melanoma. (Abstract #2507)**
J. Chesney, M. Rasku, A. C. Klarer, D. M. Miller, S. Telang
- 1:30 PM Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus. (Abstract #2508)**
J. Nesselhut, D. Marx, D. Lorenzen, N. Cillien, W. Goebel, R. Y. Chang, W. Brockmann, J. Peters, K. Nesselhut, F. Fändrich, T. Nesselhut

Discussion

- 1:45 PM** Tyler J. Curiel, MD (Abstract #2506–2508)
University of Texas Health Science Center at San Antonio
- 2:00 PM Immunotransplant for mantle cell lymphoma: Phase I/II study preliminary results. (Abstract #2509)**
J. Brody, R. Advani, W. Weng, D. Czerwinski, A. A. Alizadeh, H. E. Kohrt, R. Negrin, R. Levy
- 2:15 PM Phase I clinical trial of cancer vaccine with five novel epitope peptides for patients with metastatic colorectal cancer (mCRC). (Abstract #2510)**
S. Hazama, M. Oka, K. Yoshida, T. Tsunoda, S. Yoshino, Y. Hinoda, Y. Nakamura
- 2:30 PM The role of relative lymphocyte count as a new biomarker for the effect of catumaxomab on overall survival in patients with malignant ascites: Follow-up results from a phase II/III study. (Abstract #2512)**
M. M. Heiss, M. A. Ströhlein, C. Bokemeyer, D. Arnold, S. L. Parsons, M. G. Ott, E. Schulze, H. Lindhofer, D. Seimetz, M. Hennig

Discussion

- 2:45 PM** Eduardo M. Sotomayor, MD (Abstracts #2509–2510, 2512)
H. Lee Moffitt Cancer Center & Research Institute
- 3:00 PM A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. (Abstract #2511)**
J. M. Richards, M. A. Warso, D. Mehta, K. Christov, C. M. Schaeffer, T. Yamada, C. W. Beattie, L. R. Bressler, T. K. Das Gupta
- 3:15 PM Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma. (Abstract #2513)**
H. Oettle, A. Hilbig, T. Seufferlein, A. Tsianakas, T. Luger, R. M. Schmid, G. von Wichert, E. Endlicher, C. Garbe, K. K. Kaehler, A. Hauschild, A. Enk, P. Kiessling, S. Schmaus, H. Heinrichs, K. Schlingensiepen

MONDAY

3:30 PM **A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors. (Abstract #2514)**

L. Naumovski, M. S. Gordon, P. N. Munster, P. Hegde, J. Fredrickson, S. Bai, R. P. Funke, I. Chang, G. S. Chandler, D. S. Chen, L. S. Rosen

Discussion

3:45 PM Padmanee Sharma, MD, PhD (Abstracts #2511–2514)
University of Texas M. D. Anderson Cancer Center

Monday, June 6, 2011

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Genitourinary (Prostate) Cancer

Location: Hall D1

CME credit: 3

Track(s): Genitourinary Cancer

Joshi J. Alumkal, MD—Co-Chair

Oregon Health & Science University

Ajjai Shivaram Alva, MBBS, MS—Co-Chair

University of Michigan

- 1:00 PM** **Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). (Abstract #4515)**
M. D. Michaelson, Y. Ou, L. Sengeløv, F. Saad, N. Houede, P. J. Ostler, A. Stenzl, G. Daugaard, R. J. Jones, F. Laestadius, A. Bahl, D. E. Castellano, J. Gschwend, T. Maurina, D. Ye, I. Chen, S. Wang, E. C. Maneval, S. Oudard
- 1:15 PM** **Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. (Abstract #4516)**
M. Hussain, M. R. Smith, C. Sweeney, P. G. Corn, A. Elfiky, M. S. Gordon, N. B. Haas, A. L. Harzstark, R. Kurzrock, P. Lara Jr., C. Lin, A. Sella, E. J. Small, A. I. Spira, U. N. Vaishampayan, N. J. Vogelzang, C. Scheffold, M. D. Ballinger, F. Schimmoller, D. C. Smith
- 1:30 PM** **Evaluation of circulating tumor cell (CTCs) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. (Abstract #LBA4517)**
H. I. Scher, G. Heller, A. Molina, T. S. Kheoh, G. Attard, J. Moreira, S. K. Sandhu, C. Parker, C. Logothetis, R. T. McCormack, K. Fizazi, A. Anand, D. C. Danila, M. Fleisher, D. Olmos, C. M. Haqq, J. S. De Bono

Discussion

- 1:45 PM** Daniel J. George, MD (Abstracts #4515–LBA4517)
Duke Cancer Institute
- 2:00 PM** **Toward a rational strategy for prostate cancer screening based on long-term risk of prostate cancer metastases and death: Data from a large, unscreened, population-based cohort followed for up to 30 years. (Abstract #4512)**
H. Lilja, C. Savage, A. Gerdtsson, T. Bjork, J. Manjer, P. Nilsson, A. Dahlin, A. Bjartell, P. T. Scardino, D. Ulmert, A. J. Vickers
- 2:15 PM** **Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12). (Abstract #4513)**
K. Fizazi, F. Lesaunier, R. Delva, G. Gravis, F. Rolland, F. Priou, J. Ferrero, N. Houede, L. Mourey, C. Theodore, I. Krakowski, J. Berdah, M. Baciuchka, P. Kerbrat, J. Davin, J. Berille, M. Habibian, J. Ichante, A. Laplanche, S. Culine
- 2:30 PM** **A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). (Abstract #4514)**
J. M. Crook, C. J. O'Callaghan, K. Ding, G. Duncan, D. P. Dearnaley, C. S. Higano, E. M. Horwitz, E. Frymire, S. Malone, J. Chin, A. Nabid, P. R. Warde, T. B. Corbett, S. Angyalfi, S. L. Goldenberg, M. K. Gospodarowicz, F. Saad, J. P. Logue, P. F. Schellhammer, L. Klotz

Discussion

2:45 PM Joel B. Nelson, MD (Abstracts #4512–4514)
University of Pittsburgh

3:00 PM **Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro). (Abstract #4518)**
H. J. Meulenbeld, E. D. van Werkhoven, J. L. Coenen, G. Creemers, O. J. Loosveld, P. C. De Jong, A. J. Ten Tije, S. D. Fossa, M. Polee, W. R. Gerritsen, O. Dalesio, R. De Wit

3:15 PM **Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. (Abstract #4520)**
C. Logothetis, J. S. De Bono, A. Molina, E. M. Basch, K. Fizazi, S. A. North, K. N. Chi, R. J. Jones, O. B. Goodman, P. N. Mainwaring, C. N. Sternberg, D. D. Gagnon, R. Dhawan, M. Rothman, Y. Hao, C. S. Liu, T. S. Kheoh, H. I. Scher, C. M. Haqq

Discussion

3:30 PM Michael J. Morris, MD (Abstracts #4518 and 4520)
Memorial Sloan-Kettering Cancer Center

Monday, June 6, 2011

1:00 PM - 4:00 PM
ORAL ABSTRACT SESSION

Patient and Survivor Care

Location: S404

CME credit: 3

Track(s): Patient and Survivor Care

Teresa Gilewski, MD—Chair

Memorial Sloan-Kettering Cancer Center

1:00 PM Does circulating tumor necrosis factor (TNF) play a role in post-chemotherapy cerebral dysfunction in breast cancer survivors (BCS)? (Abstract #9008)

P. A. Ganz, S. A. Castellon, D. H. Silverman, L. Kwan, J. E. Bower, M. R. Irwin, S. W. Cole

1:15 PM Effect of yoga on QOL, cortisol rhythm, and HRV for women with breast cancer undergoing radiotherapy. (Abstract #9009)

L. Cohen, K. Chandwani, N. Raghuram, R. Haddad, G. H. Perkins, A. Spelman, R. Nagarathna, K. Johnson, A. Fortier, B. Arun, Q. Wei, C. Kirschaum, H. Nagendra

Discussion

1:30 PM Karen Michelle Mustian, PhD, MPH (Abstracts #9008–9009)
University of Rochester Medical Center

1:45 PM A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. (Abstract #9010)

Y. Guo, J. L. Palmer, A. Forman, S. R. Dakhil, M. R. Velasco, M. Weiss, P. Gilman, G. M. Mills, S. J. Noga, C. Eng, M. J. Overman, M. Fisch

2:00 PM A phase III study for prevention of delayed nausea: A University of Rochester CCOP study of 1,021 patients receiving chemotherapy. (Abstract #9012)

G. R. Morrow, J. A. Roscoe, C. Heckler, S. R. Dakhil, J. L. Wade, J. P. Kuebler, S. G. Mohile, L. J. Peppone, M. C. Janelins

2:15 PM Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT₃ antagonist with dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study. (Abstract #9013)

M. J. Brames, J. Picus, M. Yu, E. L. Johnston, B. Bottema, C. E. Williams, L. H. Einhorn

Discussion

2:30 PM Debra L. Barton, PhD, AOCN, RN (Abstracts #9010–9013)
Mayo Clinic

2:45 PM The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in cancer patients receiving chemotherapy: SAVE ONCO study. (Abstract #LBA9014)

G. Agnelli, D. J. George, W. Fisher, A. K. Kakkar, M. R. Lassen, P. Mismetti, P. Mouret, U. Chaudhari, A. G. G. Turpie

3:00 PM The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. (Abstract #CRA9015)

S. Pruthi, R. Qin, S. A. Terstriep, H. Liu, C. L. Loprinzi, T. Shah, K. F. Tucker, S. R. Dakhil, M. J. Bury, R. L. Carolla, P. D. Steen, J. Vuky, D. L. Barton

MONDAY

3:15 PM Does L-arginine/Korean ginseng/gingko biloba/damiana-based supplement improve the sexual function and quality of life of female cancer survivors? A randomized trial. (Abstract #9016)

K. Greven, L. D. Case, L. R. Nycum, P. J. Zekan, D. D. Hurd, E. P. Balcueva, G. M. Mills, R. Zon, P. J. Flynn, D. Biggs, E. G. Shaw, Comprehensive Cancer Center of Wake Forest University CCOP Research Base

Discussion

3:30 PM Vered Stearns, MD (Abstracts #LBA9014–9016)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Monday, June 6, 2011

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Breast Cancer—HER2/ER

Location: Hall A

Track(s): Breast Cancer

- Brd. 1A** Use of a gene profile to identify molecular subtypes of breast cancer. (Abstract #537)
W. Zwart, F. De Snoo, O. Krijgsman, P. Roepman, S. Tian, A. Glas, R. A. Bender, J. Carroll, R. Bernards
- Brd. 1B** Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R rs2016347 to predict tumor recurrence in estrogen receptor–positive breast cancer patients. (Abstract #538)
T. Winder, G. Giamas, W. Zhang, D. Yang, P. O. Bohanes, Y. Ning, A. Gerger, M. J. Labonte, J. Stebbing, H. Lenz
- Brd. 1C** Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive grading groups of early breast cancer (EBC) in distinct biologic entities. (Abstract #539)
A. Ferro, M. Barbareschi, C. Eccher, A. Caldara, D. Aldovini, R. Triolo, L. Cuorvo, F. Berloffia, S. Brugnara, O. Caffo, M. di Pasquale, M. Frisinghelli, V. Murgia, B. Soini, F. Valduga, A. Vecchia, E. Galligioni
- Brd. 1D** Estrogen and vascular endothelial growth factor (VEGF): Their role in breast cancer (BC) carcinogenesis and disease progression in premenopause. (Abstract #540)
F. Recchia, G. Candeloro, G. Desideri, S. Necozone, S. Rea
- Brd. 1E** An evaluation of PI3K pathway activation on the efficacy of both trastuzumab and lapatinib. (Abstract #541)
X. Hu, L. Wang, Q. Zhang, J. Zhang, H. Guo, S. Sun, B. Y. Wang, Z. Jia, Z. Shao, Z. Wang
- Brd. 1F** Long-term results of the Toronto magnetic resonance imaging (MRI) breast surveillance study of women with *BRCA1* or *BRCA2* mutations. (Abstract #542)
K. Passaperuma, D. B. Plewes, P. Causer, K. A. Hill, S. J. Messner, J. Wong, R. A. Jong, F. Wright, M. Yaffe, E. Ramsay, S. Balasingham, L. Verity, A. Eisen, B. Curpen, R. Shumak, S. Narod, E. Warner
- Brd. 1G** Survival after brain metastases in Asian patients with HER2+ breast cancer. (Abstract #543)
Y. Yap, B. C. Devi, C. Khorprasert, G. H. Cornelio, N. Sutandyo, E. Yeoh, S. Landis, M. Kobayashi, H. Moon, J. Ro
- Brd. 2A** A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC). (Abstract #544)
V. Dieras, J. Jassem, L. Y. Dirix, J. P. Guastalla, P. Bono, S. A. Hurvitz, A. Gonçalves, G. Romieu, S. A. Limentani, G. H. Jerusalem, K. Lakshmaiah, H. H. Roche, P. Sánchez-Rovira, T. Pienkowski, M. Seguí-Palmer, A. Li, Y. Sun, C. A. Pickett-Gies, H. Wildiers
- Brd. 2B** Clinical significance of metastatic-tumor HER2 status in patients with HER2-positive primary breast cancer. (Abstract #545)
N. Niikura, J. Liu, N. Hayashi, E. A. Mittendorf, Y. Gong, S. L. Palla, Y. Tokuda, A. M. Gonzalez-Angulo, G. N. Hortobagyi, N. T. Ueno
- Brd. 2C** Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. (Abstract #546)
G. Canello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G. Pruneri, E. Montagna, S. Dellapasqua, M. Iorfida, A. Cardillo, P. Veronesi, A. Luini, M. Intra, O. D. Gentilini, E. Scarano, D. Pastrello, A. Goldhirsch, M. Colleoni

- Brd. 2D** ***HLA-DRB1*07:01-DQA1*02:01 and UGT1A1*28* allele carriage in hepatic serious adverse event cases identified during lapatinib clinical trials. (Abstract #547)**
 C. F. Spraggs, L. R. Budde, L. P. Briley, C. Cox, E. Rappold, G. Aktan, L. S. Williams, V. E. Mooser, L. R. Cardon
- Brd. 2E** **Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer. (Abstract #548)**
 G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, J. H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I. B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer, R. A. Bender
- Brd. 2F** **Results of a Belgian multicenter retrospective study to determine the incidence of HER2 gene amplification in patients scored as immunohistochemistry 0 or 1+. (Abstract #549)**
 D. Larsimont, C. Colpaert, R. Salgado, N. Vermeesen, V. D'hondt, T. De Celle
- Brd. 2G** **Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer. (Abstract #550)**
 P. F. Conte, V. Guarneri, D. G. Generali, A. Bottini, L. Bazzola, F. Piacentini, F. Artioli, K. Cagossi, G. Bisagni, M. Bagnalasta, E. Tagliafico, E. Barbieri, L. Cavanna, A. Ravaoli, R. D'Amico, R. Vicini, A. Frassoldati
- Brd. 3A** **T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000+ consecutive breast cancers 2000–2006 at Kaiser Permanente, Northern California (KPNC). (Abstract #551)**
 L. Fehrenbacher, P. Shiraz, M. Sattavat, A. Capra, C. Quesenberry, R. Fulton, L. A. Habel
- Brd. 3B** **Pharmacogenetic investigation of lapatinib-associated diarrhea in metastatic breast cancer clinical trials. (Abstract #552)**
 L. P. Briley, M. Chiano, K. King, M. Casey, A. J. Preston, F. Sapunar, V. E. Mooser, L. R. Cardon, C. F. Spraggs
- Brd. 3C** **Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH). (Abstract #553)**
 V. Valero, D. J. Slamon, W. Eiermann, N. J. Robert, T. Pienkowski, M. Martin, J. R. Mackey, M. Lindsay, V. Bee-Munteanu, M. F. Press, G. Sauter, J. Crown
- Brd. 3D** **PAM50 intrinsic subtyping and pathological responses to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer. (Abstract #554)**
 P. Gomez Pardo, A. Prat, G. Bianchini, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Luch, M. Zambetti, F. Vázquez-Mazón, L. Gianni, J. Baselga
- Brd. 3E** **A molecular portrait of circulating free DNA of patients with breast cancer: High resolution analysis using SNP 6.0 arrays. (Abstract #555)**
 J. A. Shaw, K. Page, K. Blighe, N. Hava, D. Guttery, B. Ward, J. Brown, C. Ruangpratheep, R. Payne, C. Palmieri, S. Cleator, R. Walker, C. Coombes
- Brd. 3F** **Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2–98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). (Abstract #556)**
 S. Loi, R. Salgado, F. Piette, N. Sirtaine, F. Van Eenoo, R. Kammler, G. Rouas, P. A. Francis, J. Crown, B. Nordenskjold, J. Gutierrez, M. Andersson, M. M. Vila, R. Jakesz, G. Viale, E. M. Quinaux, A. Di Leo, S. Michiels, C. Sotiriou, M. J. Piccart-Gebhart

Monday, June 6, 2011

- Brd. 3G Treatment of small node-negative HER2+ invasive breast carcinomas: Forty-month update of the joint Aerio/Remagus study. (Abstract #557)**
J. Wassermann, L. Albiges, M. J. Rodrigues, E. Brain, S. Delalogue, J. Guinebretiere, M. Mathieu, E. Guillot, A. Vincent-Salomon, P. H. Cottu, AERIO/REMGUS
- Brd. 3H A study of the recurrence score by the 21-gene signature assay as a predictor of clinical response to neoadjuvant exemestane for 24 weeks in estrogen receptor-positive breast cancer. (Abstract #558)**
N. Masuda, M. Toi, T. Ueno, T. Yamanaka, S. Saji, K. Kuroi, N. Sato, H. Takei, Y. Yamamoto, S. Ohno, H. Yamashita, K. Hisamatsu, K. Aogi, H. Iwata, H. Sasano
- Brd. 4A A phase II clinical trial of drug withdrawal in women with progressive breast cancer while on aromatase inhibitor therapy. (Abstract #559)**
T. Cigler, M. J. Higgins, J. Szymonifka, A. H. Partridge, J. A. Ligibel, D. Finkelstein, S. E. Come, P. D. Ryan, P. E. Goss
- Brd. 4B Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer. (Abstract #560)**
M. Basik, D. Keilty, O. Aleynikova, D. Tu, X. Li, L. E. Shepherd, V. Bramwell
- Brd. 4C A functional assay for the identification of DNA double strand break repair deficiency in heterozygous carriers of BRCA1/2 and RAD51C mutations. (Abstract #561)**
A. Becker, M. Graeser, C. Landwehr, T. Hilger, W. Baus, R. Weber, B. Wappenschmidt, R. Schmutzler
- Brd. 4D Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer. (Abstract #562)**
V. O. Dezentje, J. den Hartigh, H. Guchelaar, T. Hensing, T. van der Straaten, J. M. Vletter - Bogaartz, R. Vree, E. Maartense, C. H. Smorenburg, H. Putter, A. Dieudonné, P. Neven, J. W. Nortier, H. Gelderblom
- Brd. 4E Elevated pretreatment serum CA9 (carbonic anhydrase 9) and correlation with progression-free and overall survival in trastuzumab-treated metastatic breast cancer. (Abstract #563)**
K. Leitzel, H. Hou, U. Anyanwu, V. Shrivastava, M. S. Evans, S. M. Ali, W. Koestler, E. Fuchs, F. J. Esteva, W. P. Carney, A. Lipton
- Brd. 4F Sequential administration of trastuzumab and a CD8 T cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone. (Abstract #564)**
A. K. Sears, G. T. Clifton, R. Patil, N. M. Shumway, M. G. Carmichael, D. C. Van Echo, J. P. Holmes, S. Ponniah, E. A. Mittendorf, G. E. Peoples
- Brd. 4G Fcγ-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab. (Abstract #565)**
N. Cresti, D. Jamieson, M. W. Verrill, M. Pinkilgton, A. V. Boddy
- Brd. 4H Body mass index (BMI) and prognosis in women with metastatic breast cancer (MBC). (Abstract #566)**
A. Gennari, M. Puntoni, O. Nanni, P. F. Conte, D. Amadori, V. Lorusso, A. De Censi, M. Sormani, V. Guarneri, M. D'Amico, A. Gozza, P. Bruzzi
- Brd. 5A Standardized uptake value (SUV) by positron emission tomography/computed tomography (PET/CT) as a prognostic variable in metastatic breast cancer (MBC). (Abstract #567)**
P. G. Morris, M. Fazio, K. L. Jhaveri, C. Serna-Tamayo, A. Eaton, S. Patil, G. Ulaner, J. Howard, S. M. Larson, C. Hudis, M. S. Jochelson, H. L. McArthur

MONDAY

- Brd. 5B** **Retreatment with trastuzumab (T)-based therapy in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) resistant to lapatinib (L)-based therapy. (Abstract #568)**
S. Gori, F. Montemurro, S. Spazzapan, G. Metro, J. Foglietta, G. Bisagni, A. Ferzi, R. R. Silva, T. Gamucci, M. Clavarezza, L. Stocchi, A. Fabi, F. Cognetti, E. Torrissi, D. Crivellari
- Brd. 5C** **Post-operative complications in neoadjuvant treatment including bevacizumab for HER2 positive inflammatory breast cancer (IBC): Results from a phase II prospective trial. (Abstract #569^)**
R. Rouzier, E. Lambaudie, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. Roche, D. Pau, P. Viens, R. J. Salmon
- Brd. 5D** **Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172). (Abstract #570)**
E. De Azambuja, M. Lemort, J. R. Rossari, C. Moulin, A. Buttice, V. D'hondt, F. Lebrun, Y. Lalami, F. Cardoso, C. Sotiropoulos, T. Gil, D. Devriendt, W. Marinus, M. Paesmans, M. Piccart, A. Awada
- Brd. 5E** **First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC. (Abstract #571)**
S. Tjulandin, A. Makhson, J. Gligorov, M. Lichinitser, A. Lluch, V. Semiglazov, N. Scotto, L. Mitchell, M. Martin
- Brd. 5F** **Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC). (Abstract #572)**
A. Berghoff, R. Bartsch, Z. Bago-Horvath, P. C. Dubsy, M. Rudas, U. Pluschnig, C. Wiltzsche, M. Gnant, G. G. Steger, C. Zielinski
- Brd. 5G** **The role of the genomic breast cancer index in predicting pathological complete response in breast cancer patients treated with neoadjuvant anthracycline plus taxane. (Abstract #573)**
M. Mathieu, N. C. Kesty, H. Li, V. Scott, V. Marty, P. Viehl, J. Delacruz, S. Delalogue, C. Schnabel, M. G. Erlander, F. Andre
- Brd. 5H** **Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer. (Abstract #574)**
D. Gajria, T. A. King, H. Pannu, R. Sakr, A. D. Seidman, A. Syldor, S. Patil, M. Maybody, L. Norton, N. Rosen, C. Hudis, S. Chandralapaty
- Brd. 6A** **Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer. (Abstract #575)**
I. Lang, R. Bell, F. Feng, R. I. Lopez, J. Jassem, V. Semiglazov, N. Al-Sakaff, E. Carreras, J. Chang
- Brd. 6B** **Are St. Gallen endocrine response classes predictive for recurrence rates over time? (Abstract #576)**
R. H. Koornstra, K. J. Beelen, A. Vincent, P. J. van Diest, S. C. Linn
- Brd. 6C** **Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (Abstract #577)**
A. Aguilar-Mahecha, M. Basik, J. W. Chapman, K. Jahan, S. Hassan, L. Zhu, C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. Pollak
- Brd. 6D** **Discordance in estrogen receptor status between primary, metastatic, and second primary breast cancers: Impact of misclassification. (Abstract #578)**
D. Huo, J. Liu, O. I. Olopade
- Brd. 6E** **Long-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC). (Abstract #579)**
C. T. Dang, P. G. Morris, S. Patil, C. Chen, A. Abbuzzi, R. Lehman, R. Steingart, L. Norton, C. Hudis

Monday, June 6, 2011

- Brd. 6F Predicting invasive disease at excision of ductal carcinoma in situ in core biopsies: A predictive model. (Abstract #580)**
C. McGathey, A. Fought, D. Scholtens, S. A. Khan
- Brd. 6G Salvage stereotactic radiosurgery (SRS) after previous whole brain radiation therapy (WBRT) for breast cancer brain metastases: Outcomes and prognostic factors including tumor phenotype. (Abstract #581)**
P. J. Kelly, N. U. Lin, E. B. Claus, S. E. Weiss, B. M. Alexander
- Brd. 6H Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC). (Abstract #582)**
J. W. Cook, E. Paxinos, L. J. Goodman, S. M. Ali, K. Leitzel, W. Koestler, A. Rivera, J. M. Weidler, W. Huang, J. Sperinde, S. J. Williams, M. Bates, A. Lipton
- Brd. 7A Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells. (Abstract #583)**
M. McDermott, B. Browne, J. Crown, N. O'Brien, D. J. Slamon, N. O'Donovan
- Brd. 7B The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor. (Abstract #584)**
M. E. Welzen, V. O. Dezentje, R. H. van Schaik, E. P. Colbers, H. Guchelaar, J. den Hartigh, D. M. Burger, H. Van Laarhoven
- Brd. 7C Discordance in pathology report after central pathology review in early breast cancer and its impact on treatment choice. (Abstract #585)**
L. Orlando, G. Viale, P. Schiavone, P. Fedele, A. Nacci, P. Rizzo, N. Calvani, F. Sponziello, C. Chetri, E. Mazzoni, M. D' Amico, A. Marino, M. Cinefra, S. Cinieri
- Brd. 7D Quantitative measurements of p95HER2 (p95) and total HER2 (H2T) protein expression in patients with trastuzumab-treated, metastatic breast cancer (MBC): Independent confirmation of clinical cutoffs. (Abstract #586)**
W. Biernat, R. Duchnowska, B. Szostakiewicz, J. Sperinde, M. Haddad, A. Paquet, Y. Lie, J. Weidler, W. Huang, J. Winslow, T. Jankowski, B. Arlukowicz-Czartoryska, P. J. Wysocki, M. Foszczynska-Kloda, B. Radecka, M. M. Litwiniuk, S. Debska, M. Bates, J. Jassem
- Brd. 7E IGF1R and phosphorylated IGF1R in HER2-positive breast cancer. (Abstract #587)**
B. Browne, J. Crown, A. J. Eustace, S. Kennedy, N. O'Brien, A. Larkin, J. Ballot, T. Mahgoub, Z. Qadir, F. Sclafani, S. F. Madden, M. J. Kennedy, M. J. Duffy, N. O'Donovan
- Brd. 7F Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43. (Abstract #588)**
K. P. Siziopikou, M. A. Cobleigh, S. J. Anderson, T. B. Julian, D. W. Arthur, P. Zheng, E. P. Mamounas, E. R. Pajon, R. J. Behrens, L. Chu, N. C. Leasure, J. N. Atkins, J. Polikoff, T. E. Seay, W. J. McCaskill-Stevens, R. Rabinovitch, N. Wolmark
- Brd. 7G Bcl2 expression and prediction of outcomes to anthracycline-based neoadjuvant chemotherapy in ER-positive breast cancer and to nonanthracycline adjuvant therapy. (Abstract #589)**
P. D. Dickinson, T. M. Abdel-Fatah, A. R. Green, P. Moseley, J. S. Reis-Filho, I. O. Ellis, S. Chan
- Brd. 7H Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer. (Abstract #590)**
S. Modi, C. Saura, C. A. Henderson, N. U. Lin, R. L. Mahtani, J. Goddard, E. Rodenas, J. O'Shaughnessy, J. Baselga
- Brd. 8A Strategies for protecting patients from anthracycline-induced cardiac dysfunction. (Abstract #591)**
A. K. Dickey, C. Geisberg, Y. R. Su, I. A. Mayer, J. A. Means-Powell, C. Silverstein, X. Peng, D. Freehardt, B. White, D. J. Lenihan, D. Sawyer

MONDAY

- Brd. 8B** **Using the 21-gene recurrence score and the recently developed recurrence score clinical pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone. (Abstract #592)**
M. Crager, G. Tang, S. Shak
- Brd. 8C** **Population-based comparison of breast cancer screening and treatment utilization by remoteness of residence in British Columbia. (Abstract #593)**
R. A. Olson, N. R. Caron, I. Olivotto, C. Speers, A. Davidson, S. K. Chia, A. Coldman, A. Nichol, C. Bajdik, S. Tyldesley
- Brd. 8D** **Association between bone turnover markers and skeletal-related events in patients with breast cancer and bone metastases on treatment with bisphosphonates (ZOMAR study results at 9 months of follow-up). (Abstract #594)**
A. Barnadas, C. De la Piedra, C. Crespo, P. Gomez Pardo, L. Calvo, E. G. Calvo, M. Ruiz-Borrego, J. Rifa, L. Manso, A. Anton, M. Codes, M. Margeli, A. Murias, J. Salvador, M. Segui-Palmer, A. De Juan, J. Gavila, D. Perez, M. Luque, I. Tusquets
- Brd. 8E** **Evaluation of neutrophil gelatinase-associated lipocalin (NGAL) as predictor of response to neoadjuvant chemotherapy (NACT) in primary breast cancer. (Abstract #595)**
A. Wenners, K. Mehta, S. Loibl, H. Park, N. Arnold, S. Hamann, J. Weimer, B. Ataseven, C. Schem, F. Khandan, C. Thomssen, W. Jonat, H. Holzhausen, G. Von Minckwitz, C. Denkert, M. Bauer
- Brd. 8F** **An analysis of vitamin D (Vit D) and serum estrogens in postmenopausal (PM) breast cancer (BC) patients receiving aromatase inhibitors (AIs). (Abstract #596)**
D. W. Cescon, M. Ennis, P. A. Ganz, S. Beddows, F. Z. Stanczyk, S. S. Sridhar, P. J. Goodwin
- Brd. 8G** **Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC). (Abstract #597)**
R. Bartsch, A. Berghoff, U. Pluschnig, Z. Bago-Horvath, P. C. Dubsy, A. Rottenfusser, C. Wenzel, M. Rudas, F. Fitzal, K. Dieckmann, M. Gnant, C. Zielinski, G. G. Steger
- Brd. 8H** **A phase II study of Ionafarnib (LF) in patients with locally advanced and metastatic breast cancer (MBC): Hoosier Oncology Group BRE07-126. (Abstract #598)**
B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. E. Williams, T. Breen, G. W. Sledge Jr.
- Brd. 9A** **The expression of GATA-3 and FOXA1 in breast cancer: The biomarkers of hormonal sensitivity in luminal type tumors. (Abstract #599)**
Y. Hisamatsu, E. Tokunaga, S. Akiyoshi, S. Okada, N. Yamashita, E. Oki, M. Morita, Y. Kakeji, Y. Maehara
- Brd. 9B** **Does metformin use influence outcome in diabetic women with invasive breast cancer? (Abstract #600)**
B. Oppong, S. Oskar, M. Stempel, A. Eaton, S. Patil, T. A. King
- Brd. 9C** **The prognostic value of the cocaine and amphetamine-regulated transcript (CART) in breast cancer (BC). (Abstract #601)**
D. P. O'Connor, D. J. Brennan, H. Laursen, S. F. McGee, S. McCarthy, R. Zagodzoon, E. Rexhepaj, A. Culhane, F. M. Martin, M. J. Duffy, G. Landberg, L. Ryden, S. M. Hewitt, M. J. Kuhar, R. Bernards, R. C. Millikan, J. Crown, K. Jirstrom, W. M. Gallagher
- Brd. 9D** **Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting. (Abstract #602)**
A. Guerin, D. Lalla, D. Latremouille-Viau, A. P. Yu, E. Q. Wu, M. Brammer, S. A. Hurvitz

Monday, June 6, 2011

- Brd. 9E High false-negative rate of HER2 qRT-PCR of the Oncotype DX test: An independent quality assurance study. (Abstract #603)**
D. J. Dabbs, M. Klein, S. Mohsin, R. R. Tubbs, R. Bhargava
- Brd. 9F Association of GP88 (progranulin) tumor expression with decreased disease-free and overall survivals in patients with breast cancer with estrogen receptor-positive invasive ductal carcinoma. (Abstract #604)**
G. Serrero, D. M. Hawkins, B. Yue, O. B. Ioffe, P. Bejarano, J. T. Phillips, J. F. Head, R. L. Elliott, A. K. Godwin, J. Weaver, W. Kim, S. Kamimura
- Brd. 9G A semiphysiologic population pharmacokinetic/pharmacodynamic (PK/PD) model of thrombocytopenia (TCP) characterizing the effect of trastuzumab-DM1 (T-DM1) on platelet counts in patients with HER2-positive MBC. (Abstract #605)**
B. C. Bender, F. Schaedeli Stark, A. Joshi, Y. Chu, H. S. Rugo, I. E. Krop, S. Girish, M. Gupta
- Brd. 9H Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer. (Abstract #606)**
O. Metzger, A. Catteau, S. Michiels, M. E. Buyse, K. V. Saini, V. Fasolo, J. Canon, P. Delrée, M. Coibion, V. Jossa, J. Kains, D. Larsimont, V. Richard, D. Faverly, N. Cornez, P. Vuylsteke, B. Vanderschueren, H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. Sotiriou
- Brd. 10A Adjuvant treatment strategy and results in small breast cancer tumors (pT1) with HER2 overexpression. (Abstract #607)**
A. Hinke, P. Dall, G. Lenzen, C. Schumacher, D. Rezek, N. Gazawi, A. Ammon, F. G. Foerster, F. Beldermann, U. Cirrincione, J. Wilke
- Brd. 10B Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. (Abstract #608)**
M. Arnedos, R. Ferraldeschi, R. A'Hern, K. Hadfield, S. Roberts, S. Drury, A. Howell, D. G. Evans, A. M. Wardley, I. E. Smith, W. G. Newman, M. Dowsett
- Brd. 10C High recurrence risk in pT1bc HER2-positive, triple-negative, node-negative early breast cancer patients. (Abstract #609)**
A. Vaccaro, F. Ciancola, L. Pizzuti, I. Sperduti, L. Moschetti, P. Vici, F. Longo, E. Ruggeri, M. Di Seri, M. Giampaolo, T. Gamucci
- Brd. 10D Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients. (Abstract #610)**
M. Giuliano, A. Giordano, A. Patt, L. Hsu, R. H. Alvarez, N. T. Ueno, V. Valero, G. N. Hortobagyi, M. Cristofanilli, J. M. Reuben
- Brd. 10E Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial. (Abstract #611)**
P. S. Bernard, C. Davis, B. Munarriz, I. J. Stijleman, M. Ruiz-Borrego, M. T. Ebbert, A. Rodriguez-Lescure, R. R. Bastien, C. Crespo, C. M. Perou, C. Rodriguez, F. I. Aranda, V. Furió, I. Alvarez, M. Seguí, E. Alba, A. Anton, E. M. Carrasco, R. Caballero, M. Martin
- Brd. 10F Evaluation of HER2 gene status by qPCR in breast cancer samples with nonconclusive FISH. (Abstract #612)**
V. Koudelakova, J. Berkovcova, R. Trojanec, L. Radova, J. Ehrmann, Z. Kolar, B. Melichar, M. Hajduch
- Brd. 10G Detection of HER2 status of circulating tumor cells and disseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology, CEE). (Abstract #613)**
S. Krishnamurthy, F. Z. Bischoff, J. A. Mayer, K. Wong, S. Mikolajczyk, T. Pham, H. M. Kuerer, A. Lodhi, A. Bhattacharyya, C. Hall, A. Lucci Jr.
- Brd. 10H Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC). (Abstract #614)**
L. Chow, B. Xu, L. Y. Dirix, B. Moy, E. Leip, N. Bardy-Bouxin, L. Duville, T. Sarosiek

- Brd. 11A Predictive value of sphingosine kinase-1 expression in neoadjuvant treatment of breast cancer. (Abstract #615)**
 E. Ruckhäberle, T. Karn, C. Denkert, S. Loibl, B. Ataseven, T. Reimer, L. C. Haker, N. Sängler, U. Holtrich, M. Kaufmann, S. Darb-Esfahani, V. Nekljudova, G. Von Minckwitz
- Brd. 11B Prognostic impact of phosphorylated HER2 in HER2-positive primary breast cancer using reverse-phase protein array. (Abstract #616)**
 N. Hayashi, T. Iwamoto, A. M. Gonzalez-Angulo, J. Ferrer-Lozano, A. Lluch, N. Niikura, C. Bartholomeusz, S. Nakamura, G. N. Hortobagyi, N. T. Ueno
- Brd. 11C Long-term survival in patients with HER2-positive metastatic breast cancer treated with trastuzumab as first-line therapy: Seven-year follow-up of the French observational hermine study. (Abstract #617)**
 E. Antoine, F. Dalenc, C. Hebert, P. Rivera, G. Romieu, N. Varoqueaux, J. P. Guastalla, M. Namer
- Brd. 11D A multicenter phase II trial of neoadjuvant letrozole plus low dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells. (Abstract #618)**
 T. Ueno, N. Masuda, S. Kamigaki, T. Morimoto, S. Nakamura, K. Kuroi, H. Iwata, S. Ohno, S. Tanaka, M. Toi
- Brd. 11E Protection of adjuvant trastuzumab in sites of early relapses. (Abstract #619)**
 M. Campiglio, E. Tagliabue, A. Balsari, R. Bufalino, E. Ferri, L. Gianni, S. Ménard, on the behalf of GHEA group
- Brd. 11F Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC). (Abstract #620)**
 K. B. Kabaker, J. Canar, R. D. Rao, M. A. Cobleigh
- Brd. 11G Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial. (Abstract #621)**
 J. D. Zubkus, D. B. Daniel, J. F. Eakle, R. G. Bechhold, M. Shastry, P. S. Tucker, H. A. Burris III, J. D. Hainsworth, D. A. Yardley
- Brd. 11H Hormonal therapy versus chemotherapy as first-line line treatment for estrogen receptor-positive metastatic breast cancer (MBC) patients. (Abstract #622)**
 T. Y. Chang, C. Lin, Y. Lu, S. H. Kuo, S. Huang, C. Huang, A. Cheng
- Brd. 12A Epithelial-mesenchymal transition in patients with HER2+ metastatic breast cancer. (Abstract #623)**
 A. Giordano, M. Mego, B. Lee, S. Anfossi, C. A. Parker, R. H. Alvarez, N. T. Ueno, V. Valero, M. Cristofanilli, J. M. Reuben
- Brd. 12B Treatment patterns in patients with HER2-positive early-stage breast cancer (ESBC) receiving adjuvant treatment with a trastuzumab containing regimen. (Abstract #624)**
 K. Sail, D. Lalla, M. Brammer, M. Halm, D. A. Patt
- Brd. 12C Evaluating utilization characteristics for the Oncotype DX recurrence score in early-stage breast cancer. (Abstract #625)**
 C. Chen, D. A. Patt, D. R. Kazzaz, J. Shankleton, M. T. Forsyth, R. Ganesh
- Brd. 12D BRCA+ test result impact and timing on surgical treatment decisions for patients with breast cancer. (Abstract #626)**
 K. M. Doll, C. B. Weldon, J. R. Trosman, H. H. Wetzel, T. J. Fallen, W. J. Gradishar, J. C. Schink
- Brd. 12E Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. (Abstract #627)**
 I. I. Abdel Halim, M. El Ashri, W. El Sadda, Clinical Oncology and Nuclear Medicine Department

Monday, June 6, 2011

- Brd. 12F Proteomics-based characterization of potential biomarkers in tamoxifen resistance in breast cancer. (Abstract #628)**
B. C. Sanchez, H. Johansson, J. Forshed, O. Stål, J. Lehtio, B. K. Linderholm
- Brd. 12G Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of Turkish Oncology Group. (Abstract #629)**
F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu, Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas, N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren, Turkish Oncology Group
- Brd. 12H Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study. (Abstract #630)**
J. De la Haba, A. Rodriguez-Lescure, J. Baena, J. Martin Liberal, S. Morales, J. Chacon, J. Lopez, I. Fernandez, D. Aguiar, A. Garcia-Palomo, R. Llorente, J. Barea, E. Alvarez, I. Blancas, Y. Fernandez, P. Sanchez Rovira, G. Vinyes
- Brd. 13A Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC). (Abstract #631)**
B. Moy, F. Lebrun, M. Bellet, L. Chow, I. Lang, B. Xu, R. A. Badwe, D. L. Hershman, E. Leip, N. Bardy-Bouxin, L. Duvillie, P. Neven
- Brd. 13B Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort. (Abstract #632)**
N. Liebermann, F. L. Baehner, L. Soussan-Gutman, S. Klang, C. Yoshizawa, S. Shak, N. Siegelmann-Danieli
- Brd. 13C Pharmacokinetic and pathophysiological covariates influencing treatment outcomes with t-DM1 in patients with HER2-positive metastatic breast cancer (MBC). (Abstract #633)**
M. Gupta, P. LoRusso, H. A. Burris III, B. Wang, A. Joshi, Y. B. Tong, Y. Chu, S. Girish
- Brd. 13D RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer. (Abstract #634)**
R. Duchnowska, J. Jassem, E. Szutowicz, W. Biernat, T. Jankowski, W. Och, R. Staszkiwicz, M. Chudzik, W. Rogowski, N. Flores, S. Woditschka, L. Li, C. Goswami, M. A. Thorat, Y. Gokmen-Polar, G. W. Sledge Jr., P. S. Steeg, D. Palmieri, S. S. Badve
- Brd. 13E Effect of a soy isoflavone intervention on estrogen-related gene expression in the healthy high risk breast. (Abstract #635)**
S. A. Khan, O. Lee, I. B. Helenowski, D. Ivancic, B. Jovanovic, R. C. Bergan
- Brd. 13F A randomized trial of exercise versus control for musculoskeletal symptoms from adjuvant anastrozole (A) for postmenopausal early breast cancer (PEBC). (Abstract #636)**
C. A. Lohrisch, D. McKenzie, P. Truong, D. Jespersion, K. A. Gelmon, S. Premji, H. F. Kennecke

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy

Location: Hall A

Track(s): Breast Cancer

- Brd. 14A Predictors of recurrence among patients with breast cancer who achieved a pathological complete response (pCR) after neoadjuvant systemic chemotherapy. (Abstract #1036)**
M. Chavez-MacGregor, X. Lei, J. K. Litton, A. Melhem, E. A. Mittendorf, F. Meric-Bernstam, A. A. Sahin, V. Valero, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 14B Radiation and survival in women over 70 with T1 N0 M0 ER-negative breast cancer from 1990–2007: A population-based analysis. (Abstract #1037)**
A. P. Wojcieszynski, X. Shen, M. V. Mishra, P. R. Anne, T. N. Showalter
- Brd. 14C Systematic comparison of tumor phenotype in primary breast cancer versus corresponding lymph nodes and disease recurrences: Results of the retrospective multicenter WSG/DETECT PriMet study. (Abstract #1038)**
C. Liedtke, O. Gluz, F. Heitz, R. Wuerstlein, R. E. Kates, J. Tio, U. Nitz, A. Du Bois, T. N. Fehm, N. Harbeck
- Brd. 14D Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. (Abstract #1039)**
X. Lei, S. S. Dawood, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 14E Multi-institutional evaluation of sentinel lymph node (SLN) examination by one-step nucleic acid amplification (OSNA) assay in breast cancer: Performance of metastases detection and prediction of additional non-sentinel lymph node (non-SLN) involvement. (Abstract #1040)**
N. Sato, K. Honma, S. Noguchi, Y. Tamaki, H. Tsuda, T. Kinoshita, S. Nakamura, K. Tsugawa, K. Suzuki, M. Tsujimoto, K. Yoshidome, F. Akiyama, T. Iwase, D. Takabatake, R. Nishimura, K. Taniyama, H. Kato, S. Umemura, Y. Tokuda, T. Kamio, OSNA Researchers' Group
- Brd. 14F A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line in locally advanced (LABC) or metastatic breast cancer (MBC). (Abstract #1041)**
V. Lorusso, F. Giotta, R. Bordonaro, E. Maiello, S. Del Prete, V. Gebbia, G. Filippelli, S. Pisconti, S. Cinieri, S. Romito, F. Riccardi, G. Cairo, V. E. Chiuri, M. Ciccarese, R. Forcignano, L. Petrucelli, V. Saracino, G. Colucci
- Brd. 14G Pathologic characteristics of second breast cancers (SBC) among women previously treated for ductal carcinoma in situ (DCIS) with breast conservation. (Abstract #1042)**
N. D. Arvold, R. S. Punglia, M. E. Hughes, W. Jiang, S. B. Edge, S. H. Javid, C. Laronga, J. C. Niland, R. L. Theriault, J. C. Weeks, Y. Wong, S. J. Lee, M. J. Hassett
- Brd. 14H Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness. (Abstract #1043)**
R. Mukhtar, A. P. Moore, V. Tandon, O. Nseyo, A. Au, F. L. Baehner, C. A. Adisa, N. Eleweke, O. I. Olopade, D. H. Moore, M. Campbell, L. Esserman
- Brd. 15A Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial. (Abstract #1044)**
S. Hegewisch-Becker, C. A. Lerchenmuller, A. Welt, T. Decker, M. Just, C. Steffens, A. Hipper, N. Marschner

Monday, June 6, 2011

- Brd. 15B** Close or positive margins after mastectomy in early-stage, node-negative breast cancer: The association of tumor grade with local recurrence. (Abstract #1045)
J. R. Hastings, S. Iganej, D. M. Bugoci, C. Huang
- Brd. 15C** Prevalence and impact of correlative science in breast cancer phase II trials. (Abstract #1046)
T. Zhang, E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, J. M. Peppercorn
- Brd. 15D** Overall survival effect of lower chemotherapy dosing in extremely obese (BMI \geq 35) patients with breast cancer based on adjusted BSA. (Abstract #1047)
P. Sharma, T. A. Samuel, J. C. Wells, E. Mebel, J. T. French, J. A. Crozier, S. W. Looney
- Brd. 15E** Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer. (Abstract #1048)
A. M. Vanderwalde, W. Ye, P. H. Frankel, D. G. Asuncion, R. D. Pezner, T. H. Luu, S. Shibata, L. A. Leong, K. A. Margolin, R. Morgan, M. Koczywas, W. A. Chow, P. Twardowski, J. Y. Wong, J. H. Doroshow, S. J. Forman, G. Somlo
- Brd. 15F** Can preoperative dynamic contrast enhanced breast MRI predict extensive occult axillary lymph node metastases in patients with positive sentinel node biopsy? (Abstract #1049)
C. R. Loiselle, P. R. Eby, J. N. Kim, K. E. Calhoun, K. H. Allison, V. K. Gadi, S. Peacock, B. Storer, D. A. Mankoff, S. C. Partridge, C. D. Lehman
- Brd. 15G** Risk and health care costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer. (Abstract #1050)
D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, G. H. Lyman
- Brd. 15H** A randomized phase II study of pemetrexed-carboplatin and gemcitabine-vinorelbine in patients with anthracycline- and taxane-pretreated advanced breast cancer. (Abstract #1051)
D. Amadori, I. La Torre, E. M. Carrasco, S. Roesel, R. Labianca, V. Moreau-Donnet, D. Desaiyah, M. Martin
- Brd. 16A** Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC). (Abstract #1052)
R. Borson, W. G. Harker, J. E. Reeves, D. Drosick, J. T. Beck, S. J. Hager, W. L. Horvath, J. Bromund, H. Zeigler, D. Tai, D. A. Yardley
- Brd. 16B** Locoregional recurrence after breast cancer surgery: A meta-analysis by molecular subtype. (Abstract #1053)
A. J. Lowery, M. R. Kell, R. W. Glynn, M. J. Kerin, K. J. Sweeney
- Brd. 16C** The effect of tetrathiomolybdate on endothelial progenitor cells in patients at high risk for breast cancer recurrence. (Abstract #1054)
S. Jain, J. A. Cohen, M. M. Ward, J. O'Loughlin, M. Boeck, N. Wiener, E. Chuang, T. Cigler, A. Moore, D. Donovan, C. Lam, M. E. Cobham, S. E. Schneider, P. J. Christos, M. E. Lane, R. Baergen, V. Mittal, S. Rafii, L. T. Vahdat
- Brd. 16D** Rechallenging taxanes in recurrent breast cancer in patients treated with (neo)adjuvant taxane-based therapy. (Abstract #1055)
X. Guo, S. Loibl, M. Untch, V. Möbus, K. Schwedler, P. A. Fasching, J. Barinoff, F. Holms, C. Thomssen, D. Zahm, R. Kreienberg, M. Hauschild, H. Eidtmann, S. Tauchert, K. Mehta, G. Von Minckwitz, German Breast Group and AGO-B Study Group
- Brd. 16E** Prognostic significance of Ki-67 in node-negative (pN0), triple-negative (TN) breast cancer (BC). (Abstract #1056)
E. Munzone, E. Botteri, A. Sciandivasci, G. Curigliano, F. Nole, N. Rotmensz, M. Colleoni, G. Viale, A. Esposito, A. Luini, M. G. Mastropasqua, A. Goldhirsch
- Brd. 16F** Clinical outcome of triple-negative primary breast cancer in older women: Comparison with their younger counterparts. (Abstract #1057)
K. Cheung, B. M. Syed, A. R. Green, D. A. Morgan, I. O. Ellis

- Brd. 16G** **0⁶-methylguanine-DNA methyltransferase (MGMT) promoter gene methylation in triple-negative breast cancer (TNBC). (Abstract #1058)**
C. Fumagalli, P. Possanzini, M. O. Biasi, M. Manzotti, M. Barberis, B. Bonanni, M. Barile, I. Feroce, G. Viale
- Brd. 16H** **SOFIA: Phase II study of neoadjuvant epirubicin, cyclophosphamide (EC) plus sorafenib (S) followed by paclitaxel (Pw) plus sorafenib (S) in women with primary breast cancer (BC; GBG 45). (Abstract #1059)**
B. Conrad, N. Harbeck, G. Von Minckwitz, M. Wuellner, M. Warm, K. Schwedler, B. Gerber, I. Schrader, H. Eidmann, K. Mehta, S. Loibl, GBG/AGO-B Study Groups
- Brd. 17A** **The relationship between age and survival outcomes for eribulin in metastatic breast cancer. (Abstract #1060)**
C. Twelves, L. T. Vahdat, J. Cortes, J. Wanders, C. E. Dutcus, S. Seegobin, H. B. Muss
- Brd. 17B** **PARP1 in triple-negative breast cancer: Expression and therapeutic potential. (Abstract #1061)**
M. B. Cotter, A. Pierce, P. M. McGowan, S. F. Madden, L. Flanagan, C. Quinn, D. Evoy, J. Crown, E. McDermott, M. J. Duffy
- Brd. 17C** **ADAMs as new therapeutic targets for triple-negative breast cancer. (Abstract #1062)**
M. Mullooly, P. M. McGowan, S. Sukor, S. F. Madden, E. McDermott, J. Crown, N. O'Donovan, M. J. Duffy
- Brd. 17D** **Triple-negative breast cancer: The effect of guideline adherent adjuvant treatment on the cumulative survival. A retrospective multicenter cohort study of 3,658 patients. (Abstract #1063)**
L. Schwentner, R. Wolters, M. Wischnewsky, R. Kreienberg, A. Wöckel
- Brd. 17E** **Effect of neoadjuvant ixabepilone (Ixa) on cell cycle genes and on tumor-initiating cell (TIC) signature in breast cancer (BC). (Abstract #1064)**
H. Chang, C. E. Horak, P. Mukhopadhyay, C. Lowery, J. Baselga, J. A. Sparano
- Brd. 17F** **Breast conservation therapy: The influence of molecules and margins. (Abstract #1065)**
S. Demirci, G. Broadwater, L. B. Marks, R. Clough, L. R. Prosnitz
- Brd. 17G** **Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory oncoType DX assessments: A Sarah Cannon Research Institute phase II trial. (Abstract #1066)**
N. W. Peacock, D. A. Yardley, C. B. Hendricks, S. Y. Huh, S. L. Ketchum, C. Chao, C. Yoshizawa, M. Shastry, B. Strike, H. A. Burris III, J. D. Hainsworth
- Brd. 17H** **A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC). (Abstract #1067)**
R. M. Connolly, M. A. Rudek, H. L. McLeod, E. Garrett-Mayer, S. C. Jeter, L. A. Wright, V. Stearns, D. K. Armstrong, J. H. Fetting, S. P. Watkins, N. E. Davidson, A. C. Wolff
- Brd. 18A** **The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: Results of a prospective practice improvement study. (Abstract #1068)**
A. W. Peled, R. D. Foster, E. Garwood, C. A. Ewing, M. Alvarado, E. S. Hwang, L. Esserman
- Brd. 18B** **Effect of estrogen receptor beta expression (ERβe) in triple-negative breast cancer (TNBC) patients treated in the neoadjuvant GeparTrio trial. (Abstract #1069)**
F. Heitz, B. Sinn, S. Loibl, A. Du Bois, C. Jackisch, S. Kuemmel, C. Denkert, J. Barinoff, K. Mehta, G. Von Minckwitz, on behalf the GeparTrio trialists
- Brd. 18C** **The SUCCESS-C trial: Interim analysis of toxicity evaluating the role of an anthracycline-free chemotherapy regimen in the adjuvant treatment of HER2/neu-negative breast cancer. (Abstract #1070)**
U. Ortmann, J. Salmen, P. G. Hepp, M. W. Beckmann, T. N. Fehm, H. Hindenburg, W. Lichtenegger, B. K. Rack, A. Schneeweiss, W. Janni

Monday, June 6, 2011

- Brd. 18D Clinical significance of time to relapse and the distinction between breast cancer recurrences and new primary tumors. (Abstract #1071)**
A. Patt, T. Li, M. Cristofanilli, G. M. Freedman, E. R. Sigurdson, R. J. Bleicher
- Brd. 18E Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial. (Abstract #1072)**
M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, D. J. Joseph, M. Bulsara, on behalf of the TARGIT Trialists' Group
- Brd. 18F Breast cancer carcinomatous meningitis: Differences in survival depending on biological subtype, performance status, and treatment methods. (Abstract #1073)**
A. M. Niwinska, H. Rudnicka, M. Murawska
- Brd. 18G Clinical risk factors as predictors of potential cardiotoxicity related to nonpegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) patients (pts) previously treated with conventional anthracyclines (A). (Abstract #1074)**
E. Muñoz-Couselo, J. M. Perez-Garcia, C. Saura, M. Vidal, M. Bellet Ezquerra, J. Balmaña, B. Graña, P. Gomez Pardo, L. De Mattos-Arruda, S. Di Cosimo, S. Muñoz, O. Vidal, B. Garcia Castro, R. Espallargas, V. Esteban, J. Tabernero, J. Baselga, J. Cortes
- Brd. 18H Phase II trial report of the new preoperative chemotherapy with S-1 and docetaxel for advanced breast cancer. (Abstract #1075)**
M. Nakagawa, M. Aoyama, M. Ikeda, M. Morimoto, H. Takechi, Y. Kawakami, K. Kennzaki, A. Tangoku
- Brd. 19A Breast cancer subtypes and outcome after local and regional relapse. (Abstract #1076)**
E. Montagna, V. Bagnardi, N. Rotmensz, G. Viale, G. Renne, G. Cancelli, A. Balduzzi, E. Scarano, D. Pastrello, P. Veronesi, A. Luini, S. Zurrida, S. Monti, M. G. Mastropasqua, L. Bottiglieri, A. Goldhirsch, M. Colleoni
- Brd. 19B Is E-cadherin a useful surrogate marker to predict chemosensitivity of chemotherapy for triple-negative breast cancer? (Abstract #1077)**
S. Kashiwagi, M. Yashiro, T. Takashima, N. Aomatsu, H. Kawajiri, N. Onoda, B. Nakata, T. Ishikawa, K. Hirakawa
- Brd. 19C Survival of triple-negative and HER2-positive breast cancer by AJCC stage. (Abstract #1078)**
V. Caggiano, K. Bauer, C. Parise
- Brd. 19D Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC). (Abstract #1079)**
P. Klare, F. G. Foerster, M. Geberth, A. Schneeweiss, H. Tesch, S. Kuemmel, C. Schumacher, W. Hollburg, U. Soeling, M. Schmidt
- Brd. 19E Capecitabine (X) in the first-line treatment of metastatic breast cancer (MBC). (Abstract #1080)**
N. Harbeck, M. Kaufmann, F. Siedentopf, P. Dalivoust, M. Debled, N. J. Robert, J. O'Shaughnessy
- Brd. 19F Prognostic implications of phosphatidylinositol 3-kinase (PI3K) pathway alterations in metastatic triple-negative breast cancer (mTNBC). (Abstract #1081)**
M. Oliveira, L. De Mattos-Arruda, G. Sánchez-Ollé, B. Graña, J. Cortes, J. M. Perez-Garcia, E. Muñoz-Consuelo, M. Vidal, M. Bellet, S. Di Cosimo, P. Gomez Pardo, J. Rodon Ahnert, J. Hernandez-Losa, A. Vivancos, L. Prudkin, C. Aura, V. Serra, J. Baselga, J. Tabernero, C. Saura
- Brd. 19G Roles of miRNAs in breast cancer stem cells, drug sensitivity, and spontaneous metastases in orthotopic human-in-mouse models. (Abstract #1082)**
H. Liu, J. Bockhorn, R. Dalton, M. Dolan, C. M. Perou, O. I. Olopade, M. F. Clarke, G. Greene

- Brd. 19H Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. (Abstract #1083)**
L. T. Vahdat, E. Vrdoljak, H. Gomez, R. K. Li, E. Thomas, L. D. Bosserman, J. A. Sparano, J. Baselga, P. Mukhopadhyay, V. Valero
- Brd. 20A Adjuvant chemotherapy in American and Italian patients with BRCA1/2-associated breast cancer. (Abstract #1084)**
A. Cappetta, R. Nanda, C. Liao, D. Huo, L. F. Chen, G. Artioli, V. Zagonel, O. I. Olopade
- Brd. 20B Modeling the risk of secondary lung malignancy in patients treated with breast radiation therapy. (Abstract #1085)**
J. Ng, I. Shuryak, A. Xu, I. Deutsch, R. J. Burri, D. J. Brenner
- Brd. 20C Utility of breast MRI for patients with breast cancer scheduled for breast conserving surgery. (Abstract #1086)**
H. Shin, W. Han, H. Moon, C. Yom, S. Ahn, H. Kim, D. Noh
- Brd. 20D Comparison of lesion size between preoperative imaging and postoperative histopathology in unifocal breast cancer. (Abstract #1087)**
C. R. Abraham, B. Whiteside, M. Schuster, D. Jones, J. Pollard, L. MacFarlan, K. Hena, M. A. Hena
- Brd. 20E Repeat use of chemotherapy in metastatic breast cancer. (Abstract #1088)**
A. Im, A. Brufsky, J. G. Reeder, M. Q. Rosenzweig, S. Y. Jung
- Brd. 20F Prognostic impact on FOXP3 expression in triple-negative breast cancer (TNBC). (Abstract #1089)**
S. Lee, Y. Park, E. Cho, Y. Ham, J. Seo, J. Ahn, Y. Im
- Brd. 20G Platinum-based chemotherapy in triple-negative breast cancer. (Abstract #1090)**
C. Villarreal-Garza, M. Clemons, F. Kassam, K. Enright, S. Verma, J. A. Myers, R. A. Dent
- Brd. 20H Is there any utility to frozen section or immunohistochemistry examination of the sentinel lymph node (SLN) in patients with ductal carcinoma in situ (DCIS)? (Abstract #1091)**
U. K. Ballehaninna, A. R. Reeves, R. S. Chamberlain
- Brd. 21A Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study. (Abstract #1092)**
E. L. Mayer, M. E. Scheulen, J. Beckman, H. Richly, A. Poli, P. Bhargava, A. Duarte, M. M. Cotreau, A. L. Strahs, M. N. Dickler
- Brd. 21B Incidence of anthracycline-induced cardiotoxicity in patients with breast cancer: A single center's experience. (Abstract #1093)**
O. Nadeem, C. Rauwerdink, V. L. Beggs, D. D. Parr, A. T. Kono, G. N. Schwartz
- Brd. 21C Sunitinib as adjuvant therapy for women with early-stage breast cancer and disseminated tumor cells in bone marrow. (Abstract #1094)**
J. Li, M. E. Melisko, P. N. Munster, M. Pelayo, M. M. Moasser, A. J. Chien, J. Scott, L. Esserman, J. W. Park, H. S. Rugo
- Brd. 21E Prevalence of synchronous metastases of breast cancer depends both on tumor subtypes and tumor burden. (Abstract #1096)**
C. Boutros, C. Mazouni, M. Saghatchian, J. Domont, C. Balleyguier, C. Bourcier, M. Mathieu, M. Spielmann, S. Delaloge
- Brd. 21F Prognostic index for patients with brain metastases from breast cancer: A validation and refinement of the breast-specific graded prognostic assessment (GPA) index. (Abstract #1097)**
H. Ahn, S. Lee, J. Sohn, S. Park, Y. Ham, J. Seo, E. Cho, D. Nam, J. Lee, D. Choi, W. Park, S. Huh, Y. Park, J. Ahn, Y. Im
- Brd. 21G Basoluminal and luminal phenotypes in triple-negative breast cancer: Immunohistochemical profiling and survival. (Abstract #1098)**
H. Sinn, Z. Elsawaf, J. L. Bermejo, S. Aulmann, J. Rom, A. Schneeweiss

Monday, June 6, 2011

- Brd. 21H Outcomes of children exposed to chemotherapy in utero for breast cancer. (Abstract #1099)**
J. K. Litton, S. Hodge, D. Mattair, M. M. Ramirez, P. H. Morrow, A. M. Gonzalez-Angulo, C. M. Barnett, G. N. Hortobagyi, R. L. Theriault
- Brd. 22A Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors. (Abstract #1100)**
M. N. Dickler, B. P. Schneider, M. Volm, J. L. Speyer, Y. Novik, L. A. Callahan, C. H. Darby, J. Barth, G. L. Elfring, A. Ogden, A. Tiersten
- Brd. 22B Febrile neutropenia rates during docetaxel and cyclophosphamide (TC) adjuvant therapy in early breast cancer (EBC). (Abstract #1101)**
D. Kotasek
- Brd. 22C Magnetic resonance imaging (MRI) as compared to mammogram (MMG) in the evaluation of size, number of lesions, and nodal positivity in breast cancer (BrCa). (Abstract #1102)**
A. Korant, M. Kanaan, S. Sirop, H. Nuthakki, L. Lawrence, R. Hicks, D. Strahle, S. Nagpal, D. Wiese, S. Saha
- Brd. 22D TITAN: Ixabepilone versus weekly paclitaxel following doxorubicin/cyclophosphamide (AC) adjuvant chemotherapy in triple-negative breast cancer (TNBC): Preliminary toxicity of a Sarah Cannon Research Institute phase III trial. (Abstract #1103)**
D. A. Yardley, J. D. Hainsworth, W. N. Harwin, S. A. Goble, B. R. Daniel, M. A. Ackerman, D. Shipley, D. R. Drosick, S. E. Hanson, P. L. Griner, H. A. Burris III
- Brd. 22E Increasing use of mastectomy with immediate reconstruction and contralateral prophylactic mastectomy in breast conservation candidates: A 14-year report from a comprehensive cancer center. (Abstract #1104)**
A. E. Dragun, J. Pan, E. C. Riley, B. B. Kruse, M. R. Wilson, S. Rai, D. Jain
- Brd. 22F Are we improving the outcomes of metastatic breast cancer (MBC)? A single academic institution experience. (Abstract #1105)**
A. Florescu, S. Giilck, C. Victor, U. Zurawska, D. A. Baribeau, S. Verma
- Brd. 22G Alterations in breast cancer resistance protein in human placentas exposed to chemotherapy. (Abstract #1106)**
M. G. Holland, A. McCampbell, J. K. Litton, R. L. Theriault, M. M. Ramirez
- Brd. 22H Oral etoposide monotherapy for Chinese patients with metastatic breast cancer: Efficacy and tolerance regardless of heavy prior therapy. (Abstract #1107)**
P. Yuan, B. Xu, F. Ma, J. Wang, Y. Fan
- Brd. 23A Comparison of indocyanine green (ICG) fluorescence imaging plus blue dye and blue dye alone in sentinel node navigation surgery (SNNS) for breast cancer. (Abstract #1108)**
A. Hirano, T. Shimizu, M. Kamimura, K. Ogura, N. Kim, Y. Setoguchi, F. Okubo, H. Inoue, R. Miyamoto, J. Kinoshita, K. Ogawa
- Brd. 23B Clinical outcome of triple-negative breast cancer with BRCA mutation in the context of dose-dense and or metronomic chemotherapy. (Abstract #1109)**
R. S. Mehta, C. Liu
- Brd. 23C Primary systemic therapy with metronomic doxorubicin, cyclophosphamide, and capecitabine in locally advanced and metastatic triple-negative breast cancer. (Abstract #1110)**
M. Skrypnikova, M. Frolova, E. Ignatova, I. Pokataev, M. Stenina, S. Tjulandin
- Brd. 23D Prediction of the nonsentinel node metastasis in patients who received neoadjuvant chemotherapy for clinically axillary lymph node metastasis. (Abstract #1111)**
S. Lee, S. Y. Jung, S. W. Kim, H. S. Kang, I. Park, K. S. Lee, J. Ro, K. Ko, Y. Kwon, K. Shin, S. Kim

- Brd. 23E First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER2-negative or recurrent mBC: First PFS analysis. (Abstract #1112)**
J. Salvador, A. Jaen, E. Ciruelos, M. Codes, M. Gil, A. Murias, A. Galan, J. De la Haba, C. Jara, J. L. Bayo, J. Baena, J. Casal, J. Mel, I. Blancas, E. Gonzalez, D. Perez, L. Manso
- Brd. 23F Paclitaxel-carboplatin (P-C) regimen for metastatic breast cancer (MBC): Single-institution retrospective evaluation. (Abstract #1113)**
M. Zambetti, G. Goisis, A. Moliterni, A. Marchianò, D. Scaramuzza, M. Carcangiu, G. Saibene, G. Mariani, G. V. Bianchi, P. Valagussa, L. Gianni
- Brd. 23G Poly (ADP-ribose) polymerase-1 (PARP) expression in triple-negative breast cancer. (Abstract #1114)**
P. Possanzini, M. O. Biasi, C. Fumagalli, M. Barberis, M. Barile, B. Bonanni, G. Viale
- Brd. 23H Lymphocyte infiltration (LI) and immunohistochemistry (IHC) classification of metastatic breast cancer (MBC) correlation with medical survival. (Abstract #1115)**
C. S. Yau, A. R. Trumbly, C. O. Ruud, V. O. Speight, C. Chisholm, J. Song
- Brd. 24A Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial. (Abstract #1116)**
J. H. Barton, K. C. Shih, E. Raefsky, D. W. Haines III, B. Strike, J. D. Hainsworth, H. A. Burris III, D. A. Yardley
- Brd. 24B Body mass index in breast cancer subtypes. (Abstract #1117)**
I. Petekkaya, C. Arslan, E. Dogan, M. Solak, Ö. Keskin, N. Kertmen, Y. Y. Ozisik, K. Altundag
- Brd. 24C Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers. (Abstract #1118)**
A. B. Zelnak, S. Harichand-Herd, T. M. Styblo, M. Rizzo, S. G. Gabram, H. L. Bumpers, R. C. Hermann, J. Srinivasiah, F. M. Schnell, R. O'Regan
- Brd. 24D Efficacy of first-line bevacizumab (Bev) combined with weekly paclitaxel (wPac) for HER2-negative metastatic breast cancer (MBC): Results of a Japanese phase II study (n=120). (Abstract #1119)**
Y. Ito, K. Aogi, N. Masuda, S. Ohno, T. Oda, H. Iwata, M. Kashiwaba, Y. Fujiwara, S. Kamigaki, T. Ueno, S. Takashima
- Brd. 24E Oral paricalcitol (19-nor-1,25-Dihydroxyvitamin D₂) in women with metastatic breast cancer receiving taxanes or ixabepilone: A feasibility trial. (Abstract #1120)**
J. Lawrence, J. Lovelace, S. A. Akman, S. A. Melin, L. D. Case, G. Schwartz
- Brd. 24F What is the survival length from the late lines of treatment in metastatic breast cancer? (Abstract #1121)**
M. Mouret-Reynier, E. Planchat, E. Thivat, C. Abrial, C. Pomel, P. Dubray-Longeras, H. Devaud, B. Nayl, A. Dillies, Q. Wang-Lopez, P. J. Chollet, H. Cure, J. Nabholtz, X. Durand
- Brd. 24G Validation study on the clinical usefulness of the ICG fluorescence method for detecting sentinel lymph node in early-stage breast cancer in comparison with the dye method. (Abstract #1122)**
T. Sugie, T. Sawada, N. Tagaya, T. Kinoshita, K. Yamagami, H. Suwa, K. Yoshimura, M. Sumi, M. Toi
- Brd. 24H Association of BRCA1 promoter methylation in triple-negative breast cancer (TNBC) with resistance to standard anthracycline-based adjuvant chemotherapy. (Abstract #1123)**
P. Sharma, B. F. Kimler, Y. A. Park, S. R. Stecklein, Q. J. Khan, B. K. Petroff, O. W. Tawfik, R. A. Jensen

Monday, June 6, 2011

- Brd. 25A** **A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: Three-year follow-up. (Abstract #1124)**
S. J. Kronowitz, W. Tereffe, K. Hunt, H. M. Kuerer, V. Valero, G. L. Robb, L. Feng, T. A. Buchholz
- Brd. 25B** **Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). (Abstract #1125)**
K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, C. R. Osborne, P. Lardelli, J. C. Terceiro, A. Florez, F. A. Holmes, S. Delalogue
- Brd. 25C** **Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. (Abstract #1126)**
D. W. Northfelt, A. C. Dueck, T. P. Flynn, P. J. Zander, P. J. Stella, M. Melnik, E. S. Pavey, E. A. Perez
- Brd. 26A** **Retrospective analysis of the effect on overall-survival of radiotherapy and chemotherapy sequence as treatment for primary breast cancer. (Abstract #1127)**
E. H. Gort, S. G. Elias, O. Visser, P. H. Elkhuizen, S. C. Linn
- Brd. 26B** **The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): A systematic review and meta-analysis. (Abstract #1128)**
J. J. Biagi, M. Raphael, W. D. King, W. Kong, C. M. Booth, W. J. Mackillop
- Brd. 26C** **The other triple-negative breast cancer: Immunohistochemical and clinicopathological characterization of the claudin-low subtype. (Abstract #1129)**
D. Voduc, M. Cheang, A. Prat, X. He, S. Tyldesley, J. Snider, K. DeSchryver, S. Davies, M. J. Ellis, C. M. Perou, T. O. Nielsen
- Brd. 27A** **Effect of body mass index on survival outcome among women with early-stage, triple-negative breast cancer. (Abstract #1130)**
S. S. Dawood, X. Lei, J. K. Litton, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo
- Brd. 27B** **Significantly different costs of adjuvant chemotherapy regimens in the United States. (Abstract #1131)**
R. G. Chellappah, P. Ravdin
- Brd. 27C** **Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study. (Abstract #1132)**
L. Wang, J. Chen, Q. Yao Sr., J. Zhang, T. Wang, H. Wang, X. Zhou, Y. Huan, J. Wang
- Brd. 28A** **Neoadjuvant chemotherapy (NACT) in hormonal receptor-positive (HR+) or triple-negative (TN), operable breast cancer (BC): A randomized study comparing standard to response-adapted sequence. (Abstract #1133)**
H. Cure, Q. Wang-Lopez, M. Mouret-Reynier, X. Durando, C. Jouannaud, J. Charpentier, J. Eymard, P. J. Chollet, C. Garbar, E. Brabencova, I. Raoelfils, F. Penault-Llorca, J. Nabholz
- Brd. 28B** **Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis. (Abstract #1134)**
N. Ngamphaiboon, P. P. Advani, T. L. O'Connor, F. O. Ademuyiwa, E. G. Levine, G. Riebandt, E. B. Kossoff
- Brd. 28C** **Phase II trial, open, single arm: Cisplatin combined with paclitaxel and doxorubicin in operable or locally advanced, triple-negative breast cancer. (Abstract #1135)**
A. Alvarado Miranda, F. Lara Medina, C. Arce, N. Castañeda-Soto, C. Cano Blanco, J. Aguilar Ponce, E. Bargallo Rocha, V. Perez-Sanchez

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Leukemia, Myelodysplasia, and Transplantation

Location: Hall A

Track(s): Leukemia, Myelodysplasia, and Transplantation

- Brd. 29A Correlation of RASGRP1:APTX expression assay with response to tipifarnib plus etoposide in elderly patients with newly diagnosed AML. (Abstract #6534)**
T. I. Vener, C. Derecho, S. Galkin, J. Greer, M. J. Levis, C. D. Gocke, S. Malek, J. F. Palma, M. Raponi, Y. Wang, J. J. Wright, J. E. Karp
- Brd. 29B Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL). (Abstract #6535)**
T. H. Brummendorf, J. E. Cortes, H. Kantarjian, C. Gambacorti-Passerini, M. Baccarani, D. Kim, A. Zaritsky, J. Navarro, A. Rapoport, P. E. Dorlhiac-Llacer, J. Milone, M. Zanichelli, N. Besson, E. Leip, V. Kelly, H. J. Khoury
- Brd. 29C Tyrosine kinase inhibitors in BCR/ABL positive ALL . (Abstract #6536)**
A. T. Lopez-Enriquez
- Brd. 30A A phase II study with decitabine, low dose cytarabine, and G-CSF priming in high-risk myelodysplastic syndromes, refractory/relapsed acute myelogenous leukemia, or acute myeloid leukemia in patients with significant comorbidities. (Abstract #6537)**
J. Butera, E. Winer, C. Wang, J. J. Castillo, A. G. Thomas, H. Safran, A. E. Mega, G. A. Colvin, B. Rathore, P. J. Quesenberry, Brown Oncology Group
- Brd. 30B Serum galactomannan (GM) assay for invasive aspergillosis (IA) in acute leukemia (AL) and hematopoietic stem cell transplantation (HSCT). (Abstract #6538)**
I. Ghosh, V. Raina, L. Kumar, A. Sharma, S. Bakhshi, S. Iqbal
- Brd. 30C Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia. (Abstract #6539)**
G. Nair, R. Karmali, S. A. Gregory, J. M. Shammo, H. C. Fung, A. Jimenez, P. Venugopal, M. L. Larson
- Brd. 31A Successful autologous hematopoietic stem cell (AHSC) mobilization with salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose chemotherapy (HDC) and AHSC transplantation (AH SCT) in relapsed malignancies: preliminary single center experience. (Abstract #6540)**
C. Kosmas, A. Athanasopoulos, P. Politis, T. Papachrysanthou, T. Daladimos, A. Papadaki, E. Panagiotidi, D. Moschovis, N. Ziras, A. Karabelis, N. Mylonakis
- Brd. 31B Results of employing a plerixafor dosing algorithm to mobilize hematopoietic stem cells in patients with multiple myeloma and lymphoma. (Abstract #6541)**
T. Bechtel, Y. A. Efebera, S. M. Devine, P. Elder
- Brd. 31C A meta-analysis of the complete remission ratio with replaced or refractory acute promyelocytic leukemia. (Abstract #6542)**
B. Jiang, Q. Gong, H. Watanabe, S. Zhu, J. Xie, Y. Ohashi
- Brd. 31D Prevention of mucositis with KGF in patients undergoing allogeneic stem cell transplantation. (Abstract #6543)**
J. D. Goldberg, J. Zheng, H. Castro-Malaspina, A. A. Jakubowski, G. Heller, M. R. Van Den Brink, M. Perales
- Brd. 31E FLT3 positive acute myeloid leukemia: Does timed sequential induction therapy influence outcome? (Abstract #6544)**
D. Rifai, M. L. Larson, M. C. Keller, P. Venugopal
- Brd. 31F High-dose melphalan on day 2 versus 1 before autologous stem cell transplantation for multiple myeloma. (Abstract #6545)**
K. Rakszawski, J. J. Drabick, N. G. Dolloff, J. M. Sivik, J. Malysz, D. Claxton, W. C. Ehmann, W. B. Rybka, G. Talamo

Monday, June 6, 2011

- Brd. 31G Targeting multiple signal pathways simultaneously might provide effective therapeutic strategies in acute myeloid leukemia . (Abstract #6546)**
H. Liu, E. Diaz-Flores, X. Poire, G. Koval, G. Malnassy, M. M. Le Beau, K. Shannon, O. Odenike, W. Stock
- Brd. 31H Immunosuppressive properties of human placenta-derived mesenchymal stem cells on control of acute graft-versus-host disease in mice. (Abstract #6547)**
M. Jang, S. Oh, H. Kim, H. Shin, G. Kim, S. Chong, D. Oh, H. Chung
- Brd. 32A Second cancers after hematopoietic stem cell transplantation with total body irradiation conditioning regimen in hematologic disorders. (Abstract #6548)**
J. Kim, M. Chung, J. Lee, B. Choi, S. Chung
- Brd. 32B Study of oral clofarabine plus low-dose cytarabine in previously treated AML and high-risk MDS patients at least 60 years of age. (Abstract #6549)**
K. M. Smith, E. Estey, J. M. Pagel
- Brd. 32C Long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia (CML-CP) after interferon alpha (IFN) failure. (Abstract #6550)**
J. Shan, S. M. O'Brien, G. Garcia-Manero, S. Faderl, F. Ravandi, E. Jabbour, J. E. Cortes, H. Kantarjian
- Brd. 32D Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (Abstract #6551)**
B. Mistry, L. Gibiansky, Z. Hussein
- Brd. 32E Healthcare utilization and costs in patients with early onset myelodysplastic syndrome in a commercially insured population. (Abstract #6552)**
A. Powers, K. Stein, R. L. Knoth, M. Broder, E. Chang
- Brd. 32F Impact of cytogenetics at diagnosis on outcome of CML: Results from the randomized German CML Study IV. (Abstract #6553)**
A. Leitner, S. Saussele, C. Haferlach, G. Goehring, B. Schlegelberger, S. Jung-Munkwitz, U. Proetel, M. Lauseker, M. Pfirrmann, J. Hasford, A. Hochhaus, R. Hehlmann, German CML Study group
- Brd. 32G Hyper-CVAD plus nelarabine in the treatment of newly diagnosed patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LL). (Abstract #6554)**
A. Al-Ameri, D. A. Thomas, F. Ravandi, S. M. O'Brien, H. Kantarjian, G. Borthakur, T. M. Kadia, M. Kelly, R. Garris, S. Faderl
- Brd. 32H Survival differences in chronic myeloid leukemia by race in pre- and post-imatinib era. (Abstract #6555)**
R. Mandal, D. M. Bolt, B. K. Shah
- Brd. 33A LeukemiaNet: A transnational model for cooperative leukemia research. (Abstract #6556)**
R. Hehlmann, B. Simonsson, M. Bacarani, D. Grimwade, J. Apperley, T. Barbui, M. C. Bene, T. Buchner, T. J. de Witte, R. Foà, C. Haferlach, M. Hallek, J. Hasford, A. Hochhaus, D. Hoelzer, P. Ljungman, D. Niederwieser, M. . Sanz, S. Saussele
- Brd. 33B Improved survival in chronic myeloid leukemia (CML) since introduction of imatinib therapy: A single-institution experience in 1,570 patients referred within 1 month from diagnosis. (Abstract #6557)**
A. Quintas-Cardama, J. E. Cortes, E. Jabbour, S. M. O'Brien, G. Garcia-Manero, J. Shan, F. Ravandi, S. Faderl, T. M. Kadia, G. Borthakur, H. Kantarjian
- Brd. 33C Lenalidomide following rituximab and fludarabine in untreated CLL. (Abstract #6558)**
C. S. Ujjani, S. Jamshed, K. Fitzpatrick, E. A. Gehan, J. Crawford, C. M. Broome, P. Cohen, C. Kessler, B. D. Cheson

- Brd. 33D Intermediate-dose cyclophosphamide (1.5 Gm/M2) with G-CSF as the primary peripheral blood progenitor mobilization strategy: A single institution experience. (Abstract #6559)**
A. Padmanabhan, J. W. Hayslip, G. P. Monohan, S. D. Sutphin, H. Weiss, D. S. Howard
- Brd. 33E Relationship between age and healthcare utilization in patients with myelodysplastic syndrome receiving supportive care. (Abstract #6560)**
K. Stein, A. Powers, R. L. Knoth, M. Broder, E. Chang
- Brd. 33F Impact of combined lymphocyte and monocyte recovery on survival post myeloablative allogeneic hematopoietic stem cell transplant for acute leukemia. (Abstract #6561)**
M. Thoma, T. Huneke, L. DeCook, N. Johnson, R. Wiegand, M. R. Litzow, W. J. Hogan, L. F. Porrata, S. G. Holtan
- Brd. 33G An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia. (Abstract #6562)**
S. Hashmi, E. S. Rich, S. Basu, J. J. Maciejewski, S. Nathan, P. Venugopal, S. A. Gregory, H. C. Fung, J. M. Shammo
- Brd. 33H Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS. (Abstract #6563)**
M. R. Khawaja, J. E. Schwartz, M. Yu, M. J. Robertson, G. H. Vance, S. Srivastava, L. L. Wood, R. Abonour, K. Cornetta, S. Farag, L. D. Cripe, R. P. Nelson Jr.
- Brd. 34A Expression of topoisomerase (topo) II in adult acute myeloid leukemia (AML): Relationships to immunophenotype and treatment outcomes. (Abstract #6564)**
A. P. Michelson, K. J. Kopecky, E. R. Koegle, J. E. Anderson, J. E. Godwin, S. H. Petersdorf, A. F. List, C. L. Willman, F. R. Appelbaum, J. P. Radich, M. K. Ganapathi, R. N. Ganapathi, A. Advani
- Brd. 34B Autologous stem cell transplantation (ASCT) as upfront or salvage therapy for non-cutaneous T-cell lymphoma (TCL): The University of Texas M. D. Anderson Cancer Center (MDACC) experience. (Abstract #6565)**
A. Beitinjaneh, R. Saliba, G. Okoroji, A. M. Alousi, U. R. Popat, M. Korbling, P. Anderlini, M. Qazilbash, P. Kebriaei, C. Hosing, R. E. Champlin, I. F. Khouri
- Brd. 34C An evaluation of the risk/benefit ratio of low molecular weight heparin to reduce the high risk of venous thromboembolism in acute leukemia. (Abstract #6566)**
G. L. Simmons, B. E. Hillner, T. J. Smith
- Brd. 34D Therapy-related acute promyelocytic leukemia (t-APL): Observations on APL pathogenesis. (Abstract #6567)**
M. A. Elliott, L. Letendre, A. Tefferi, W. J. Hogan, C. C. Hook, R. Pruthi, S. H. Kaufmann, A. D. Pardani, K. Begna, A. Ashrani, A. P. Wolanskyj, A. Al-Kali, M. R. Litzow
- Brd. 34E A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). (Abstract #6568)**
H. Ghanem, H. Kantarjian, G. Garcia-Manero, F. Ravandi, S. Faderl, J. E. Cortes, A. Reyes, S. M. O'Brien, G. Borthakur, T. M. Kadia, J. A. Burger, M. Konopleva, E. Jabbour
- Brd. 34F Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blastic crisis: A retrospective analysis. (Abstract #6569)**
N. Thota, S. Gundeti, P. Coca, J. Srirambhatla, R. Parimkayala, V. Linga, S. Bheemnathi Hanuman, L. S. Maddali, R. Digumarti

Monday, June 6, 2011

- Brd. 34G Long-term estimate of quality-adjusted life expectancy for nilotinib and imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP). (Abstract #6570)**
M. Botteman, J. Stephens, S. J. Snedecor, X. Ji, M. Hussein, J. Coombs
- Brd. 34H Interim PK analysis results of a phase IIa, open-label, randomized, pharmacokinetic comparative, cross-over study of melphalan HCl for injection (Propylene Glycol-Free) and alkeran for injection for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation. (Abstract #6571)**
O. S. Aljotawi, S. Ganguly, S. H. Abhyankar, D. Robinson, R. Marks, J. Pipkin, J. McGuirk
- Brd. 35A Cost-effectiveness of nilotinib versus imatinib as first-line treatment for newly diagnosed patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP): Swedish perspective. (Abstract #6572)**
A. Ovanfors, J. Stephens, S. J. Snedecor, D. Patel, X. Ji, K. T. Carpiuc, J. Coombs, M. Botteman
- Brd. 35B Distinctions between adult T-cell leukemia-lymphoma (ATLL) secondary to human T-cell lymphotropic virus 1 (HTLV1) and peripheral T-cell lymphoma (TCL). (Abstract #6573)**
G. D. Ayalew, J. Yao, K. A. Killoran, K. Laveaux, C. A. Axiotis, A. S. Braverman
- Brd. 35C Phase II study of AZD2171 for the treatment of patients with acute myelogenous leukemia. (Abstract #6574)**
M. Juckett, B. LaPlant, P. J. Flynn, A. Jumonville, A. Moreno-Aspitia, C. Erlichman
- Brd. 35D Mediation of LA-4 lung epithelial cell injury by alloreactive donor T cells. (Abstract #6575)**
S. V. Radhakrishnan, T. Obermeier, G. Mueller, G. C. Hildebrandt
- Brd. 35E The diagnostic and prognostic implications of nucleated red blood cells in myelophthisis. (Abstract #6576)**
J. L. Schering, J. Munoz, E. Raybon, S. Hegab, A. S. Hanbali, P. Kuriakose
- Brd. 35F Vaginal bleeding in women with leukemia. (Abstract #6577)**
S. Ghazal, S. Barton, R. Boyajian, J. H. Antin, R. M. Stone, E. S. Ginsburg
- Brd. 35G TLI-ATG for nonmyeloablative stem cell transplant: A single center experience. (Abstract #6578)**
D. A. Wong, A. S. Steinberg, C. Bresee, A. M. Lopez, S. Lim, M. Lill
- Brd. 35H Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multiagent chemotherapy. (Abstract #6579)**
S. B. Patel, I. Gojo, M. Tidwell, Y. Ning, X. F. Zhao, E. A. Sausville, M. R. Baer
- Brd. 36A Effect of lenalidomide on antileukemia activity in vitro against adult T-cell leukemia (ATL). (Abstract #6580)**
Y. Kitagawa, M. Matsuoka, S. Mitani
- Brd. 36B Relation of methylenetetrahydrofolate reductase C677T polymorphism to chronic myeloid leukemia in serbia. (Abstract #6581)**
R. N. Jankovic, K. Jakovljevic, M. Cavic, E. Malisic
- Brd. 36C Enhanced risk stratification in young and elderly patients treated with induction chemotherapy as well as in frail patients with AML. (Abstract #6582)**
S. Wilop, T. H. Brummendorf, M. Crysandt
- Brd. 36D UCBT with ATG in adult patients. (Abstract #6583)**
W. M. Linkesch, D. Strunk, W. Zinke-Cerwenka, H. Sill, P. Neumeister
- Brd. 36E Clinico-hematological characteristics and outcome assessment of chronic lymphocytic leukemia patients: A single institution study of 285 cases. (Abstract #6584)**
A. Gogia, A. Sharma, V. Raina, L. Kumar, R. Kumar, R. Gupta, S. Vishnubhatla

- Brd. 36F Evaluation of the JAK2 V617F mutational status in coronary patients. (Abstract #6585)**
K. Gasser, A. Muendlein, N. Stark, T. Winder, P. Rein, C. H. Saely, K. Geiger, S. Geller-Rhomberg, B. L. Hartmann, B. Kohler, H. Drexel, A. Lang
- Brd. 36G Time from relapse after allogeneic stem cell transplantation (SCT) to donor leukocyte infusion (DLI) is longer, incidence of GVHD is higher, but survival is similar for recipients of unrelated DLI compared to matched sibling DLI. (Abstract #6586)**
A. Kumar, N. V. Frey, P. Vassilev, S. Goldstein, E. O. Hexner, A. W. Loren, R. Reshef, S. M. Luger, D. L. Porter, E. A. Stadtmauer
- Brd. 36H Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. (Abstract #6587)**
F. Ravandi, S. Faderl, J. E. Cortes, G. Garcia-Manero, E. Jabbour, P. A. Boone, T. M. Kadia, G. Borthakur, W. G. Wierda, J. H. Chiao, H. Kantarjian
- Brd. 37A Comparison of cytarabine, mitoxantrone and CNDAC in vitro treatment of AML bone marrow and peripheral blood cells. (Abstract #6588)**
S. Jagan, L. A. Paganessi, S. Gezer, A. Rizman, D. Rifai, M. C. Keller, M. L. Larson, P. Venugopal, S. Frame, K. W. Christopherson II
- Brd. 37B Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML). (Abstract #6589)**
M. Ulcickas Yood, S. A. Oliveria, I. Hirji, S. Phillips, M. J. Cziraky, C. C. Davis
- Brd. 37C Altered mitochondrial metabolism as a target in acute myeloid leukemia. (Abstract #6590)**
T. S. Pardee, D. A. Levitan, D. D. Hurd
- Brd. 37D LACE: A conditioning regimen for lymphoma patients undergoing autologous transplant. (Abstract #6591)**
R. Thippeswamy, L. Mathew, B. Bhosale, N. Kumar, S. Kannan, A. Joshi, V. Rangarajan, N. Khattry
- Brd. 37E The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients. (Abstract #6592)**
H. J. Lee, K. M. Wright, E. Kandeel, W. Tan, G. E. Wilding, L. Ford, S. N. Sait, A. W. Block, M. P. Barcos, P. L. McCarthy, C. E. Vigil, E. A. Griffiths, J. E. Thompson, E. S. Wang, P. K. Wallace, M. Wetzler
- Brd. 37F Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience. (Abstract #6593)**
A. Ganetsky, N. G. Adel, M. G. Frattini, P. G. Maslak, M. L. Heaney, J. G. Jurcic, M. S. Tallman
- Brd. 37G Prognostic factors of long-term survival in patients with acute myeloid leukemia after allogeneic or autologous stem cell transplantation. (Abstract #6594)**
L. Wang, C. Corona, X. Nie, L. Mejias, S. j. Hou, R. Mullaney, K. M. Ward, D. L. Topolsky, M. Styler, P. A. Crilley
- Brd. 37H Prevalence of venous thromboembolism (VTE) among patients (pts) with acute leukemia (AL) prior to treatment. (Abstract #6595)**
N. V. Luong, S. Faderl, H. Kantarjian, K. Vu
- Brd. 38A Relevance of PIG-A mutation in aplastic anemia and myelodysplastic syndromes. (Abstract #6596)**
J. J. Pu, R. Hu, G. Mukhina, R. A. Brodsky
- Brd. 38B Risk of progression to myelofibrosis and acute myeloid leukemia in patients with essential thrombocythemia and polycythemia vera with prior malignancy. (Abstract #6597)**
M. A. Cherry, H. Pham, H. Kantarjian, J. E. Cortes, S. Pierce, L. Zhou, S. Verstovsek

Monday, June 6, 2011

- Brd. 38C Retrospective analysis of prognostic factors associated with response and overall survival in patients with RAEB-t MDS treated with decitabine. (Abstract #6598)**
A. Malik, G. Garcia-Manero, M. Welch, H. Kantarjian, K. Stein, A. Teng, E. Jabbour
- Brd. 38D Genetic variation in vitamin D pathway and graft-versus-host disease risk after blood and marrow transplantation. (Abstract #6599)**
K. Robien, L. G. Strayer, T. E. DeFor, B. Thyagarajan, D. Lazovich, S. A. Cooley, J. A. Ross, K. S. Baker
- Brd. 38E Retrospective analysis of effects of dose modification and overall survival in patients with myelodysplastic syndromes. (Abstract #6600)**
M. Cornelison, G. Garcia-Manero, J. E. Cortes, F. Ravandi, H. Kantarjian, K. Stein, A. Teng, E. Jabbour
- Brd. 38F Pharmacogenetic variants and outcomes after hematopoietic cell transplantation. (Abstract #6601)**
B. Thyagarajan, P. Jacobson, S. Jackson, S. Basu, D. J. Weisdorf, M. Gross, M. Arora
- Brd. 38G Chronic lymphocytic leukemia (CLL) patients at a VA medical center: Comorbidity and survival. (Abstract #6602)**
L. Soriano, S. Srinivas, M. Tufail, K. Kim, R. Paulin, V. T. Chang, B. Kasimis, M. L. Gonzalez
- Brd. 38H Role of topotecan, vinorelbine, thiotepa, and gemcitabine (TVTG) chemotherapy in relapsed/refractory adult acute leukemia: A single-institution retrospective analysis. (Abstract #6603)**
S. A. Srouf, M. A. Cherry, E. Borders, H. Parekh, J. L. Holter, T. S. Herman, G. B. Selby
- Brd. 39A Model-based prediction of patient-specific residual disease levels for imatinib-treated chronic myeloid leukemia. (Abstract #6604)**
M. Loeffler, M. Horn, I. Glauche, M. C. Müller, A. Hochhaus, I. Roeder
- Brd. 39B Analysis of patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes. (Abstract #6605)**
P. Laneville, M. Baccarani, J. E. Cortes, A. Hochhaus, H. Kantarjian, N. P. Shah, M. Bradley-Garelik, C. Zhu, K. Porkka
- Brd. 39C Disease management and treatment of chronic myeloid leukemia (CML): Experience from the patient (pt) perspective. (Abstract #6606)**
T. W. Victor, M. Talpaz, A. Buzyn, C. B. Lemoine, A. Moadel, E. Olavarria, S. Leighton, S. Gupta, I. Hirji, C. C. Davis
- Brd. 39D Validation of a transplant-related mortality (TRM) risk score for pediatric patients undergoing allogeneic haematopoietic stem cells transplantation. (Abstract #6607)**
P. Angelini, A. Gassas, I. Zaidman, J. Doyle, T. Schechter
- Brd. 39E Analysis of outcomes in relapsed/refractory acute promyelocytic leukemia (APL) patients (pts) treated with and without high-dose chemotherapy and hematopoietic stem cell transplantation (HCT). (Abstract #6608)**
N. Pemmaraju, F. Ravandi, G. Rondon, S. Giralt, J. Chen, S. Pierce, R. E. Champlin, M. De Lima, M. Qazilbash
- Brd. 39F Romiplostim for the treatment of amegakaryocytic thrombocytopenia secondary to remission-inducing immunomodulation in a patient with relapsing acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. (Abstract #6609)**
L. Volodin, V. K. Bhandari, J. Shahan, C. Leary, G. Jean, J. Comeau, J. Cotelingam, G. C. Hildebrandt

MONDAY

- Brd. 39G Symptomatic burden in myelofibrosis (MF): Prospective international assessment in 128 MF patients. (Abstract #6610)**
 R. M. Scherber, A. C. Dueck, P. Johansson, T. Barbui, G. Barosi, A. M. Vannucchi, F. Passamonti, B. I. Andreasson, M. L. Ferarri, A. Rambaldi, J. Samuelsson, G. Birgegard, A. Tefferi, N. Maldonado, F. Sackmann, P. Muxi, D. Hernandez-Maraver, J. Kiladjan, R. A. Mesa
- Brd. 39H Leukemia regression by targeting c-Kit activity with pazopanib. (Abstract #6611)**
 A. Trujillo, C. S. McGee, E. Gars, R. Bosse, A. Meacham, E. Wise, S. Bais, C. R. Cogle
- Brd. 40A Health-related quality of life (HRQoL) in newly diagnosed chronic phase chronic myelogenous leukemia (CP CML) patients (pts) treated with bosutinib (BOS) or imatinib (IM). (Abstract #6612)**
 J. H. Lipton, P. C. Trask, D. Cella, L. Duville, C. Powell, M. V. Ramanan, Z. Maslyak, D. Kim
- Brd. 40B Investigation of thrombopoietin (TPO) function in primary chronic lymphocytic leukemia cells. (Abstract #6613)**
 R. D. Loberg, S. Wang, S. D. Patterson, I. McCaffery
- Brd. 40C Association between chronic myeloid leukemia (CML) treatment responses and patient satisfaction, functioning, and quality of life (QOL): Patient survey results. (Abstract #6614)**
 S. Goldberg, V. K. Bollu, R. Morlock, A. Niyazov, A. Guo, E. Jabbour
- Brd. 40D Open-label study evaluating change in chronic low-grade (LG) non-hematologic (heme) adverse events (AEs) in Philadelphia positive (Ph+) CML-CP patients (pts) switched from imatinib (IM) to nilotinib (NL). (Abstract #6615)**
 J. E. Cortes, C. B. Miller, J. H. Lipton, L. Busque, L. P. Akard, J. Pinilla-Ibarz, S. Ericson, M. J. Mauro
- Brd. 40E Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML). (Abstract #6616)**
 E. Q. Wu, A. Guerin, V. K. Bollu, A. Guo, M. Cloutier, D. Ponce de Leon Barido, S. Ericson, A. Quintas-Cardama
- Brd. 40F Retrospective analysis of effects of transfusion status on response to decitabine and survival in patients with myelodysplastic syndromes. (Abstract #6617)**
 T. M. Kadia, G. Garcia-Manero, H. Kantarjian, N. Pemmaraju, K. Stein, A. Teng, J. E. Cortes
- Brd. 40G Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate dose or low dose AraC. (Abstract #6618)**
 T. Lange, D. Niederwieser, V. Hoffmann, M. Pffirmann, G. Maschmeyer, T. Fischer, M. Herold, H. G. Sayer, C. Junghanss, R. Krahl, H. Al-Ali, W. Pönisch, V. Vucinic, G. Doelken, M. C. Sauerland, A. Heinecke, D. Hoelzer, R. Hehlmann, W. E. Berdel, T. Buchner
- Brd. 40H Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL. (Abstract #6619)**
 D. D. Shepard, H. E. Kohrt, T. L. Rosenblatt, J. G. Jurcic, J. H. Park, A. Goldman, J. S. Dalal, P. G. Maslak, A. A. Jakubowski, V. Klimek, E. Berman, S. Nand, S. E. Coutre, M. S. Tallman, H. P. Erba
- Brd. 41A Health-related quality of life (HRQoL) of bosutinib (SKI-606) in imatinib-resistant (IM-R) or imatinib-intolerant (IM-I) chronic phase chronic myeloid leukemia (CP CML). (Abstract #6620)**
 P. C. Trask, D. Cella, N. Besson, V. Kelly, T. Masszi, D. Kim

Monday, June 6, 2011

- Brd. 41B Secondary malignancies in essential thrombocythemia and polycythemia vera: A retrospective analysis of 437 patients from a single institution. (Abstract #6621)**
S. Pierce, M. A. Cherry, H. Pham, H. Kantarjian, A. Al-Ameri, J. E. Cortes, L. Zhou, S. Verstovsek
- Brd. 41C Incidence of cytogenetic (CG) abnormalities in acute myeloid leukemia (AML) in African American (AA) population. (Abstract #6622)**
R. Khillan, A. S. Braverman, C. A. Axiotis, R. Latif, G. S. Sidhu
- Brd. 41D Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. (Abstract #6623)**
J. M. Flynn, J. A. Jones, L. Andritsos, K. A. Blum, A. J. Johnson, J. Hessler, E. Wiley, N. A. Heerema, J. Poon, K. A. Small, Y. Jou, D. Zhang, P. Statkevich, M. R. Grever, R. Bannerji, J. C. Byrd
- Brd. 41E Modulation of nuclear factor-kb (NF-kb), Ikb kinase (IKK), and inducible nitric oxide synthase (iNOS) via proinflammatory cytokines with adjuvant selenomethionine (Se-Met) in chronic myelogenous leukemia (CML) patients with imatinib mesylate (IM) overexpression of bcr-abl fusion protein. (Abstract #6624)**
E. McPherson, K. Patel, P. Tassy, J. Kleinfeld
- Brd. 41F Chronic myelomonocytic leukemia (CMML) associated with symptomatic pericardial effusion. (Abstract #6625)**
M. I. Ibrahim, P. G. Maslak, M. L. Heaney, M. S. George, R. J. Downey, M. S. Tallman
- Brd. 41G Cytomorphologic and clinical features of AML with translocation (8;16) mimicking APL. (Abstract #6626)**
S. Jhanwar, A. Diab, L. Zickl, G. A. Manji, J. Patel, O. I. Abdel-Wahab, J. G. Jurcic, P. G. Maslak, P. G. Steinherz, E. Paietta, J. Feldstein, R. L. Levine, M. S. Tallman
- Brd. 41H Chemotherapeutic drugs-induced apoptosis-related mRNAs in whole blood ex vivo as a new diagnostic markers for the prediction of clinical outcome of AML. (Abstract #6627)**
N. Usui, K. Mitani, T. Maeda, T. Sakura, N. Dobashi, F. Yagasaki, K. Obata, M. Mitsubashi, S. Miyawaki
- Brd. 42A Influence of type of antecedent disorder on outcome of therapy-related AML. (Abstract #6628)**
S. R. Mohan, P. Elson, M. E. Kalaycio, R. V. Tiu, A. S. Advani, E. A. Copelan, J. P. Maciejewski, M. A. Sekeres
- Brd. 42B A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. (Abstract #6629)**
F. R. Mauro, S. Ciolli, F. Di Raimondo, G. Del Poeta, F. Forconi, A. Cuneo, A. Cortellezzi, F. Nobile, M. Brugiattelli, M. Massaia, S. Molica, L. Trentin, R. Rizzi, L. Orsucci, M. Mura, A. Alietti, E. J. Runggaldier, E. Gamba, A. Guarini, R. Foa
- Brd. 42C Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents. (Abstract #6630)**
C. E. Vigil, W. Tan, G. E. Wilding, G. Garcia-Manero, E. S. Wang, M. Wetzler, A. F. List
- Brd. 42D Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. (Abstract #6631)**
S. E. Coutre, J. C. Byrd, R. R. Furman, J. R. Brown, D. M. Benson Jr., N. D. Wagner-Johnston, I. W. Flinn, B. S. Kahl, S. E. Spurgeon, B. J. Lannutti, H. K. Hsu, R. Ulrich, S. Peterman, L. Holes, L. L. Miller, A. S. Yu
- Brd. 42E Effects of eltrombopag on human cord blood hematopoietic stem cell/primitive progenitor cell expansion. (Abstract #6632)**
H. Sun, Y. Tsai, J. Liesveld, K. L. Dawson, C. L. Erickson-Miller, Y. Chen

MONDAY

1:00 PM - 5:00 PM
GENERAL POSTER SESSION

Lymphoma and Plasma Cell Disorders

Location: Hall A

Track(s): Lymphoma and Plasma Cell Disorders

- Brd. 43A** **Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients with aggressive CD20⁺ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL. (Abstract #8029)**
M. Pfreundschuh, M. Ziepert, S. Zeynalova, E. Lengfelder, H. Steinhauer, M. R. Clemens, C. Nickenig, A. D. Ho, L. H. Truemper, M. Hoffmann, R. H. Mertelsmann, B. Metzner, H. Mergenthaler, V. Poeschel, N. Schmitz, M. Loeffler, German Non-Hodgkin Lymphoma Study Group (DSHNHL)
- Brd. 43B** **High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. (Abstract #8030)**
F. Samaniego, F. Hagemeister, P. McLaughlin, L. W. Kwak, J. Romaguera, M. A. Fanale, S. S. Neelapu, L. Fayad, R. Z. Orlowski, M. Wang, L. Lacerte, N. H. Fowler
- Brd. 43C** **Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). (Abstract #8031)**
R. W. Chen, A. K. Gopal, S. E. Smith, S. M. Ansell, J. D. Rosenblatt, K. J. Savage, J. M. Connors, A. Engert, E. K. Larsen, D. A. Kennedy, E. L. Sievers, A. Younes
- Brd. 43D** **Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). (Abstract #8032)**
B. Pro, R. Advani, P. Brice, N. Bartlett, J. D. Rosenblatt, T. Illidge, J. Matous, R. Ramchandren, M. A. Fanale, J. M. Connors, Y. Yang, E. L. Sievers, D. A. Kennedy, A. R. Shustov
- Brd. 43E** **Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). (Abstract #8033)**
S. M. Horwitz, B. Coiffier, F. M. Foss, H. M. Prince, L. Sokol, M. Greenwood, D. Caballero, P. Borchmann, F. Morschhauser, M. Wilhelm, L. C. Pinter-Brown, S. Padmanabhan, A. R. Shustov, J. Nichols, J. Balsem, S. Carroll, B. Pro
- Brd. 43F** **The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. (Abstract #8034)**
K. J. Savage, J. M. Connors, R. J. Klasa, P. Hoskins, T. N. Shenker, R. D. Gascoyne, S. Bhimji, T. Pickles, F. Benard, D. Wilson, L. H. Sehn
- Brd. 43G** **Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496. (Abstract #8035)**
A. M. Evens, F. Hong, L. I. Gordon, R. I. Fisher, N. Bartlett, J. M. Connors, H. Wagner, M. K. Gospodarowicz, B. D. Cheson, R. Advani, B. S. Kahl, R. T. Hoppe, S. J. Horning
- Brd. 43H** **Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. (Abstract #8036)**
A. K. Nooka, N. J. DeJoubner, C. Nabhan, X. Zhou, M. Taylor, M. Byrtek, T. P. Miller, J. W. Friedberg, A. D. Zelenetz, B. K. Link, J. R. Cerhan, H. Dillon, D. Levy, J. Hirata, C. Flowers
- Brd. 44A** **Long-term survival among Hodgkin lymphoma (HL) patients with gastrointestinal (GI) cancers: A population-based study. (Abstract #8037)**
P. Youn, H. Li, M. T. Milano, M. Stovall, L. S. Constine, L. B. Travis

Monday, June 6, 2011

- Brd. 44B Aggressive craniofacial lymphoma in the prerituximab and rituximab era. (Abstract #8038)**
V. Poeschel, N. Murawski, B. Glass, S. Zeynalova, J. Fleckenstein, M. Ziepert, B. Kempf, M. Loeffler, N. Schmitz, M. Pfreundschuh, German Non-Hodgkin Lymphoma Study Group (DSHNHL)
- Brd. 44C Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). (Abstract #8039)**
Y. L. Kasamon, H. A. Jacene, L. J. Swinnen, L. Popplewell, B. K. Link, T. M. Habermann, J. M. Herman, R. J. Jones, R. F. Ambinder
- Brd. 44D The impact of high-intensity conditioning prior to allogeneic stem cell transplantation in patients with chemorefractory or relapsed T-cell lymphoma. (Abstract #8040)**
B. Glass, J. Hasenkamp, W. Jung, C. Wilhelm, G. Held, M. Nickelsen, M. Pfreundschuh, N. Schmitz, L. H. Truemper, G. Wulf
- Brd. 44E Patients' versus physicians' roles in detecting recurrent Hodgkin lymphoma. (Abstract #8041)**
A. Bestawros, L. Foltz, N. Srour, J. M. Connors
- Brd. 44F Multicenter analysis of more than 300 very elderly non-Hodgkin lymphoma (NHL) patients (pts): Impact of comorbidities and functional status on outcome. (Abstract #8042)**
C. Nabhan, S. M. Smith, I. B. Helenowski, E. E. Ramsdale, R. Karmali, B. M. Parsons, J. Feliciano, B. Hanson, S. E. Smith, J. M. Mckoy, A. Larsen, A. Hantel, S. A. Gregory, A. M. Evens
- Brd. 44G Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation (ASCT) for Hodgkin lymphoma (HL). (Abstract #8043)**
B. M. William, F. R. Loberiza Jr., V. Whalen, P. J. Bierman, G. Bociek, J. Vose, J. O. Armitage
- Brd. 44H PET scans in HIV-related Hodgkin lymphoma (HIV-HL): Results of a retrospective study. (Abstract #8044)**
M. Hentrich, M. Berger, C. Hoffmann, J. Siehl, T. Wolf, M. Nickelsen, J. Rockstroh, D. Schuermann, A. Rieke, R. Schmidmaier, H. Knechten, M. Mueller, G. Fätkenheuer, R. Meyer, K. Arastéh, F. A. Mosthaf Sr., C. Wyen
- Brd. 45B Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT). (Abstract #8046)**
S. J. Harrison, A. K. Hsu, P. J. Neeson, A. Younes, A. Sureda, A. Engert, M. Li, P. Savage, R. Bugarini, C. Le Corre, D. E. Williams, J. D. Gallagher, A. Shen, D. Ritchie
- Brd. 45C Activity of anti-CD20-interferon- α fusion protein against human B-cell lymphomas. (Abstract #8047)**
G. Ngarmchamnanrith, R. E. Yamada, K. K. Steward, S. Khare, R. Sachdev, S. L. Morrison, J. Timmerman
- Brd. 45D Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: Meta-analysis of five clinical trials and 9 years of post-approval safety data. (Abstract #8048)**
J. W. Kylstra, T. E. Witzig, M. Huang, C. E. Emmanouilides, A. Hagenbeek, G. F. Tidmarsh
- Brd. 45E Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study. (Abstract #8049)**
B. K. Link, T. P. Miller, M. Byrtek, J. R. Cerhan, A. D. Zelenetz, H. Dillon, C. Flowers, J. W. Friedberg

- Brd. 45F** **The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous stem cell rescue (HDT/ASCT). (Abstract #8050)**
T. Feldman, A. R. Mato, T. Zielonka, S. D. Rowley, S. Goldberg, M. Donato, D. S. Siegel, K. Facchin, A. Campaiola, D. H. Vesole, C. Bejot, S. Stives, M. Curtin, M. Miller, H. Agress, D. Panush, P. Lizotte, P. Bhattacharyya, A. Pecora, A. Goy
- Brd. 45G** **A new predictive model based on age, pretreatment LDH, and post-therapy PET-CT in patients with MCL treated with dose-intensive strategies. (Abstract #8051)**
A. R. Mato, T. Feldman, T. Zielonka, S. Goldberg, S. D. Rowley, M. Donato, D. S. Siegel, D. H. Vesole, A. Campaiola, K. Facchin, S. Stives, C. Bejot, M. Curtin, M. Miller, H. Agress, D. Panush, P. Lizotte, A. Pecora, P. Bhattacharyya, A. Goy
- Brd. 45H** **Variation of hepatitis C virus genotype distribution between geographically related patients: A retrospective multicenter study. (Abstract #8052)**
H. A. Torres, M. Nevah-Rubin, B. J. Barnett, P. Mahale, D. P. Kontoyiannis, L. Mishra, M. Hassan, I. Raad
- Brd. 46A** **Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). (Abstract #8053)**
M. A. Rodriguez, J. Durand, A. B. Astrow, M. J. Bury, M. A. Fanale, F. B. Hagemeyer Jr., X. Huang, P. McLaughlin, S. S. Neelapu, B. Pro, L. W. Kwak, L. Fayad, J. E. Romaguera, A. Younes, M. Fisch
- Brd. 46B** **Allograft versus non-allograft post-transplant lymphoproliferative disorder, characterization of two distinct subtypes as defined by presentation, histology, and outcome: A case series of 165 patients. (Abstract #8054)**
D. E. Tsai, I. S. Hagemann, J. J. Morrisette, R. Daber, D. Xu, S. J. Schuster, R. D. Bloom, V. N. Ahya, M. Jessup, G. A. Makar, S. Chen, R. Reshef
- Brd. 46C** **Identification of prognostic tumor markers in HIV+ diffuse large B-cell lymphoma (DLBCL). (Abstract #8055)**
C. Chao, M. Silverberg, D. I. Abrams, R. Haque, H. D. Zha, O. Martinez-Maza, M. McGuire, M. D. Chi, B. Castor, L. Xu, J. Said
- Brd. 46D** **Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. (Abstract #8056)**
M. Cotto, F. Cabanillas, G. Garcia-Manero, H. Yang, M. Bruno, O. A. Pavia, E. Rivera, I. Liboy, M. Tirado-Gomez
- Brd. 46E** **Prognostic significance of absolute lymphocyte count in patients with early-stage diffuse large B-cell lymphoma treated with RCHOP. (Abstract #8057)**
Y. Chae, Y. Lee, B. Kang, J. Moon, J. Kim, S. Sohn, D. Yang, J. Lee, T. Park
- Brd. 46F** **A phase II study of R-COMP14 in elderly patients with high-risk diffuse large B-cell lymphoma (DLBCL) and moderate to high "life threat" impact cardiopathy. (Abstract #8058)**
G. Corazzelli, F. Frigeri, M. Arcamone, A. Lucania, G. Capobianco, M. Villa, F. Russo, S. Crisci, G. Marcacci, C. Becchimanzi, E. Morelli, F. Volzone, R. De Filippi, A. Pinto
- Brd. 46G** **Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). (Abstract #8059)**
C. A. Thompson, M. J. Maurer, C. Allmer, S. L. Slager, K. J. Yost, W. R. Macon, S. M. Ansell, D. J. Inwards, T. M. Habermann, B. K. Link, J. R. Cerhan
- Brd. 46H** **Differences in regulatory T cells (Tregs) in responding and non-responding patients with indolent B-cell or mantle cell lymphoma during treatment with lenalidomide and rituximab ± dexamethasone. (Abstract #8060)**
N. Aqul, A. Gordon, Y. Xu, E. A. Chong, L. Leinbach, T. Ahmadi, S. Nasta, J. Svoboda, S. J. Schuster

Monday, June 6, 2011

- Brd. 47A Cell cycle effects of CDK 4/6 inhibitor PD 0332991 in diffuse large B-cell lymphoma cell lines in vitro. (Abstract #8061)**
H. A. Eradat, M. A. Eckardt, E. Dorfman, H. Hamidi, C. Ginther, R. S. Finn, G. Los, J. G. Christensen, S. De Vos, D. J. Slamon
- Brd. 47B Piracy of COX-2/PGE2/EP receptor pathway by Kaposi's sarcoma associated herpes virus (KSHV): A potential Achilles' heel of KSHV-related diseases. (Abstract #8062)**
A. G. Paul, N. Sharma-Walia, B. Chandran
- Brd. 47C Preliminary evaluation of radioimmunotherapy with Tenarad, a I-131 labeled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin lymphoma. (Abstract #8063)**
L. Aloj, L. D'Ambrosio, M. Aurilio, R. Marreno, D. Neri, H. D. Menssen, L. Giovannoni, F. Di Gennaro, C. Caraco, M. Arcamone, F. Frigeri, A. Pinto, S. Lastoria
- Brd. 47D Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. (Abstract #8064)**
R. Advani, S. J. Horning, E. Jonathan, S. Daadi, J. Allen, S. A. Rosenberg, R. T. Hoppe
- Brd. 47E Outcomes following involved field radiotherapy (IFRT) with or without rituximab in patients (Pts) with limited-stage low-grade non-Hodgkin lymphoma (NHL) staged with CT versus PET. (Abstract #8065)**
J. N. Lukens, S. Nasta, E. Glatstein, J. P. Plastaras
- Brd. 47F Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies. (Abstract #8066)**
B. D. Cheson, C. S. Ujjani, E. A. Gehan, S. M. Karim, T. Goswami, J. Crawford
- Brd. 47G Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide. (Abstract #8067)**
J. Mikhael, V. Rajkumar, V. Roy, S. R. Hayman, R. Fonseca, K. Detweiler Short, B. LaPlant, K. M. Laumann, A. Dispenzieri, M. Lacy
- Brd. 47H Extramedullary disease (EMD): A common terminal pathway in multiple myeloma (MM) progression. (Abstract #8068)**
S. Z. Usmani, A. Mitchell, J. Szymonifka, J. D. Shaughnessy Jr., A. Hoering, Y. Alsayed, S. Waheed, B. Nair, J. Crowley, B. Barlogie
- Brd. 48A Survival outcomes of patients with multiple myeloma (MM) achieving stringent complete response (sCR) following upfront autologous stem cell transplantation (SCT). (Abstract #8069)**
P. Kapoor, S. Kumar, A. Dispenzieri, M. Lacy, D. Dingli, S. R. Hayman, F. Buadi, P. R. Greipp, R. A. Kyle, S. V. Rajkumar, M. A. Gertz
- Brd. 48B Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial. (Abstract #8070)**
J. R. Berenson, O. Yellin, A. Bessudo, R. Boccia, S. Noga, D. Gravenor, D. Patel-Donnelly, R. S. Siegel, T. Kewalramani, E. J. Gorak, R. Swift, D. Bensen-Kennedy
- Brd. 48C Outcomes of a late second autologous hematopoietic stem cell transplant compared to nontransplantation salvage therapy in relapsed multiple myeloma after upfront transplant. (Abstract #8071)**
J. M. Azar, S. Abdelqader, R. Abonour, A. Suvannasankha, R. Tabbey, S. Farag
- Brd. 48D Impact of baseline characteristics on efficacy and safety after bortezomib-based induction and maintenance in newly diagnosed multiple myeloma (MM) patients ineligible for transplant in the phase IIIb UPFRONT study. (Abstract #8072)**
R. Niesvizky, I. W. Flinn, R. M. Rifkin, N. Gabrail, V. Charu, Y. Gaffar, R. Neuwirth, D. Corzo, J. Reeves

MONDAY

- Brd. 48E Association of familial disease status with inferior treatment outcome in patients with Waldenstrom's macroglobulinemia. (Abstract #8073)**
Z. R. Hunter, C. Hanzis, L. Ioakimidis, C. Tripsas, R. J. Manning, C. J. Patterson, P. Sheehy, B. Turnbull, S. P. Treon
- Brd. 48F Efficacy and improved toxicity profile of once a week bortezomib (BZ) with dexamethasone (dex) in newly diagnosed multiple myeloma (NDMM) patients (pts) with older age and comorbidities: Preliminary results of an ongoing clinical study. (Abstract #8074^)**
N. C. Munshi, S. Lee, S. Kambhampati, A. Mohiuddin, M. G. Rose, C. Behler, A. Han, Y. A. Efebera, A. Houranieh, M. T. Brophy, A. Zimelman, R. H. Prabhala, T. Grady, C. E. Klein, P. Mehta, T. G. Hayes, G. D. Roodman, A. Lichtenstein
- Brd. 48G A phase Ib study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. (Abstract #8075)**
J. F. San-Miguel, P. G. Richardson, O. Sezer, A. Guenther, D. S. Siegel, J. Blade, R. LeBlanc, H. J. Sutherland, M. Mateos, M. Gramatzki, K. M. Hazell, B. Bengoudifa, P. M. Bourquelot, K. C. Anderson
- Brd. 48H Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. (Abstract #8076)**
S. Lonial, R. Vij, T. Facon, P. Moreau, X. Leleu, A. Mazumder, J. L. Kaufman, C. Westland, C. Tsao, A. K. Singhal, S. Jagannath
- Brd. 49A Prevalence of interleukin-6 receptor polymorphism in Castleman disease and association with increased soluble interleukin-6 receptor levels. (Abstract #8077)**
K. Stone, E. Woods, S. M. Szmania, O. Stephens, T. K. Garg, A. Moreno-Bost, B. Barlogie, J. D. Shaughnessy Jr., B. Hall, M. P. Reddy, F. Van Rhee
- Brd. 49B Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. (Abstract #8078)**
J. Endell, C. Samuelsson, R. Boxhammer, S. Strauss, S. Steidl
- Brd. 49C Evaluation of pretransplant variables predicting cardiomyopathy following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. (Abstract #8079)**
J. S. Bleeker, M. A. Gertz, P. A. Pellikka, F. Buadi, D. Dingli, A. Dispenzieri, S. R. Hayman, W. J. Hogan, S. Kumar, M. Lacy
- Brd. 49D Single-agent lenalidomide for newly diagnosed myeloma with on-demand dexamethasone: A phase II trial. (Abstract #8080)**
F. Buadi, M. Lacy, A. Dispenzieri, B. LaPlant, K. M. Laumann, G. S. Nowakowski, S. R. Hayman, K. Detweiler Short, D. Dingli, M. A. Gertz, P. R. Greipp, J. A. Lust, T. E. Witzig, S. R. Zeldenrust, S. J. Russell, V. Rajkumar, S. Kumar
- Brd. 49E The impact of frontline risk-adapted strategy on the overall survival (OS) of patients with newly diagnosed multiple myeloma (MM): A population study in Singapore (SG). (Abstract #8081)**
D. C. Tan, K. H. Ong, L. P. Koh, S. S. Wong, M. T. Khin, L. H. Lee, Y. T. Goh, W. J. Chng
- Brd. 49F A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone, and lenalidomide (DVD-R) for patients with relapsed/refractory (R/R) multiple myeloma (MM). (Abstract #8082)**
O. Yellin, J. R. Berenson, T. Kazamel, C. Chen, A. Cartmel, T. B. Woliver, M. S. Flam, E. N. Bravin, Y. Nassir, R. A. Vescio, R. Swift
- Brd. 49G Defining the biological subgroup of multiple myeloma patients which benefits maximally from the overall survival (OS) benefit associated with treatment with zoledronic acid (ZOL). (Abstract #8083)**
G. J. Morgan, F. Davies, W. Gregory, S. E. Bell, A. Szubert, N. Navarro Coy, M. Drayson, R. G. Owen, S. Feyler, J. Ashcroft, F. Ross, J. Byrne, H. Roddie, C. Rudin, G. Cook, G. H. Jackson, K. Boyd, J. A. Child, P. Wu

Monday, June 6, 2011

- Brd. 49H** **An evaluation of MIST 1 as an indicator of plasmacytic differentiation. (Abstract #8084)**
C. C. Yeung, J. Mills, J. Frater
- Brd. 50A** **Effect of NF-kB2 mutation on pathway activation in the pathogenesis of B-cell lymphomas. (Abstract #8085)**
B. A. McCarthy, L. Yang, D. Liu, J. Ding, H. Ding
- Brd. 50B** **Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data. (Abstract #8086)**
B. G. Durie, G. Morgan, J. F. San-Miguel, R. Z. Orlowski, S. Lonial, R. Niesvizky, Z. Yu, K. C. Anderson

MONDAY

**1:15 PM - 2:30 PM
SPECIAL SESSION**

ASCO/Union for International Cancer Control (UICC) Joint Session: Breast Cancer Health Disparities—Challenges and Opportunities from an International Perspective

Location: Hall B1

CME credit: 1.25

Track(s): Breast Cancer, International, Special Session

Eduardo L. Cazap, MD—Co-Chair

Latin American-Caribbean Society of Medical Oncology

George W. Sledge Jr., MD—Co-Chair

Indiana University Simon Cancer Center

Larry Norton, MD

Memorial Sloan-Kettering Cancer Center

Developing a Strategy for Independent Breast Cancer Research

Benjamin O. Anderson, MD

University of Washington

Controversies in Screening for Breast Cancer

Mary K. Gospodarowicz, MD

Princess Margaret Hospital and University of Toronto

Role of Radiotherapy in Low-resource Scenarios

Gabriel N. Hortobagyi, MD

University of Texas M. D. Anderson Cancer Center

How to Treat Advanced Breast Cancer with Limited Resources

Monday, June 6, 2011

1:15 PM - 2:30 PM
EDUCATION SESSIONS

Challenges in Treating Children, Adolescents, and Adults with Benign and Malignant Vascular Tumors

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology

Denise Adams, MD—Chair

Cincinnati Children's Hospital

Multidisciplinary Strategies for the Treatment of Vascular Malformations and Tumors in Children

Anthony Montag, MD

The University of Chicago Medical Center

The Pathology and Biology of Vascular Tumors in Children and Young Adults

Steven J. Fishman, MD

Children's Hospital Boston

The Role of the Surgeon in the Diagnosis and Management of Vascular Tumors

Evolving Therapy of Hodgkin Lymphoma

Location: S406

CME credit: 1.25

Track(s): Lymphoma and Plasma Cell Disorders, General Oncology

Joseph M. Connors, MD—Chair

British Columbia Cancer Agency Center for Lymphoid Cancer

Advanced-stage Hodgkin Lymphoma

Andreas Engert, MD

University Hospital of Cologne

Limited-stage Hodgkin Lymphoma

Francisco J. Hernandez-Ilizaliturri, MD

Roswell Park Cancer Institute

New Therapies in Hodgkin Lymphoma

How to Advise the Patient with Early-stage Esophageal Carcinoma and High-grade Dysplasia Arising in Barrett's Esophagus: Endoluminal Therapies to Resection

Location: Hall D2

CME credit: 1.25

Track(s): Gastrointestinal (Noncolorectal) Cancer

Martin S. Karpeh Jr., MD—Chair

Beth Israel Medical Center

What Are the Surgical Options for High-grade Dysplasia and Carcinoma in Situ?

Blair A. Jobe, MD

University of Pittsburgh

What Are the Endoluminal Therapies for High-grade Dysplasia or Carcinoma in Situ?

MONDAY

Myelodysplastic Disorders and Myeloproliferative Disorders: New Therapeutic Developments

Location: E354a

CME credit: 1.25

Track(s): Leukemia, Myelodysplasia, and Transplantation

Alan F. List, MD—Chair

H. Lee Moffitt Cancer Center & Research Institute

Update of Therapy for Myelodysplastic Syndromes

Pierre Fenaux, MD, PhD

Hopital Avicenne

The Biology and Prognostic Factors of Myelodysplastic Syndromes

Srdan Verstovsek, MD, PhD

University of Texas M. D. Anderson Cancer Center

Myeloproliferative Disorders: JAK2 and Beyond

Optimizing Data Collection for Clinical Trials to Support Clinically Relevant Decisions (eQuestions Session)

Location: E353

CME credit: 1.25

Track(s): Clinical Trials

Richard L. Schilsky, MD—Chair

The University of Chicago

Data Collection and Optimization in the Cooperative Group Setting

Jeffrey S. Abrams, MD

National Cancer Institute

Challenges in the Coordination of Clinical Trials

Ann T. Farrell, MD

U.S. Food and Drug Administration

FDA Recommendations for Sponsors on Data Collection for Cancer Clinical Trials

Peter C. Adamson, MD

Children's Hospital of Philadelphia

Data Collection Standards to Establish Safety and Efficacy in Pediatric Clinical Trials

Monday, June 6, 2011

**1:15 PM - 2:30 PM
MEET THE PROFESSOR SESSIONS**

Non-oncogene Addiction to Stress: A Cancer Cell Fix Exploited for Cancer Therapy (M23)—Ticketed Session

Location: E451b

CME credit: 1.25

Track(s): Tumor Biology, Developmental Therapeutics

Kapil N. Bhalla, MD

University of Kansas Cancer Center

Oncogene and Non-oncogene Addiction in Cancer

Sex and the Survivor (M16)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Patient and Survivor Care

Leslie R. Schover, PhD

University of Texas M. D. Anderson Cancer Center

MONDAY

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

BRAF: From Biology to Patients

Location: E354b

CME credit: 1.5

Track(s): Melanoma/Skin Cancers

Keith T. Flaherty, MD—Co-Chair

Massachusetts General Hospital

Richard Kefford, MD, PhD—Co-Chair

Westmead Institute for Cancer Research

Discussion

1:15 PM Levi A. Garraway, MD, PhD
 Dana-Farber Cancer Institute

1:30 PM **Clinical characteristics and outcomes associated with *BRAF* and *NRAS* mutations in metastatic melanoma. (Abstract #8500)**
 J. A. Jakob, R. L. Bassett Jr., C. S. Ng, A. J. Lazar, G. C. Alvarado, M. L. Rohlfs, J. Richard, J. E. Gershenwald, P. Hwu, K. B. Kim, M. A. Davies

1:45 PM **Tumor genetic analyses of patients with metastatic melanoma treated with the *BRAF* inhibitor GSK2118436 (GSK436). (Abstract #8501)**
 K. L. Nathanson, A. Martin, R. Letrero, K. P. D'Andrea, S. O'Day, J. R. Infante, G. S. Falchook, M. Millward, C. M. Curtis Jr., B. Ma, R. C. Gagnon, P. F. Lebowitz, G. V. Long, R. F. Kefford

2:00 PM **Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from *BRAF* mutation-positive metastatic melanoma patients (pts). (Abstract #8502)**
 G. A. McArthur, A. Ribas, P. B. Chapman, K. T. Flaherty, K. B. Kim, I. Puzanov, K. L. Nathanson, R. J. Lee, A. Koehler, O. Spleiss, G. Bollag, W. Wu, K. Trunzer, J. A. Sosman

2:15 PM **Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral *BRAF* inhibitor GSK2118436 (GSK436). (Abstract #CRA8503)**
 J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, H. A. Burris III, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, K. Patel, P. F. Lebowitz, K. T. Flaherty

Discussion

2:30 PM Reinhard Dummer, MD (Abstracts #8500–CRA8503)
 University Hospital of Zurich

Monday, June 6, 2011

1:15 PM - 2:45 PM
CLINICAL SCIENCE SYMPOSIUM

Molecular Biomarkers in Neuro-oncology: Ready for Clinical Practice?

Location: S100bc

CME credit: 1.5

Track(s): Central Nervous System Tumors

Markus Bredel, MD, PhD—Co-Chair

University of Freiburg

Rimas Vincas Lukas, MD—Co-Chair

The University of Chicago

Discussion

1:15 PM Martin J. Van Den Bent, MD
Daniel den Hoed Cancer Center

1:30 PM **RTOG 0525: Molecular correlates from randomized phase III trial of newly diagnosed glioblastoma. (Abstract #LBA2000)**
K. D. Aldape, M. Wang, E. P. Sulman, D. P. Cahill, M. Hegi, H. Colman, G. Jones, A. Chakravarti, M. P. Mehta, D. W. Andrews, L. Long, K. Diefes, L. Heathcock, R. Jenkins, C. J. Schultz, M. R. Gilbert

1:45 PM **Impact of MGMT promoter methylation in glioblastoma of the elderly. (Abstract #2001)**
M. Weller, B. Hentschel, J. Felsberg, G. Schackert, M. Simon, O. Schnell, M. Westphal, W. Wick, T. Pietsch, M. Loeffler, G. Reifenberger, German Glioma Network

2:00 PM **Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas. (Abstract #2002)**
J. Frene, C. Leux, D. Loussouarn, A. Le Loupp, F. Leclair, A. Von Deimling, M. Aumont, S. Martin, M. G. Denis, M. Campone

2:15 PM **Prediction of glioblastoma outcome using combined analysis of MGMT protein expression and promoter methylation (Abstract #2003)**
A. Lai, S. Lalezari, A. P. Chou, A. Tran, O. E. Solis, J. A. Carrillo, W. Chen, P. S. Mischel, R. M. Green, P. L. Nghiemphu, L. M. Liau, H. Wang, R. M. Elashoff, T. F. Cloughesy, W. H. Yong

Discussion

2:30 PM Michael Prados, MD (Abstract #LBA2000–2003)
University of California, San Francisco

MONDAY

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Gastrointestinal (Noncolorectal) Cancer

Display Time: 2:00 PM - 6:00 PM

Display Location: E450b

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: Hall D1

CME credit: 1

Track(s): Gastrointestinal (Noncolorectal) Cancer

Abby B. Siegel, MD, MS—Co-Chair

Columbia University

Gauri R. Varadhachary, MD—Co-Chair

University of Texas M. D. Anderson Cancer Center

Discussion

5:00 PM Alexandria T. Phan, MD (Abstracts #4008–4011)
University of Texas M. D. Anderson Cancer Center

Discussion

5:15 PM Ian Chau, MD (Abstracts #4012–4019)
The Royal Marsden Hospital

Discussion

5:30 PM Eunice Lee Kwak, MD, PhD (Abstracts #4020–4027)
Massachusetts General Hospital and Harvard Medical School

Discussion

5:45 PM Colin D. Weekes, MD, PhD (Abstracts #4028–LBA4032)
University of Colorado Cancer Center

Brd. 1 Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). (Abstract #4008)

E. Raymond, P. Niccoli, J. Raoul, Y. Bang, I. Borbath, C. Lombard-Bohas, J. W. Valle, P. Metrakos, D. Smith, A. Vinik, J. Chen, D. Hoersch, D. E. Castellano, H. F. Kennecke, J. Picus, G. Van Hazel, D. Lu, S. Patyna, R. C. Chao, E. Van Cutsem

Brd. 2 Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3). (Abstract #4009)

J. R. Strosberg, J. Lincy, R. E. Winkler, E. M. Wolin

Brd. 3 Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial. (Abstract #4010)

M. H. Shah, C. Lombard-Bohas, T. Ito, E. M. Wolin, E. Van Cutsem, C. Sachs, R. E. Winkler, J. Lincy, T. J. Hobday, J. C. Yao

Brd. 4 Everolimus plus octreotide LAR versus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET): Updated safety and efficacy results from RADIANT-2. (Abstract #4011)

J. C. Yao, S. Ricci, R. E. Winkler, V. Jehl, M. E. Pavel

Brd. 5 HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). (Abstract #4012)

H. H. Yoon, Q. Shi, W. R. Sukov, A. E. Wiktor, M. Khan, C. A. Sattler, A. Grothey, T. Wu, R. B. Diasio, R. B. Jenkins, F. Sinicrope

Monday, June 6, 2011

- Brd. 6** **Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study. (Abstract #4013)**
M. Terashima, A. Ochiai, K. Kitada, W. Ichikawa, I. Kurahashi, S. Sakuramoto, T. Fukagawa, T. Sano, H. Imamura, M. Sasako
- Brd. 7** **Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis. (Abstract #4014)**
M. A. Shah, Y. Y. Janjigian, C. Pauligk, D. Werner, D. P. Kelsen, E. Jaeger, H. Altmannsberger, E. Robinson, L. H. Tang, V. V. Barbashina, S. Al-Batran
- Brd. 8** **Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. (Abstract #4015)**
D. A. Richards, D. M. Kocs, A. I. Spira, A. D. McCollum, K. A. Boehm, F. Zhan, L. Asmar
- Brd. 9** **Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. (Abstract #4016)**
M. Fujii, Y. H. Kim, T. Satoh, H. Hosaka, T. Kim, A. Tsuji, M. Inokuchi, A. Takagane, S. Oh, K. Tanabe, T. Okuno, K. Chin, T. Ura, J. I. Lee, Y. Kakudo, K. Yamaguchi, S. Iijima, M. Takeuchi, H. Kim, T. Nakajima, Japan Clinical Cancer Research Organization and Korean Cancer Study Group Inter-Group Study
- Brd. 10** **SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer. (Abstract #4017)**
A. Tsuburaya, K. Yoshida, M. Kobayashi, S. Yoshino, Y. Miyashita, S. Morita, K. Oba, M. E. Buysse, J. S. Macdonald, J. Sakamoto
- Brd. 11** **Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. (Abstract #4018)**
E. Van Cutsem, C. Boni, J. Tabernero, B. Massuti, D. A. Richards, H. Prenen, I. Steinberg, P. Rougier
- Brd. 12** **A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. (Abstract #4019)**
J. Li, S. Qin, J. Xu, W. j. Guo, J. p. Xiong, Y. Bai, G. Sun, Y. Yang, L. Wang, N. Xu, Y. Cheng, W. Zhe-Hai, L. Zheng, M. Tao
- Brd. 13** **Evaluation of putative prognostic tissue biomarkers in pancreatic ductal adenocarcinoma. (Abstract #4020)**
J. M. Winter, L. H. Tang, D. S. Klimstra, M. F. Brennan, E. M. O'Reilly, W. R. Jarnagin, P. J. Allen
- Brd. 14** **Molecular prognostic markers in advanced gastric cancer: Correlative study in the Japan Clinical Oncology Group trial JCOG9912. (Abstract #4021)**
Y. Yamada, J. Mizusawa, A. Takashima, K. Nakamura, Y. Tsuji, Y. Suzuki, K. Amagai, K. Yamaguchi, K. Konishi, T. Yoshino, T. Denda, W. Koizumi, S. Ohkawa, H. Kawai, H. Kojima, H. Nishizaki, T. Nishina, A. Tsuji, H. Fukuda, N. Boku
- Brd. 15** **Genome-wide interaction study of gemcitabine treatment and genotype on survival in pancreatic cancer. (Abstract #4022)**
R. R. McWilliams, W. R. Bamlet, M. Matsumoto, G. P. Kim, P. A. Burch, D. Grendahl, G. M. Petersen

- Brd. 16 Association of excision repair cross-complementation group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study (SWOG S0356). (Abstract #4023)**
P. O. Bohanes, B. H. Goldman, L. P. Leichman, C. D. Blanke, S. Iqbal, C. R. Thomas Jr., C. L. Corless, K. G. Billingsley, K. D. Danenberg, W. Zhang, J. K. Benedetti, P. J. Gold, H. Lenz
- Brd. 17 Prediction of gemcitabine benefit after curative-intent resection of pancreatic adenocarcinoma using HENT1 and dCK protein expression. (Abstract #4024)**
R. Maréchal, J. Bachet, J. R. Mackey, P. Demetter, K. Graham, A. Couvelard, M. Svrcek, A. Bardier, P. Hammel, A. Sauvanet, C. Louvet, F. Paye, P. Rougier, L. Hannoun, T. Andre, C. M. Dumontet, C. Cass, I. Salmon, J. Emile, J. Van Laethem
- Brd. 18 Comparing the classification precision and prognostic performance of an intrinsic gastric cancer signature with existing genomic signatures in six independent datasets. (Abstract #4025)**
I. B. Tan, H. Grabsch, H. Toh, J. Lee, A. Boussioutas, S. Y. Rha, J. A. Ajani, P. Tan
- Brd. 19 Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. (Abstract #4026)**
M. M. Javle, G. R. Varadhachary, D. R. Fogelman, R. T. Shroff, M. J. Overman, L. Ukegbu, B. N. Bekele, S. P. Kar, R. A. Wolff, J. L. Abbruzzese
- Brd. 20 Validated biomarker signatures that predict pathologic response to preoperative chemoradiation therapy (CRT) with high specificity and desirable sensitivity levels in patients with esophageal cancer (EC). (Abstract #4027)**
J. A. Ajani, X. Wang, Y. Hayashi, D. Maru, J. Welsh, W. L. Hofstetter, J. H. Lee, M. S. Bhutani, A. Suzuki, D. A. Berry, J. Izzo
- Brd. 21 BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer. (Abstract #4028)**
A. Goncalves, F. Viret, E. François, L. Dahan, H. Perrier, R. Lamy, D. Re, R. Largillier, M. Gasmí, X. Tchiknavorian, O. Turrini, L. Moureau-Zabotto, J. Delpero, P. Viens
- Brd. 22 A randomized phase II study of gemcitabine plus S-1 versus gemcitabine alone in patients with unresectable pancreatic cancer. (Abstract #4029)**
Y. Omuro, T. Ikari, H. Ishii, M. Ozaka, M. Suyama, Y. Matsumura, T. Itoi, N. Egawa, S. Yano, K. Hanada, Y. Kimura, T. Ukita, Y. Ishida, M. Tani, S. Ohoka, Y. Hirose, S. Hijioaka, R. Watanabe, T. Ikeda, T. Nakajima, Japan Clinical Cancer Research Organization
- Brd. 23 Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. (Abstract #4030)**
G. P. Kim, N. R. Foster, M. Salim, P. J. Flynn, D. F. Moore, R. Zon, R. B. Mowat, M. Wiesenfeld, A. E. McCullough, S. R. Alberts
- Brd. 24 Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). (Abstract #4031)**
B. M. Wolpin, E. M. O'Reilly, Y. Ko, L. S. Blaszkowsky, M. U. Rarick, C. S. Rocha Lima, P. S. Ritch, E. Chan, J. L. Sprattlin, T. Macarulla, E. McWhirter, D. Pezet, M. Lichinitser, L. D. Roman, A. Hartford, L. Jackson, M. Vincent, L. M. Reyno, M. Hidalgo
- Brd. 25 Phase III study of gemcitabine/oxaliplatin (GEMOX) with or without erlotinib in unresectable, metastatic biliary tract carcinoma. (Abstract #LBA4032)**
H. Y. Lim, J. Lee, H. M. Chang, J. S. Kim, H. J. Choi, M. A. Lee, J. S. Jang, H. C. Jeung, J. H. Kang, H. W. Lee, D. Shin, H. J. Jang, J. M. Sun, S. H. Park, J. O. Park, Y. Park, W. K. Kang

Monday, June 6, 2011

2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION

Health Services Research

Display Time: 2:00 PM - 6:00 PM
Display Location: S403
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: S404
CME credit: 1
Track(s): Health Services Research

Michael J. Hassett, MD, MPH—Co-Chair
Dana-Farber Cancer Institute
Scott Michael Gilbert, MD, MS—Co-Chair
University of Florida

Discussion

5:00 PM Scott David Ramsey, MD, PhD (Abstracts #6012–6016)
Fred Hutchinson Cancer Research Center

Discussion

5:15 PM Jennifer J. Griggs, MD, MPH (Abstracts #6017–6023)
University of Michigan

Discussion

5:30 PM Lynne I. Wagner, PhD (Abstracts #6024–6028)
Northwestern University

Discussion

5:45 PM Michael J. Hall, MD (Abstracts #6029–6036)
Fox Chase Cancer Center

Brd. 1 **Validation of specific chemotherapy drugs in Medicare data. (Abstract #6012)**
J. L. Lund, T. Sturmer, R. S. Sandler, H. K. Sanoff, L. C. Harlan, J. L. Warren

Brd. 2 **Changes in cancer survival by ethnicity between 1992–1996 and 2002–2006: Are survival disparities increasing or decreasing? (Abstract #6013)**
D. Pulte, T. Redaniel, H. Brenner, M. Jeffreys

Brd. 3 **High-cost imaging for managed care Medicare beneficiaries with cancer, 2001–2006. (Abstract #6014)**
E. T. Loggers, P. A. Fishman, M. C. Hornbrook, C. C. Greenberg, M. C. O’Keeffe-Rosetti, A. Ramaprasan, N. Q. Vanneman, E. H. Wagner, J. C. Weeks, D. P. Ritzwoller

Brd. 4 **Costs and trends in pancreatic cancer treatment: A population-based analysis. (Abstract #6015)**
C. B. O’Neill, C. L. Atoria, E. M. O’Reilly, J. LaFemina, E. B. Elkin

Brd. 5 **Costs of medical care after open or minimally-invasive prostate cancer surgery: A population-based analysis. (Abstract #6016)**
E. B. Elkin, W. T. Lowrance, B. Denton, J. N. Mirkin, J. A. Eastham

Brd. 6 **Different risk factors for mortality in younger and older women after breast-conserving surgery. (Abstract #6017)**
G. G. Kimmick, F. Camacho, W. Hwang, H. B. Mackley, J. H. Stewart IV, R. T. Anderson

Brd. 7 **Associations between county-level surgeon density and colorectal cancer (CRC) mortality. (Abstract #6018)**
J. S. Albarrak, M. Y. Ho, W. Y. Cheung

Brd. 8 **Concordance with NCCN practice guidelines for local therapies as a measure of quality of care: Review of practice and identification of quality gaps. (Abstract #6019)**
V. Francescutti, N. L. Watroba, S. B. Edge

MONDAY

- Brd. 9 Physicians characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer. (Abstract #6020)**
J. D. Wright, A. I. Neugut, E. T. Wilde, D. Buono, J. Malin, W. Tsai, D. L. Hershman
- Brd. 10 Patient access to breast reconstruction after mastectomy and long-term outcomes. (Abstract #6021)**
M. Morrow, A. K. Alderman, S. T. Hawley, S. J. Katz
- Brd. 11 Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database. (Abstract #6022)**
J. L. Vandergrift, J. C. Niland, R. L. Theriault, S. B. Edge, Y. Wong, L. S. Loftus, T. M. Breslin, C. Hudis, S. H. Javid, H. S. Rugo, S. M. Silver, E. M. Lepisto, J. C. Weeks
- Brd. 12 The association of obesity, smoking, and access to oncology services with cancer mortality in the United States. (Abstract #6023)**
A. J. Hayanga, S. B. Zeliadt, D. E. Wood, L. M. Backhus
- Brd. 13 Early palliative care, depression, and survival in metastatic NSCLC. (Abstract #6024)**
W. F. Pirl, J. A. Greer, E. R. Gallagher, V. A. Jackson, I. T. Lennes, J. S. Temel
- Brd. 14 Fertility concerns in young women with breast cancer: Results from a prospective cohort study. (Abstract #6025)**
K. J. Ruddy, S. Gelber, R. M. Tamimi, E. S. Ginsburg, L. Schapira, S. E. Come, M. E. Meyer, E. P. Winer, A. H. Partridge
- Brd. 15 Discussions about end-of-life care planning between physicians and patients with stage IV lung or colorectal cancer. (Abstract #6026)**
J. W. Mack, A. Cronin, N. Taback, H. Huskamp, N. L. Keating, J. L. Malin, C. Earle, J. C. Weeks
- Brd. 16 Patient perspectives on a treatment plan and summary program in community oncology care. (Abstract #6027)**
V. S. Blinder, V. W. Norris, N. W. Peacock, J. J. Griggs, D. P. Harrington, A. Moore, R. L. Theriault, A. H. Partridge
- Brd. 17 Evaluation of an intervention to improve communication about phase I/II trials. (Abstract #6028)**
L. Fallowfield, I. Solis-Trapala, C. I. Langridge, V. A. Jenkins
- Brd. 18 Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer. (Abstract #6029)**
N. T. Brewer, C. M. Walko, W. K. Chiu, L. G. Dressler, A. Yuen, P. Rubin, O. A. Olajide, S. G. Moore, R. E. Raab, D. R. Carrizosa, S. W. Corso, G. Schwartz, J. M. Peppercorn, H. L. McLeod, L. A. Carey, W. J. Irvin Jr.
- Brd. 19 The balance between benefits and harms of molecular targeted agents. (Abstract #6030)**
S. Niraula, E. Amir, A. Ocana, B. Seruga, I. Tannock
- Brd. 20 Adjuvant hormone therapy use in early-stage breast cancer patients insured by the New York State Medicaid program. (Abstract #6031)**
R. L. Yung, M. J. Hassett, K. Chen, F. C. Gesten, P. R. Roohan, F. P. Boscoe, A. H. Sinclair, M. J. Schymura, D. Schrag
- Brd. 21 Persistence with adjuvant hormonal therapy in older breast cancer survivors. (Abstract #6032)**
T. Hedin, C. Guo, A. Nattinger
- Brd. 22 Anthracycline adherence in older patients with breast cancer. (Abstract #6033)**
C. H. Barcenas, N. Zhang, H. Zhao, Z. Duan, G. N. Hortobagyi, S. H. Giordano
- Brd. 23 Racial disparities in chemotherapy for breast cancer: Are delays explained by hospital quality and volume? (Abstract #6034)**
R. A. Freedman, Y. He, N. L. Keating

Monday, June 6, 2011

- Brd. 24 Preoperative breast MRI in early-stage breast cancer: A decision analysis. (Abstract #6035)**
P. Young, B. Kim, J. Malin
- Brd. 25 Abandoning oral oncolytic prescriptions at the pharmacy: Patient and health plan factors influencing adherence. (Abstract #6036)**
L. S. Schwartzberg, S. B. Streeter, N. Husain, M. Johnsrud

MONDAY

2:00 PM - 6:00 PM POSTER DISCUSSION SESSION

Lung Cancer—Metastatic/Non-small Cell

Display Time: 2:00 PM - 6:00 PM

Display Location: E450a

Discussion Time: 5:00 PM - 6:00 PM

Discussion Location: Hall D2

CME credit: 1

Track(s): Lung Cancer

Shadia Ibrahim Jalal, MD—Co-Chair

Indiana University Simon Cancer Center

Robert Charles Doebele, MD, PhD—Co-Chair

University of Colorado Denver

Discussion

5:00 PM Kenneth John O'Byrne, MD (Abstracts #LBA7512–7518)
St. James Hospital

Discussion

5:15 PM Rebecca Suk Heist, MD (Abstracts #7519–7523)
Massachusetts General Hospital Cancer Center

Discussion

5:30 PM Shirish M. Gadgeel, MD (Abstracts #7524–7529)
Karmanos Cancer Institute

Discussion

5:45 PM Fred R. Hirsch, MD (Abstracts #7530–7536)
University of Colorado Denver

Brd. 1 **An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). (Abstract #LBA7512)**

G. Scagliotti, I. Vynnychenko, Y. Ichinose, K. Park, K. Kubota, F. H. Blackhall, R. Pirker, R. Galiulin, T. E. Ciuleanu, O. Sydorenko, M. Dediu, Z. Papai-Szekely, N. Martinez Banaclocha, S. McCoy, B. Yao, Y. J. Hei, D. R. Spigel

Brd. 2 **A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second line therapy in advanced non-small cell lung cancer (NSCLC) of non-squamous histology: NCCTG N0626 study. (Abstract #7513)**

J. R. Molina, G. K. Dy, N. R. Foster, K. L. Allen Ziegler, A. Adjei, K. M. Rowland, M. Aubry, P. J. Flynn, S. J. Mandrekar, S. E. Schild, A. A. Adjei, North Central Cancer Treatment Group (NCCTG)

Brd. 3 **Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. (Abstract #7514)**

L. Crinò, D. Kim, G. J. Riely, P. A. Janne, F. H. Blackhall, D. R. Camidge, V. Hirsh, T. Mok, B. J. Solomon, K. Park, S. M. Gadgeel, R. Martins, J. Han, T. M. De Pas, A. Bottomley, A. Polli, J. Petersen, V. R. Tassell, A. T. Shaw

Brd. 4 **Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors. (Abstract #7515)**

D. Kim, J. Lee, H. S. Park, K. Kulig, T. M. Kim, S. Lee, Y. Jeon, D. H. Chung, D. S. Heo, W. Kim, Y. Bang

Brd. 5 **Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC). (Abstract #7516)**

G. J. Riely, S. N. Gettinger, R. G. Stoller, N. Y. Gabrail, G. K. Dy, G. J. Weiss, C. Tunkey, G. Skliris, S. Strychor, J. Dunbar, D. DeLucia, R. W. Ross, J. E. Gray

Monday, June 6, 2011

- Brd. 6** **The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI). (Abstract #7517)**
T. M. Ortiz, V. A. Joshi, S. Heon, M. Butaney, L. Chen, D. M. Jackman, D. J. Kwiatkowski, N. I. Lindeman, P. A. Janne, B. E. Johnson
- Brd. 7** **SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. (Abstract #7518)**
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, J. S. Temel, I. T. Lennes, E. Bast, B. A. Waltman, M. Lanuti, A. Muzikansky, M. Mino-Kenudson, A. J. Iafrate, D. R. Borger, D. Dias-Santagata, J. A. Engelman
- Brd. 8** **Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. (Abstract #7519)**
A. Inoue, K. Kobayashi, M. Maemondo, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, Y. Saijo, H. Yoshizawa, S. Morita, K. Hagiwara, T. Nukiwa, North-East Japan Study Group
- Brd. 9** **Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib versus gemcitabine/ carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC). (Abstract #7520)**
C. Zhou, Y. Wu, G. Chen, J. Feng, X. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang, On behalf of the OPTIMAL investigators
- Brd. 10** **IFCT-0504 trial: Mucinous (M) and non-mucinous (NM) cytological subtypes interaction effect in first-line treatment of advanced bronchioloalveolar carcinoma (BAC), by erlotinib (E) or carboplatin/paclitaxel (C/P). (Abstract #7521)**
J. Cadranet, R. Gervais, M. Wislez, P. Merle, D. Moro-Sibilot, V. Westeel, L. Bigay-Game, E. A. Quoix, S. Friard, F. Barlesi, M. Zaegel, L. Moreau, I. Monnet, J. Duhamel, G. Oliviero, P. J. Souquet, L. Thiberville, L. Baudrin, F. Morin, G. Zalcman, on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)
- Brd. 11** **A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). (Abstract #7522)**
Y. Sun, Y. Shi, L. Zhang, X. Liu, C. Zhou, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. Feng, Y. Cheng, H. Zhang, Y. Wu, N. Xu, J. Zhou
- Brd. 12** **An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib. (Abstract #7523)**
J. F. Hilton, L. Seymour, A. Le Maitre, D. Tu, F. A. Shepherd, P. A. Bradbury
- Brd. 13** **A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G) (Abstract #7524)**
N. Yamamoto, N. Katakami, S. Atagi, T. Hida, K. Goto, T. Horai, A. Inoue, Y. Ichinose, K. Kobayashi, K. Takeda, K. Kiura, H. Saka, T. Tamura, I. Okamoto, N. Nogami, R. Morinaga, K. Nishio, Y. Seki, R. M. Lorence, M. Shahidi
- Brd. 14** **Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. (Abstract #7525^)**
Y. Y. Janjigian, H. J. Groen, L. Horn, E. F. Smit, Y. Fu, F. Wang, M. Shahidi, L. J. Denis, W. Pao, V. A. Miller
- Brd. 15** **A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC. (Abstract #7526)**
J. Von Pawel, Z. Papai-Szekely, N. Vinolas, C. Sederholm, M. Klima, D. Desaiah, M. I. Leschinger, C. Dittrich

MONDAY

- Brd. 16** **Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced stage non-small cell lung cancer (NSCLC). (Abstract #7527)**
S. S. Ramalingam, D. R. Spigel, M. Steins, J. A. Engelman, C. Schneider, S. Novello, W. E. Eberhardt, L. Crino, P. A. Janne, L. Liu, C. M. Brownstein, M. Reck
- Brd. 17** **Apricot-I: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. (Abstract #7528)**
B. J. Gitlitz, E. D. Bernstein, G. P. Keogh, E. S. Santos, G. A. Otterson, G. Milne, M. Syto, S. L. Zaknoen
- Brd. 18** **Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAB in patients with advanced non-small-cell lung cancer (NSCLC). (Abstract #7529)**
W. Yu, A. Pandita, E. Penuel, R. Raja, J. Zha, S. Mohan, R. D. Patel, R. Desai, L. Fu, A. Do, J. Mango, V. Parab, M. Lipkind, J. Huang, M. Lazarov, V. Ramakrishnan, L. C. Amler, A. C. Peterson, P. H. Patel, R. L. Yauch
- Brd. 19** **Use of negative thyroid transcription factor (TTF-1) status to predict for negative epidermal growth factor receptor (EGFR) mutations (Mts) status with a high negative predictive value (NPV) in patients (pts) with adenocarcinomas (AC) of the lung. (Abstract #7530)**
N. Somaiah, E. Garrett-Mayer, X. Huang, A. E. Wahlquist, K. Danenberg, G. R. Simon
- Brd. 20** **Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. (Abstract #7531)**
S. Yano, T. Yamada, S. Takeuchi, K. Tachibana, Y. Minami, M. Noguchi, F. R. Hirsch
- Brd. 21** **An evaluation of phosphorylated EGFR expression in predicting outcome of EGFR-TKI therapy for the advanced NSCLC patients with EGFR wild type. (Abstract #7532)**
F. Wang, J. Wang, H. Bai, J. Zhao, Z. Wang, M. Zhuo, T. An, J. Duan, L. Yang, M. Wu, Y. Wang, S. Wang, X. Liu
- Brd. 22** **Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (Abstract #7533)**
D. Soulieres, J. Wolf, F. A. Shepherd, F. Cappuzzo, P. A. Bunn, R. S. Herbst, F. R. Hirsch, K. M. Kerr, T. Mitsudomi, M. S. Tsao, C. Yang, F. C. Richardson, B. Klughammer, B. Wacker, D. Sternberg, A. M. Davies
- Brd. 23** **Comparison of high sensitive IHC, FISH, and RT-PCR direct sequencing for detection of ALK translocation in lung cancer. (Abstract #7534)**
T. Mitsudomi, K. Tomizawa, Y. Horio, T. Hida, Y. Yatabe
- Brd. 24** **Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC). (Abstract #7535)**
B. H. Grønberg, M. Lund-Iversen, E. H. Strøm, O. Brustugun, H. Scott, Norwegian Lung Cancer Study Group
- Brd. 25** **Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study. (Abstract #7536)**
M. Joerger, S. A. Burgers, P. Baas, E. F. Smit, T. J. Haitjema, M. P. Bard, V. D. Doodeman, P. H. Smits, A. Vincent, A. Huitema, J. H. Beijnen, J. H. Schellens

Monday, June 6, 2011

**3:00 PM - 4:15 PM
SPECIAL SESSION**

Why Isn't Cancer Research More Successful?

Location: E354b

CME credit: 1.25

Track(s): Special Session

Laurence H. Baker, DO—Chair

University of Michigan

You Reap What You Sow: Research Goals (Incremental versus Large Gains) and Practical Barriers

Lee M. Ellis, MD

University of Texas M. D. Anderson Cancer Center

Challenges in Translating Success from the Lab to the Clinic: A Perspective on Our Current Infrastructure and Suggestions on Ways to Improve It

Andrea Denicoff, RN, MSN, ANP

National Cancer Institute

Science of Patient Participation: Ethics, Decision-making Process, and Informed Consent

MONDAY

3:00 PM - 4:15 PM
EDUCATION SESSIONS

From Minimalist Therapy to Bilateral Mastectomy: Controversies in Loco-regional Management of Breast Cancer

Location: Hall B1

CME credit: 1.25

Track(s): Breast Cancer

Armando E. Giuliano, MD—Chair

John Wayne Cancer Institute

Overview and Evolution of Axillary Management: What to Do With Isolated Tumor Cells and When Do You Need to Dissect the Axilla?

Julia R. White, MD

Radiation Therapy Oncology Group and Medical College of Wisconsin

What Are the Clinical Data Regarding Partial Breast and Other Novel Radiation Techniques and Schedules?

Monica Morrow, MD

Memorial Sloan-Kettering Cancer Center

The Bilateral Mastectomy Epidemic

Managing Electronic Education (eQuestions Session)

Location: E353

CME credit: 1.25

Track(s): Professional Development, Practice Management and Information Technology

Michael Fisch, MD, MPH—Chair

University of Texas M. D. Anderson Cancer Center

Mobile Applications for Professional and Patient Education

Peter Ravdin, MD, PhD

University of Texas M. D. Anderson Cancer Center

Using ASCO and Non-ASCO Web-based Resources

David L. Graham, MD

Carle Clinic Associates

Professional and Social Networking Resources for Oncologists: Using Electronic Media to Improve Cancer Care

Recent Advances in Non-small Cell Lung Cancer: Best of 2010 Basic and Clinical Research in Lung Cancer

Location: Hall D2

CME credit: 1.25

Track(s): Lung Cancer, General Oncology

Lawrence H. Einhorn, MD—Chair

Indiana University Simon Cancer Center

Best of 2010: In the Context of My Own Four Decades of Experience

Pasi A. Janne, MD, PhD

Dana-Farber Cancer Institute

Best of 2010: Basic Research in Lung Cancer

Gregory Peter Kalemkerian, MD

University of Michigan Comprehensive Cancer Center

Best of 2010: Lung Cancer Clinical Research

Monday, June 6, 2011

Update on Quality Improvement Initiatives in Oncology

Location: S504

CME credit: 1.25

Track(s): Health Services Research, Practice Management and Information Technology

Michael N. Neuss, MD—Chair

Oncology/Hematology Care, Inc.

Quality Oncology Practice Initiative (QOPI) and QOPI Certification

Andrew Stewart, MA

Commission on Cancer, American College of Surgeons

American College of Surgeons Electronic Quality Improvement Packets (e-QulP)

Steven M. Asch, MD, MPH

VA Greater Los Angeles Healthcare System

The VA's Cancer Quality Improvement Toolkits

MONDAY

3:00 PM - 4:15 PM
MEET THE PROFESSOR SESSION

Update on the Treatment of Adolescents and Young Adults with Acute Lymphocytic Leukemia (M17)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation

Stephen Hunger, MD

University of Colorado Denver Health Science Center

Monday, June 6, 2011

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Cancer Prevention/Epidemiology

Location: S100bc

CME credit: 3

Track(s): Cancer Prevention/Epidemiology

Michaela Jane Higgins, MD—Co-Chair

Massachusetts General Hospital

Dean E. Brenner, MD—Co-Chair

University of Michigan Medical Center

3:00 PM Tamoxifen and risk of contralateral breast cancer for *BRCA1* and *BRCA2* mutation carriers: A combined analysis from the Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer (kConFab), the International *BRCA1* and *BRCA2* Carrier Cohort Study (IBCCS), and the Breast Cancer Family Registry (BCFR). (Abstract #1500)

K. Phillips, R. L. Milne, M. A. Rookus, D. Goldgar, M. Friedlander, S. McLachlan, S. S. Buys, A. C. Antoniou, K. E. Birch, M. Terry, D. Easton, P. Weideman, M. B. Daly, N. Andrieu, E. M. John, M. Hoening, I. L. Andrulis, T. Caldes, H. Olsson, J. L. Hopper

3:15 PM Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in *BRCA1* (B1)- and *BRCA2* (B2)-mutation carriers associated with an increased risk of breast cancer? (Abstract #1501)

S. M. Domchek, T. Friebel, S. L. Neuhausen, H. T. Lynch, C. F. Singer, R. A. Eeles, C. Isaacs, N. M. Tung, P. A. Ganz, F. J. Couch, J. N. Weitzel, O. I. Olopade, W. S. Rubinstein, G. E. Tomlinson, G. C. Pichert, M. B. Daly, E. T. Matloff, D. G. Evans, J. E. Garber, T. R. Rebbeck, PROSE Consortium

3:30 PM Past use of hormone therapy and breast cancer risk. (Abstract #1502)

W. Y. Chen, B. A. Rosner, S. E. Hankinson, Nurses' Health Study Research Group

Discussion

3:45 PM Lynn C. Hartmann, MD (Abstracts #1500–1502)

Mayo Clinic

4:00 PM Metformin and breast cancer incidence in postmenopausal diabetic women in the Women's Health Initiative (WHI). (Abstract #1503)

R. T. Chlebowski, A. McTiernan, A. K. Aragaki, T. Rohan, J. Wactawski-Wende, E. Ipp, D. Euhus, V. G. Kaklamani, M. Vitolins, R. B. Wallace, S. Liu, M. J. Gunter, L. Phillips, H. Strickler, B. Howard

4:15 PM Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial. (Abstract #1504)

L. Bordeleau, G. Dagenais, N. Yakubovich, S. Yusuf, J. Probstfield, M. Riddle, L. Ryden, L. Xu, J. Bosch, H. Gerstein

4:30 PM Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). (Abstract #1505)

S. R. Land, N. Christian, D. L. Wickerham, J. P. Costantino, P. A. Ganz

Discussion

4:45 PM Pamela Jean Goodwin, MD (Abstracts #1503–1505)

Mount Sinai Hospital

5:00 PM DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. (Abstract #1506)

P. Saintigny, J. Jelinek, C. R. Pickering, W. Lang, M. J. Frederick, L. Zhang, H. Ren, V. Papadimitrakopoulou, J. Lee, E. S. Kim, Y. H. Fan, A. K. El-Naggar, W. K. Hong, J. Myers, J. J. Issa, S. M. Lippman, L. Mao

5:15 PM Final results of a chemoprevention trial with enzastaurin in former smokers. (Abstract #1507)

J. E. Gray, S. Altiok, M. Alexandrow, F. Walsh, J. Chen, D. Tai, G. Bepler

MONDAY

- 5:30 PM** **Cervical cancer risk for 330,000 women undergoing concurrent HPV testing and cervical cytology in routine clinical practice. (Abstract #1508)**
H. A. Katki, W. K. Kinney, B. Fetterman, T. Lorey, N. E. Poitras, L. Cheung,
F. Demuth, M. Schiffman, S. Wacholder, P. E. Castle

Discussion

- 5:45 PM** Eva Szabo, MD (Abstracts #1506–1507)
National Cancer Institute

Monday, June 6, 2011

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Head and Neck Cancer

Location: S406

CME credit: 3

Track(s): Head and Neck Cancer

Ezra E. W. Cohen, MD—Co-Chair

The University of Chicago

David N. Hayes, MD, MPH—Co-Chair

University of North Carolina at Chapel Hill

3:00 PM A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). (Abstract #5500)

K. Ang, Q. Zhang, D. I. Rosenthal, P. Nguyen-Tan, E. J. Sherman, R. S. Weber, J. M. Galvin, D. L. Schwartz, A. K. El-Naggar, M. L. Gillison, R. Jordan, M. A. List, A. A. Kanski, W. L. Thorstad, A. Trotti, J. J. Beitler, A. S. Garden, W. J. Spanos, S. Yom, R. S. Axelrod

3:15 PM Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Results of the randomized phase II TREMPLIN study. (Abstract #5501)

J. Lefebvre, Y. Pointreau, F. Rolland, M. Alfonsi, A. Baudoux, C. Sire, D. De Raucourt, E. Bardet, C. Tchuais, P. Garaud, G. Calais

Discussion

3:30 PM Ezra E. W. Cohen, MD (Abstracts #5500–5501)
The University of Chicago

3:45 PM A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial. (Abstract #5502)

J. A. Sosa, R. Elisei, B. Jarzab, C. S. Bal, H. Koussis, A. W. Gramza, R. Ben-Yosef, B. J. Gitlitz, B. Haugen, S. M. Karandikar, F. R. Khuri, L. F. Licitra, S. C. Remick, S. Marur, C. Lu, F. G. Ondrey, S. Lu, J. Balkissoon

4:00 PM A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). (Abstract #5503)

S. I. Sherman, B. Jarzab, M. E. Cabanillas, L. F. Licitra, F. Pacini, R. Martins, B. Robinson, D. Ball, J. McCaffrey, M. H. Shah, D. Bodenner, R. Allison, K. Newbold, R. Elisei, J. P. O'Brien, M. Schlumberger

Discussion

4:15 PM Marcia S. Brose, MD, PhD (Abstracts #5502–5503)
University of Pennsylvania

4:30 PM Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC). (Abstract #5504)

J. N. Waldron, R. W. Gilbert, L. Eapen, A. Hammond, D. I. Hodson, A. Hendler, B. Perez-Ordonez, C. Gu, J. A. Julian, D. H. Julian, M. N. Levine

Discussion

4:45 PM Randal S. Weber, MD (Abstract #5504)
University of Texas M. D. Anderson Cancer Center

5:00 PM Prediction of clinical outcome in patients with primary laryngeal carcinoma using gene expression profiling. (Abstract #5505)

E. Fountzilas, N. Angouridakis, I. Karasmanis, R. M. Wirtz, A. G. Eleftheraki, E. Veltrup, K. Markou, A. Nikolaou, P. Konstantinopoulos, V. Kotoula, D. Spentzos, G. Fountzilas

5:15 PM **Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (Abstract #5506)**
A. M. Lim, D. Rischin, H. Cao, R. Fisher, G. A. McArthur, L. J. Peters, R. J. Young, Q. Le

Discussion

5:30 PM David N. Hayes, MD, MPH (Abstracts #5505–5506)
University of North Carolina at Chapel Hill

Monday, June 6, 2011

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Sarcoma

Location: E354a

CME credit: 3

Track(s): Sarcoma

Andrew J. Wagner, MD, PhD—Co-Chair

Dana-Farber Cancer Institute

Bruce Brockstein, MD—Co-Chair

NorthShore University Health System

3:00 PM Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. (Abstract #10000)

G. K. Schwartz, R. G. Maki, M. J. Ratain, S. D. Undevia, R. L. Jones, C. M. Rudin, L. L. Siu, B. Brockstein, D. Khayat, T. Gil, M. J. De Jonge, M. B. Sawyer, T. Evans, J. Medioni, P. J. O'Dwyer, C. Hartman, V. Poulart, I. B. Walters

3:15 PM An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). (Abstract #10001)

S. Kummar, A. Strassberger, A. Monks, S. P. Ivy, I. B. Turkbey, P. L. Choyke, S. M. Steinberg, R. Simon, J. H. Doroshow, L. J. Helman, Developmental Therapeutics Clinical Group, National Cancer Institute

3:30 PM PALETTE: A randomized, double-blind, phase III trial of pazopanib versus (vs) placebo in patients (pts) with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy—An EORTC STBSG global network study (EORTC 62072). (Abstract #LBA10002)

W. T. A. Van Der Graaf, J. Y. Blay, S. P. Chawla, D. W. Kim, B. Bui Nguyen, P. G. Casali, P. Schöffski, M. Aglietta, A. P. Staddon, Y. Beppu, A. Le Cesne, H. Gelderblom, I. R. Judson, N. Araki, M. Ouali, S. Marreaud, R. Hodge, M. Dewji, A. P. Dei Tos, and P. Hohenberger

Discussion

3:45 PM Shreyaskumar Patel, MD (Abstracts #10000–LBA10002)
University of Texas M. D. Anderson Cancer Center

4:00 PM Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. (Abstract #10003)

S. Schuetze, L. Zhao, R. Chugh, M. Zalupski, D. Thomas, D. R. Lucas, L. H. Baker

4:15 PM Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors. (Abstract #10004)

P. Schoffski, D. Adkins, J. Blay, T. Gil, A. D. Elias, P. Rutkowski, G. K. Pennock, H. Youssoufian, N. J. Zojwalla, R. Willey, D. O. Grebennik

4:30 PM Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). (Abstract #10005)

S. P. Chawla, J. Blay, I. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, R. F. Riedel, B. Bui Nguyen, L. D. Cranmer, P. Reichardt, E. Bompas, Y. Song, R. Lee, J. E. Eid, J. Loewy, F. G. Haluska, P. F. Diodon, G. D. Demetri

Discussion

4:45 PM Scott H. Okuno, MD (Abstracts #10003–10005)
Mayo Clinic

5:00 PM A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). (Abstract #10006)

J. C. Trent, K. Wathen, M. von Mehren, B. L. Samuels, A. P. Staddon, E. Choy, J. E. Butrynski, R. Chugh, W. A. Chow, D. A. Rushing, C. A. Forscher, L. H. Baker, S. Schuetze, Sarcoma Alliance for Research through Collaboration

- 5:15 PM** **A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). (Abstract #10007)**
S. George, M. von Mehren, M. C. Heinrich, Q. Wang, C. L. Corless, J. E. Butrynski, J. A. Morgan, A. J. Wagner, E. Choy, W. D. Tap, J. Manola, J. T. Yap, A. D. Van Den Abbeele, S. Solomon, J. A. Fletcher, G. D. Demetri
- 5:30 PM** **Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study. (Abstract #10007b)**
I. Ray-Coquard, J. Y. Blay, A. Italiano, A. Le Cesne, N. Penel, J. Zhi, A. Beryozkina, F. Heil, R. Rueger, G. L. Nichols, and B. Bui Nguyen
- Discussion**
- 5:45 PM** Jaap Verweij, MD, PhD (Abstracts #10006–1007b)
Erasmus University Medical Center

Monday, June 6, 2011

3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION

Tumor Biology

Location: S100a

CME credit: 3

Track(s): Tumor Biology

Robert Arthur Kratzke, MD—Co-Chair

University of Minnesota

Kapil N. Bhalla, MD—Co-Chair

University of Kansas Cancer Center

3:00 PM Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. (Abstract #10500)

E. Vakiani, M. Janakiraman, R. Shen, Z. Zeng, A. Cercek, N. E. Kemeny, A. Heguy, P. Paty, T. A. Chan, L. Saltz, M. R. Weiser, D. B. Solit

3:15 PM Exomic sequencing of pancreatic neuroendocrine tumors: Detection of alterations in chromatin remodeling and mTOR pathway genes. (Abstract #10501)

L. A. Diaz, Y. Jiao, C. Shi, B. H. Edil, R. de Wilde, D. S. Klimstra, A. Maitra, L. H. Tang, A. L. Blackford, V. Velculescu, B. Vogelstein, K. W. Kinzler, R. H. Hruban, N. Papadopoulos

3:30 PM Tumor genomic profiling of FFPE samples by massively parallel sequencing. (Abstract #10502)

N. Wagle, M. F. Berger, M. J. Davis, B. Blumenstiel, M. DeFelice, W. C. Hahn, M. Meyerson, S. B. Gabriel, L. E. MacConaill, L. A. Garraway

Discussion

3:45 PM A. John Iafrate, MD, PhD (Abstracts #10500–10502)
Massachusetts General Hospital

4:00 PM Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. (Abstract #10503)

M. M. Reinholz, A. C. Dueck, B. Chen, X. Geiger, A. E. McCullough, R. B. Jenkins, W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge Jr., L. Harris, J. Gralow, E. A. Perez

4:15 PM Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. (Abstract #10504)

E. A. Perez, A. C. Dueck, M. M. Reinholz, B. Chen, X. Geiger, R. B. Jenkins, W. L. Lingle, C. Andorfer, N. E. Davidson, S. Martino, P. A. Kaufman, L. A. Kutteh, G. W. Sledge Jr., L. Harris, J. Gralow, A. E. McCullough

4:30 PM Genomic patterns resembling BRCA-mutated breast cancers and benefit of intensified carboplatin-based chemotherapy in HER2-negative breast cancer. (Abstract #10505)

S. C. Linn, E. H. Lips, P. M. Nederlof, L. F. Wessels, J. Wesseling, M. van de Vijver, E. De Vries, H. van Tinteren, J. Jonkers, M. Hauptmann, S. Rodenhuis, M. A. Vollebergh

Discussion

4:45 PM Ana M. Gonzalez-Angulo, MD, MSc (Abstracts #10503–10505)
University of Texas M. D. Anderson Cancer Center

5:00 PM Detection of circulating miRNAs in serum from patients with breast cancer and their association with the presence of metastatic disease. (Abstract #10506)

E. van Schooneveld, M. Wouters, I. Van der Auwera, D. Peeters, P. Huget, P. A. van Dam, P. B. Vermeulen, S. J. Van Laere, L. Y. Dirix, Translational Cancer Research Group Antwerp, GZA Hospitals Sint-Augustinus

5:15 PM **Screening for *PIK3CA* mutations, PTEN loss, and *RAS/RAF* mutations in early-phase protocols with PI3K/mTOR pathway inhibitors. (Abstract #10507)**
F. Janku, I. Garrido-Laguna, J. J. Wheeler, D. S. Hong, A. Naing, G. S. Falchook, S. Fu, S. L. Moulder, R. Luthra, J. Lee, A. M. Tsimberidou, R. Kurzrock

5:30 PM **Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. (Abstract #10508)**
A. B. Nixon, H. Pang, M. Starr, D. Hollis, P. N. Friedman, M. M. Bertagnolli, H. L. Kindler, R. M. Goldberg, A. P. Venook, H. Hurwitz

Discussion

5:45 PM David Paul Carbone, MD, PhD (Abstracts #10506–10508)
Vanderbilt-Ingram Cancer Center

Monday, June 6, 2011

4:45 PM - 6:00 PM
EDUCATION SESSIONS

Developing and Implementing More Informative Phase II Oncology Clinical Trials

Location: Arie Crown Theater

CME credit: 1.25

Track(s): Clinical Trials, Genitourinary Cancer, Lung Cancer

David B. Solit, MD—Chair

Memorial Sloan-Kettering Cancer Center

How Do We Improve Phase II Trial Designs to Better Ensure Success in Phase III?

Catherine M. Tangen, PhD

Fred Hutchinson Cancer Research Center

The Randomized Phase II Trial: Is it Useful in Predicting Results of Phase III Studies?

Primo Lara, MD

University of California, Davis

Pitfalls in the Use of Progression-free Survival in Patients with Lung and Prostate Cancer

Implementing an Electronic Health Record (EHR) in Different Practice Settings: Strategies for Success (eQuestions Session)

Location: E353

CME credit: 1.25

Track(s): Practice Management and Information Technology, Professional Development

William M. Jordan, DO—Chair

The Center for Cancer and Blood Disorders

EHR Implementation: Community Practice Perspective

Nancy T. Sklarin, MD

Memorial Sloan-Kettering Cancer Center

EHR Implementation: Academic Practice Perspective

Carolyn P. Hartley, MD

Physician's EHR

The Practice EHR Implementation Team

To Transplant or Not to Transplant? Current Controversies in Transplantation for Pediatric Acute Leukemias

Location: S504

CME credit: 1.25

Track(s): Pediatric Oncology, Leukemia, Myelodysplasia, and Transplantation

Michael Pulsipher, MD—Chair

University of Utah

Chemotherapy versus Transplant for Pediatric Acute Lymphoblastic Leukemia

Richard Aplenc, MD

The Children's Hospital of Philadelphia

Chemotherapy versus Transplant for Pediatric Acute Myeloblastic Leukemia

Saro Armenian, DO, MPH

City of Hope

Long-term Outcome of Children with Leukemia after Treatment with Stem Cell Transplant

MONDAY

Treating Genitourinary Malignancies (Prostate, Kidney, and Urothelial Cancers): The Latest and Greatest

Location: Hall B1

CME credit: 1.25

Track(s): Genitourinary Cancer, Clinical Trials, General Oncology

Gary R. MacVicar, MD—Chair

Northwestern University Feinberg School of Medicine

Advances in Prostate Cancer Therapeutics

Christopher Sweeney, MBBS

Dana-Farber Cancer Institute

What's New in Urothelial Cancer

Elisabeth I. Heath, MD

Karmanos Cancer Institute

Renal Cell Cancer Update

Monday, June 6, 2011

**4:45 PM - 6:00 PM
MEET THE PROFESSOR SESSION**

Finding the Best Job for You/Contract Negotiation (M18)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Professional Development, Practice Management and Information Technology

Douglas W. Blayney, MD
Stanford University

MONDAY

7:30 AM - 9:00 AM
HIGHLIGHTS OF THE DAY SESSION

Highlights of the Day III

Location: Hall D1

CME credit: 1.5

Track(s): Special Session, General Oncology

Ronald Levy, MD—Chair

Stanford University School of Medicine

7:30 AM

Stephen K. L. Chia, MD

British Columbia Cancer Agency

Breast Cancer—Triple-negative/Cytotoxics/Local Therapy and Cancer Prevention/Epidemiology

7:50 AM

A. Oliver Sartor, MD

Tulane University School of Medicine

Genitourinary (Prostate and Nonprostate) Cancer

8:10 AM

Vassiliki Papadimitrakopoulou, MD

University of Texas M. D. Anderson Cancer Center

Head and Neck Cancer

8:25 AM

Thomas J. Smith, MD

Massey Cancer Center of Virginia Commonwealth University

Patient and Survivor Care

8:40 AM

Jean-Yves Blay, MD, PhD

Centre Léon Bérard

Sarcoma

Tuesday, June 7, 2011

**8:00 AM - 9:15 AM
EDUCATION SESSIONS**

How the Human Genome Project Will Help Us in the Clinic

Location: S100a

CME credit: 1.25

Track(s): Tumor Biology, Cancer Genetics, Developmental Therapeutics

Todd Golub, MD—Chair

Dana-Farber Cancer Institute

Genomic Mutations Mediating Sensitivity and Resistance to Targeted Therapies

Jordi Barretina, PhD

Broad Institute of MIT and Harvard

Exploiting Genomic Mutations and Pathway Analysis for the Rationale Development of Effective Therapeutics

Joe W. Gray, PhD

Oregon Health and Science University

The Future of Genomics in Directing Personalized Cancer Therapy

Targeting Angiogenesis in Breast Cancer: Where Do We Stand in 2011?

Location: E354a

CME credit: 1.25

Track(s): Breast Cancer, Tumor Biology

Maura N. Dickler, MD—Chair

Memorial Sloan-Kettering Cancer Center

Antiangiogenic Therapy in Breast Cancer: The Current Status and Controversy

Robert S. Kerbel, PhD

Sunnybrook Research Institute

Angiogenesis as a Target

Daniel J. Sargent, PhD

Mayo Clinic

Appropriate Endpoints for Clinical Trials and Source of U.S. Food and Drug Administration/Oncologic Drugs Advisory Committee Controversy

8:00 AM - 9:15 AM
MEET THE PROFESSOR SESSION

Orthopedic Oncology for the Rest of Us (M19)—Ticketed Session

Location: E451a

CME credit: 1.25

Track(s): Sarcoma

R. Lor Randall, MD

Huntsman Cancer Institute, University of Utah

Kristy Weber, MD

The Johns Hopkins University School of Medicine

Tuesday, June 7, 2011

8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM

Immune Correlates of Clinical Outcomes

Location: E354b

CME credit: 1.5

Track(s): Developmental Therapeutics

Thomas Gajewski, MD, PhD—Chair

The University of Chicago

8:00 AM Pharmacodynamic and predictive markers of ipilimumab on melanoma patients' T cells. (Abstract #2503)

J. S. Weber, B. Yu, M. Hall, D. Morelli, D. Yu, Y. Zhang, X. Zhao, A. Sarnaik, W. Wang

Discussion

8:15 AM Thomas Gajewski, MD, PhD (Abstract #2503)
The University of Chicago

8:30 AM Phase II cancer vaccination trial with multiple peptides derived from novel oncoantigens against advanced esophageal cancer. (Abstract #2504)

K. Kono, H. Iinuma, Y. Akutsu, H. Tanaka, N. Hayashi, Y. Uchikado, T. Noguchi, H. Fujii, R. Fukushima, H. Matsubara, K. Hirakawa, H. Baba, S. Natsugoe, S. Kitano, K. Yoshida, T. Tsunoda, Y. Nakamura

Discussion

8:45 AM Mary L. Disis, MD (Abstract #2504)
University of Washington

9:00 AM Evaluation of serum IL-17 levels during ipilimumab therapy: Correlation with colitis. (Abstract #2505)

M. K. Callahan, A. Yang, S. Tandon, Y. Xu, S. K. Subudhi, R. Roman, A. I. Heine, E. Pogoriler, D. Kuk, K. Panageas, J. D. Yuan, J. P. Allison, J. D. Wolchok

Discussion

9:15 AM To be determined

TUESDAY

8:00 AM - 11:00 AM
ORAL ABSTRACT SESSION

Lung Cancer—Local-regional and Adjuvant Therapy/Small Cell

Location: Arie Crown Theater

CME credit: 3

Track(s): Lung Cancer

Tom Stinchcombe, MD—Co-Chair

University of North Carolina at Chapel Hill

Wilfried Ernst Erich Eberhardt, MD—Co-Chair

University Hospital—University Duisburg-Essen

8:00 AM Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). (Abstract #7000)

R. Jotte, J. Von Pawel, D. R. Spigel, M. A. Socinski, M. O'Brien, E. H. Paschold, J. Mezger, M. Steins, L. Bosquée, J. A. Bubis, K. Nackaerts, J. Trigo Perez, P. R. Clingan, W. Schuette, P. Lorigan, M. Reck, M. Domine, F. A. Shepherd, R. McNally, M. F. Renschler

8:15 AM A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). (Abstract #7001)

C. J. Langer, I. Albert, P. Kovacs, L. Blakely, G. Pajkos, P. Petrov, A. Somfay, A. Szczesna, P. Zatloukal, A. Kazarnowicz, M. M. Moezi, M. T. Schreeder, J. Schnyder, M. S. Berger

Discussion

8:30 AM Bonnie S. Glisson, MD (Abstracts #7000–7001)
 University of Texas M. D. Anderson Cancer Center

8:45 AM Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT. (Abstract #7002)

M. Kreuter, J. F. Vansteenkiste, J. R. Fischer, W. E. Eberhardt, H. Zabeck, J. Kollmeier, M. H. Serke, N. Frickhofen, M. Reck, W. Engel-Riedel, S. Neumann, M. Thomeer, C. Schumann, P. Deleyn, T. Graeter, G. Stamatis, I. Zuna, F. Griesinger, M. Thomas

Discussion

9:00 AM Heather A. Wakelee, MD (Abstracts #7002)
 Stanford University School of Medicine

9:15 AM Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. (Abstract #7003)

D. Harpole, K. V. Ballman, A. L. Oberg, G. Whiteley, R. Cerfolio, R. Keenan, D. R. Jones, T. A. D'Amico, J. Shrager, J. B. Putnam, American College of Surgeons Oncology Group

Discussion

9:30 AM To be determined

9:45 AM Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (Abstract #7004)

S. Michiels, A. Mauguen, D. Fisher, S. Burdett, R. Paulus, S. J. Mandrekar, C. P. Belani, F. A. Shepherd, T. Eisen, H. Pang, L. Collette, C. Le Pechoux, J. Pignon, Surrogate Lung Project Collaborative Group

10:00 AM Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. (Abstract #7005)

S. J. Mandrekar, Y. Qi, K. Allen-Ziegler, S. L. Hillman, M. W. Redman, S. E. Schild, D. R. Gandara, A. A. Adjei

Tuesday, June 7, 2011

Discussion

10:15 AM Suzanne Eleanor Dahlberg, PhD (Abstracts #7004–7005)
Dana-Farber Cancer Institute

10:30 AM **A multicenter, randomized phase III maintenance study of thalidomide (arm A) versus observation (arm B) in patients with malignant pleural mesothelioma (MPM) after induction chemotherapy. (Abstract #7006)**
P. Baas, W. Buikhuisen, O. Dalesio, A. Vincent, N. Pavlakis, R. Van Klaveren, F. Schramel, F. Custers, H. Schouwink, S. A. Burgers

Discussion

10:45 AM Rolf A. Stahel, MD (Abstract #7006)
University Hospital Zurich

TUESDAY

**8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION**

Breast Cancer—HER2/ER

Display Time: 8:00 AM - 12:00 PM
 Display Location: E450a
 Discussion Time: 11:30 AM - 12:30 PM
 Discussion Location: Arie Crown Theater
CME credit: 1
 Track(s): Breast Cancer

Herve R. Bonnefoi, MD—Co-Chair

Institut Bergonie Cancer Center

Anne F. Schott, MD—Co-Chair

University of Michigan

Discussion

11:30 AM Jennifer J. Griggs, MD, MPH (Abstracts #512–520)
 University of Michigan

Discussion

11:45 AM Charles L. Loprinzi, MD (Abstracts #521–526)
 Mayo Clinic

Discussion

12:00 PM Herve R. Bonnefoi, MD (Abstracts #527–532)
 Institut Bergonie Cancer Center

Discussion

12:15 PM Anne F. Schott, MD (Abstracts #533–536)
 University of Michigan

Brd. 1 **Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. (Abstract #512)**

R. Segal, G. R. Pond, M. Vallis, M. Dion, K. I. Pritchard, J. A. Ligibel, M. N. Levine, P. J. Goodwin

Brd. 2 **Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. (Abstract #513)**

R. Yerushalmi, B. Dong, J. W. Chapman, P. E. Goss, M. N. Pollak, M. J. Burnell, V. H. Bramwell, M. N. Levine, K. I. Pritchard, T. J. Whelan, J. N. Ingle, W. Parulekar, L. E. Shepherd, K. A. Gelmon

Brd. 3 **Effect of change of body mass index (BMI) during therapy on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the ABCSG-12 trial. (Abstract #514)**

G. Pfeiler, R. Königsberg, B. Mlineritsch, H. Stoger, C. F. Singer, S. Poestlberger, G. G. Steger, M. Seifert, P. C. Dubsy, R. Jakesz, H. Samonigg, V. Bjelic-Radicic, R. Greil, C. Marth, C. Fesl, M. Gnant

Brd. 4 **Effects of body mass index (BMI) on plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment. (Abstract #515)**

G. Lunardi, L. Del Mastro, C. Bighin, G. Bisagni, P. Driol, O. Garrone, S. Giraudi, P. Marroni, P. Piccioli, R. Ponzzone, M. Porpiglia, M. Venturini, Gruppo Italiano Mammella (GIM)

Brd. 5 **Bone mineral density (BMD) in participants (pts) of trial BIG 1–98 comparing adjuvant letrozole (L) versus tamoxifen (T) or their sequence. (Abstract #516)**

A. De Censi, Z. Sun, B. J. Thurlimann, C. McIntosh, A. Guerrieri-Gonzaga, A. Monnier, C. Tondini, M. Campone, L. Mauriac, K. Zaman, A. Schoenberger, K. N. Price, R. D. Gelber, A. Goldhirsch, A. S. Coates, S. P. Aebi, BIG 1–98 Collaborative and International Breast Cancer Study Groups

- Brd. 6** **Bone effects of adjuvant tamoxifen (T), letrozole (L), or L + zoledronic acid (Z) in early breast cancer (EBC): The phase III HOBEOE study. (Abstract #517)**
F. Perrone, C. Gallo, S. Lastoria, F. Nuzzo, A. Gravina, G. Landi, E. Rossi, C. Pacilio, V. Labonia, F. Di Rella, M. De Laurentiis, M. Piccirillo, M. Di Maio, P. Giordano, G. Daniele, G. De Feo, R. Fiore, S. Signoriello, G. Esposito, A. de Matteis
- Brd. 7** **Effects of adjuvant exemestane versus anastrozole on bone mineral density: Two-year results of the NCIC CTG MA.27 bone companion study. (Abstract #518)**
D. L. Hershman, A. M. Cheung, J. W. Chapman, J. N. Ingle, F. Ahmed, H. Hu, J. Scher, S. Leeson, C. Elliott, A. Le Maitre, L. E. Shepherd, P. E. Goss
- Brd. 8** **A population-based assessment of the risk of fragility fracture associated with the use of adjuvant hormone therapy for early breast cancer in older women. (Abstract #519)**
K. Enright, M. E. Trudeau, N. Taback, M. K. Krzyzanowska
- Brd. 9** **Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12. (Abstract #520)**
M. Gnant, B. Milneritsch, H. Stoeger, G. Luschin-Ebengreuth, S. Poestlberger, P. C. Dubsy, R. Jakesz, C. F. Singer, H. Eidtmann, R. Greil
- Brd. 10** **Incidence and predictors of ovarian function recovery (OFR) in exemestane patients with breast cancer (BC) with chemotherapy-induced amenorrhea (CIA) using two estradiol assays. (Abstract #521)**
A. Guerrero-Zotano, J. Gavila, E. Folkerd, B. Ortiz, T. Labrador, F. Martinez, A. Garcia, M. Climent, V. Guillem, M. Dowsett, A. Ruiz
- Brd. 11** **Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. (Abstract #522)**
J. B. Huober, B. F. Cole, J. Wu, A. Giobbie-Hurder, M. Rabaglio, H. T. Mouridsen, L. Mauriac, J. F. Forbes, R. Paridaens, I. Lang, I. E. Smith, A. M. Wardley, K. N. Price, A. Goldhirsch, A. S. Coates, B. J. Thurlimann, BIG 1-98 Collaborative and International Breast Cancer Study Groups
- Brd. 12** **Increased progression-free and overall survival in patients with breast cancer with menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen: Results of the German TEAM trial. (Abstract #523)**
D. G. Kieback, P. Hadji, T. Menschik, A. Hasenburg, J. Tams, M. Ziller
- Brd. 13** **Symptom experiences and nonadherent medication-taking behaviors of breast cancer patients taking adjuvant hormone therapy. (Abstract #524)**
R. A. Shelby, F. J. Keefe, S. N. Red, K. L. Blackwell, J. M. Peppercorn, P. K. Marcom, G. G. Kimmick
- Brd. 14** **Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. (Abstract #525)**
V. Stearns, J. W. Chapman, C. X. Ma, M. J. Ellis, J. N. Ingle, K. I. Pritchard, G. T. Budd, M. Rabaglio, G. W. Sledge Jr., A. Le Maitre, J. Kundapur, L. E. Shepherd, P. E. Goss
- Brd. 15** **24-month follow-up from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer. (Abstract #526)**
H. Lück, P. Hadji, N. Harbeck, C. Jackisch, M. Blettner, M. Glados, J. Terhaag, R. Hackenberg, T. Goehler, S. Zaun, A. Rexrodt von Fircks, R. Kreienberg
- Brd. 16** **TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). (Abstract #527)**
N. U. Lin, I. A. Mayer, J. S. Najita, T. J. Hobday, C. I. Falkson, E. C. Dees, M. F. Rimawi, R. Nanda, R. S. Gelman, K. Josephs, A. Richardson, L. Flores, A. D. Van Den Abbeele, J. T. Yap, C. L. Arteaga, A. C. Wolff, I. E. Krop, E. P. Winer, Translational Breast Cancer Research Consortium

- Brd. 17 The role of EGFR amplification in trastuzumab resistance: A correlative analysis of TBCRC003. (Abstract #528)**
 I. E. Krop, L. Flores, J. S. Najita, I. A. Mayer, T. J. Hobday, C. I. Falkson, C. L. Arteaga, A. C. Wolff, E. C. Dees, M. F. Rimawi, R. Nanda, K. Josephs, N. U. Lin, E. P. Winer, Translational Breast Cancer Research Consortium
- Brd. 18 Response to neoadjuvant trastuzumab and chemotherapy in ER+ and ER-HER2-positive breast cancers: Gene expression analysis. (Abstract #529)**
 G. Bianchini, A. Prat, M. Pickl, A. Belousov, A. Koehler, V. Semiglazov, W. Eiermann, S. Tjulandin, M. Biakhov, A. Lluch, M. Zambetti, F. J. Vazquez Mazon, J. Baselga, L. Gianni
- Brd. 19 Validation of p95 as predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study. (Abstract #530)**
 S. Loibl, J. Bruey, G. Von Minckwitz, J. B. Huober, M. F. Press, S. Darb-Esfahani, C. Solbach, C. Denkert, H. Tesch, F. Holms, T. N. Fehm, K. Mehta, M. Untch
- Brd. 20 Primary efficacy analysis of a phase II study of neoadjuvant bevacizumab (BEV), chemotherapy (CT), and trastuzumab (H) in HER2-positive inflammatory breast cancer (IBC): BEVERLY2 study. (Abstract #531)**
 P. Viens, J. Pierga, T. Petit, T. Delozier, J. Ferrero, M. Campone, J. Gligorov, F. Lerebours, H. H. Roche, M. Pavlyuk, T. D. Bachelot, E. Charafe-Jauffret
- Brd. 21 Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. (Abstract #532)**
 S. Bayraktar, A. M. Gonzalez-Angulo, X. Lei, A. Buzdar, V. Valero, A. Melhem, H. M. Kuerer, G. N. Hortobagyi, A. A. Sahin, F. Meric-Bernstam
- Brd. 22 Etoricoxib and anastrozole in adjuvant early breast cancer: ETAN trial (phase III). (Abstract #533)**
 M. S. Rosati, M. Di Seri, G. Baciarello, V. LO Russo, P. Grassi, L. Marchetti, S. Giovannoni, M. Basile, L. Frati
- Brd. 23 Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer. (Abstract #534)**
 A. M. Thompson, T. Iwamoto, L. Jordan, C. Purdie, S. E. Bray, L. Baker, G. Hardie, L. Pusztai, S. L. Moulder, J. A. Dewar, S. M. Hadad
- Brd. 24 Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma. (Abstract #535)**
 D. Fumagalli, O. Metzger, I. Veys, A. Catteau, S. Michiels, H. Sandy, R. Salgado, S. K. Singhal, K. V. Saini, C. Galant, N. Galland, F. Bertucci, H. P. Peyro Saint Paul, M. J. Piccart-Gebhart, C. Sotiriou, D. Larsimont
- Brd. 25 A randomized controlled trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with breast carcinoma of high estrogen receptor content: Long-term results at 20 years of follow-up. (Abstract #536)**
 S. J. Johnston, F. S. Kenny, B. M. Syed, J. F. Robertson, S. Pinder, L. Winterbottom, I. O. Ellis, R. W. Blamey, K. Cheung

Tuesday, June 7, 2011

8:00 AM - 12:30 PM
POSTER DISCUSSION SESSION

Genitourinary (Nonprostate) Cancer

Display Time: 8:00 AM - 12:00 PM

Display Location: E450b

Discussion Time: 11:30 AM - 12:30 PM

Discussion Location: E354a

CME credit: 1

Track(s): Genitourinary Cancer

Emmanuel S. Antonarakis, MD—Co-Chair

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Scott E. Eggener, MD—Co-Chair

The University of Chicago

Discussion

11:30 AM Walter Michael Stadler, MD (Abstracts #4546–4552)
The University of Chicago

Discussion

11:45 AM Thomas Powles, MD (Abstracts #4553–4560)
St. Bartholomew's Hospital

Discussion

12:00 PM Christian K. Kollmannsberger, MD (Abstracts #4561–4565)
British Columbia Cancer Agency

Discussion

12:15 PM Matt D. Galsky, MD (Abstracts #4566–4570)
Tisch Cancer Institute, Mount Sinai Medical Center

Brd. 1 **BEVLin: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon- α 2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (Abstract #4546)**

B. Melichar, S. Bracarda, V. Matveev, I. Rusakov, A. Kaprin, A. Zyryanov, R. Janciauskiene, E. Fernebro, G. H. Mickisch, M. E. Gore, A. Schulze, S. Jethwa, V. Sneller, P. Mulders, J. Bellmunt, on behalf of the BEVLin Investigators

Brd. 2 **Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. (Abstract #4547)**

R. J. Motzer, T. de La Motte Rouge, A. L. Harzstark, D. Michaelson, G. Liu, V. Gruenwald, A. Ingrosso, M. A. Tortorici, P. W. Bycott, S. Kim, B. I. Rini

Brd. 3 **Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. (Abstract #4548)**

J. R. Merchan, H. C. Pitot, R. Qin, G. Liu, T. R. Fitch, W. J. Maples, J. Picus, C. Erlichman

Brd. 4 **Results from a phase I trial of tivozanib (AV-951) combined with temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). (Abstract #4549)**

F. F. Kabbina, S. Srinivas, R. J. Hauke, R. J. Amato, W. B. Esteves, M. M. Cotreau, A. L. Strahs, P. Bhargava, M. N. Fishman

Brd. 5 **Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). (Abstract #4550)**

D. Nosov, P. Bhargava, W. B. Esteves, A. L. Strahs, O. N. Lipatov, O. O. Lyulko, A. O. Anischenko, R. T. Chacko, D. Doval, W. J. Slichenmyer

Brd. 6 **A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). (Abstract #4551)**

E. Angevin, V. Grünwald, A. Ravaud, D. E. Castellano, C. Lin, J. E. Gschwend, A. L. Harzstark, J. Chang, Y. Wang, M. M. Shi, B. J. Escudier

- Brd. 7** **A noninterventional study of everolimus in metastatic renal cell cancer after use of one VEGFR-TKI: Results of a preplanned interim analysis of a prospective study. (Abstract #4552)**
L. Bergmann, U. Kube, M. Kindler, T. Koepke, G. Steiner, J. Janssen, S. Fries, P. Goebell, A. Jakob, T. Steiner, M. D. Staehler, F. Overkamp, M. Albrecht, C. Doehn
- Brd. 8** **Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC). (Abstract #4553)**
Y. Liu, H. T. Tran, Y. Lin, A. Martin, A. J. Zurita, C. N. Sternberg, R. G. Amado, L. N. Pandite, J. Heymach, VEG105192 Team
- Brd. 9** **Risk factor migration and survival: Analysis from international dataset of 3,748 metastatic renal cell carcinoma (mRCC) patients treated on clinical trials. (Abstract #4554)**
S. Patil, J. Manola, P. Elson, W. Bro, S. Negrier, B. Escudier, R. M. Bukowski, R. J. Motzer
- Brd. 10** **The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts). (Abstract #4555)**
M. Y. Al-Marrawi, B. I. Rini, L. C. Harshman, G. A. Bjarnason, L. Wood, U. N. Vaishampayan, M. J. MacKenzie, J. J. Knox, N. Agarwal, C. K. Kollmannsberger, M. Tan, S. Y. Rha, F. Donskov, S. A. North, T. K. Choueiri, D. Y. Heng, International mRCC Database Consortium
- Brd. 11** **Molecular classification of sunitinib response in metastatic renal cell carcinoma (mRCC) patients by gene expression profiling. (Abstract #4556)**
V. J. Thodima, A. M. Molina, X. Jia, J. Zhang, M. E. Georges, S. Patil, V. E. Reuter, R. J. Motzer, R. S. Chaganti
- Brd. 12** **Host-mediated changes in patients receiving antiangiogenic therapy for resected RCC. (Abstract #4557)**
R. S. Bhatt, J. Manola, A. J. Bullock, L. Zhang, N. B. Haas, M. Pins, M. B. Atkins, R. S. DiPaola
- Brd. 13** **Association of germ-line SNPs with overall survival (OS) in pazopanib-treated patients (Pts) with advanced renal cell carcinoma (RCC). (Abstract #4558)**
C. Xu, N. Bing, H. A. Ball, C. N. Sternberg, I. D. Davis, Z. Xue, L. McCann, K. King, J. C. Whittaker, C. F. Spraggs, V. E. Mooser, L. N. Pandite
- Brd. 14** **Polymorphisms as markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: Final results of a multicentric prospective study by the Spanish Oncology Genitourinary Group. (Abstract #4559)**
J. Garcia-Donas, E. Esteban, L. J. Leandro-García, D. E. Castellano, A. Gonzalez del Alba, M. Climent, J. A. Arranz, E. Gallardo, J. Puente, J. Bellmunt, B. Mellado, E. Martínez, F. Moreno, A. Font, M. Robledo, C. Rodriguez de Antona, Spanish Oncology GenitoUrinary Group (SOGUG)
- Brd. 15** **External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy. (Abstract #4560)**
D. Y. Heng, W. Xie, L. C. Harshman, G. A. Bjarnason, U. N. Vaishampayan, J. Lebert, L. Wood, F. Donskov, M. Tan, S. Y. Rha, C. Wells, Y. Wang, C. K. Kollmannsberger, B. I. Rini, T. K. Choueiri, International mRCC Database Consortium
- Brd. 16** **Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial. (Abstract #4561)**
P. S. Grimison, D. B. Thomson, M. R. Stockler, M. D. Chatfield, M. Friedlander, V. GebSKI, A. L. Boland, B. B. Houghton, H. Gurney, M. Rosenthal, N. Singhal, G. Kichenadasse, S. S. Wong, C. R. Lewis, P. A. Vasey, G. C. Toner, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

- Brd. 17** Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants. (Abstract #4562)
B. P. Mulherin, M. J. Brames, L. H. Einhorn
- Brd. 18** Reproduction rates prior to diagnosis of testicular cancer: Does the testicular dysgenesis syndrome exist? (Abstract #4563)
M. Cvancarova, J. Oldenburg, M. Sprauten, H. Stensheim, S. D. Fossa
- Brd. 19** Association of single-nucleotide polymorphism (SNP) in the 5-alpha-reductase gene (SRD5A2) with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer (TC) survivors. (Abstract #4564)
H. Boer, C. Meijer, J. D. Dijck-Brouwer, I. P. Kema, J. D. Lefrandt, N. Zwart, H. M. Boezen, A. J. Smit, J. A. Gietema
- Brd. 20** Evaluation of low-dose CT scans for surveillance in stage I testicular cancer. (Abstract #4565)
P. W. Chung, M. O'Malley, M. A. Jewett, T. Panzarella, D. Hogg, M. J. Moore, P. Bedard, L. Anson-Cartwright, B. Tew-George, M. A. Haider, M. K. Gospodarowicz, P. R. Warde
- Brd. 21** Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC). (Abstract #4566)
A. V. Balar, M. I. Milowsky, A. B. Apolo, I. Ostrovnya, A. Iasonos, A. Trout, A. M. Regazzi, I. R. Garcia-Grossman, D. J. Gallagher, D. F. Bajorin
- Brd. 22** Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC). (Abstract #4567)
W. M. Stadler, D. J. Vaughn, G. Sonpavde, N. J. Vogelzang, S. T. Tagawa, D. P. Petrylak, P. J. Rosen, C. Lin, J. F. Mahoney, S. S. Modi, P. Lee, M. S. Ernstoff, W. Su, A. I. Spira, M. Ould Kaci, J. M. Watrous, T. Taube, R. Vinisko, C. Schloss, C. Zhao, M. A. Carducci
- Brd. 23** Identification of ALK gene alterations in urothelial carcinoma (UC). (Abstract #4568)
J. Bellmunt, S. Selvarajah, S. Rodig, M. Salido, I. Costa, B. Bellosillo, L. Werner, C. Namgyal, F. A. Schutz, F. Pons, R. O'Brien, J. Barretina, S. Signoretti, M. Loda, J. Albanell, T. K. Choueiri, D. M. Berman, P. W. Kantoff, J. E. Rosenberg
- Brd. 24** Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (Abstract #4569)
J. E. Rosenberg, L. Werner, S. Selvarajah, B. Weir, M. M. Regan, S. J. Jacobus, D. M. Berman, F. A. Schutz, R. O'Brien, T. K. Choueiri, J. Barretina, S. Signoretti, M. Loda, E. A. Guancial, E. Gallardo, F. G. Rojo, J. Lloreta, W. C. Hahn, P. W. Kantoff, J. Bellmunt
- Brd. 25** Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (Abstract #4570)
K. M. Krajewski, R. Fougeray, T. K. Choueiri, F. Pons, F. A. Schutz, J. E. Rosenberg, Y. Salhi, J. Bellmunt

9:30 AM - 12:30 PM
ORAL ABSTRACT SESSION

Gastrointestinal (Noncolorectal) Cancer

Location: Hall D1

CME credit: 3

Track(s): Gastrointestinal (Noncolorectal) Cancer

Jennifer J. Knox, MD—Co-Chair

Princess Margaret Hospital

Andrea Wang-Gillam, MD, PhD—Co-Chair

Washington University School of Medicine

9:30 AM Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). (Abstract #4000)
A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo, S. Qin, M. Omata, S. W. Pitman Lowenthal, S. Lanzalone, L. Yang, M. Lechuga, E. Raymond, SUN1170 HCC Study Group

9:45 AM Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. (Abstract #4001)
J. A. Marrero, R. Lencioni, M. Kudo, S. Ye, K. Nakajima, F. Cihon, A. P. Venook

Discussion

10:00 AM Bert H. O'Neil, MD (Abstracts #4000–4001)
 University of North Carolina at Chapel Hill

10:15 AM Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial. (Abstract #LBA4002)
Y. J. Bang, Y. W. Kim, H. K. Yang, H. C. Chung, Y. K. Park, K. W. Lee, K. H. Lee, Y. H. Kim, S. I. Noh, J. Ji, M. Johnston, F. Sirzen, and S. H. Noh

10:30 AM Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. (Abstract #4003)
C. S. Fuchs, J. E. Tepper, D. Niedzwiecki, D. Hollis, H. J. Mamon, R. Swanson, D. G. Haller, T. Dragovich, S. R. Alberts, G. A. Bjarnason, C. G. Willett, P. C. Enzinger, R. M. Goldberg, A. P. Venook, R. J. Mayer

10:45 AM A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC). (Abstract #4004)
S. Park, D. Lim, K. Park, S. Lee, S. Oh, H. Kwon, J. Kang, I. Hwang, J. Lee, J. Park, Y. Park, H. Lim, W. Kang

Discussion

11:00 AM Florian Lordick, MD (Abstracts #LBA4002–4004)
 Klinikum Rechts der Isar, Technische Universitaet Muenchen

11:15 AM Long-term update of U.S. GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5FU-mitomycin versus RT+5FU-cisplatin. (Abstract #4005)
L. L. Gunderson, K. A. Winter, J. A. Ajani, J. E. Pedersen, A. B. Benson, C. R. Thomas Jr., R. J. Mayer, M. G. Haddock, T. A. Rich, C. G. Willett

Discussion

11:30 AM Theodore S. Hong, MD (Abstract #4005)
 Massachusetts General Hospital

Tuesday, June 7, 2011

11:45 AM Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater. (Abstract #LBA4006)

J. P. Neoptolemos, M. J. Moore, T. F. Cox, J. W. Valle, D. H. Palmer, A. McDonald, R. Carter, N. C. Tebbutt, C. Dervenis, D. Smith, B. Glimelius, F. Y. Coxon, F. Lacaine, M. R. Middleton, P. Ghaneh, C. Bassi, C. Halloran, A. Olah, C. L. Rawcliffe, and M. W. Büchler

12:00 PM Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. (Abstract #4007)

T. Ioka, M. Ikeda, S. Ohkawa, H. Yanagimoto, A. Fukutomi, K. Sugimori, H. Baba, K. Yamao, T. Shimamura, J. Chen, K. Mizumoto, J. Furuse, A. Funakoshi, T. Hatori, T. Yamaguchi, S. Egawa, A. Sato, Y. Ohashi, A. Cheng, T. Okusaka

Discussion

12:15 PM Dan Laheru, MD (Abstracts #LBA4006–4007)
The Johns Hopkins University School of Medicine

TUESDAY

9:45 AM - 11:00 AM
EDUCATION SESSIONS

Biomarkers for Vascular Endothelial Growth Factor (VEGF)-targeted Agents

Location: S100a

CME credit: 1.25

Track(s): Tumor Biology

Michael L. Maitland, MD, PhD—Chair

The University of Chicago

Hypertension Is a Biomarker for Vascular Endothelial Growth Factor (VEGF)-targeted Therapies

Herbert Hurwitz, MD

Duke University Medical Center

Hypertension Is Not a Biomarker for VEGF-targeted Therapies

Bryan P. Schneider, MD

Indiana University School of Medicine

Single-nucleotide Polymorphisms (SNPs) as Potential Predictive Biomarkers for VEGF-targeted Agents

Emile E. Voest, MD, PhD

University Medical Center Utrecht

Novel Approaches to Identify Predictive Biomarkers for VEGF-targeted Therapies

Effective Time Management for the Busy Oncologist

Location: E353

CME credit: 1.25

Track(s): Professional Development, General Oncology, Practice Management and Information Technology

Timothy Jerome Moynihan, MD—Chair

Mayo Clinic

What Is Effective Time Management?

Martha P. Mims, MD, PhD

Baylor College of Medicine

Developing a Healthy Balance of Work and Home-life Duties

David H. Johnson, MD

University of Texas Southwestern Medical Center

How to Protect “Protected Time”: Prioritizing Competing Responsibilities

The Changing Face of Castration-resistant Prostate Cancer: Standard Therapy and New Targets

Location: E354a

CME credit: 1.25

Track(s): Genitourinary Cancer, Geriatric Oncology

Kim N. Chi, MD—Chair

British Columbia Cancer Agency

Emerging Investigational Therapies in Castration-resistant Prostate Cancer

Charles G. Drake, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Immunotherapy in Castration-resistant Prostate Cancer

Thomas W. Flaig, MD

University of Colorado Denver

New Standards in the Medical Management of Castration-resistant Prostate Cancer

Tuesday, June 7, 2011

**9:45 AM - 11:00 AM
MEET THE PROFESSOR SESSION**

**Non-melanoma Skin Cancer: Surgical Management of Aggressive Cases and
Molecular Targeted Therapies (M24)—Ticketed Session**

Location: E451a

CME credit: 1.25

Track(s): Head and Neck Cancer, Melanoma/Skin Cancers

Randal S. Weber, MD

University of Texas M. D. Anderson Cancer Center

Surgical Management of Aggressive Squamous Cell Carcinoma of the Skin

David G. Pfister, MD

Memorial Sloan-Kettering Cancer Center

Role of Molecularly Targeted Therapy in the Management of Non-melanoma Skin Cancer

9:45 AM - 11:15 AM
CLINICAL SCIENCE SYMPOSIUM

Emerging Issues in Comparative Effectiveness Research

Location: S100bc

CME credit: 1.5

Track(s): Health Services Research

Sharon Hermes Giordano, MD, MPH—Chair

University of Texas M. D. Anderson Cancer Center

9:45 AM Development of a guideline for including patient-reported outcomes in post-approval clinical trials of oncology drugs for comparative effectiveness research. (Abstract #6000)

E. M. Basch, A. P. Abernethy, C. D. Mullins, M. R. Tiglaio, S. R. Tunis

10:15 AM The relationship between cost, quality, and outcomes among women with breast cancer in SEER–Medicare. (Abstract #6001)

M. J. Hassett, B. A. Neville, J. C. Weeks

Discussion

10:30 AM Steven J. Katz, MD, MPH (Abstract #6001)
University of Michigan Medical School

10:45 AM Utilization and costs of nonevidence-based antineoplastic agents in patients with metastatic colon cancer. (Abstract #6002)

J. A. de Souza, B. N. Polite, S. Zhu, J. J. Dignam, N. J. Meropol, M. J. Ratain,
L. N. Newcomer, G. C. Alexander

Discussion

11:00 AM Marcelo Blaya, MD (Abstract #6002)
Tulane University Health Sciences Center

Tuesday, June 7, 2011

**11:30 AM - 12:45 PM
EDUCATION SESSIONS**

Cancer Stem Cells as a Therapeutic Target: Fact or Fiction?

Location: S100a

CME credit: 1.25

Track(s): Tumor Biology, Developmental Therapeutics

Max Wicha, MD—Chair

University of Michigan Cancer Center

Targeted Cancer Stem Cells: Is This Really the Answer?

Michael Kahn, PhD

University of Southern California

Targeting Wnt-B-catenin Signaling in Cancer Stem Cells

Joan Seoane, PhD

Vall d'Hebron University Hospital, Institut d'Oncologia

Targeting Signaling Pathways That Mediate Cancer Stem Cell Survival

The Importance of Histology and Molecular Testing (EGFR and EML4-ALK) in the Initial Evaluation of Advanced Non-small Cell Lung Cancer

Location: E354b

CME credit: 1.25

Track(s): Lung Cancer

Renato Martins, MD, MPH—Chair

Seattle Cancer Care Alliance

Epidermal Growth Factor Receptor Testing: Who, What, When, and How?

David N. Hayes, MD, MPH

University of North Carolina at Chapel Hill

The Role of Histology in Managing Non-small Cell Lung Cancer

Alice Tsang Shaw, MD, PhD

Massachusetts General Hospital Cancer Center

EML4-ALK Testing: Who, What, When, and How?

TUESDAY

11:30 AM - 12:45 PM
MEET THE PROFESSOR SESSION

**How to Develop a Successful Career in Health Services Research
(M25)—Ticketed Session**

Location: E451a

CME credit: 1.25

Track(s): Health Services Research, Professional Development

Jane C. Weeks, MD, MSc
Dana-Farber Cancer Institute

